

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
28 October 2004 (28.10.2004)

PCT

(10) International Publication Number
WO 2004/092209 A2

(51) International Patent Classification⁷: **C07K 14/315**

(21) International Application Number:
PCT/EP2004/003984

(22) International Filing Date: 15 April 2004 (15.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
03450087.6 15 April 2003 (15.04.2003) EP

(71) Applicant (for all designated States except US): **INTER-CELL AG** [AT/AT]; Campus Vienna Biocenter 6, A-1030 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MEINKE, Andreas** [DE/AT]; Piettegassee 26/1, A-3013 Pressbaum (AT). **NAGY, Eszter** [HU/AT]; Taborstrasse 9, A-1020 Vienna (AT). **HANNER, Markus** [AT/AT]; Jacquingasse 5/6, A-1030 Vienna (AT). **DEWASTHALY, Shailesh** [IN/AT]; Anschützgassee 23/10, A-1150 Vienna (AT). **STIER-SCHNEIDER, Ulrike** [AT/AT]; Kaiserstrasse 66/2/14, A-1070 Vienna (AT).

(74) Agent: **SONN & PARTNER**; Riemergasse 14, A-1010 Vienna (AT).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- of inventorship (Rule 4.17(iv)) for US only

Published:

- without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **S. PNEUMONIAE ANTIGENS**

(57) Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from *S. pneumoniae*, methods for isolating such antigens and specific uses thereof.

WO 2004/092209 A2

S.PNEUMONIAE ANTIGENS

The present invention relates to isolated nucleic acid molecules, which encode antigens for *Streptococcus pneumoniae*, which are suitable for use in preparation of pharmaceutical medicaments for the prevention and treatment of bacterial infections caused by *Streptococcus pneumoniae*.

Streptococcus pneumoniae (*Pneumococcus*) is a lancet-shaped, gram-positive, facultative anaerobic bacterium. It is only the encapsulated organism that is pathogenic for humans and experimental animals. Capsules are antigenic and form the basis for classifying pneumococci by serotypes. Ninety serotypes have been identified, based on their reaction with type-specific antisera. Most *S. pneumoniae* serotypes have been shown to cause serious disease, and the ten most common serotypes are estimated to account for about 62% of invasive disease worldwide. The ranking and serotype prevalence differs by age group and geographic area.

Pneumococci are common inhabitants of the respiratory tract, and may be isolated from the nasopharynx of 5% to 70% of normal adults. Rates of asymptomatic carriage vary with age, environment, and the presence of upper respiratory infections. Only 5%-10% of adults without children are carriers. In schools and orphanages, 27% to 58% of students and residents may be carriers. On military installations, as many as 50% to 60% of service personnel may be carriers. The duration of carriage varies and is generally longer in children than adults (reviewed in Epidemiology and Prevention of Vaccine-Preventable Diseases, 7th Edition-Second Printing, The Pink Book).

The relationship of carriage to the development of natural immunity is poorly understood. In addition, the immunologic mechanism that allows disease to occur in a carrier is poorly understood.

Streptococcus pneumoniae is an important agent of human disease at the extremes of age and in those who have underlying disease. Pneumococcal disease kills more people – in the US 40,000 or more each year – than all other vaccine preventable diseases combined. The major clinical syndromes of pneumococcal disease include pneumonia, bacteremia, and meningitis. The disease most often occurs when a predisposing condition exists, particularly pulmonary disease. It is a common bacterial complication of antecedent viral respiratory infection such as influenza and measles, and of chronic conditions such as chronic obstructive pulmonary disease, diabetes, congestive heart failure, renal failure, smoking and alcoholism. Pneumococcal infections are more common during the winter and in early spring when respiratory diseases are more prevalent. Immunodeficiency (splenic dysfunction, iatrogen, etc.) is a risk factor for development of fatal pneumococcal infections, because of decreased bacterial clearance and lack of antibodies. The incubation period is short, 1-3 days. Symptoms include an abrupt onset of fever and shaking chills or rigor, productive cough, pleuritic chest pain, dyspnoea, tachycardia and hypoxia.

S. pneumoniae is responsible for 88% of bacteremia infections in the US. Pneumonia is the most common form of invasive pneumococcal diseases: 150,000-570,000 cases per year (US). 36% of adult community-acquired and 50% of hospital-acquired pneumonia is caused by *S. pneumoniae* (US). The incidence of disease among adults aged 65 years and older has been reported to be ~60 cases/100,000. Case fatality rates for this disease increase from 1.4% for those aged two or younger to as high as 20.6% among those aged 80 or older. Diseases caused by influenza and *Pneumococcus* are together the fifth leading cause of death for persons aged 65 and older. Mortality attributable to these pathogens is more than 90% in this age group. Bacteremia occurs in about 25-30% of patients with pneumonia. The overall mortality rate of bacteremia is about 20%, but may be as high as 60% in elderly people. In 1998, 51% of all deaths attributable to invasive pneumococcal diseases occurred in age group above 65 years. Pneumococci cause 13%-19% of all cases of bacterial meningitis in the United States. An estimated 3,000 to 6,000 cases of pneumococcal meningitis occur each year. One-quarter of patients with pneumococcal meningitis also have pneumonia. The clinical symptoms, spinal fluid profile and neurologic complications are similar to other forms of purulent bacterial meningitis (reviewed in Epidemiology and Prevention of Vaccine-Preventable Diseases, 7th Edition-Second Printing, The Pink Book).

In children, Pneumococci are a common cause of acute otitis media, and are detected in 28%-55% of middle ear aspirates. By age 12 months, 62% of children have had at least one episode of acute otitis media. Middle ear infections are the most frequent reasons for pediatric office visits in the United States, resulting in over 20 million visits annually. Complications of pneumococcal otitis media may include mastoiditis and meningitis. Bacteremia without a known site of infection is the most common invasive clinical presentation among children <2 years of age, accounting for approximately 70% of invasive disease in this age group. Bacteremic pneumonia accounts for 12%-16% of invasive pneumococcal disease among children <2 years of age. With the decline of invasive Hib disease, *S. pneumoniae* has become the leading cause of bacterial meningitis among children <5 years of age in the United States. Children <1 year have the highest rates of pneumococcal meningitis, approximately 10 cases per 100,000 population. The burden of pneumococcal disease among children <5 years of age is significant. An estimated 17,000 cases of invasive disease occur each year, of which 13,000 are bacteremia without a known site of infection and about 700 are of meningitis. An estimated 200 children die every year as a result of invasive pneumococcal disease. Although not considered invasive disease, an estimated 5 million cases of acute otitis media occur each year among children <5 years of age (reviewed Epidemiology and Prevention of Vaccine-Preventable Diseases, 7th Edition-Second Printing, The Pink Book).

A definitive diagnosis of infection with *Streptococcus pneumoniae* generally relies on isolation of the organism from blood or other normally sterile body sites. Tests are also available to detect capsular polysaccharide antigen in body fluids.

Penicillin is the drug of choice for treatment. However, successful implementation of anti-infective therapy has become increasingly difficult because of widespread antimicrobial resistance. Resistance to penicillin is rising, and according to recent reports it reaches ~ 25% in the US [Whitney, C. et al., 2000]. The proportion of macrolide-resistant strains reached ~ 20 % [Hyde, T. et al., 2001]. Use of antimicrobial agents is highly correlated with the increase in resistance of *S. pneumoniae* to β -lactams and macrolides [McCormick, A. et al., 2003].

However, even with effective antibiotic therapy (sensitive strains), the case fatality rate of invasive disease is high with an average of 10% in the developed world and can be much higher with certain serotypes, in elderly patients and in cases of bacteremia or meningitis (up to 80%).

Thus, there remains a need for an effective treatment to prevent or ameliorate pneumococcal infections. A vaccine could not only prevent infections by streptococci, but more specifically prevent or ameliorate colonization of host tissues (esp. in nasopharynx), thereby reducing the incidence of upper respiratory infections and other suppurative infections, such as otitis media. Elimination of invasive diseases - pneumonia, bacteremia and meningitis, and sepsis - would be a direct consequence of reducing the incidence of acute infection and carriage of the organism. Vaccines capable of showing cross-protection against the majority of *S. pneumoniae* strains causing human infections would also be useful to prevent or ameliorate infections caused by all other streptococcal species, namely groups A, B, C and G.

A vaccine can contain a whole variety of different antigens. Examples of antigens are whole-killed or attenuated organisms, subfractions of these organisms/tissues, proteins, or, in their most simple form, peptides. Antigens can also be recognized by the immune system in form of glycosylated proteins or peptides and may also be or contain polysaccharides or lipids. Short peptides can be used since for example cytotoxic T-cells (CTL) recognize antigens in form of short usually 8-11 amino acids long peptides in conjunction with major histocompatibility complex (MHC). B-cells can recognize linear epitopes as short as 4-5 amino acids, as well as three-dimensional structures (conformational epitopes). In order to obtain sustained, antigen-specific immune responses, adjuvants need to trigger immune cascades that involve all cells of the immune system. Primarily, adjuvants are acting, but are not restricted in their mode of action, on so-called antigen presenting cells (APCs). These cells usually first

- 3 -

encounter the antigen(s) followed by presentation of processed or unmodified antigen to immune effector cells. Intermediate cell types may also be involved. Only effector cells with the appropriate specificity are activated in a productive immune response. The adjuvant may also locally retain antigens and co-injected other factors. In addition the adjuvant may act as a chemoattractant for other immune cells or may act locally and/or systemically as a stimulating agent for the immune system.

Efforts to develop effective pneumococcal vaccines began as early as 1911. However, with the advent of penicillin in the 1940s, interest in the vaccine declined, until it was observed that many patients still died despite antibiotic treatment. By the late 60s, efforts were again being made to develop a polyvalent vaccine. The first pneumococcal vaccines contained purified capsular polysaccharide antigen from 14 different types of pneumococcal bacteria. In 1983, a 23-valent polysaccharide vaccine (PPV23) was licensed and replaced the 14-valent vaccine, which is no longer produced. PPV23 contains polysaccharide antigen from 23 types of pneumococcal bacteria which cause 88% of bacteremic pneumococcal disease. In addition, cross-reactivity occurs for several capsular types which account for an additional 8% of bacteremic disease. Two polysaccharide vaccines are available in the United States (Pneumovax 23, Merck, and Pnu-Immune 23, Wyeth-Lederle). Both vaccines contain 25 µg of each antigen per dose and include either phenol or thimerosal as a preservative.

The first pneumococcal conjugate vaccine (PCV7, Prevnar) was licensed in the United States in 2000. It includes purified capsular polysaccharide of 7 serotypes of *S. pneumoniae* (4, 9V, 14, 19F, 23F, 18C, and 6B) conjugated to a nontoxic variant of diphtheria toxin known as CRM197. The serotypes included in Prevnar accounted for 86% of bacteremia, 83% of meningitis, and 65% of acute otitis media among children <6 years of age in the United States during 1978-1994 (reviewed in Epidemiology and Prevention of Vaccine-Preventable Diseases, 7th Edition-Second Printing, The Pink Book). Additional pneumococcal polysaccharide conjugate vaccines containing 9 and 11 serotypes of *S. pneumoniae* are being developed. The vaccine is administered intramuscularly. After 4 doses of Prevnar vaccine, virtually all healthy infants develop antibody to all 7 serotypes contained in the vaccine. Prevnar has also been shown to be immunogenic in infants and children, including those with sickle cell disease and HIV infection. In a large clinical trial, Prevnar was shown to reduce invasive disease caused by vaccine serotypes, and reduce invasive disease caused by all serotypes, including serotypes not in the vaccine. Children who received Prevnar had fewer episodes of acute otitis media and underwent fewer tympanostomy tube placements than unvaccinated children. The duration of protection following Prevnar is currently unknown. Immunization with Prevnar reduces the rate of nasopharyngeal carriage of the vaccine serotypes, while the overall carriage rate is unaffected. Unfortunately, it has also been shown to induce serotype redistribution, that is the replacement of vaccine serotypes by strains, which are not covered by Prevnar [Pelton, S. et al., 2003].

Pneumococcal vaccine is recommended to be administered routinely to i., all children as part of the routine childhood immunization schedule, ii., adults 65 years of age and older and iii., persons aged >2 years with normal immune systems who have chronic illnesses, including cardiovascular disease, pulmonary disease, diabetes, alcoholism, cirrhosis, or cerebrospinal fluid leaks. In the elderly population the target groups for pneumococcal vaccine and influenza vaccine overlap. These vaccines can be given at the same time at different sites without increased side effects.

High mortality is observed among high-risk individuals (with underlying disease – mainly viral respiratory infection, immunocompromise) even with effective antibiotic therapy. The mAb approach targets patients with serious disease and provides immediate immune enhancement for the clearance of the bacteria. Through opsonization bacteria are killed within phagocytic cells and not lysed in the blood by antibiotics. This mechanism of action can help to eliminate the release of toxins (such as pneumolysin and other cytotoxins), which worsen the clinical condition of septic patients. Recent advances in the technology of monoclonal antibody production provide the means to generate human antibody reagents and reintroduce antibody therapies, while avoiding the toxicities associated with serum therapy.

- 4 -

Immunoglobulins are an extremely versatile class of antimicrobial proteins that can be used to prevent and treat emerging infectious diseases. Antibody therapy has been effective against a variety of diverse microorganisms reviewed in {Burnie, J. et al., 1998}.

Although capsular specific antibodies have been shown to be highly protective, it remains unclear what concentration of these serotype-specific antibodies protect against disease and more recently it has become clear that opsonic activity and avidity of these antibodies are more critical determinants of protection than concentration.

Protein conjugate vaccines are no doubt a great new addition to the armamentarium in the battle against pneumococcal disease, but the vaccine contains a limited number of pneumococcal serotypes and given adequate ecological pressure, replacement disease by non-vaccine serotypes remains a real threat, particularly in areas with very high disease burden.

During the last decade the immunogenicity and protective capacity of several pneumococcal proteins have been described in animal models and these are now being explored for the development of species-common protein based vaccines. Such proteins are the Pneumococcal surface protein A (PspA, {McDaniel, L. et al., 1991}; {Roche, H. et al., 2003}), Pneumococcal surface adhesin A (PsaA, {Talkington, D. et al., 1996}), Choline binding protein A (CbpA, {Rosenow, C. et al., 1997}), LytB glucosaminidase, LytC muramidase, PrtA serine protease, PhtA (histidine triad A) and Pneumococcal vaccine antigen A (PvaA) {Wizemann, T. et al., 2001}; {Adamou, J. et al., 2001}.

Certain proteins or enzymes displayed on the surface of gram-positive organisms significantly contribute to pathogenesis, and might be involved in the disease process caused by these pathogens. Often, these proteins are involved in direct interactions with host tissues or in concealing the bacterial surface from the host defense mechanisms {Navarre, W. et al., 1999}. *S. pneumoniae* is not an exception in this regard. Several surface proteins are characterized by as virulence factors, important for pneumococcal pathogenicity reviewed in {Jedrzejewski, M., 2001}. If antibodies to these proteins could offer better protection to humans, they could provide the source of a novel, protein-based pneumococcal vaccine to be used in conjunction with or in place of the more traditional capsular polysaccharide vaccine. The use of some of the above-described proteins as antigens for a potential vaccine as well as a number of additional candidates reviewed in {Di Guilmi, A. et al., 2002} resulted mainly from a selection based on easiness of identification or chance of availability. There is a demand to identify relevant antigens for *S. pneumoniae* in a more comprehensive way.

The present inventors have developed a method for identification, isolation and production of hyperimmune serum reactive antigens from a specific pathogen, especially from *Staphylococcus aureus* and *Staphylococcus epidermidis* (WO 02/059148). However, given the differences in biological property, pathogenic function and genetic background, *Streptococcus pneumoniae* is distinctive from *Staphylococcus* strains. Importantly, the selection of sera for the identification of antigens from *S. pneumoniae* is different from that applied to the *S. aureus* screens. Three major types of human sera were collected for that purpose. First, healthy adults below <45 years of age preferably with small children in the household were tested for nasopharyngeal carriage of *S. pneumoniae*. A large percentage of young children are carriers of *S. pneumoniae*, and they are considered to be a source for exposure for their family members. Based on correlative data, protective (colonization neutralizing) antibodies are likely to be present in exposed individuals (children with high carriage rate in the household) who are not carriers of *S. pneumoniae*. To be able to select for relevant serum sources, a series of ELISAs measuring anti-*S. pneumoniae* IgG and IgA antibody levels were performed with bacterial lysates and culture supernatant proteins. Sera from high titer non-carriers were included in the genomic-based antigen identification. This approach for selection of human sera is basically very different from that used for *S. aureus*, where carriage or non-carriage state couldn't be associated with antibody levels. Second, serum samples from

convalescent phase patients with invasive pneumococcal diseases were characterized and selected in the same way. The third group of sera, containing longitudinally collected samples were also obtained from individuals with invasive disease and were used mainly for validation purposes. The main value of this collection is that one can follow the changes in antigen-specific antibody levels before disease (prae-), at the time of onset (acute) and during recovery (convalescent). This latter group helps in the selection of epitopes, which induce antibodies during disease and missing in the prae-disease state.

The genomes of the two bacterial species *S. pneumoniae* and *S. aureus* by itself show a number of important differences. The genome of *S. pneumoniae* contains app. 2.16 Mb, while *S. aureus* harbours 2.85 Mb. They have an average GC content of 39.7 and 33%, respectively and approximately 30 to 45% of the encoded genes are not shared between the two pathogens. In addition, the two bacterial species require different growth conditions and media for propagation. While *S. pneumoniae* is a strictly human pathogen, *S. aureus* can also be found infecting a range of warm-blooded animals. A list of the most important diseases, which can be inflicted by the two pathogens is presented below. *S. aureus* causes mainly nosocomial, opportunistic infections: impetigo, folliculitis, abscesses, boils, infected lacerations, endocarditis, meningitis, septic arthritis, pneumonia, osteomyelitis, scalded skin syndrome (SSS), toxic shock syndrome. *S. pneumoniae* causes mainly community acquired infections: upper (pharyngitis, otitis media) and lower respiratory infections (pneumonia), as well as bacteremia, sepsis and meningitis.

The complete genome sequence of a capsular serotype 4 isolate of *S. pneumoniae*, designated TIGR4 was determined by the random shotgun sequencing strategy (GenBank accession number AE005672; see www.tigr.org/tigrscripts/CMR2/CMRHomePage.spl). This clinical isolate was taken from the blood of a 30-year-old male patient in Kongsvinger, Norway, and is highly invasive and virulent in a mouse model of infection.

The problem underlying the present invention was to provide means for the development of medicaments such as vaccines against *S. pneumoniae* infection. More particularly, the problem was to provide an efficient, relevant and comprehensive set of nucleic acid molecules or hyperimmune serum reactive antigens from *S. pneumoniae* that can be used for the manufacture of said medicaments.

Therefore, the present invention provides an isolated nucleic acid molecule encoding a hyperimmune serum reactive antigen or a fragment thereof comprising a nucleic acid sequence, which is selected from the group consisting of:

- a) a nucleic acid molecule having at least 70% sequence identity to a nucleic acid molecule selected from Seq ID No 1, 101-144.
- b) a nucleic acid molecule which is complementary to the nucleic acid molecule of a),
- c) a nucleic acid molecule comprising at least 15 sequential bases of the nucleic acid molecule of a) or b)
- d) a nucleic acid molecule which anneals under stringent hybridisation conditions to the nucleic acid molecule of a), b), or c)
- e) a nucleic acid molecule which, but for the degeneracy of the genetic code, would hybridise to the nucleic acid molecule defined in a), b), c) or d).

According to a preferred embodiment of the present invention the sequence identity is at least 80%, preferably at least 95%, especially 100%.

Furthermore, the present invention provides an isolated nucleic acid molecule encoding a hyperimmune serum reactive antigen or a fragment thereof comprising a nucleic acid sequence selected from the group consisting of

- a) a nucleic acid molecule having at least 96% sequence identity to a nucleic acid molecule selected from Seq ID No 2-6, 8, 10-16, 18-23, 25-31, 34, 36, 38-42, 44, 47-48, 51, 53, 55-62, 64, 67, 71-76, 78-79, 81-94, 96-100.

- 6 -

- b) a nucleic acid molecule which is complementary to the nucleic acid molecule of a),
- c) a nucleic acid molecule comprising at least 15 sequential bases of the nucleic acid molecule of a) or b)
- d) a nucleic acid molecule which anneals under stringent hybridisation conditions to the nucleic acid molecule of a), b) or c),
- e) a nucleic acid molecule which, but for the degeneracy of the genetic code, would hybridise to the nucleic acid defined in a), b), c) or d).

According to another aspect, the present invention provides an isolated nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of

- a) a nucleic acid molecule selected from Seq ID No 9, 17, 24, 32, 37, 43, 52, 54, 65-66, 70, 80.
- b) a nucleic acid molecule which is complementary to the nucleic acid of a),
- c) a nucleic acid molecule which, but for the degeneracy of the genetic code, would hybridise to the nucleic acid defined in a), b), c) or d).

Preferably, the nucleic acid molecule is DNA or RNA.

According to a preferred embodiment of the present invention, the nucleic acid molecule is isolated from a genomic DNA, especially from a *S. pneumoniae* genomic DNA.

According to the present invention a vector comprising a nucleic acid molecule according to any of the present invention is provided.

In a preferred embodiment the vector is adapted for recombinant expression of the hyperimmune serum reactive antigens or fragments thereof encoded by the nucleic acid molecule according to the present invention.

The present invention also provides a host cell comprising the vector according to the present invention.

According to another aspect the present invention further provides a hyperimmune serum-reactive antigen comprising an amino acid sequence being encoded by a nucleic acid molecule according to the present invention.

In a preferred embodiment the amino acid sequence (polypeptide) is selected from the group consisting of Seq ID No 145, 245-288.

In another preferred embodiment the amino acid sequence (polypeptide) is selected from the group consisting of Seq ID No 146-150, 152, 154-160, 162-167, 169-175, 178, 180, 182-186, 188, 191-192, 195, 197, 199-206, 208, 211, 215-220, 222-223, 225-238, 240-244.

In a further preferred embodiment the amino acid sequence (polypeptide) is selected from the group consisting of Seq ID No 153, 161, 168, 176, 181, 187, 196, 198, 209-210, 214, 224.

According to a further aspect the present invention provides fragments of hyperimmune serum-reactive antigens selected from the group consisting of peptides comprising amino acid sequences of column "predicted immunogenic aa" and "location of identified immunogenic region" of Table 1; the serum reactive epitopes of Table 2, especially peptides comprising amino acids 4-11, 35-64, 66-76, 101-108, 111-119 and 57-114 of Seq ID No 145; 5-27, 32-64, 92-102, 107-113, 119-125, 133-139, 148-162, 177-187, 195-201, 207-214, 241-251, 254-269, 285-300, 302-309, 317-324, 332-357, 365-404, 411-425, 443-463, 470-477, 479-487, 506-512, 515-520, 532-547, 556-596, 603-610, 616-622, 624-629, 636-642, 646-665, 667-674, 687-692, 708-720, 734-739, 752-757, 798-820, 824-851, 856-865 and 732-763 of Seq ID No 146; 14-21, 36-44, 49-66, 102-127, 162-167, 177-196, 45-109 and 145-172 of Seq ID No 147; 17-35, 64-75, 81-92, 100-119, 125-172, 174-183, 214-

222, 230-236, 273-282, 287-303, 310-315, 331-340, 392-398, 412-420, 480-505, 515-523, 525-546, 553-575, 592-598, 603-609, 617-625, 631-639, 644-651, 658-670, 681-687, 691-704, 709-716, 731-736, 739-744, 750-763, 774-780, 784-791, 799-805, 809-822, 859-870, 880-885, 907-916, 924-941, 943-949, 973-986, 1010-1016, 1026-1036, 1045-1054, 1057-1062, 1082-1088, 1095-1102, 1109-1120, 1127-1134, 1140-1146, 1152-1159, 1169-1179, 1187-1196, 1243-1251, 1262-1273, 1279-1292, 1306-1312, 1332-1343, 1348-1364, 1379-1390, 1412-1420, 1427-1436, 1458-1468, 1483-1503, 1524-1549, 1574-1588, 1614-1619, 1672-1685, 1697-1707, 1711-1720, 1738-1753, 1781-1787, 1796-1801, 1826-1843, 132-478, 508-592 and 1753-1810 of Seq ID No 148; 15-43, 49-55, 71-77, 104-110, 123-130, 162-171, 180-192, 199-205, 219-227, 246-254, 264-270, 279-287, 293-308, 312-322, 330-342, 349-356, 369-377, 384-394, 401-406, 416-422, 432-439, 450-460, 464-474, 482-494, 501-508, 521-529, 536-546, 553-558, 568-574, 584-591, 602-612, 616-626, 634-646, 653-660, 673-681, 688-698, 705-710, 720-726, 736-749, 833-848, 1-199, 200-337, 418-494 and 549-647 of Seq ID No 149; 9-30, 65-96, 99-123, 170-178 and 1-128 of Seq ID No 150; 7-32, 34-41, 96-106, 127-136, 154-163, 188-199, 207-238, 272-279, 306-312, 318-325, 341-347, 353-360, 387-393, 399-406, 434-440, 452-503, 575-580, 589-601, 615-620, 635-640, 654-660, 674-680, 696-701, 710-731, 1-548 and 660-691 of Seq ID No 151; 4-19, 35-44, 48-59, 77-87, 93-99, 106-111, 130-138, 146-161 and 78-84 of Seq ID No 152; 24-30, 36-43, 64-86, 93-99, 106-130, 132-145, 148-165, 171-177, 189-220, 230-249, 251-263, 293-300, 302-312, 323-329, 338-356, 369-379, 390-412 and 179-193 of Seq ID No 153; 30-39, 61-67, 74-81, 90-120, 123-145, 154-167, 169-179, 182-197, 200-206, 238-244, 267-272 and 230-265 of Seq ID No 154; 14-20, 49-65, 77-86 and 2-68 of Seq ID No 155; 4-9, 26-35, 42-48, 53-61, 63-85, 90-101, 105-111, 113-121, 129-137, 140-150, 179-188, 199-226, 228-237, 248-255, 259-285, 299-308, 314-331, 337-343, 353-364, 410-421, 436-442 and 110-144 of Seq ID No 156; 36-47, 55-63, 94-108, 129-134, 144-158, 173-187, 196-206, 209-238, 251-266, 270-285, 290-295, 300-306, 333-344, 346-354, 366-397, 404-410, 422-435, 439-453, 466-473, 515-523, 529-543, 554-569, 571-585, 590-596, 607-618, 627-643, 690-696, 704-714, 720-728, 741-749, 752-767, 780-799, 225-247 and 480-507 of Seq ID No 157; 16-25, 36-70, 80-93, 100-106 and 78-130 of Seq ID No 158; 18-27, 41-46, 50-57, 65-71, 79-85, 93-98, 113-128, 144-155, 166-178, 181-188, 201-207, 242-262, 265-273, 281-295, 303-309, 318-327 and 36-64 of Seq ID No 159; 7-29, 31-44, 50-59, 91-96, 146-153, 194-201, 207-212, 232-238, 264-278, 284-290, 296-302, 326-353, 360-370, 378-384, 400-405, 409-418, 420-435, 442-460, 499-506, 529-534, 556-562, 564-576, 644-651, 677-684, 687-698, 736-743, 759-766, 778-784, 808-814, 852-858, 874-896, 920-925, 929-935, 957-965, 1003-1012, 1021-1027, 1030-1044, 1081-1087, 1101-1111, 1116-1124, 1148-1159, 1188-1196, 1235-1251, 1288-1303, 1313-1319, 1328-1335, 1367-1373, 1431-1437, 1451-1458, 1479-1503, 1514-1521, 1530-1540, 1545-1552, 1561-1568, 1598-1605, 1617-1647, 1658-1665, 1670-1676, 1679-1689, 1698-1704, 1707-1713, 1732-1738, 1744-1764, 1-70, 154-189, 922-941, 1445-1462 and 1483-1496 of Seq ID No 160; 6-51, 81-91, 104-113, 126-137, 150-159, 164-174, 197-209, 215-224, 229-235, 256-269, 276-282, 307-313, 317-348, 351-357, 376-397, 418-437, 454-464, 485-490, 498-509, 547-555, 574-586, 602-619 and 452-530 of Seq ID No 161; 25-31, 39-47, 49-56, 99-114, 121-127, 159-186, 228-240, 253-269, 271-279, 303-315, 365-382, 395-405, 414-425, 438-453 and 289-384 of Seq ID No 162; 9-24, 41-47, 49-54, 68-78, 108-114, 117-122, 132-140, 164-169, 179-186, 193-199, 206-213, 244-251, 267-274, 289-294, 309-314, 327-333, 209-249 and 286-336 of Seq ID No 163; 9-28, 53-67, 69-82, 87-93, 109-117, 172-177, 201-207, 220-227, 242-247, 262-268, 305-318, 320-325 and 286-306 of Seq ID No 164; 4-10, 26-39, 47-58, 63-73, 86-96, 98-108, 115-123, 137-143, 148-155, 160-176, 184-189, 194-204, 235-240, 254-259, 272-278 and 199-283 of Seq ID No 165; 4-26, 33-39, 47-53, 59-65, 76-83, 91-97, 104-112, 118-137, 155-160, 167-174, 198-207, 242-268, 273-279, 292-315, 320-332, 345-354, 358-367, 377-394, 403-410, 424-439, 445-451, 453-497, 511-518, 535-570, 573-589, 592-601, 604-610 and 202-242 of Seq ID No 166; 8-30, 36-45, 64-71, 76-82, 97-103, 105-112, 134-151, 161-183, 211-234, 253-268, 270-276, 278-284, 297-305, 309-315, 357-362, 366-372, 375-384, 401-407, 409-416, 441-455, 463-470, 475-480, 490-497, 501-513, 524-537, 552-559, 565-576, 581-590, 592-600, 619-625, 636-644, 646-656 and 316-419 of Seq ID No 167; 4-17, 52-58, 84-99, 102-110, 114-120, 124-135, 143-158, 160-173, 177-196, 201-216, 223-250, 259-267, 269-275 and 1-67 of Seq ID No 168; 6-46, 57-67, 69-80, 82-133, 137-143, 147-168, 182-187, 203-209, 214-229, 233-242, 246-280 and 53-93 of Seq ID No 169; 7-40, 50-56, 81-89, 117-123, 202-209, 213-218, 223-229, 248-261, 264-276, 281-288, 303-308, 313-324, 326-332, 340-346, 353-372, 434-443, 465-474, 514-523, 556-564, 605-616, 620-626, 631-636, 667-683, 685-699, 710-719, 726-732, 751-756, 760-771, 779-788, 815-828, 855-867, 869-879, 897-902, 917-924, 926-931, 936-942, 981-1000, 1006-1015, 1017-1028, 1030-1039, 1046-1054, 1060-1066, 1083-1092, 1099-1112, 1122-1130, 1132-1140, 1148-1158, 1161-1171, 1174-1181, 1209-1230, 1236-1244, 1248-1254, 1256-1267, 1269-1276, 1294-1299, 1316-1328, 1332-1354, 1359-1372, 1374-1380, 1384-1390, 1395-1408, 1419-1425, 1434-1446, 1453-1460, 1465-1471, 1474-

1493, 1505-1515, 1523-1537, 1547-1555, 1560-1567, 1577-1605, 1633-1651, 1226-1309, 1455-1536 and 1538-1605 of Seq ID No 170; 4-10, 31-39, 81-88, 106-112, 122-135, 152-158, 177-184, 191-197, 221-227, 230-246, 249-255, 303-311, 317-326, 337-344, 346-362, 365-371, 430-437, 439-446, 453-462, 474-484 and 449-467 of Seq ID No 171; 9-15, 24-35, 47-55, 122-128, 160-177, 188-196, 202-208, 216-228, 250-261, 272-303, 318-324, 327-339, 346-352, 355-361, 368-373, 108-218 and 344-376 of Seq ID No 172; 6-14, 17-48, 55-63, 71-90, 99-109, 116-124, 181-189, 212-223, 232-268, 270-294, 297-304, 319-325, 340-348, 351-370, 372-378, 388-394, 406-415, 421-434 and 177-277 of Seq ID No 173; 21-39, 42-61, 65-75, 79-85, 108-115 and 11-38 of Seq ID No 174; 4-17, 26-39, 61-76, 103-113, 115-122, 136-142, 158-192, 197-203, 208-214, 225-230, 237-251 and 207-225 of Seq ID No 175; 5-11, 27-36, 42-53, 62-70, 74-93, 95-104, 114-119, 127-150, 153-159, 173-179, 184-193, 199-206, 222-241, 248-253, 257-280, 289-295, 313-319, 322-342, 349-365, 368-389, 393-406, 408-413, 426-438, 447-461, 463-470, 476-495, 532-537, 543-550 and 225-246 of Seq ID No 176; 4-29, 68-82, 123-130, 141-147, 149-157, 178-191, 203-215, 269-277, 300-307, 327-335, 359-370, 374-380, 382-388, 393-400, 410-417, 434-442, 483-492, 497-503, 505-513, 533-540, 564-569, 601-607, 639-647, 655-666, 693-706, 712-718, 726-736, 752-758, 763-771, 774-780, 786-799, 806-812, 820-828, 852-863, 884-892, 901-909, 925-932, 943-948, 990-996, 1030-1036, 1051-1059, 1062-1068, 1079-1086, 1105-1113, 1152-1162, 1168-1179, 1183-1191, 1204-1210, 1234-1244, 1286-1295, 1318-1326, 1396-1401, 1451-1460, 1465-1474, 1477-1483, 1488-1494, 1505-1510, 1514-1521, 1552-1565, 1593-1614, 1664-1672, 1677-1685, 1701-1711, 1734-1745, 1758-1770, 1784-1798, 1840-1847, 1852-1873, 1885-1891, 1906-1911, 1931-1939, 1957-1970, 1977-1992, 2014-2020, 2026-2032, 2116-2134, 1-348, 373-490, 573-767, 903-1043, 1155-1198, 1243-1482, 1550-1595, 1682-1719, 1793-1921 and 2008-2110 of Seq ID No 177; 10-35, 39-52, 107-112, 181-188, 226-236, 238-253, 258-268, 275-284, 296-310, 326-338, 345-368, 380-389, 391-408, 410-418, 420-429, 444-456, 489-505, 573-588, 616-623, 637-643, 726-739, 741-767, 785-791, 793-803, 830-847, 867-881, 886-922, 949-956, 961-980, 988-1004, 1009-1018, 1027-1042, 1051-1069, 1076-1089, 1108-1115, 1123-1135, 1140-1151, 1164-1179, 1182-1191, 1210-1221, 1223-1234, 1242-1250, 1255-1267, 1281-1292, 1301-1307, 1315-1340, 1348-1355, 1366-1373, 1381-1413, 1417-1428, 1437-1444, 1453-1463, 1478-1484, 1490-1496, 1498-1503, 1520-1536, 1538-1546, 1548-1570, 1593-1603, 1612-1625, 1635-1649, 1654-1660, 1670-1687, 1693-1700, 1705-1711, 1718-1726, 1729-1763, 1790-1813, 1871-1881, 1893-1900, 1907-1935, 1962-1970, 1992-2000, 2006-2013, 2033-2039, 2045-2051, 2055-2067, 2070-2095, 2097-2110, 2115-2121, 2150-2171, 2174-2180, 2197-2202, 2206-2228 and 1526-1560 of Seq ID No 178; 4-17, 35-48, 54-76, 78-107, 109-115, 118-127, 134-140, 145-156, 169-174, 217-226, 232-240, 256-262, 267-273, 316-328, 340-346, 353-360, 402-409, 416-439, 448-456, 506-531, 540-546, 570-578, 586-593, 595-600, 623-632, 662-667, 674-681, 689-705, 713-724, 730-740, 757-763, 773-778, 783-796, 829-835, 861-871, 888-899, 907-939, 941-955, 957-969, 986-1000, 1022-1028, 1036-1044, 1068-1084, 1095-1102, 1118-1124, 1140-1146, 1148-1154, 1168-1181, 1185-1190, 1197-1207, 1218-1226, 1250-1270, 1272-1281, 1284-1296, 1312-1319, 1351-1358, 1383-1409, 1422-1428, 1438-1447, 1449-1461, 1482-1489, 1504-1510, 1518-1527, 1529-1537, 1544-1551, 1569-1575, 1622-1628, 1631-1637, 1682-1689, 1711-1718, 1733-1740, 1772-1783, 1818-1834, 1859-1872, 1-64 and 128-495 of Seq ID No 179; 8-28, 32-37, 62-69, 119-125, 137-149, 159-164, 173-189, 200-205, 221-229, 240-245, 258-265, 268-276, 287-293, 296-302, 323-329 and 1-95 of Seq ID No 180; 9-18, 25-38, 49-63, 65-72, 74-81, 94-117, 131-137, 139-146, 149-158, 162-188, 191-207, 217-225, 237-252, 255-269, 281-293, 301-326, 332-342, 347-354, 363-370, 373-380, 391-400, 415-424, 441-447 and 75-107 of Seq ID No 181; 4-24, 64-71, 81-87, 96-116, 121-128, 130-139, 148-155, 166-173, 176-184, 203-215, 231-238, 243-248, 256-261, 280-286, 288-306, 314-329 and 67-148 of Seq ID No 182; 4-10, 19-37, 46-52, 62-81, 83-89, 115-120, 134-139, 141-151, 168-186, 197-205, 209-234, 241-252, 322-335, 339-345, 363-379, 385-393, 403-431, 434-442, 447-454, 459-465, 479-484, 487-496 and 404-420 of Seq ID No 183; 10-35, 46-66, 71-77, 84-93, 96-122, 138-148, 154-172, 182-213, 221-233, 245-263, 269-275, 295-301, 303-309, 311-320, 324-336, 340-348, 351-359, 375-381 and 111-198 of Seq ID No 184; 14-25, 30-42, 47-61, 67-75, 81-91, 98-106, 114-122, 124-135, 148-193, 209-227 and 198-213 of Seq ID No 185; 5-18, 45-50, 82-90, 97-114, 116-136, 153-161, 163-171, 212-219, 221-227, 240-249, 267-281, 311-317, 328-337, 375-381, 390-395, 430-436, 449-455, 484-495, 538-543, 548-554, 556-564, 580-586, 596-602 and 493-606 of Seq ID No 186; 9-25, 28-34, 37-44, 61-68, 75-81, 88-96, 98-111, 119-133, 138-150, 152-163, 168-182, 186-194, 200-205, 216-223, 236-245, 257-264, 279-287, 293-304, 311-318, 325-330, 340-346, 353-358, 365-379, 399-409, 444-453 and 303-391 of Seq ID No 187; 16-36, 55-61, 66-76, 78-102, 121-130, 134-146, 150-212, 221-239, 255-276, 289-322, 329-357 and 29-59 of Seq ID No 188; 8-27, 68-74, 77-99, 110-116, 124-141, 171-177, 202-217, 221-228, 259-265, 275-290, 293-303, 309-325, 335-343, 345-351, 365-379, 384-394, 406-414, 423-437, 452-465, 478-507, 525-534, 554-560, 611-624, 628-651, 669-682, 742-747, 767-778, 782-

792, 804-812, 820-836, 79-231 and 359-451 of Seq ID No 189; 5-28, 39-45, 56-62, 67-74, 77-99, 110-117, 124-141, 168-176, 200-230, 237-244, 268-279, 287-299, 304-326, 329-335, 348-362, 370-376, 379-384, 390-406, 420-429, 466-471, 479-489, 495-504, 529-541, 545-553, 561-577, 598-604, 622-630, 637-658, 672-680, 682-688, 690-696, 698-709, 712-719, 724-736, 738-746, 759-769, 780-786, 796-804, 813-818, 860-877, 895-904, 981-997, 1000-1014, 1021-1029, 1-162, 206-224, 254-350, 414-514 and 864-938 of Seq ID No 190; 4-11, 19-49, 56-66, 68-101, 109-116, 123-145, 156-165, 177-185, 204-221, 226-234, 242-248, 251-256, 259-265, 282-302, 307-330, 340-349, 355-374, 377-383, 392-400, 422-428, 434-442, 462-474 and 266-322 of Seq ID No 191; 14-43, 45-57, 64-74, 80-87, 106-127, 131-142, 145-161, 173-180, 182-188, 203-210, 213-219, 221-243, 245-254, 304-311, 314-320, 342-348, 354-365, 372-378, 394-399, 407-431, 436-448, 459-465, 470-477, 484-490, 504-509, 531-537, 590-596, 611-617, 642-647, 723-734, 740-751, 754-762, 764-774, 782-797, 807-812, 824-831, 838-845, 877-885, 892-898, 900-906, 924-935, 940-946, 982-996, 1006-1016, 1033-1043, 1051-1056, 1058-1066, 1094-1108, 1119-1126, 1129-1140, 1150-1157, 1167-1174, 1176-1185, 1188-1201, 1209-1216, 1220-1228, 1231-1237, 1243-1248, 1253-1285, 1288-1297, 1299-1307, 1316-1334, 1336-1343, 1350-1359, 1365-1381, 1390-1396, 1412-1420, 1427-1439, 1452-1459, 1477-1484, 1493-1512, 1554-1559, 1570-1578, 1603-1608, 1623-1630, 1654-1659, 1672-1680, 1689-1696, 1705-1711, 1721-1738, 1752-1757, 1773-1780, 1817-1829, 1844-1851, 1856-1863, 1883-1895, 1950-1958, 1974-1990, 172-354, 384-448, 464-644, 648-728 and 1357-1370 of Seq ID No 192; 8-27, 58-74, 77-99, 110-116, 124-141, 169-176, 201-216, 220-227, 258-264, 274-289, 292-302, 308-324, 334-342, 344-350, 364-372, 377-387, 399-407, 416-429, 445-458, 471-481, 483-500, 518-527, 547-553, 604-617, 621-644, 662-675, 767-778, 809-816, 15-307, 350-448 and 496-620 of Seq ID No 193; 4-17, 24-29, 53-59, 62-84, 109-126, 159-164, 189-204, 208-219, 244-249, 274-290, 292-302, 308-324, 334-342, 344-350, 378-389, 391-397, 401-409, 424-432, 447-460, 470-479, 490-504, 521-529, 538-544, 549-555, 570-577, 583-592, 602-608, 615-630, 635-647, 664-677, 692-698, 722-731, 733-751, 782-790, 793-799, 56-267, 337-426 and 495-601 of Seq ID No 194; 12-22, 49-59, 77-89, 111-121, 136-148, 177-186, 207-213, 217-225, 227-253, 259-274, 296-302, 328-333, 343-354, 374-383, 424-446, 448-457, 468-480, 488-502, 507-522, 544-550, 553-560, 564-572, 587-596, 604-614, 619-625, 629-635, 638-656, 662-676, 680-692, 697-713, 720-738, 779-786, 833-847, 861-869, 880-895, 897-902, 911-917, 946-951, 959-967, 984-990, 992-1004, 1021-1040, 1057-1067, 1073-1080 and 381-403 of Seq ID No 195; 4-10, 26-31, 46-56, 60-66, 70-79, 86-94, 96-102, 109-118, 132-152, 164-187, 193-206, 217-224 and 81-149 of Seq ID No 196; 4-21, 26-37, 48-60, 71-82, 109-117, 120-128, 130-136, 142-147, 181-187, 203-211, 216-223, 247-255, 257-284, 316-325, 373-379, 395-400, 423-435, 448-456, 479-489, 512-576, 596-625, 641-678, 680-688, 692-715 and 346-453 of Seq ID No 197; 10-16, 25-31, 34-56, 58-69, 71-89, 94-110, 133-176, 186-193, 208-225, 240-250, 259-266, 302-307, 335-341, 376-383, 410-416 and 316-407 of Seq ID No 198; 11-29, 42-56, 60-75, 82-88, 95-110, 116-126, 132-143, 145-160, 166-172, 184-216 and 123-164 of Seq ID No 199; 11-29, 54-63, 110-117, 139-152, 158-166, 172-180, 186-193, 215-236, 240-251, 302-323, 330-335, 340-347, 350-366, 374-381 and 252-299 of Seq ID No 200; 18-27, 35-42, 50-56, 67-74, 112-136, 141-153, 163-171, 176-189, 205-213, 225-234, 241-247, 253-258, 269-281, 288-298, 306-324, 326-334, 355-369, 380-387 and 289-320 of Seq ID No 201; 7-15, 19-41, 56-72, 91-112, 114-122, 139-147, 163-183, 196-209, 258-280, 326-338, 357-363, 391-403, 406-416 and 360-378 of Seq ID No 202; 11-18, 29-41, 43-49, 95-108, 142-194, 204-212, 216-242, 247-256, 264-273 and 136-149 of Seq ID No 203; 18-24, 33-40, 65-79, 89-102, 113-119, 130-137, 155-161, 173-179, 183-203, 205-219, 223-231, 245-261, 267-274, 296-306, 311-321, 330-341, 344-363, 369-381, 401-408, 415-427, 437-444, 453-464, 472-478, 484-508, 517-524, 526-532, 543-548 and 59-180 of Seq ID No 204; 5-13, 52-65, 67-73, 97-110, 112-119, 134-155 and 45-177 of Seq ID No 205; 6-28, 34-43, 57-67, 75-81, 111-128, 132-147, 155-163, 165-176, 184-194, 208-216, 218-229, 239-252, 271-278, 328-334, 363-376, 381-388, 426-473, 481-488, 492-498, 507-513, 536-546, 564-582, 590-601, 607-623, 148-269, 420-450 and 610-648 of Seq ID No 206; 4-12, 20-38, 69-75, 83-88, 123-128, 145-152, 154-161, 183-188, 200-213, 245-250, 266-272, 306-312, 332-339, 357-369, 383-389, 395-402, 437-453, 455-470, 497-503 and 1-112 of Seq ID No 207; 35-59, 74-86, 111-117, 122-137 and 70-154 of Seq ID No 208; 26-42, 54-61, 65-75, 101-107, 123-130, 137-144, 148-156, 164-172, 177-192, 213-221, 231-258 and 157-249 of Seq ID No 209; 29-38, 61-67, 77-87, 94-100, 105-111, 118-158 and 1-97 of Seq ID No 210; 7-21, 30-48, 51-58, 60-85, 94-123, 134-156, 160-167, 169-183, 186-191, 216-229, 237-251, 257-267, 272-282, 287-298 and 220-243 of Seq ID No 211; 6-29, 34-47, 56-65, 69-76, 83-90, 123-134, 143-151, 158-178, 197-203, 217-235, 243-263, 303-309, 320-333, 338-348, 367-373, 387-393, 407-414, 416-427, 441-457, 473-482, 487-499, 501-509, 514-520, 530-535, 577-583, 590-602, 605-612, 622-629, 641-670, 678-690, 37-71 and 238-307 of Seq ID No 212; 7-40, 121-132, 148-161, 196-202, 209-215, 221-235, 248-255, 271-280, 288-295, 330-339, 395-409, 414-420, 446-451, 475-487, 556-563, 568-575, 580-586, 588-595,

633-638, 643-648, 652-659, 672-685, 695-700, 710-716, 737-742, 749-754, 761-767, 775-781, 796-806, 823-835, 850-863, 884-890, 892-900, 902-915, 934-941 and 406-521 of Seq ID No 213; 9-18, 24-46, 51-58, 67-77, 85-108, 114-126, 129-137, 139-146, 152-165, 173-182, 188-195, 197-204, 217-250, 260-274, 296-313, 343-366, 368-384, 427-434, 437-446, 449-455, 478-484, 492-506, 522-527, 562-591, 599-606, 609-618, 625-631, 645-652 and 577-654 of Seq ID No 214; 13-20, 26-37, 41-53, 56-65, 81-100, 102-114, 118-127, 163-188, 196-202, 231-238, 245-252, 266-285, 293-298, 301-306 and 19-78 of Seq ID No 215; 10-23, 32-42, 54-66, 73-91, 106-113, 118-127, 139-152, 164-173, 198-207, 210-245, 284-300, 313-318, 330-337, 339-346, 354-361, 387-393, 404-426, 429-439, 441-453, 467-473, 479-485, 496-509, 536-544, 551-558, 560-566, 569-574, 578-588, 610-615, 627-635, 649-675, 679-690, 698-716, 722-734, 743-754, 769-780, 782-787 and 480-550 of Seq ID No 216; 6-39, 42-50, 60-68, 76-83, 114-129, 147-162, 170-189, 197-205, 217-231, 239-248, 299-305, 338-344, 352-357, 371-377, 380-451, 459-483, 491-499, 507-523, 537-559, 587-613, 625-681, 689-729, 737-781, 785-809, 817-865, 873-881, 889-939, 951-975, 983-1027, 1031-1055, 1063-1071, 1079-1099, 1103-1127, 1151-1185, 1197-1261, 1269-1309, 1317-1333, 1341-1349, 1357-1465, 1469-1513, 1517-1553, 1557-1629, 1637-1669, 1677-1701, 1709-1725, 1733-1795, 1823-1849, 1861-1925, 1933-1973, 1981-2025, 2029-2053, 2061-2109, 2117-2125, 2133-2183, 2195-2219, 2227-2271, 2275-2299, 2307-2315, 2323-2343, 2347-2371, 2395-2429, 2441-2529, 2537-2569, 2577-2601, 2609-2625, 2633-2695, 2699-2737, 2765-2791, 2803-2867, 2889-2913, 2921-2937, 2945-2969, 2977-2985, 2993-3009, 3023-3045, 3073-3099, 3111-3167, 3175-3215, 3223-3267, 3271-3295, 3303-3351, 3359-3367, 3375-3425, 3437-3461, 3469-3513, 3517-3541, 3549-3557, 3565-3585, 3589-3613, 3637-3671, 3683-3747, 3755-3795, 3803-3819, 3827-3835, 3843-3951, 3955-3999, 4003-4039, 4043-4115, 4123-4143, 4147-4171, 4195-4229, 4241-4305, 4313-4353, 4361-4377, 4385-4393, 4401-4509, 4513-4557, 4561-4597, 4601-4718, 4749-4768, 74-171, 452-559 and 2951-3061 of Seq ID No 217; 16-22, 30-51, 70-111, 117-130, 137-150, 171-178, 180-188, 191-196 and 148-181 of Seq ID No 218; 6-19, 21-46, 50-56, 80-86, 118-126, 167-186, 189-205, 211-242, 244-267, 273-286, 290-297, 307-316, 320-341 and 34-60 of Seq ID No 219; 5-26, 33-43, 48-54, 58-63, 78-83, 113-120, 122-128, 143-152, 157-175, 185-192, 211-225, 227-234, 244-256, 270-281, 284-290, 304-310, 330-337, 348-355, 362-379, 384-394, 429-445, 450-474, 483-490, 511-520, 537-546, 548-554, 561-586, 590-604, 613-629, 149-186, 285-431 and 573-659 of Seq ID No 220; 5-26, 49-59, 61-67, 83-91, 102-111, 145-157, 185-192, 267-272, 279-286, 292-298, 306-312, 134-220, 235-251 and 254-280 of Seq ID No 221; 5-19, 72-79, 83-92, 119-124, 140-145, 160-165, 167-182, 224-232, 240-252, 259-270, 301-310, 313-322, 332-343, 347-367, 384-398, 416-429, 431-446, 454-461 and 1-169 of Seq ID No 222; 8-17, 26-31, 56-62, 75-83, 93-103, 125-131, 135-141, 150-194, 205-217, 233-258, 262-268, 281-286 and 127-168 of Seq ID No 223; 6-12, 69-75, 108-115, 139-159, 176-182, 194-214 and 46-161 of Seq ID No 224; 6-13, 18-27, 39-48, 51-59, 66-73, 79-85, 95-101, 109-116, 118-124, 144-164, 166-177, 183-193, 197-204, 215-223, 227-236, 242-249, 252-259, 261-270, 289-301, 318-325 and 12-58 of Seq ID No 225; 4-10, 26-32, 48-60, 97-105, 117-132, 138-163, 169-185, 192-214, 219-231, 249-261, 264-270, 292-308, 343-356, 385-392, 398-404, 408-417, 435-441 and 24-50 of Seq ID No 226; 10-40, 42-48, 51-61, 119-126 and 1-118 of Seq ID No 227; 5-17, 40-58, 71-83, 103-111, 123-140, 167-177, 188-204 and 116-128 of Seq ID No 228; 4-9, 11-50, 57-70, 112-123, 127-138 and 64-107 of Seq ID No 229; 9-39, 51-67 and 1-101 of Seq ID No 230; 5-14, 17-25, 28-46, 52-59, 85-93, 99-104, 111-120, 122-131, 140-148, 158-179, 187-197, 204-225, 271-283, 285-293 and 139-155 of Seq ID No 231; 42-70, 73-90, 92-108, 112-127, 152-164, 166-172, 181-199, 201-210, 219-228, 247-274, 295-302, 322-334, 336-346, 353-358, 396-414, 419-425, 432-438, 462-471, 518-523, 531-536, 561-567, 576-589, 594-612, 620-631, 665-671, 697-710, 718-731, 736-756, 765-771, 784-801 and 626-653 of Seq ID No 232; 8-28, 41-51, 53-62, 68-74, 79-85, 94-100, 102-108, 114-120, 130-154, 156-162, 175-180, 198-204, 206-213, 281-294, 308-318, 321-339, 362-368, 381-386, 393-399, 407-415 and 2-13 of Seq ID No 233; 4-39, 48-65, 93-98, 106-112, 116-129 and 10-36 of Seq ID No 234; 25-32, 35-50, 66-71, 75-86, 90-96, 123-136, 141-151, 160-179, 190-196, 209-215, 222-228, 235-242, 257-263, 270-280 and 209-247 of Seq ID No 235; 5-29, 31-38, 50-57, 62-75, 83-110, 115-132, 168-195, 197-206, 216-242, 249-258, 262-269, 333-340, 342-350, 363-368, 376-392, 400-406, 410-421, 423-430, 436-442, 448-454, 460-466, 471-476, 491-496, 511-516, 531-536, 551-556, 571-576, 585-591, 599-605, 27-70, 219-293, 441-504 and 512-584 of Seq ID No 236; 4-12, 14-34, 47-75, 83-104, 107-115, 133-140, 148-185, 187-196, 207-212, 224-256, 258-265, 281-287, 289-296, 298-308, 325-333, 345-355, 365-371, 382-395, 424-435, 441-457, 465-472, 483-491, 493-505, 528-534, 536-546, 552-558, 575-584, 589-600, 616-623 and 576-591 of Seq ID No 237; 4-76, 78-89, 91-126, 142-148, 151-191, 195-208, 211-223, 226-240, 256-277, 279-285, 290-314, 317-323, 358-377, 381-387, 391-396, 398-411, 415-434, 436-446, 454-484, 494-512, 516-523, 538-552, 559-566, 571-577, 579-596, 599-615, 620-627, 635-644, 694-707, 720-734, 737-759, 761-771 and 313-329 of Seq ID No

238; 7-38, 44-49, 79-89, 99-108, 117-123, 125-132, 137-146, 178-187, 207-237, 245-255, 322-337, 365-387, 398-408, 445-462, 603-608, 623-628, 644-650, 657-671, 673-679 and 111-566 of Seq ID No 239; 6-20, 22-35, 39-45, 58-64, 77-117, 137-144, 158-163, 205-210, 218-224, 229-236, 239-251, 263-277, 299-307, 323-334, 353-384, 388-396, 399-438, 443-448, 458-463, 467-478, 481-495, 503-509, 511-526, 559-576, 595-600, 612-645, 711-721, 723-738, 744-758, 778-807 and 686-720 of Seq ID No 240; 10-33, 35-41, 72-84, 129-138, 158-163, 203-226, 243-252, 258-264, 279-302, 322-329, 381-386, 401-406, 414-435 and 184-385 of Seq ID No 241; 4-9, 19-24, 41-47, 75-85, 105-110, 113-146 and 45-62 of Seq ID No 242; 4-25, 52-67, 117-124, 131-146, 173-180, 182-191, 195-206, 215-221, 229-236, 245-252, 258-279, 286-291, 293-302, 314-320, 327-336, 341-353, 355-361, 383-389 and 1-285 of Seq ID No 243; 14-32, 38-50, 73-84, 93-105, 109-114 and 40-70 of Seq ID No 244; 5-26 and 22-34 of Seq ID No 245; 23-28 and 13-39 of Seq ID No 246; 8-14 and 21-34 of Seq ID No 247; 4-13, 20-29, 44-50, 59-74 and 41-69 of Seq ID No 248; 4-9, 19-42, 48-59, 71-83 and 57-91 of Seq ID No 249; 4-14 and 10-28 of Seq ID No 250; 22-28, 32-42, 63-71, 81-111, 149-156, 158-167, 172-180, 182-203, 219-229 and 27-49 of Seq ID No 251; 17-27 and 23-32 of Seq ID No 252; 18-24 and 28-38 of Seq ID No 253; 9-15 and 13-27 of Seq ID No 254; 13-22 and 18-29 of Seq ID No 255; 17-26 and 2-11 of Seq ID No 256; 4-33 and 16-32 of Seq ID No 257; 4-10, 37-43, 54-84, 92-127 and 15-62 of Seq ID No 258; 4-14, 20-32, 35-60, 69-75, 79-99, 101-109, 116-140 and 124-136 of Seq ID No 259; 2-13 of Seq ID No 260; 4-13, 28-42 and 42-57 of Seq ID No 261; 4-14, 27-44 and 14-35 of Seq ID No 262; 4-12 and 1-27 of Seq ID No 263; 4-18, 39-45, 47-74 and 35-66 of Seq ID No 264; 8-20, 43-77 and 17-36 of Seq ID No 265; 4-30, 35-45, 51-57 and 35-49 of Seq ID No 266; 4-24, 49-57 and 15-34 of Seq ID No 267; 4-22 and 8-27 of Seq ID No 268; 13-25, 32-59, 66-80 and 21-55 of Seq ID No 269; 4-10, 24-33, 35-42, 54-65, 72-82, 98-108 and 15-30 of Seq ID No 270; 8-19 and 17-47 of Seq ID No 271; 12-18, 40-46 and 31-52 of Seq ID No 272; 4-20, 35-78, 83-102, 109-122 and 74-86 of Seq ID No 273; 7-17, 21-41, 46-63 and 2-20 of Seq ID No 274; 30-37 and 2-33 of Seq ID No 275; 4-13, 17-25 and 1-15 of Seq ID No 276; 17-31, 44-51 and 20-51 of Seq ID No 277; 20-30 and 5-23 of Seq ID No 278; 13-33, 48-71 and 92-110 of Seq ID No 279; 4-9, 50-69, 76-88, 96-106, 113-118 and 12-34 of Seq ID No 280; 4-24 and 6-26 of Seq ID No 281; 7-26 and 14-30 of Seq ID No 282; 9-39, 46-68, 75-82, 84-103 and 26-44 of Seq ID No 283; 4-30, 33-107 and 58-84 of Seq ID No 284; 4-12 and 9-51 of Seq ID No 285; 12-18, 29-37 and 6-37 of Seq ID No 286; 4-21, 33-52, 64-71 and 16-37 of Seq ID No 287; 9-19 and 2-30 of Seq ID No 288; 20-37 of Seq ID No 245; 8-27 of Seq ID No 246; 10-27 of Seq ID No 247; 42-59 and 52-69 of Seq ID No 248; 63-80 and 74-91 of Seq ID No 249; 11-28 of Seq ID No 250; 28-49 of Seq ID No 251; 15-32 of Seq ID No 252; 4-20 of Seq ID No 253; 10-27 of Seq ID No 254; 17-34 of Seq ID No 255; 1-18 of Seq ID No 256; 16-33 of Seq ID No 257; 16-36, 30-49 and 43-62 of Seq ID No 258; 122-139 of Seq ID No 259; 1-18 of Seq ID No 260; 41-58 of Seq ID No 261; 15-35 of Seq ID No 262; 2-27 of Seq ID No 263; 18-36 of Seq ID No 265; 34-51 of Seq ID No 266; 9-27 of Seq ID No 268; 22-47 of Seq ID No 269; 18-36 and 29-47 of Seq ID No 271; 32-52 of Seq ID No 272; 72-89 of Seq ID No 273; 3-20 of Seq ID No 274; 3-21 and 15-33 of Seq ID No 275; 1-18 of Seq ID No 276; 6-23 of Seq ID No 278; 93-110 of Seq ID No 279; 13-34 of Seq ID No 280; 7-26 and 9-26 of Seq ID No 281; 16-33 of Seq ID No 282; 27-44 of Seq ID No 283; 67-84 of Seq ID No 284; 10-33 and 26-50 of Seq ID No 285; 7-25 and 19-37 of Seq ID No 286; 17-37 of Seq ID No 287; 3-20 and 13-30 of Seq ID No 288; 62-80 and 75-93 of Seq ID No 145; 92-108 of Seq ID No 147; 332-349, 177-200 and 1755-1777 of Seq ID No 148; 109-133, 149-174, 260-285 and 460-485 of Seq ID No 149; 26-47 and 42-64 of Seq ID No 150; 22-41, 35-54, 115-130, 306-325, 401-420 and 454-478 of Seq ID No 151; 22-45 of Seq ID No 155; 156-174, 924-940, 1485-1496, 1447-1462 and 1483-1498 of Seq ID No 160; 457-475 of Seq ID No 161; 302-325 of Seq ID No 163; 288-305 of Seq ID No 164; 244-266 and 260-282 of Seq ID No 165; 204-225 and 220-241 of Seq ID No 166; 324-345, 340-361, 356-377, 372-393 and 388-408 of Seq ID No 167; 39-64 of Seq ID No 168; 54-76 and 70-92 of Seq ID No 169; 1227-1247, 1539-1559, 1554-1574, 1569-1589, 1584-1604, 1242-1262, 1272-1292, 1287-1308, 1456-1477, 1472-1494, 1488-1510 and 1505-1526 of Seq ID No 170; 351-368 of Seq ID No 172; 179-200, 195-216, 211-232, 227-248 and 243-263 of Seq ID No 173; 13-37 of Seq ID No 174; 208-224 of Seq ID No 175; 42-64, 59-81, 304-328, 323-348, 465-489, 968-992, 1399-1418, 1412-1431 and 2092-2111 of Seq ID No 177; 1528-1547 and 1541-1560 of Seq ID No 178; 184-200, 367-388, 382-403, 409-429, 425-444 and 438-457 of Seq ID No 179; 27-50 and 45-67 of Seq ID No 180; 114-131 and 405-419 of Seq ID No 183; 113-134, 129-150, 145-166, 161-182 and 177-198 of Seq ID No 184; 495-515 of Seq ID No 186; 346-358 of Seq ID No 187; 208-224 of Seq ID No 190; 178-194, 202-223, 217-238, 288-308 and 1355-1372 of Seq ID No 192; 57-78 of Seq ID No 194; 347-369, 364-386, 381-403, 398-420, 415-437 and 432-452 of Seq ID No 197; 347-372 of Seq ID No 198;

- 12 -

147-163 of Seq ID No 199; 263-288 of Seq ID No 200; 361-377 of Seq ID No 202; 82-104, 99-121, 116-138, 133-155 and 150-171 of Seq ID No 204; 110-130 and 125-145 of Seq ID No 205; 613-631, 626-644 and 196-213 of Seq ID No 206; 78-100, 95-117, 112-134 and 129-151 of Seq ID No 208; 158-180, 175-197, 192-214, 209-231 and 226-248 of Seq ID No 209; 30-50, 45-65 and 60-79 of Seq ID No 210; 431-455 and 450-474 of Seq ID No 213; 579-601, 596-618, 613-635 and 630-653 of Seq ID No 214; 920-927, 98-119, 114-135, 130-151, 146-167 and 162-182 of Seq ID No 217; 36-59 of Seq ID No 219; 194-216 and 381-404 of Seq ID No 220; 236-251 and 255-279 of Seq ID No 221; 80-100 and 141-164 of Seq ID No 222; 128-154 of Seq ID No 223; 82-100, 95-116 and 111-134 of Seq ID No 224; 55-76, 71-92 and 87-110 of Seq ID No 227; 91-106 of Seq ID No 229; 74-96 of Seq ID No 230; 140-157 of Seq ID No 231; 4-13 of Seq ID No 233; 41-65 and 499-523 of Seq ID No 236; 122-146, 191-215, 288-313, 445-469 and 511-535 of Seq ID No 239; 347-368 of Seq ID No 241; 46-61 of Seq ID No 242; 15-37, 32-57, 101-121, 115-135, 138-158, 152-172, 220-242 and 236-258 of Seq ID No 243.

The present invention also provides a process for producing a *S. pneumoniae* hyperimmune serum reactive antigen or a fragment thereof according to the present invention comprising expressing one or more of the nucleic acid molecules according to the present invention in a suitable expression system.

Moreover, the present invention provides a process for producing a cell, which expresses a *S. pneumoniae* hyperimmune serum reactive antigen or a fragment thereof according to the present invention comprising transforming or transfecting a suitable host cell with the vector according to the present invention.

According to the present invention a pharmaceutical composition, especially a vaccine, comprising a hyperimmune serum-reactive antigen or a fragment thereof as defined in the present invention or a nucleic acid molecule as defined in the present invention is provided.

In a preferred embodiment the pharmaceutical composition further comprises an immunostimulatory substance, preferably selected from the group comprising polycationic polymers, especially polycationic peptides, immunostimulatory deoxynucleotides (ODNs), peptides containing at least two LysLeuLys motifs, especially KLKLLLLK, neuroactive compounds, especially human growth hormone, alum, Freund's complete or incomplete adjuvants or combinations thereof.

In a more preferred embodiment the immunostimulatory substance is a combination of either a polycationic polymer and immunostimulatory deoxynucleotides or of a peptide containing at least two LysLeuLys motifs and immunostimulatory deoxynucleotides.

In a still more preferred embodiment the polycationic polymer is a polycationic peptide, especially polyarginine.

According to the present invention the use of a nucleic acid molecule according to the present invention or a hyperimmune serum-reactive antigen or fragment thereof according to the present invention for the manufacture of a pharmaceutical preparation, especially for the manufacture of a vaccine against *S. pneumoniae* infection, is provided.

Also an antibody, or at least an effective part thereof, which binds at least to a selective part of the hyperimmune serum-reactive antigen or a fragment thereof according to the present invention, is provided herewith.

In a preferred embodiment the antibody is a monoclonal antibody.

In another preferred embodiment the effective part of the antibody comprises Fab fragments.

In a further preferred embodiment the antibody is a chimeric antibody.

In a still preferred embodiment the antibody is a humanized antibody.

The present invention also provides a hybridoma cell line, which produces an antibody according to the present invention.

Moreover, the present invention provides a method for producing an antibody according to the present invention, characterized by the following steps:

- initiating an immune response in a non-human animal by administering an hyperimmune serum-reactive antigen or a fragment thereof, as defined in the invention, to said animal,
- removing an antibody containing body fluid from said animal, and
- producing the antibody by subjecting said antibody containing body fluid to further purification steps.

Accordingly, the present invention also provides a method for producing an antibody according to the present invention, characterized by the following steps:

- initiating an immune response in a non-human animal by administering an hyperimmune serum-reactive antigen or a fragment thereof, as defined in the present invention, to said animal,
- removing the spleen or spleen cells from said animal,
- producing hybridoma cells of said spleen or spleen cells,
- selecting and cloning hybridoma cells specific for said hyperimmune serum-reactive antigens or a fragment thereof,
- producing the antibody by cultivation of said cloned hybridoma cells and optionally further purification steps.

The antibodies provided or produced according to the above methods may be used for the preparation of a medicament for treating or preventing *S. pneumoniae* infections.

According to another aspect the present invention provides an antagonist, which binds to a hyperimmune serum-reactive antigen or a fragment thereof according to the present invention.

Such an antagonist capable of binding to a hyperimmune serum-reactive antigen or fragment thereof according to the present invention may be identified by a method comprising the following steps:

- a) contacting an isolated or immobilized hyperimmune serum-reactive antigen or a fragment thereof according to the present invention with a candidate antagonist under conditions to permit binding of said candidate antagonist to said hyperimmune serum-reactive antigen or fragment, in the presence of a component capable of providing a detectable signal in response to the binding of the candidate antagonist to said hyperimmune serum reactive antigen or fragment thereof; and
- b) detecting the presence or absence of a signal generated in response to the binding of the antagonist to the hyperimmune serum reactive antigen or the fragment thereof.

An antagonist capable of reducing or inhibiting the interaction activity of a hyperimmune serum-reactive antigen or a fragment thereof according to the present invention to its interaction partner may be identified by a method comprising the following steps:

- a) providing a hyperimmune serum reactive antigen or a hyperimmune fragment thereof according to the present invention,
- b) providing an interaction partner to said hyperimmune serum reactive antigen or a fragment thereof, especially an antibody according to the present invention,
- c) allowing interaction of said hyperimmune serum reactive antigen or fragment thereof to said interaction partner to form an interaction complex,

- d) providing a candidate antagonist,
- e) allowing a competition reaction to occur between the candidate antagonist and the interaction complex ,
- f) determining whether the candidate antagonist inhibits or reduces the interaction activities of the hyperimmune serum reactive antigen or the fragment thereof with the interaction partner.

The hyperimmune serum reactive antigens or fragments thereof according to the present invention may be used for the isolation and/or purification and/or identification of an interaction partner of said hyperimmune serum reactive antigen or fragment thereof.

The present invention also provides a process for *in vitro* diagnosing a disease related to expression of a hyperimmune serum-reactive antigen or a fragment thereof according to the present invention comprising determining the presence of a nucleic acid sequence encoding said hyperimmune serum reactive antigen or fragment thereof according to the present invention or the presence of the hyperimmune serum reactive antigen or fragment thereof according to the present invention.

The present invention also provides a process for *in vitro* diagnosis of a bacterial infection, especially a *S. pneumoniae* infection, comprising analyzing for the presence of a nucleic acid sequence encoding said hyperimmune serum reactive antigen or fragment thereof according to the present invention or the presence of the hyperimmune serum reactive antigen or fragment thereof according to the present invention.

Moreover, the present invention provides the use of a hyperimmune serum reactive antigen or fragment thereof according to the present invention for the generation of a peptide binding to said hyperimmune serum reactive antigen or fragment thereof, wherein the peptide is an anticaline.

The present invention also provides the use of a hyperimmune serum-reactive antigen or fragment thereof according to the present invention for the manufacture of a functional nucleic acid, wherein the functional nucleic acid is selected from the group comprising aptamers and spiegelmers.

The nucleic acid molecule according to the present invention may also be used for the manufacture of a functional ribonucleic acid, wherein the functional ribonucleic acid is selected from the group comprising ribozymes, antisense nucleic acids and siRNA.

The present invention advantageously provides an efficient, relevant and comprehensive set of isolated nucleic acid molecules and their encoded hyperimmune serum reactive antigens or fragments thereof identified from *S. pneumoniae* using an antibody preparation from multiple human plasma pools and surface expression libraries derived from the genome of *S. pneumoniae*. Thus, the present invention fulfils a widely felt demand for *S. pneumoniae* antigens, vaccines, diagnostics and products useful in procedures for preparing antibodies and for identifying compounds effective against *S. pneumoniae* infection.

An effective vaccine should be composed of proteins or polypeptides, which are expressed by all strains and are able to induce high affinity, abundant antibodies against cell surface components of *S. pneumoniae*. The antibodies should be IgG1 and/or IgG3 for opsonization, and any IgG subtype and IgA for neutralisation of adherence and toxin action. A chemically defined vaccine must be definitely superior compared to a whole cell vaccine (attenuated or killed), since components of *S. pneumoniae*, which cross-react with human tissues or inhibit opsonization can be eliminated, and the individual proteins inducing protective antibodies and/or a protective immune response can be selected.

The approach, which has been employed for the present invention, is based on the interaction of pneumococcal proteins or peptides with the antibodies present in human sera. The antibodies produced against *S. pneumoniae* by the human immune system and present in human sera are indicative of the *in*

in vivo expression of the antigenic proteins and their immunogenicity. In addition, the antigenic proteins as identified by the bacterial surface display expression libraries using pools of pre-selected sera, are processed in a second and third round of screening by individual selected or generated sera. Thus the present invention supplies an efficient, relevant, comprehensive set of pneumococcal antigens as a pharmaceutical composition, especially a vaccine preventing infection by *S. pneumoniae*.

In the antigen identification program for identifying a comprehensive set of antigens according to the present invention, at least two different bacterial surface expression libraries are screened with several serum pools or plasma fractions or other pooled antibody containing body fluids (antibody pools). The antibody pools are derived from a serum collection, which has been tested against antigenic compounds of *S. pneumoniae*, such as whole cell extracts and culture supernatant proteins. Preferably, two distinct serum collections are used: 1. With very stable antibody repertoire: normal adults, clinically healthy people, who are non-carriers and overcame previous encounters or currently carriers of *S. pneumoniae* without acute disease and symptoms, 2. With antibodies induced acutely by the presence of the pathogenic organism: patients with acute disease with different manifestations (e.g. *S. pneumoniae* pharyngitis, pneumonia, bacteraemia, peritonitis, meningitis and sepsis). Sera have to react with multiple *Pneumococcus*-specific antigens in order to be considered hyperimmune and therefore relevant in the screening method applied for the present invention.

The expression libraries as used in the present invention should allow expression of all potential antigens, e.g. derived from all secreted and surface proteins of *S. pneumoniae*. Bacterial surface display libraries will be represented by a recombinant library of a bacterial host displaying a (total) set of expressed peptide sequences of *S. pneumoniae* on two selected outer membrane proteins (LamB and FhuA) at the bacterial host membrane (Georgiou, G., 1997); (Etz, H. et al., 2001). One of the advantages of using recombinant expression libraries is that the identified hyperimmune serum-reactive antigens may be instantly produced by expression of the coding sequences of the screened and selected clones expressing the hyperimmune serum-reactive antigens without further recombinant DNA technology or cloning steps necessary.

The comprehensive set of antigens identified by the described program according to the present invention is analysed further by one or more additional rounds of screening. Therefore individual antibody preparations or antibodies generated against selected peptides, which were identified as immunogenic are used. According to a preferred embodiment the individual antibody preparations for the second round of screening are derived from patients who have suffered from an acute infection with *S. pneumoniae*, especially from patients who show an antibody titer above a certain minimum level, for example an antibody titer being higher than 80 percentile, preferably higher than 90 percentile, especially higher than 95 percentile of the human (patient or healthy individual) sera tested. Using such high titer individual antibody preparations in the second screening round allows a very selective identification of the hyperimmune serum-reactive antigens and fragments thereof from *S. pneumoniae*.

Following the comprehensive screening procedure, the selected antigenic proteins, expressed as recombinant proteins or *in vitro* translated products, in case it can not be expressed in prokaryotic expression systems, or the identified antigenic peptides (produced synthetically) are tested in a second screening by a series of ELISA and Western blotting assays for the assessment of their immunogenicity with a large human serum collection (minimum ~150 healthy and patients sera).

It is important that the individual antibody preparations (which may also be the selected serum) allow a selective identification of the most promising candidates of all the hyperimmune serum-reactive antigens from all the promising candidates from the first round. Therefore, preferably at least 10 individual antibody preparations (i.e. antibody preparations (e.g. sera) from at least 10 different individuals having suffered from an infection to the chosen pathogen) should be used in identifying these antigens in the second screening round. Of course, it is possible to use also less than 10 individual preparations,

however, selectivity of the step may not be optimal with a low number of individual antibody preparations. On the other hand, if a given hyperimmune serum-reactive antigen (or an antigenic fragment thereof) is recognized by at least 10 individual antibody preparations, preferably at least 30, especially at least 50 individual antibody preparations, identification of the hyperimmune serum-reactive antigen is also selective enough for a proper identification. Hyperimmune serum-reactivity may of course be tested with as many individual preparations as possible (e.g. with more than 100 or even with more than 1,000).

Therefore, the relevant portion of the hyperimmune serum-reactive antibody preparations according to the method of the present invention should preferably be at least 10, more preferred at least 30, especially at least 50 individual antibody preparations. Alternatively (or in combination) hyperimmune serum-reactive antigens may preferably be also identified with at least 20%, preferably at least 30%, especially at least 40% of all individual antibody preparations used in the second screening round.

According to a preferred embodiment of the present invention, the sera from which the individual antibody preparations for the second round of screening are prepared (or which are used as antibody preparations), are selected by their titer against *S. pneumoniae* (e.g. against a preparation of this pathogen, such as a lysate, cell wall components and recombinant proteins). Preferably, some are selected with a total IgA titer above 2,000 U, especially above 4,000 U, and/or an IgG titer above 5,000 U, especially above 12,000 U (U = units, calculated from the OD_{405nm} reading at a given dilution) when the whole organism (total lysate or whole cells) is used as antigen in the ELISA.

The antibodies produced against streptococci by the human immune system and present in human sera are indicative of the *in vivo* expression of the antigenic proteins and their immunogenicity. The recognition of linear epitopes recognized by serum antibodies can be based on sequences as short as 4-5 amino acids. Of course it does not necessarily mean that these short peptides are capable of inducing the given antibody *in vivo*. For that reason the defined epitopes, polypeptides and proteins are further to be tested in animals (mainly in mice) for their capacity to induce antibodies against the selected proteins *in vivo*.

The preferred antigens are located on the cell surface or are secreted, and are therefore accessible extracellularly. Antibodies against cell wall proteins are expected to serve multiple purposes: to inhibit adhesion, to interfere with nutrient acquisition, to inhibit immune evasion and to promote phagocytosis [Hornef, M. et al., 2002]. Antibodies against secreted proteins are beneficial in neutralisation of their function as toxin or virulence component. It is also known that bacteria communicate with each other through secreted proteins. Neutralizing antibodies against these proteins will interrupt growth-promoting cross-talk between or within streptococcal species. Bioinformatic analyses (signal sequences, cell wall localisation signals, transmembrane domains) proved to be very useful in assessing cell surface localisation or secretion. The experimental approach includes the isolation of antibodies with the corresponding epitopes and proteins from human serum, and the generation of immune sera in mice against (poly)peptides selected by the bacterial surface display screens. These sera are then used in a third round of screening as reagents in the following assays: cell surface staining of *S. pneumoniae* grown under different conditions (FACS or microscopy), determination of neutralizing capacity (toxin, adherence), and promotion of opsonization and phagocytosis (*in vitro* phagocytosis assay).

For that purpose, bacterial *E. coli* clones are directly injected into mice and immune sera are taken and tested in the relevant *in vitro* assay for functional opsonic or neutralizing antibodies. Alternatively, specific antibodies may be purified from human or mouse sera using peptides or proteins as substrate.

Host defence against *S. pneumoniae* relies mainly on opsonophagocytic killing mechanism. Inducing high affinity antibodies of the opsonic and neutralizing type by vaccination helps the innate immune system to eliminate bacteria and toxins. This makes the method according to the present invention an optimal tool

for the identification of pneumococcal antigenic proteins.

The skin and mucous membranes are formidable barriers against invasion by streptococci. However, once the skin or the mucous membranes are breached the first line of non-adaptive cellular defence begins its co-ordinate action through complement and phagocytes, especially the polymorphonuclear leukocytes (PMNs). These cells can be regarded as the cornerstones in eliminating invading bacteria. As *Streptococcus pneumoniae* is a primarily extracellular pathogen, the major anti-streptococcal adaptive response comes from the humoral arm of the immune system, and is mediated through three major mechanisms: promotion of opsonization, toxin neutralisation, and inhibition of adherence. It is believed that opsonization is especially important, because of its requirement for an effective phagocytosis. For efficient opsonization the microbial surface has to be coated with antibodies and complement factors for recognition by PMNs through receptors to the Fc fragment of the IgG molecule or to activated C3b. After opsonization, streptococci are phagocytosed and killed. Antibodies bound to specific antigens on the cell surface of bacteria serve as ligands for the attachment to PMNs and to promote phagocytosis. The very same antibodies bound to the adhesins and other cell surface proteins are expected to neutralize adhesion and prevent colonization. The selection of antigens as provided by the present invention is thus well suited to identify those that will lead to protection against infection in an animal model or in humans.

According to the antigen identification method used herein, the present invention can surprisingly provide a set of comprehensive novel nucleic acids and novel hyperimmune serum reactive antigens and fragments thereof of *S. pneumoniae*, among other things, as described below. According to one aspect, the invention particularly relates to the nucleotide sequences encoding hyperimmune serum reactive antigens which sequences are set forth in the Sequence listing Seq ID No: 1-144, 289-303 and the corresponding encoded amino acid sequences representing hyperimmune serum reactive antigens are set forth in the Sequence Listing Seq ID No 145-288 and 304-318.

In a preferred embodiment of the present invention, a nucleic acid molecule is provided which exhibits 70% identity over their entire length to a nucleotide sequence set forth with Seq ID No 1, 101-144. Most highly preferred are nucleic acids that comprise a region that is at least 80% or at least 85% identical over their entire length to a nucleic acid molecule set forth with Seq ID No 1, 101-144. In this regard, nucleic acid molecules at least 90%, 91%, 92%, 93%, 94%, 95%, or 96% identical over their entire length to the same are particularly preferred. Furthermore, those with at least 97% are highly preferred, those with at least 98% and at least 99% are particularly highly preferred, with at least 99% or 99.5% being the more preferred, with 100% identity being especially preferred. Moreover, preferred embodiments in this respect are nucleic acids which encode hyperimmune serum reactive antigens or fragments thereof (polypeptides) which retain substantially the same biological function or activity as the mature polypeptide encoded by said nucleic acids set forth in the Seq ID No 1, 101-144.

Identity, as known in the art and used herein, is the relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences. In the art, identity also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences. Identity can be readily calculated. While there exist a number of methods to measure identity between two polynucleotide or two polypeptide sequences, the term is well known to skilled artisans (e.g. *Sequence Analysis in Molecular Biology*, von Heinje, G., Academic Press, 1987). Preferred methods to determine identity are designed to give the largest match between the sequences tested. Methods to determine identity are codified in computer programs. Preferred computer program methods to determine identity between two sequences include, but are not limited to, GCG program package {Devereux, J. et al., 1984}, BLASTP, BLASTN, and FASTA {Altschul, S. et al., 1990}.

According to another aspect of the invention, nucleic acid molecules are provided which exhibit at least 96% identity to the nucleic acid sequence set forth with Seq ID No 2-6, 8, 10-16, 18-23, 25-31, 34, 36, 38-42,

44, 47-48, 51, 53, 55-62, 64, 67, 71-76, 78-79, 81-94, 96-100.

According to a further aspect of the present invention, nucleic acid molecules are provided which are identical to the nucleic acid sequences set forth with Seq ID No 9, 17, 24, 32, 37, 43, 52, 54, 65-66, 70, 80.

The nucleic acid molecules according to the present invention can as a second alternative also be a nucleic acid molecule which is at least essentially complementary to the nucleic acid described as the first alternative above. As used herein complementary means that a nucleic acid strand is base pairing via Watson-Crick base pairing with a second nucleic acid strand. Essentially complementary as used herein means that the base pairing is not occurring for all of the bases of the respective strands but leaves a certain number or percentage of the bases unpaired or wrongly paired. The percentage of correctly pairing bases is preferably at least 70 %, more preferably 80 %, even more preferably 90 % and most preferably any percentage higher than 90 %. It is to be noted that a percentage of 70 % matching bases is considered as homology and the hybridization having this extent of matching base pairs is considered as stringent. Hybridization conditions for this kind of stringent hybridization may be taken from Current Protocols in Molecular Biology (John Wiley and Sons, Inc., 1987). More particularly, the hybridization conditions can be as follows:

- Hybridization performed e.g. in 5 x SSPE, 5 x Denhardt's reagent, 0.1% SDS, 100 g/mL sheared DNA at 68°C
- Moderate stringency wash in 0.2xSSC, 0.1% SDS at 42°C
- High stringency wash in 0.1xSSC, 0.1% SDS at 68°C

Genomic DNA with a GC content of 50% has an approximate T_m of 96°C. For 1% mismatch, the T_m is reduced by approximately 1°C.

In addition, any of the further hybridization conditions described herein are in principle applicable as well.

Of course, all nucleic acid sequence molecules which encode the same polypeptide molecule as those identified by the present invention are encompassed by any disclosure of a given coding sequence, since the degeneracy of the genetic code is directly applicable to unambiguously determine all possible nucleic acid molecules which encode a given polypeptide molecule, even if the number of such degenerated nucleic acid molecules may be high. This is also applicable for fragments of a given polypeptide, as long as the fragments encode a polypeptide being suitable to be used in a vaccination connection, e.g. as an active or passive vaccine.

The nucleic acid molecule according to the present invention can as a third alternative also be a nucleic acid which comprises a stretch of at least 15 bases of the nucleic acid molecule according to the first and second alternative of the nucleic acid molecules according to the present invention as outlined above. Preferably, the bases form a contiguous stretch of bases. However, it is also within the scope of the present invention that the stretch consists of two or more moieties, which are separated by a number of bases.

The present nucleic acids may preferably consist of at least 20, even more preferred at least 30, especially at least 50 contiguous bases from the sequences disclosed herein. The suitable length may easily be optimized due to the planned area of use (e.g. as (PCR) primers, probes, capture molecules (e.g. on a (DNA) chip), etc.). Preferred nucleic acid molecules contain at least a contiguous 15 base portion of one or more of the predicted immunogenic amino acid sequences listed in tables 1 and 2, especially the sequences of table 2 with scores of more than 10, preferably more than 20, especially with a score of more than 25. Specifically preferred are nucleic acids containing a contiguous portion of a DNA sequence of any sequence in the sequence protocol of the present application which shows 1 or more, preferably more

than 2, especially more than 5, non-identical nucleic acid residues compared to the published *Streptococcus pneumoniae* strain TIGR4 genome ([Tettelin, H. et al., 2001]; GenBank accession AE005672) and/or any other published *S. pneumoniae* genome sequence or parts thereof, especially of the strain R6 ([Hoskins, J. et al., 2001]; GenBank accession AE007317). Specifically preferred non-identical nucleic acid residues are residues, which lead to a non-identical amino acid residue. Preferably, the nucleic acid sequences encode for polypeptides having at least 1, preferably at least 2, preferably at least 3 different amino acid residues compared to the published *S. pneumoniae* counterparts mentioned above. Also such isolated polypeptides, being fragments of the proteins (or the whole protein) mentioned herein e.g. in the sequence listing, having at least 6, 7, or 8 amino acid residues and being encoded by these nucleic acids are preferred.

The nucleic acid molecule according to the present invention can as a fourth alternative also be a nucleic acid molecule which anneals under stringent hybridisation conditions to any of the nucleic acids of the present invention according to the above outlined first, second, and third alternative. Stringent hybridisation conditions are typically those described herein.

Finally, the nucleic acid molecule according to the present invention can as a fifth alternative also be a nucleic acid molecule which, but for the degeneracy of the genetic code, would hybridise to any of the nucleic acid molecules according to any nucleic acid molecule of the present invention according to the first, second, third, and fourth alternative as outlined above. This kind of nucleic acid molecule refers to the fact that preferably the nucleic acids according to the present invention code for the hyperimmune serum reactive antigens or fragments thereof according to the present invention. This kind of nucleic acid molecule is particularly useful in the detection of a nucleic acid molecule according to the present invention and thus the diagnosis of the respective microorganisms such as *S. pneumoniae* and any disease or diseased condition where this kind of microorganisms is involved. Preferably, the hybridisation would occur or be performed under stringent conditions as described in connection with the fourth alternative described above.

Nucleic acid molecule as used herein generally refers to any ribonucleic acid molecule or deoxyribonucleic acid molecule, which may be unmodified RNA or DNA or modified RNA or DNA. Thus, for instance, nucleic acid molecule as used herein refers to, among other, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded RNA, and RNA that is a mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded, or triple-stranded, or a mixture of single- and double-stranded regions. In addition, nucleic acid molecule as used herein refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The strands in such regions may be from the same molecule or from different molecules. The regions may include all of one or more of the molecules, but more typically involve only a region of some of the molecules. One of the molecules of a triple-helical region often is an oligonucleotide. As used herein, the term nucleic acid molecule includes DNAs or RNAs as described above that contain one or more modified bases. Thus, DNAs or RNAs with backbones modified for stability or for other reasons are "nucleic acid molecule" as that term is intended herein. Moreover, DNAs or RNAs comprising unusual bases, such as inosine, or modified bases, such as tritylated bases, to name just two examples, are nucleic acid molecule as the term is used herein. It will be appreciated that a great variety of modifications have been made to DNA and RNA that serve many useful purposes known to those of skill in the art. The term nucleic acid molecule as it is employed herein embraces such chemically, enzymatically or metabolically modified forms of nucleic acid molecule, as well as the chemical forms of DNA and RNA characteristic of viruses and cells, including simple and complex cells, *inter alia*. The term nucleic acid molecule also embraces short nucleic acid molecules often referred to as oligonucleotide(s). "Polynucleotide" and "nucleic acid" or "nucleic acid molecule" are often used interchangeably herein.

Nucleic acid molecules provided in the present invention also encompass numerous unique fragments,

both longer and shorter than the nucleic acid molecule sequences set forth in the sequencing listing of the *S. pneumoniae* coding regions, which can be generated by standard cloning methods. To be unique, a fragment must be of sufficient size to distinguish it from other known nucleic acid sequences, most readily determined by comparing any selected *S. pneumoniae* fragment to the nucleotide sequences in computer databases such as GenBank.

Additionally, modifications can be made to the nucleic acid molecules and polypeptides that are encompassed by the present invention. For example, nucleotide substitutions can be made which do not affect the polypeptide encoded by the nucleic acid, and thus any nucleic acid molecule which encodes a hyperimmune serum reactive antigen or fragments thereof is encompassed by the present invention.

Furthermore, any of the nucleic acid molecules encoding hyperimmune serum reactive antigens or fragments thereof provided by the present invention can be functionally linked, using standard techniques such as standard cloning techniques, to any desired regulatory sequences, whether a *S. pneumoniae* regulatory sequence or a heterologous regulatory sequence, heterologous leader sequence, heterologous marker sequence or a heterologous coding sequence to create a fusion protein.

Nucleic acid molecules of the present invention may be in the form of RNA, such as mRNA or cRNA, or in the form of DNA, including, for instance, cDNA and genomic DNA obtained by cloning or produced by chemical synthetic techniques or by a combination thereof. The DNA may be triple-stranded, double-stranded or single-stranded. Single-stranded DNA may be the coding strand, also known as the sense strand, or it may be the non-coding strand, also referred to as the anti-sense strand.

The present invention further relates to variants of the herein above described nucleic acid molecules which encode fragments, analogs and derivatives of the hyperimmune serum reactive antigens and fragments thereof having a deduced *S. pneumoniae* amino acid sequence set forth in the Sequence Listing. A variant of the nucleic acid molecule may be a naturally occurring variant such as a naturally occurring allelic variant, or it may be a variant that is not known to occur naturally. Such non-naturally occurring variants of the nucleic acid molecule may be made by mutagenesis techniques, including those applied to nucleic acid molecules, cells or organisms.

Among variants in this regard are variants that differ from the aforementioned nucleic acid molecules by nucleotide substitutions, deletions or additions. The substitutions, deletions or additions may involve one or more nucleotides. The variants may be altered in coding or non-coding regions or both. Alterations in the coding regions may produce conservative or non-conservative amino acid substitutions, deletions or additions. Preferred are nucleic acid molecules encoding a variant, analog, derivative or fragment, or a variant, analogue or derivative of a fragment, which have a *S. pneumoniae* sequence as set forth in the Sequence Listing, in which several, a few, 5 to 10, 1 to 5, 1 to 3, 2, 1 or no amino acid(s) is substituted, deleted or added, in any combination. Especially preferred among these are silent substitutions, additions and deletions, which do not alter the properties and activities of the *S. pneumoniae* polypeptides set forth in the Sequence Listing. Also especially preferred in this regard are conservative substitutions.

The peptides and fragments according to the present invention also include modified epitopes wherein preferably one or two of the amino acids of a given epitope are modified or replaced according to the rules disclosed in e.g. {Tourdot, S. et al., 2000}, as well as the nucleic acid sequences encoding such modified epitopes.

It is clear that also epitopes derived from the present epitopes by amino acid exchanges improving, conserving or at least not significantly impeding the T cell activating capability of the epitopes are covered by the epitopes according to the present invention. Therefore the present epitopes also cover epitopes, which do not contain the original sequence as derived from *S. pneumoniae*, but trigger the same or preferably an improved T cell response. These epitope are referred to as "heteroclitic"; they need to

have a similar or preferably greater affinity to MHC/HLA molecules, and the need the ability to stimulate the T cell receptors (TCR) directed to the original epitope in a similar or preferably stronger manner.

Heteroclitic epitopes can be obtained by rational design i.e. taking into account the contribution of individual residues to binding to MHC/HLA as for instance described by [Rammensee, H. et al., 1999], combined with a systematic exchange of residues potentially interacting with the TCR and testing the resulting sequences with T cells directed against the original epitope. Such a design is possible for a skilled man in the art without much experimentation.

Another possibility includes the screening of peptide libraries with T cells directed against the original epitope. A preferred way is the positional scanning of synthetic peptide libraries. Such approaches have been described in detail for instance by [Hemmer, B. et al., 1999] and the references given therein.

As an alternative to epitopes represented by the present derived amino acid sequences or heteroclitic epitopes, also substances mimicking these epitopes e.g. "peptidemimetica" or "retro-inverso-peptides" can be applied.

Another aspect of the design of improved epitopes is their formulation or modification with substances increasing their capacity to stimulate T cells. These include T helper cell epitopes, lipids or liposomes or preferred modifications as described in WO 01/78767.

Another way to increase the T cell stimulating capacity of epitopes is their formulation with immune stimulating substances for instance cytokines or chemokines like interleukin-2, -7, -12, -18, class I and II interferons (IFN), especially IFN-gamma, GM-CSF, TNF-alpha, flt3-ligand and others.

As discussed additionally herein regarding nucleic acid molecule assays of the invention, for instance, nucleic acid molecules of the invention as discussed above, may be used as a hybridization probe for RNA, cDNA and genomic DNA to isolate full-length cDNAs and genomic clones encoding polypeptides of the present invention and to isolate cDNA and genomic clones of other genes that have a high sequence similarity to the nucleic acid molecules of the present invention. Such probes generally will comprise at least 15 bases. Preferably, such probes will have at least 20, at least 25 or at least 30 bases, and may have at least 50 bases. Particularly preferred probes will have at least 30 bases, and will have 50 bases or less, such as 30, 35, 40, 45, or 50 bases.

For example, the coding region of a nucleic acid molecule of the present invention may be isolated by screening a relevant library using the known DNA sequence to synthesize an oligonucleotide probe. A labeled oligonucleotide having a sequence complementary to that of a gene of the present invention is then used to screen a library of cDNA, genomic DNA or mRNA to determine to which members of the library the probe hybridizes.

The nucleic acid molecules and polypeptides of the present invention may be employed as reagents and materials for development of treatments of and diagnostics for disease, particularly human disease, as further discussed herein relating to nucleic acid molecule assays, *inter alia*.

The nucleic acid molecules of the present invention that are oligonucleotides can be used in the processes herein as described, but preferably for PCR, to determine whether or not the *S. pneumoniae* genes identified herein in whole or in part are present and/or transcribed in infected tissue such as blood. It is recognized that such sequences will also have utility in diagnosis of the stage of infection and type of infection the pathogen has attained. For this and other purposes the arrays comprising at least one of the nucleic acids according to the present invention as described herein, may be used.

The nucleic acid molecules according to the present invention may be used for the detection of nucleic acid molecules and organisms or samples containing these nucleic acids. Preferably such detection is for diagnosis, more preferable for the diagnosis of a disease related or linked to the presence or abundance of *S. pneumoniae*.

Eukaryotes (herein also "individual(s)"), particularly mammals, and especially humans, infected with *S. pneumoniae* may be identifiable by detecting any of the nucleic acid molecules according to the present invention detected at the DNA level by a variety of techniques. Preferred nucleic acid molecules candidates for distinguishing a *S. pneumoniae* from other organisms can be obtained.

The invention provides a process for diagnosing disease, arising from infection with *S. pneumoniae*, comprising determining from a sample isolated or derived from an individual an increased level of expression of a nucleic acid molecule having the sequence of a nucleic acid molecule set forth in the Sequence Listing. Expression of nucleic acid molecules can be measured using any one of the methods well known in the art for the quantitation of nucleic acid molecules, such as, for example, PCR, RT-PCR, Rnase protection, Northern blotting, other hybridisation methods and the arrays described herein.

Isolated as used herein means separated "by the hand of man" from its natural state; i.e., that, if it occurs in nature, it has been changed or removed from its original environment, or both. For example, a naturally occurring nucleic acid molecule or a polypeptide naturally present in a living organism in its natural state is not "isolated," but the same nucleic acid molecule or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein. As part of or following isolation, such nucleic acid molecules can be joined to other nucleic acid molecules, such as DNAs, for mutagenesis, to form fusion proteins, and for propagation or expression in a host, for instance. The isolated nucleic acid molecules, alone or joined to other nucleic acid molecules such as vectors, can be introduced into host cells, in culture or in whole organisms. Introduced into host cells in culture or in whole organisms, such DNAs still would be isolated, as the term is used herein, because they would not be in their naturally occurring form or environment. Similarly, the nucleic acid molecules and polypeptides may occur in a composition, such as a media formulations, solutions for introduction of nucleic acid molecules or polypeptides, for example, into cells, compositions or solutions for chemical or enzymatic reactions, for instance, which are not naturally occurring compositions, and, therein remain isolated nucleic acid molecules or polypeptides within the meaning of that term as it is employed herein.

The nucleic acids according to the present invention may be chemically synthesized. Alternatively, the nucleic acids can be isolated from *S. pneumoniae* by methods known to the one skilled in the art.

According to another aspect of the present invention, a comprehensive set of novel hyperimmune serum reactive antigens and fragments thereof are provided by using the herein described antigen identification method. In a preferred embodiment of the invention, a hyperimmune serum-reactive antigen comprising an amino acid sequence being encoded by any one of the nucleic acids molecules herein described and fragments thereof are provided. In another preferred embodiment of the invention a novel set of hyperimmune serum-reactive antigens which comprises amino acid sequences selected from a group consisting of the polypeptide sequences as represented in Seq ID No 145, 245-288 and fragments thereof are provided. In a further preferred embodiment of the invention hyperimmune serum-reactive antigens which comprise amino acid sequences selected from a group consisting of the polypeptide sequences as represented in Seq ID No 146-150, 152, 154-160, 162-167, 169-175, 178, 180, 182-186, 188, 191-192, 195, 197, 199-206, 208, 211, 215-220, 222-223, 225-238, 240-244 and fragments thereof are provided. In a still preferred embodiment of the invention hyperimmune serum-reactive antigens which comprise amino acid sequences selected from a group consisting of the polypeptide sequences as represented in Seq ID No 153, 161, 168, 176, 181, 187, 196, 198, 209-210, 214, 224 and fragments thereof are provided.

The hyperimmune serum reactive antigens and fragments thereof as provided in the invention include

any polypeptide set forth in the Sequence Listing as well as polypeptides which have at least 70% identity to a polypeptide set forth in the Sequence Listing, preferably at least 80% or 85% identity to a polypeptide set forth in the Sequence Listing, and more preferably at least 90% similarity (more preferably at least 90% identity) to a polypeptide set forth in the Sequence Listing and still more preferably at least 95%, 96%, 97%, 98%, 99% or 99.5% similarity (still more preferably at least 95%, 96%, 97%, 98%, 99%, or 99.5% identity) to a polypeptide set forth in the Sequence Listing and also include portions of such polypeptides with such portion of the polypeptide generally containing at least 4 amino acids and more preferably at least 8, still more preferably at least 30, still more preferably at least 50 amino acids, such as 4, 8, 10, 20, 30, 35, 40, 45 or 50 amino acids.

The invention also relates to fragments, analogs, and derivatives of these hyperimmune serum reactive antigens and fragments thereof. The terms "fragment", "derivative" and "analog" when referring to an antigen whose amino acid sequence is set forth in the Sequence Listing, means a polypeptide which retains essentially the same or a similar biological function or activity as such hyperimmune serum reactive antigen and fragment thereof.

The fragment, derivative or analog of a hyperimmune serum reactive antigen and fragment thereof may be 1) one in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code, or 2) one in which one or more of the amino acid residues includes a substituent group, or 3) one in which the mature hyperimmune serum reactive antigen or fragment thereof is fused with another compound, such as a compound to increase the half-life of the hyperimmune serum reactive antigen and fragment thereof (for example, polyethylene glycol), or 4) one in which the additional amino acids are fused to the mature hyperimmune serum reactive antigen or fragment thereof, such as a leader or secretory sequence or a sequence which is employed for purification of the mature hyperimmune serum reactive antigen or fragment thereof or a proprotein sequence. Such fragments, derivatives and analogs are deemed to be within the scope of those skilled in the art from the teachings herein.

The present invention also relates to antigens of different *S. pneumoniae* isolates. Such homologues may easily be isolated based on the nucleic acid and amino acid sequences disclosed herein. There are more than 90 serotypes in more than 40 serogroups distinguished to date and the typing is based on serotype specific antisera. The presence of any antigen can accordingly be determined for every serotype. In addition it is possible to determine the variability of a particular antigen in the various serotypes as described for the *S. pyogenes* sic gene [Hoe, N. et al., 2001]. The contribution of the various serotypes to the different pneumococcal infections varies in the different age groups and geographical regions [Gray, B. et al., 1979]; [Gray, B. et al., 1986]; [Orange, M. et al., 1993], reviewed in Epidemiology and Prevention of Vaccine-Preventable Diseases, 7th Edition-Second Printing, The Pink Book). It is an important aspect that the most valuable protective antigens are expected to be conserved among various clinical strains.

Among the particularly preferred embodiments of the invention in this regard are the hyperimmune serum reactive antigens set forth in the Sequence Listing, variants, analogs, derivatives and fragments thereof, and variants, analogs and derivatives of fragments. Additionally, fusion polypeptides comprising such hyperimmune serum reactive antigens, variants, analogs, derivatives and fragments thereof, and variants, analogs and derivatives of the fragments are also encompassed by the present invention. Such fusion polypeptides and proteins, as well as nucleic acid molecules encoding them, can readily be made using standard techniques, including standard recombinant techniques for producing and expression of a recombinant polynucleic acid encoding a fusion protein.

Among preferred variants are those that vary from a reference by conservative amino acid substitutions. Such substitutions are those that substitute a given amino acid in a polypeptide by another amino acid of like characteristics. Typically seen as conservative substitutions are the replacements, one for another,

among the aliphatic amino acids Ala, Val, Leu and Ile; interchange of the hydroxyl residues Ser and Thr, exchange of the acidic residues Asp and Glu, substitution between the amide residues Asn and Gln, exchange of the basic residues Lys and Arg and replacements among the aromatic residues Phe and Tyr.

Further particularly preferred in this regard are variants, analogs, derivatives and fragments, and variants, analogs and derivatives of the fragments, having the amino acid sequence of any polypeptide set forth in the Sequence Listing, in which several, a few, 5 to 10, 1 to 5, 1 to 3, 2, 1 or no amino acid residues are substituted, deleted or added, in any combination. Especially preferred among these are silent substitutions, additions and deletions, which do not alter the properties and activities of the polypeptide of the present invention. Also especially preferred in this regard are conservative substitutions. Most highly preferred are polypeptides having an amino acid sequence set forth in the Sequence Listing without substitutions.

The hyperimmune serum reactive antigens and fragments thereof of the present invention are preferably provided in an isolated form, and preferably are purified to homogeneity.

Also among preferred embodiments of the present invention are polypeptides comprising fragments of the polypeptides having the amino acid sequence set forth in the Sequence Listing, and fragments of variants and derivatives of the polypeptides set forth in the Sequence Listing.

In this regard a fragment is a polypeptide having an amino acid sequence that entirely is the same as part but not all of the amino acid sequence of the afore mentioned hyperimmune serum reactive antigen and fragment thereof, and variants or derivative, analogs, fragments thereof. Such fragments may be "free-standing", i.e., not part of or fused to other amino acids or polypeptides, or they may be comprised within a larger polypeptide of which they form a part or region. Also preferred in this aspect of the invention are fragments characterised by structural or functional attributes of the polypeptide of the present invention, i.e. fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta-amphipathic regions, flexible regions, surface-forming regions, substrate binding regions, and high antigenic index regions of the polypeptide of the present invention, and combinations of such fragments. Preferred regions are those that mediate activities of the hyperimmune serum reactive antigens and fragments thereof of the present invention. Most highly preferred in this regard are fragments that have a chemical, biological or other activity of the hyperimmune serum reactive antigen and fragments thereof of the present invention, including those with a similar activity or an improved activity, or with a decreased undesirable activity. Particularly preferred are fragments comprising receptors or domains of enzymes that confer a function essential for viability of *S. pneumoniae* or the ability to cause disease in humans. Further preferred polypeptide fragments are those that comprise or contain antigenic or immunogenic determinants in an animal, especially in a human.

An antigenic fragment is defined as a fragment of the identified antigen, which is for itself antigenic or may be made antigenic when provided as a hapten. Therefore, also antigens or antigenic fragments showing one or (for longer fragments) only a few amino acid exchanges are enabled with the present invention, provided that the antigenic capacities of such fragments with amino acid exchanges are not severely deteriorated on the exchange(s), i.e., suited for eliciting an appropriate immune response in an individual vaccinated with this antigen and identified by individual antibody preparations from individual sera.

Preferred examples of such fragments of a hyperimmune serum-reactive antigen are selected from the group consisting of peptides comprising amino acid sequences of column "predicted immunogenic aa", and "Location of identified immunogenic region" of Table 1; the serum reactive epitopes of Table 2, especially peptides comprising amino acid 4-11, 35-64, 66-76, 101-108, 111-119 and 57-114 of Seq ID No

145; 5-27, 32-64, 92-102, 107-113, 119-125, 133-139, 148-162, 177-187, 195-201, 207-214, 241-251, 254-269, 285-300, 302-309, 317-324, 332-357, 365-404, 411-425, 443-463, 470-477, 479-487, 506-512, 515-520, 532-547, 556-596, 603-610, 616-622, 624-629, 636-642, 646-665, 667-674, 687-692, 708-720, 734-739, 752-757, 798-820, 824-851, 856-865 and 732-763 of Seq ID No 146; 14-21, 36-44, 49-66, 102-127, 162-167, 177-196, 45-109 and 145-172 of Seq ID No 147; 17-35, 64-75, 81-92, 100-119, 125-172, 174-183, 214-222, 230-236, 273-282, 287-303, 310-315, 331-340, 392-398, 412-420, 480-505, 515-523, 525-546, 553-575, 592-598, 603-609, 617-625, 631-639, 644-651, 658-670, 681-687, 691-704, 709-716, 731-736, 739-744, 750-763, 774-780, 784-791, 799-805, 809-822, 859-870, 880-885, 907-916, 924-941, 943-949, 973-986, 1010-1016, 1026-1036, 1045-1054, 1057-1062, 1082-1088, 1095-1102, 1109-1120, 1127-1134, 1140-1146, 1152-1159, 1169-1179, 1187-1196, 1243-1251, 1262-1273, 1279-1292, 1306-1312, 1332-1343, 1348-1364, 1379-1390, 1412-1420, 1427-1436, 1458-1468, 1483-1503, 1524-1549, 1574-1588, 1614-1619, 1672-1685, 1697-1707, 1711-1720, 1738-1753, 1781-1787, 1796-1801, 1826-1843, 132-478, 508-592 and 1753-1810 of Seq ID No 148; 15-43, 49-55, 71-77, 104-110, 123-130, 162-171, 180-192, 199-205, 219-227, 246-254, 264-270, 279-287, 293-308, 312-322, 330-342, 349-356, 369-377, 384-394, 401-406, 416-422, 432-439, 450-460, 464-474, 482-494, 501-508, 521-529, 536-546, 553-558, 568-574, 584-591, 602-612, 616-626, 634-646, 653-660, 673-681, 688-698, 705-710, 720-726, 736-749, 833-848, 1-199, 200-337, 418-494 and 549-647 of Seq ID No 149; 9-30, 65-96, 99-123, 170-178 and 1-128 of Seq ID No 150; 7-32, 34-41, 96-106, 127-136, 154-163, 188-199, 207-238, 272-279, 306-312, 318-325, 341-347, 353-360, 387-393, 399-406, 434-440, 452-503, 575-580, 589-601, 615-620, 635-640, 654-660, 674-680, 696-701, 710-731, 1-548 and 660-691 of Seq ID No 151; 4-19, 35-44, 48-59, 77-87, 93-99, 106-111, 130-138, 146-161 and 78-84 of Seq ID No 152; 24-30, 36-43, 64-86, 93-99, 106-130, 132-145, 148-165, 171-177, 189-220, 230-249, 251-263, 293-300, 302-312, 323-329, 338-356, 369-379, 390-412 and 179-193 of Seq ID No 153; 30-39, 61-67, 74-81, 90-120, 123-145, 154-167, 169-179, 182-197, 200-206, 238-244, 267-272 and 230-265 of Seq ID No 154; 14-20, 49-65, 77-86 and 2-68 of Seq ID No 155; 4-9, 26-35, 42-48, 53-61, 63-85, 90-101, 105-111, 113-121, 129-137, 140-150, 179-188, 199-226, 228-237, 248-255, 259-285, 299-308, 314-331, 337-343, 353-364, 410-421, 436-442 and 110-144 of Seq ID No 156; 36-47, 55-63, 94-108, 129-134, 144-158, 173-187, 196-206, 209-238, 251-266, 270-285, 290-295, 300-306, 333-344, 346-354, 366-397, 404-410, 422-435, 439-453, 466-473, 515-523, 529-543, 554-569, 571-585, 590-596, 607-618, 627-643, 690-696, 704-714, 720-728, 741-749, 752-767, 780-799, 225-247 and 480-507 of Seq ID No 157; 16-25, 36-70, 80-93, 100-106 and 78-130 of Seq ID No 158; 18-27, 41-46, 50-57, 65-71, 79-85, 93-98, 113-128, 144-155, 166-178, 181-188, 201-207, 242-262, 265-273, 281-295, 303-309, 318-327 and 36-64 of Seq ID No 159; 7-29, 31-44, 50-59, 91-96, 146-153, 194-201, 207-212, 232-238, 264-278, 284-290, 296-302, 326-353, 360-370, 378-384, 400-405, 409-418, 420-435, 442-460, 499-506, 529-534, 556-562, 564-576, 644-651, 677-684, 687-698, 736-743, 759-766, 778-784, 808-814, 852-858, 874-896, 920-925, 929-935, 957-965, 1003-1012, 1021-1027, 1030-1044, 1081-1087, 1101-1111, 1116-1124, 1148-1159, 1188-1196, 1235-1251, 1288-1303, 1313-1319, 1328-1335, 1367-1373, 1431-1437, 1451-1458, 1479-1503, 1514-1521, 1530-1540, 1545-1552, 1561-1568, 1598-1605, 1617-1647, 1658-1665, 1670-1676, 1679-1689, 1698-1704, 1707-1713, 1732-1738, 1744-1764, 1-70, 154-189, 922-941, 1445-1462 and 1483-1496 of Seq ID No 160; 6-51, 81-91, 104-113, 126-137, 150-159, 164-174, 197-209, 215-224, 229-235, 256-269, 276-282, 307-313, 317-348, 351-357, 376-397, 418-437, 454-464, 485-490, 498-509, 547-555, 574-586, 602-619 and 452-530 of Seq ID No 161; 25-31, 39-47, 49-56, 99-114, 121-127, 159-186, 228-240, 253-269, 271-279, 303-315, 365-382, 395-405, 414-425, 438-453 and 289-384 of Seq ID No 162; 9-24, 41-47, 49-54, 68-78, 108-114, 117-122, 132-140, 164-169, 179-186, 193-199, 206-213, 244-251, 267-274, 289-294, 309-314, 327-333, 209-249 and 286-336 of Seq ID No 163; 9-28, 53-67, 69-82, 87-93, 109-117, 172-177, 201-207, 220-227, 242-247, 262-268, 305-318, 320-325 and 286-306 of Seq ID No 164; 4-10, 26-39, 47-58, 63-73, 86-96, 98-108, 115-123, 137-143, 148-155, 160-176, 184-189, 194-204, 235-240, 254-259, 272-278 and 199-283 of Seq ID No 165; 4-26, 33-39, 47-53, 59-65, 76-83, 91-97, 104-112, 118-137, 155-160, 167-174, 198-207, 242-268, 273-279, 292-315, 320-332, 345-354, 358-367, 377-394, 403-410, 424-439, 445-451, 453-497, 511-518, 535-570, 573-589, 592-601, 604-610 and 202-242 of Seq ID No 166; 8-30, 36-45, 64-71, 76-82, 97-103, 105-112, 134-151, 161-183, 211-234, 253-268, 270-276, 278-284, 297-305, 309-315, 357-362, 366-372, 375-384, 401-407, 409-416, 441-455, 463-470, 475-480, 490-497, 501-513, 524-537, 552-559, 565-576, 581-590, 592-600, 619-625, 636-644, 646-656 and 316-419 of Seq ID No 167; 4-17, 52-58, 84-99, 102-110, 114-120, 124-135, 143-158, 160-173, 177-196, 201-216, 223-250, 259-267, 269-275 and 1-67 of Seq ID No 168; 6-46, 57-67, 69-80, 82-133, 137-143, 147-168, 182-187, 203-209, 214-229, 233-242, 246-280 and 53-93 of Seq ID No 169; 7-40, 50-56, 81-89, 117-123, 202-209, 213-218, 223-229, 248-261, 264-276, 281-288, 303-308, 313-324, 326-332, 340-346, 353-372, 434-443,

465-474, 514-523, 556-564, 605-616, 620-626, 631-636, 667-683, 685-699, 710-719, 726-732, 751-756, 760-771, 779-788, 815-828, 855-867, 869-879, 897-902, 917-924, 926-931, 936-942, 981-1000, 1006-1015, 1017-1028, 1030-1039, 1046-1054, 1060-1066, 1083-1092, 1099-1112, 1122-1130, 1132-1140, 1148-1158, 1161-1171, 1174-1181, 1209-1230, 1236-1244, 1248-1254, 1256-1267, 1269-1276, 1294-1299, 1316-1328, 1332-1354, 1359-1372, 1374-1380, 1384-1390, 1395-1408, 1419-1425, 1434-1446, 1453-1460, 1465-1471, 1474-1493, 1505-1515, 1523-1537, 1547-1555, 1560-1567, 1577-1605, 1633-1651, 1226-1309, 1455-1536 and 1538-1605 of Seq ID No 170; 4-10, 31-39, 81-88, 106-112, 122-135, 152-158, 177-184, 191-197, 221-227, 230-246, 249-255, 303-311, 317-326, 337-344, 346-362, 365-371, 430-437, 439-446, 453-462, 474-484 and 449-467 of Seq ID No 171; 9-15, 24-35, 47-55, 122-128, 160-177, 188-196, 202-208, 216-228, 250-261, 272-303, 318-324, 327-339, 346-352, 355-361, 368-373, 108-218 and 344-376 of Seq ID No 172; 6-14, 17-48, 55-63, 71-90, 99-109, 116-124, 181-189, 212-223, 232-268, 270-294, 297-304, 319-325, 340-348, 351-370, 372-378, 388-394, 406-415, 421-434 and 177-277 of Seq ID No 173; 21-39, 42-61, 65-75, 79-85, 108-115 and 11-38 of Seq ID No 174; 4-17, 26-39, 61-76, 103-113, 115-122, 136-142, 158-192, 197-203, 208-214, 225-230, 237-251 and 207-225 of Seq ID No 175; 5-11, 27-36, 42-53, 62-70, 74-93, 95-104, 114-119, 127-150, 153-159, 173-179, 184-193, 199-206, 222-241, 248-253, 257-280, 289-295, 313-319, 322-342, 349-365, 368-389, 393-406, 408-413, 426-438, 447-461, 463-470, 476-495, 532-537, 543-550 and 225-246 of Seq ID No 176; 4-29, 68-82, 123-130, 141-147, 149-157, 178-191, 203-215, 269-277, 300-307, 327-335, 359-370, 374-380, 382-388, 393-400, 410-417, 434-442, 483-492, 497-503, 505-513, 533-540, 564-569, 601-607, 639-647, 655-666, 693-706, 712-718, 726-736, 752-758, 763-771, 774-780, 786-799, 806-812, 820-828, 852-863, 884-892, 901-909, 925-932, 943-948, 990-996, 1030-1036, 1051-1059, 1062-1068, 1079-1086, 1105-1113, 1152-1162, 1168-1179, 1183-1191, 1204-1210, 1234-1244, 1286-1295, 1318-1326, 1396-1401, 1451-1460, 1465-1474, 1477-1483, 1488-1494, 1505-1510, 1514-1521, 1552-1565, 1593-1614, 1664-1672, 1677-1685, 1701-1711, 1734-1745, 1758-1770, 1784-1798, 1840-1847, 1852-1873, 1885-1891, 1906-1911, 1931-1939, 1957-1970, 1977-1992, 2014-2020, 2026-2032, 2116-2134, 1-348, 373-490, 573-767, 903-1043, 1155-1198, 1243-1482, 1550-1595, 1682-1719, 1793-1921 and 2008-2110 of Seq ID No 177; 10-35, 39-52, 107-112, 181-188, 226-236, 238-253, 258-268, 275-284, 296-310, 326-338, 345-368, 380-389, 391-408, 410-418, 420-429, 444-456, 489-505, 573-588, 616-623, 637-643, 726-739, 741-767, 785-791, 793-803, 830-847, 867-881, 886-922, 949-956, 961-980, 988-1004, 1009-1018, 1027-1042, 1051-1069, 1076-1089, 1108-1115, 1123-1135, 1140-1151, 1164-1179, 1182-1191, 1210-1221, 1223-1234, 1242-1250, 1255-1267, 1281-1292, 1301-1307, 1315-1340, 1348-1355, 1366-1373, 1381-1413, 1417-1428, 1437-1444, 1453-1463, 1478-1484, 1490-1496, 1498-1503, 1520-1536, 1538-1546, 1548-1570, 1593-1603, 1612-1625, 1635-1649, 1654-1660, 1670-1687, 1693-1700, 1705-1711, 1718-1726, 1729-1763, 1790-1813, 1871-1881, 1893-1900, 1907-1935, 1962-1970, 1992-2000, 2006-2013, 2033-2039, 2045-2051, 2055-2067, 2070-2095, 2097-2110, 2115-2121, 2150-2171, 2174-2180, 2197-2202, 2206-2228 and 1526-1560 of Seq ID No 178; 4-17, 35-48, 54-76, 78-107, 109-115, 118-127, 134-140, 145-156, 169-174, 217-226, 232-240, 256-262, 267-273, 316-328, 340-346, 353-360, 402-409, 416-439, 448-456, 506-531, 540-546, 570-578, 586-593, 595-600, 623-632, 662-667, 674-681, 689-705, 713-724, 730-740, 757-763, 773-778, 783-796, 829-835, 861-871, 888-899, 907-939, 941-955, 957-969, 986-1000, 1022-1028, 1036-1044, 1068-1084, 1095-1102, 1118-1124, 1140-1146, 1148-1154, 1168-1181, 1185-1190, 1197-1207, 1218-1226, 1250-1270, 1272-1281, 1284-1296, 1312-1319, 1351-1358, 1383-1409, 1422-1428, 1438-1447, 1449-1461, 1482-1489, 1504-1510, 1518-1527, 1529-1537, 1544-1551, 1569-1575, 1622-1628, 1631-1637, 1682-1689, 1711-1718, 1733-1740, 1772-1783, 1818-1834, 1859-1872, 1-64 and 128-495 of Seq ID No 179; 8-28, 32-37, 62-69, 119-125, 137-149, 159-164, 173-189, 200-205, 221-229, 240-245, 258-265, 268-276, 287-293, 296-302, 323-329 and 1-95 of Seq ID No 180; 9-18, 25-38, 49-63, 65-72, 74-81, 94-117, 131-137, 139-146, 149-158, 162-188, 191-207, 217-225, 237-252, 255-269, 281-293, 301-326, 332-342, 347-354, 363-370, 373-380, 391-400, 415-424, 441-447 and 75-107 of Seq ID No 181; 4-24, 64-71, 81-87, 96-116, 121-128, 130-139, 148-155, 166-173, 176-184, 203-215, 231-238, 243-248, 256-261, 280-286, 288-306, 314-329 and 67-148 of Seq ID No 182; 4-10, 19-37, 46-52, 62-81, 83-89, 115-120, 134-139, 141-151, 168-186, 197-205, 209-234, 241-252, 322-335, 339-345, 363-379, 385-393, 403-431, 434-442, 447-454, 459-465, 479-484, 487-496 and 404-420 of Seq ID No 183; 10-35, 46-66, 71-77, 84-93, 96-122, 138-148, 154-172, 182-213, 221-233, 245-263, 269-275, 295-301, 303-309, 311-320, 324-336, 340-348, 351-359, 375-381 and 111-198 of Seq ID No 184; 14-25, 30-42, 47-61, 67-75, 81-91, 98-106, 114-122, 124-135, 148-193, 209-227 and 198-213 of Seq ID No 185; 5-18, 45-50, 82-90, 97-114, 116-136, 153-161, 163-171, 212-219, 221-227, 240-249, 267-281, 311-317, 328-337, 375-381, 390-395, 430-436, 449-455, 484-495, 538-543, 548-554, 556-564, 580-586, 596-602 and 493-606 of Seq ID No 186; 9-25, 28-34, 37-44, 61-68, 75-81, 88-96, 98-111, 119-133, 138-150, 152-163, 168-182, 186-194, 200-

205, 216-223, 236-245, 257-264, 279-287, 293-304, 311-318, 325-330, 340-346, 353-358, 365-379, 399-409, 444-453 and 303-391 of Seq ID No 187; 16-36, 55-61, 66-76, 78-102, 121-130, 134-146, 150-212, 221-239, 255-276, 289-322, 329-357 and 29-59 of Seq ID No 188; 8-27, 68-74, 77-99, 110-116, 124-141, 171-177, 202-217, 221-228, 259-265, 275-290, 293-303, 309-325, 335-343, 345-351, 365-379, 384-394, 406-414, 423-437, 452-465, 478-507, 525-534, 554-560, 611-624, 628-651, 669-682, 742-747, 767-778, 782-792, 804-812, 820-836, 79-231 and 359-451 of Seq ID No 189; 5-28, 39-45, 56-62, 67-74, 77-99, 110-117, 124-141, 168-176, 200-230, 237-244, 268-279, 287-299, 304-326, 329-335, 348-362, 370-376, 379-384, 390-406, 420-429, 466-471, 479-489, 495-504, 529-541, 545-553, 561-577, 598-604, 622-630, 637-658, 672-680, 682-688, 690-696, 698-709, 712-719, 724-736, 738-746, 759-769, 780-786, 796-804, 813-818, 860-877, 895-904, 981-997, 1000-1014, 1021-1029, 1-162, 206-224, 254-350, 414-514 and 864-938 of Seq ID No 190; 4-11, 19-49, 56-66, 68-101, 109-116, 123-145, 156-165, 177-185, 204-221, 226-234, 242-248, 251-256, 259-265, 282-302, 307-330, 340-349, 355-374, 377-383, 392-400, 422-428, 434-442, 462-474 and 266-322 of Seq ID No 191; 14-43, 45-57, 64-74, 80-87, 106-127, 131-142, 145-161, 173-180, 182-188, 203-210, 213-219, 221-243, 245-254, 304-311, 314-320, 342-348, 354-365, 372-378, 394-399, 407-431, 436-448, 459-465, 470-477, 484-490, 504-509, 531-537, 590-596, 611-617, 642-647, 723-734, 740-751, 754-762, 764-774, 782-797, 807-812, 824-831, 838-845, 877-885, 892-898, 900-906, 924-935, 940-946, 982-996, 1006-1016, 1033-1043, 1051-1056, 1058-1066, 1094-1108, 1119-1126, 1129-1140, 1150-1157, 1167-1174, 1176-1185, 1188-1201, 1209-1216, 1220-1228, 1231-1237, 1243-1248, 1253-1285, 1288-1297, 1299-1307, 1316-1334, 1336-1343, 1350-1359, 1365-1381, 1390-1396, 1412-1420, 1427-1439, 1452-1459, 1477-1484, 1493-1512, 1554-1559, 1570-1578, 1603-1608, 1623-1630, 1654-1659, 1672-1680, 1689-1696, 1705-1711, 1721-1738, 1752-1757, 1773-1780, 1817-1829, 1844-1851, 1856-1863, 1883-1895, 1950-1958, 1974-1990, 172-354, 384-448, 464-644, 648-728 and 1357-1370 of Seq ID No 192; 8-27, 68-74, 77-99, 110-116, 124-141, 169-176, 201-216, 220-227, 258-264, 274-289, 292-302, 308-324, 334-342, 344-350, 364-372, 377-387, 399-407, 416-429, 445-458, 471-481, 483-500, 518-527, 547-553, 604-617, 621-644, 662-675, 767-778, 809-816, 15-307, 350-448 and 496-620 of Seq ID No 193; 4-17, 24-29, 53-59, 62-84, 109-126, 159-164, 189-204, 208-219, 244-249, 274-290, 292-302, 308-324, 334-342, 344-350, 378-389, 391-397, 401-409, 424-432, 447-460, 470-479, 490-504, 521-529, 538-544, 549-555, 570-577, 583-592, 602-608, 615-630, 635-647, 664-677, 692-698, 722-731, 733-751, 782-790, 793-799, 56-267, 337-426 and 495-601 of Seq ID No 194; 12-22, 49-59, 77-89, 111-121, 136-148, 177-186, 207-213, 217-225, 227-253, 259-274, 296-302, 328-333, 343-354, 374-383, 424-446, 448-457, 468-480, 488-502, 507-522, 544-550, 553-560, 564-572, 587-596, 604-614, 619-625, 629-635, 638-656, 662-676, 680-692, 697-713, 720-738, 779-786, 833-847, 861-869, 880-895, 897-902, 911-917, 946-951, 959-967, 984-990, 992-1004, 1021-1040, 1057-1067, 1073-1080 and 381-403 of Seq ID No 195; 4-10, 26-31, 46-56, 60-66, 70-79, 86-94, 96-102, 109-118, 132-152, 164-187, 193-206, 217-224 and 81-149 of Seq ID No 196; 4-21, 26-37, 48-60, 71-82, 109-117, 120-128, 130-136, 142-147, 181-187, 203-211, 216-223, 247-255, 257-284, 316-325, 373-379, 395-400, 423-435, 448-456, 479-489, 512-576, 596-625, 641-678, 680-688, 692-715 and 346-453 of Seq ID No 197; 10-16, 25-31, 34-56, 58-69, 71-89, 94-110, 133-176, 186-193, 208-225, 240-250, 259-266, 302-307, 335-341, 376-383, 410-416 and 316-407 of Seq ID No 198; 11-29, 42-56, 60-75, 82-88, 95-110, 116-126, 132-143, 145-160, 166-172, 184-216 and 123-164 of Seq ID No 199; 11-29, 54-63, 110-117, 139-152, 158-166, 172-180, 186-193, 215-236, 240-251, 302-323, 330-335, 340-347, 350-366, 374-381 and 252-299 of Seq ID No 200; 18-27, 35-42, 50-56, 67-74, 112-136, 141-153, 163-171, 176-189, 205-213, 225-234, 241-247, 253-258, 269-281, 288-298, 306-324, 326-334, 355-369, 380-387 and 289-320 of Seq ID No 201; 7-15, 19-41, 56-72, 91-112, 114-122, 139-147, 163-183, 196-209, 258-280, 326-338, 357-363, 391-403, 406-416 and 360-378 of Seq ID No 202; 11-18, 29-41, 43-49, 95-108, 142-194, 204-212, 216-242, 247-256, 264-273 and 136-149 of Seq ID No 203; 18-24, 33-40, 65-79, 89-102, 113-119, 130-137, 155-161, 173-179, 183-203, 205-219, 223-231, 245-261, 267-274, 296-306, 311-321, 330-341, 344-363, 369-381, 401-408, 415-427, 437-444, 453-464, 472-478, 484-508, 517-524, 526-532, 543-548 and 59-180 of Seq ID No 204; 5-13, 52-65, 67-73, 97-110, 112-119, 134-155 and 45-177 of Seq ID No 205; 6-28, 34-43, 57-67, 75-81, 111-128, 132-147, 155-163, 165-176, 184-194, 208-216, 218-229, 239-252, 271-278, 328-334, 363-376, 381-388, 426-473, 481-488, 492-498, 507-513, 536-546, 564-582, 590-601, 607-623, 148-269, 420-450 and 610-648 of Seq ID No 206; 4-12, 20-38, 69-75, 83-88, 123-128, 145-152, 154-161, 183-188, 200-213, 245-250, 266-272, 306-312, 332-339, 357-369, 383-389, 395-402, 437-453, 455-470, 497-503 and 1-112 of Seq ID No 207; 35-59, 74-86, 111-117, 122-137 and 70-154 of Seq ID No 208; 26-42, 54-61, 65-75, 101-107, 123-130, 137-144, 148-156, 164-172, 177-192, 213-221, 231-258 and 157-249 of Seq ID No 209; 29-38, 61-67, 77-87, 94-100, 105-111, 118-158 and 1-97 of Seq ID No 210; 7-21, 30-48, 51-58, 60-85, 94-123, 134-156, 160-167, 169-183, 186-191, 216-229, 237-251,

257-267, 272-282, 287-298 and 220-243 of Seq ID No 211; 6-29, 34-47, 56-65, 69-76, 83-90, 123-134, 143-151, 158-178, 197-203, 217-235, 243-263, 303-309, 320-333, 338-348, 367-373, 387-393, 407-414, 416-427, 441-457, 473-482, 487-499, 501-509, 514-520, 530-535, 577-583, 590-602, 605-612, 622-629, 641-670, 678-690, 37-71 and 238-307 of Seq ID No 212; 7-40, 121-132, 148-161, 196-202, 209-215, 221-235, 248-255, 271-280, 288-295, 330-339, 395-409, 414-420, 446-451, 475-487, 556-563, 568-575, 580-586, 588-595, 633-638, 643-648, 652-659, 672-685, 695-700, 710-716, 737-742, 749-754, 761-767, 775-781, 796-806, 823-835, 850-863, 884-890, 892-900, 902-915, 934-941 and 406-521 of Seq ID No 213; 9-18, 24-46, 51-58, 67-77, 85-108, 114-126, 129-137, 139-146, 152-165, 173-182, 188-195, 197-204, 217-250, 260-274, 296-313, 343-366, 368-384, 427-434, 437-446, 449-455, 478-484, 492-506, 522-527, 562-591, 599-606, 609-618, 625-631, 645-652 and 577-654 of Seq ID No 214; 13-20, 26-37, 41-53, 56-65, 81-100, 102-114, 118-127, 163-188, 196-202, 231-238, 245-252, 266-285, 293-298, 301-306 and 19-78 of Seq ID No 215; 10-23, 32-42, 54-66, 73-91, 106-113, 118-127, 139-152, 164-173, 198-207, 210-245, 284-300, 313-318, 330-337, 339-346, 354-361, 387-393, 404-426, 429-439, 441-453, 467-473, 479-485, 496-509, 536-544, 551-558, 560-566, 569-574, 578-588, 610-615, 627-635, 649-675, 679-690, 698-716, 722-734, 743-754, 769-780, 782-787 and 480-550 of Seq ID No 216; 6-39, 42-50, 60-68, 76-83, 114-129, 147-162, 170-189, 197-205, 217-231, 239-248, 299-305, 338-344, 352-357, 371-377, 380-451, 459-483, 491-499, 507-523, 537-559, 587-613, 625-681, 689-729, 737-781, 785-809, 817-865, 873-881, 889-939, 951-975, 983-1027, 1031-1055, 1063-1071, 1079-1099, 1103-1127, 1151-1185, 1197-1261, 1269-1309, 1317-1333, 1341-1349, 1357-1465, 1469-1513, 1517-1553, 1557-1629, 1637-1669, 1677-1701, 1709-1725, 1733-1795, 1823-1849, 1861-1925, 1933-1973, 1981-2025, 2029-2053, 2061-2109, 2117-2125, 2133-2183, 2195-2219, 2227-2271, 2275-2299, 2307-2315, 2323-2343, 2347-2371, 2395-2429, 2441-2529, 2537-2569, 2577-2601, 2609-2625, 2633-2695, 2699-2737, 2765-2791, 2803-2867, 2889-2913, 2921-2937, 2945-2969, 2977-2985, 2993-3009, 3023-3045, 3073-3099, 3111-3167, 3175-3215, 3223-3267, 3271-3295, 3303-3351, 3359-3367, 3375-3425, 3437-3461, 3469-3513, 3517-3541, 3549-3557, 3565-3585, 3589-3613, 3637-3671, 3683-3747, 3755-3795, 3803-3819, 3827-3835, 3843-3951, 3955-3999, 4003-4039, 4043-4115, 4123-4143, 4147-4171, 4195-4229, 4241-4305, 4313-4353, 4361-4377, 4385-4393, 4401-4509, 4513-4557, 4561-4597, 4601-4718, 4749-4768, 74-171, 452-559 and 2951-3061 of Seq ID No 217; 16-22, 30-51, 70-111, 117-130, 137-150, 171-178, 180-188, 191-196 and 148-181 of Seq ID No 218; 6-19, 21-46, 50-56, 80-86, 118-126, 167-186, 189-205, 211-242, 244-267, 273-286, 290-297, 307-316, 320-341 and 34-60 of Seq ID No 219; 5-26, 33-43, 48-54, 58-63, 78-83, 113-120, 122-128, 143-152, 157-175, 185-192, 211-225, 227-234, 244-256, 270-281, 284-290, 304-310, 330-337, 348-355, 362-379, 384-394, 429-445, 450-474, 483-490, 511-520, 537-546, 548-554, 561-586, 590-604, 613-629, 149-186, 285-431 and 573-659 of Seq ID No 220; 5-26, 49-59, 61-67, 83-91, 102-111, 145-157, 185-192, 267-272, 279-286, 292-298, 306-312, 134-220, 235-251 and 254-280 of Seq ID No 221; 5-19, 72-79, 83-92, 119-124, 140-145, 160-165, 167-182, 224-232, 240-252, 259-270, 301-310, 313-322, 332-343, 347-367, 384-398, 416-429, 431-446, 454-461 and 1-169 of Seq ID No 222; 8-17, 26-31, 56-62, 75-83, 93-103, 125-131, 135-141, 150-194, 205-217, 233-258, 262-268, 281-286 and 127-168 of Seq ID No 223; 6-12, 69-75, 108-115, 139-159, 176-182, 194-214 and 46-161 of Seq ID No 224; 6-13, 18-27, 39-48, 51-59, 66-73, 79-85, 95-101, 109-116, 118-124, 144-164, 166-177, 183-193, 197-204, 215-223, 227-236, 242-249, 252-259, 261-270, 289-301, 318-325 and 12-58 of Seq ID No 225; 4-10, 26-32, 48-60, 97-105, 117-132, 138-163, 169-185, 192-214, 219-231, 249-261, 264-270, 292-308, 343-356, 385-392, 398-404, 408-417, 435-441 and 24-50 of Seq ID No 226; 10-40, 42-48, 51-61, 119-126 and 1-118 of Seq ID No 227; 5-17, 40-58, 71-83, 103-111, 123-140, 167-177, 188-204 and 116-128 of Seq ID No 228; 4-9, 11-50, 57-70, 112-123, 127-138 and 64-107 of Seq ID No 229; 9-39, 51-67 and 1-101 of Seq ID No 230; 5-14, 17-25, 28-46, 52-59, 85-93, 99-104, 111-120, 122-131, 140-148, 158-179, 187-197, 204-225, 271-283, 285-293 and 139-155 of Seq ID No 231; 42-70, 73-90, 92-108, 112-127, 152-164, 166-172, 181-199, 201-210, 219-228, 247-274, 295-302, 322-334, 336-346, 353-358, 396-414, 419-425, 432-438, 462-471, 518-523, 531-536, 561-567, 576-589, 594-612, 620-631, 665-671, 697-710, 718-731, 736-756, 765-771, 784-801 and 626-653 of Seq ID No 232; 8-28, 41-51, 53-62, 68-74, 79-85, 94-100, 102-108, 114-120, 130-154, 156-162, 175-180, 198-204, 206-213, 281-294, 308-318, 321-339, 362-368, 381-386, 393-399, 407-415 and 2-13 of Seq ID No 233; 4-39, 48-65, 93-98, 106-112, 116-129 and 10-36 of Seq ID No 234; 25-32, 35-50, 66-71, 75-86, 90-96, 123-136, 141-151, 160-179, 190-196, 209-215, 222-228, 235-242, 257-263, 270-280 and 209-247 of Seq ID No 235; 5-29, 31-38, 50-57, 62-75, 83-110, 115-132, 168-195, 197-206, 216-242, 249-258, 262-269, 333-340, 342-350, 363-368, 376-392, 400-406, 410-421, 423-430, 436-442, 448-454, 460-466, 471-476, 491-496, 511-516, 531-536, 551-556, 571-576, 585-591, 599-605, 27-70, 219-293, 441-504 and 512-584 of Seq ID No 236; 4-12, 14-34, 47-75, 83-104, 107-115, 133-140, 148-185, 187-196, 207-212, 224-256, 258-265, 281-287, 289-296,

298-308, 325-333, 345-355, 365-371, 382-395, 424-435, 441-457, 465-472, 483-491, 493-505, 528-534, 536-546, 552-558, 575-584, 589-600, 616-623 and 576-591 of Seq ID No 237; 4-76, 78-89, 91-126, 142-148, 151-191, 195-208, 211-223, 226-240, 256-277, 279-285, 290-314, 317-323, 358-377, 381-387, 391-396, 398-411, 415-434, 436-446, 454-484, 494-512, 516-523, 538-552, 559-566, 571-577, 579-596, 599-615, 620-627, 635-644, 694-707, 720-734, 737-759, 761-771 and 313-329 of Seq ID No 238; 7-38, 44-49, 79-89, 99-108, 117-123, 125-132, 137-146, 178-187, 207-237, 245-255, 322-337, 365-387, 398-408, 445-462, 603-608, 623-628, 644-650, 657-671, 673-679 and 111-566 of Seq ID No 239; 6-20, 22-35, 39-45, 58-64, 77-117, 137-144, 158-163, 205-210, 218-224, 229-236, 239-251, 263-277, 299-307, 323-334, 353-384, 388-396, 399-438, 443-448, 458-463, 467-478, 481-495, 503-509, 511-526, 559-576, 595-600, 612-645, 711-721, 723-738, 744-758, 778-807 and 686-720 of Seq ID No 240; 10-33, 35-41, 72-84, 129-138, 158-163, 203-226, 243-252, 258-264, 279-302, 322-329, 381-386, 401-406, 414-435 and 184-385 of Seq ID No 241; 4-9, 19-24, 41-47, 75-85, 105-110, 113-146 and 45-62 of Seq ID No 242; 4-25, 52-67, 117-124, 131-146, 173-180, 182-191, 195-206, 215-221, 229-236, 245-252, 258-279, 286-291, 293-302, 314-320, 327-336, 341-353, 355-361, 383-389 and 1-285 of Seq ID No 243; 14-32, 38-50, 73-84, 93-105, 109-114 and 40-70 of Seq ID No 244; 5-26 and 22-34 of Seq ID No 245; 23-28 and 13-39 of Seq ID No 246; 8-14 and 21-34 of Seq ID No 247; 4-13, 20-29, 44-50, 59-74 and 41-69 of Seq ID No 248; 4-9, 19-42, 48-59, 71-83 and 57-91 of Seq ID No 249; 4-14 and 10-28 of Seq ID No 250; 22-28, 32-42, 63-71, 81-111, 149-156, 158-167, 172-180, 182-203, 219-229 and 27-49 of Seq ID No 251; 17-27 and 23-32 of Seq ID No 252; 18-24 and 28-38 of Seq ID No 253; 9-15 and 13-27 of Seq ID No 254; 13-22 and 18-29 of Seq ID No 255; 17-26 and 2-11 of Seq ID No 256; 4-33 and 16-32 of Seq ID No 257; 4-10, 37-43, 54-84, 92-127 and 15-62 of Seq ID No 258; 4-14, 20-32, 35-60, 69-75, 79-99, 101-109, 116-140 and 124-136 of Seq ID No 259; 2-13 of Seq ID No 260; 4-13, 28-42 and 42-57 of Seq ID No 261; 4-14, 27-44 and 14-35 of Seq ID No 262; 4-12 and 1-27 of Seq ID No 263; 4-18, 39-45, 47-74 and 35-66 of Seq ID No 264; 8-20, 43-77 and 17-36 of Seq ID No 265; 4-30, 35-45, 51-57 and 35-49 of Seq ID No 266; 4-24, 49-57 and 15-34 of Seq ID No 267; 4-22 and 8-27 of Seq ID No 268; 13-25, 32-59, 66-80 and 21-55 of Seq ID No 269; 4-10, 24-33, 35-42, 54-65, 72-82, 98-108 and 15-30 of Seq ID No 270; 8-19 and 17-47 of Seq ID No 271; 12-18, 40-46 and 31-52 of Seq ID No 272; 4-20, 35-78, 83-102, 109-122 and 74-86 of Seq ID No 273; 7-17, 21-41, 46-63 and 2-20 of Seq ID No 274; 30-37 and 2-33 of Seq ID No 275; 4-13, 17-25 and 1-15 of Seq ID No 276; 17-31, 44-51 and 20-51 of Seq ID No 277; 20-30 and 5-23 of Seq ID No 278; 13-33, 48-71 and 92-110 of Seq ID No 279; 4-9, 50-69, 76-88, 96-106, 113-118 and 12-34 of Seq ID No 280; 4-24 and 6-26 of Seq ID No 281; 7-26 and 14-30 of Seq ID No 282; 9-39, 46-68, 75-82, 84-103 and 26-44 of Seq ID No 283; 4-30, 33-107 and 58-84 of Seq ID No 284; 4-12 and 9-51 of Seq ID No 285; 12-18, 29-37 and 6-37 of Seq ID No 286; 4-21, 33-52, 64-71 and 16-37 of Seq ID No 287; 9-19 and 2-30 of Seq ID No 288; 20-37 of Seq ID No 245; 8-27 of Seq ID No 246; 10-27 of Seq ID No 247; 42-59 and 52-69 of Seq ID No 248; 63-80 and 74-91 of Seq ID No 249; 11-28 of Seq ID No 250; 28-49 of Seq ID No 251; 15-32 of Seq ID No 252; 4-20 of Seq ID No 253; 10-27 of Seq ID No 254; 17-34 of Seq ID No 255; 1-18 of Seq ID No 256; 16-33 of Seq ID No 257; 16-36, 30-49 and 43-62 of Seq ID No 258; 122-139 of Seq ID No 259; 1-18 of Seq ID No 260; 41-58 of Seq ID No 261; 15-35 of Seq ID No 262; 2-27 of Seq ID No 263; 18-36 of Seq ID No 265; 34-51 of Seq ID No 266; 9-27 of Seq ID No 268; 22-47 of Seq ID No 269; 18-36 and 29-47 of Seq ID No 271; 32-52 of Seq ID No 272; 72-89 of Seq ID No 273; 3-20 of Seq ID No 274; 3-21 and 15-33 of Seq ID No 275; 1-18 of Seq ID No 276; 6-23 of Seq ID No 278; 93-110 of Seq ID No 279; 13-34 of Seq ID No 280; 7-26 and 9-26 of Seq ID No 281; 16-33 of Seq ID No 282; 27-44 of Seq ID No 283; 67-84 of Seq ID No 284; 10-33 and 26-50 of Seq ID No 285; 7-25 and 19-37 of Seq ID No 286; 17-37 of Seq ID No 287; 3-20 and 13-30 of Seq ID No 288; 62-80 and 75-93 of Seq ID No 145; 92-108 of Seq ID No 147; 332-349, 177-200 and 1755-1777 of Seq ID No 148; 109-133, 149-174, 260-285 and 460-485 of Seq ID No 149; 26-47 and 42-64 of Seq ID No 150; 22-41, 35-54, 115-130, 306-325, 401-420 and 454-478 of Seq ID No 151; 22-45 of Seq ID No 155; 156-174, 924-940, 1485-1496, 1447-1462 and 1483-1498 of Seq ID No 160; 457-475 of Seq ID No 161; 302-325 of Seq ID No 163; 288-305 of Seq ID No 164; 244-266 and 260-282 of Seq ID No 165; 204-225 and 220-241 of Seq ID No 166; 324-345, 340-361, 356-377, 372-393 and 388-408 of Seq ID No 167; 39-64 of Seq ID No 168; 54-76 and 70-92 of Seq ID No 169; 1227-1247, 1539-1559, 1554-1574, 1569-1589, 1584-1604, 1242-1262, 1272-1292, 1287-1308, 1456-1477, 1472-1494, 1488-1510 and 1505-1526 of Seq ID No 170; 351-368 of Seq ID No 172; 179-200, 195-216, 211-232, 227-248 and 243-263 of Seq ID No 173; 13-37 of Seq ID No 174; 208-224 of Seq ID No 175; 42-64, 59-81, 304-328, 323-348, 465-489, 968-992, 1399-1418, 1412-1431 and 2092-2111 of Seq ID No 177; 1528-1547 and 1541-1560 of Seq ID No

178; 184-200, 367-388, 382-403, 409-429, 425-444 and 438-457 of Seq ID No 179; 27-50 and 45-67 of Seq ID No 180; 114-131 and 405-419 of Seq ID No 183; 113-134, 129-150, 145-166, 161-182 and 177-198 of Seq ID No 184; 495-515 of Seq ID No 186; 346-358 of Seq ID No 187; 208-224 of Seq ID No 190; 178-194, 202-223, 217-238, 288-308 and 1355-1372 of Seq ID No 192; 57-78 of Seq ID No 194; 347-369, 364-386, 381-403, 398-420, 415-437 and 432-452 of Seq ID No 197; 347-372 of Seq ID No 198; 147-163 of Seq ID No 199; 263-288 of Seq ID No 200; 361-377 of Seq ID No 202; 82-104, 99-121, 116-138, 133-155 and 150-171 of Seq ID No 204; 110-130 and 125-145 of Seq ID No 205; 613-631, 626-644 and 196-213 of Seq ID No 206; 78-100, 95-117, 112-134 and 129-151 of Seq ID No 208; 158-180, 175-197, 192-214, 209-231 and 226-248 of Seq ID No 209; 30-50, 45-65 and 60-79 of Seq ID No 210; 431-455 and 450-474 of Seq ID No 213; 579-601, 596-618, 613-635 and 630-653 of Seq ID No 214; 920-927, 98-119, 114-135, 130-151, 146-167 and 162-182 of Seq ID No 217; 36-59 of Seq ID No 219; 194-216 and 381-404 of Seq ID No 220; 236-251 and 255-279 of Seq ID No 221; 80-100 and 141-164 of Seq ID No 222; 128-154 of Seq ID No 223; 82-100, 95-116 and 111-134 of Seq ID No 224; 55-76, 71-92 and 87-110 of Seq ID No 227; 91-106 of Seq ID No 229; 74-96 of Seq ID No 230; 140-157 of Seq ID No 231; 4-13 of Seq ID No 233; 41-65 and 499-523 of Seq ID No 236; 122-146, 191-215, 288-313, 445-469 and 511-535 of Seq ID No 239; 347-368 of Seq ID No 241; 46-61 of Seq ID No 242; 15-37, 32-57, 101-121, 115-135, 138-158, 152-172, 220-242 and 236-258 of Seq ID No 243, and fragments comprising at least 6, preferably more than 8, especially more than 10 aa and preferably not more than 70, 50, 40, 20, 15, 11 aa of said sequences. All these fragments individually and each independently form a preferred selected aspect of the present invention.

All linear hyperimmune serum reactive fragments of a particular antigen may be identified by analysing the entire sequence of the protein antigen by a set of peptides overlapping by 1 amino acid with a length of at least 10 amino acids. Subsequently, non-linear epitopes can be identified by analysis of the protein antigen with hyperimmune sera using the expressed full-length protein or domain polypeptides thereof. Assuming that a distinct domain of a protein is sufficient to form the 3D structure independent from the native protein, the analysis of the respective recombinant or synthetically produced domain polypeptide with hyperimmune serum would allow the identification of conformational epitopes within the individual domains of multi-domain proteins. For those antigens where a domain possesses linear as well as conformational epitopes, competition experiments with peptides corresponding to the linear epitopes may be used to confirm the presence of conformational epitopes.

It will be appreciated that the invention also relates to, among others, nucleic acid molecules encoding the aforementioned fragments, nucleic acid molecules that hybridise to nucleic acid molecules encoding the fragments, particularly those that hybridise under stringent conditions, and nucleic acid molecules, such as PCR primers, for amplifying nucleic acid molecules that encode the fragments. In these regards, preferred nucleic acid molecules are those that correspond to the preferred fragments, as discussed above.

The present invention also relates to vectors, which comprise a nucleic acid molecule or nucleic acid molecules of the present invention, host cells which are genetically engineered with vectors of the invention and the production of hyperimmune serum reactive antigens and fragments thereof by recombinant techniques.

A great variety of expression vectors can be used to express a hyperimmune serum reactive antigen or fragment thereof according to the present invention. Generally, any vector suitable to maintain, propagate or express nucleic acids to express a polypeptide in a host may be used for expression in this regard. In accordance with this aspect of the invention the vector may be, for example, a plasmid vector, a single or double-stranded phage vector, a single or double-stranded RNA or DNA viral vector. Starting plasmids disclosed herein are either commercially available, publicly available, or can be constructed from available plasmids by routine application of well-known, published procedures. Preferred among vectors, in certain respects, are those for expression of nucleic acid molecules and hyperimmune serum reactive antigens or fragments thereof of the present invention. Nucleic acid constructs in host cells can

be used in a conventional manner to produce the gene product encoded by the recombinant sequence. Alternatively, the hyperimmune serum reactive antigens and fragments thereof of the invention can be synthetically produced by conventional peptide synthesizers. Mature proteins can be expressed in mammalian cells, yeast, bacteria, or other cells under the control of appropriate promoters. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA construct of the present invention.

Host cells can be genetically engineered to incorporate nucleic acid molecules and express nucleic acid molecules of the present invention. Representative examples of appropriate hosts include bacterial cells, such as streptococci, staphylococci, *E. coli*, *Streptomyces* and *Bacillus subtilis* cells; fungal cells, such as yeast cells and *Aspergillus* cells; insect cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, 293 and Bowes melanoma cells; and plant cells.

The invention also provides a process for producing a *S. pneumoniae* hyperimmune serum reactive antigen and a fragment thereof comprising expressing from the host cell a hyperimmune serum reactive antigen or fragment thereof encoded by the nucleic acid molecules provided by the present invention. The invention further provides a process for producing a cell, which expresses a *S. pneumoniae* hyperimmune serum reactive antigen or a fragment thereof comprising transforming or transfecting a suitable host cell with the vector according to the present invention such that the transformed or transfected cell expresses the polypeptide encoded by the nucleic acid contained in the vector.

The polypeptide may be expressed in a modified form, such as a fusion protein, and may include not only secretion signals but also additional heterologous functional regions. Thus, for instance, a region of additional amino acids, particularly charged amino acids, may be added to the N- or C-terminus of the polypeptide to improve stability and persistence in the host cell, during purification or during subsequent handling and storage. Also, regions may be added to the polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide moieties to polypeptides to engender secretion or excretion, to improve stability or to facilitate purification, among others, are familiar and routine techniques in the art. A preferred fusion protein comprises a heterologous region from immunoglobulin that is useful to solubilize or purify polypeptides. For example, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another protein or part thereof. In drug discovery, for example, proteins have been fused with antibody Fc portions for the purpose of high-throughout screening assays to identify antagonists. See for example, {Bennett, D. et al., 1995} and {Johanson, K. et al., 1995}.

The *S. pneumoniae* hyperimmune serum reactive antigen or a fragment thereof can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, hydroxylapatite chromatography and lectin chromatography.

The hyperimmune serum reactive antigens and fragments thereof according to the present invention can be produced by chemical synthesis as well as by biotechnological means. The latter comprise the transfection or transformation of a host cell with a vector containing a nucleic acid according to the present invention and the cultivation of the transfected or transformed host cell under conditions, which are known to the ones skilled in the art. The production method may also comprise a purification step in order to purify or isolate the polypeptide to be manufactured. In a preferred embodiment the vector is a vector according to the present invention.

The hyperimmune serum reactive antigens and fragments thereof according to the present invention may be used for the detection of the organism or organisms in a sample containing these organisms or

polypeptides derived thereof. Preferably such detection is for diagnosis, more preferable for the diagnosis of a disease, most preferably for the diagnosis of a diseases related or linked to the presence or abundance of Gram-positive bacteria, especially bacteria selected from the group comprising streptococci, staphylococci and lactococci. More preferably, the microorganisms are selected from the group comprising *Streptococcus agalactiae*, *Streptococcus pyogenes* and *Streptococcus mutans*, especially the microorganism is *Streptococcus pyogenes*.

The present invention also relates to diagnostic assays such as quantitative and diagnostic assays for detecting levels of the hyperimmune serum reactive antigens and fragments thereof of the present invention in cells and tissues, including determination of normal and abnormal levels. Thus, for instance, a diagnostic assay in accordance with the invention for detecting over-expression of the polypeptide compared to normal control tissue samples may be used to detect the presence of an infection, for example, and to identify the infecting organism. Assay techniques that can be used to determine levels of a polypeptide, in a sample derived from a host are well known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays. Among these, ELISAs frequently are preferred. An ELISA assay initially comprises preparing an antibody specific to the polypeptide, preferably a monoclonal antibody. In addition, a reporter antibody generally is prepared which binds to the monoclonal antibody. The reporter antibody is attached to a detectable reagent such as radioactive, fluorescent or enzymatic reagent, such as horseradish peroxidase enzyme.

The hyperimmune serum reactive antigens and fragments thereof according to the present invention may also be used for the purpose of or in connection with an array. More particularly, at least one of the hyperimmune serum reactive antigens and fragments thereof according to the present invention may be immobilized on a support. Said support typically comprises a variety of hyperimmune serum reactive antigens and fragments thereof whereby the variety may be created by using one or several of the hyperimmune serum reactive antigens and fragments thereof according to the present invention and/or hyperimmune serum reactive antigens and fragments thereof being different. The characterizing feature of such array as well as of any array in general is the fact that at a distinct or predefined region or position on said support or a surface thereof, a distinct polypeptide is immobilized. Because of this any activity at a distinct position or region of an array can be correlated with a specific polypeptide. The number of different hyperimmune serum reactive antigens and fragments thereof immobilized on a support may range from as little as 10 to several 1000 different hyperimmune serum reactive antigens and fragments thereof. The density of hyperimmune serum reactive antigens and fragments thereof per cm^2 is in a preferred embodiment as little as 10 peptides/polypeptides per cm^2 to at least 400 different peptides/polypeptides per cm^2 and more particularly at least 1000 different hyperimmune serum reactive antigens and fragments thereof per cm^2 .

The manufacture of such arrays is known to the one skilled in the art and, for example, described in US patent 5,744,309. The array preferably comprises a planar, porous or non-porous solid support having at least a first surface. The hyperimmune serum reactive antigens and fragments thereof as disclosed herein, are immobilized on said surface. Preferred support materials are, among others, glass or cellulose. It is also within the present invention that the array is used for any of the diagnostic applications described herein. Apart from the hyperimmune serum reactive antigens and fragments thereof according to the present invention also the nucleic acid molecules according to the present invention may be used for the generation of an array as described above. This applies as well to an array made of antibodies, preferably monoclonal antibodies as, among others, described herein.

In a further aspect the present invention relates to an antibody directed to any of the hyperimmune serum reactive antigens and fragments thereof, derivatives or fragments thereof according to the present invention. The present invention includes, for example, monoclonal and polyclonal antibodies, chimeric, single chain, and humanized antibodies, as well as Fab fragments, or the product of a Fab expression

library. It is within the present invention that the antibody may be chimeric, i. e. that different parts thereof stem from different species or at least the respective sequences are taken from different species.

Antibodies generated against the hyperimmune serum reactive antigens and fragments thereof corresponding to a sequence of the present invention can be obtained by direct injection of the hyperimmune serum reactive antigens and fragments thereof into an animal or by administering the hyperimmune serum reactive antigens and fragments thereof to an animal, preferably a non-human. The antibody so obtained will then bind the hyperimmune serum reactive antigens and fragments thereof itself. In this manner, even a sequence encoding only a fragment of a hyperimmune serum reactive antigen and fragments thereof can be used to generate antibodies binding the whole native hyperimmune serum reactive antigen and fragments thereof. Such antibodies can then be used to isolate the hyperimmune serum reactive antigens and fragments thereof from tissue expressing those hyperimmune serum reactive antigens and fragments thereof.

For preparation of monoclonal antibodies, any technique known in the art, which provides antibodies produced by continuous cell line cultures can be used (as described originally in {Kohler, G. et al., 1975}).

Techniques described for the production of single chain antibodies (U.S. Patent No. 4,946,778) can be adapted to produce single chain antibodies to immunogenic hyperimmune serum reactive antigens and fragments thereof according to this invention. Also, transgenic mice, or other organisms such as other mammals, may be used to express humanized antibodies to immunogenic hyperimmune serum reactive antigens and fragments thereof according to this invention.

Alternatively, phage display technology or ribosomal display could be utilized to select antibody genes with binding activities towards the hyperimmune serum reactive antigens and fragments thereof either from repertoires of PCR amplified v-genes of lymphocytes from humans screened for possessing respective target antigens or from naïve libraries {McCafferty, J. et al., 1990}; {Marks, J. et al., 1992}. The affinity of these antibodies can also be improved by chain shuffling {Clackson, T. et al., 1991}.

If two antigen binding domains are present, each domain may be directed against a different epitope – termed ‘bispecific’ antibodies.

The above-described antibodies may be employed to isolate or to identify clones expressing the hyperimmune serum reactive antigens and fragments thereof or purify the hyperimmune serum reactive antigens and fragments thereof of the present invention by attachment of the antibody to a solid support for isolation and/or purification by affinity chromatography.

Thus, among others, antibodies against the hyperimmune serum reactive antigens and fragments thereof of the present invention may be employed to inhibit and/or treat infections, particularly bacterial infections and especially infections arising from *S. pneumoniae*.

Hyperimmune serum reactive antigens and fragments thereof include antigenically, epitopically or immunologically equivalent derivatives, which form a particular aspect of this invention. The term “antigenically equivalent derivative” as used herein encompasses a hyperimmune serum reactive antigen and fragments thereof or its equivalent which will be specifically recognized by certain antibodies which, when raised to the protein or hyperimmune serum reactive antigen and fragments thereof according to the present invention, interfere with the interaction between pathogen and mammalian host. The term “immunologically equivalent derivative” as used herein encompasses a peptide or its equivalent which when used in a suitable formulation to raise antibodies in a vertebrate, the antibodies act to interfere with the interaction between pathogen and mammalian host.

The hyperimmune serum reactive antigens and fragments thereof, such as an antigenically or

immunologically equivalent derivative or a fusion protein thereof can be used as an antigen to immunize a mouse or other animal such as a rat or chicken. The fusion protein may provide stability to the hyperimmune serum reactive antigens and fragments thereof. The antigen may be associated, for example by conjugation, with an immunogenic carrier protein, for example bovine serum albumin (BSA) or keyhole limpet haemocyanin (KLH). Alternatively, an antigenic peptide comprising multiple copies of the protein or hyperimmune serum reactive antigen and fragments thereof, or an antigenically or immunologically equivalent hyperimmune serum reactive antigen and fragments thereof, may be sufficiently antigenic to improve immunogenicity so as to obviate the use of a carrier.

Preferably the antibody or derivative thereof is modified to make it less immunogenic in the individual. For example, if the individual is human the antibody may most preferably be "humanized", wherein the complementarity determining region(s) of the hybridoma-derived antibody has been transplanted into a human monoclonal antibody, for example as described in [Jones, P. et al., 1986] or [Tempest, P. et al., 1991].

The use of a polynucleotide of the invention in genetic immunization will preferably employ a suitable delivery method such as direct injection of plasmid DNA into muscle, delivery of DNA complexed with specific protein carriers, coprecipitation of DNA with calcium phosphate, encapsulation of DNA in various forms of liposomes, particle bombardment [Tang, D. et al., 1992]; [Eisenbraun, M. et al., 1993] and *in vivo* infection using cloned retroviral vectors [Seeger, C. et al., 1984].

In a further aspect the present invention relates to a peptide binding to any of the hyperimmune serum reactive antigens and fragments thereof according to the present invention, and a method for the manufacture of such peptides whereby the method is characterized by the use of the hyperimmune serum reactive antigens and fragments thereof according to the present invention and the basic steps are known to the one skilled in the art.

Such peptides may be generated by using methods according to the state of the art such as phage display or ribosome display. In case of phage display, basically a library of peptides is generated, in form of phages, and this kind of library is contacted with the target molecule, in the present case a hyperimmune serum reactive antigen and fragments thereof according to the present invention. Those peptides binding to the target molecule are subsequently removed, preferably as a complex with the target molecule, from the respective reaction. It is known to the one skilled in the art that the binding characteristics, at least to a certain extent, depend on the particularly realized experimental set-up such as the salt concentration and the like. After separating those peptides binding to the target molecule with a higher affinity or a bigger force, from the non-binding members of the library, and optionally also after removal of the target molecule from the complex of target molecule and peptide, the respective peptide(s) may subsequently be characterised. Prior to the characterisation optionally an amplification step is realized such as, e. g. by propagating the peptide encoding phages. The characterisation preferably comprises the sequencing of the target binding peptides. Basically, the peptides are not limited in their lengths, however, preferably peptides having a lengths from about 8 to 20 amino acids are preferably obtained in the respective methods. The size of the libraries may be about 10^2 to 10^{18} , preferably 10^8 to 10^{15} different peptides, however, is not limited thereto.

A particular form of target binding hyperimmune serum reactive antigens and fragments thereof are the so-called "anticalines" which are, among others, described in German patent application DE 197 42 706.

In a further aspect the present invention relates to functional nucleic acids interacting with any of the hyperimmune serum reactive antigens and fragments thereof according to the present invention, and a method for the manufacture of such functional nucleic acids whereby the method is characterized by the use of the hyperimmune serum reactive antigens and fragments thereof according to the present invention and the basic steps are known to the one skilled in the art. The functional nucleic acids are

preferably aptamers and spiegelmers.

Aptamers are D-nucleic acids, which are either single stranded or double stranded and which specifically interact with a target molecule. The manufacture or selection of aptamers is, e.g. described in European patent EP 0 533 838. Basically the following steps are realized. First, a mixture of nucleic acids, i. e. potential aptamers, is provided whereby each nucleic acid typically comprises a segment of several, preferably at least eight subsequent randomised nucleotides. This mixture is subsequently contacted with the target molecule whereby the nucleic acid(s) bind to the target molecule, such as based on an increased affinity towards the target or with a bigger force thereto, compared to the candidate mixture. The binding nucleic acid(s) are/is subsequently separated from the remainder of the mixture. Optionally, the thus obtained nucleic acid(s) is amplified using, e.g. polymerase chain reaction. These steps may be repeated several times giving at the end a mixture having an increased ratio of nucleic acids specifically binding to the target from which the final binding nucleic acid is then optionally selected. These specifically binding nucleic acid(s) are referred to as aptamers. It is obvious that at any stage of the method for the generation or identification of the aptamers samples of the mixture of individual nucleic acids may be taken to determine the sequence thereof using standard techniques. It is within the present invention that the aptamers may be stabilized such as, e. g., by introducing defined chemical groups which are known to the one skilled in the art of generating aptamers. Such modification may for example reside in the introduction of an amino group at the 2'-position of the sugar moiety of the nucleotides. Aptamers are currently used as therapeutical agents. However, it is also within the present invention that the thus selected or generated aptamers may be used for target validation and/or as lead substance for the development of medicaments, preferably of medicaments based on small molecules. This is actually done by a competition assay whereby the specific interaction between the target molecule and the aptamer is inhibited by a candidate drug whereby upon replacement of the aptamer from the complex of target and aptamer it may be assumed that the respective drug candidate allows a specific inhibition of the interaction between target and aptamer, and if the interaction is specific, said candidate drug will, at least in principle, be suitable to block the target and thus decrease its biological availability or activity in a respective system comprising such target. The thus obtained small molecule may then be subject to further derivatisation and modification to optimise its physical, chemical, biological and/or medical characteristics such as toxicity, specificity, biodegradability and bioavailability.

Spiegelmers and their generation or manufacture is based on a similar principle. The manufacture of spiegelmers is described in international patent application WO 98/08856. Spiegelmers are L-nucleic acids, which means that they are composed of L-nucleotides rather than D-nucleotides as aptamers are. Spiegelmers are characterized by the fact that they have a very high stability in biological systems and, comparable to aptamers, specifically interact with the target molecule against which they are directed. In the process of generating spiegelmers, a heterogeneous population of D-nucleic acids is created and this population is contacted with the optical antipode of the target molecule, in the present case for example with the D-enantiomer of the naturally occurring L-enantiomer of the hyperimmune serum reactive antigens and fragments thereof according to the present invention. Subsequently, those D-nucleic acids are separated which do not interact with the optical antipode of the target molecule. But those D-nucleic acids interacting with the optical antipode of the target molecule are separated, optionally identified and/or sequenced and subsequently the corresponding L-nucleic acids are synthesized based on the nucleic acid sequence information obtained from the D-nucleic acids. These L-nucleic acids which are identical in terms of sequence with the aforementioned D-nucleic acids interacting with the optical antipode of the target molecule, will specifically interact with the naturally occurring target molecule rather than with the optical antipode thereof. Similar to the method for the generation of aptamers it is also possible to repeat the various steps several times and thus to enrich those nucleic acids specifically interacting with the optical antipode of the target molecule.

In a further aspect the present invention relates to functional nucleic acids interacting with any of the nucleic acid molecules according to the present invention, and a method for the manufacture of such

functional nucleic acids whereby the method is characterized by the use of the nucleic acid molecules and their respective sequences according to the present invention and the basic steps are known to the one skilled in the art. The functional nucleic acids are preferably ribozymes, antisense oligonucleotides and siRNA.

Ribozymes are catalytically active nucleic acids which preferably consist of RNA which basically comprises two moieties. The first moiety shows a catalytic activity whereas the second moiety is responsible for the specific interaction with the target nucleic acid, in the present case the nucleic acid coding for the hyperimmune serum reactive antigens and fragments thereof according to the present invention. Upon interaction between the target nucleic acid and the second moiety of the ribozyme, typically by hybridisation and Watson-Crick base pairing of essentially complementary stretches of bases on the two hybridising strands, the catalytically active moiety may become active which means that it catalyses, either intramolecularly or intermolecularly, the target nucleic acid in case the catalytic activity of the ribozyme is a phosphodiesterase activity. Subsequently, there may be a further degradation of the target nucleic acid, which in the end results in the degradation of the target nucleic acid as well as the protein derived from the said target nucleic acid. Ribozymes, their use and design principles are known to the one skilled in the art, and, for example described in {Doherty, E. et al., 2001} and {Lewin, A. et al., 2001}.

The activity and design of antisense oligonucleotides for the manufacture of a medicament and as a diagnostic agent, respectively, is based on a similar mode of action. Basically, antisense oligonucleotides hybridise based on base complementarity, with a target RNA, preferably with a mRNA, thereby activating RNase H. RNase H is activated by both phosphodiester and phosphorothioate-coupled DNA. Phosphodiester-coupled DNA, however, is rapidly degraded by cellular nucleases with the exception of phosphorothioate-coupled DNA. These resistant, non-naturally occurring DNA derivatives do not inhibit RNase H upon hybridisation with RNA. In other words, antisense polynucleotides are only effective as DNA RNA hybrid complexes. Examples for this kind of antisense oligonucleotides are described, among others, in US-patent US 5,849,902 and US 5,989,912. In other words, based on the nucleic acid sequence of the target molecule which in the present case are the nucleic acid molecules for the hyperimmune serum reactive antigens and fragments thereof according to the present invention, either from the target protein from which a respective nucleic acid sequence may in principle be deduced, or by knowing the nucleic acid sequence as such, particularly the mRNA, suitable antisense oligonucleotides may be designed base on the principle of base complementarity.

Particularly preferred are antisense-oligonucleotides, which have a short stretch of phosphorothioate DNA (3 to 9 bases). A minimum of 3 DNA bases is required for activation of bacterial RNase H and a minimum of 5 bases is required for mammalian RNase H activation. In these chimeric oligonucleotides there is a central region that forms a substrate for RNase H that is flanked by hybridising "arms" comprised of modified nucleotides that do not form substrates for RNase H. The hybridising arms of the chimeric oligonucleotides may be modified such as by 2'-O-methyl or 2'-fluoro. Alternative approaches used methylphosphonate or phosphoramidate linkages in said arms. Further embodiments of the antisense oligonucleotide useful in the practice of the present invention are P-methoxyoligonucleotides, partial P-methoxyoligodeoxyribonucleotides or P-methoxyoligonucleotides.

Of particular relevance and usefulness for the present invention are those antisense oligonucleotides as more particularly described in the above two mentioned US patents. These oligonucleotides contain no naturally occurring 5'→3'-linked nucleotides. Rather the oligonucleotides have two types of nucleotides: 2'-deoxyphosphorothioate, which activate RNase H, and 2'-modified nucleotides, which do not. The linkages between the 2'-modified nucleotides can be phosphodiester, phosphorothioate or P-methoxyphosphodiester. Activation of RNase H is accomplished by a contiguous RNase H-activating region, which contains between 3 and 5 2'-deoxyphosphorothioate nucleotides to activate bacterial RNase H and between 5 and 10 2'-deoxyphosphorothioate nucleotides to activate eucaryotic and, particularly,

mammalian RNase H. Protection from degradation is accomplished by making the 5' and 3' terminal bases highly nuclease resistant and, optionally, by placing a 3' terminal blocking group.

More particularly, the antisense oligonucleotide comprises a 5' terminus and a 3' terminus; and from position 11 to 59 5'→3'-linked nucleotides independently selected from the group consisting of 2'-modified phosphodiester nucleotides and 2'-modified P-alkoxyphosphotriester nucleotides; and wherein the 5'-terminal nucleoside is attached to an RNase H-activating region of between three and ten contiguous phosphorothioate-linked deoxyribonucleotides, and wherein the 3'-terminus of said oligonucleotide is selected from the group consisting of an inverted deoxyribonucleotide, a contiguous stretch of one to three phosphorothioate 2'-modified ribonucleotides, a biotin group and a P-alkoxyphosphotriester nucleotide.

Also an antisense oligonucleotide may be used wherein not the 5' terminal nucleoside is attached to an RNase H-activating region but the 3' terminal nucleoside as specified above. Also, the 5' terminus is selected from the particular group rather than the 3' terminus of said oligonucleotide.

The nucleic acids as well as the hyperimmune serum reactive antigens and fragments thereof according to the present invention may be used as or for the manufacture of pharmaceutical compositions, especially vaccines. Preferably such pharmaceutical composition, preferably vaccine is for the prevention or treatment of diseases caused by, related to or associated with *S. pneumoniae*. In so far another aspect of the invention relates to a method for inducing an immunological response in an individual, particularly a mammal, which comprises inoculating the individual with the hyperimmune serum reactive antigens and fragments thereof of the invention, or a fragment or variant thereof, adequate to produce antibodies to protect said individual from infection, particularly *streptococcal* infection and most particularly *S. pneumoniae* infections.

Yet another aspect of the invention relates to a method of inducing an immunological response in an individual which comprises, through gene therapy or otherwise, delivering a nucleic acid functionally encoding hyperimmune serum reactive antigens and fragments thereof, or a fragment or a variant thereof, for expressing the hyperimmune serum reactive antigens and fragments thereof, or a fragment or a variant thereof *in vivo* in order to induce an immunological response to produce antibodies or a cell mediated T cell response, either cytokine-producing T cells or cytotoxic T cells, to protect said individual from disease, whether that disease is already established within the individual or not. One way of administering the gene is by accelerating it into the desired cells as a coating on particles or otherwise.

A further aspect of the invention relates to an immunological composition which, when introduced into a host capable of having induced within it an immunological response, induces an immunological response in such host, wherein the composition comprises recombinant DNA which codes for and expresses an antigen of the hyperimmune serum reactive antigens and fragments thereof of the present invention. The immunological response may be used therapeutically or prophylactically and may take the form of antibody immunity or cellular immunity such as that arising from CTL or CD4+ T cells.

The hyperimmune serum reactive antigens and fragments thereof of the invention or a fragment thereof may be fused with a co-protein which may not by itself produce antibodies, but is capable of stabilizing the first protein and producing a fused protein which will have immunogenic and protective properties. This fused recombinant protein preferably further comprises an antigenic co-protein, such as Glutathione-S-transferase (GST) or beta-galactosidase, relatively large co-proteins which solubilise the protein and facilitate production and purification thereof. Moreover, the co-protein may act as an adjuvant in the sense of providing a generalized stimulation of the immune system. The co-protein may be attached to either the amino or carboxy terminus of the first protein.

Also, provided by this invention are methods using the described nucleic acid molecule or particular

fragments thereof in such genetic immunization experiments in animal models of infection with *S. pneumoniae*. Such fragments will be particularly useful for identifying protein epitopes able to provoke a prophylactic or therapeutic immune response. This approach can allow for the subsequent preparation of monoclonal antibodies of particular value from the requisite organ of the animal successfully resisting or clearing infection for the development of prophylactic agents or therapeutic treatments of *S. pneumoniae* infection in mammals, particularly humans.

The hyperimmune serum reactive antigens and fragments thereof may be used as an antigen for vaccination of a host to produce specific antibodies which protect against invasion of bacteria, for example by blocking adherence of bacteria to damaged tissue. Examples of tissue damage include wounds in skin or connective tissue and mucosal tissues caused e.g. by viral infection (esp. respiratory, such as the flu) mechanical, chemical or thermal damage or by implantation of indwelling devices, or wounds in the mucous membranes, such as the mouth, mammary glands, urethra or vagina.

The present invention also includes a vaccine formulation, which comprises the immunogenic recombinant protein together with a suitable carrier. Since the protein may be broken down in the stomach, it is preferably administered parenterally, including, for example, administration that is subcutaneous, intramuscular, intravenous, intradermal intranasal or transdermal. Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the bodily fluid, preferably the blood, of the individual; and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials, and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use. The vaccine formulation may also include adjuvant systems for enhancing the immunogenicity of the formulation, such as oil-in-water systems and other systems known in the art. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.

According to another aspect, the present invention relates to a pharmaceutical composition comprising such a hyperimmune serum-reactive antigen or a fragment thereof as provided in the present invention for *S. pneumoniae*. Such a pharmaceutical composition may comprise one, preferably at least two or more hyperimmune serum reactive antigens or fragments thereof against *S. pneumoniae*. Optionally, such *S. pneumoniae* hyperimmune serum reactive antigens or fragments thereof may also be combined with antigens against other pathogens in a combination pharmaceutical composition. Preferably, said pharmaceutical composition is a vaccine for preventing or treating an infection caused by *S. pneumoniae* and/or other pathogens against which the antigens have been included in the vaccine.

According to a further aspect, the present invention relates to a pharmaceutical composition comprising a nucleic acid molecule encoding a hyperimmune serum-reactive antigen or a fragment thereof as identified above for *S. pneumoniae*. Such a pharmaceutical composition may comprise one or more nucleic acid molecules encoding hyperimmune serum reactive antigens or fragments thereof against *S. pneumoniae*. Optionally, such *S. pneumoniae* nucleic acid molecules encoding hyperimmune serum reactive antigens or fragments thereof may also be combined with nucleic acid molecules encoding antigens against other pathogens in a combination pharmaceutical composition. Preferably, said pharmaceutical composition is a vaccine for preventing or treating an infection caused by *S. pneumoniae* and/or other pathogens against which the antigens have been included in the vaccine.

The pharmaceutical composition may contain any suitable auxiliary substances, such as buffer substances, stabilisers or further active ingredients, especially ingredients known in connection of pharmaceutical composition and/or vaccine production.

A preferable carrier/or excipient for the hyperimmune serum-reactive antigens, fragments thereof or a

coding nucleic acid molecule thereof according to the present invention is an immunostimulatory compound for further stimulating the immune response to the given hyperimmune serum-reactive antigen, fragment thereof or a coding nucleic acid molecule thereof. Preferably the immunostimulatory compound in the pharmaceutical preparation according to the present invention is selected from the group of polycationic substances, especially polycationic peptides, immunostimulatory nucleic acids molecules, preferably immunostimulatory deoxynucleotides, alum, Freund's complete adjuvants, Freund's incomplete adjuvants, neuroactive compounds, especially human growth hormone, or combinations thereof.

It is also within the scope of the present invention that the pharmaceutical composition, especially vaccine, comprises apart from the hyperimmune serum reactive antigens, fragments thereof and/or coding nucleic acid molecules thereof according to the present invention other compounds which are biologically or pharmaceutically active. Preferably, the vaccine composition comprises at least one polycationic peptide. The polycationic compound(s) to be used according to the present invention may be any polycationic compound, which shows the characteristic effects according to the WO 97/30721. Preferred polycationic compounds are selected from basic polypeptides, organic polycations, basic polyamino acids or mixtures thereof. These polyamino acids should have a chain length of at least 4 amino acid residues (WO 97/30721). Especially preferred are substances like polylysine, polyarginine and polypeptides containing more than 20 %, especially more than 50 % of basic amino acids in a range of more than 8, especially more than 20, amino acid residues or mixtures thereof. Other preferred polycations and their pharmaceutical compositions are described in WO 97/30721 (e.g. polyethyleneimine) and WO 99/38528. Preferably these polypeptides contain between 20 and 500 amino acid residues, especially between 30 and 200 residues.

These polycationic compounds may be produced chemically or recombinantly or may be derived from natural sources.

Cationic (poly)peptides may also be anti-microbial with properties as reviewed in {Ganz, T., 1999}. These (poly)peptides may be of prokaryotic or animal or plant origin or may be produced chemically or recombinantly (WO 02/13857). Peptides may also belong to the class of defensins (WO 02/13857). Sequences of such peptides can be, for example, found in the Antimicrobial Sequences Database under the following internet address:

<http://www.bbcm.univ.trieste.it/~tossi/pag2.html>

Such host defence peptides or defensives are also a preferred form of the polycationic polymer according to the present invention. Generally, a compound allowing as an end product activation (or down-regulation) of the adaptive immune system, preferably mediated by APCs (including dendritic cells) is used as polycationic polymer.

Especially preferred for use as polycationic substances in the present invention are cathelicidin derived antimicrobial peptides or derivatives thereof (International patent application WO 02/13857, incorporated herein by reference), especially antimicrobial peptides derived from mammalian cathelicidin, preferably from human, bovine or mouse.

Polycationic compounds derived from natural sources include HIV-REV or HIV-TAT (derived cationic peptides, antennapedia peptides, chitosan or other derivatives of chitin) or other peptides derived from these peptides or proteins by biochemical or recombinant production. Other preferred polycationic compounds are cathelin or related or derived substances from cathelin. For example, mouse cathelin is a peptide which has the amino acid sequence NH₂-RLAGLLRKGGEKIGEKLLKIGOKIKNFFQKLVPQPE-COOH. Related or derived cathelin substances contain the whole or parts of the cathelin sequence with at least 15-20 amino acid residues. Derivations may include the substitution or modification of the natural

amino acids by amino acids which are not among the 20 standard amino acids. Moreover, further cationic residues may be introduced into such cathelin molecules. These cathelin molecules are preferred to be combined with the antigen. These cathelin molecules surprisingly have turned out to be also effective as an adjuvant for an antigen without the addition of further adjuvants. It is therefore possible to use such cathelin molecules as efficient adjuvants in vaccine formulations with or without further immunactivating substances.

Another preferred polycationic substance to be used according to the present invention is a synthetic peptide containing at least 2 KLK-motifs separated by a linker of 3 to 7 hydrophobic amino acids (International patent application WO 02/32451, incorporated herein by reference).

The pharmaceutical composition of the present invention may further comprise immunostimulatory nucleic acid(s). Immunostimulatory nucleic acids are e. g. neutral or artificial CpG containing nucleic acids, short stretches of nucleic acids derived from non-vertebrates or in form of short oligonucleotides (ODNs) containing non-methylated cytosine-guanine di-nucleotides (CpG) in a certain base context (e.g. described in WO 96/02555). Alternatively, also nucleic acids based on inosine and cytidine as e.g. described in the WO 01/93903, or deoxynucleic acids containing deoxy-inosine and/or deoxyuridine residues (described in WO 01/93905 and PCT/EP 02/05448, incorporated herein by reference) may preferably be used as immunostimulatory nucleic acids for the present invention. Preferably, the mixtures of different immunostimulatory nucleic acids may be used according to the present invention.

It is also within the present invention that any of the aforementioned polycationic compounds is combined with any of the immunostimulatory nucleic acids as aforementioned. Preferably, such combinations are according to the ones as described in WO 01/93905, WO 02/32451, WO 01/54720, WO 01/93903, WO 02/13857 and PCT/EP 02/05448 and the Austrian patent application A 1924/2001, incorporated herein by reference.

In addition or alternatively such vaccine composition may comprise apart from the hyperimmune serum reactive antigens and fragments thereof, and the coding nucleic acid molecules thereof according to the present invention a neuroactive compound. Preferably, the neuroactive compound is human growth factor as, e.g. described in WO 01/24822. Also preferably, the neuroactive compound is combined with any of the polycationic compounds and/or immunostimulatory nucleic acids as afore-mentioned.

In a further aspect the present invention is related to a pharmaceutical composition. Such pharmaceutical composition is, for example, the vaccine described herein. Also a pharmaceutical composition is a pharmaceutical composition which comprises any of the following compounds or combinations thereof: the nucleic acid molecules according to the present invention, the hyperimmune serum reactive antigens and fragments thereof according to the present invention, the vector according to the present invention, the cells according to the present invention, the antibody according to the present invention, the functional nucleic acids according to the present invention and the binding peptides such as the anticalines according to the present invention, any agonists and antagonists screened as described herein. In connection therewith any of these compounds may be employed in combination with a non-sterile or sterile carrier or carriers for use with cells, tissues or organisms, such as a pharmaceutical carrier suitable for administration to a subject. Such compositions comprise, for instance, a media additive or a therapeutically effective amount of a hyperimmune serum reactive antigen and fragments thereof of the invention and a pharmaceutically acceptable carrier or excipient. Such carriers may include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol and combinations thereof. The formulation should suit the mode of administration.

The pharmaceutical compositions may be administered in any effective, convenient manner including, for instance, administration by topical, oral, anal, vaginal, intravenous, intraperitoneal, intramuscular, subcutaneous, intranasal, intratracheal or intradermal routes among others.

In therapy or as a prophylactic, the active agent may be administered to an individual as an injectable composition, for example as a sterile aqueous dispersion, preferably isotonic.

Alternatively the composition may be formulated for topical application, for example in the form of ointments, creams, lotions, eye ointments, eye drops, ear drops, mouthwash, impregnated dressings and sutures and aerosols, and may contain appropriate conventional additives, including, for example, preservatives, solvents to assist drug penetration, and emollients in ointments and creams. Such topical formulations may also contain compatible conventional carriers, for example cream or ointment bases, and ethanol or oleyl alcohol for lotions. Such carriers may constitute from about 1 % to about 98 % by weight of the formulation; more usually they will constitute up to about 80 % by weight of the formulation.

In addition to the therapy described above, the compositions of this invention may be used generally as a wound treatment agent to prevent adhesion of bacteria to matrix proteins exposed in wound tissue and for prophylactic use in dental treatment as an alternative to, or in conjunction with, antibiotic prophylaxis.

A vaccine composition is conveniently in injectable form. Conventional adjuvants may be employed to enhance the immune response. A suitable unit dose for vaccination is 0.05-5 μ g antigen / per kg of body weight, and such dose is preferably administered 1-3 times and with an interval of 1-3 weeks.

With the indicated dose range, no adverse toxicological effects should be observed with the compounds of the invention, which would preclude their administration to suitable individuals.

In a further embodiment the present invention relates to diagnostic and pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention. The ingredient(s) can be present in a useful amount, dosage, formulation or combination. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, reflecting approval by the agency of the manufacture, use or sale of the product for human administration.

In connection with the present invention any disease related use as disclosed herein such as, e. g. use of the pharmaceutical composition or vaccine, is particularly a disease or diseased condition which is caused by, linked or associated with Streptococci, more preferably, *S. pneumoniae*. In connection therewith it is to be noted that *S. pneumoniae* comprises several strains including those disclosed herein. A disease related, caused or associated with the bacterial infection to be prevented and/or treated according to the present invention includes besides others bacterial pharyngitis, otitis media, pneumonia, bacteremia, meningitis, peritonitis and sepsis in humans.

In a still further embodiment the present invention is related to a screening method using any of the hyperimmune serum reactive antigens or nucleic acids according to the present invention. Screening methods as such are known to the one skilled in the art and can be designed such that an agonist or an antagonist is screened. Preferably an antagonist is screened which in the present case inhibits or prevents the binding of any hyperimmune serum reactive antigen and fragment thereof according to the present invention to an interaction partner. Such interaction partner can be a naturally occurring interaction partner or a non-naturally occurring interaction partner.

The invention also provides a method of screening compounds to identify those, which enhance (agonist) or block (antagonist) the function of hyperimmune serum reactive antigens and fragments thereof or nucleic acid molecules of the present invention, such as its interaction with a binding molecule. The

method of screening may involve high-throughput.

For example, to screen for agonists or antagonists, the interaction partner of the nucleic acid molecule and nucleic acid, respectively, according to the present invention, maybe a synthetic reaction mix, a cellular compartment, such as a membrane, cell envelope or cell wall, or a preparation of any thereof, may be prepared from a cell that expresses a molecule that binds to the hyperimmune serum reactive antigens and fragments thereof of the present invention. The preparation is incubated with labelled hyperimmune serum reactive antigens and fragments thereof in the absence or the presence of a candidate molecule, which may be an agonist or antagonist. The ability of the candidate molecule to bind the binding molecule is reflected in decreased binding of the labelled ligand. Molecules which bind gratuitously, i. e., without inducing the functional effects of the hyperimmune serum reactive antigens and fragments thereof, are most likely to be good antagonists. Molecules that bind well and elicit functional effects that are the same as or closely related to the hyperimmune serum reactive antigens and fragments thereof are good agonists.

The functional effects of potential agonists and antagonists may be measured, for instance, by determining the activity of a reporter system following interaction of the candidate molecule with a cell or appropriate cell preparation, and comparing the effect with that of the hyperimmune serum reactive antigens and fragments thereof of the present invention or molecules that elicit the same effects as the hyperimmune serum reactive antigens and fragments thereof. Reporter systems that may be useful in this regard include but are not limited to colorimetric labelled substrate converted into product, a reporter gene that is responsive to changes in the functional activity of the hyperimmune serum reactive antigens and fragments thereof, and binding assays known in the art.

Another example of an assay for antagonists is a competitive assay that combines the hyperimmune serum reactive antigens and fragments thereof of the present invention and a potential antagonist with membrane-bound binding molecules, recombinant binding molecules, natural substrates or ligands, or substrate or ligand mimetics, under appropriate conditions for a competitive inhibition assay. The hyperimmune serum reactive antigens and fragments thereof can be labelled such as by radioactivity or a colorimetric compound, such that the molecule number of hyperimmune serum reactive antigens and fragments thereof bound to a binding molecule or converted to product can be determined accurately to assess the effectiveness of the potential antagonist.

Potential antagonists include small organic molecules, peptides, polypeptides and antibodies that bind to a hyperimmune serum reactive antigen and fragments thereof of the invention and thereby inhibit or extinguish its activity. Potential antagonists also may be small organic molecules, a peptide, a polypeptide such as a closely related protein or antibody that binds to the same sites on a binding molecule without inducing functional activity of the hyperimmune serum reactive antigens and fragments thereof of the invention.

Potential antagonists include a small molecule, which binds to and occupies the binding site of the hyperimmune serum reactive antigens and fragments thereof thereby preventing binding to cellular binding molecules, such that normal biological activity is prevented. Examples of small molecules include but are not limited to small organic molecules, peptides or peptide-like molecules.

Other potential antagonists include antisense molecules (see {Okano, H. et al., 1991}; OLIGODEOXYNUCLEOTIDES AS ANTISENSE INHIBITORS OF GENE EXPRESSION; CRC Press, Boca Ration, FL (1988), for a description of these molecules).

Preferred potential antagonists include derivatives of the hyperimmune serum reactive antigens and fragments thereof of the invention.

As used herein the activity of a hyperimmune serum reactive antigen and fragment thereof according to the present invention is its capability to bind to any of its interaction partner or the extent of such capability to bind to its or any interaction partner.

In a particular aspect, the invention provides the use of the hyperimmune serum reactive antigens and fragments thereof, nucleic acid molecules or inhibitors of the invention to interfere with the initial physical interaction between a pathogen and mammalian host responsible for sequelae of infection. In particular the molecules of the invention may be used: i) in the prevention of adhesion of *S. pneumoniae* to mammalian extracellular matrix proteins at mucosal surfaces and on in-dwelling devices or to extracellular matrix proteins in wounds; ii) to block bacterial adhesion between mammalian extracellular matrix proteins and bacterial proteins which mediate tissue damage or invasion iii) or lead to evasion of immune defense; iv) to block the normal progression of pathogenesis in infections initiated other than by the implantation of in-dwelling devices or by other surgical techniques, e.g. through inhibiting nutrient acquisition [Brown, J. et al., 2001].

Each of the DNA coding sequences provided herein may be used in the discovery and development of antibacterial compounds. The encoded protein upon expression can be used as a target for the screening of antibacterial drugs. Additionally, the DNA sequences encoding the amino terminal regions of the encoded protein or Shine-Delgarno or other translation facilitating sequences of the respective mRNA can be used to construct antisense sequences to control the expression of the coding sequence of interest.

The antagonists and agonists may be employed, for instance, to inhibit diseases arising from infection with *Streptococcus*, especially *S. pneumoniae*, such as sepsis.

In a still further aspect the present invention is related to an affinity device such affinity device comprises at least a support material and any of the hyperimmune serum reactive antigens and fragments thereof according to the present invention, which is attached to the support material. Because of the specificity of the hyperimmune serum reactive antigens and fragments thereof according to the present invention for their target cells or target molecules or their interaction partners, the hyperimmune serum reactive antigens and fragments thereof allow a selective removal of their interaction partner(s) from any kind of sample applied to the support material provided that the conditions for binding are met. The sample may be a biological or medical sample, including but not limited to, fermentation broth, cell debris, cell preparation, tissue preparation, organ preparation, blood, urine, lymph liquid, liquor and the like.

The hyperimmune serum reactive antigens and fragments thereof may be attached to the matrix in a covalent or non-covalent manner. Suitable support material is known to the one skilled in the art and can be selected from the group comprising cellulose, silicon, glass, aluminium, paramagnetic beads, starch and dextrane.

The present invention is further illustrated by the following figures, examples and the sequence listing, from which further features, embodiments and advantages may be taken. It is to be understood that the present examples are given by way of illustration only and not by way of limitation of the disclosure.

In connection with the present invention

Figure 1 shows the characterization of *S. pneumoniae* specific human sera.

Figure 2 shows the characterization of the small fragment genomic library, LSPn-70, from *Streptococcus pneumoniae* serotype 4.

Figure 3 shows the selection of bacterial cells by MACS using biotinylated human IgGs.

Figure 4 shows an example for the gene distribution study with the identified antigens.

Figure 5 shows examples of changes in epitope-specific antibody levels in the different age groups and during the course of pneumococcal disease.

Figure 6 shows examples for cell surface staining with epitope-specific antisera by flow cytometry.

Figure 7 shows the determination of bactericidal activity of antibodies induced by selected epitopes in an *in vitro* assay.

Figure 8 shows the protective effect of active immunization with selected *S. pneumoniae* antigens in a murine lethality sepsis model.

Figure 9 shows the protective effect of passive immunization with sera generated with selected *S. pneumoniae* antigens in a murine lethality sepsis model.

Figure 10 shows the identification of the protective domain within the SP2216 antigen.

Figure 11 shows that antibodies induced by protective antigens are cross-reactive with the different *S. pneumoniae* serotypes.

Figure 12 shows the alignment of amino acid sequences of natural SP2216 variants

Figure 13 shows the alignment of amino acid sequences of natural SP1732 variants

Figure 14 shows the alignment of amino acid sequences of natural SP2190 variants

Table 1 shows the summary of all screens performed with genomic *S. pneumoniae* libraries and human serum.

Table 2 shows the summary of epitope serology analysis with human sera.

Table 3 shows the summary of the gene distribution analysis for the identified antigens in 50 *S. pneumoniae* strains.

Table 4 shows the summary of the surface staining and bactericidal activity measurements.

The figures to which it might be referred to in the specification are described in the following in more details.

Figure 1 shows the characterization of human sera for anti-*S. pneumoniae* antibodies as measured by immune assays. Total anti-*S. pneumoniae* IgG and IgA antibody levels were measured by standard ELISA using total bacterial lysates or culture supernat fractions prepared from *S. pneumoniae* serotype 4 capsule negative mutant strain as coating antigens. 97 serum samples from convalescing patients with invasive diseases or 50 sera from healthy adults without nasopharyngeal carriage of *S. pneumoniae* were analysed at three different serum dilutions. Results of representative experiments are shown with (A) patients' sera with bacterial lysate and (B) healthy adult sera with culture supernatant proteins. Data are expressed as ELISA units calculated from absorbance at 405nm at a serum dilution in the linear range of detection (10,000X for IgA, 50,000 for IgG). 2x5 sera from both donor groups were selected and pooled for antigen identification by bacterial surface display. Selected sera included in the two patient (PSPn3-IgG, -IgA and PSPn7-IgG) and two healthy pools (NSPn4-IgG, -IgA and NSPn5-IgG) are indicated by circles. (C) Immunoblot analysis was performed on sera pre-selected by ELISA in order to ensure multiple immune

reactivity with protein antigens. Results of a representative experiment using total bacterial lysate prepared from *S. pneumoniae* serotype 4 capsule negative mutant strain and selected patients' sera at 5.000X dilution are shown. Not selected, low titer sera were included as negative controls. Mw: molecular weight markers. (D) Surface staining of *S. pneumoniae* serotype 4 capsule negative mutant strain was performed by FACS to compare antibody binding to surface located antigens. Human sera were used at different concentrations (0.5-5%). Representative data are shown with patients' sera used at 0.5% final concentration. Signal was detected with FITC-labeled anti-human IgGFab and analysed with the computer program CELLQuest. (E) Correlation between IgG titers measured by ELISA using total bacterial lysates and surface staining of whole living *S. pneumoniae* with serum IgGs is shown. IgG titer is expressed as ELISA units, while surface staining is expressed as mean fluorescence of stained bacteria calculated by the computer program CELLQuest.

Figure 2 (A) shows the fragment size distribution of the *Streptococcus pneumoniae* type 4 small fragment genomic library, LSPn-70. After sequencing 609 randomly selected clones sequences were trimmed to eliminate vector residues and the number of clones with various genomic fragment sizes were plotted. (B) shows graphic illustration of the distribution of the same set of randomly sequenced clones of LSPn-70 over the *S. pneumoniae* chromosome (according to the TIGR4 genome data). Circles indicate matching sequences to annotated ORFs and rectangles represent fully matched clones to non-coding chromosomal sequences in +/+ or +/- orientation. Diamonds position all clones with chimeric sequences. Numeric distances in base pairs are indicated over the circular genome for orientation. Partitioning of various clone sets within the library is given in numbers and percentage at the bottom of the figure.

Figure 3 (A) shows the MACS selection with biotinylated human IgGs. The LSPn-70 library in pMAL9.1 was screened with 10 µg biotinylated IgG (PSPn3-IgG, purified from human serum). As negative control, no serum was added to the library cells for screening. Number of cells selected after the 1st and 2nd elution are shown for each selection round (upper and lower panel, respectively). (B) shows the reactivity of specific clones (1-26) selected by bacterial surface display as analysed by immunoblot analysis with the human serum IgG pool (PSPn7-IgG, 4µg/µl) used for selection by MACS at a dilution of 1:3,000. As a loading control the same blot was also analysed with antibodies directed against the platform protein LamB at a dilution of 1:5,000 of hyperimmune rabbit serum. LB, Extract from a clone expressing LamB without foreign peptide insert.

Figure 4 (A) shows the representation of different serotypes of *S. pneumoniae* clinical isolates analysed for the gene distribution study. (B) shows the PCR analysis for the gene distribution of SP1604 with the respective oligonucleotides. The predicted size of the PCR fragments is 470 bp. 1-50, *S. pneumoniae* strains, clinical isolates as listed under A; -, no genomic DNA added; +, genomic DNA from *S. pneumoniae* serotype 4, which served as template for library construction.

Figure 5 shows the ELISA measurement of epitope-specific human serum IgG antibody levels during pneumococcal disease. Three serum samples were collected longitudinally from patients with invasive pneumococcal disease, before disease occurred (pre), in the acute and convalescent phases. Representative experiments are shown with two sets of sera from two different patients, (A) P1147 and (B) P1150 reacted with peptides representing the identified antigens SP0069, SP0082, SP0117, SP1175, SP1937, SP2190 and SP2216, as indicated. Biotin-labeled peptides were reacted with human serum samples at 200X and 1.000X dilutions and data are expressed as ELISA units.

Figure 6 shows the detection of specific antibody binding on the cell surface of *Streptococcus pneumoniae* by flow cytometry. In Figure 5A preimmune mouse sera and polyclonal sera raised against *S. pneumoniae* serotype 4 lysate were incubated with *S. pneumoniae* strain serotype 4 and analysed by flow cytometry. Control shows the level of non-specific binding of the secondary antibody to the surface of *S. pneumoniae* cells. The histograms in figure 5B indicates the increased fluorescence due to specific binding of anti-SP2216, anti-SP0117, anti-SP0454 and anti-CRF1992 antibodies in comparison to the control sera against

the platform protein LamB.

Figure 7 shows the bactericidal activity of epitope specific antibodies as determined in *in vitro* killing assay. The killing activity of immune sera is measured parallel with and calculated relative to the appropriate control sera. Data are expressed as percentage of killing, that is the reduction on bacterial cfu numbers as a consequence of the presence of antibodies in hyperimmune (HI) polyclonal mouse sera generated with *S. pneumoniae* lysate (A), in immune sera generated with SP0117 epitopes expressed in the LamB platform protein (B), and in mouse immune sera generated with SP1287 epitopes expressed in the FhuA platform protein (C). The control sera represent preimmune sera (PI), sera induced with Lamb or FhuA expressing *E. coli* clones without *S. pneumoniae*-derived epitopes. *S. pneumoniae* serotype 4 cells were incubated with mouse phagocytic cells for 60 min, and surviving bacteria were quantified by counting cfus after plating on blood agar.

Figure 8 shows the protection achieved by active immunization with selected *S. pneumoniae* antigens in a mouse lethality model. C3H mice (10 in each test groups) were immunized with recombinant antigens cloned from a serotype 4 *S. pneumoniae* strain and challenged with serotype 6B strain. Survival was monitored for 2 to 3 weeks post-challenge. A: Mice were immunized with SP0368, SP0667, SP2190 and SP2216 antigens and challenged intravenously with 10^4 cfu bacteria. Nonimmunized mice were used as negative controls, while PspA (SP0117) served as positive control. B: Mice were immunized with SP2190 and SP2216 antigens and challenged intraperitoneally with 10^5 cfu bacteria. Mice injected with PBS or mock immunized with the adjuvants only (CFA/IFA) were used as negative controls, while PspA (SP0117) served as positive control. C: Mice were immunized with SP0498 and SP1732 antigens and challenged intraperitoneally with 10^5 cfu bacteria. Mice injected with PBS were used as negative controls, while PspA (SP0117) served as positive control.

Figure 9 shows the protection achieved by passive immunization with hyperimmune mouse sera generated with selected *S. pneumoniae* antigens in a mouse lethality model. C3H mice (10 in each test groups) were given mouse sera intraperitoneally 2 hrs before intraperitoneal challenge with 10^5 cfu *S. pneumoniae* serotype 6B bacteria. Survival was monitored for 3 weeks post-challenge. 150µl immune sera generated with SP2190 or SP2216 were given and supplemented with 150µl serum from naive mice, except for mice receiving 100µl each of anti-SP2190, anti-SP2216 immune sera and 100 µl serum from naive mice. Negative controls were treated either with 300µl sera from PBS injected, noninjected (naive) or nonimmune CFA/IFA injected mice.

Figure 10 shows the identification of the protective domain within the SP2216 antigen. A: Schematic representation of the SP2216 antigen indicating the two subdomains predicted by *in silico* (structural prediction) analysis and the localization of epitopes identified by bacterial surface display (grey bars and arrows). B: C3H mice (10 in each test groups) were immunized with recombinant SP2216 antigens: full-length, N-terminal or C-terminal domains and challenged with *S. pneumoniae* serotype 6B strain given intraperitoneally 10^5 cfus. Survival was monitored for 2 to 3 weeks post-challenge. Nonimmunized (CFA/IFA adjuvant injected) mice were used as negative controls, while PspA (SP0117) served as positive control.

Figure 11 shows the cross-reactivity of antibodies by analysing different *S. pneumoniae* serotypes. Immunoblot analysis was performed with bacterial lysates prepared from 60 clinical isolates of *S. pneumoniae* representing 48 different serotypes and using sera generated with SP1732, SP2190 and SP2216 recombinant antigens cloned from a serotype 4 strain in order to test the cross-reactivity of antibodies. Results with seven different serotypes (Lanes 1-7) are shown as representative data taken from the complete analysis. Mw: molecular weight markers.

Figure 12 shows the amino acid exchanges detected in natural SP2216 variants expressed in different clinical isolates of *S. pneumoniae*. The SP2216 gene from 47 different clinical isolates representing 47 different *S. pneumoniae* serotypes were analysed by DNA sequencing. The translated amino acid

sequences are shown for those serotypes where amino acid exchanges were detected relative to the published TIGR4 genome sequences.

Figure 13 shows the amino acid exchanges detected in natural SP1732 variants expressed in different clinical isolates of *S. pneumoniae*. The SP1732 gene from six different clinical isolates representing six major *S. pneumoniae* serotypes (4, 6B, 9V, 18C, 19F, 23F) were analysed by DNA sequencing. The translated amino acid sequences are shown for those serotypes where amino acid exchanges were detected relative to the published TIGR4 (serotype 4) genome sequences.

Figure 14 shows the amino acid exchanges detected in natural SP2190 variants expressed in different clinical isolates of *S. pneumoniae*. The SP2190 gene from seven different clinical isolates representing seven major *S. pneumoniae* serotypes (4, 6B, 9V, 14, 18C, 19F, 23F) were analysed by DNA sequencing. The translated amino acid sequences are shown for those serotypes where amino acid exchanges were detected relative to the published TIGR4 (serotype 4) genome sequences. Due to missing sequence information from the middle part of some of the genes, the N-terminal and C-terminal aa alignments are shown separately. A: N-terminal amino acid sequences; B: C-terminal amino acid sequences.

Table 1: Immunogenic proteins identified by bacterial surface display.

A, 300bp library in fhuA with NSPn4-IgA (362), B, 300bp library in fhuA with NSPn4-IgG (832), C, 300bp library in fhuA with NSPn5-IgG (872), D, 300bp library in fhuA with PSPn3-IgA (361), E, 300bp library in fhuA with PSPn3-IgG (575), F, 300bp library in fhuA with PSPn7-IgG (795), G, 70bp library in lamB with NSPn4-IgA (1043), H, 70bp library in lamB with NSPn4-IgG (929), I, 70bp library in lamB with NSPn5-IgG (527), K, 70bp library in lamB with PSPn3-IgA (1121), L, 70bp library in lamB with PSPn3-IgG (1242), M, 70bp library in lamB with PSPn7-IgG (514); *, prediction of antigenic sequences longer than 5 amino acids was performed with the program ANTIGENIC [Kolaskar, A. et al., 1990].

Table 2: Epitope serology with human sera.

Immune reactivity of individual synthetic peptides representing selected epitopes with individual human sera is shown. Extent of reactivity is pattern/grey coded; white: - (<50U), light grey: + (50-119U), dark grey: ++ (120-199U), black: +++ (200-500U) and vertically crossed: ++++ (> 500U). ELISA units (U) are calculated from OD_{405nm} readings and the serum dilution after correction for background. S stands for score, calculated as the sum of all reactivities (addition of the number of all +); P1 to P13 sera are measured to be high titer and are from patients with invasive pneumococcal diseases and N1 to N10 sera are from healthy adults with high anti-*S. pneumoniae* titers. S stands for score. Which is the sum of immune reactivities: - =0; + =1; ++ =2; +++ =3 and ++++ =4. Location of synthetic peptides within the antigenic ORFs according to the genome annotation of TIGR4 strain are given in columns from and to indicating the first and last amino acid residues, respectively. Peptide names: SP0117.1-7 present in annotated ORFSP0117; ARF0408.1, potential novel ORF in alternative reading-frame of SP0408; CRF0129.1, potential novel ORF on complement of SP0129.

Table 3: Gene distribution in *S. pneumoniae* strains.

Fifty *S. pneumoniae* strains as shown in Figure 4A were tested by PCR with oligonucleotides specific for the genes encoding relevant antigens. The PCR fragment of one selected PCR fragment was sequenced in order to confirm the amplification of the correct DNA fragment. *, number of amino acid substitutions in a serotype 14 strain as compared to *S. pneumoniae* TIGR4 (serotype 4). #, alternative strain used for sequencing, because gene was not present in the serotype 14 strain.

Table 4: Surface location of antigenic epitopes and the functionality of the epitope-specific antibodies.

45 *S. pneumoniae* antigens were tested for surface localization in the way described and presented in Figure 6 by using mouse sera generated by immunization with *E. coli* clones harboring plasmids encoding the platform proteins LamB or FhuA fused to a *S. pneumoniae* peptide. Data are summarized in the column labeled FACS. The very same immune reagents were used in an *in vitro* killing assay, as

shown in Figure 7 for the examples, and presented for all antigens tested positive by FACS in column PK (phagocytic killing). -: negative result, +: not consistently positive in all assays performed, ++ and +++ are consistently positive relative to control reagents.

EXAMPLES

Example 1: Characterization and selection of human sera based anti-*S. pneumoniae* antibodies, preparation of antibody screening reagents

Experimental procedures

Enzyme linked immune assay (ELISA).

ELISA plates (Maxisorb, Millipore) were coated with 5-10 µg/ml total protein diluted in coating buffer (0.1M sodium carbonate pH 9.2). Three dilutions of sera (2,000X, 10,000X, 50,000X) were made in PBS-BSA. Highly specific Horse Radish Peroxidase (HRP)-conjugated anti-human IgG or anti-human IgA secondary antibodies (Southern Biotech) were used according to the manufacturers' recommendations (dilution: 1,000x). Antigen-antibody complexes were quantified by measuring the conversion of the substrate (ABTS) to colored product based on OD_{405nm} readings by automatic ELIAS reader (TECAN SUNRISE).

Preparation of bacterial antigen extracts

Total bacterial lysate: Bacteria were grown overnight in THB (Todd-Hewitt Broth) and lysed by repeated freeze-thaw cycles: incubation on dry ice/ethanol-mixture until frozen (1 min), then thawed at 37°C (5 min): repeated 3 times. This was followed by sonication and collection of supernatant by centrifugation (3,500 rpm, 15 min, 4°C).

Culture supernatant: After removal of bacteria by centrifugation, the supernatant of overnight grown bacterial cultures was precipitated with ice-cold ethanol by mixing 1 part supernatant with 3 parts abs. ethanol and incubated overnight at -20°C. Precipitates were collected by centrifugation (2,600 g, for 15 min). Dry pellets were dissolved either in PBS for ELISA, or in urea and SDS-sample buffer for SDS-PAGE and immunoblotting. The protein concentration of samples was determined by Bradford assay.

Immunoblotting

Total bacterial lysate and culture supernatant samples were prepared from *in vitro* grown *S. pneumoniae* serotype 4 uncapsulated mutant strain. 10 to 25µg total protein/lane was separated by SDS-PAGE using the BioRad Mini-Protean 3 Cell electrophoresis system and proteins transferred to nitrocellulose membrane (ECL, Amersham Pharmacia). After overnight blocking in 5% milk, human sera were added at 2,000x dilution, and HRPO labeled anti-human IgG was used for detection.

Surface staining of bacteria

Flow cytometric analysis was carried out as follows. *S. pneumoniae* serotype 4 uncapsulated mutant strain was grown in Todd-Hewitt broth overnight until early stationary phase. Cells were collected and washed twice in Hanks Balanced Salt Solution (HBSS) and the cell density was adjusted to approximately 1 X 10⁶ CFU in 100µl HBSS with 0.5% BSA based on OD_{600 nm} readings. After incubation with human sera at 0.5 and 2% final concentration for 60 min at 4°C, unbound antibodies were washed away by centrifugation in excess HBSS, 0.5% BSA. For detection fluorescein (FITC) labeled secondary goat anti-human IgG (F(ab')₂ fragment specific) was incubated with the cells at 4°C for 30 min. After washing the cells, cells were fixed with 2% paraformaldehyde. Surface staining antibodies were detected using a Becton Dickinson FACScan flow cytometer and data further analyzed with the computer program CELLQuest.

Purification of antibodies for genomic screening. Five sera from both the patient and the healthy group were selected based on the overall anti-streptococcal titers for a serum pool used in the screening procedure.

Antibodies against *E. coli* proteins were removed by incubating the heat-inactivated sera with whole cell *E. coli* cells (DH5alpha, transformed with pHIE11, grown under the same condition as used for bacterial surface display). Highly enriched preparations of IgGs from the pooled, depleted sera were generated by protein G affinity chromatography, according to the manufacturer's instructions (UltraLink Immobilized Protein G, Pierce). IgA antibodies were purified also by affinity chromatography using biotin-labeled anti-human IgA (Southern Biotech) immobilized on Streptavidin-agarose (GIBCO BRL). The efficiency of depletion and purification was checked by SDS-PAGE, Western blotting, ELISA and protein concentration measurements.

Results

The antibodies produced against *S. pneumoniae* by the human immune system and present in human sera are indicative of the *in vivo* expression of the antigenic proteins and their immunogenicity. These molecules are essential for the identification of individual antigens in the approach as described in the present invention, which is based on the interaction of the specific anti-streptococcal antibodies and the corresponding *S. pneumoniae* peptides or proteins. To gain access to relevant antibody repertoires, human sera were collected from

I. convalescent patients with invasive *S. pneumoniae* infections, such as pneumonia, bacteraemia and meningitis. (*S. pneumoniae* was shown to be the causative agent by medical microbiological tests),

II healthy adults without carriage at the time of sampling. *S. pneumoniae* colonization and infections are common, and antibodies are present as a consequence of natural immunization from previous encounters.

97 serum samples from patient and 50 sera from healthy adults were characterized for anti-*S. pneumoniae* antibodies by a series of immune assays. Primary characterization was done by ELISA using two different antigen preparations, such as total bacterial extract and culture supernatant proteins prepared from *S. pneumoniae* serotype 4 uncapsulated mutant strain. It is an important aspect that we analysed uncapsulated strain, since we avoided the reactivities coming from serotype specific abundant anti-capsular polysaccharide antibodies.

Recently it was reported that not only IgG, but also IgA serum antibodies can be recognized by the FcR3 receptors of PMNs and promote opsonization (Phillips-Quagliata, J. et al., 2000); (Shibuya, A. et al., 2000). The primary role of IgA antibodies is neutralization, mainly at the mucosal surface. The level of serum IgA reflects the quality, quantity and specificity of the dimeric secretory IgA. For that reason the serum collection was not only analyzed for anti-streptococcal IgG, but also for IgA levels. In the ELISA assays highly specific secondary reagents were used to detect antibodies from the high affinity types, such as IgG and IgA, but avoided IgM. Production of IgM antibodies occurs during the primary adaptive humoral response, and results in low affinity antibodies, while IgG and IgA antibodies had already undergone affinity maturation, and are more valuable in fighting or preventing disease. Antibody titers were compared at given dilutions where the response was linear (Fig. 1A and 1B.). Sera were ranked based on the IgG and IgA reactivity against the two complex antigenic mixtures, and the highest ones were selected for further testing by immunoblotting. This analysis confirmed a high antibody reactivity of the pre-selected sera against multiple pneumococcal proteins, especially when compared to not selected, low-titer sera (Fig 1C). ELISA ranking of sera also correlated very well with surface staining of the same *S. pneumoniae* strain (Fig. 1D and 1E) suggesting that the majority of the antibodies detected by ELISA corresponded to surface antigens. This extensive antibody characterization approach has led to the unambiguous identification of anti-pneumococcal hyperimmune sera.

Selected sera, 2x5 from both the patient and healthy donor groups were pooled to further enrich for abundant antibodies, but still having a representation of antibody repertoires of different individuals. IgG and IgA antibodies were purified from pooled sera by affinity chromatography and depleted of *E. coli* -reactive antibodies to avoid background in the bacterial surface display screen.

Example 2: Generation of highly random, frame-selected, small-fragment, genomic DNA libraries of *Streptococcus pneumoniae****Experimental procedures***

Preparation of streptococcal genomic DNA. 50 ml Todd-Hewitt Broth medium was inoculated with *S. pneumoniae* serotype 4 (clinical isolate, typed with conventional serotyping) bacteria from a frozen stab and grown with aeration and shaking for 18 h at 37°C. The culture was then harvested, centrifuged with 1,600x g for 15 min and the supernatant was removed. Bacterial pellets were washed 3 x with PBS and carefully re-suspended in 0.5 ml of Lysozyme solution (100 mg/ml). 0.1 ml of 10 mg/ml heat treated RNase A and 20 U of RNase T1 were added, mixed carefully and the solution was incubated for 1 h at 37°C. Following the addition of 0.2 ml of 20 % SDS solution and 0.1 ml of Proteinase K (10 mg/ml) the tube was incubated overnight at 55°C. 1/3 volume of saturated NaCl was then added and the solution was incubated for 20 min at 4°C. The extract was pelleted in a microfuge (13,000 rpm) and the supernatant transferred into a new tube. The solution was extracted with PhOH/CHCl₃/IAA (25:24:1) and with CHCl₃/IAA (24:1). DNA was precipitated at room temperature by adding 0.6x volume of Isopropanol, spooled from the solution with a sterile Pasteur pipette and transferred into tubes containing 80% ice-cold ethanol. DNA was recovered by centrifuging the precipitates with 10-12,000x g, then dried on air and dissolved in ddH₂O.

Preparation of small genomic DNA fragments. Genomic DNA fragments were mechanically sheared into fragments ranging in size between 150 and 300 bp using a cup-horn sonicator (Bandelin Sonoplus UV 2200 sonicator equipped with a BB5 cup horn, 10 sec. pulses at 100 % power output) or into fragments of size between 50 and 70 bp by mild DNase I treatment (Novagen). It was observed that sonication yielded a much tighter fragment size distribution when breaking the DNA into fragments of the 150-300 bp size range. However, despite extensive exposure of the DNA to ultrasonic wave-induced hydromechanical shearing force, subsequent decrease in fragment size could not be efficiently and reproducibly achieved. Therefore, fragments of 50 to 70 bp in size were obtained by mild DNase I treatment using Novagen's shotgun cleavage kit. A 1:20 dilution of DNase I provided with the kit was prepared and the digestion was performed in the presence of MnCl₂ in a 60 µl volume at 20°C for 5 min to ensure double-stranded cleavage by the enzyme. Reactions were stopped with 2 µl of 0.5 M EDTA and the fragmentation efficiency was evaluated on a 2% TAE-agarose gel. This treatment resulted in total fragmentation of genomic DNA into near 50-70 bp fragments. Fragments were then blunt-ended twice using T4 DNA Polymerase in the presence of 100 µM each of dNTPs to ensure efficient flushing of the ends. Fragments were used immediately in ligation reactions or frozen at -20°C for subsequent use.

Description of the vectors. The vector pMAL4.31 was constructed on a pASK-IBA backbone [Skerra, A., 1994] with the beta-lactamase (*bla*) gene exchanged with the Kanamycin resistance gene. In addition the *bla* gene was cloned into the multiple cloning site. The sequence encoding mature beta-lactamase is preceded by the leader peptide sequence of *ompA* to allow efficient secretion across the cytoplasmic membrane. Furthermore a sequence encoding the first 12 amino acids (spacer sequence) of mature beta-lactamase follows the *ompA* leader peptide sequence to avoid fusion of sequences immediately after the leader peptidase cleavage site, since e.g. clusters of positive charged amino acids in this region would decrease or abolish translocation across the cytoplasmic membrane [Kajava, A. et al., 2000]. A *Sma*I restriction site serves for library insertion. An upstream *Fse*I site and a downstream *Not*I site, which were used for recovery of the selected fragment, flank the *Sma*I site. The three restriction sites are inserted after the sequence encoding the 12 amino acid spacer sequence in such a way that the *bla* gene is transcribed in the -1 reading frame resulting in a stop codon 15 bp after the *Not*I site. A +1 bp insertion restores the *bla* ORF so that beta-lactamase protein is produced with a consequent gain of Ampicillin resistance.

The vector pMAL9.1 was constructed by cloning the *lamB* gene into the multiple cloning site of pEH1 [Hashemzadeh-Bonehi, L. et al., 1998]. Subsequently, a sequence was inserted in *lamB* after amino acid

- 51 -

154, containing the restriction sites *FseI*, *SmaI* and *NotI*. The reading frame for this insertion was constructed in such a way that transfer of frame-selected DNA fragments excised by digestion with *FseI* and *NotI* from plasmid pMAL4.31 yields a continuous reading frame of *lamB* and the respective insert.

The vector pMAL10.1 was constructed by cloning the *btuB* gene into the multiple cloning site of pEH1. Subsequently, a sequence was inserted in *btuB* after amino acid 236, containing the restriction sites *FseI*, *XbaI* and *NotI*. The reading frame for this insertion was chosen in a way that transfer of frame-selected DNA fragments excised by digestion with *FseI* and *NotI* from plasmid pMAL4.31 yields a continuous reading frame of *btuB* and the respective insert.

The vector pHIE11 was constructed by cloning the *fhuA* gene into the multiple cloning site of pEH1. Thereafter, a sequence was inserted in *fhuA* after amino acid 405, containing the restriction site *FseI*, *XbaI* and *NotI*. The reading frame for this insertion was chosen in a way that transfer of frame-selected DNA fragments excised by digestion with *FseI* and *NotI* from plasmid pMAL4.31 yields a continuous reading frame of *fhuA* and the respective insert.

Cloning and evaluation of the library for frame selection. Genomic *S. pneumoniae* DNA fragments were ligated into the *SmaI* site of the vector pMAL4.31. Recombinant DNA was electroporated into DH10B electrocompetent *E. coli* cells (GIBCO BRL) and transformants plated on LB-agar supplemented with Kanamycin (50 µg/ml) and Ampicillin (50 µg/ml). Plates were incubated over night at 37°C and colonies collected for large scale DNA extraction. A representative plate was stored and saved for collecting colonies for colony PCR analysis and large-scale sequencing. A simple colony PCR assay was used to initially determine the rough fragment size distribution as well as insertion efficiency. From sequencing data the precise fragment size was evaluated, junction intactness at the insertion site as well as the frame selection accuracy (3n+1 rule).

Cloning and evaluation of the library for bacterial surface display. Genomic DNA fragments were excised from the pMAL4.31 vector, containing the *S. pneumoniae* library with the restriction enzymes *FseI* and *NotI*. The entire population of fragments was then transferred into plasmids pMAL9.1 (LamB) or pHIE11 (FhuA), which have been digested with *FseI* and *NotI*. Using these two restriction enzymes, which recognise an 8 bp GC rich sequence, the reading frame that was selected in the pMAL4.31 vector is maintained in each of the platform vectors. The plasmid library was then transformed into *E. coli* DH5alpha cells by electroporation. Cells were plated onto large LB-agar plates supplemented with 50 µg/ml Kanamycin and grown over night at 37°C at a density yielding clearly visible single colonies. Cells were then scraped off the surface of these plates, washed with fresh LB medium and stored in aliquots for library screening at -80°C.

Results

Libraries for frame selection. Two libraries (LSPn70 and LSPn300) were generated in the pMAL4.31 vector with sizes of approximately 70 and 300 bp, respectively. For each library, ligation and subsequent transformation of approximately 1 µg of pMAL4.31 plasmid DNA and 50 ng of fragmented genomic *S. pneumoniae* DNA yielded 4×10^5 to 2×10^6 clones after frame selection. To assess the randomness of the libraries, approximately 600 randomly chosen clones of LSPn70 were sequenced. The bioinformatic analysis showed that of these clones only very few were present more than once. Furthermore, it was shown that 90% of the clones fell in the size range between 25 and 100 bp with an average size of 52 bp (Figure 2). Almost all sequences followed the 3n+1 rule, showing that all clones were properly frame selected.

Bacterial surface display libraries. The display of peptides on the surface of *E. coli* required the transfer of the inserts from the LSPn libraries from the frame selection vector pMAL4.31 to the display plasmids pMAL9.1 (LamB) or pHIE11 (FhuA). Genomic DNA fragments were excised by *FseI* and *NotI* restriction

and ligation of 5ng inserts with 0.1µg plasmid DNA and subsequent transformation into DH5alpha cells resulted in 2-5x 10⁶ clones. The clones were scraped off the LB plates and frozen without further amplification.

Example 3: Identification of highly immunogenic peptide sequences from *S. pneumoniae* using bacterial surface displayed genomic libraries and human serum

Experimental procedures

MACS screening. Approximately 2.5x 10⁸ cells from a given library were grown in 5 ml LB-medium supplemented with 50 µg/ml Kanamycin for 2 h at 37°C. Expression was induced by the addition of 1 mM IPTG for 30 min. Cells were washed twice with fresh LB medium and approximately 2x 10⁷ cells re-suspended in 100 µl LB medium and transferred to an Eppendorf tube.

10 µg of biotinylated, human IgGs purified from serum was added to the cells and the suspension incubated overnight at 4°C with gentle shaking. 900 µl of LB medium was added, the suspension mixed and subsequently centrifuged for 10 min at 6,000 rpm at 4°C (For IgA screens, 10 µg of purified IgAs were used and these captured with biotinylated anti-human-IgG secondary antibodies). Cells were washed once with 1 ml LB and then re-suspended in 100 µl LB medium. 10 µl of MACS microbeads coupled to streptavidin (Miltenyi Biotech, Germany) were added and the incubation continued for 20 min at 4°C. Thereafter 900 µl of LB medium was added and the MACS microbead cell suspension was loaded onto the equilibrated MS column (Miltenyi Biotech, Germany) which was fixed to the magnet. (The MS columns were equilibrated by washing once with 1 ml 70% EtOH and twice with 2 ml LB medium.)

The column was then washed three times with 3 ml LB medium. After removal of the magnet, cells were eluted by washing with 2 ml LB medium. After washing the column with 3 ml LB medium, the 2 ml eluate was loaded a second time on the same column and the washing and elution process repeated. The loading, washing and elution process was performed a third time, resulting in a final eluate of 2 ml.

A second round of screening was performed as follows. The cells from the final eluate were collected by centrifugation and re-suspended in 1 ml LB medium supplemented with 50 µg/ml Kanamycin. The culture was incubated at 37°C for 90 min and then induced with 1 mM IPTG for 30 min. Cells were subsequently collected, washed once with 1 ml LB medium and suspended in 10 µl LB medium. 10 µg of human, biotinylated IgGs were added again and the suspension incubated over night at 4°C with gentle shaking. All further steps were exactly the same as in the first selection round. Cells selected after two rounds of selection were plated onto LB-agar plates supplemented with 50 µg/ml Kanamycin and grown over night at 37°C.

Evaluation of selected clones by sequencing and Western blot analysis. Selected clones were grown overnight at 37°C in 3 ml LB medium supplemented with 50 µg/ml Kanamycin to prepare plasmid DNA using standard procedures. Sequencing was performed at MWG (Germany) or in collaboration with TIGR (U.S.A.).

For Western blot analysis approximately 10 to 20 µg of total cellular protein was separated by 10% SDS-PAGE and blotted onto HybondC membrane (Amersham Pharmacia Biotech, England). The LamB or FhuA fusion proteins were detected using human serum as the primary antibody at a dilution of approximately 1:5,000 and anti-human IgG or IgA antibodies coupled to HRP at a dilution of 1:5,000 as secondary antibodies. Detection was performed using the ECL detection kit (Amersham Pharmacia Biotech, England). Alternatively, rabbit anti-FhuA or rabbit anti-LamB polyclonal immune sera were used as primary antibodies in combination with the respective secondary antibodies coupled to HRP for the detection of the fusion proteins.

Results

Screening of bacterial surface display libraries by magnetic activated cell sorting (MACS) using biotinylated Igs. The libraries LSPn70 in pMAL9.1 and LSPn300 in pHIE11 were screened with pools of biotinylated, human IgGs and IgAs from patient sera or sera from healthy individuals (see Example 1: *Preparation of antibodies from human serum*). The selection procedure was performed as described under Experimental procedures. Figure 3A shows a representative example of a screen with the LSPn-70 library and PSPn3-IgGs. As can be seen from the colony count after the first selection cycle from MACS screening, the total number of cells recovered at the end is drastically reduced from 2×10^7 cells to approximately 5×10^4 cells, whereas the selection without antibodies added showed a reduction to about 2×10^3 cells (Figure 3A). After the second round, a similar number of cells was recovered with PSPn3-IgGs, while fewer than 10 cells were recovered when no IgGs from human serum were added, clearly showing that selection was dependent on *S. pneumoniae* specific antibodies. To evaluate the performance of the screen, 26 selected clones were picked randomly and subjected to immunoblot analysis with screening IgG pool (PSPn7) (Figure 3B). This analysis revealed that ~90% of the selected clones showed reactivity with antibodies present in the relevant serum whereas the control strain expressing LamB without a *S. pneumoniae* specific insert did not react with the same serum. In general, the rate of reactivity was observed to lie within the range of 35 to 90%. Colony PCR analysis showed that all selected clones contained an insert in the expected size range.

Subsequent sequencing of a larger number of randomly picked clones (600 to 1200 per screen) led to the identification of the gene and the corresponding peptide or protein sequence that was specifically recognized by the human serum antibodies used for screening. The frequency with which a specific clone is selected reflects at least in part the abundance and/or affinity of the specific antibodies in the serum used for selection and recognizing the epitope presented by this clone. In that regard it is striking that clones derived from some ORFs (e.g. SP2216, SP0117, SP0641, SP2136, SP2190, SP0107, SP0082) were picked more than 100 times, indicating their highly immunogenic property. Table 1 summarizes the data obtained for all 12 performed screens. All clones that are presented in Table 1 have been verified by immunoblot analysis using whole cellular extracts from single clones to show the indicated reactivity with the pool of human serum used in the respective screen. As can be seen from Table 1, distinct regions of the identified ORF are identified as immunogenic, since variably sized fragments of the proteins are displayed on the surface by the platform proteins.

It is further worth noticing that most of the genes identified by the bacterial surface display screen encode proteins that are either attached to the surface of *S. pneumoniae* and/or are secreted. This is in accordance with the expected role of surface attached or secreted proteins in virulence of *S. pneumoniae*.

Example 4: Assessment of the reactivity of highly immunogenic peptide sequences with individual human sera.

Experimental procedures

Peptide synthesis

Peptides were synthesized in small scale (4 mg resin; up to 288 in parallel) using standard F-moc chemistry on a Rink amide resin (PepChem, Tübingen, Germany) using a SyroII synthesizer (MultisynTech, Witten, Germany). After the sequence was assembled, peptides were elongated with Fmoc-epsilon-aminohexanoic acid (as a linker) and biotin (Sigma, St. Louis, MO; activated like a normal amino acid). Peptides were cleaved off the resin with 93%TFA, 5% triethylsilane, and 2% water for one hour. Peptides were dried under vacuum and freeze dried three times from acetonitrile/water (1:1). The presence of the correct mass was verified by mass spectrometry on a Reflex III MALDI-TOF (Bruker,

Bremen Germany). The peptides were used without further purification.

Enzyme linked immune assay (ELISA).

Biotin-labeled peptides (at the N-terminus) were coated on Streptavidin ELISA plates (EXICON) at 10 µg/ml concentration according to the manufacturer's instructions. Highly specific Horse Radish Peroxidase (HRP)-conjugated anti-human IgG secondary antibodies (Southern Biotech) were used according to the manufacturers' recommendations (dilution: 1,000x). Sera were tested at two serum dilutions, 200X and 1,000X. Following manual coating, peptide plates were processed and analyzed by the Gemini 160 ELISA robot (TECAN) with a built-in ELISA reader (GENIOS, TECAN).

Approximately 110 patients and 60 healthy adult sera were included in the analysis. Following the bioinformatic analysis of selected clones, corresponding peptides were designed and synthesized. In case of epitopes with more than 26 amino acid residues, overlapping peptides were made. All peptides were synthesized with a N-terminal biotin-tag and used as coating reagents on Streptavidin-coated ELISA plates.

The analysis was performed in two steps. First, peptides were selected based on their reactivity with the individual sera, which were included in the serum pools used for preparations of IgG and IgA screening reagents for bacterial surface display. A summary for serum reactivity of 224 peptides representing *S. pneumoniae* epitopes from the genomic screen analysed with 20 human sera (representing 4 different pools of five sera) used for the antigen identification is shown in Table 2. The peptides were compared by the score calculated for each peptide based on the number of positive sera and the extent of reactivity. Peptides range from highly and widely reactive to weakly positive ones. Among the most reactive ones there are known antigens, some of them are also protective in animal challenge models for nasopharyngeal carriage or sepsis (e.g. PspA/SP0117, serine protease/SP0641, histidine triad protein/SP1175). Peptides not displaying a positive reaction were not included in further, more detailed studies.

Second, a large number of not pre-selected individual sera from patients with invasive pneumococcal disease or from healthy adults and children were tested against the peptides showing specific and high reactivity with the screening sera. Seroconversion during disease was tested for highly positive peptides by using three serial serum samples collected longitudinally from patients with invasive pneumococcal disease, the first before disease occurred (pre), the second in the acute phase (within 5 days after onset) and the third in the convalescent phase (> 3 weeks after onset) of the disease. Two representative ELISA experiments are shown with two different patients, displaying seroconversion to multiple peptides, suggesting that epitope-specific antibody levels were low before disease occurred, and were induced in the acute and convalescent phase (Fig. 5). The antigens showing this antibody profile are especially valuable for vaccine development (e.g. SP2216, SP2109, SP1175, SP0117, SP0082).

Example 5: Gene distribution studies with highly immunogenic proteins identified from *S. pneumoniae*.

Experimental procedures

Gene distribution of pneumococcal antigens by PCR. An ideal vaccine antigen would be an antigen that is present in all, or the vast majority of strains of the target organism to which the vaccine is directed. In order to establish whether the genes encoding the identified *Streptococcus pneumoniae* antigens occur ubiquitously in *S. pneumoniae* strains, PCR was performed on a series of independent *S. pneumoniae* isolates with primers specific for the gene of interest. *S. pneumoniae* isolates were obtained covering the serotypes most frequently present in patients as shown in Figure 4A. Oligonucleotide sequences as primers were designed for all identified ORFs yielding products of approximately 1,000 bp, if possible

covering all identified immunogenic epitopes. Genomic DNA of all *S. pneumoniae* strains was prepared as described under Example 2. PCR was performed in a reaction volume of 25 µl using Taq polymerase (1U), 200 nM dNTPs, 10 pMol of each oligonucleotide and the kit according to the manufacturers instructions (Invitrogen, The Netherlands). As standard, 30 cycles (1x: 5min. 95°C, 30x: 30sec. 95°C, 30sec. 56°C, 30sec. 72°C, 1x 4min. 72°C) were performed, unless conditions had to be adapted for individual primer pairs.

Results

All identified genes encoding immunogenic proteins were tested by PCR for their presence in 50 different strains of *S. pneumoniae* (Figure 4A). As an example, figure 4B shows the PCR reaction for SP1604 with all indicated 50 strains. As clearly visible, the gene is present in all strains analysed. The PCR fragment from a type 14 strain was sequenced and showed that of 414 bp, 6 bp are different as compared to the *S. pneumoniae* type 4 strain, resulting in three amino acid difference between the two isolates.

From a total of 50 genes analysed, 31 were present in all strains tested, while 9 genes were absent in more than 10 of the tested 50 strains (Table 3). Several genes (SP0667, SP0930) showed variation in size and were not present in all strain isolates. Some genes showed variation in size, but were otherwise conserved in all tested strains. Sequencing of the generated PCR fragment from one strain and subsequent comparison to the type 4 strain confirmed the amplification of the correct DNA fragment and revealed a degree of sequence divergence as indicated in Table 3. Importantly, many of the identified antigens are well conserved in all strains in sequence and size and are therefore novel vaccine candidates to prevent infections by pneumococci.

Example 6: Characterization of immune sera obtained from mice immunized with highly immunogenic proteins/peptides from *S. pneumoniae* displayed on the surface of *E. coli*.

Experimental procedures

Generation of immune sera from mice

E. coli clones harboring plasmids encoding the platform protein fused to a *S. pneumoniae* peptide, were grown in LB medium supplemented with 50µg/ml Kanamycin at 37°C. Overnight cultures were diluted 1:10, grown until an OD₆₀₀ of 0.5 and induced with 0.2 mM IPTG for 2 hours. Pelleted bacterial cells were suspended in PBS buffer and disrupted by sonication on ice, generating a crude cell extract. According to the OD₆₀₀ measurement, an aliquot corresponding to 5x10⁷ cells was injected into NMRI mice i.v., followed by a boost after 2 weeks. Serum was taken 1 week after the second injection. Epitope specific antibody levels were measured by peptide ELISA.

In vitro expression of antigens

Expression of antigens by *in vitro* grown *S. pneumoniae* serotype 4 was tested by immunoblotting. Different growth media and culture conditions were tested to detect the presence of antigens in total lysates and bacterial culture supernatants. Expression was considered confirmed when a specific band corresponding to the predicted molecular weight and electrophoretic mobility was detected.

Cell surface staining

Flow cytometric analysis was carried out as follows. Bacteria were grown under culture conditions, which resulted in expression of the antigen as shown by the immunoblot analysis. Cells were washed twice in Hanks Balanced Salt Solution (HBSS) and the cell density was adjusted to approximately 1 X 10⁶ CFU in 100µl HBSS, 0.5% BSA. After incubation for 30 to 60 min at 4°C with mouse antisera diluted 50 to 100-fold, unbound antibodies were washed away by centrifugation in excess HBSS, 0.5% BSA. Secondary goat anti-mouse antibody (F(ab')₂ fragment specific) labeled with fluorescein (FITC) was incubated with the cells at 4°C for 30 to 60 min. After washing, cells were fixed with 2% paraformaldehyde. Bound antibodies were detected using a Becton Dickinson FACScan flow cytometer and data further analyzed

with the computer program CELLQuest. Negative control sera included mouse pre-immune serum and mouse polyclonal serum generated with lysates prepared from IPTG induced *E. coli* cells transformed with plasmids encoding the genes *lamB* or *fhuA* without *S. pneumoniae* genomic insert.

Bactericidal (killing) assay

Murine macrophage cells (RAW246.7 or P388.D1) and bacteria were incubated and the loss of viable bacteria after 60 min was determined by colony counting. In brief, bacteria were washed twice in Hanks Balanced Salt Solution (HBSS) and the cell density was adjusted to approximately 1×10^5 CFU in 50 μ l HBSS. Bacteria were incubated with mouse sera (up to 25%) and guinea pig complement (up to 5%) in a total volume of 100 μ l for 60 min at 4°C. Pre-opsonized bacteria were mixed with macrophages (murine cell line RAW264.7 or P388.D1; 2×10^6 cells per 100 μ l) at a 1:20 ratio and were incubated at 37°C on a rotating shaker at 500 rpm. An aliquot of each sample was diluted in sterile water and incubated for 5 min at room temperature to lyse macrophages. Serial dilutions were then plated onto Todd-Hewitt Broth agar plates. The plates were incubated overnight at 37°C, and the colonies were counted with the CounterMat flash colony counter (IUL Instruments). Control sera included mouse pre-immune serum and mouse polyclonal serum generated with lysates prepared from IPTG induced *E. coli* transformed with plasmids harboring the genes *lamB* or *fhuA* without *S. pneumoniae* genomic insert.

Results

In vitro expression of antigens. The expression of the antigenic proteins was analyzed *in vitro* in *S. pneumoniae* serotype 4 by using sera raised against *E. coli* clones harboring plasmids encoding the platform protein fused to a *S. pneumoniae* peptide. First, the presence of specific antibodies was determined by peptide ELISA and/or immunoblotting using the *E. coli* clone expressing the given epitope embedded in LamB or FhuA platform proteins. Positive sera were then analysed by immunoblotting using total bacterial lysates and culture supernatants prepared from *S. pneumoniae* serotype 4 strain (data not shown). This analysis served as a first step to determine whether a protein is expressed at all, and if, under which growth conditions, in order to evaluate surface expression of the polypeptide by FACS analysis. It was anticipated based on literature data that not all proteins would be expressed under *in vitro* conditions.

Cell surface staining of S. pneumoniae. Cell surface accessibility for several antigenic proteins was subsequently demonstrated by an assay based on flow cytometry. Streptococci were incubated with preimmune and polyclonal mouse sera raised against *S. pneumoniae* lysate or *E. coli* clones harboring plasmids encoding the platform protein fused to a *S. pneumoniae* peptide, follow by detection with fluorescently tagged secondary antibody. As shown in Fig. 6A, antisera raised against *S. pneumoniae* lysate contains antibodies against surface components, demonstrated by a significant shift in fluorescence of the *S. pneumoniae* serotype 4 cell population. Similar cell surface staining of *S. pneumoniae* serotype 4 cells was observed with polyclonal sera raised against peptides of many of the pneumococcal antigens identified (Fig. 6B and Table 4.). In some instances, a subpopulation of the bacteria was not stained, as indicated by the detection of two peaks in the histograms (Fig. 6B). This phenomenon may be a result of differential expression of the gene products during the growth of the bacterium, insufficient antibody levels or partial inhibition of antibody binding caused by other surface molecules or plasma proteins.

In vitro bactericidal activity. Opsonophagocytic killing is the cornerstone of host defense against extracellular bacteria, such as *S. pneumoniae*. Cell surface binding of antibodies to bacterial antigens are opsonizing and induce killing (bactericidal) by phagocytic cells (macrophages and neutrophil granulocytes) if the antibodies induced by the particular antigens can bind activated complement components (C3bi). It has been shown that anti-pneumococcal bactericidal activity of human sera measured in *in vitro* assays can be correlated with *in vivo* protection of vaccinated individuals [Romero-Steiner, S. et al., 1999]. In Figure 7 examples are shown and in Table 4 a summary is presented on bactericidal activity measured by antigen-specific antibodies generated in mice with corresponding

epitopes. According to these data, several of the novel pneumococcal antigens induce functional antibodies (e.g. SP0082, SP2216, SP2136, SP0454, SP0069, SP0369, etc.). Importantly, a well-known protective pneumoniae antigen, PspA (SP0117) is proved to be strongly positive in the very same assay.

These experiments confirmed the bioinformatic prediction that many of the proteins are exported due to their signal peptide sequence and in addition showed that they are present on the cell surface of *S. pneumoniae* serotype 4. They also confirm that these proteins are available for recognition by human antibodies with functional properties and make them valuable candidates for the development of a vaccine against pneumococcal diseases.

Example 7: Identification of pneumococcal antigens inducing protective immune responses

Experimental procedures

Expression of recombinant pneumococcal proteins

Cloning of genes/DNA fragments: The gene/DNA fragment of interest was amplified from the genomic DNA of *S. pneumoniae* (strain T4, Capsular type 4) by PCR using gene specific primers. Apart from the gene specific part, the primers had restriction sites that aided in a directional cloning of the amplified PCR product. The gene annealing (specific) part of the primer ranged between 15-24 bases in length. The PCR products obtained were digested with the appropriate restriction enzyme and cloned into pET28b(+) vector (NOVAGEN). Once the recombinant plasmid was confirmed to contain the gene of interest, *E. coli* BL21 star[®] cells (INVITROGEN) that served as expression hosts were transformed. These cells were optimized to efficiently express the gene of interest. **Expression and purification of proteins:** *E. coli* BL21 star[®] cells harbouring the recombinant plasmid was grown until log phase in a required culture volume. Once the OD_{600nm} of 0.8 was reached the culture was induced with 1 mM IPTG for 3 hours at 37°C. The cells were harvested by centrifugation, lysed by a combination of freeze-thaw method followed by disruption of cells with 'Bug-buster[®]', NOVAGEN'. The lysate was separated by centrifugation into soluble (supernatant) and insoluble (pellet) fractions. Depending on the location of the protein different purification strategies was followed. In case the protein was in the soluble fraction, purification of the protein was done by binding the above supernatant with Ni-Agarose beads (Ni-NTA-Agarose[®], QIAGEN). Due to the presence of the penta Histidine (HIS) at the C or N or both termini of the expressed protein, it bound to the Ni-agarose while the other contaminating proteins were washed from the column by wash buffer. The proteins were eluted by 100 mM imidazole and the eluate was concentrated, assayed by Bradford for protein concentration and checked by PAGE and Western blot. In case the protein was present in the insoluble fraction the pellet was solubilized in buffer containing 8 M Urea. The purification was done under denaturing conditions (in buffer containing 8M Urea) using the same materials and procedure as mentioned above. The eluate was concentrated and dialyzed to remove all the urea in a gradual stepwise manner. The proteins were checked by SDS-PAGE and concentrations measured by Bradford method.

Animal protection studies

Animals: C3H (HeNHsd; A, B, C, D: agouti, wild type, inbred) female mice were used. **Active immunization:** 50 µg of recombinant proteins were injected subcutaneously and adjuvanted with Complete Freund Adjuvant (CFA). Animals were boosted twice with the same amount of protein, but adjuvanted with Incomplete Freund Adjuvant (IFA) at days 14 and 28. A well-known protective antigen PspA (SP0117) was used as a positive control, while nonimmunized (PBS or CFA/IFA adjuvant injected) mice served as negative controls. Antibody titers were measured at days 35-38 by ELISA using the respective recombinant proteins, and were determined to be in the range of 200.00-1.000.000 (end-point titer). **Passive immunization:** Naïve mice were injected with 150-300µl mouse sera intraperitoneally 2hrs before intraperitoneal inoculation with *S. pneumoniae*. **Bacterial challenge:** A frozen glycerol stock of *S. pneumoniae* serotype 6B was prepared and used for all experiments. The approximate estimated cell number was determined by OD_{600nm} measurements. In order to determine the real viable cell numbers

References

- Adamou, J., et al. (2001). Infect Immun 69: 949-58.
- Altschul, S., et al. (1990). Journal of Molecular Biology 215: 403-10.
- Bennett, D., et al. (1995). J Mol Recognit 8: 52-8.
- Brown, J., et al. (2001). Infect Immun 69: 6702-6.
- Burnie, J., et al. (1998). J Antimicrob Chemother 41: 319-22.
- Clackson, T., et al. (1991). Nature 352: 624-8.
- Devereux, J., et al. (1984). Nucleic acids research 12: 387-95.
- Di Guilmi, A., et al. (2002). EMBO Rep 3: 728-34.
- Doherty, E., et al. (2001). Annu Rev Biophys Biomol Struct 30: 457-475.
- Eisenbraun, M., et al. (1993). DNA Cell Biol 12: 791-7.
- Epidemiology and Prevention of Vaccine-Preventable Diseases, 7th Edition-Second Printing (The Pink Book). The Pink Book is published by the Centers for Disease Control and Prevention, U.S. Department of Health and Human Services.
- Etz, H., et al. (2001). J Bacteriol 183: 6924-35.
- Ganz, T. (1999). Science 286: 420-421.
- Georgiou, G. (1997). Nature Biotechnology 15: 29-34.
- Gray, B., et al. (1979). J Infect Dis 140: 979-83.
- Gray, B., et al. (1986). Pediatr Infect Dis 5: 201-7.
- Hashemzadeh-Bonehi, L., et al. (1998). Mol Microbiol 30: 676-678.
- Hausdorff, W., et al. (2001). Lancet 357: 950-2.
- Heinje, von G. (1987) e.g. Sequence Analysis in Molecular Biology, Academic Press
- Hemmer, B., et al. (1999). Nat Med 5: 1375-82.
- Hoe, N., et al. (2001). J Infect Dis 183: 633-9.
- Hornef, M., et al. (2002). Nat Immunol 3: 1033-40.
- Hoskins, J., et al. (2001). J Bacteriol 183: 5709-17.
- Hyde, T., et al. (2001). JAMA 286: 1857-62.
- Jedrzejewski, M. (2001). Microbiol Mol Biol Rev 65: 187-207.
- Johanson, K., et al. (1995). J Biol Chem 270: 9459-71.
- Jones, P., et al. (1986). Nature 321: 522-5.
- Kajava, A., et al. (2000). J Bacteriol 182: 2163-9.
- Kohler, G., et al. (1975). Nature 256: 495-7.
- Kolaskar, A., et al. (1990). FEBS Lett 276: 172-4.
- Lewin, A., et al. (2001). Trends Mol Med 7: 221-8.
- Marks, J., et al. (1992). Biotechnology (N Y) 10: 779-83.
- McCafferty, J., et al. (1990). Nature 348: 552-4.
- McCormick, A., et al. (2003). Nat Med 9: 424-30.
- McDaniel, L., et al. (1991). Infect Immun 59: 222-8.
- Navarre, W., et al. (1999). Microbiol Mol Biol Rev 63: 174-229.
- Okano, H., et al. (1991). J Neurochem 56: 560-7.
- Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression; CRC Press, Boca Tation, FL (1988) for a description of these molecules
- Orange, M., et al. (1993). Pediatr Infect Dis J 12: 244-6.
- Pelton, S., et al. (2003). Vaccine 21: 1562-71.
- Phillips-Quagliata, J., et al. (2000). J Immunol 165: 2544-55.
- Rammensee, H., et al. (1999). Immunogenetics 50: 213-9.
- Roche, H., et al. (2003). Infect Immun 71: 1033-41.
- Romero-Steiner, S., et al. (1999). Clin Infect Dis 29: 281-8.
- Rosenow, C., et al. (1997). Mol Microbiol 25: 819-29.
- Seeger, C., et al. (1984). Proc Natl Acad Sci U S A 81: 5849-52.
- Shibuya, A., et al. (2000). Nature Immunology 1: 441-6.

- 61 -

- Skerra, A. (1994). Gene 151: 131-5.
- Talkington, D., et al. (1996). Microb Pathog 21: 17-22.
- Tang, D., et al. (1992). Nature 356: 152-4.
- Tempest, P., et al. (1991). Biotechnology (N Y) 9: 266-71.
- Tettelin, H., et al. (2001). Science 293: 498-506.
- Tourdot, S., et al. (2000). Eur J Immunol 30: 3411-21.
- Whitney, C., et al. (2000). N Engl J Med 343: 1917-24.
- Wiley, J., et al. (1987) Current Protocols in Molecular Biology.
- Wizemann, T., et al. (2001). Infect Immun 69: 1593-8.

present in the inoculum prepared from the frozen glycerol stock cultures, cfus were determined via plating using six serial dilutions. 10^4 - 10^8 bacteria/mouse was injected either intravenously in the tail vein or intraperitoneally. Protective effect of immunizations was measured by monitoring survival rates for 2 to 3 weeks post-challenge and was expressed in % of total number of animals (10/ group).

Results

In the present invention six different pneumococcal antigens identified by bacterial surface display were determined to have protective effect in a mouse sepsis/lethality model. The best levels of protection were achieved by immunization with recombinant antigens representing the SP2190, SP2216 and SP0667 protein, while SP0368, SP1732 and SP0498 displayed lower levels of protection (Fig. 8). The protective effect was mediated by antibodies as it has been demonstrated by passive serum transfer experiments (Fig. 9). Naïve mice receiving specific anti-SP2190 and anti-SP2216 antibodies were protected from death relative to mice from the negative control groups. Importantly, the combination of these antigens resulted in improved protection, as it has been shown in Fig. 9. Passive immunization with 150 µl immune serum generated either with recombinant SP2190 or with recombinant SP2216 (supplemented with 150µl naïve serum) resulted in lower survival rate compared to serum therapy with 100µl each of specific antisera (supplemented with 100µl naïve serum). These experiments strongly support that combination of these antigens has beneficial effects in vaccination against pneumococcal diseases.

Since the antigens used for immunization were derived from a serotype 4 strain and the challenge strain was a serotype 6B, these experiments established that the antigens were cross-protective.

The SP2216, SP2190 and SP1732 recombinant proteins detected the highest levels of antibodies in sera of patients convalescing from invasive pneumococcal diseases, as well as in those of healthy individuals exposed to *Pneumococcus* (children in the household) (data not shown). The most frequently identified antigen in bacterial surface display screens was the SP2216 protein. It was a special interest to compare the protectivity of the subdomains of this protein selected (N-terminal amino acid sequences) or not selected (C-terminal amino acid sequences) by human antibodies (Fig. 10A). Upon immunization with the two different domains (expressed as recombinant antigens) it became evident that the immunogenic part of the SP2216 protein carried the protective potential, while the non-selected domain was ineffective and comparable to the negative control (Fig. 10B). Based on this experiment the epitopes detected by bacterial surface display identifies protective epitopes and regions of bacterial proteins and this information can be used for rational design of subunit vaccines based on the antigens described in the present invention.

Example 8: Determination of sequence conservation of protective antigens

Experimental procedures

Immunoblotting

Total bacterial lysate and culture supernatant samples were prepared from *in vitro* grown *S. pneumoniae* strains. 60 (clinical isolates) representing 48 different serotypes were included in the study. Approximately 25µg total protein/lane was separated by SDS-PAGE using the BioRad Mini-Protean 3 Cell electrophoresis system and proteins transferred to nitrocellulose membrane (ECL, Amersham Pharmacia). After overnight blocking in 5% milk, hyperimmune mouse sera generated by immunization with the recombinant proteins SP2216, SP1732 and SP2190 (and SP0117/PspA as internal control) derived from serotype 4 strain were added at 5,000x dilution, and HRP0 labeled anti-mouse IgG was used for detection.

DNA sequencing

The genes of SP1732, SP2190 and SP22126 were amplified from the genomic DNA of *S. pneumoniae* (serotype 4, 6B, 9V, 14, 18C, 19F and 23F) by PCR using a proofreading polymerase Expand (ROCHE). Gene specific primers, ranging between 27-31 bases in length, were used to amplify the entire open reading frames. The PCR products obtained were cloned into pCR®2.1-TOPO vector (Invitrogen). The recombinant plasmid DNA was purified using a QIAprep® miniprep kit (Qiagen) before the sequence was confirmed (MWG). In addition to the seven serotypes, the gene of SP2216 from other 41 different serotypes was amplified by PCR and the purified PCR products were sequenced.

Results

Identification of conserved antigens inducing antibodies that are cross-reactive with different clinical isolates is crucial for the development effective vaccines. It is especially relevant for protein-based vaccines targeting pneumococcal diseases, since more than 90 different serotypes of *Streptococcus pneumoniae* (*Pneumococcus*) have been associated with human infections.

In a thorough analysis it was determined that the antibodies induced by SP2216, SP2190 and SP1732 all derived from a serotype 4 strain broadly cross-reacted with all the different serotypes tested in the immunoblot analysis (Fig. 11). Notably, the SP2190 antigen that showed variation in electrophoretic mobility (indicating different sizes) preserved the antibody reactivity strongly suggesting that immunodominant epitopes are conserved. In contrast, we detected lower cross-reactivity with anti-PspA antibodies that is in accordance with the known differences in immunogenic amino acid sequences of this antigen.

In order to directly address the question whether the identified protective antigens are conserved among the different serotypes of *S. pneumoniae*, DNA sequence analysis was performed on the SP2216, SP1732 and SP2190 genes. SP2216 and SP1732 are highly conserved, only few amino acid changes were detected. The SP2216 gene was sequenced from 47 different clinical isolates representing 47 different *S. pneumoniae* serotypes and only single amino acid exchanges were detected and only in 2 of the analysed strains (Fig. 12). In the SP1732 gene one or two amino acid exchanges were detected in the majority (in four of the six) of strains analysed (Fig. 13). The 2190 antigen showed a great variability in the amino acid sequences of the corresponding genes as it is shown in Fig. 14. The insertions and deletions makes it difficult to calculate an exact amino acid homology among the different SP2190 variants, but it can be estimated to be between approx. 60 and 90%. However, the amino acid identity was sufficient to induce cross-reactive and cross-protective antibodies based on the experiments presented in Fig. 8,9 and 11.

Table 1: Immunogenic proteins identified by bacterial surface display.

<i>S. pneumoniae</i> antigenic protein	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region (aa)	Seq. ID (DNA, Prot.)
SP0008	hypothetical protein	4-11,35-64,66-76,101-108,111-119	G:15	57-114	1, 145
SP0032	DNA polymerase I (polA)	5-27,32-64,92-102,107-113,119-125,133-139,148- 162,177-187,195-201,207-214,241-251,254-269,285- 300,302-309,317-324,332-357,365-404,411-425,443- 463,470-477,479-487,506-512,515-520,532-547,556- 596,603-610,616-622,624-629,636-642,646-665,667- 674,687-692,708-720,734-739,752-757,798-820,824- 851,856-865	H:39, I:6, L:2	732-763	2, 146
SP0069	Choline binding protein I	14-21,36-44,49-66,102-127,162-167,177-196	G:1, H:2, I:1, K:44, L:3, M:1	45-109 145-172	3, 147
SP0071	immunoglobulin A1 protease (iga-1)	17-35,64-75,81-92,100-119,125-172,174-183,214- 222,230-236,273-282,287-303,310-315,331-340,392- 398,412-420,480-505,515-523,525-546,553-575,592- 598,603-609,617-625,631-639,644-651,658-670,681- 687,691-704,709-716,731-736,739-744,750-763,774- 780,784-791,799-805,809-822,859-870,880-885,907- 916,924-941,943-949,973-986,1010-1016,1026- 1036,1045-1054,1057-1062,1082-1088,1095-1102,1109- 1120,1127-1134,1140-1146,1152-1159,1169-1179,1187- 1196,1243-1251,1262-1273,1279-1292,1306-1312,1332- 1343,1348-1364,1379-1390,1412-1420,1427-1436,1458- 1468,1483-1503,1524-1549,1574-1588,1614-1619,1672- 1685,1697-1707,1711-1720,1738-1753,1781-1787,1796- 1801,1826-1843	A:3, C:1, D:9, E:9, F:4, G:21, I:34, K:61, L:20, M:2	132-478 508-592 1753-1810	4, 148
SP0082	Cell wall surface anchor	15-43,49-55,71-77,104-110,123-130,162-171,180- 192,199-205,219-227,246-254,264-270,279-287,293- 308,312-322,330-342,349-356,369-377,384-394,401- 406,416-422,432-439,450-460,464-474,482-494,501- 508,521-529,536-546,553-558,568-574,584-591,602- 612,616-626,634-646,653-660,673-681,688-698,705- 710,720-726,736-749,833-848	C:9, E:4, F:2, I:26, L:4, M:67	1-199 200-337 418-494 549-647	5, 149
SP0107	LysM domain protein	9-30,65-96,99-123,170-178	A :3, B :16, C :15, D :1, E :5, F :178,	1-128	6, 150

<i>S. pneumoniae</i> antigenic protein	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region (aa)	Seq. ID (DNA, Prot.)
			M:1		
SP0117	pneumococcal surface protein A (pspA)	7-32,34-41,96-106,127-136,154-163,188-199,207- 238,272-279,306-312,318-325,341-347,353-360,387- 393,399-406,434-440,452-503,575-580,589-601,615- 620,635-640,654-660,674-680,696-701,710-731	A:13, B:11, C:10, D:4, E:31, F:6, G:33, H:13, I:9, K:64, L:32, M:46	1-548 660-691	7, 151
SP0191	hypothetical protein	4-19,35-44,48-59,77-87,93-99,106-111,130-138,146-161	E:1, I:2	78-84	8, 152
SP0197	dihydrofolate synthetase, putative	24-30,36-43,64-86,93-99,106-130,132-145,148-165,171- 177,189-220,230-249,251-263,293-300,302-312,323- 329,338-356,369-379,390-412	L:9	179-193	9, 153
SP0212	Ribosomal protein L2	30-39,61-67,74-81,90-120,123-145,154-167,169-179,182- 197,200-206,238-244,267-272	L:10	230-265	10, 154
SP0222	Ribosomal protein S14	14-20,49-65,77-86	H:14, L:8, M:3	2-68	11, 155
SP0239	Conserved hypothetical protein	4-9,26-35,42-48,53-61,63-85,90-101,105-111,113- 121,129-137,140-150,179-188,199-226,228-237,248- 255,259-285,299-308,314-331,337-343,353-364,410- 421,436-442	L:2, M:1	110-144	12, 156
SP0251	formate acetyltransferase, putative	36-47,55-63,94-108,129-134,144-158,173-187,196- 206,209-238,251-266,270-285,290-295,300-306,333- 344,346-354,366-397,404-410,422-435,439-453,466- 473,515-523,529-543,554-569,571-585,590-596,607- 618,627-643,690-696,704-714,720-728,741-749,752- 767,780-799	G:2, H:7, I:1, M:5	225-247 480-507	13, 157
SP0295	ribosomal protein S9 (rpsI)	16-25,36-70,80-93,100-106	I:4	78-130	14, 158
SP0330	sugar binding transcriptional regulator RegR	18-27,41-46,50-57,65-71,79-85,93-98,113-128,144- 155,166-178,181-188,201-207,242-262,265-273,281- 295,303-309,318-327	G:1, H:1, L:4	36-64	15, 159
SP0368	cell wall surface anchor family protein	7-29,31-44,50-59,91-96,146-153,194-201,207-212,232- 238,264-278,284-290,296-302,326-353,360-370,378- 384,400-405,409-418,420-435,442-460,499-506,529- 534,556-562,564-576,644-651,677-684,687-698,736- 743,759-766,778-784,808-814,852-858,874-896,920- 925,929-935,957-965,1003-1012,1021-1027,1030- 1044,1081-1087,1101-1111,1116-1124,1148-1159,1188-	D:1, H:3, I:1, L:1, M:3	1-70 154-189 922-941 1445-1462 1483-1496	16, 160

<i>S. pneumoniae</i> antigenic protein	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region (aa)	Seq. ID (DNA, Prot.)
		1196,1235-1251,1288-1303,1313-1319,1328-1335,1367-1373,1431-1437,1451-1458,1479-1503,1514-1521,1530-1540,1545-1552,1561-1568,1598-1605,1617-1647,1658-1665,1670-1676,1679-1689,1698-1704,1707-1713,1732-1738,1744-1764			
SP0369	Penicillin binding protein 1A	6-51,81-91,104-113,126-137,150-159,164-174,197-209,215-224,229-235,256-269,276-282,307-313,317-348,351-357,376-397,418-437,454-464,485-490,498-509,547-555,574-586,602-619	B:1, E:1, L:13, M:1	452-530	17, 161
SP0374	hypothetical protein	25-31,39-47,49-56,99-114,121-127,159-186,228-240,253-269,271-279,303-315,365-382,395-405,414-425,438-453	E:4, I:1, L:3	289-384	18, 162
SP0377	Choline binding protein C	9-24,41-47,49-54,68-78,108-114,117-122,132-140,164-169,179-186,193-199,206-213,244-251,267-274,289-294,309-314,327-333	G:5, H:4, I:1, K:88, L:3, M:8	209-249 286-336	19, 163
SP0378	choline binding protein J (cbpJ)	9-28,53-67,69-82,87-93,109-117,172-177,201-207,220-227,242-247,262-268,305-318,320-325	K:47, L:6, M:5	286-306	20, 164
SP0390	choline binding protein G (cbpG)	4-10,26-39,47-58,63-73,86-96,98-108,115-123,137-143,148-155,160-176,184-189,194-204,235-240,254-259,272-278	G:1, K:69, M:6	199-283	21, 165
SP0454	hypothetical protein	4-26,33-39,47-53,59-65,76-83,91-97,104-112,118-137,155-160,167-174,198-207,242-268,273-279,292-315,320-332,345-354,358-367,377-394,403-410,424-439,445-451,453-497,511-518,535-570,573-589,592-601,604-610	H:1, I:1, L:6	202-242	22, 166
SP0463	cell wall surface anchor family protein	8-30,36-45,64-71,76-82,97-103,105-112,134-151,161-183,211-234,253-268,270-276,278-284,297-305,309-315,357-362,366-372,375-384,401-407,409-416,441-455,463-470,475-480,490-497,501-513,524-537,552-559,565-576,581-590,592-600,619-625,636-644,646-656	A:1, B:2, C:4, E:1, F:4,	316-419	23, 167
SP0466	sortase, putative	4-17,52-58,84-99,102-110,114-120,124-135,143-158,160-173,177-196,201-216,223-250,259-267,269-275	E:1, M:2	1-67	24, 168
SP0468	Sortase, putative	6-46,57-67,69-80,82-133,137-143,147-168,182-187,203-209,214-229,233-242,246-280	G:24, H:20, L:1	53-93	25, 169
SP0498	endo-beta-N- acetylglucosaminidas e, putative	7-40,50-56,81-89,117-123,202-209,213-218,223-229,248-261,264-276,281-288,303-308,313-324,326-332,340-346,353-372,434-443,465-474,514-523,556-564,605-616,620-626,631-636,667-683,685-699,710-719,726-732,751-756,760-771,779-788,815-828,855-867,869-	B:5, C:1, E:2, F:1, G:2	1226-1309 1455-1536 1538-1605	26, 170

<i>S. pneumoniae</i> antigenic protein	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region (aa)	Seq. ID (DNA, Prot.)
		879,897-902,917-924,926-931,936-942,981-1000,1006-1015,1017-1028,1030-1039,1046-1054,1060-1066,1083-1092,1099-1112,1122-1130,1132-1140,1148-1158,1161-1171,1174-1181,1209-1230,1236-1244,1248-1254,1256-1267,1269-1276,1294-1299,1316-1328,1332-1354,1359-1372,1374-1380,1384-1390,1395-1408,1419-1425,1434-1446,1453-1460,1465-1471,1474-1493,1505-1515,1523-1537,1547-1555,1560-1567,1577-1605,1633-1651			
SP0509	type I restriction-modification system, M subunit	4-10,31-39,81-88,106-112,122-135,152-158,177-184,191-197,221-227,230-246,249-255,303-311,317-326,337-344,346-362,365-371,430-437,439-446,453-462,474-484	L:2	449-467	27, 171
SP0519	dnaJ protein (dnaJ)	9-15,24-35,47-55,122-128,160-177,188-196,202-208,216-228,250-261,272-303,318-324,327-339,346-352,355-361,368-373	A:1, D:2, H:2	108-218 344-376	28, 172
SP0529	BlpC ABC transporter (blpB)	6-14,17-48,55-63,71-90,99-109,116-124,181-189,212-223,232-268,270-294,297-304,319-325,340-348,351-370,372-378,388-394,406-415,421-434	A:1, B:3, C:3, D:1, F:4,	177-277	29, 173
SP0564	hypothetical protein	21-39,42-61,65-75,79-85,108-115	H:3	11-38	30, 174
SP0609	amino acid ABC transporter, amino acid-binding protein	4-17,26-39,61-76,103-113,115-122,136-142,158-192,197-203,208-214,225-230,237-251	I:3	207-225	31, 175
SP0613	metallo-beta-lactamase superfamily protein	5-11,27-36,42-53,62-70,74-93,95-104,114-119,127-150,153-159,173-179,184-193,199-206,222-241,248-253,257-280,289-295,313-319,322-342,349-365,368-389,393-406,408-413,426-438,447-461,463-470,476-495,532-537,543-550	I:12	225-246	32, 176
SP0641	Serine protease	4-29,68-82,123-130,141-147,149-157,178-191,203-215,269-277,300-307,327-335,359-370,374-380,382-388,393-400,410-417,434-442,483-492,497-503,505-513,533-540,564-569,601-607,639-647,655-666,693-706,712-718,726-736,752-758,763-771,774-780,786-799,806-812,820-828,852-863,884-892,901-909,925-932,943-948,990-996,1030-1036,1051-1059,1062-1068,1079-1086,1105-1113,1152-1162,1168-1179,1183-1191,1204-1210,1234-1244,1286-1295,1318-1326,1396-1401,1451-1460,1465-1474,1477-1483,1488-1494,1505-1510,1514-1521,1552-1565,1593-1614,1664-1672,1677-1685,1701-1711,1734-1745,1758-1770,1784-1798,1840-	A:19, B:72, C:34, D:5, E:21, F:86, G:26, H:86, I:17, L:130, M:29	1-348 373-490 573-767 903-1043 1155-1198 1243-1482 1550-1595 1682-1719 1793-1921 2008-2110	33, 177

<i>S. pneumoniae</i> antigenic protein	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region (aa)	Seq. ID (DNA, Prot.)
		1847,1852-1873,1885-1891,1906-1911,1931-1939,1957-1970,1977-1992,2014-2020,2026-2032,2116-2134			
SP0648	beta-galactosidase (bgaA)	10-35,39-52,107-112,181-188,226-236,238-253,258-268,275-284,296-310,326-338,345-368,380-389,391-408,410-418,420-429,444-456,489-505,573-588,616-623,637-643,726-739,741-767,785-791,793-803,830-847,867-881,886-922,949-956,961-980,988-1004,1009-1018,1027-1042,1051-1069,1076-1089,1108-1115,1123-1135,1140-1151,1164-1179,1182-1191,1210-1221,1223-1234,1242-1250,1255-1267,1281-1292,1301-1307,1315-1340,1348-1355,1366-1373,1381-1413,1417-1428,1437-1444,1453-1463,1478-1484,1490-1496,1498-1503,1520-1536,1538-1546,1548-1570,1593-1603,1612-1625,1635-1649,1654-1660,1670-1687,1693-1700,1705-1711,1718-1726,1729-1763,1790-1813,1871-1881,1893-1900,1907-1935,1962-1970,1992-2000,2006-2013,2033-2039,2045-2051,2055-2067,2070-2095,2097-2110,2115-2121,2150-2171,2174-2180,2197-2202,2206-2228	C:1, E:1, F:1, G:1, H:4, I:1, M:2	1526-1560	34, 178
SP0664	Zinc metalloprotease ZmpB, putative	4-17,35-48,54-76,78-107,109-115,118-127,134-140,145-156,169-174,217-226,232-240,256-262,267-273,316-328,340-346,353-360,402-409,416-439,448-456,506-531,540-546,570-578,586-593,595-600,623-632,662-667,674-681,689-705,713-724,730-740,757-763,773-778,783-796,829-835,861-871,888-899,907-939,941-955,957-969,986-1000,1022-1028,1036-1044,1068-1084,1095-1102,1118-1124,1140-1146,1148-1154,1168-1181,1185-1190,1197-1207,1218-1226,1250-1270,1272-1281,1284-1296,1312-1319,1351-1358,1383-1409,1422-1428,1438-1447,1449-1461,1482-1489,1504-1510,1518-1527,1529-1537,1544-1551,1569-1575,1622-1628,1631-1637,1682-1689,1711-1718,1733-1740,1772-1783,1818-1834,1859-1872	A:9, B:25, C:13, D:7, E:14, F:77, G:12, H:10, K:67, L:13, M:6	1-64 128-495	35, 179
SP0667	pneumococcal surface protein, putative	8-28,32-37,62-69,119-125,137-149,159-164,173-189,200-205,221-229,240-245,258-265,268-276,287-293,296-302,323-329	A:72, B:80, C:90, D:20, E:12, F:53	1-95	36, 180
SP0688	UDP-N- acetylmuramoylalanine- D-glutamate ligase	9-18,25-38,49-63,65-72,74-81,94-117,131-137,139-146,149-158,162-188,191-207,217-225,237-252,255-269,281-293,301-326,332-342,347-354,363-370,373-	E:3	75-107	37, 181

<i>S. pneumoniae</i> antigenic protein	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region (aa)	Seq. ID (DNA, Prot.)
		380,391-400,415-424,441-447			
SP0749	branched-chain amino acid ABC transporter	4-24,64-71,81-87,96-116,121-128,130-139,148-155,166- 173,176-184,203-215,231-238,243-248,256-261,280- 286,288-306,314-329	E:2, I:8, L:8	67-148	38, 182
SP0770	ABC transporter, ATP-binding protein	4-10,19-37,46-52,62-81,83-89,115-120,134-139,141- 151,168-186,197-205,209-234,241-252,322-335,339- 345,363-379,385-393,403-431,434-442,447-454,459- 465,479-484,487-496	L:2	404-420	39, 183
SP0785	conserved hypothetical protein	10-35,46-66,71-77,84-93,96-122,138-148,154-172,182- 213,221-233,245-263,269-275,295-301,303-309,311- 320,324-336,340-348,351-359,375-381	C:1, E:2, I:1	111-198	40, 184
SP0914	nodulin-related protein, truncation	14-25,30-42,47-61,67-75,81-91,98-106,114-122,124- 135,148-193,209-227	L:2	198-213	41, 185
SP0930	choline binding protein E (cbpE)	5-18,45-50,82-90,97-114,116-136,153-161,163-171,212- 219,221-227,240-249,267-281,311-317,328-337,375- 381,390-395,430-436,449-455,484-495,538-543,548- 554,556-564,580-586,596-602	E:4, G:2, H:1, I:2, K:5	493-606	42, 186
SP0943	Gid protein (gid)	9-25,28-34,37-44,61-68,75-81,88-96,98-111,119-133,138- 150,152-163,168-182,186-194,200-205,216-223,236- 245,257-264,279-287,293-304,311-318,325-330,340- 346,353-358,365-379,399-409,444-453	E:2, L:24	303-391	43, 187
SP0952	alanine dehydrogenase, authentic frameshift (ald)	16-36,55-61,66-76,78-102,121-130,134-146,150-212,221- 239,255-276,289-322,329-357	G:3, H:4	29-59	44, 188
SP1003	conserved hypothetical protein (PAT)	8-27,68-74,77-99,110-116,124-141,171-177,202-217,221- 228,259-265,275-290,293-303,309-325,335-343,345- 351,365-379,384-394,406-414,423-437,452-465,478- 507,525-534,554-560,611-624,628-651,669-682,742- 747,767-778,782-792,804-812,820-836	A:2, B:5, C:8, D:5, E:13, F:3, M:2	79-231 359-451	45, 189
SP1004	Conserved hypothetical protein	5-28,39-45,56-62,67-74,77-99,110-117,124-141,168- 176,200-230,237-244,268-279,287-299,304-326,329- 335,348-362,370-376,379-384,390-406,420-429,466- 471,479-489,495-504,529-541,545-553,561-577,598- 604,622-630,637-658,672-680,682-688,690-696,698- 709,712-719,724-736,738-746,759-769,780-786,796- 804,813-818,860-877,895-904,981-997,1000-1014,1021- 1029	A:5, B:4, C:4, D:9, E:12, F:4, H:3, I:1, L:1	1-162 206-224 254-350 414-514 864-938	46, 190

<i>S. pneumoniae</i> antigenic protein	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region (aa)	Seq. ID (DNA, Prot.)
SP1124	glycogen synthase (glgA)	4-11,19-49,56-66,68-101,109-116,123-145,156-165,177-185,204-221,226-234,242-248,251-256,259-265,282-302,307-330,340-349,355-374,377-383,392-400,422-428,434-442,462-474	M:1	266-322	47, 191
SP1154	IgA1 protease	14-43,45-57,64-74,80-87,106-127,131-142,145-161,173-180,182-188,203-210,213-219,221-243,245-254,304-311,314-320,342-348,354-365,372-378,394-399,407-431,436-448,459-465,470-477,484-490,504-509,531-537,590-596,611-617,642-647,723-734,740-751,754-762,764-774,782-797,807-812,824-831,838-845,877-885,892-898,900-906,924-935,940-946,982-996,1006-1016,1033-1043,1051-1056,1058-1066,1094-1108,1119-1126,1129-1140,1150-1157,1167-1174,1176-1185,1188-1201,1209-1216,1220-1228,1231-1237,1243-1248,1253-1285,1288-1297,1299-1307,1316-1334,1336-1343,1350-1359,1365-1381,1390-1396,1412-1420,1427-1439,1452-1459,1477-1484,1493-1512,1554-1559,1570-1578,1603-1608,1623-1630,1654-1659,1672-1680,1689-1696,1705-1711,1721-1738,1752-1757,1773-1780,1817-1829,1844-1851,1856-1863,1883-1895,1950-1958,1974-1990	A:6, B:2, C:9, D:3, E:4, F:2, G:6, H:4, I:13, L:12	172-354 384-448 464-644 648-728 1357-1370	48, 192
SP1174	conserved domain protein (PAT)	8-27,68-74,77-99,110-116,124-141,169-176,201-216,220-227,258-264,274-289,292-302,308-324,334-342,344-350,364-372,377-387,399-407,416-429,445-458,471-481,483-500,518-527,547-553,604-617,621-644,662-675,767-778,809-816	B:14, C:17, D:6, E:18, F:16, I:1, K:5, L:1, M:8	15-307 350-448 496-620	49, 193
SP1175	conserved domain protein	4-17,24-29,53-59,62-84,109-126,159-164,189-204,208-219,244-249,274-290,292-302,308-324,334-342,344-350,378-389,391-397,401-409,424-432,447-460,470-479,490-504,521-529,538-544,549-555,570-577,583-592,602-608,615-630,635-647,664-677,692-698,722-731,733-751,782-790,793-799	A:1, B:4, C:3, D:3, E:9, F:2, H:2, M:4	56-267 337-426 495-601	50, 194
SP1221	type II restriction endonuclease	12-22,49-59,77-89,111-121,136-148,177-186,207-213,217-225,227-253,259-274,296-302,328-333,343-354,374-383,424-446,448-457,468-480,488-502,507-522,544-550,553-560,564-572,587-596,604-614,619-625,629-635,638-656,662-676,680-692,697-713,720-738,779-786,833-847,861-869,880-895,897-902,911-917,946-951,959-967,984-990,992-1004,1021-1040,1057-	G:2, H:1, K:1, L:4	381-403	51, 195

<i>S. pneumoniae</i> antigenic protein	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region (aa)	Seq. ID (DNA, Prot.)
		1067,1073-1080			
SP1227	DNA-binding response regulator	4-10,26-31,46-56,60-66,70-79,86-94,96-102,109-118,132-152,164-187,193-206,217-224	E:1, L:3	81-149	52, 196
SP1241	amino acid ABC transporter, amino acid-binding pro	4-21,26-37,48-60,71-82,109-117,120-128,130-136,142-147,181-187,203-211,216-223,247-255,257-284,316-325,373-379,395-400,423-435,448-456,479-489,512-576,596-625,641-678,680-688,692-715	B:2, C:1, E:2, I:1	346-453	53, 197
SP1287	signal recognition particle protein (ffh)	10-16,25-31,34-56,58-69,71-89,94-110,133-176,186-193,208-225,240-250,259-266,302-307,335-341,376-383,410-416	B:8, C:8, H:3, M:1	316-407	54, 198
SP1330	N- acetylmannosamine- 6-P epimerase, putative (nanE)	11-29,42-56,60-75,82-88,95-110,116-126,132-143,145-160,166-172,184-216	L:45	123-164	55, 199
SP1374	Chorismate sythetase (aroC)	11-29,54-63,110-117,139-152,158-166,172-180,186-193,215-236,240-251,302-323,330-335,340-347,350-366,374-381	G:1, L:29, M:14	252-299	56, 200
SP1378	conserved hypothetical protein	18-27,35-42,50-56,67-74,112-136,141-153,163-171,176-189,205-213,225-234,241-247,253-258,269-281,288-298,306-324,326-334,355-369,380-387	H:2	289-320	57, 201
SP1429	peptidase, U32 family	7-15,19-41,56-72,91-112,114-122,139-147,163-183,196-209,258-280,326-338,357-363,391-403,406-416	H:4	360-378	58, 202
SP1478	oxidoreductase, aldo/keto reductase family	11-18,29-41,43-49,95-108,142-194,204-212,216-242,247-256,264-273	H:11	136-149	59, 203
SP1518	conserved hypothetical protein	18-24,33-40,65-79,89-102,113-119,130-137,155-161,173-179,183-203,205-219,223-231,245-261,267-274,296-306,311-321,330-341,344-363,369-381,401-408,415-427,437-444,453-464,472-478,484-508,517-524,526-532,543-548	A:10, E:4, G:5, H:1	59-180	60, 204
SP1522	conserved domain protein	5-13,52-65,67-73,97-110,112-119,134-155	B:4, C:6, E:1, H:7, L:3	45-177	61, 205
SP1527	oligopeptide ABC transporter	6-28,34-43,57-67,75-81,111-128,132-147,155-163,165-176,184-194,208-216,218-229,239-252,271-278,328-334,363-376,381-388,426-473,481-488,492-498,507-513,536-546,564-582,590-601,607-623	A:1, B:1, C:4, F:1, G:26, H:18, I:10, L:2, M:1	148-269 420-450 610-648	62, 206

- 70 -

<i>S. pneumoniae</i> antigenic protein	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region (aa)	Seq. ID (DNA, Prot.)
SP1573	lysozyme (lytC)	4-12,20-38,69-75,83-88,123-128,145-152,154-161,183-188,200-213,245-250,266-272,306-312,332-339,357-369,383-389,395-402,437-453,455-470,497-503	A:40, B:27, C:24, D:2, E:6, G:11, K:1	1-112	63, 207
SP1604	hypothetical protein	35-59,74-86,111-117,122-137	A:1, C:3, E:1, G:1, I:1	70-154	64, 208
SP1661	cell division protein DivIVA	26-42,54-61,65-75,101-107,123-130,137-144,148-156,164-172,177-192,213-221,231-258	E:2	157-249	65, 209
SP1664	ylmF protein (ylmF)	29-38,61-67,77-87,94-100,105-111,118-158	B:1, C:42, I:3	1-97	66, 210
SP1676	N-acetylneuraminate lyase, putative	7-21,30-48,51-58,60-85,94-123,134-156,160-167,169-183,186-191,216-229,237-251,257-267,272-282,287-298	H:2	220-243	67, 211
SP1687	neuraminidase B (nanB)	6-29,34-47,56-65,69-76,83-90,123-134,143-151,158-178,197-203,217-235,243-263,303-309,320-333,338-348,367-373,387-393,407-414,416-427,441-457,473-482,487-499,501-509,514-520,530-535,577-583,590-602,605-612,622-629,641-670,678-690	B:3, E:2, L:1, M:2	37-71 238-307	68, 212
SP1693	neuraminidase A (nanA)	7-40,121-132,148-161,196-202,209-215,221-235,248-255,271-280,288-295,330-339,395-409,414-420,446-451,475-487,556-563,568-575,580-586,588-595,633-638,643-648,652-659,672-685,695-700,710-716,737-742,749-754,761-767,775-781,796-806,823-835,850-863,884-890,892-900,902-915,934-941	C:3, D:5, E:3, F:1, G:7, H:1, I:3, K:20, L:4	406-521	69, 213
SP1732	serine/threonine protein kinase	9-18,24-46,51-58,67-77,85-108,114-126,129-137,139-146,152-165,173-182,188-195,197-204,217-250,260-274,296-313,343-366,368-384,427-434,437-446,449-455,478-484,492-506,522-527,562-591,599-606,609-618,625-631,645-652	E:2, H:1	577-654	70, 214
SP1735	methionyl-tRNA formyltransferase (fmt)	13-20,26-37,41-53,56-65,81-100,102-114,118-127,163-188,196-202,231-238,245-252,266-285,293-298,301-306	K:13, M:13	19-78	71, 215
SP1759	preprotein translocase, SecA subunit (secA-2)	10-23,32-42,54-66,73-91,106-113,118-127,139-152,164-173,198-207,210-245,284-300,313-318,330-337,339-346,354-361,387-393,404-426,429-439,441-453,467-473,479-485,496-509,536-544,551-558,560-566,569-574,578-588,610-615,627-635,649-675,679-690,698-716,722-734,743-754,769-780,782-787	I:6, L:2, M:2	480-550	72, 216

<i>S. pneumoniae</i> antigenic protein	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region (aa)	Seq. ID (DNA, Prot.)
SP1772	cell wall surface anchor family protein	5-39,42-50,60-68,76-83,114-129,147-162,170-189,197- 205,217-231,239-248,299-305,338-344,352-357,371- 377,380-451,459-483,491-499,507-523,537-559,587- 613,625-681,689-729,737-781,785-809,817-865,873- 881,889-939,951-975,983-1027,1031-1055,1063- 1071,1079-1099,1103-1127,1151-1185,1197-1261,1269- 1309,1317-1333,1341-1349,1357-1465,1469-1513,1517- 1553,1557-1629,1637-1669,1677-1701,1709-1725,1733- 1795,1823-1849,1861-1925,1933-1973,1981-2025,2029- 2053,2061-2109,2117-2125,2133-2183,2195-2219,2227- 2271,2275-2299,2307-2315,2323-2343,2347-2371,2395- 2429,2441-2529,2537-2569,2577-2601,2609-2625,2633- 2695,2699-2737,2765-2791,2803-2867,2889-2913,2921- 2937,2945-2969,2977-2985,2993-3009,3023-3045,3073- 3099,3111-3167,3175-3215,3223-3267,3271-3295,3303- 3351,3359-3367,3375-3425,3437-3461,3469-3513,3517- 3541,3549-3557,3565-3585,3589-3613,3637-3671,3683- 3747,3755-3795,3803-3819,3827-3835,3843-3951,3955- 3999,4003-4039,4043-4115,4123-4143,4147-4171,4195- 4229,4241-4305,4313-4353,4361-4377,4385-4393,4401- 4509,4513-4557,4561-4597,4601-4718,4749-4768	B:9, C:1, D:1, F:13, G:1, H:3, I:1, L:1, M:2	74-171 452-559 2951-3061	73, 217
SP1804	general stress protein 24, putative	16-22,30-51,70-111,117-130,137-150,171-178,180- 188,191-196	E:4	148-181	74, 218
SP1888	oligopeptide ABC transporter, ATP- binding protein AmiE	6-19,21-46,50-56,80-86,118-126,167-186,189-205,211- 242,244-267,273-286,290-297,307-316,320-341	H:1	34-60	75, 219
SP1891	oligopeptide ABC transporter,	5-26,33-43,48-54,58-63,78-83,113-120,122-128,143- 152,157-175,185-192,211-225,227-234,244-256,270- 281,284-290,304-310,330-337,348-355,362-379,384- 394,429-445,450-474,483-490,511-520,537-546,548- 554,561-586,590-604,613-629	A:2, B:3, E:1, F:1, G:13, H:8	149-186 285-431 573-659	76, 220
SP1937	Autolysin (lytA)	5-26,49-59,61-67,83-91,102-111,145-157,185-192,267- 272,279-286,292-298,306-312	D:3, F:1, G:1, H:2, K:11, M:1	134-220 235-251 254-280	77, 221
SP1954	serine protease, subtilase family, authentic frame	5-19,72-79,83-92,119-124,140-145,160-165,167-182,224- 232,240-252,259-270,301-310,313-322,332-343,347- 367,384-398,416-429,431-446,454-461	C:43, E:6, I:4, K:21, L:50	I:1-169	78, 222
SP1980	cmp-binding-factor 1	8-17,26-31,56-62,75-83,93-103,125-131,135-141,150-	H:9	127-168	79, 223

- 72 -

<i>S. pneumoniae</i> antigenic protein	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region (aa)	Seq. ID (DNA, Prot.)
	(cbfI)	194,205-217,233-258,262-268,281-286			
SP1992	cell wall surface anchor family protein	6-12,69-75,108-115,139-159,176-182,194-214	B:5, C:1, F:4, I:1	46-161	80, 224
SP1999	catabolite control protein A (ccpA)	6-13,18-27,39-48,51-59,66-73,79-85,95-101,109-116,118- 124,144-164,166-177,183-193,197-204,215-223,227- 236,242-249,252-259,261-270,289-301,318-325	I:2	12-58	81, 225
SP2021	glycosyl hydrolase	4-10,26-32,48-60,97-105,117-132,138-163,169-185,192- 214,219-231,249-261,264-270,292-308,343-356,385- 392,398-404,408-417,435-441	L:3	24-50	82, 226
SP2027	Conserved hypothetical protein	10-40,42-48,51-61,119-126	A:1, E:1, G:19, H:12, I:16, L:5	I-118	83, 227
SP2039	conserved hypothetical protein	5-17,40-58,71-83,103-111,123-140,167-177,188-204	G:1, L:3	116-128	84, 228
SP2048	Conserved hypothetical protein	4-9,11-50,57-70,112-123,127-138	I:1, L:4	64-107	85, 229
SP2051	Competence protein CglC	9-39,51-67	D:1, G:3, I:8, L:26	I-101	86, 230
SP2092	UTP-glucose-1- phosphate uridylyltransferase (galU)	5-14,17-25,28-46,52-59,85-93,99-104,111-120,122- 131,140-148,158-179,187-197,204-225,271-283,285-293	H:2	139-155	87, 231
SP2099	Penicillin binding protein 1B	42-70,73-90,92-108,112-127,152-164,166-172,181- 199,201-210,219-228,247-274,295-302,322-334,336- 346,353-358,396-414,419-425,432-438,462-471,518- 523,531-536,561-567,576-589,594-612,620-631,665- 671,697-710,718-731,736-756,765-771,784-801	A:1, B:9, C:11, D:1, E:6, F:1, H:4, K:1	626-653	88, 232
SP2108	Maltose ABC transporter	8-28,41-51,53-62,68-74,79-85,94-100,102-108,114- 120,130-154,156-162,175-180,198-204,206-213,281- 294,308-318,321-339,362-368,381-386,393-399,407-415	G:10, H:1, L:10, M:1	2-13	89, 233
SP2120	hypothetical protein	4-39,48-65,93-98,106-112,116-129	I:2	10-36	90, 234
SP2128	transketolase, N- terminal subunit	25-32,35-50,66-71,75-86,90-96,123-136,141-151,160- 179,190-196,209-215,222-228,235-242,257-263,270-280	H:2	209-247	91, 235
SP2136	choline binding protein PcpA	5-29,31-38,50-57,62-75,83-110,115-132,168-195,197- 206,216-242,249-258,262-269,333-340,342-350,363- 368,376-392,400-406,410-421,423-430,436-442,448- 454,460-466,471-476,491-496,511-516,531-536,551-	C:3, F:1, G:24, H:32, I:13, K:177,	27-70 219-293 441-504 512-584	92, 236

<i>S. pneumoniae</i> antigenic protein	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region (aa)	Seq. ID (DNA, Prot.)
		556,571-576,585-591,599-605	L:34, M:18		
SP2141	glycosyl hydrolase- related protein	4-12,14-34,47-75,83-104,107-115,133-140,148-185,187- 196,207-212,224-256,258-265,281-287,289-296,298- 308,325-333,345-355,365-371,382-395,424-435,441- 457,465-472,483-491,493-505,528-534,536-546,552- 558,575-584,589-600,616-623	L:3	576-591	93, 237
SP2180	conserved hypothetical protein	4-76, 78-89, 91-126, 142-148, 151-191, 195-208, 211-223, 226-240, 256-277, 279-285, 290-314, 317- 323, 358-377, 381-387, 391-396, 398-411, 415-434, 436-446, 454-484, 494-512, 516-523, 538-552, 559- 566, 571-577, 579-596, 599-615, 620-627, 635-644, 694-707, 720-734, 737-759, 761-771	L:3	313-329	94, 238
SP2190	choline binding protein A (cbpA)	7-38,44-49,79-89,99-108,117-123,125-132,137-146,178- 187,207-237,245-255,322-337,365-387,398-408,445- 462,603-608,623-628,644-650,657-671,673-679	A:6, B:12, C:9, D:6, E:30, F:8, G:65, H:72, I:76, K:222, L:99, M:37	111-566	95, 239
SP2194	ATP-dependent Clp protease, ATP- binding subunit	6-20,22-35,39-45,58-64,77-117,137-144,158-163,205- 210,218-224,229-236,239-251,263-277,299-307,323- 334,353-384,388-396,399-438,443-448,458-463,467- 478,481-495,503-509,511-526,559-576,595-600,612- 645,711-721,723-738,744-758,778-807	H:1	686-720	96, 240
SP2201	choline binding protein D (cbpD)	10-33,35-41,72-84,129-138,158-163,203-226,243- 252,258-264,279-302,322-329,381-386,401-406,414-435	B:4, C:3, D:1, E:7, F:1, G:1, H:2, K:26, M:1	184-385	97, 241
SP2204	ribosomal protein L9	4-9,19-24,41-47,75-85,105-110,113-146	H:3, L:4	45-62	98, 242
SP2216	secreted 45 kd protein - homology to glucan binding protein (GbpB) S.mutant	4-25,52-67,117-124,131-146,173-180,182-191,195- 206,215-221,229-236,245-252,258-279,286-291,293- 302,314-320,327-336,341-353,355-361,383-389	A:130, B:414, C:450, D:162, E:166, F:284, G:90, H:16, I:4, K:10, L:29,	1-285	99, 243

- 74 -

<i>S. pneumoniae</i> antigenic protein	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region (aa)	Seq. ID (DNA, Prot.)
			M:11		
SP-NRF1	Choline binding protein	14-32,38-50,73-84,93-105,109-114	H:1	40-70	100, 244
ARF0408	Hypothetical protein	5-26	L:3	22-34	101, 245
ARF0441	Hypothetical protein	23-28	H:3	13-39	102, 246
ARF0690	Hypothetical protein	8-14	L:2	21-34	103, 247
ARF0878	Hypothetical protein	4-13,20-29,44-50,59-74	H:3	41-69	104, 248
ARF0921	Hypothetical protein	4-9, 19-42, 48-59, 71-83	M:4	57-91	105, 249
ARF1153	Hypothetical protein	4-14	M:7	10-28	106, 250
ARF1515	Hypothetical protein	22-28,32-42,63-71,81-111,149-156,158-167,172-180,182-203,219-229	G:4, H:5	27-49	107, 251
ARF1519	Hypothetical protein	17-27	H:3	23-32	108, 252
ARF1905	Hypothetical protein	18-24	H:2	28-38	109, 253
ARF2044	Hypothetical protein	9-15	G:2, H:5	13-27	110, 254
ARF2155	Hypothetical protein	13-22	H:3	18-29	111, 255
ARF2199	Hypothetical protein	17-26	M:3	2-11	112, 256
CRF0129	Hypothetical protein	4-33	L:4	16-32	113, 257
CRF0200	Hypothetical protein	4-10,37-43,54-84,92-127	H:5, L:1	15-62	114, 258
CRF0236	Hypothetical protein	4-14,20-32,35-60,69-75,79-99,101-109,116-140	L:3	124-136	115, 259
CRF0394	Hypothetical protein	none	H:7	2-13	116, 260
CRF0408	Hypothetical protein	4-13,28-42	L:11	42-57	117, 261
CRF0430	Hypothetical protein	4-14,27-44	G:4, H:8	14-35	118, 262
CRF0498	Hypothetical protein	4-12	H:4	1-27	119, 263
CRF0519	Hypothetical protein	4-18,39-45,47-74	G:5, H:3	35-66	120, 264
CRF0573	Hypothetical protein	8-20,43-77	L:3, L:9	17-36	121, 265
CRF0713	Hypothetical protein	4-30,35-45,51-57	L:3	35-49	122, 266
CRF0722	Hypothetical protein	4-24,49-57	G:18	15-34	123, 267
CRF0764	Hypothetical protein	4-22	L:4	8-27	124, 268
CRF1079	Hypothetical protein	13-25,32-59,66-80	H:5	21-55	125, 269
CRF1248	Hypothetical protein	4-10,24-33,35-42,54-65,72-82,98-108	H:1	15-30	126, 270
CRF1398	Hypothetical protein	8-19	H:1, L:3	17-47	127, 271
CRF1412	Hypothetical protein	12-18,40-46	L:8	31-52	128, 272
CRF1467	Hypothetical protein	4-20,35-78,83-102,109-122	L:4	74-86	129, 273
CRF1484	Hypothetical protein	7-17,21-41,46-63	L:5	2-20	130, 274
CRF1587	Hypothetical protein	30-37	G:3, H:3	2-33	131, 275

- 75 -

<i>S. pneumoniae</i> antigenic protein	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region (aa)	Seq. ID (DNA, Prot.)
			L:4		
CRF1606	Hypothetical protein	4-13,17-25	L:3	1-15	132, 276
CRF1623	Hypothetical protein	17-31,44-51	M:6	20-51	133, 277
CRF1625	Hypothetical protein	20-30	L:10	5-23	134, 278
CRF1640	Hypothetical protein	13-33,48-71	L:5	92-110	135, 279
CRF1702	Hypothetical protein	4-9,50-69,76-88,96-106,113-118	L:6	12-34	136, 280
CRF1825	Hypothetical protein	4-24	L:11	6-26	137, 281
CRF1883	Hypothetical protein	7-26	H:61, L:77	14-30	138, 282
CRF1991	Hypothetical protein	9-39,46-68,75-82,84-103	H:6, L:2	26-44	139, 283
CRF1992	Hypothetical protein	4-30,33-107	M:7	58-84	140, 284
CRF2004	Hypothetical protein	4-12	L:3	9-51	141, 285
		12-18,29-37	H:5, L:1, M:1	6-37	142, 286
CRF2030	Hypothetical protein				
CRF2065	Hypothetical protein	4-21,33-52,64-71	L:1, M:6	16-37	143, 287
CRF2232	Hypothetical protein	9-19	L:3	2-30	144, 288

Table 2. Immunogenicity of epitopes in peptide ELISA

Peptides	P1	P2	P3	P4	P5	P6	P7	P8	P9	P10	P11	P12	P13	N1	N2	N3	N4	N5	N6	N7	N8	N9	N10	S	from	to	Seq ID
ARF0408.1	nd					nd		nd																15	20	37	245
ARF0441.1	nd					nd		nd																26	8	27	246
ARF0600.1	nd					nd		nd																20	10	27	247
ARF0878.1						nd						nd	nd											22	42	59	248
ARF0878.2						nd						nd	nd											11	52	69	248
ARF0921.1						nd						nd	nd											15	63	80	249
ARF0921.2						nd						nd	nd											14	74	91	249
ARF1153.1	nd					nd		nd																19	11	28	250
ARF1515.1	nd					nd		nd																16	28	49	251
ARF1519.1	nd					nd		nd																15	15	32	252
ARF1905.1	nd					nd		nd																21	4	20	253
ARF2044.1	nd					nd		nd																18	10	27	254
ARF2155.1	nd					nd		nd																15	17	34	255
ARF2199.1	nd					nd		nd																19	1	18	256
CRF0129.1	nd					nd		nd																15	16	33	257
CRF0200.1	nd					nd		nd																12	16	36	258
CRF0200.2	nd					nd		nd																9	30	49	258
CRF0200.3	nd					nd		nd																10	43	62	258
CRF0236.1						nd						nd	nd											19	122	139	259
CRF0394.1	nd					nd		nd																20	1	18	260
CRF0408.1	nd					nd		nd																19	41	58	261
CRF0430.1	nd					nd		nd																15	15	35	262
CRF0498.1	nd					nd		nd																21	2	27	263
CRF0573.1						nd						nd	nd											22	18	36	265
CRF0713.1	nd					nd		nd																20	34	51	266
CRF0764.1	nd					nd		nd																16	9	27	268
CRF1079.1	nd					nd		nd																27	22	47	269
CRF1398.1	nd					nd		nd																24	18	36	271
CRF1398.2	nd					nd		nd																21	29	47	271
CRF1412.1						nd						nd	nd											9	32	52	272
CRF1467.1	nd					nd		nd																	72	89	273
CRF1484.1	nd					nd		nd																	3	20	274
CRF1587.1	nd					nd		nd																23	3	21	275
CRF1587.2	nd					nd		nd																21	15	33	275
CRF1606.1	nd					nd		nd																22	1	18	276
CRF1625.1	nd					nd		nd																23	6	23	278
CRF1640.1	nd					nd		nd																18	93	110	279
CRF1702.1						nd						nd	nd											18	13	34	280
CRF1825.1	nd					nd		nd																24	7	26	281
CRF1825.2	nd					nd		nd																24	9	26	281
CRF1883.1	nd					nd		nd																20	16	33	282
CRF1991.1	nd					nd		nd																24	27	44	283
CRF1992.1	nd							nd			nd													19	67	84	284
CRF2004.1	nd					nd		nd																20	10	33	285
CRF2004.2	nd					nd		nd																22	26	50	285
CRF2030.1	nd					nd		nd																21	7	25	286

CRF2030.2	nd					nd	nd													20	19	37	286
CRF2065.1	nd					nd	nd													21	17	37	287
CRF2232.1	nd					nd	nd													23	3	20	288
CRF2232.2	nd					nd	nd													19	13	30	288
SP0008.1								nd	nd	nd										28	62	80	145
SP0008.2								nd	nd	nd										21	75	93	145
SP0069.1						nd				nd	nd									17	92	108	147
SP0071.1	nd					nd	nd													15	332	349	148
SP0071.2						nd				nd	nd									13	177	200	148
SP0071.3						nd				nd	nd									4	1755	1777	148
SP0082.1						nd				nd	nd									4	109	133	149
SP0082.2	nd					nd	nd													24	149	174	149
SP0082.3	nd					nd	nd													26	260	285	149
SP0082.4						nd					nd	nd								20	460	485	149
SP0107.1	nd						nd			nd										10	26	47	150
SP0107.2	nd						nd			nd										11	42	64	150
SP0117.1								nd	nd	nd										18	22	41	151
SP0117.2								nd	nd	nd										57	35	54	151
SP0117.3								nd	nd	nd										64	115	130	151
SP0117.4								nd	nd	nd										17	306	325	151
SP0117.5								nd	nd	nd										15	401	420	151
SP0117.6								nd	nd	nd										68	454	478	151
SP0222.1						nd				nd	nd									15	22	45	155
SP0368.1						nd				nd	nd									22	156	174	160
SP0368.2								nd	nd	nd										32	924	940	160
SP0368.2b						nd				nd	nd									12	1485	1496	160
SP0368.3						nd				nd	nd									14	1447	1462	160
SP0368.4						nd				nd	nd									11	1483	1498	160
SP0369.1						nd				nd	nd									16	457	475	161
SP0377.1						nd				nd	nd									11	302	325	163
SP0378.1						nd				nd	nd									17	288	305	164
SP0390.1						nd				nd	nd									11	244	266	165
SP0390.2						nd	nd													24	260	282	165
SP0454.1								nd	nd	nd										64	204	225	166
SP0454.2								nd	nd	nd										38	220	241	166
SP0463.1	nd					nd		nd												20	324	345	167
SP0463.2	nd					nd		nd												26	340	361	167
SP0463.3	nd					nd		nd												19	356	377	167
SP0463.4	nd					nd		nd												9	372	393	167
SP0463.5	nd					nd		nd												13	388	408	167
SP0466.1	nd					nd	nd													22	39	64	168
SP0468.1	nd					nd		nd												21	54	76	169
SP0468.2	nd					nd		nd												24	70	92	169
SP0498.1	nd					nd			nd											13	1227	1247	170
SP0498.2	nd					nd			nd											8	1539	1559	170
SP0498.3	nd					nd			nd											16	1554	1574	170
SP0498.4	nd					nd			nd											13	1569	1589	170
SP0498.5	nd					nd			nd											15	1584	1604	170
SP0498.6	nd					nd			nd											11	1242	1262	170
SP0498.8	nd					nd			nd											24	1272	1292	170

SP1241.3	nd					nd		nd												25	381	403	197
SP1241.4	nd					nd		nd												21	398	420	197
SP1241.5	nd					nd		nd												28	415	437	197
SP1241.6	nd					nd		nd												16	432	452	197
SP1287.1	nd					nd		nd												20	347	372	198
SP1330.1	nd					nd		nd												18	147	163	199
SP1374.1	nd					nd		nd												15	263	288	200
SP1429.1	nd					nd		nd												20	361	377	202
SP1518.1	nd																			19	82	104	204
SP1518.2	nd																			28	99	121	204
SP1518.3	nd																			21	116	138	204
SP1518.4	nd																			26	133	155	204
SP1518.5	nd																			19	150	171	204
SP1522.1	nd																			12	110	130	205
SP1522.2	nd																			13	125	145	205
SP1527.1	nd																			22	613	631	206
SP1527.2	nd																			20	626	644	206
SP1527.3	nd																			16	196	213	206
SP1604.1	nd																			13	78	100	208
SP1604.2	nd																			20	95	117	208
SP1604.3	nd																			15	112	134	208
SP1604.4	nd																			25	129	151	208
SP1661.1	nd																			18	158	180	209
SP1661.2	nd																			10	175	197	209
SP1661.3	nd																			13	192	214	209
SP1661.4	nd																			16	209	231	209
SP1661.5	nd																			12	226	248	209
SP1664.1	nd																			24	30	50	210
SP1664.2	nd																			26	45	65	210
SP1664.3	nd																			11	60	79	210
SP1693.1	nd																			20	431	455	213
SP1693.2	nd																			18	450	474	213
SP1732.1	nd																			25	579	601	214
SP1732.2	nd																			15	596	618	214
SP1732.3	nd																			19	613	635	214
SP1732.4	nd																			22	630	653	214
SP1772.1	nd																			27	920	927	217
SP1772.1b	nd																			12	98	119	217
SP1772.2	nd																			20	114	135	217
SP1772.3	nd																			11	130	151	217
SP1772.4	nd																			30	146	167	217
SP1772.5	nd																			19	162	182	217
SP1888.1	nd																			16	36	59	219
SP1891.1	nd																			14	194	216	220
SP1891.2	nd																			12	381	404	220
SP1937.1	nd																			20	236	251	221
SP1937.2	nd																			26	255	279	221
SP1954.1	nd																			15	80	100	222
SP1954.2	nd																			14	141	164	222
SP1980.1	nd																			18	128	154	223

Table 3: Gene distribution in *S. pneumoniae* strains.

ORF	Common name	Gene distribution (present of 50)	Amino acid substitutions (in serotype 14 strain)*	Homology 0	Seq. ID (DNA, Prot.)
SP0008	hypothetical protein	n.d.	n.d.		1, 145
SP0032	DNA polymerase I (polA)	n.d.	n.d.		2, 146
SP0069	Choline binding protein I	7	0/166#		3, 147
SP0071	immunoglobulin A1 protease (iga-1)	7	0/477#		4, 148
SP0082	Cell wall surface anchor	50	5/385		5, 149
SP0107	LysM domain protein	50	1/173		6, 150
SP0117	pneumococcal surface protein A (pspA)	n.d.	n.d.		7, 151
SP0191	hypothetical protein	n.d.	n.d.		8, 152
SP0197	dihydrofolate synthetase, putative	n.d.	n.d.		9, 153
SP0212	Ribosomal protein L2	50	0/232		10, 154
SP0222	Ribosomal protein S14	n.d.	n.d.		11, 155
SP0239	Conserved hypothetical protein	n.d.	n.d.		12, 156
SP0251	formate acetyltransferase, putative	n.d.	n.d.		13, 157
SP0295	ribosomal protein S9 (rpsI)	50	1/121		14, 158
SP0330	sugar binding transcriptional regulator RegR	n.d.	n.d.		15, 159
SP0368	cell wall surface anchor family protein	46	4/422#		16, 160
SP0369	Penicillin binding protein 1A	50	1/346		17, 161
SP0374	hypothetical protein	n.d.	n.d.		18, 162
SP0377	Choline binding protein C	29	0/114		19, 163
SP0378	choline binding protein J (cbpJ)	50	2/104		20, 164
SP0390	choline binding protein G (cbpG)	50	3/171#		21, 165
SP0454	hypothetical protein	48	1/303#		22, 166
SP0463	cell wall surface anchor family protein	10	0/298#		23, 167
SP0466	sortase, putative	44	4/243#		24, 168
SP0468	Sortase, putative	18	0/254#		25, 169
SP0498	endo-beta-N-acetylglucosaminidase, putative	50	4/334		26, 170
SP0509	type I restriction-modification system, M subunit	n.d.	n.d.		27, 171
SP0519	dnaJ protein (dnaJ)	50	2/312		28, 172
SP0529	BlpC ABC transporter (blpB)	50	6/306		29, 173
SP0564	hypothetical protein	50	1/127		30, 174

ORF	Common name	Gene distribution (present of 50)	Amino acid substitutions (in serotype 14 strain)*	Homology 0	Seq. ID (DNA, Prot.)
SP0609	amino acid ABC transporter, amino acid-binding pro	50	0/232		31, 175
SP0613	metallo-beta-lactamase superfamily protein	n.d.	n.d.		32, 176
SP0641	Serine protease	n.d.	n.d.		33, 177
SP0648	beta-galactosidase (bgaA)	50	0/304		34, 178
SP0664	Zinc metalloprotease ZmpB, putative	n.d.	n.d.		35, 179
SP0667	pneumococcal surface protein, putative	45	18/297		36, 180
SP0688	UDP-N-acetylmuramoylalanine--D- glutamate ligase	n.d.	n.d.		37, 181
SP0749	branched-chain amino acid ABC transporter	50	4/303		38, 182
SP0770	ABC transporter, ATP-binding protein	50	0/307		39, 183
SP0785	conserved hypothetical protein	50	0/304		40, 184
SP0914	nodulin-related protein, truncation	n.d.	n.d.		41, 185
SP0930	choline binding protein E (cbpE)	47	17/294		42, 186
SP0943	Gid protein (gid)	n.d.	n.d.		43, 187
SP0952	alanine dehydrogenase, authentic frameshift (ald)	n.d.	n.d.		44, 188
SP1003	conserved hypothetical protein (PAT)	n.d.	n.d.		45, 189
SP1004	Conserved hypothetical protein	n.d.	n.d.		46, 190
SP1124	glycogen synthase (glgA)	n.d.	n.d.		47, 191
SP1154	IgA1 protease	28	13/470; 80missing		48, 192
SP1174	conserved domain protein (PAT)	n.d.	n.d.		49, 193
SP1175	conserved domain protein	n.d.	n.d.		50, 194
SP1221	type II restriction endonuclease	n.d.	n.d.		51, 195
SP1227	DNA-binding response regulator	n.d.	n.d.		52, 196
SP1241	amino acid ABC transporter, amino acid-binding protein	50	0/285		53, 197
SP1287	signal recognition particle protein (ffh)	49	0/300		54, 198
SP1330	N-acetylmannosamine-6-P epimerase, putative (nanE)	14	0/211#		55, 199
SP1374	Chorismate sythetase (aroC)	50	0/289		56, 200
SP1378	conserved hypothetical protein	n.d.	n.d.		57, 201
SP1429	peptidase, U32 family	50	8/305		58, 202
SP1478	oxidoreductase, aldo/keto reductase	n.d.	n.d.		59, 203

ORF	Common name	Gene distribution (present of 50)	Amino acid substitutions (in serotype 14 strain)*	Homology ()	Seq. ID (DNA, Prot.)
	family				
SP1518	conserved hypothetical protein	50	4/313; 3 additional		60, 204
SP1522	conserved domain protein	n.d.	n.d.		61, 205
SP1527	oligopeptide ABC transporter	50	0/463		62, 206
SP1573	lysozyme (lytC)	n.d.	n.d.		63, 207
SP1604	hypothetical protein	50	3/138		64, 208
SP1661	cell division protein DivIVA	50	3/236		65, 209
SP1664	ylmF protein (ylmF)	50	0/164		66, 210
SP1676	N-acetylneuraminate lyase, putative	n.d.	n.d.		67, 211
SP1687	neuraminidase B (nanB)	n.d.	n.d.		68, 212
SP1693	neuraminidase A (nanA)	n.d.	n.d.		69, 213
SP1732	serine/threonine protein kinase	49	2/293		70, 214
SP1735	methionyl-tRNA formyltransferase (fmt)	n.d.	n.d.		71, 215
SP1759	preprotein translocase, SecA subunit (secA-2)	n.d.	n.d.		72, 216
SP1772	cell wall surface anchor family protein	23	12/253#		73, 217
SP1804	general stress protein 24, putative	n.d.	n.d.		74, 218
SP1888	oligopeptide ABC transporter, ATP- binding protein AmiE	n.d.	n.d.		75, 219
SP1891	oligopeptide ABC transporter,	n.d.	n.d.		76, 220
SP1937	Autolysin (lytA)	50	0/275		77, 221
SP1954	serine protease, subtilase family, authentic frame	12	0/305#		78, 222
SP1980	cmp-binding-factor 1 (cbf1)	n.d.	n.d.		79, 223
SP1992	cell wall surface anchor family protein	50	4/197		80, 224
SP1999	catabolite control protein A (ccpA)	n.d.	n.d.		81, 225
SP2021	glycosyl hydrolase	n.d.	n.d.		82, 226
SP2027	Conserved hypothetical protein	n.d.	n.d.		83, 227
SP2039	conserved hypothetical protein	n.d.	n.d.		84, 228
SP2048	Conserved hypothetical protein	50	8/134		85, 229
SP2051	Competence protein CglC	50	8/92		86, 230
SP2092	UTP-glucose-1-phosphate uridylyltransferase (galU)	n.d.	n.d.		87, 231
SP2099	Penicillin binding protein 1B	n.d.	n.d.		88, 232
SP2108	Maltose ABC transporter	50	1/279		89, 233
SP2120	hypothetical protein	n.d.	n.d.		90, 234

ORF	Common name	Gene distribution (present of 50)	Amino acid substitutions (in serotype 14 strain)*	Homology ()	Seq. ID (DNA, Prot.)
SP2128	transketolase, N-terminal subunit	n.d.	n.d.		91, 235
SP2136	choline binding protein PcpA	45	1/382		92, 236
SP2141	glycosyl hydrolase-related protein	n.d.	n.d.		93, 237
SP2180	conserved hypothetical protein	n.d.	n.d.		94, 238
SP2190	choline binding protein A (cbpA)	47	for: 48,8%; rev: 2 /17#		95, 239
SP2194	ATP-dependent Clp protease, ATP- binding subunit	50	1/262		96, 240
SP2201	choline binding protein D (cbpD)	50	7/384		97, 241
SP2204	ribosomal protein L9	n.d.	n.d.		98, 242
SP2216	secreted 45 kd protein - homology to glucan binding protein (GbpB) S.mutant	50	0/347		99, 243
SP-NRF1	Choline binding protein	n.d.	n.d.		100, 244
ARF0408	Hypothetical protein	n.d.	n.d.		101, 245
ARF0441	Hypothetical protein	n.d.	n.d.		102, 246
ARF0690	Hypothetical protein	n.d.	n.d.		103, 247
ARF0878	Hypothetical protein	n.d.	n.d.		104, 248
ARF0921	Hypothetical protein	n.d.	n.d.		105, 249
ARF1153	Hypothetical protein	n.d.	n.d.		106, 250
ARF1515	Hypothetical protein	n.d.	n.d.		107, 251
ARF1519	Hypothetical protein	n.d.	n.d.		108, 252
ARF1905	Hypothetical protein	n.d.	n.d.		109, 253
ARF2044	Hypothetical protein	n.d.	n.d.		110, 254
ARF2155	Hypothetical protein	n.d.	n.d.		111, 255
ARF2199	Hypothetical protein	n.d.	n.d.		112, 256
CRF0129	Hypothetical protein	n.d.	n.d.		113, 257
CRF0200	Hypothetical protein	n.d.	n.d.		114, 258
CRF0236	Hypothetical protein	n.d.	n.d.		115, 259
CRF0394	Hypothetical protein	n.d.	n.d.		116, 260
CRF0408	Hypothetical protein	n.d.	n.d.		117, 261
CRF0430	Hypothetical protein	n.d.	n.d.		118, 262
CRF0498	Hypothetical protein	n.d.	n.d.		119, 263
CRF0519	Hypothetical protein	n.d.	n.d.		120, 264
CRF0573	Hypothetical protein	n.d.	n.d.		121, 265
CRF0713	Hypothetical protein	n.d.	n.d.		122, 266
CRF0722	Hypothetical protein	n.d.	n.d.		123, 267
CRF0764	Hypothetical protein	n.d.	n.d.		124, 268

ORF	Common name	Gene distribution (present of 50)	Amino acid substitutions (in serotype 14 strain)*	Homology ()	Seq. ID (DNA, Prot.)
CRF1079	Hypothetical protein	n.d.	n.d.		125, 269
CRF1248	Hypothetical protein	n.d.	n.d.		126, 270
CRF1398	Hypothetical protein	n.d.	n.d.		127, 271
CRF1412	Hypothetical protein	n.d.	n.d.		128, 272
CRF1467.1	Hypothetical protein	n.d.	n.d.		129, 273
CRF1484	Hypothetical protein	n.d.	n.d.		130, 274
CRF1587	Hypothetical protein	n.d.	n.d.		131, 275
CRF1606	Hypothetical protein	n.d.	n.d.		132, 276
CRF1623	Hypothetical protein	n.d.	n.d.		133, 277
CRF1625	Hypothetical protein	n.d.	n.d.		134, 278
CRF1640	Hypothetical protein	n.d.	n.d.		135, 279
CRF1702	Hypothetical protein	n.d.	n.d.		136, 280
CRF1825	Hypothetical protein	n.d.	n.d.		137, 281
CRF1883	Hypothetical protein	n.d.	n.d.		138, 282
CRF1991	Hypothetical protein	n.d.	n.d.		139, 283
CRF1992	Hypothetical protein	n.d.	n.d.		140, 284
CRF2004	Hypothetical protein	n.d.	n.d.		141, 285
CRF2030	Hypothetical protein	n.d.	n.d.		142, 286
CRF2065	Hypothetical protein	n.d.	n.d.		143, 287
CRF2232	Hypothetical protein	n.d.	n.d.		144, 288

Table 4.

ORF	Common Name	FACS	PK
ARF0878	hypothetical protein	+	nd
ARF0921	hypothetical protein	+	nd
CRF0236	hypothetical protein	++	-
CRF0573	hypothetical protein	+	nd
CRF1412	hypothetical protein	+	nd
CRF1702	hypothetical protein	+	nd
CRF1992	hypothetical protein	++	++
SP0008	hypothetical protein	+	-
SP0069	Choline binding protein I	++	++
SP0082	Cell wall surface anchor	+	-
SP0117	pneumococcal surface protein A (pspA)	+++	+++
SP0212	Ribosomal protein L2	+	++
SP0295	ribosomal protein S9 (rpsI)	++	+++
SP0368	cell wall surface anchor family protein	++	+++
SP0369	Penicillin binding protein 1A	++	++
SP0377	Choline binding protein C	++	++
SP0378	choline binding protein J (cbpJ)	++	nd
SP0390	choline binding protein G (cbpG)	++	+
SP0454	hypothetical protein	++	+++
SP0463	cell wall surface anchor family protein	+	++
SP0466	sortase, putative	++	++
SP0468	Sortase, putative	++	++
SP0519	dnaJ protein (dnaJ)	++	+
SP0609	amino acid ABC transporter, amino acid-bind	++	+
SP0641	Serine protease	+	-
SP0664	Zinc metalloprotease ZmpB	+	++
SP0749	branched-chain amino acid ABC transporter	+	+
SP0770	ABC transporter, ATP-binding protein	++	++
SP1154	IgA1 protease	++	++
SP1287	signal recognition particle protein (ffh)	+	++
SP1330	N-acetylmannosamine-6-P	++	-
SP1429	peptidase, U32 family	+	++
SP1527	oligopeptide ABC transporter	+	++
SP1759	preprotein translocase, SecA subunit (wrong clone!!!)	+	-
SP1772	cell wall surface anchor family protein	+	+
SP1891	oligopeptide ABC transporter	+	++
SP1937	Autolysin (lytA)	+	-
SP1954	serine protease, subtilase family, auth frame	+	++
SP1980	cmp-binding-factor 1 (cbf1)	+	-
SP2108	Maltose ABC transporter	+	++
SP2136	choline binding protein PcpA	+	++
SP2190	choline binding protein A (cbpA)	+	++
SP2194	ATP-dependent Clp protease, ATP-bind subu	++	++
SP2201	choline binding protein D (cbpD)	+	++
SP2216	secreted 45 kd protein	+	++

Claims:

1. An isolated nucleic acid molecule encoding a hyperimmune serum reactive antigen or a fragment thereof comprising a nucleic acid sequence, which is selected from the group consisting of:
 - a) a nucleic acid molecule having at least 70% sequence identity to a nucleic acid molecule selected from Seq ID No 1, 101-144.
 - b) a nucleic acid molecule which is complementary to the nucleic acid molecule of a),
 - c) a nucleic acid molecule comprising at least 15 sequential bases of the nucleic acid molecule of a) or b)
 - d) a nucleic acid molecule which anneals under stringent hybridisation conditions to the nucleic acid molecule of a), b), or c)
 - e) a nucleic acid molecule which, but for the degeneracy of the genetic code, would hybridise to the nucleic acid molecule defined in a), b), c) or d).
2. The isolated nucleic acid molecule according to claim 1, wherein the sequence identity is at least 80%, preferably at least 95%, especially 100%.
3. An isolated nucleic acid molecule encoding a hyperimmune serum reactive antigen or a fragment thereof comprising a nucleic acid sequence selected from the group consisting of
 - a) a nucleic acid molecule having at least 96% sequence identity to a nucleic acid molecule selected from Seq ID No 2-6, 8, 10-16, 18-23, 25-31, 34, 36, 38-42, 44, 47-48, 51, 53, 55-62, 64, 67, 71-76, 78-79, 81-94, 96-100.
 - b) a nucleic acid molecule which is complementary to the nucleic acid molecule of a),
 - c) a nucleic acid molecule comprising at least 15 sequential bases of the nucleic acid molecule of a) or b)
 - d) a nucleic acid molecule which anneals under stringent hybridisation conditions to the nucleic acid molecule of a), b) or c),
 - e) a nucleic acid molecule which, but for the degeneracy of the genetic code, would hybridise to the nucleic acid defined in a), b), c) or d).
4. An isolated nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of
 - a) a nucleic acid molecule selected from Seq ID No 9, 17, 24, 32, 37, 43, 52, 54, 65-66, 70, 80,
 - b) a nucleic acid molecule which is complementary to the nucleic acid of a),
 - c) a nucleic acid molecule which, but for the degeneracy of the genetic code, would hybridise to the nucleic acid defined in a), b), c) or d).
5. The nucleic acid molecule according to any one of the claims 1, 2, 3 or 4, wherein the nucleic acid is DNA.
6. The nucleic acid molecule according to any one of the claims 1, 2, 3, 4, or 5 wherein the nucleic acid is RNA.
7. An isolated nucleic acid molecule according to any one of claims 1 to 5, wherein the nucleic acid molecule is isolated from a genomic DNA, especially from a *S. pneumoniae* genomic DNA.
8. A vector comprising a nucleic acid molecule according to any one of claims 1 to 7.
9. A vector according to claim 8, wherein the vector is adapted for recombinant expression of the hyperimmune serum reactive antigens or fragment thereof encoded by the nucleic acid molecule according to any one of claims 1 to 7.

10. A host cell comprising the vector according to claim 8 or 9.
11. A hyperimmune serum-reactive antigen comprising an amino acid sequence being encoded by a nucleic acid molecule according to any one of the claims 1, 2, 5, 6 or 7 and fragments thereof, wherein the amino acid sequence is selected from the group consisting of Seq ID No 145, 245-288.
12. A hyperimmune serum-reactive antigen comprising an amino acid sequence being encoded by a nucleic acid molecule according to any one of the claims 3, 5, 6, or 7 and fragments thereof, wherein the amino acid sequence is selected from the group consisting of Seq ID No 146-150, 152, 154-160, 162-167, 169-175, 178, 180, 182-186, 188, 191-192, 195, 197, 199-206, 208, 211, 215-220, 222-223, 225-238, 240-244.
13. A hyperimmune serum-reactive antigen comprising an amino acid sequence being encoded by a nucleic acid molecule according to any one of the claims 4, 5, 6, or 7 and fragments thereof, wherein the amino acid sequence is selected from the group consisting of Seq ID No 153, 161, 168, 176, 181, 187, 196, 198, 209-210, 214, 224.
14. Fragments of hyperimmune serum-reactive antigens selected from the group consisting of peptides comprising amino acid sequences of column "predicted immunogenic aa" and "location of identified immunogenic region" of Table 2; the serum reactive epitopes of Table 2, especially peptides comprising amino acid 4-11, 35-64, 66-76, 101-108, 111-119 and 57-114 of Seq ID No 145; 5-27, 32-64, 92-102, 107-113, 119-125, 133-139, 148-162, 177-187, 195-201, 207-214, 241-251, 254-269, 285-300, 302-309, 317-324, 332-357, 365-404, 411-425, 443-463, 470-477, 479-487, 506-512, 515-520, 532-547, 556-596, 603-610, 616-622, 624-629, 636-642, 646-665, 667-674, 687-692, 708-720, 734-739, 752-757, 798-820, 824-851, 856-865 and 732-763 of Seq ID No 146; 14-21, 36-44, 49-66, 102-127, 162-167, 177-196, 45-109 and 145-172 of Seq ID No 147; 17-35, 64-75, 81-92, 100-119, 125-172, 174-183, 214-222, 230-236, 273-282, 287-303, 310-315, 331-340, 392-398, 412-420, 480-505, 515-523, 525-546, 553-575, 592-598, 603-609, 617-625, 631-639, 644-651, 658-670, 681-687, 691-704, 709-716, 731-736, 739-744, 750-763, 774-780, 784-791, 799-805, 809-822, 859-870, 880-885, 907-916, 924-941, 943-949, 973-986, 1010-1016, 1026-1036, 1045-1054, 1057-1062, 1082-1088, 1095-1102, 1109-1120, 1127-1134, 1140-1146, 1152-1159, 1169-1179, 1187-1196, 1243-1251, 1262-1273, 1279-1292, 1306-1312, 1332-1343, 1348-1364, 1379-1390, 1412-1420, 1427-1436, 1458-1468, 1483-1503, 1524-1549, 1574-1588, 1614-1619, 1672-1685, 1697-1707, 1711-1720, 1738-1753, 1781-1787, 1796-1801, 1826-1843, 132-478, 508-592 and 1753-1810 of Seq ID No 148; 15-43, 49-55, 71-77, 104-110, 123-130, 162-171, 180-192, 199-205, 219-227, 246-254, 264-270, 279-287, 293-308, 312-322, 330-342, 349-356, 369-377, 384-394, 401-406, 416-422, 432-439, 450-460, 464-474, 482-494, 501-508, 521-529, 536-546, 553-558, 568-574, 584-591, 602-612, 616-626, 634-646, 653-660, 673-681, 688-698, 705-710, 720-726, 736-749, 833-848, 1-199, 200-337, 418-494 and 549-647 of Seq ID No 149; 9-30, 65-96, 99-123, 170-178 and 1-128 of Seq ID No 150; 7-32, 34-41, 96-106, 127-136, 154-163, 188-199, 207-238, 272-279, 306-312, 318-325, 341-347, 353-360, 387-393, 399-406, 434-440, 452-503, 575-580, 589-601, 615-620, 635-640, 654-660, 674-680, 696-701, 710-731, 1-548 and 660-691 of Seq ID No 151; 4-19, 35-44, 48-59, 77-87, 93-99, 106-111, 130-138, 146-161 and 78-84 of Seq ID No 152; 24-30, 36-43, 64-86, 93-99, 106-130, 132-145, 148-165, 171-177, 189-220, 230-249, 251-263, 293-300, 302-312, 323-329, 338-356, 369-379, 390-412 and 179-193 of Seq ID No 153; 30-39, 61-67, 74-81, 90-120, 123-145, 154-167, 169-179, 182-197, 200-206, 238-244, 267-272 and 230-265 of Seq ID No 154; 14-20, 49-65, 77-86 and 2-68 of Seq ID No 155; 4-9, 26-35, 42-48, 53-61, 63-85, 90-101, 105-111, 113-121, 129-137, 140-150, 179-188, 199-226, 228-237, 248-255, 259-285, 299-308, 314-331, 337-343, 353-364, 410-421, 436-442 and 110-144 of Seq ID No 156; 36-47, 55-63, 94-108, 129-134, 144-158, 173-187, 196-206, 209-238, 251-266, 270-285, 290-295, 300-306, 333-344, 346-354, 366-397, 404-410, 422-435, 439-453, 466-473, 515-523, 529-543, 554-569, 571-585, 590-596, 607-618, 627-643, 690-696, 704-714, 720-728, 741-749, 752-767, 780-799, 225-247 and 480-507 of Seq ID No 157; 16-25, 36-70, 80-

93, 100-106 and 78-130 of Seq ID No 158; 18-27, 41-46, 50-57, 65-71, 79-85, 93-98, 113-128, 144-155, 166-178, 181-188, 201-207, 242-262, 265-273, 281-295, 303-309, 318-327 and 36-64 of Seq ID No 159; 7-29, 31-44, 50-59, 91-96, 146-153, 194-201, 207-212, 232-238, 264-278, 284-290, 296-302, 326-353, 360-370, 378-384, 400-405, 409-418, 420-435, 442-460, 499-506, 529-534, 556-562, 564-576, 644-651, 677-684, 687-698, 736-743, 759-766, 778-784, 808-814, 852-858, 874-896, 920-925, 929-935, 957-965, 1003-1012, 1021-1027, 1030-1044, 1081-1087, 1101-1111, 1116-1124, 1148-1159, 1188-1196, 1235-1251, 1288-1303, 1313-1319, 1328-1335, 1367-1373, 1431-1437, 1451-1458, 1479-1503, 1514-1521, 1530-1540, 1545-1552, 1561-1568, 1598-1605, 1617-1647, 1658-1665, 1670-1676, 1679-1689, 1698-1704, 1707-1713, 1732-1738, 1744-1764, 1-70, 154-189, 922-941, 1445-1462 and 1483-1496 of Seq ID No 160; 6-51, 81-91, 104-113, 126-137, 150-159, 164-174, 197-209, 215-224, 229-235, 256-269, 276-282, 307-313, 317-348, 351-357, 376-397, 418-437, 454-464, 485-490, 498-509, 547-555, 574-586, 602-619 and 452-530 of Seq ID No 161; 25-31, 39-47, 49-56, 99-114, 121-127, 159-186, 228-240, 253-269, 271-279, 303-315, 365-382, 395-405, 414-425, 438-453 and 289-384 of Seq ID No 162; 9-24, 41-47, 49-54, 68-78, 108-114, 117-122, 132-140, 164-169, 179-186, 193-199, 206-213, 244-251, 267-274, 289-294, 309-314, 327-333, 209-249 and 286-336 of Seq ID No 163; 9-28, 53-67, 69-82, 87-93, 109-117, 172-177, 201-207, 220-227, 242-247, 262-268, 305-318, 320-325 and 286-306 of Seq ID No 164; 4-10, 26-39, 47-58, 63-73, 86-96, 98-108, 115-123, 137-143, 148-155, 160-176, 184-189, 194-204, 235-240, 254-259, 272-278 and 199-283 of Seq ID No 165; 4-26, 33-39, 47-53, 59-65, 76-83, 91-97, 104-112, 118-137, 155-160, 167-174, 198-207, 242-268, 273-279, 292-315, 320-332, 345-354, 358-367, 377-394, 403-410, 424-439, 445-451, 453-497, 511-518, 535-570, 573-589, 592-601, 604-610 and 202-242 of Seq ID No 166; 8-30, 36-45, 64-71, 76-82, 97-103, 105-112, 134-151, 161-183, 211-234, 253-268, 270-276, 278-284, 297-305, 309-315, 357-362, 366-372, 375-384, 401-407, 409-416, 441-455, 463-470, 475-480, 490-497, 501-513, 524-537, 552-559, 565-576, 581-590, 592-600, 619-625, 636-644, 646-656 and 316-419 of Seq ID No 167; 4-17, 52-58, 84-99, 102-110, 114-120, 124-135, 143-158, 160-173, 177-196, 201-216, 223-250, 259-267, 269-275 and 1-67 of Seq ID No 168; 6-46, 57-67, 69-80, 82-133, 137-143, 147-168, 182-187, 203-209, 214-229, 233-242, 246-280 and 53-93 of Seq ID No 169; 7-40, 50-56, 81-89, 117-123, 202-209, 213-218, 223-229, 248-261, 264-276, 281-288, 303-308, 313-324, 326-332, 340-346, 353-372, 434-443, 465-474, 514-523, 556-564, 605-616, 620-626, 631-636, 667-683, 685-699, 710-719, 726-732, 751-756, 760-771, 779-788, 815-828, 855-867, 869-879, 897-902, 917-924, 926-931, 936-942, 981-1000, 1006-1015, 1017-1028, 1030-1039, 1046-1054, 1060-1066, 1083-1092, 1099-1112, 1122-1130, 1132-1140, 1148-1158, 1161-1171, 1174-1181, 1209-1230, 1236-1244, 1248-1254, 1256-1267, 1269-1276, 1294-1299, 1316-1328, 1332-1354, 1359-1372, 1374-1380, 1384-1390, 1395-1408, 1419-1425, 1434-1446, 1453-1460, 1465-1471, 1474-1493, 1505-1515, 1523-1537, 1547-1555, 1560-1567, 1577-1605, 1633-1651, 1226-1309, 1455-1536 and 1538-1605 of Seq ID No 170; 4-10, 31-39, 81-88, 106-112, 122-135, 152-158, 177-184, 191-197, 221-227, 230-246, 249-255, 303-311, 317-326, 337-344, 346-362, 365-371, 430-437, 439-446, 453-462, 474-484 and 449-467 of Seq ID No 171; 9-15, 24-35, 47-55, 122-128, 160-177, 188-196, 202-208, 216-228, 250-261, 272-303, 318-324, 327-339, 346-352, 355-361, 368-373, 108-218 and 344-376 of Seq ID No 172; 6-14, 17-48, 55-63, 71-90, 99-109, 116-124, 181-189, 212-223, 232-268, 270-294, 297-304, 319-325, 340-348, 351-370, 372-378, 388-394, 406-415, 421-434 and 177-277 of Seq ID No 173; 21-39, 42-61, 65-75, 79-85, 108-115 and 11-38 of Seq ID No 174; 4-17, 26-39, 61-76, 103-113, 115-122, 136-142, 158-192, 197-203, 208-214, 225-230, 237-251 and 207-225 of Seq ID No 175; 5-11, 27-36, 42-53, 62-70, 74-93, 95-104, 114-119, 127-150, 153-159, 173-179, 184-193, 199-206, 222-241, 248-253, 257-280, 289-295, 313-319, 322-342, 349-365, 368-389, 393-406, 408-413, 426-438, 447-461, 463-470, 476-495, 532-537, 543-550 and 225-246 of Seq ID No 176; 4-29, 68-82, 123-130, 141-147, 149-157, 178-191, 203-215, 269-277, 300-307, 327-335, 359-370, 374-380, 382-388, 393-400, 410-417, 434-442, 483-492, 497-503, 505-513, 533-540, 564-569, 601-607, 639-647, 655-666, 693-706, 712-718, 726-736, 752-758, 763-771, 774-780, 786-799, 806-812, 820-828, 852-863, 884-892, 901-909, 925-932, 943-948, 990-996, 1030-1036, 1051-1059, 1062-1068, 1079-1086, 1105-1113, 1152-1162, 1168-1179, 1183-1191, 1204-1210, 1234-1244, 1286-1295, 1318-1326, 1396-1401, 1451-1460, 1465-1474, 1477-1483, 1488-1494, 1505-1510, 1514-1521, 1552-1565, 1593-1614, 1664-1672, 1677-1685, 1701-1711, 1734-1745, 1758-1770, 1784-1798, 1840-1847, 1852-1873, 1885-1891, 1906-1911, 1931-1939, 1957-1970, 1977-1992, 2014-2020, 2026-2032, 2116-2134, 1-348, 373-490, 573-767, 903-1043, 1155-1198, 1243-1482, 1550-1595, 1682-1719, 1793-1921 and 2008-2110 of Seq ID No 177; 10-35, 39-52, 107-112, 181-188, 226-236, 238-253,

258-268, 275-284, 296-310, 326-338, 345-368, 380-389, 391-408, 410-418, 420-429, 444-456, 489-505, 573-588, 616-623, 637-643, 726-739, 741-767, 785-791, 793-803, 830-847, 867-881, 886-922, 949-956, 961-980, 988-1004, 1009-1018, 1027-1042, 1051-1069, 1076-1089, 1108-1115, 1123-1135, 1140-1151, 1164-1179, 1182-1191, 1210-1221, 1223-1234, 1242-1250, 1255-1267, 1281-1292, 1301-1307, 1315-1340, 1348-1355, 1366-1373, 1381-1413, 1417-1428, 1437-1444, 1453-1463, 1478-1484, 1490-1496, 1498-1503, 1520-1536, 1538-1546, 1548-1570, 1593-1603, 1612-1625, 1635-1649, 1654-1660, 1670-1687, 1693-1700, 1705-1711, 1718-1726, 1729-1763, 1790-1813, 1871-1881, 1893-1900, 1907-1935, 1962-1970, 1992-2000, 2006-2013, 2033-2039, 2045-2051, 2055-2067, 2070-2095, 2097-2110, 2115-2121, 2150-2171, 2174-2180, 2197-2202, 2206-2228 and 1526-1560 of Seq ID No 178; 4-17, 35-48, 54-76, 78-107, 109-115, 118-127, 134-140, 145-156, 169-174, 217-226, 232-240, 256-262, 267-273, 316-328, 340-346, 353-360, 402-409, 416-439, 448-456, 506-531, 540-546, 570-578, 586-593, 595-600, 623-632, 662-667, 674-681, 689-705, 713-724, 730-740, 757-763, 773-778, 783-796, 829-835, 861-871, 888-899, 907-939, 941-955, 957-969, 986-1000, 1022-1028, 1036-1044, 1068-1084, 1095-1102, 1118-1124, 1140-1146, 1148-1154, 1168-1181, 1185-1190, 1197-1207, 1218-1226, 1250-1270, 1272-1281, 1284-1296, 1312-1319, 1351-1358, 1383-1409, 1422-1428, 1438-1447, 1449-1461, 1482-1489, 1504-1510, 1518-1527, 1529-1537, 1544-1551, 1569-1575, 1622-1628, 1631-1637, 1682-1689, 1711-1718, 1733-1740, 1772-1783, 1818-1834, 1859-1872, 1-64 and 128-495 of Seq ID No 179; 8-28, 32-37, 62-69, 119-125, 137-149, 159-164, 173-189, 200-205, 221-229, 240-245, 258-265, 268-276, 287-293, 296-302, 323-329 and 1-95 of Seq ID No 180; 9-18, 25-38, 49-63, 65-72, 74-81, 94-117, 131-137, 139-146, 149-158, 162-188, 191-207, 217-225, 237-252, 255-269, 281-293, 301-326, 332-342, 347-354, 363-370, 373-380, 391-400, 415-424, 441-447 and 75-107 of Seq ID No 181; 4-24, 64-71, 81-87, 96-116, 121-128, 130-139, 148-155, 166-173, 176-184, 203-215, 231-238, 243-248, 256-261, 280-286, 288-306, 314-329 and 67-148 of Seq ID No 182; 4-10, 19-37, 46-52, 62-81, 83-89, 115-120, 134-139, 141-151, 168-186, 197-205, 209-234, 241-252, 322-335, 339-345, 363-379, 385-393, 403-431, 434-442, 447-454, 459-465, 479-484, 487-496 and 404-420 of Seq ID No 183; 10-35, 46-66, 71-77, 84-93, 96-122, 138-148, 154-172, 182-213, 221-233, 245-263, 269-275, 295-301, 303-309, 311-320, 324-336, 340-348, 351-359, 375-381 and 111-198 of Seq ID No 184; 14-25, 30-42, 47-61, 67-75, 81-91, 98-106, 114-122, 124-135, 148-193, 209-227 and 198-213 of Seq ID No 185; 5-18, 45-50, 82-90, 97-114, 116-136, 153-161, 163-171, 212-219, 221-227, 240-249, 267-281, 311-317, 328-337, 375-381, 390-395, 430-436, 449-455, 484-495, 538-543, 548-554, 556-564, 580-586, 596-602 and 493-606 of Seq ID No 186; 9-25, 28-34, 37-44, 61-68, 75-81, 88-96, 98-111, 119-133, 138-150, 152-163, 168-182, 186-194, 200-205, 216-223, 236-245, 257-264, 279-287, 293-304, 311-318, 325-330, 340-346, 353-358, 365-379, 399-409, 444-453 and 303-391 of Seq ID No 187; 16-36, 55-61, 66-76, 78-102, 121-130, 134-146, 150-212, 221-239, 255-276, 289-322, 329-357 and 29-59 of Seq ID No 188; 8-27, 68-74, 77-99, 110-116, 124-141, 171-177, 202-217, 221-228, 259-265, 275-290, 293-303, 309-325, 335-343, 345-351, 365-379, 384-394, 406-414, 423-437, 452-465, 478-507, 525-534, 554-560, 611-624, 628-651, 669-682, 742-747, 767-778, 782-792, 804-812, 820-836, 79-231 and 359-451 of Seq ID No 189; 5-28, 39-45, 56-62, 67-74, 77-99, 110-117, 124-141, 168-176, 200-230, 237-244, 268-279, 287-299, 304-326, 329-335, 348-362, 370-376, 379-384, 390-406, 420-429, 466-471, 479-489, 495-504, 529-541, 545-553, 561-577, 598-604, 622-630, 637-658, 672-680, 682-688, 690-696, 698-709, 712-719, 724-736, 738-746, 759-769, 780-786, 796-804, 813-818, 860-877, 895-904, 981-997, 1000-1014, 1021-1029, 1-162, 206-224, 254-350, 414-514 and 864-938 of Seq ID No 190; 4-11, 19-49, 56-66, 68-101, 109-116, 123-145, 156-165, 177-185, 204-221, 226-234, 242-248, 251-256, 259-265, 282-302, 307-330, 340-349, 355-374, 377-383, 392-400, 422-428, 434-442, 462-474 and 266-322 of Seq ID No 191; 14-43, 45-57, 64-74, 80-87, 106-127, 131-142, 145-161, 173-180, 182-188, 203-210, 213-219, 221-243, 245-254, 304-311, 314-320, 342-348, 354-365, 372-378, 394-399, 407-431, 436-448, 459-465, 470-477, 484-490, 504-509, 531-537, 590-596, 611-617, 642-647, 723-734, 740-751, 754-762, 764-774, 782-797, 807-812, 824-831, 838-845, 877-885, 892-898, 900-906, 924-935, 940-946, 982-996, 1006-1016, 1033-1043, 1051-1056, 1058-1066, 1094-1108, 1119-1126, 1129-1140, 1150-1157, 1167-1174, 1176-1185, 1188-1201, 1209-1216, 1220-1228, 1231-1237, 1243-1248, 1253-1285, 1288-1297, 1299-1307, 1316-1334, 1336-1343, 1350-1359, 1365-1381, 1390-1396, 1412-1420, 1427-1439, 1452-1459, 1477-1484, 1493-1512, 1554-1559, 1570-1578, 1603-1608, 1623-1630, 1654-1659, 1672-1680, 1689-1696, 1705-1711, 1721-1738, 1752-1757, 1773-1780, 1817-1829, 1844-1851, 1856-1863, 1883-1895, 1950-1958, 1974-1990, 172-354, 384-448, 464-644, 648-728 and 1357-1370 of Seq ID No 192; 8-27, 68-74, 77-99, 110-116, 124-141, 169-

176, 201-216, 220-227, 258-264, 274-289, 292-302, 308-324, 334-342, 344-350, 364-372, 377-387, 399-407, 416-429, 445-458, 471-481, 483-500, 518-527, 547-553, 604-617, 621-644, 662-675, 767-778, 809-816, 15-307, 350-448 and 496-620 of Seq ID No 193; 4-17, 24-29, 53-59, 62-84, 109-126, 159-164, 189-204, 208-219, 244-249, 274-290, 292-302, 308-324, 334-342, 344-350, 378-389, 391-397, 401-409, 424-432, 447-460, 470-479, 490-504, 521-529, 538-544, 549-555, 570-577, 583-592, 602-608, 615-630, 635-647, 664-677, 692-698, 722-731, 733-751, 782-790, 793-799, 56-267, 337-426 and 495-601 of Seq ID No 194; 12-22, 49-59, 77-89, 111-121, 136-148, 177-186, 207-213, 217-225, 227-253, 259-274, 296-302, 328-333, 343-354, 374-383, 424-446, 448-457, 468-480, 488-502, 507-522, 544-550, 553-560, 564-572, 587-596, 604-614, 619-625, 629-635, 638-656, 662-676, 680-692, 697-713, 720-738, 779-786, 833-847, 861-869, 880-895, 897-902, 911-917, 946-951, 959-967, 984-990, 992-1004, 1021-1040, 1057-1067, 1073-1080 and 381-403 of Seq ID No 195; 4-10, 26-31, 46-56, 60-66, 70-79, 86-94, 96-102, 109-118, 132-152, 164-187, 193-206, 217-224 and 81-149 of Seq ID No 196; 4-21, 26-37, 48-60, 71-82, 109-117, 120-128, 130-136, 142-147, 181-187, 203-211, 216-223, 247-255, 257-284, 316-325, 373-379, 395-400, 423-435, 448-456, 479-489, 512-576, 596-625, 641-678, 680-688, 692-715 and 346-453 of Seq ID No 197; 10-16, 25-31, 34-56, 58-69, 71-89, 94-110, 133-176, 186-193, 208-225, 240-250, 259-266, 302-307, 335-341, 376-383, 410-416 and 316-407 of Seq ID No 198; 11-29, 42-56, 60-75, 82-88, 95-110, 116-126, 132-143, 145-160, 166-172, 184-216 and 123-164 of Seq ID No 199; 11-29, 54-63, 110-117, 139-152, 158-166, 172-180, 186-193, 215-236, 240-251, 302-323, 330-335, 340-347, 350-366, 374-381 and 252-299 of Seq ID No 200; 18-27, 35-42, 50-56, 67-74, 112-136, 141-153, 163-171, 176-189, 205-213, 225-234, 241-247, 253-258, 269-281, 288-298, 306-324, 326-334, 355-369, 380-387 and 289-320 of Seq ID No 201; 7-15, 19-41, 56-72, 91-112, 114-122, 139-147, 163-183, 196-209, 258-280, 326-338, 357-363, 391-403, 406-416 and 360-378 of Seq ID No 202; 11-18, 29-41, 43-49, 95-108, 142-194, 204-212, 216-242, 247-256, 264-273 and 136-149 of Seq ID No 203; 18-24, 33-40, 65-79, 89-102, 113-119, 130-137, 155-161, 173-179, 183-203, 205-219, 223-231, 245-261, 267-274, 296-306, 311-321, 330-341, 344-363, 369-381, 401-408, 415-427, 437-444, 453-464, 472-478, 484-508, 517-524, 526-532, 543-548 and 59-180 of Seq ID No 204; 5-13, 52-65, 67-73, 97-110, 112-119, 134-155 and 45-177 of Seq ID No 205; 6-28, 34-43, 57-67, 75-81, 111-128, 132-147, 155-163, 165-176, 184-194, 208-216, 218-229, 239-252, 271-278, 328-334, 363-376, 381-388, 426-473, 481-488, 492-498, 507-513, 536-546, 564-582, 590-601, 607-623, 148-269, 420-450 and 610-648 of Seq ID No 206; 4-12, 20-38, 69-75, 83-88, 123-128, 145-152, 154-161, 183-188, 200-213, 245-250, 266-272, 306-312, 332-339, 357-369, 383-389, 395-402, 437-453, 455-470, 497-503 and 1-112 of Seq ID No 207; 35-59, 74-86, 111-117, 122-137 and 70-154 of Seq ID No 208; 26-42, 54-61, 65-75, 101-107, 123-130, 137-144, 148-156, 164-172, 177-192, 213-221, 231-258 and 157-249 of Seq ID No 209; 29-38, 61-67, 77-87, 94-100, 105-111, 118-158 and 1-97 of Seq ID No 210; 7-21, 30-48, 51-58, 60-85, 94-123, 134-156, 160-167, 169-183, 186-191, 216-229, 237-251, 257-267, 272-282, 287-298 and 220-243 of Seq ID No 211; 6-29, 34-47, 56-65, 69-76, 83-90, 123-134, 143-151, 158-178, 197-203, 217-235, 243-263, 303-309, 320-333, 338-348, 367-373, 387-393, 407-414, 416-427, 441-457, 473-482, 487-499, 501-509, 514-520, 530-535, 577-583, 590-602, 605-612, 622-629, 641-670, 678-690, 37-71 and 238-307 of Seq ID No 212; 7-40, 121-132, 148-161, 196-202, 209-215, 221-235, 248-255, 271-280, 288-295, 330-339, 395-409, 414-420, 446-451, 475-487, 556-563, 568-575, 580-586, 588-595, 633-638, 643-648, 652-659, 672-685, 695-700, 710-716, 737-742, 749-754, 761-767, 775-781, 796-806, 823-835, 850-863, 884-890, 892-900, 902-915, 934-941 and 406-521 of Seq ID No 213; 9-18, 24-46, 51-58, 67-77, 85-108, 114-126, 129-137, 139-146, 152-165, 173-182, 188-195, 197-204, 217-250, 260-274, 296-313, 343-366, 368-384, 427-434, 437-446, 449-455, 478-484, 492-506, 522-527, 562-591, 599-606, 609-618, 625-631, 645-652 and 577-654 of Seq ID No 214; 13-20, 26-37, 41-53, 56-65, 81-100, 102-114, 118-127, 163-188, 196-202, 231-238, 245-252, 266-285, 293-298, 301-306 and 19-78 of Seq ID No 215; 10-23, 32-42, 54-66, 73-91, 106-113, 118-127, 139-152, 164-173, 198-207, 210-245, 284-300, 313-318, 330-337, 339-346, 354-361, 387-393, 404-426, 429-439, 441-453, 467-473, 479-485, 496-509, 536-544, 551-558, 560-566, 569-574, 578-588, 610-615, 627-635, 649-675, 679-690, 698-716, 722-734, 743-754, 769-780, 782-787 and 480-550 of Seq ID No 216; 6-39, 42-50, 60-68, 76-83, 114-129, 147-162, 170-189, 197-205, 217-231, 239-248, 299-305, 338-344, 352-357, 371-377, 380-451, 459-483, 491-499, 507-523, 537-559, 587-613, 625-681, 689-729, 737-781, 785-809, 817-865, 873-881, 889-939, 951-975, 983-1027, 1031-1055, 1063-1071, 1079-1099, 1103-1127, 1151-1185, 1197-1261, 1269-1309, 1317-1333, 1341-1349, 1357-1465, 1469-1513, 1517-1553, 1557-1629, 1637-1669, 1677-1701, 1709-1725,

1733-1795, 1823-1849, 1861-1925, 1933-1973, 1981-2025, 2029-2053, 2061-2109, 2117-2125, 2133-2183, 2195-2219, 2227-2271, 2275-2299, 2307-2315, 2323-2343, 2347-2371, 2395-2429, 2441-2529, 2537-2569, 2577-2601, 2609-2625, 2633-2695, 2699-2737, 2765-2791, 2803-2867, 2889-2913, 2921-2937, 2945-2969, 2977-2985, 2993-3009, 3023-3045, 3073-3099, 3111-3167, 3175-3215, 3223-3267, 3271-3295, 3303-3351, 3359-3367, 3375-3425, 3437-3461, 3469-3513, 3517-3541, 3549-3557, 3565-3585, 3589-3613, 3637-3671, 3683-3747, 3755-3795, 3803-3819, 3827-3835, 3843-3951, 3955-3999, 4003-4039, 4043-4115, 4123-4143, 4147-4171, 4195-4229, 4241-4305, 4313-4353, 4361-4377, 4385-4393, 4401-4509, 4513-4557, 4561-4597, 4601-4718, 4749-4768, 74-171, 452-559 and 2951-3061 of Seq ID No 217; 16-22, 30-51, 70-111, 117-130, 137-150, 171-178, 180-188, 191-196 and 148-181 of Seq ID No 218; 6-19, 21-46, 50-56, 80-86, 118-126, 167-186, 189-205, 211-242, 244-267, 273-286, 290-297, 307-316, 320-341 and 34-60 of Seq ID No 219; 5-26, 33-43, 48-54, 58-63, 78-83, 113-120, 122-128, 143-152, 157-175, 185-192, 211-225, 227-234, 244-256, 270-281, 284-290, 304-310, 330-337, 348-355, 362-379, 384-394, 429-445, 450-474, 483-490, 511-520, 537-546, 548-554, 561-586, 590-604, 613-629, 149-186, 285-431 and 573-659 of Seq ID No 220; 5-26, 49-59, 61-67, 83-91, 102-111, 145-157, 185-192, 267-272, 279-286, 292-298, 306-312, 134-220, 235-251 and 254-280 of Seq ID No 221; 5-19, 72-79, 83-92, 119-124, 140-145, 160-165, 167-182, 224-232, 240-252, 259-270, 301-310, 313-322, 332-343, 347-367, 384-398, 416-429, 431-446, 454-461 and 1-169 of Seq ID No 222; 8-17, 26-31, 56-62, 75-83, 93-103, 125-131, 135-141, 150-194, 205-217, 233-258, 262-268, 281-286 and 127-168 of Seq ID No 223; 6-12, 69-75, 108-115, 139-159, 176-182, 194-214 and 46-161 of Seq ID No 224; 6-13, 18-27, 39-48, 51-59, 66-73, 79-85, 95-101, 109-116, 118-124, 144-164, 166-177, 183-193, 197-204, 215-223, 227-236, 242-249, 252-259, 261-270, 289-301, 318-325 and 12-58 of Seq ID No 225; 4-10, 26-32, 48-60, 97-105, 117-132, 138-163, 169-185, 192-214, 219-231, 249-261, 264-270, 292-308, 343-356, 385-392, 398-404, 408-417, 435-441 and 24-50 of Seq ID No 226; 10-40, 42-48, 51-61, 119-126 and 1-118 of Seq ID No 227; 5-17, 40-58, 71-83, 103-111, 123-140, 167-177, 188-204 and 116-128 of Seq ID No 228; 4-9, 11-50, 57-70, 112-123, 127-138 and 64-107 of Seq ID No 229; 9-39, 51-67 and 1-101 of Seq ID No 230; 5-14, 17-25, 28-46, 52-59, 85-93, 99-104, 111-120, 122-131, 140-148, 158-179, 187-197, 204-225, 271-283, 285-293 and 139-155 of Seq ID No 231; 42-70, 73-90, 92-108, 112-127, 152-164, 166-172, 181-199, 201-210, 219-228, 247-274, 295-302, 322-334, 336-346, 353-358, 396-414, 419-425, 432-438, 462-471, 518-523, 531-536, 561-567, 576-589, 594-612, 620-631, 665-671, 697-710, 718-731, 736-756, 765-771, 784-801 and 626-653 of Seq ID No 232; 8-28, 41-51, 53-62, 68-74, 79-85, 94-100, 102-108, 114-120, 130-154, 156-162, 175-180, 198-204, 206-213, 281-294, 308-318, 321-339, 362-368, 381-386, 393-399, 407-415 and 2-13 of Seq ID No 233; 4-39, 48-65, 93-98, 106-112, 116-129 and 10-36 of Seq ID No 234; 25-32, 35-50, 66-71, 75-86, 90-96, 123-136, 141-151, 160-179, 190-196, 209-215, 222-228, 235-242, 257-263, 270-280 and 209-247 of Seq ID No 235; 5-29, 31-38, 50-57, 62-75, 83-110, 115-132, 168-195, 197-206, 216-242, 249-258, 262-269, 333-340, 342-350, 363-368, 376-392, 400-406, 410-421, 423-430, 436-442, 448-454, 460-466, 471-476, 491-496, 511-516, 531-536, 551-556, 571-576, 585-591, 599-605, 27-70, 219-293, 441-504 and 512-584 of Seq ID No 236; 4-12, 14-34, 47-75, 83-104, 107-115, 133-140, 148-185, 187-196, 207-212, 224-256, 258-265, 281-287, 289-296, 298-308, 325-333, 345-355, 365-371, 382-395, 424-435, 441-457, 465-472, 483-491, 493-505, 528-534, 536-546, 552-558, 575-584, 589-600, 616-623 and 576-591 of Seq ID No 237; 4-76, 78-89, 91-126, 142-148, 151-191, 195-208, 211-223, 226-240, 256-277, 279-285, 290-314, 317-323, 358-377, 381-387, 391-396, 398-411, 415-434, 436-446, 454-484, 494-512, 516-523, 538-552, 559-566, 571-577, 579-596, 599-615, 620-627, 635-644, 694-707, 720-734, 737-759, 761-771 and 313-329 of Seq ID No 238; 7-38, 44-49, 79-89, 99-108, 117-123, 125-132, 137-146, 178-187, 207-237, 245-255, 322-337, 365-387, 398-408, 445-462, 603-608, 623-628, 644-650, 657-671, 673-679 and 111-566 of Seq ID No 239; 6-20, 22-35, 39-45, 58-64, 77-117, 137-144, 158-163, 205-210, 218-224, 229-236, 239-251, 263-277, 299-307, 323-334, 353-384, 388-396, 399-438, 443-448, 458-463, 467-478, 481-495, 503-509, 511-526, 559-576, 595-600, 612-645, 711-721, 723-738, 744-758, 778-807 and 686-720 of Seq ID No 240; 10-33, 35-41, 72-84, 129-138, 158-163, 203-226, 243-252, 258-264, 279-302, 322-329, 381-386, 401-406, 414-435 and 184-385 of Seq ID No 241; 4-9, 19-24, 41-47, 75-85, 105-110, 113-146 and 45-62 of Seq ID No 242; 4-25, 52-67, 117-124, 131-146, 173-180, 182-191, 195-206, 215-221, 229-236, 245-252, 258-279, 286-291, 293-302, 314-320, 327-336, 341-353, 355-361, 383-389 and 1-285 of Seq ID No 243; 14-32, 38-50, 73-84, 93-105, 109-114 and 40-70 of Seq ID No 244; 5-26 and 22-34 of Seq ID No 245; 23-28 and 13-39 of Seq ID No 246; 8-14 and 21-34 of

Seq ID No 247; 4-13, 20-29, 44-50, 59-74 and 41-69 of Seq ID No 248; 4-9, 19-42, 48-59, 71-83 and 57-91 of Seq ID No 249; 4-14 and 10-28 of Seq ID No 250; 22-28, 32-42, 63-71, 81-111, 149-156, 158-167, 172-180, 182-203, 219-229 and 27-49 of Seq ID No 251; 17-27 and 23-32 of Seq ID No 252; 18-24 and 28-38 of Seq ID No 253; 9-15 and 13-27 of Seq ID No 254; 13-22 and 18-29 of Seq ID No 255; 17-26 and 2-11 of Seq ID No 256; 4-33 and 16-32 of Seq ID No 257; 4-10, 37-43, 54-84, 92-127 and 15-62 of Seq ID No 258; 4-14, 20-32, 35-60, 69-75, 79-99, 101-109, 116-140 and 124-136 of Seq ID No 259; 2-13 of Seq ID No 260; 4-13, 28-42 and 42-57 of Seq ID No 261; 4-14, 27-44 and 14-35 of Seq ID No 262; 4-12 and 1-27 of Seq ID No 263; 4-18, 39-45, 47-74 and 35-66 of Seq ID No 264; 8-20, 43-77 and 17-36 of Seq ID No 265; 4-30, 35-45, 51-57 and 35-49 of Seq ID No 266; 4-24, 49-57 and 15-34 of Seq ID No 267; 4-22 and 8-27 of Seq ID No 268; 13-25, 32-59, 66-80 and 21-55 of Seq ID No 269; 4-10, 24-33, 35-42, 54-65, 72-82, 98-108 and 15-30 of Seq ID No 270; 8-19 and 17-47 of Seq ID No 271; 12-18, 40-46 and 31-52 of Seq ID No 272; 4-20, 35-78, 83-102, 109-122 and 74-86 of Seq ID No 273; 7-17, 21-41, 46-63 and 2-20 of Seq ID No 274; 30-37 and 2-33 of Seq ID No 275; 4-13, 17-25 and 1-15 of Seq ID No 276; 17-31, 44-51 and 20-51 of Seq ID No 277; 20-30 and 5-23 of Seq ID No 278; 13-33, 48-71 and 92-110 of Seq ID No 279; 4-9, 50-69, 76-88, 96-106, 113-118 and 12-34 of Seq ID No 280; 4-24 and 6-26 of Seq ID No 281; 7-26 and 14-30 of Seq ID No 282; 9-39, 46-68, 75-82, 84-103 and 26-44 of Seq ID No 283; 4-30, 33-107 and 58-84 of Seq ID No 284; 4-12 and 9-51 of Seq ID No 285; 12-18, 29-37 and 6-37 of Seq ID No 286; 4-21, 33-52, 64-71 and 16-37 of Seq ID No 287; 9-19 and 2-30 of Seq ID No 288; 20-37 of Seq ID No 245; 8-27 of Seq ID No 246; 10-27 of Seq ID No 247; 42-59 and 52-69 of Seq ID No 248; 63-80 and 74-91 of Seq ID No 249; 11-28 of Seq ID No 250; 28-49 of Seq ID No 251; 15-32 of Seq ID No 252; 4-20 of Seq ID No 253; 10-27 of Seq ID No 254; 17-34 of Seq ID No 255; 1-18 of Seq ID No 256; 16-33 of Seq ID No 257; 16-36, 30-49 and 43-62 of Seq ID No 258; 122-139 of Seq ID No 259; 1-18 of Seq ID No 260; 41-58 of Seq ID No 261; 15-35 of Seq ID No 262; 2-27 of Seq ID No 263; 18-36 of Seq ID No 265; 34-51 of Seq ID No 266; 9-27 of Seq ID No 268; 22-47 of Seq ID No 269; 18-36 and 29-47 of Seq ID No 271; 32-52 of Seq ID No 272; 72-89 of Seq ID No 273; 3-20 of Seq ID No 274; 3-21 and 15-33 of Seq ID No 275; 1-18 of Seq ID No 276; 6-23 of Seq ID No 278; 93-110 of Seq ID No 279; 13-34 of Seq ID No 280; 7-26 and 9-26 of Seq ID No 281; 16-33 of Seq ID No 282; 27-44 of Seq ID No 283; 67-84 of Seq ID No 284; 10-33 and 26-50 of Seq ID No 285; 7-25 and 19-37 of Seq ID No 286; 17-37 of Seq ID No 287; 3-20 and 13-30 of Seq ID No 288; 62-80 and 75-93 of Seq ID No 145; 92-108 of Seq ID No 147; 332-349, 177-200 and 1755-1777 of Seq ID No 148; 109-133, 149-174, 260-285 and 460-485 of Seq ID No 149; 26-47 and 42-64 of Seq ID No 150; 22-41, 35-54, 115-130, 306-325, 401-420 and 454-478 of Seq ID No 151; 22-45 of Seq ID No 155; 156-174, 924-940, 1485-1496, 1447-1462 and 1483-1498 of Seq ID No 160; 457-475 of Seq ID No 161; 302-325 of Seq ID No 163; 288-305 of Seq ID No 164; 244-266 and 260-282 of Seq ID No 165; 204-225 and 220-241 of Seq ID No 166; 324-345, 340-361, 356-377, 372-393 and 388-408 of Seq ID No 167; 39-64 of Seq ID No 168; 54-76 and 70-92 of Seq ID No 169; 1227-1247, 1539-1559, 1554-1574, 1569-1589, 1584-1604, 1242-1262, 1272-1292, 1287-1308, 1456-1477, 1472-1494, 1488-1510 and 1505-1526 of Seq ID No 170; 351-368 of Seq ID No 172; 179-200, 195-216, 211-232, 227-248 and 243-263 of Seq ID No 173; 13-37 of Seq ID No 174; 208-224 of Seq ID No 175; 42-64, 59-81, 304-328, 323-348, 465-489, 968-992, 1399-1418, 1412-1431 and 2092-2111 of Seq ID No 177; 1528-1547 and 1541-1560 of Seq ID No 178; 184-200, 367-388, 382-403, 409-429, 425-444 and 438-457 of Seq ID No 179; 27-50 and 45-67 of Seq ID No 180; 114-131 and 405-419 of Seq ID No 183; 113-134, 129-150, 145-166, 161-182 and 177-198 of Seq ID No 184; 495-515 of Seq ID No 186; 346-358 of Seq ID No 187; 208-224 of Seq ID No 190; 178-194, 202-223, 217-238, 288-308 and 1355-1372 of Seq ID No 192; 57-78 of Seq ID No 194; 347-369, 364-386, 381-403, 398-420, 415-437 and 432-452 of Seq ID No 197; 347-372 of Seq ID No 198; 147-163 of Seq ID No 199; 263-288 of Seq ID No 200; 361-377 of Seq ID No 202; 82-104, 99-121, 116-138, 133-155 and 150-171 of Seq ID No 204; 110-130 and 125-145 of Seq ID No 205; 613-631, 626-644 and 196-213 of Seq ID No 206; 78-100, 95-117, 112-134 and 129-151 of Seq ID No 208; 158-180, 175-197, 192-214, 209-231 and 226-248 of Seq ID No 209; 30-50, 45-65 and 60-79 of Seq ID No 210; 431-455 and 450-474 of Seq ID No 213; 579-601, 596-618, 613-635 and 630-653 of Seq ID No 214; 920-927, 98-119, 114-135, 130-151, 146-167 and 162-182 of Seq ID No 217; 36-59 of Seq ID No 219; 194-216 and 381-404 of Seq ID No 220; 236-251 and 255-279 of Seq ID No 221; 80-100 and

141-164 of Seq ID No 222; 128-154 of Seq ID No 223; 82-100, 95-116 and 111-134 of Seq ID No 224; 55-76, 71-92 and 87-110 of Seq ID No 227; 91-106 of Seq ID No 229; 74-96 of Seq ID No 230; 140-157 of Seq ID No 231; 4-13 of Seq ID No 233; 41-65 and 499-523 of Seq ID No 236; 122-146, 191-215, 288-313, 445-469 and 511-535 of Seq ID No 239; 347-368 of Seq ID No 241; 46-61 of Seq ID No 242; 15-37, 32-57, 101-121, 115-135, 138-158, 152-172, 220-242 and 236-258 of Seq ID No 243.

15. A process for producing a *S. pneumoniae* hyperimmune serum reactive antigen or a fragment thereof according to any one of the claims 11 to 14 comprising expressing the nucleic acid molecule according to any one of claims 1 to 7.
16. A process for producing a cell, which expresses a *S. pneumoniae* hyperimmune serum reactive antigen or a fragment thereof according to any one of the claims 11 to 14 comprising transforming or transfecting a suitable host cell with the vector according to claim 8 or claim 9.
17. A pharmaceutical composition, especially a vaccine, comprising a hyperimmune serum-reactive antigen or a fragment thereof, as defined in any one of claims 11 to 14 or a nucleic acid molecule according to any one of claims 1 to 7.
18. A pharmaceutical composition, especially a vaccine, according to claim 17, characterized in that it further comprises an immunostimulatory substance, preferably selected from the group comprising polycationic polymers, especially polycationic peptides, immunostimulatory deoxynucleotides (ODNs), peptides containing at least two LysLeuLys motifs, neuroactive compounds, especially human growth hormone, alum, Freund's complete or incomplete adjuvants or combinations thereof.
19. Use of a nucleic acid molecule according to any one of claims 1 to 7 or a hyperimmune serum-reactive antigen or fragment thereof according to any one of claims 11 to 14 for the manufacture of a pharmaceutical preparation, especially for the manufacture of a vaccine against *S. pneumoniae* infection.
20. An antibody, or at least an effective part thereof, which binds at least to a selective part of the hyperimmune serum-reactive antigen or a fragment thereof according to any one of claims 11 to 14.
21. An antibody according to claim 20, wherein the antibody is a monoclonal antibody.
22. An antibody according to claim 20 or 21, wherein said effective part comprises Fab fragments.
23. An antibody according to any one of claims 20 to 22, wherein the antibody is a chimeric antibody.
24. An antibody according to any one of claims 20 to 23, wherein the antibody is a humanized antibody.
25. A hybridoma cell line, which produces an antibody according to any one of claims 20 to 24.
26. A method for producing an antibody according to claim 20, characterized by the following steps:
 - initiating an immune response in a non-human animal by administering an hyperimmune serum-reactive antigen or a fragment thereof, as defined in any one of the claims 11 to 14, to said animal,
 - removing an antibody containing body fluid from said animal, and
 - producing the antibody by subjecting said antibody containing body fluid to further purification steps.

27. Method for producing an antibody according to claim 21, characterized by the following steps:
- initiating an immune response in a non-human animal by administering an hyperimmune serum-reactive antigen or a fragment thereof, as defined in any one of the claims 12 to 15, to said animal,
 - removing the spleen or spleen cells from said animal,
 - producing hybridoma cells of said spleen or spleen cells,
 - selecting and cloning hybridoma cells specific for said hyperimmune serum-reactive antigens or a fragment thereof,
 - producing the antibody by cultivation of said cloned hybridoma cells and optionally further purification steps.
28. Use of the antibodies according to any one of claims 20 to 24 for the preparation of a medicament for treating or preventing *S. pneumoniae* infections.
29. An antagonist, which binds to the hyperimmune serum-reactive antigen or a fragment thereof according to any one of claims 11 to 14.
30. A method for identifying an antagonist capable of binding to the hyperimmune serum-reactive antigen or fragment thereof according to any one of claims 11 to 14 comprising:
- a) contacting an isolated or immobilized hyperimmune serum-reactive antigen or a fragment thereof according to any one of claims 11 to 14 with a candidate antagonist under conditions to permit binding of said candidate antagonist to said hyperimmune serum-reactive antigen or fragment, in the presence of a component capable of providing a detectable signal in response to the binding of the candidate antagonist to said hyperimmune serum reactive antigen or fragment thereof; and
 - b) detecting the presence or absence of a signal generated in response to the binding of the antagonist to the hyperimmune serum reactive antigen or the fragment thereof.
31. A method for identifying an antagonist capable of reducing or inhibiting the interaction activity of a hyperimmune serum-reactive antigen or a fragment thereof according to any one of claims 11 to 14 to its interaction partner comprising:
- a) providing a hyperimmune serum reactive antigen or a hyperimmune fragment thereof according to any one of claims 11-14,
 - b) providing an interaction partner to said hyperimmune serum reactive antigen or a fragment thereof, especially an antibody according to any one of the claims 20 to 24,
 - c) allowing interaction of said hyperimmune serum reactive antigen or fragment thereof to said interaction partner to form a interaction complex,
 - d) providing a candidate antagonist,
 - e) allowing a competition reaction to occur between the candidate antagonist and the interaction complex,
 - f) determining whether the candidate antagonist inhibits or reduces the interaction activities of the hyperimmune serum reactive antigen or the fragment thereof with the interaction partner.
32. Use of any of the hyperimmune serum reactive antigen or fragment thereof according to any one of claims 11 to 14 for the isolation and/or purification and/or identification of an interaction partner of said hyperimmune serum reactive antigen or fragment thereof.
33. A process for *in vitro* diagnosing a disease related to expression of the hyperimmune serum-reactive antigen or a fragment thereof according to any one of claims 11 to 14 comprising determining the presence of a nucleic acid sequence encoding said hyperimmune serum reactive antigen and fragment according to any one of claims 1 to 7 or the presence of the hyperimmune

serum reactive antigen or fragment thereof according to any one of claims 11-14.

34. A process for *in vitro* diagnosis of a bacterial infection, especially a *S. pneumoniae* infection, comprising analysing for the presence of a nucleic acid sequence encoding said hyperimmune serum reactive antigen and fragment according to any one of claims 1 to 7 or the presence of the hyperimmune serum reactive antigen or fragment thereof according to any one of claims 11 to 14.
35. Use of the hyperimmune serum reactive antigen or fragment thereof according to any one of claims 11 to 14 for the generation of a peptide binding to said hyperimmune serum reactive antigen or fragment thereof, wherein the peptide is selected from the group comprising anticalines.
36. Use of the hyperimmune serum-reactive antigen or fragment thereof according to any one of claims 11 to 14 for the manufacture of a functional nucleic acid, wherein the functional nucleic acid is selected from the group comprising aptamers and spiegelmers.
37. Use of a nucleic acid molecule according to any one of claims 11 to 14 for the manufacture of a functional ribonucleic acid, wherein the functional ribonucleic acid is selected from the group comprising ribozymes, antisense nucleic acids and siRNA.

1/20




Fig. 1





Fig.1

3/20




Fig.1

4/20




Fig. 2

5/20




Fig. 3

6/20




Fig. 4

7/20




Fig. 5

8/20




Fig. 6

9/20




Fig. 7

10/20





Fig. 8

11/20




Fig. 8

12/20




Fig. 9

13/20




Fig. 10

14/20




Fig. 11

	1	MKKKILASLL	LSTVMVSQVA	VLTTAHAETT	DDKIAAQDNK	ISNLTAQQQE	AQKVVDQIQE	QVSAIQAEQS	NLQAENDRLQ	AESKKLEGEI	90
TIGR4		MKKKILASLL	LSTVMVSQVA	VLTTAHAETT	DDKIAAQDNK	ISNLTAQQQE	AQKVVDQIQE	QVSAIQAEQS	NLQAENDRLQ	AESKKLEGEI	
14		MKKKILASLL	LSTVMVSQVA	VLTTAHAETT	DDKIAAQDNK	ISNLTAQQQE	AQKVVDQIQE	QVSAIQAEQS	NLQAENDRLQ	AESKKLEGEI	
19F		MKKKILASLL	LSTVMVSQVA	VLTTAHAETT	DDKIAAQDNK	ISNLTAQQQE	AQKVVDQIQE	QVSAIQAEQS	NLQAENDRLQ	AESKKLEGEI	
Consensus		mkkkilasll	lstvmvsqva	vlttahaett	ddkiaaqdnk	isnltaqqqe	akqvvdqiqe	qvsaiaeqs	nlsaendrllq	aeskklegei	
	91	TELSKNIVSR	NQSLEKQARS	AQTNGAVTSY	INTIVNSKSI	TEAISRVAAM	SEIVSANNKM	LEQQKADKKA	I SEKQVANND	AINTVIANQQ	180
TIGR4		TELSKNIVSR	NQSLEKQARS	AQTNGAVTSY	INTIVNSKSI	TEAISRVAAM	SEIVSANNKM	LEQQKADKKA	I SEKQVANND	AINTVIANQQ	
14		TELSKNIVSR	NQSLEKQARS	AQTNGAVTSY	INTIVNSKSI	TEAISRVAAM	SEIVSANNKM	LEQQKADKKA	I SEKQVANND	AINTVIANQQ	
19F		TELSKNIVSR	NQSLEKQARS	AQTNGAVTSY	INTIVNSKSI	TEAISRVAAM	SEIVSANNKM	LEQQKADKKA	I SEKQVANND	AINTVIANQQ	
Consensus		telsknivsr	nqslekqars	aqtngavtsy	intivnsksi	teaisrvaam	seivsannkm	leqqkadkka	i sekqvannnd	aintvianqq	
	181	KLADDAQAL T	TKQAE LKAAE	LSLAAEKATA	EGEKASLLEQ	KAAAEAEARA	AAVAEEAAYKE	KRASQQQS VL	ASANTNLT AQ	VQAVSESAAAA	270
TIGR4		KLADDAQAL T	TKQAE LKAAE	LSLAAEKATA	EGEKASLLEQ	KAAAEAEARA	AAVAEEAAYKE	KRASQQQS VL	ASANTNLT AQ	VQAVSESAAAA	
14		KLADDAQAL T	TKQAE LKAAE	LSLAAEKATA	EGEKASLLEQ	KAAAEAEARA	AAVAEEAAYKE	KRASQQQS VL	ASANTNLT AQ	VQAVSESAAAA	
19F		KLADDAQAL T	TKQAE LKAAE	LSLAAEKATA	EGEKASLLEQ	KAAAEAEARA	AAVAEEAAYKE	KRASQQQS VL	ASANTNLT AQ	VQAVSESAAAA	
Consensus		kладаақалт	tkqaelkaae	lslaaeekata	egekasslleq	kaaaeeaeaara	avaaeaaayke	krasqqqs vl	asantnlt aq	vqavsesaaaa	
	271	PVRAKVRPTY	STNASSYP I G	ECTWGVKT LA	PWAGDYWG NG	AQWATSAAAA	GFR TGSTP QV	GAIA CWNDGG	YGH VAVVT AV	ESTTR IQVSE	360
TIGR4		PVRAKVRPTY	STNASSYP I G	ECTWGVKT LA	PWAGDYWG NG	AQWATSAAAA	GFR TGSTP QV	GAIA CWNDGG	YGH VAVVT AV	ESTTR IQVSE	
14		PVRAKVRPTY	STNASSYP I G	ECTWGVKT LA	PWAGDYWG NG	AQWATSAAAA	GFR TGSTP QV	GAIA CWNDGG	YGH VAVVT AV	ESTTR IQVSE	
19F		PVRAKVRPTY	STNASSYP I G	ECTWGVKT LA	PWAGDYWG NG	AQWATSAAAA	GFR TGSTP QV	GAIA CWNDGG	YGH VAVVT AV	ESTTR IQVSE	
Consensus		pvrakvrpty	stnassypig	ectwgvktla	pwagdywgng	aqwatsaaaa	gfrtgstpqv	gaia cwndgg	yghvavvtav	esttriqvse	
	361	SNYAGNRTIG	NHRGWFNP TT	TSEG FVTy i Y AD	392						
TIGR4		SNYAGNRTIG	NHRGWFNP TT	TSEG FVTy i Y AD	392						
14		SNYAGNRTIG	NHRGWFNP TT	TSEG FVTy i Y AD	392						
19F		SNYAGNRTIG	NHRGWFNP TT	TSEG FVTy i Y AD	392						
Consensus		snynagnrtig	nhrgwfnptt	tsegfvtyiy ad	392						

Fig. 12

1	MIQIGKIFAG	RYRIVKQIGR	GGMADVYLAK	DLILDGEEVA	VKVLRTNYQT	DPIAVARFQR	EARAMADLDH	PHIVRITDIG	EEDGQQYLAM	90
TIGR4										
4	MIQIGKIFAG	RYRIVKQIGR	GGMADVYLAK	DLILDGEEVA	VKVLRTNYQT	DPIAVARFQR	EARAMADLDH	PHIVRITDIG	EEDGQQYLAM	
6B	MIQIGKIFAG	RYRIVKQIGR	GGMADVYLAK	DLILDGEEVA	VKVLRTNYQT	DPIAVARFQR	EARAMADLDH	PHIVRITDIG	EEDGQQYLAM	
9V	MIQIGKIFAG	RYRIVKQIGR	GGMADVYLAK	DLILDGEEVA	VKVLRTNYQT	DPIAVARFQR	EARAMADLDH	PHIVRITDIG	EEDGQQYLAM	
18C	MIQIGKIFAG	RYRIVKQIGR	GGMADVYLAK	DLILDGEEVA	VKVLRTNYQT	DPIAVARFQR	EARAMADLDH	PHIVRITDIG	EEDGQQYLAM	
R6	MIQIGKIFAG	RYRIVKQIGR	GGMADVYLAK	DLILDGEEVA	VKVLRTNYQT	DPIAVARFQR	EARAMADLDH	PHIVRITDIG	EEDGQQYLAM	
91										180
TIGR4	EYVAGLDLKR	YIKEHYPLSN	EEAVRIMGQI	LLAMRLAHTR	GIVHRDLKPQ	NILLTPDGTA	KVTDGFIATA	FAETSLTQTN	SMLGSVHYLS	
4	EYVAGLDLKR	YIKEHYPLSN	EEAVRIMGQI	LLAMRLAHTR	GIVHRDLKPQ	NILLTPDGTA	KVTDGFIATA	FAETSLTQTN	SMLGSVHYLS	
6B	EYVAGLDLKR	YIKEHYPLSN	EEAVRIMGQI	LLAMRLAHTR	GIVHRDLKPQ	NILLTPDGTA	KVTDGFIATA	FAETSLTQTN	SMLGSVHYLS	
9V	EYVAGLDLKR	YIKEHYPLSN	EEAVRIMGQI	LLAMRLAHTR	GIVHRDLKPQ	NILLTPDGTA	KVTDGFIATA	FAETSLTQTN	SMLGSVHYLS	
18C	EYVAGLDLKR	YIKEHYPLSN	EEAVRIMGQI	LLAMRLAHTR	GIVHRDLKPQ	NILLTPDGTA	KVTDGFIATA	FAETSLTQTN	SMLGSVHYLS	
R6	EYVAGLDLKR	YIKEHYPLSN	EEAVRIMGQI	LLAMRLAHTR	GIVHRDLKPQ	NILLTPDGTA	KVTDGFIATA	FAETSLTQTN	SMLGSVHYLS	
181										270
TIGR4	PEQARGSKAT	VQSDIYAMGI	IFYEMLTGHI	PYDGDSAVTI	ALQHFQKPLP	SVIAENPSVP	QALENVIKA	TAKKLTNRYR	SVSEMYVDLS	
4	PEQARGSKAT	VQSDIYAMGI	IFYEMLTGHI	PYDGDSAVTI	ALQHFQKPLP	SVIAENPSVP	QALENVIKA	TAKKLTNRYR	SVSEMYVDLS	
6B	PEQARGSKAT	VQSDIYAMGI	IFYEMLTGHI	PYDGDSAVTI	ALQHFQKPLP	SVIAENPSVP	QALENVIKA	TAKKLTNRYR	SVSEMYVDLS	
9V	PEQARGSKAT	VQSDIYAMGI	IFYEMLTGHI	PYDGDSAVTI	ALQHFQKPLP	SVIAENPSVP	QALENVIKA	TAKKLTNRYR	SVSEMYVDLS	
18C	PEQARGSKAT	VQSDIYAMGI	IFYEMLTGHI	PYDGDSAVTI	ALQHFQKPLP	SVIAENPSVP	QALENVIKA	TAKKLTNRYR	SVSEMYVDLS	
R6	PEQARGSKAT	VQSDIYAMGI	IFYEMLTGHI	PYDGDSAVTI	ALQHFQKPLP	SVIAENPSVP	QALENVIKA	TAKKLTNRYR	SVSEMYVDLS	
271										360
TIGR4	SSLSYNRRNE	SKLIFDETSK	ADTKTLPKVS	QSTLTSIPKV	QAQTEHKSIC	NPSQAVTEET	YQOQAPKKHR	FKMRYLILIA	SLVLVAASLI	
4	SSLSYNRRNE	SKLIFDETSK	ADTKTLPKVS	QSTLTSIPKV	QAQTEHKSIC	NPSQAVTEET	YQOQAPKKHR	FKMRYLILIA	SLVLVAASLI	
6B	SSLSYNRRNE	SKLIFDETSK	ADTKTLPKVS	QSTLTSIPKV	QAQTEHKSIC	NPSQAVTEET	YQOQAPKKHR	FKMRYLILIA	SLVLVAASLI	
9V	SSLSYNRRNE	SKLIFDETSK	ADTKTLPKVS	QSTLTSIPKV	QAQTEHKSIC	NPSQAVTEET	YQOQAPKKHR	FKMRYLILIA	SLVLVAASLI	
18C	SSLSYNRRNE	SKLIFDETSK	ADTKTLPKVS	QSTLTSIPKV	QAQTEHKSIC	NPSQAVTEET	YQOQAPKKHR	FKMRYLILIA	SLVLVAASLI	
R6	SSLSYNRRNE	SKLIFDETSK	ADTKTLPKVS	QSTLTSIPKV	QAQTEHKSIC	NPSQAVTEET	YQOQAPKKHR	FKMRYLILIA	SLVLVAASLI	

Fig. 13

TIGR4	450	361	WILSRTPATI	AIPDVAGQTV	AEAKATLKKA	NFEIGEEKTE	ASEKVEEGRI	IRTDPGAGTG	RKEGTKINLV	VSSGKQSFQI	SNYVGRKSSD
		4	WILSRTPATI	AIPDVAGQTV	AEAKATLKKA	NFEIGEEKTE	ASEKVEEGRI	IRTDPGAGTG	RKEGTKINLV	VSSGKQSFQI	SNYVGRKSSD
		6B	WILSRTPATI	AIPDVAGQTV	AEAKATLKKA	NFEIGEEKTE	ASEKVEEGRI	IRTDPGAGTG	RKEGTKINLV	VSSGKQSFQI	SNYVGRKSSD
		9V	WILSRTPATI	AIPDVAGQTV	AEAKATLKKA	NFEIGEEKTE	ASEKVEEGRI	IRTDPGAGTG	RKEGTKINLV	VSSGKQSFQI	SNYVGRKSSD
		18C	WILSRTPATI	AIPDVAGQTV	AEAKATLKKA	NFEIGEEKTE	ASEKVEEGRI	IRTDPGAGTG	RKEGTKINLV	VSSGKQSFQI	SNYVGRKSSD
		R6	WILSRTPATI	AIPDVAGQTV	AEAKATLKKA	NFEIGEEKTE	ASEKVEEGRI	IRTDPGAGTG	RKEGTKINLV	VSSGKQSFQI	SNYVGRKSSD
TIGR4	540	451	VIAELKEKKV	PDNLIKIEEE	ESNESEAGTV	LKQSLPEGTT	YDLSKATQIV	LTVAKKATTI	QLGNYIGRNS	TEVISELKQK	KVPENLIKIE
		4	VIAELKEKKV	PDNLIKIEEE	ESNESEAGTV	LKQSLPEGTT	YDLSKATQI-	-----	-----	-----	-----
		6B	VIAELKEKKV	PDNLIKIEEE	ESNESEAGTV	LKQSLPEGTT	YDLSKATQIV	LTVAKKATTI	QLGNYIGRNS	TEVISELKQK	KVPENLIKIE
		9V	VIAELKEKKV	PDNLIKIEEE	ESNESEAGTV	LKQSLPEGTT	YDLSKATQIV	LTVAKKATTI	QLGNYIGRNS	TEVISELKQK	KVPENLIKIE
		18C	VIAELKEKKV	PDNLIKIEEE	ESNESEAGTV	LKQSLPEGTT	YDLSKATQII	LTVAKKATTI	QLGNYIGRNS	TEVISELKQK	KVPENLIKIE
		R6	VIAELKEKKV	PDNLIKIEEE	ESNESEAGTV	LKQSLPEGTT	YDLSKATQIV	LTVAKKATTI	QLGNYIGRNS	TEVISELKQK	KVPENLIKIE
TIGR4	630	541	EEESSESEPG	TIMKQSPGAG	TTYDVSKPTQ	IVLTVAKKVT	SVAMPSYIGS	SLEFTKNNLI	QIVGIKEANI	EVVEVTTAPA	GSAEGMVVEQ
		4	-----	-----	-----	-VLTVAKKVT	SVAMPSYIGS	SLEFTKNNLI	QIVGIKEANI	EVVEVTTAPA	GSAEGMVVEQ
		6B	EEESSESEPG	TIMKQSPGAG	TTYDVSKPTQ	IVLTVAKKVT	SVAMPSYIGS	SLEFTKNNLI	QIVGIKEANI	EVVEVTTAPA	GSAEGMVVEQ
		9V	EEESSESEPG	TIMKQSPGAG	TTYDVSKPTQ	IVLTVAKKVT	SVAMPSYIGS	SLEFTKNNLI	QIVGIKEANI	EVVEVTTAPA	GSAEGMVVEQ
		18C	EEESSESEPG	TIMKQSPGAG	TTYDVSKPTQ	IVLTVAKKVT	SVAMPSYIGS	SLEFTKNNLI	QIVGIKEANI	EVVEVTTAPA	GSAEGMVVEQ
		R6	EEESSESEPG	TIMKQSPGAG	TTYDVSKPTQ	IVLTVAKKVT	SVAMPSYIGS	SLEFTKNNLI	QIVGIKEANI	EVVEVTTAPA	GSAEGMVVEQ
TIGR4	659	631	SPRAGEKVDL	NKTRVKISY	KPKTTSATP						
		4	SPRAGEKVDL	NKTRVKISY	KPKTTSATP						
		6B	SPRAGEKVDL	NKTRVKISY	KPKTTSATP						
		9V	SPRAGEKVDL	NKTRVKISY	KPKTTSATP						
		18C	SPRAGEKVDL	NKTRVKISY	KPKTTSATP						
		R6	SPRAGEKVDL	NKTRVKISY	KPKTTSATP						

Fig. 13

A	1	TIGR4	MFASKSERKV	HYSIRKFSVG	VASVVVASLV	MGSVVHATEN	EGATQVPTSS	NRANESQAEQ	GEQPKKLDSE	RDKARKEVEE	YVKKIVGESY	90
		R6	MFASKSERKV	HYSIRKFSIG	VASVAVASLV	MGSVVHATEN	EGSTQATSS	NMAKTEH---	-----	RKAAKQVVDE	YIEKMLRE--	
		4	MFASKSERKV	HYSIRKFSVG	VASVVVASLV	MGSVVHATEN	EGATQVPTSS	NRANESQAEQ	GEQPKKLDSE	RDKARKEVEE	YVKKIVGESY	
		9V	MFASKSERKV	HYSIRKFSVG	VASVAVASLV	MGSVVHATEN	ERTTQVPTSS	NRGKPER---	-----	RKAAEQF-DE	YINKM-----	
		14	MFASKSERKV	HYSIRKFSIG	VASVAVASLV	LGGVWHA-EG	VRSENTPKVT	SSGDE-----	-----	-----VDE	YIKKMLSE--	
		18C	MFASKSERKV	HYSIRKFSIG	VASVAVASLV	MGSVVHATEK	EVTTQVPTYS	NMAKTEH---	-----	RKAAKQVVDE	YIEKMLRE--	
		19F	MFASKSERKV	HYSIRKFSIG	VASVAVASLV	LGGVWHA-EG	VRSENTPKVT	SSGDE-----	-----	-----VDE	YIKKMLSE--	
		23F	MFASKSERKV	HYSIRKFSIG	VASVAVASLV	MGSVVHATEK	EVTTQVATSS	NKANKSQ---	-----TE	HMKAAKQVDE	YIKKKL----	
		Consensus	MFASKSERKV	HYSIRKFSIG	VASVAVASLV	\$gsVVHate.	e..t#vptss	n.a.e.....	r..a...v#E	Y!kKml.e...	
												180
	91	TIGR4	AKSTKKRHTI	TVALVNLNN	IKNEYLNKI-	VESTSESQIQ	ILMMESRSKV	DEAVSKFEKD	SSSSSSSDSS	TKPEASDTAK	PNKPTEPGEK	
		R6	IQLDRRKHTQ	NVALNIKLSA	IKTKYLREL-	-NVLEEKSKD	ELPSEIKAKL	DAAFKFKKD	T-----	-----	-----LKPGEK	
		4	AKSTKKRHTI	TVALVNLNN	IKNEYLNKI-	VESTSESQIQ	ILMMESRSKV	DEAVSKFEKD	SPSSSSSDSS	TKPE		
		9V	IQLDRRKHTQ	NLAFNIQLSR	IKTEYLNGL-	---KEKSEA	ELPSKIKAE	DAAFKQFKD	TLPTPE---	-----	-KKVAEAEKK	
		14	IQLDRRKHTH	NFALNLKLSR	IKTEYLYKLK	VNVLEEKSKA	ELTSKTKKEV	DAAFKFKKD	T-----	-----	-----LKLGEK	
		18C	IQLDRRKHTQ	NFAFNMKLSA	IKTEYLYGL-	---KEKSEA	ELPSS-EAEL	PSEVKA-KLD	AAFEQFK---	-----	-KDTLKLGEK	
		19F	IQLDRRKHTH	NFALNLKLSR	IKTEYLYKLK	VNVLEEKSKA	ELTSKTKKEV	DAAFKFKKD	T-----	-----	-----LKLGEK	
		23F	-QLDRRKHTQ	NVGLLTKLGV	IKTEYLHGL-	-SVSKKKSEA	ELPSEIKAKL	DAAFKQFKKD	TLP-----	-----	-----TEPGKK	
		Consensus	iqldrkrkht.	n.aln.kls.	IKTEYL.kl.	v....eks.a	eL.s..k.ev	daaf.kfkkd	t.....gek	
												270
	181	TIGR4	VAEAKKKVEE	AEKKAQDQKE	EDRRNYPTIT	YKTLELEIAE	SDVEVKKAEL	ELVKVKANEP	RDEQIKQAE	AEVESKQAEA	TRLKKIKTDR	
		R6	VAEAKKKVEE	AKKKAEDQKE	EDRRNYPTNT	YKTLELEIAE	FDVKVKEAEL	ELVKEEAKES	RNEGTIKQAK	EKVESKKAEE	TRLENIKTDR	
		9V	VEEAEKKVAE	AKKKAQAKQE	EDHRNYPTIT	YKTLDLEIAE	FDVKVKEAEL	ELVKKEADES	RNEGTTINQAK	AKVESEKAE	TRLKKIKTDR	
		14	VAEAKKKVEE	AKKKAQDQKE	EDHRNYPTIT	YKTLELEIAE	SDVKVKEAEL	ELLKEEA-KT	RNEDTTINQAK	AKVKSEQAEA	TRLKKIKTDR	
		18C	VAEAKKKVAE	AEKKAQAKQE	EDRRNYPTIT	YKTLDLEIAE	SDVEVKKAEL	ELLKEEA-KT	RNKDTIKQAK	AKVESKKAEE	TKLEETIKTDR	
		19F	VAEAKKKVEE	AKKKAQDQKE	EDHRNYPTNT	YKTLELEIAE	SDVKVKEAEL	ELLKEEA-KT	RNEDTTINQAK	AKVKSEQAEA	TRLKKIKTDR	
		23F	VAEAKKKVEE	AKKKAEDQKE	KDLRNYPTNT	YKTLELDIAE	SDVEVKKAEL	ELVKGSYRNL	ETRKLIKQS	EKLRIKQLML	Q	
		Consensus	vaea.kkvee	akkkakdqke	ed.rnypt.t	yktleleiae	sdv.vk.ael	el.k.ea...	rne.tl.qak	akv.s..aea	trl..ikttr	
												360
	271	TIGR4	EEAEEE-AKR	RADAK-----	----EQGPKP	GRAKRGVPGE	LATPDKKEND	AKSSDSSVGE	ETLPSPSLKP	EKKVAEAEKK	VEEAKKKAED	
		R6	KAEEEE-AKR	KADAKLKEAN	VATSDQGPKE	GRAKRGVPGE	LATPDKKEND	AKSSDSSVGE	ETLPSSSLKS	GKKVAEAEKK	VEEAEKKAKD	
		9V	EKAEEEEAKR	RADAKKEQDES								
		14	EQAEAT									
		18C	KAEEEE									
		19F	EQAEATRIEN	IKTDREK---	---AEEAKRK	AE						
		Consensus	..ae.....	

Fig. 14

B

TIGR4 R6 4 6B 9V 14 18C 19F 23F Consensus	361	QKEEDRRNYP	TNTYKTTLELE	IAESDVEVK	AELELVKEEA	KEPRNEEKVK	QAKAEVESKK	AEATRLEKIK	TDRKKAEEEA	450	KRKAEEEDKV
		QKEEDRRNYP	TNTYKTTLDLE	IAESDVKVKE	AELELVKEEA	KEPRDEEEKIK	QAKAKVESKK	AEATRLENIK	TDRKKAEEEA		KRKAEEEDKV
				AEEDVEVK	AELELVKEEA	KEPRNEEKVK	QAKAEVESKK	AEATRLEKIK	TDRKKAEEEA		KRKAEEEDKV
			LK	LLSPMWKLKK	RSLTS-KEEA	KKPLNEGTVR	QAKAEVESKK	AEATRLEKIK	TDRKKAEEEA		KRKAEEEDKV
				IAESDVKVKE	AELELVKEEA	KEPRNEEKIK	QAKAKVESKK	AEATRLEKIK	TDRKKAEEEA		KRKAEEEDKV
				IAESDVKVKE	AELELVKEEA	KEPRDEEEKIK	QAKAEVESKK	AEATRLEKIK	TDRKKAEEEA		KRKAEEEDKV
				IAESDVKVKE	AELELVKEEA	KEPRNEEKVK	QAKAKVESKK	AEATRLEKIK	TDRKKAEEEA		KRKAEEEDKV
			LE	IAESDVKVKE	AELELVKEEA	KEPRNEEKVK	QAKAKVESKK	AEATRLEKIK	TDRKKAEEEA		KRKAEEEDKV
				iaesdvkve	aelelvkeea	keprneek.k	qaka.veskk	aeatrlekik	tdrkaeeea		krkaeeedkv
TIGR4 R6 4 6B 9V 14 18C 19F 23F Consensus	451	KEKPAEQPQP	APAPKAEEKPA	-----PAP	KPENPAEQPK	AEKPA-----	-----	---DQQAED	YARRSEEEYN	540	RLTQQQPPKT
		KEKPAEQPQP	APATQPEKPA	-----P--	KPEKPAEQPK	AEKTD-----	-----	---DQQAED	YARRSEEEYN		RLTQQQPPKT
		KEKPAEQPQP	APAPKAEEKP-	-----APAP	KPENPAEQPK	AEKPA-----	-----	---DQQAED	YARRSEEEYN		RLTQQQPPKT
		KEKPAEQPQP	APAPQPEKPT	EEPENVPAP	KPEKPAEQPK	PEKPAEQPKP	EKPAEQPKAE	KTDDQQAED	YARRSEEEYN		RLTQQQPPKP
		KEKPAEQPQP	APAPKPENPA	EEPENVPAP	KPENPAEQPK	AEKPA-----	-----	---DQQAED	YARRSEEEYN		RLTQQQPPKP
		KEKPAEQPQP	APAPQPEKPT	PKPEKPAPAP	KPENPAEQPK	AEKPA-----	-----	---DQQAED	YARRSEEEYN		RLTQQQPPKT
		KEKPAEQPQP	APAPQPEKPT	EEPENPAPAP	KPEKPAEQPK	AEKPA-----	-----	---DQQAED	YARRSEEEYN		RLTQQQPPKT
		KEKPAEQPQP	APAPQPEKPT	-----APAP	KPENPAEQPK	AEKPA-----	-----	---DQQAED	YARRSEEEYN		RLTQQQPPKT
								VQNGMW	YFYNTDGSMA		TGWLQNNNGSW
			pap	kpenpaepkp	aeqpa.....dqQaeed	Yarrs#eeyn		rltqQ#ppkt
TIGR4 R6 4 6B 9V 14 18C 19F 23F Consensus	541	EKPAQPSPPK	TGWKQENGMMW	YFYNTDGSMA	TGWLQNNNGSW	YYLNSNGAMA	TGWLQNNNGSW	YYLNANGSMA	TGWLQNNNGSW	630	YYLNANGSMA
		EKPAQPSPPK	TGWKQENGMMW	YFYNTDGSMA	TGWLQNNNGSW	YYLNANGAMA	TGWLQNNNGSW	YYLNANGSMA	TGWLQNNNGSW		YYLNANGAMA
		EKPAQPSPPK	TGWKQENGMMW	YFYNTDGSMA	TGWLQNNNGSW	YYLNSNGAMA	TGWLQNNNGSW	YYLNANGSMA	TGWLQNNNGSW		YYLNANGSMA
		EQPAP--APK	IGWKQENGMMW	YFYNTDGSMA	TGWLQ-----	-----	-----	-----	-----		-----
		EQPAP--APK	IGWKQENGMMW	YFYNTDGSMA	TGWLQNNNGSW	YYLNSNGAMA	TGWLQNNNGSW	YYLNANGSMA	TGWLQNNNGSW		YYLNANGDMA
		EKPAQPSPPK	TGWKQENGMMW	YFYNTDGSMA	TGWLQYNGSW	YYLNANGDMA	TGWLQNNNGSW	YYLNANGDMA	TGWLQNNNGSW		YYLNANG---
		EKPAQPSPPK	TGWKQENGMMW	YFYNTDGSMA	TGWLQNNNGSW	YYLNSNGAMA	TGWLQYNGSW	YYLNANGDMA	TGWLQNNNGSW		YYLNANGDMA
		EKPAQPSPPK	TGWKQENGMMW	YFYNTDGSMA	TGWLQYNGSW	YYLNANGDMA	TGWLQNNNGSW	YYLNANGDMA	TGWLQNNNGSW		YYLNANG---
		YYLNSNGAMA	TGWLQNNNGSW	YYLNSNGAMA	TGWLQYNGSW	YYLNANGDMA	TGWLQYNGSW	YYLNANGDMA	TGWLQYNGSW		YYLNANGDMA
		ekpaqpstpk	tgwkQ#NgmW	Y%yNt#GsmA	TGWLQ.ngsw	yyln.ng.ma	tgwlqnnngsw	yylnang.ma	tgwlqnnngsw		yylnang.ma

Fig. 14

[illegible]

Fig. 14

SEQUENCE LISTING

SeqID 1

atgtctaaaa	atattgtaca	attgaataat	tctttttattc	aaaatgaata	ccaacgtcgt	60
cgctacctga	tgaaagaacg	acaaaaacgg	aatcgtttta	tgggaggggt	attgattttg	120
attatgctat	tatttatctt	gccaaactttt	aatttagcgc	agagttatca	gcaattactc	180
caaagacgtc	agcaattagc	agacttgcaa	actcagtatc	aaactttgag	tgatgaaaaa	240
gataaggaga	cagcattttg	taccaagttg	aaagatgaag	attatgctgc	taaatataca	300
cgagcggaag	actattattc	taagtcgagg	gaaaaagttt	atacgattcc	tgacttgctt	360
caaagg						366

SeqID 2

atggataaga	aaaaattatt	attgattgat	gggtcttctg	tagcttttcg	ggcgtttttt	60
gcgctgtatc	agcagttgga	ccgttttaag	aatgtggctg	gtttgcatac	caatgcgatt	120
tatggttttc	agttgatgtt	gagtcattta	ttggagcggg	ttgagccgag	tcataatttg	180
gtggcctttg	atgctggaaa	gacgaccttc	cggacagaga	tgtatgcgga	ctataagggg	240
ggctggggcca	agactcctga	tgagtttcgt	gagcaatttc	ctttcattcg	tgagttgctg	300
gatcatatgg	ggattcgtca	ctatgatctg	gctcagtatg	aggcggatga	catcattggg	360
acgctggata	agctagcaga	gcaggatggg	tttgatatta	ctattgtcag	tggggacaag	420
gatttgattc	agctgacgga	tgagcatacg	gtggttgaaa	tttccaagaa	aggtgtggct	480
gagtttgagg	ccctttacgcc	agattacctc	atgggaagaa	tgggcctcac	accagctcag	540
tttatcgaac	tcaaggcgct	catgggtgat	aagtcggata	atatccctgg	ggtgaccaa	600
gtcgggtgaaa	agacgggtat	taagctcttg	ctggagcatg	gttcgcttga	ggggatttat	660
gaaaatattg	atggaatgaa	gacttctaag	atgaaggaaa	atctcatcaa	tgacaaggaa	720
caggcctttt	tgtctaaaac	actagcgacc	attgatacca	aggcaccgat	tgcgattggg	780
ttagaggact	ttgtctatag	tggtccagat	gttgaaaatc	ttgggaaatt	ctacgatgag	840
atgggcttca	aacagctaaa	gcaggcttta	aatgtgtcgt	cagctgatgt	gtctgagagt	900
ttggatttta	ctattgttga	ccaaatcagt	caagatatgc	tgagtgaaga	gtctatcttc	960
cacttttgagc	tttttggtga	gaattaccat	acggataaatt	tggttggtat	tgtctgggtc	1020
tgtggggata	agctctatgc	cacagacaag	cttgagctgt	tgcaagacct	gattttcaag	1080
gatttcttag	aaaaaacatc	tctgagagtt	tatgacttta	agaaggttaa	agttcttttg	1140
caacgctttg	gtgtggattt	gcaggcgctt	gcttttgaca	tccgtttggc	taaatacctc	1200
ctttcgactg	tggaggacaa	tgaaattgag	accatcgcta	gtctttatgg	tcagacttac	1260
ttgggtgatg	atgaaacttt	ctacggtaag	ggtgttataa	aggccattcc	tgaaactgag	1320
aaattcttgg	aacacttagc	ttgtaaactt	gctgttttgg	tagaaacaga	gcctatttta	1380
cttgaaaaac	tcagcgaaaa	tgggcaatta	gagcttcttt	atgatatgga	gcaacctctg	1440
gcttttgtcc	tgccaagat	ggaattatgg	ggtgattatg	tcaagaaaga	gaccttgctt	1500
gagatgcagg	ctgaaaatga	gcttgtcatt	gaaaaactga	ctcaagagat	ttacgagctg	1560
gctgggtgagg	agtttaaatg	caactcgctt	aagcagttgg	gcgtgcttct	ctttgagaaa	1620
ttgggacttc	ctctagaata	cactaagaaa	accaagacag	gttattcgac	agcagtggtg	1680
gttttagagc	gtctcgctcc	tattgtctcg	attgttaaga	aaatcctgga	ttaccgtcaa	1740
attgctaaga	ttcaatctac	ttatgtaatt	ggcttgacag	actggatttt	ggctgatgga	1800
aagattcata	ctcgctatgt	gcaggatttg	accagaccg	ggcgtttgtc	tagtgtggat	1860
ccaaacttgc	aaaatattcc	tgcccgattg	gaacaggggc	gcttgattcg	gaaggctttt	1920
gtgccagagt	gggaggatag	tgtgctactc	agctctgact	attcacagat	tgaattgcgc	1980
gttttgccgc	atatttctaa	ggatgagcac	ttgatgaagg	ccttccaaga	gggggcagat	2040
atccataact	cgacagccat	gcggttcttt	ggcattgagc	gtcctgatga	tgtagctgca	2100
aacgacgctc	gcaatgccaa	ggcagttaac	tttgagtggt	tttatgggat	ttcagacttt	2160
ggcttgtcta	ataatttggg	aattagtctg	aagggaagcca	aagcctacat	tgataacctac	2220
tttgaacgtt	ttccaggtat	taaaaactac	atggatgaag	tgggtgcggga	ggcgctgat	2280
aagggtctatg	tagagaccct	ctttaagcgt	cgccgtgagt	tgccagatat	caattcgccg	2340
aacttcaata	ttcgtgggtt	tgccgagcga	actgctatca	actcacctat	ccagggttcg	2400
gcagcagata	ttctcaagat	tgccatgatt	cagctggata	aagccttggg	tgcaagtggt	2460
tatcagacta	agatgctgtt	acaagtgcac	gatgaaatcg	tccttgaaag	gcctaaatct	2520
gaattggtag	agatgaaaaa	attggtgaaa	caaaccatgg	aagaagccat	tcaactcagt	2580
gttctcttta	tcgcagatga	gaatgaaggg	gcaacctggt	acgaggctaa	a	2631

SeqID 3

atggggtagg	cagcttttta	aaatcctaac	aatcaataca	aagctattac	aattgctcaa	60
actctagggtg	atgatgcttc	ttcagaggaa	ttggctggta	gatatgggtc	tgctgttcag	120
tgtacagaag	tgactgcctc	aaacctttca	acagttaaaa	ctaaagctac	ggttgtagaa	180
aaaccactga	aagatttttag	agcgtctacg	tctgatcagt	ctgggtgggt	ggaatcta	240
ggtaaatggg	atttctatga	gtctgggtgat	gtgaagacag	gttgggtgaa	aacagatggg	300
aaatgggtact	atttgaatga	cttaggtgtc	atgcagactg	gatttgtaaa	attttctggg	360
agctgggtatt	acttgagcaa	ttcaggtgct	atgtttacag	gctggggaa	agatggtagc	420
agatgggttct	actttgacgg	ctcaggagct	atgaagacag	gctgggtacaa	ggaaaaatgg	480
acttgggtatt	accttgacga	agcaggtatc	atgaagacag	gttgggttaa	agtcggacca	540
cactgggtact	atgcctacgg	ttcaggagct	ttggctgtga	gcacaacaac	accagatggg	600

CONFIRMATION COPY

taccgtgtaa atggtaatgg tgaatgggta aac

633

SeqID 4

atgagccgaa	aaagcattgg	tgagaaacgc	catagtttct	cgatgagaaa	gttgtcagtg	60
ggattgggtat	cagttactgt	atctagtttc	ttttttagta	gtcaagggat	tcaatcggta	120
tcggccgata	atatggaaag	tccaattcat	tataagtata	tgaccgaggg	taaattgaca	180
gacgaggaaa	aatccttgct	ggtagaggcc	cttcacacac	tggtgaaga	atcagatgat	240
acttattact	tggtttatag	atctcaacag	tttttaccga	atacaggttt	taacccaact	300
gttgggtactt	tcctttttac	tgaggagattg	agcttggttag	ttttattggg	ttctaaaagg	360
gaaaatggaa	agaaacgact	tggtcatttt	ctgctgttga	ctagcatggg	agttcaattg	420
ttgccggcca	gtgcttttgg	gttgaccagc	cagattttat	ctgcctataa	tagtcagctt	480
tctatcggag	tcggggaaca	tttaccagag	cctctgaaaa	tcgaagggtta	tcaatatatt	540
ggttatatca	aaactaagaa	acaggataat	acagagcttt	caaggacagt	tgatgggaaa	600
tactctgctc	aaagagatag	tcaaccaaac	tctacaaaaa	catcagatgt	agttcattca	660
gctgatttag	aatggaacca	aggacagggg	aagggttagtt	tacaagggtga	agcatcaggg	720
gatgtagggc	tttcagaaaa	atcttctata	gcagcagaca	atctatcttc	taatgattca	780
ttcgcaagtc	aagttgagca	gaatccggat	cacaaaggag	aatctgtagt	tcgaccaaca	840
gtgccagAAC	aaggaaatcc	tgtgtctgct	acaacgggtc	agagtgcgga	agaggaagta	900
ttggcgacga	caaatgatcg	accagagtat	aaacttccat	tggaaccaa	aggcacgcaa	960
gaacccggtc	atgagggtga	agccgcagtc	cgtgaagact	taccagtcta	cactaagcca	1020
ctagaaacca	aagggtacaca	aggacccgga	catgaagggtg	aagctgcagt	tcgcgaggaa	1080
gaaccagctt	acacagaacc	gtagcaacg	aaaggcacgc	aagagccagg	tcagaggggc	1140
aaagctacag	tcgcggaaga	gactctagag	tacacggaac	cggtagcgac	aaaaggcaca	1200
caagaacccg	aacatgaggg	cgaagcggca	gtagaagaag	aacttccggc	tttagaggtc	1260
actacacgaa	atagaacgga	aatccagaat	attccttata	caacagaaga	aattcaggat	1320
ccaacacttc	tgaaaaatcg	tcgtaagatt	gaacgacaag	ggcaagcagg	gacacgtaca	1380
attcaatatg	aagactacat	cgtaaatggg	aatgtcgtag	aaactaaaga	agtgtcacga	1440
actgaagtag	ctccggtcaa	cgaagtcggt	aaagtaggaa	cacttgtgaa	agttaaacct	1500
acagtagaaa	ttacaaactt	aacaaaagtt	gagaacaaaa	aatctataac	tgtaagttat	1560
aacttaatag	acactacctc	agcatatggt	tctgcaaaaa	cgcaagtttt	ccatggagac	1620
aagctagtta	aagaggtgga	tatagaaaat	cctgccaaag	agcaagtaat	atcaggttta	1680
gattactaca	caccgtatac	agttaaaaca	cacctaaactt	ataatttggg	tgaaaataat	1740
gaggaaaata	ctgaaaacatc	aactcaagat	ttccaattag	agtataagaa	aatagagatt	1800
aaagatatgg	attcagtaga	attatacggg	aaagaaaaatg	atcggttatcg	tagatatatta	1860
agtctaagtg	aagcgcggac	tgatacggct	aaatactttg	taaaagtga	atcagatcgc	1920
ttcaaagaaa	tgtacctacc	tgtaaaatct	attacagaaa	atacggatgg	aacgtataaa	1980
gtgacggtag	ccgttgatca	acttgtcgaa	gaaggtacag	acggttacaa	agatgattac	2040
acatttactg	tagctaaatc	taaagcagag	caaccaggag	tttacacatc	ctttaaacag	2100
ctggtaacag	ccatgcgaag	caatctgtct	ggtgtctata	cattggcttc	agatatgacc	2160
gcagatgagg	tgagcttagg	cgataagcag	acaagttatc	tcacaggtgc	atttacaggg	2220
agcttgatcg	gttctgatgg	aacaaaatcg	tatgccattt	atgatttgaa	gaaaccatta	2280
tttgatacat	taaatgggtgc	tacagttaga	gatttggata	ttaaaactgt	ttctgctgat	2340
agtaaaagaaa	atgtcgcagc	gctggcgaa	gcagcgaata	gcgcgaatat	taataatggt	2400
gcagtgaag	gaaaaatctc	aggtgcgaaa	tctgttcg	gatttagtagc	gagcgcaaca	2460
aatacagtga	tagaaaacag	ctcggtttaca	gggaaactta	tcgcaaatca	ccaggacagt	2520
aataaaaaatg	atactggagg	aatagtaggt	aatataacag	gaaatagttc	gagagttaat	2580
aaagttaggg	tagatgcctt	aatctctact	aatgcacgca	ataataacca	aacagctgga	2640
gggatagtag	gtagattaga	aatgggtgca	ttgatatacta	attcgggttc	tactggagaa	2700
atacgaatg	gtcaaggata	ttctagagtc	ggaggaatag	taggatctac	gtggcaaac	2760
ggtcgagtaa	ataatggtgt	gagtaacgta	gatgttgag	atggttatgt	tatcacgggt	2820
gatcaatac	cagcagcaga	tgtgaaaaat	gcaagtacat	cagttgataa	tagaaaaagca	2880
gacagattcg	ctacaaaatt	atcaaaagac	caaataagac	cgaaggttgc	tgattatgga	2940
atcacagtaa	ctcttgatga	tactgggcaa	gattttaa	gtaatctaag	agaagttgat	3000
tatacaagac	taaataaagc	agaagctgaa	agaaaagtag	cttatagcaa	catagaaaaa	3060
ctgatgccat	tctacaataa	agacctagta	gttactatg	gtaacaaagt	agcgacaaca	3120
gataaaacttt	acactacaga	attgttagat	gttgtgccga	tgaaagatga	tgaagttagta	3180
acggatatta	ataataagaa	aaattcaata	aataaagtta	tgttacattt	caaagataat	3240
acagtagaat	acctagatgt	aacattcaaa	gaaaacttca	taaacagtc	agtaatcgaa	3300
tacaatggtta	caggaaaaga	atatatatct	acaccagaag	catttgtttc	agactataca	3360
gcgataacga	ataacgtact	aagcgacttg	caaaatgtaa	cacttaactc	agaagctact	3420
aaaaaagtag	taggagcagc	gaatgatgca	cgttagata	acctatactt	agatagacaa	3480
tttgaaagaa	ttaaagctaa	tatagcagaa	cacctaaagaa	aagtattagc	gatggataaa	3540
tcaatcaata	ctacaggaga	cgggtgtagt	gaatacgtaa	gtgagaaaat	caaaaataac	3600
aaagaagcat	ttatgctagg	tcttacttat	atgaaccgtt	ggtacgatat	taattatggt	3660
aaaatgaata	caaaagattt	atctacgtac	aagtttgact	ttaacggaaa	taatgagact	3720
tcaacgttgg	atactattgt	cgcattagga	aatagtggac	tagataacct	gagagcttca	3780
aatactgtag	gttttatatgc	gaataaactt	gcacggttaa	aaggagaaga	ttcagttctt	3840
gacttcgtag	aagcgtatag	aaaactgttc	ttaccaaaaca	aaacaaataa	cgagtgggtt	3900

aaagaaaata	caaaggcata	tatagtcgaa	atgaagtctg	atattgcaga	agtacgagaa	3960
aaacaagaat	caccaacagc	cgatagaaaa	tattcattag	gagtttacga	tagaatatca	4020
gcaccaagtt	gggggcataa	gagtatgtta	ttaccactac	taactttacc	tgaagaatct	4080
gtgtatattt	catcgaatat	gtctacactt	gcattcgggt	cgtatgaaa	atatcgtgat	4140
agtgtggatg	gagttattct	ttcaggagat	gctttacgaa	cttatgtaa	aaatagagtt	4200
gatatagcag	cgaagaggca	tagagaccat	tatgatattt	ggtacaatct	tcttgacagt	4260
gcttcaaaag	aaaaactttt	ccgttctgtg	atagtttatg	atggattcaa	tgtaaaagat	4320
gagacaggaa	gaacttattg	ggcaagggtt	acggataaaa	acatcggctc	tattaaagaa	4380
ttcttcggac	ctgttgaggaa	atgggtatgag	tataatagta	gtgcaggagc	gtatgcgaat	4440
ggaagtttaa	cgcactttgt	gttagataga	ttattagatg	cttatggaa	gtcggtttat	4500
actcatgaaa	tggttcataa	ttctgattct	gcaatctact	ttgaaggaaa	tggtagacgt	4560
gaaggattgg	gagcggagtt	atacgcactt	ggtttactgc	aatctgtaga	tagtgtaaat	4620
tctcatattt	tagctttaaa	tacgtttatat	aaagcagaaa	aagatgattt	gaatagattg	4680
catacatata	atccgggtgga	acgtttcgat	tcggatgagg	cgcttcaaa	ttatatgcat	4740
ggatcatatg	atgtaatgta	tacacttgat	gcgatggaag	caaaagcgat	attagctcaa	4800
aataatgatg	ttaagaaaaa	atggtttaga	aaaatagaaa	attattacgt	tcgtgatact	4860
agacataata	aagatacaca	tgaggaaaat	aaagtcgctc	cattaacaga	tgaagaagta	4920
gctaacttaa	catcgttaaa	ctcatatc	gacaacgaca	tcataaatag	acgtagctat	4980
gatgatagta	gagaatataa	acgaaatggc	tactatacta	taagtatgtt	ctctcctgta	5040
tacgcagcgc	taagcaattc	gaaaggtgct	cctggagata	ttatgtttag	aaaaatagct	5100
tatgaattac	ttgcggaaaa	aggttatcac	aaaggattcc	taccttatgt	ttctaatacag	5160
tacggagcag	aagcatttgc	cagcgggaagc	aaaacattct	catcatggca	tggaagagat	5220
gttgctttag	tgacagatga	tttagtattt	aagaaagtat	tcaatggtga	gtactcatca	5280
tgggctgatt	tcaaaaaagc	aatgttttaa	caacgtatag	ataaacaaga	taactctgaa	5340
ccaataacaa	ttcaatacga	attaggtaat	cctaatagta	caaaagaagt	aactataaca	5400
acggctgcac	aaatgcaaca	attaattaat	gaagcggctg	cgaagatat	tactaatata	5460
gatcgtgcaa	cgagtcatac	cccagcaagt	tggtgctcatt	tattaaaaa	aaaaatctat	5520
aatgcatatc	ttcgactac	agatgacttt	agaaattcta	tatataaa		5568

SeqID 5

atgaaattca	atccaaatca	aagatatact	cggttggtcta	ttcgccgtct	cagtgctcgg	60
gttgccctcag	ttgttggtggc	tagtggcttc	tttgtcctag	ttggtcagcc	aagttctgta	120
cgtgccgatg	ggctcaatcc	aaccaccagg	caagtcctac	ctgaagagac	atcgggaacg	180
aaagagggtg	acttatcaga	aaaaccagga	gacaccgttc	tactcaagc	gaaacctgag	240
ggcggttactg	gaaatacgaa	ttcacttcgg	acacctacag	aaagaactga	agtgcgcgag	300
gaaacaagcc	ctcttagtct	ggatacactt	tttgaataag	atgaagaagc	tcaaaaaaat	360
ccagagctaa	cagatgtctt	aaaagaaact	gtagatacag	ctgatgtgga	tggaacacaa	420
gcaagtccag	cagaaactac	tcctgaacaa	gtaaaagggtg	gagtgaaga	aaatacaaaa	480
gacagcatcg	atgttctctg	tgcttatctt	gaaaaagctg	aagggaagg	tcctttcact	540
gccggtgtaa	accaagtaat	tccttatgaa	ctattcgtcg	gtgatggat	gttaactcgt	600
ctattactaa	aagcttcgga	taatgctcct	tggtctgaca	atggtactgc	taaaaatcct	660
gctttacctc	ctcttgagg	attaacaaaa	gggaataact	tctatgaagt	agacttaaat	720
ggcaatactg	ttggtaaaca	aggtcaagct	ttaattgatc	aacttcgcgc	taatggtact	780
caaaacttata	aagctactgt	taaagtttac	ggaaataaag	acggtaaagc	tgacttgact	840
aatctagttg	ctactaaaaa	tgtagacatc	aacatcaatg	gattagttgc	taaagaaaca	900
gttcaaaaag	cggttgcaga	caacgtttaa	gacagtatcg	atgttccagc	agcctacctt	960
gaaaaagcca	aggttgagg	tccattcaca	gcagggtgca	accatgtgat	tccatacga	1020
ctcttcgcag	gtgatggcat	gttgactcgt	ctcttgctca	aggcatctga	caaggcacca	1080
tggtcagata	acggcgacgc	taaaaaccca	gccttatctc	cactaggcga	aaacgtgaag	1140
accaaaggtc	aatacttcta	tcaagtagcc	ttggacggaa	atgtagctgg	caaagaaaaa	1200
caagcgctca	ttgaccagtt	ccgagcaaat	ggtactcaaa	cttacagcgc	tacagtcaat	1260
gtctatggtt	acaaagacgg	taaaccagac	ttggacaaca	tcgtagcaac	taaaaaagtc	1320
actattaaca	taaacggttt	aatttctaaa	gaaacagttc	aaaaagccgt	tgacagacaac	1380
gttaaagaca	gtatcgatgt	tccagcagcc	tacctagaaa	aagccaagg	tgaaggcca	1440
ttcacagcag	gtgtcaacca	tgtgattcca	tacgaactct	tcgcagggtga	tggtatgttg	1500
actcgtctct	tgctcaaggc	atctgacaag	gcaccatggt	cagataacgg	tgacgctaaa	1560
aaccagccc	tatctccact	aggtgaaaac	gtgaagacca	aaggtcaata	cttctatcaa	1620
ttagccttgg	acggaaatgt	agctggcaaa	gaaaaacaa	cgctcattga	ccagttccga	1680
gcaaacggta	ctcaaaactt	cagcgctaca	gtcaatgtct	atggttaaca	agacggtaaa	1740
ccagacttgg	acaacatcgt	agcaactaaa	aaagtcacta	ttaacataaa	cggtttaatt	1800
tctaaagaaa	cagttcaaaa	agccgttgca	gacaacgtta	aggacagtat	cgatgttcca	1860
gcagccctacc	tagaaaaagg	caagggtgaa	ggtccattca	cagcagggtg	caaccatgtg	1920
attccatagc	aactcttcgc	aggtgatggc	atgttgactc	gtctcttgct	caaggcatct	1980
gacaaggcac	catggtcaga	taacggcgac	gctaaaaacc	cagctctatc	tccactaggt	2040
gaaaacgtga	agaccaaagg	tcaatacttc	tatcaagtag	ccttgagcgg	aaatgtagct	2100
ggcaaaagaaa	aacaagcgct	cattgaccag	ttccgagcaa	acggtactca	aacttacagc	2160
gctacagtca	atgtctatgg	taacaaagac	ggtaaaccag	acttgacaaa	catcgtagca	2220
actaaaaaag	tcactattaa	gataaatgtt	aaagaaacat	cagacacagc	aaatggttca	2280

ttatcacctt	ctaactctgg	ttctggcggtg	actccgatga	atcacacatca	tgtacaggt	2340
actacagata	gcatgcctgc	tgacaccatg	acaagttcta	ccaacacgat	ggcaggtgaa	2400
aacatggctg	cttctgctaa	caagatgtct	gatacgatga	tgtcagagga	taaagctatg	2460
ctaccaata	ctggtgagac	tcaaacatca	atggcaagta	ttggtttcct	tgggcttgcg	2520
cttgacaggtt	tactcggtgg	tctaggtttg	aaaaacaaaa	aagaagaaaa	c	2571

SeqID 6

atgaaatcaa	taactaaaaa	gattaaagca	actcttgacg	gagtagctgc	cttggtttgca	60
gtattttgtc	catcatttgt	atctgctcaa	gaatcatcaa	cttactactgt	taaagaaggt	120
gatacacttt	cagaatctgc	tgaaactcac	aacacacacg	ttgaaaaatt	ggcagaaaaac	180
aaccacattg	ataacattca	tttgatttat	gttgatcaag	agttggttat	cgatggcctt	240
gtagcgctcg	ttgcaacacc	agcgccagct	acttatgcgg	caccagccgc	tcaagatgaa	300
actgtttcag	ctccagtagc	agaaactcca	gtagtaagtg	aaacagttgt	ttcaactgta	360
agcggtatctg	aagcagaagc	caaagaatgg	atcgctcaaa	aagaatcagg	tggtagctat	420
acagctacaa	atggacgtta	tatcggtacg	taccaattaa	cagattcata	cctgaacggt	480
gactactcag	ctgaaaacca	agaacgtgta	gcagatgcct	acgttgacgg	acgttacggt	540
tcatggactg	ctgctaaaaa	cttctggctt	aacaatggct	ggtat		585

SeqID 7

atgaataaga	aaaaaatgat	tttaacaagt	ctagccagcg	tcgctatctt	aggggctggt	60
tttgttacgt	ctcagcctac	ttttgtaaga	gcagaagaat	ctccacaagt	tgtcgaaaaa	120
tcttcattag	agaagaata	tgaggaagca	aaagcaaaag	ctgatactgc	caagaaagat	180
tacgaaacgg	ctaaaaagaa	agcagaagac	gctcagaaaa	agtatgaaga	tgatcagaag	240
agaactgagg	agaaagctcg	aaaagaagca	gaagcatctc	aaaaattgaa	tgatgtggcg	300
cttggtgttc	aaaaatgcata	taaagagtac	cgagaagttc	aaaatcaacg	tagtaaatat	360
aaatctgacg	ctgaatatca	gaaaaaatta	acagaggtcg	actctaaaat	agagaaggct	420
aggaaagagc	aacaggactt	gcaaaaataa	tttaatgaag	taagagcagt	tgtagtccct	480
gaaccaatg	cgttggctga	gactaagaaa	aaagcagaag	aagctaaagc	agaagaaaaa	540
gtactgaaga	gaaaatatga	ttatgcaact	ctaaaggtag	cactagcgaa	gaaagaagta	600
gaggctaagg	aacttgaaat	tgaaaaactt	caatatgaaa	tttctacttt	ggaacaagaa	660
gttgctactg	ctcaacatca	agtagataat	ttgaaaaaac	ttcttgctgg	tgcggtacct	720
gatgatggca	cagaagttat	agaagctaaa	ttaaaaaaag	gagaagctga	gctaaacgct	780
aaacaagctg	agttagcaaa	aaaacaaaca	gaacttgaaa	aacttcttga	cagccttgat	840
cctgaaggtg	agactcagga	tgaattagat	aaagaagcag	aagaagctga	gttggaataa	900
aaagctgatg	aacttcaaaa	taaagttgct	gttttagaaa	aagaaattag	taaccttgaa	960
atattacttg	gaggggctga	tcctgaagat	gatactgctg	ctcttcaaaa	taaattagct	1020
gctaaaaaag	ctgagttagc	aaaaaaacaa	acagaacttg	aaaaacttct	tgacagcctt	1080
gatcctgaag	gtaagactca	ggatgaatta	gataaagaag	cagaagaagc	tgagttggat	1140
aaaaaagctg	atgaacttca	aaataaagtt	gctgatttag	aaaaagaaat	tagtaacctt	1200
gaaatattac	ttggaggggc	tgattctgaa	gatgatactg	ctgctcttca	aaataaatta	1260
gctactaaaa	aagctgaatt	ggaaaaaact	caaaaagaat	tagatgcagc	tcttaatgag	1320
ttaggccctg	atggagatga	agaagaaact	ccagcgccgg	ctcctcaacc	agagcaacca	1380
gctcctgcac	caaaaccaga	gcaaccagct	ccagctccaa	aaccagagca	accagctcct	1440
gcaccaaaac	caagcaaac	agctccagct	ccaaaaccag	agcaaccagc	tccagctcca	1500
aaaccagagc	aaccagctaa	gccggagaaa	cagctgaag	agcctactca	accagaaaaa	1560
ccagccactc	caaaaacagg	ctggaaacaa	gaaaacggta	tgtggtattt	ctacaatact	1620
gatgggtcaa	tggaataagg	ttggctccaa	aacaacggtt	catggtacta	cctaaacgct	1680
aacggcgcta	tggaacagg	ttgggtgaaa	gatggagata	cctggtacta	tcttgaagca	1740
tcaggtgcta	tgaaagcaag	ccaatgggtc	aaagtatcag	ataaatggta	ctatgtcaac	1800
agcaatggcg	ctatggcgac	aggctggctc	caatacaatg	gctcatggta	ctacctcaac	1860
gctaattggtg	atatggcgac	aggatggctc	caatacaacg	gttcatggta	ttacctcaac	1920
gctaattggtg	atatggcgac	aggatgggtc	aaagtcaacg	gttcatggta	ctacctaaac	1980
gctaacggtg	ctatggctac	aggttgggtc	aaagtcaacg	gttcatggta	ctacctaaac	2040
gctaacgggtt	caatggcaac	aggttgggtg	aaagatggag	atacctggta	ctatcttgaa	2100
gcatcaggtg	ctatgaaagc	aagccaatgg	ttcaaagtat	cagataaatg	gtactatgtc	2160
aatggcttag	gtgcccttgc	agtcaacaca	actgtagatg	gctataaagt	caatgccaat	2220
ggtgaatggg	tt					2232

SeqID 8

atgaaaaaaa	tagttcttgt	tagtctagct	ttcctttttg	tcctgggttg	ttgcggacag	60
aaaaaagaaa	ctggaccagc	tacaaaaaca	gaaaaagata	cgcttcagtc	ggcatttgcca	120
gttattgaaa	atgctgagaa	gaatacagtt	gtaactaaga	ctttgggtctt	gcccaagtca	180
gatgatggta	gccagcagac	acaaacaatt	acttacaaag	acaagacttt	tttgagtcta	240
gctatccaac	aaaaacgtcc	agtctctgat	gagttgaaga	cttatattga	ccaacatgga	300
gtggaggaaa	ctcaaaaagc	tcttcttgaa	gcggaggaga	aggataagtc	tatcattgaa	360
gctcgtaaat	tgccagggtt	caaacttgaa	acaaaactat	tgagcgcaac	ggaacttcaa	420
acaacgacta	gttttgattt	tcaagttctg	gatgtcaaga	aggcttccca	gttggaaacat	480
ctgaagaata	ttggtttgga	aaatcttttg	aaaaatgaac	caagcaaaata	tatttcagat	540

agattggcaa atggcgcgac agaacia 567

SeqID 9

atgtttgaag	tagaagaatg	gtcccatagt	cggattgggt	tgaattttcg	atcaggtttg	60
ggcgaatgc	agcaagcgt	ggatttgta	ggaaatcctg	agcagtctta	ccctattatc	120
cacgtaacag	ggactaatgg	gaaaggatct	accattgctt	ttatgaggga	attattttatg	180
gggcatggca	aaaaagttgc	gacctttacc	tccctcata	tcgtctctat	caatgaccga	240
atctgcatta	atgggcagcc	tatagcagac	gcagacttta	tccgtttgac	tgatcaggtc	300
aaggagatgg	agaaaacgct	tctgcaaaact	cctgccagct	tgctctttt	tgaattgctg	360
accttggttg	cttttcttta	ttttagggag	caggaggtgg	atttggtttt	attagaagtg	420
ggaattgggtg	gcttacttga	cacgaccaat	gtgtaactg	gagagtgtgc	tgatcatcacc	480
tccattgggc	ttgaccatca	agaaaccttg	ggtgatagtc	tagaagcaat	tgacagagcag	540
aaagctggta	ttttcaaggc	tggttaagaag	gcagtgattg	cgaaattgcc	tccagaagct	600
aggcttgcc	gtcagaaaaa	agccgaatct	ttagctgtta	acctttatca	ggcagggtcaa	660
gatttttttaa	tgctgaatgg	tgatttttca	agctctttac	taaatctttc	acagctgaac	720
ataggcttag	aaggagtcta	tcagcaggag	aatgcagcct	tggcgttgca	aacttttctt	780
ctttttatga	gagaaagaaa	ggaagctggt	gatgaacagg	ctgtaagaaa	ggccttgga	840
cagacccatt	gggctggctg	cttgagcgt	attcgccac	agatttattt	ggatgggtgct	900
cataacctcc	ctgcttgac	tcgcttggt	gagtttatca	aagaaaaaga	gcaggaaggc	960
tatcgacctc	aaatcctctt	tggatccttg	aaacgtaagg	attatcaagg	gatgttgggt	1020
tatctgactg	aaaaattgcc	tcaggtggaa	ctcaagggtga	cggcctttga	ctatcagggg	1080
gctttggacg	aaagggatgt	gacaggttac	gatatagttt	cttcttaccg	agaattttatc	1140
agcgattttg	aagaaaaggc	agacgctcaa	gacttgctgt	tcgttacagg	gtctctctat	1200
tttatctcag	aagtacgggg	ctacctgctg	gaccgtgagc	agataaat		1248

SeqID 10

gtgggaattc	gtgtttataa	accaacaaca	aacggctgcc	gtaatatgac	ttctttggat	60
ttcgctgaaa	tcacaacaag	cactcctgaa	aatcattgc	ttgttgcat	gaagagcaag	120
gctggtcgta	acaacaacgg	tcgtatcaca	gttcgtcacc	aaggtgggtg	acacaaacgt	180
ttctaccgtt	tggttgactt	caaacgtaat	aaagacaacg	ttgaagcagt	tgtaaaaaca	240
atcgagtacg	atccaaacgg	ttctgcaaac	atcgctcttg	tacactacac	tgacgggtgtg	300
aaagcatata	tcacgctcc	aaaaggtctt	gaagtaggtc	aacgtatcgt	ttcagggtcca	360
gaagcagata	tcaagtcgg	aaacgctctt	ccacttgcta	acatcccagt	tggtactttg	420
attcacaca	tcgagttgaa	accaggtcgt	ggtggtgaat	tggtacgtgc	tgctgggtgca	480
tctgctcaag	tattgggttc	tgaaggtaaa	tatgttcttg	ttcgtcttca	atcagggtgaa	540
gttcgtatga	ttcttggaac	ttgccgtgct	acagttggtg	ttgtcggaaa	cgaacaacat	600
ggacttgtaa	accttggtta	agcaggacgt	agccgttgga	aaggtatccg	cccaacagtt	660
gctgggtctg	taatgaaccc	taacgatcac	ccacacggtg	gtggtgaagg	taaagcacca	720
gttggctgta	aagcaccatc	tactccatgg	ggcaaacctg	ctcttggtct	taaaactcgt	780
aacaagaaag	cgaaatctga	caaacttata	gttcgtcgtc	gcaacgagaa	a	831

SeqID 11

atgggtaaaa	aatcaatggt	agctagagag	gctaaacgcc	aaaaaattgt	tgaccgttat	60
gctgaaaaaac	gtgctgcatt	aaaggcggca	ggggactacg	aaggtttatc	taaattacct	120
cgcaacgcct	caccgactcg	tttacataat	cgttgtaggg	ttacggggcg	cccacattca	180
gtttaccgca	aatttggtct	gagtcgtatc	gcttttcgcg	aacttgcgca	taaagggtcaa	240
attcctgggtg	taacaaaaagc	atcttg				267

SeqID 12

atggatatta	gacaagttac	tgaaccatc	gccatgattg	aggagcaaaa	cttcgatatt	60
agaaccatta	ccatggggat	ttctcttttg	gactgtatcg	atccagatat	caatcgtgct	120
gcggagaaaa	tctatcaaaa	aattacgaca	aaggcggcta	atttagtagc	tggttggtgat	180
gaaattgcgg	ctgagttggg	aattcctatc	gttaataaagc	gtgtatcgg	gacacctatt	240
tctctgattg	gggcagcgac	agatgcgacg	gactacgtgg	ttctggcaaa	agcgttgat	300
aaggctgcga	aagagattgg	tgtggacttt	attggtggtt	ttctgcctt	agtacaaaa	360
ggttatcaaa	agggagatga	gattctcatc	aattccattc	ctcgcgcttt	ggctgagacg	420
gataaggtct	gctcgtcagt	caatatcggc	tcaaccaagt	ctggtattaa	tatgacggct	480
gtggcagata	tgggacgaat	tatcaaggaa	acagcaaatc	tttcagatat	gggagtggcc	540
aagtgggttg	tattcgctaa	tgctgttgag	gacaatccat	ttatggcggg	tgctttcat	600
ggtgttgggg	aagcagatgt	tatcatcaat	gtcggagttt	ctggctcctg	tggttgtaaa	660
cgtgctttgg	aaaaagttcg	tggacagagc	tttgatgtag	tagccgaaac	agttaagaaa	720
actgccttta	aaatcactcg	tatcggtcaa	ttggttggtc	aaatggccag	tgagagactg	780
ggtgtggagt	ttggtattgt	ggacttgagt	ttggcaccaa	cccctgcgg	tgagactct	840
gtggcacgtg	tccttgagga	aatggggcta	gaaacagttg	gcacgcagtg	aacgacggct	900
gccttggccc	tcttgaacga	ccaagttaaa	aaggtgggag	tgatggcctg	caaccaagtc	960
ggtggtttat	ctggtgcctt	tatccctgtt	tctgaggatg	aaggaatgat	tgctgcagtg	1020
caaaatggct	ctcttaattt	agaaaaacta	gaagctatga	cggctatctg	ttctgttggg	1080
ttggatatga	ttgccatccc	agaagatacg	cctgctgaaa	ctattgcggc	tatgattgcg	1140

gatgaagcag	caatcgggtg	tatcaacatg	aaaacaacag	ctgttcggtat	cattcccaaa	1200
ggaaaaagaag	gcgatatgat	tgagtttggt	gggtctattag	gaactgcacc	cgttatgaag	1260
gttaaatgggg	cttcgtctgt	cgacttcac	tctcgcggtg	gacaaatccc	agcaccaatt	1320
catagtttta	aaaat					1335

SeqID 13

atggtaata	cagaagtagc	aagaacaaca	atcaagacag	aatatttttg	cagccttact	60
gaaaggatga	acaaatatcg	agaagatggt	ttaaataaaa	aaccttatat	tgatgctgag	120
agagcagttc	tagcaacacg	cgcctatgaa	cgatacaagg	aacaacctaa	tgctctaaaa	180
cgtgcatata	tgctgaaaga	aatttttgaa	aatatgacta	tctatattga	agaagaatct	240
atgattgcgg	gaaatcaagc	ttcttccaat	aaagatgctc	ctatttttcc	ggaatatagc	300
ctagaatttg	ttctcaatga	gttgatctct	tttgaaaagc	gtgatggaga	tgttttctat	360
attacagaag	aaacaaaaga	acaacttaga	agtattgctc	cgttttggga	aaataataat	420
ttacgtgcta	gagctgggtg	cttattacct	gaagaagtgt	ctgtttatat	ggaaacagga	480
ttcttcggta	tggaaggtaa	gatgaattct	ggagatgctc	acttagcagt	taactatcag	540
aaacttttgc	aatttgggtt	aagagggttt	gaagagcggg	ctcgtaaagc	aaaagtagct	600
ctagatttaa	cagatccagc	aagtattgat	aaatatcatt	tttacgactc	tatattttatc	660
gtaattcgatg	ctattaaagt	atatgcaaag	cgctttgttg	ctcttgctaa	aagtttagcc	720
gaaaatgcaa	atcctaaacg	taagaaagaa	ttacttgaga	ttgcagatat	ttgctctaga	780
gtcccatatg	aaccggcaac	tacttttgca	gaagctatcc	aatcagtttg	gtttattcaa	840
tgtattttac	aaattgaatc	taatggccac	tctctttcat	atggccggtt	tgatcaatat	900
atgtatccat	atatgaaggc	tgatttagaa	agtggtaaag	aaacagaaga	tagcattggt	960
gaacgtctga	caaatctttg	gattaagaca	attacaatta	ataaggttcg	cagtcaatca	1020
catcacatttt	cttcagcagg	aagtccttta	tatcaaaatg	ttacaattgg	tggaagagact	1080
cgagataaga	aggatgctgt	taaccattta	tcttatttgg	tattaaaatc	agttgcacaa	1140
acccatctac	cgcaacctaa	tctaactgta	cgttaccatg	caggtttaga	tgctcgtttc	1200
atgaatgagt	gtattgaagt	gatgaaactt	ggttttggta	tgctgcattt	taataatgat	1260
gagattatta	ttccttcttt	tattgcaaaa	ggagtattgg	aagatgatgc	ttatgattac	1320
agtgccattg	gatgtgttga	aacggcagtt	ccagggaagt	ggggctatcg	ttgcacaggt	1380
atgagttata	tgaacttccc	taaggttcta	cttatcacga	tgaatgatgg	aattgatccg	1440
gcttcgggta	aacggtttgc	accaagcttt	ggctggttta	aggatatgaa	gaacttttct	1500
gaattagaaa	atgcttgagg	taaaacacta	agatatttga	cacgaatgag	tggtattggt	1560
gaaaattcta	ttgattttatc	attggaacga	gaagttcctg	atattctatg	ttcagcattg	1620
actgatgatt	gtattgggtc	tggaacacac	cttaagaag	gtggagcagt	atatgattat	1680
atatcaggat	tgcaagttgg	aattgcaaat	ttgtcggatt	cattagctgc	aattaaaaaa	1740
ttgggtgttg	aggaagaacg	tataagccca	agtcagcttt	ggcatgcact	ggaaacagat	1800
tatgccggag	agaaggttaa	ggtcattcaa	gaaatgttga	ttcatgatgc	acctaagtat	1860
ggtaatgatg	atgattatgc	tgacaaattg	gttactgctg	cttatgacat	ttatgttgat	1920
gaaattgcta	aatatcctaa	tacacgttat	ggaagagggc	ctattggagg	aattcgttat	1980
tcaggaaacat	cttctatctc	agccaacgta	gggcagggac	gtggaacatt	agcaactcca	2040
gatggacgca	acgcgggtac	acggttagca	gaggggtgtt	caccatcaca	taatatggat	2100
caacacggcc	ctacatctgt	tttaaaatct	gtttcaaaat	taccaacaga	tgaaatcgta	2160
gggtgggttc	tcttaaatca	gaaagtaaat	cctcaaacgt	tagccaaaga	agaagataaa	2220
ttaaaactaa	ttgctttgtt	acgaacattc	tttaatcggt	tacatgggta	ccatattcaa	2280
tacaatgttg	tttccagaga	gacgctgatt	gacgctcaga	aacatcctga	aaaacacaga	2340
gacttaattg	ttcgtgttgc	aggataactc	gcattcttca	atgttctttc	taaggcaacc	2400
caagatgaca	ttataggacg	tactgagcat	actttg			2436

SeqID 14

atgtcacaa	gacaatatgc	aggtactgga	cgctgtaaaa	acgctgttgc	acgcgttcgc	60
cttgctccag	gaactggtaa	aatcactgtt	aacaaaaaag	atgttgaaaga	gtacatccca	120
cacgctgacc	ttcgtcttgt	catcaaccaa	ccattcgcag	ttacttcaac	tgtaggttca	180
tacgacgttt	tcgttaacgt	tataggtggt	ggatacgtg	gtcaatcagg	agctatccgt	240
cacggtatcg	ctcgtgccct	tcttcaagta	gaccagact	tccgcgattc	attgaaacgc	300
gcaggacttc	ttacacgtga	ctcacgtaaa	ggtgaacgta	agaaaccagg	tcttaagaaa	360
gctcgtaaa	catcacaatt	tagtaaacgt				390

SeqID 15

ttggagaaga	aactgaccat	aaaagacatt	gcggaaatgg	ctcagacctc	gaaaacaacc	60
gtgtcatatt	acctaaccg	gaaatatgaa	aaaatgtccc	aagagacacg	tgaaaagatt	120
gaaaaagtta	ttcatgaaac	aaattacaaa	ccgagcattg	ttgcgcgtag	cttaaaactcc	180
aaacgaacaa	aattaatcgg	tgttttgatt	ggtgatatta	ccaacagttt	ctcaaaccaa	240
attgttaagg	gaattgagga	tatcgccagc	cagaatggct	accaggtaat	gataggaaat	300
agtaattaca	gccaagagag	tgaggaccgg	tatattgaaa	gcatgcttct	cttgggagta	360
gacggcttta	ttattcagcc	gacctcta	ttccgaaaat	attctcgtat	catcgatgag	420
aaaaagaaga	aaatgggtctt	ttttgatagt	cagctctatg	aacaccggac	tagctgggtt	480
aaaaccaata	actatgatgc	cgtttatgac	atgacccagt	cctgtatcga	aaaaggttat	540
gaacattttc	tcttgattac	agcggatacg	agtcggttga	gtactcggat	tgagcgggca	600

agtgggttttg	tggatgcttt	aacagatgct	aatatgcgtc	acgccagtct	aaccattgaa	660
gataagcata	cgaatttggg	acaaattaag	gaatttttac	aaaaagaaat	cgatcccgat	720
gaaaaaactc	tggatatttat	ccctaactgt	tgggccctac	ctctagtctt	taccgttatc	780
aaagagttga	attataactt	gccacaagtt	gggttgattg	gttttgacaa	tacggagtgg	840
acttgctttt	cttctccaag	tgtttcgacg	ctgggtcagc	cctcctttga	ggaaggacaa	900
caggctacaa	agattttgat	tgaccagatt	gaaggtcgca	atcaagaaga	aaggcaacaa	960
gtcttggtt	gtagtgtgaa	ttggaaagag	tcgactttc			999

SeqID 16

atgaataaag	gattatttga	aaaacgttgt	aatatagta	ttcggaaatt	ttcattaggt	60
gttgcttctg	ttatgattgg	agctgcattc	tttgggacaa	gtccggttct	tgcatagac	120
gtgcagtctg	gttccacggc	gaactacca	gctgatttag	ctactgctct	tgcaacagca	180
aaagagaatg	atgggcgtga	ttttgaagcg	cctaaggtgg	gagaagacca	aggttctcca	240
gaagttacag	atggacctaa	gacagaagaa	gaactattag	cacttgaaaa	agaaaaaccg	300
gctgaagaaa	aaccaaaga	ggataaacct	gcagctgcta	aacctgaaac	acctaagacg	360
gtaacccctg	aatggcaaac	ggtagcgaat	aaagagcaac	agggaaacgt	cactatccga	420
gaagaaaaag	gtgtccgcta	caaccaacta	tcctcaactg	ctcaaaatga	taacgcaggc	480
aaaccagccc	tgtttgaaaa	gaagggttg	accgttgatg	ccaatggaaa	tgcaactgtt	540
gatttaacct	tcaaagatga	ttctgaaaag	ggcaaatac	gctttggtgt	ctttttgaaa	600
tttaagata	ccaagaataa	tgttttgtc	ggttatgaca	aggatggctg	gttctgggag	660
tataaatctc	caacaactag	cacttggtat	agaggtagtc	gtgttgctgc	tcctgaaaca	720
ggatcaacaa	accgtctctc	tatcactctc	aagtcagacg	gtcagctaaa	tgccagcaat	780
aatgatgtca	atctctttga	cacagtga	ctaccagctg	cggatcaatga	ccatcttaaa	840
aatgagaaga	agattcttct	caaggcgggc	tcttatgacg	atgagcgaac	agttgttagc	900
gttaaaacgg	ataaccaaga	gggggtaaaa	acagaggata	cccctgctga	aaaagaaaca	960
ggctctgaag	ttgatgatag	caaggtgact	tatgacacga	ttcagctctaa	ggctctcaaa	1020
gcagtgattg	accaagcctt	ccctcgtgtc	aaggaataca	gcttgaacgg	gcatactttg	1080
ccaggacagg	tgcaacagtt	caaccaagtc	tttatcaata	accaccgaat	caccctgaa	1140
gtcacttata	agaaaatcaa	tgagacaaca	cgagagtact	tgatgaagct	tcgcgatgat	1200
gctcacttaa	tcaatgcgga	aatgacagta	cgcttgcaag	ttgtagacaa	tcaattgcac	1260
tttgatgtga	ctaagattgt	caaccacaat	caagtcactc	caggtcaaaa	gattgatgac	1320
gaaagcaaac	tactttcttc	tattagtttc	ctcggcaatg	cttttagctc	tgtttctagt	1380
aatcaaaactg	gtgctaagtt	tgatggggca	accatgtcaa	acaatacgca	tgtcagcgga	1440
gatgatcata	tcgatgtaac	caatccaatg	aaggatttgg	ctaagggtta	catgtatgga	1500
tttgtttcta	cagataagct	tgctgctggt	gtttggagta	actctcaaaa	cagctatggg	1560
gggtggttga	atgactggac	tcgtttgaca	gcttataaag	aaacagtcgg	aaatgccaac	1620
tatgtaggaa	tccacagctc	tgaatggcaa	tgggaaaaag	cttataaagg	cattgttttc	1680
ccagaataca	cgaaggaact	tccaagtgtc	aaggttggtt	tcactgaaga	tgccaatgca	1740
gacaagaacg	ttgattggca	agatgggtgc	attgcttatc	gtagcattat	gaacaatcct	1800
caaggttggg	aaaaagttaa	ggatatcaca	gcttaccgta	tcgcgatgaa	ctttggttct	1860
caagcacaaa	accatttctt	tatgaccttg	gatggtatca	agaaaatcaa	tctccataca	1920
gatggtcttg	ggcaaggtgt	tctccttaaa	ggataggtta	gcgaaggcca	tgactctggg	1980
cacttgaaact	atgctgatat	tggtaaagct	atcggtgggtg	tcgaagactt	caagacccta	2040
attgagaagg	ctaagaaata	tggagctcat	ctaggtatcc	acgttaacgc	ttcagaaact	2100
tatctgagt	ctaataactt	caatgaaaaa	attctcgtga	agaatccaga	tggaagctat	2160
agctatgggt	ggaactggct	agatcaaggt	atcaacattg	atgctgccta	tgacctagct	2220
catggctggt	tggaacgttg	ggaagatttg	aagaaaaaac	ttggtgacgg	tctcgacttt	2280
atctatgtgg	acgtttgggg	taatgggtcaa	tcaggtgata	acgggtgcctg	ggctaccac	2340
gttcttgccta	agaaaattaa	caaacaaggc	tggcgctttg	cgatcgagtg	gggccatggt	2400
ggtgagtacg	actctacctt	ccatcactgg	gcagctgact	tgacctacgg	tggtctacac	2460
aataaaggta	tcaacagtgc	catcacccgc	tttatccgta	accacaaaaa	agatgcttgg	2520
gtaggggact	acagaagtta	tggtgggtgca	gccaactatc	cactgctagg	tggtctacagc	2580
atgaaagact	ttgaaggctg	gcagggaaga	agtgactaca	atggctatgt	aaccaactta	2640
tttgcccatg	acgtcatgac	taagtacttc	caacacttca	ctgtaagtaa	atgggaaaaa	2700
ggtacaccgg	tgactatgac	cgataacggg	agcacctata	aatggactcc	agaaatgcga	2760
gtggaattgg	tagatgctga	caataataaa	gtagttgtaa	ctcgtaagtc	aaatgatgtc	2820
aatagtccac	aatatcgcca	acgtacagta	acgctcaacg	gacgtgtcat	ccaagatggg	2880
tcagcttact	tgactccttg	gaactgggat	gcaaatggta	agaaactttc	tactgataag	2940
gaaaagatgt	actacttcaa	tacgcaggcc	gggtgcaaaa	cttggaccct	tccaagcgat	3000
tgggcaaaaga	gcaaggttta	cctttacaag	ctaactgacc	aaggttaagac	agaagagcaa	3060
gaactaactg	taaaagatgg	taaaattacc	ctagatcttc	tagcaaatca	accatacggt	3120
ctctatcggt	cgaacaacaa	taactcctgaa	atgtcatgga	gtgaaggcat	gcacatctat	3180
gaccaaggat	ttaatagcgg	taccttgaaa	cattggacca	tttcaggcga	tgcttctaag	3240
gcagaaattg	tcaagtctca	aggggcaaac	gatatgcttc	gtattcaagg	aaacaaagaa	3300
aaagtttagtc	tcactcagaa	attaactggc	ttgaaaccaa	ataccaagta	tgccgtttat	3360
gttgggttag	ataaccgtag	taatgccaag	gcaagtatca	ctgtgaatac	tggtgaaaaa	3420
gaagtacta	cttatccaa	taagtctctc	gcgctcaact	atgttaaggc	ctacgccac	3480
aatacacgtc	gtgacaatgc	tacagttgac	gatacaagtt	acttccaaaa	catgtacgcc	3540

ttctttacaa	ctggagcggg	cgtctcaaat	gttactctga	cattgagtcg	tgaagctggg	3600
gatcaagcaa	cttactttga	tgaatttcgt	acctttgaaa	acaattcaag	catgtacggg	3660
gacaagcatg	atacaggtaa	aggcaccttc	aagcaagact	ttgaaaatgt	tgctcagggg	3720
atcttcccat	ttgtagtggg	tggtgtcgaa	gggtgtgaag	ataaccgcac	tcacttgtct	3780
gaaaaacaca	atccatatac	acaacgtggg	tggaatggta	agaaagtcga	tgatgtttac	3840
gaaggaaatt	ggctactcaa	gacaaaatgga	ctagttagcc	gtcgtaaactt	ggtttaccac	3900
accatcccac	aaaacttccg	ttttgaagca	ggtaagacct	accgtgtaac	ctttgaatac	3960
gaagcaggat	cagacaatac	ctatgctttt	gtagtccgta	agggagaatt	ccagtcaggg	4020
cgtcgtggta	ctcaagcaag	caacttggaa	atgcatgaat	tgccaaatac	ttggacagat	4080
tctaagaaag	ccaagaaggc	aaccttcctt	gtgacagggt	cagaaacagg	cgatacttgg	4140
gtagggtatct	actcaactgg	aaatgcaagt	aatactcgtg	gtgattctgg	tggaatggc	4200
aacttccgtg	gttataacga	cttcatgatg	gataatcttc	aaatcgaaga	aattacccta	4260
acaggtaaga	tggtgacaga	aaatgctctg	aagaactact	tgccaacggg	tgccatgact	4320
aactacacca	aagagtctat	ggatgctttg	aaagaggcgg	tctttaacct	cagtcaggcc	4380
gatgatgata	tcagtgtgga	agaagcgcgt	gcagagattg	ccaagattga	agctttgaag	4440
aatgcttttg	ttcagaagaa	gacggctttg	gtagcagatg	actttgcaag	tcttacagct	4500
cctgctcagg	ctcaagaagg	tcttgcaaat	gcctttgatg	gcaatgtgtc	tagtctatgg	4560
catacatctt	ggaatgggtg	agatgtaggc	aagcctgcaa	ctatggctct	gaaagaacca	4620
actgaaatca	caggacttcg	ctatgttccg	cgtggatcag	gttcaaatgg	taacttgcca	4680
gatgtgaaac	ttgttgtgac	agatgagtct	ggcaaggagc	atacctttac	tgcaactgat	4740
tgccaaataa	acaacaaacc	aaaagatatt	gactttggta	agacaatcaa	ggctaagaaa	4800
attgtcctta	ctggtaccac	gacatacggg	gatgggtggg	ataaatacca	atctgcagcg	4860
gaacttatct	ttactcgtcc	acaggttagc	gaaacacctc	ttgacttgtc	aggctatgaa	4920
gcagcttttg	ttaaggctca	gaaattaaca	gacaaagaca	atcaagagga	agtagctagc	4980
gttcaggcaa	gcatgaaata	tgcgacggat	aacctctctc	tgacggaaag	aatggtggaa	5040
tactttgcag	attatctcaa	ccaattaaaa	gattctgcta	cgaaaccaga	tgctccaact	5100
gtagagaaac	ctgagtttaa	acttagatct	ttagcttccg	agcaaggtaa	gacgccagat	5160
tataagcaag	aaatagctag	accagaaaca	cctgaacaaa	tcttgccagc	aacagggtgag	5220
agtcaatctg	acacagccct	catccttagc	agtgttagtc	tagccctatc	tgctctcttt	5280
gtagtataaa	cgaagaaaga	c				5301

SeqID 17

atgaacaaac	caacgattct	gcgccctaate	aagtatctga	gcattagctt	cttaagcttg	60
gttatcgag	ccattgtctt	aggcggaggga	gtttttttct	actacgttag	caaggctcct	120
agcctatccg	agagtaaact	agttgcaaca	acttctagta	aaatctacga	caataaaaaat	180
caactcattg	ctgacttggg	ttctgaacgc	cgcgtcaatg	cccaagctaa	tgatattccc	240
acagatttgg	ttaaggcaat	cgtttctatc	gaagaccatc	gcttcttcga	ccacaggggg	300
attgatacca	tcogtatcct	gggagctttc	ttgcgcaatc	tgcaaaagca	ttccctccaa	360
gggtggatcaa	tccaccaca	acagttagatt	aagttgactt	acttttcaac	ttcgacttcc	420
gaccagacta	tttctcgtaa	ggctcaggaa	gcttgggttag	cgattcagtt	agaacaaaaa	480
gcaaccaagc	aagaaatctt	gacctactat	ataaataagg	tctacatgtc	taatgggaac	540
tatggaatgc	agacagcagc	tcaaaactac	tatggtaaaag	acctcaataa	tttaagttta	600
cctcagttag	ccttgcctggc	tggaatgect	caggcaccaa	accaatatga	cccctattca	660
catccagaag	cagcccaaga	cgcgcgaaac	ttggtcttat	ctgaaatgaa	aaatcaaggc	720
tacatctctg	ctgaacagta	tgagaaagca	gtcaatacac	caattactga	tggaactaca	780
agtctcaaat	cagcaagtaa	ttaccctgct	tacatggata	attacctcaa	ggaagtcac	840
aatcaagttg	aagaagaaac	aggctataac	ctactcaca	ctgggatgga	tgtctacaca	900
aatgtagacc	aagaagctca	aaaacatctg	tgggatattt	acaatacaga	cgaatacgtt	960
gcctatccag	acgatgaatt	gcaagtcgct	tctaccattg	ttgatgtttc	taacggtaaa	1020
gtcattgccc	agcttaggagc	acgccatcag	tcaagtaatg	tttccttcgg	aattaaccaa	1080
gcagtagaaa	caaaccgcga	ctggggatca	actatgaaac	cgatcacaga	ctatgctcct	1140
gccttggagt	acggtgtcta	cgattcaact	gctactatcg	ttcacgatga	gccctataac	1200
taccctggga	caaatactcc	tgtttataac	tgggataggg	gctacttttg	caacatcacc	1260
ttgcaatacg	ccctgcaaca	atcgcgaaac	gtcccagccg	tggaactctt	aaacaaggctc	1320
ggactcaacc	gcgccaaagac	tttcttaaat	ggcttaggaa	tcgactaccc	aagtattcac	1380
tactcaaatg	ccatttcaag	taacacaacc	gaatcagaca	aaaaatatgg	agcaagtagt	1440
gaaaagatgg	ctgctgctta	cgtgcctttt	gcaaatgggtg	gaacttacta	taaaccaatg	1500
tatatccata	aagtcgtctt	tagtgatggg	agtgaataag	agttctctaa	tgtcggaact	1560
cgtgccatga	aggaaacgac	agcctatatg	atgaccgaca	tgatgaaaac	agtcttgact	1620
tatggaaactg	gacgaaatgc	ctatcttgct	tggtccctc	aggctggtaa	aacaggaacc	1680
tctaactata	cagacgagga	aattgaaaac	cacatcaaga	cctctcaatt	tgtagcacct	1740
gatgaactat	ttgctggcta	tacgcgtaaa	tattcaatgg	ctgtatggac	aggctattct	1800
aaccgtctga	caccatttgt	aggcaatggc	cttacggtcg	ctgccaaagt	ttaccgctct	1860
atgatgacct	acctgtctga	aggaagcaat	ccagaagatt	ggaatatacc	agaggggctc	1920
tacagaatag	gagaattcgt	atttaaaaat	gggtgctcgtt	ctacgtggaa	ctcacctgct	1980
ccacaacaac	ccccatcaac	tgaaagttca	agtcacatca	cagatagttc	aacttcacag	2040
tctagctcaa	ccactccaag	cacaaaataat	agtcagacta	ccaatcctaa	caataatacag	2100
caacaatcaa	atacaacccc	tgatcaacaa	aatcagaatc	ctcaaccagc	acaacca	2157

SeqID 18

atgagtaaaa	aaagacgaaa	tcgtcataaa	aaagaaggctc	aagaaccgca	atttgatttt	60
gatgaagcaa	aagagctaac	agttgggtcaa	gctattcgta	aaaatgaaga	agtggaaatca	120
ggagtccttg	ctgaggattc	catttttgac	aagtatgtta	agcaacacag	agatgaaatt	180
gaggcggata	agtttgcgac	tcgtcaatac	aaaaaaggagg	agttcgttga	aactcagagt	240
ctggatgatt	taattcaaga	gatgcgtgag	gctgtagaga	agtcagaagc	ttcttcggag	300
gaagttccat	cttctgaaga	catcttacta	cccttgccctc	tggacgatga	ggagcaaggc	360
ttggatcctc	tattgctaga	tgatgaaaat	ccaacagaaa	tgactgaaga	agtggaaagag	420
gagcaaaaacc	tttctcgtct	ggatcaagag	gactcagaaa	agaaaagtaa	aaaaggcctt	480
atthtgaccg	ttttggcgct	tgtatcagta	attatttgtg	tcagtgccta	ttatgtctac	540
cgtcaagtgg	ctcgttcgac	taaggaaatt	gaaacttctc	aatcaactac	agccaatcaa	600
tcggatgtgg	atgattttaa	tacactttat	gacgcctttt	acacagatag	caataaaacg	660
gctttgaaaa	atagccagtt	tgataaaactg	agtcaactca	agactttact	tgataagctg	720
gaaggtagtc	gtgaacatac	gcttgccaaa	tctaaatatg	atagtctagc	aacgcaaatc	780
aaggctattc	aagatgtcaa	tgctcaattt	gagaaaccag	ctattgtgga	tgggtgtgtg	840
gataccaatg	ccaaagccaa	atcggatgct	aaatttacgg	atattaaaac	tggaaatcag	900
gagcttgata	aagtgcctaga	taaggctatc	agctcttggt	agagccagca	aacaagtact	960
tctagctcaa	gttcaagtca	aactagcagc	tcaagttcaa	gtcaagcaag	ttcaaatacg	1020
actagtgagc	caaaaccaag	tagttcaaata	gagactagaa	gtagtcgcag	tgaagtcaat	1080
atgggtctct	cgagtgcagg	ggttgctgtt	caaagaagtg	ccagtcgtgt	tgccataaat	1140
cagtctgcta	ttgatgatag	taataactct	gcctgggatt	ttgcggatgg	tgtcttggaa	1200
caaattctag	cgacttcacg	ttcacgtggc	tatatcactg	gagaccaata	tatccttgaa	1260
cgtgtcaata	tcgttaacgg	caatgggtat	tacaacctct	acaagccaga	tggaaacctat	1320
ctctttaccc	ttaactgtaa	gacaggctac	tttgctggaa	atggcgctgg	tcatgcggat	1380
gacttagatt	ac					1392

SeqID 19

atgaagcttt	tgaaaaaaat	gatgcaagtc	gcattagcag	tctttttctt	tggtttgcta	60
gctacaaata	cggatatttg	gaataccaca	gggtggccgat	ttgttgataa	ggataataga	120
aaatattatg	taaaagatga	tcataaagca	atctattggc	ataaaataga	cggtaaaact	180
tactattttg	gtgatatttg	agagatgggt	gtcgggtggc	aatacttaga	aattcctgga	240
acagggtatc	gtgataattt	attcgataac	caaccagtta	atgaaattgg	ccttcaggag	300
aagtggatct	attttggaca	agatgggtgct	ttgctagaac	aaacagataa	acaagtacta	360
gaggcaaaaa	cgtctgaaaa	tacaggaaaa	gtatacggtg	aacaatatcc	tctatctgct	420
gaaaagagaa	cttattatth	tgataataat	tatgctgtaa	agacaggctg	gatttatgaa	480
gagggtcatt	ggtattatth	aaataagcta	ggaaattttg	gcgatgatcc	ttacaatcca	540
ctaccaattg	gtgaagttgc	taagggttgg	actcaagatt	ttcatgttac	tattgacatt	600
gatagaagca	aacctgctcc	atggtactac	ctagatgctt	caggttaagat	gcttacagat	660
tggcaaaaag	taaacggaaa	atggtattat	tttggtcctc	ctggttctat	ggcaacagg	720
tggaaatatg	tacgaggcaa	atggtattac	ttagataata	aaaatggtga	tatgaaaaca	780
ggatggcaat	accttggtta	caagtgttac	tacctccgtt	catcaggagc	tatggttaact	840
ggctgggtatc	aagatgggtc	aacttgggtac	tatttagatc	cttctaattg	agatatgaaa	900
ataggttgga	caaaagtaaa	tggaaaatgg	tattatctca	attcaaatgg	agcaatgggt	960
acaggtagcc	aaactatcga	tggtaaagtt	tataatttcg	cctcatctgg	tgaatggatt	1020

SeqID 20

atgaaaaattt	tgaaaaaaac	tatgcaagtt	ggactgacag	tatttttctt	tggtttgcta	60
gggaccagta	cagtatttgc	agatgattct	gaaggatggc	agtttgtcca	agaaaaaggca	120
agaacctact	acaaaaaggg	ggacctcaaa	gaaacctact	ggcagtgatg	tgatggtaag	180
tactattatt	ttgattctct	atctggagag	atgggtgtcg	gctggcaata	tatcccgttt	240
ccatctaaag	gtagtacaat	tggtccttac	ccaaatggta	tcagattaga	aggttttcca	300
aagtcagagt	ggtactactt	cgataaaaaat	ggagtgtctac	aagagtttgt	tggttggaaa	360
acattagaga	ttaaaactaa	agacagtgtt	ggaagaaagt	acggggaaaa	acgtgaagat	420
tcagaagata	aagaagagaa	gcgttattat	acgaactatt	actttaatca	aaatcattct	480
ttagagacag	gttggcttta	tgatcagctc	aactgggtatt	atctagctaa	gacggaaatt	540
aatggagaaa	actaccttgg	tgggtgaaaga	cgtgcggggg	ggataaacga	tgattcgact	600
tggtagtacc	tagatccaac	aactgggtatt	atgcaaacag	gttggcaata	tctaggtaat	660
aagtgggtact	acctccgttc	ctcaggagca	atggccactg	gctggtatca	ggaagggtacc	720
acttgggtatt	atthtagacca	cccaaatggc	gatatgaaaa	caggttgga	aaaccttggg	780
aacaaatggg	actactctcg	ttcatcagga	gctatggcaa	ctggttggt	tcaagatggg	840
tcacacttgg	actaccta	tgcaggtaat	ggagacatga	agacaggttg	gttccaggtc	900
aatggcaact	ggtactatgc	ttatagctca	ggtgctttgg	cagtgaatac	gaccgtagat	960
ggctattctg	tcaactataa	tggcgaatgg	gttcgg			996

SeqID 21

atgggttttat	ctaagtatta	tggagtagcc	gatggaatga	atgtagaagg	gaggggaagt	60
gcgaattttta	ttaaagataa	tgtgttaatt	acagcggtc	acaactacta	cagacatgac	120

tatgggaaag	aagcggatga	tatttatgtt	cttccggctg	ttagtccaag	tcaagaacca	180
tttggaaaga	tcaaagtaaa	ggaagttcgt	tatttgaagg	aatttagaaa	tttaaattct	240
aaggatgcaa	gggaatatga	cttggcttta	ttaattctag	aagagcccat	tgggtgcaaaa	300
ttagggtactt	tgggtcttcc	tactagtcaa	aaaaatttga	caggaataac	tgtgactatc	360
acaggctatc	catcatataa	ttttaaaatt	catcaaatgt	atacagataa	aaaacaagtt	420
ttaagtgatg	atggcatggt	cttggattac	caagttgata	ctttagaggg	gtctagtggg	480
tctacagttt	atgatgctag	tcaccgtgta	gtaggagtgc	atactttagg	agatggagct	540
aatcaaatga	acagtgcagt	taaattaaat	gaacgaaatt	tgccatttat	ttattcgggt	600
cttaaaaggtt	actctcttga	aggatggaag	aaaaataatg	gtagttggta	ccattataga	660
caacatgata	aacaaacggg	ttggcaggag	ataaatgata	cttgggtatta	tttagacagt	720
tccggttaaga	tgcttacaga	ttggcaaaaa	gtaaatggaa	aatgggtatta	tctcaattca	780
aatggagcaa	tgggttacagg	tagccaaact	atcgatggta	aagtttataa	cttcgcttca	840
tctggtgagt	ggatt					855

SeqID 22

ttgatgaaaa	aaactttttt	cttactgggtg	ttaggcttgt	tttgcttctt	tccactctct	60
gtttttgcca	ttgatttcaa	gataaactct	tatcaagggg	atttgtatat	tcatgcagac	120
aatacggcag	agtttagaca	gaagatagtt	taccagtttg	aggaggactt	taagggccaa	180
atcgtgggac	ttggacgtgc	tggtaagatg	cctagcgggt	ttgacattga	ccctcatcca	240
aagattcagg	cgcgaaaaaa	cgggtgcagaa	ctagcagatg	tgactagcga	agtaacagaa	300
gaagcggatg	gttatactgt	gagagtctat	aatccaggctc	aggagggcga	catagttgaa	360
gttgacctcg	tctgggaactt	aaaaaattta	cttttctttt	atgatgatat	cgtgaaatta	420
aattggcaac	ctctgacaga	tagttcagag	tctattgaaa	agtttgaatt	tcatgtaagg	480
ggagacaagg	gggctgaaaa	actctttttc	catacaggga	aacttttttag	agagggaaacg	540
attgaaaaga	gtaaccttga	ttatactatc	cgtttagaca	atcttccggc	taagcgtgga	600
gttgagttgc	atgcctattg	gcctcggacc	gattttgcta	gcgctaggga	tcagggattg	660
aaagggaatc	gtttagaaga	gtttaataag	atagaagact	cgattgttag	agaaaaagat	720
cagagtaaac	aactcgttac	ttgggtcctc	cttcgatcc	tttccatctc	cttggtattg	780
agtgtctgct	tctattttat	ttatagaaga	aagaccactc	cttcagtcaa	atatgccaaa	840
aatcatcgct	tctatgaacc	accaatggaa	tttaggccta	tggttttatc	agaagcagtc	900
tactcgacct	ccttggagga	agtgagtcct	ttgggtcaagg	gagctggaaa	attcaccttt	960
gatcaactta	ttcaagctac	cttgctagat	gtgatagacc	gtgggaatgt	ctctatcatt	1020
tcagaaggag	atgcagttgg	tttgaggcta	gtaaaaagaag	atgggtttgtc	aagcctttgag	1080
aaagactgcc	taaatctagc	tttttcaggt	aaaaaagaag	aaactctttc	caatttgttt	1140
gcggattaca	aggtatctga	tagtctttat	cgtagagcca	aagtttctga	tgaaaaacgg	1200
attcaagcaa	gagggcttca	actcaaatct	tcttttgaa	aggtattgaa	ccagatgcaa	1260
gaaggagtga	gaaaacagag	ttccttctgg	gggctcccag	attattatcg	tcctttaact	1320
gggtgggaaa	aggccttgca	agtgggtatg	ggtgccttga	ctatcctgcc	cctatttatc	1380
ggattttggtt	tggtcttgta	cagtttagac	gttcattggt	atcctttacct	ccctttgcca	1440
atacttgggtt	ttctagggtt	agttttgtct	gttttctatt	attggaagct	tcgactagat	1500
aatcgtgatg	gtgttctaaa	tgaagcggga	gctgaggtct	actatctctg	gaccagtttt	1560
gaaaatatgt	tgcttgagat	tgccagattg	gatcaggctg	aactggaaag	tattgtgggtc	1620
tggaatcgcc	tcttgggtcta	tgccacctta	tttggctatg	cggacaaggt	tagtcatttg	1680
atgaaggttc	atcagattca	agtggaaaat	ccagatatca	atctctatgt	agccttatgg	1740
tggcacagta	cgtttttatca	ttcaacagca	caaatgagcc	attatgctag	tgtcgcaaat	1800
acagcaagca	cctactctgt	atcttctgga	agtgggaagtt	ctgggtgggtg	cttctctgga	1860
ggcggaggtg	gcggcagtat	cgggtgccttt				1890

SeqID 23

atgaaatcaa	tcaacaaatt	tttaacaatg	cttgctgcct	tattactgac	agcgagtagc	60
ctgttttcag	ctgcaacagt	ttttgcggct	gggacgacaa	caacatctgt	taccgttcat	120
aaactatttg	caacagatgg	ggatatggat	aaaattgcaa	atgagttaga	aacaggtaac	180
tatgtctgga	ataaagtggg	tggtctacct	gcaaatgcaa	aagaaattgc	cgggtgttatg	240
ttcgtttgga	caaatactaa	taatgaaatt	attgatgaaa	atggccaaac	tctaggagtg	300
aatattgatc	cacaaacatt	taaactctca	ggggcaatgc	cggcaactgc	aatgaaaaaa	360
ttaacagaag	ctgaaggagc	taaatttaac	acggcaaat	taccagctgc	taagtataaa	420
atztatgaaa	ttcacagttt	atcaacttat	gtcgggtgaag	atggagcaac	cttaacaggt	480
ctaaagcag	ttccaattga	aattgaatta	ccattgaacg	atgttgtgga	tgcgcatgtg	540
atccaaaaa	atacagaagc	aaagcaaaaa	attgataaag	atttcaaagg	taaagcaaat	600
ccagatacac	cacgtgtaga	taaagataca	cctgtgaacc	accaagttgg	agatgttgta	660
yagtacgaaa	ttgttacaaa	aattccagca	cttgctaatt	atgcaacagc	aaactggagc	720
yatagaatga	ctgaaggttt	ggcattcaac	aaaggtacag	tgaagtaac	tgttgatgat	780
ytgcaacttg	aagcaggtga	ttatgctcta	acagaagtag	caactggttt	tgatttgaaa	840
taacagatg	ctgggtttagc	taaagtgaat	gacaaaaacg	ctgaaaaaac	tgtgaaaatc	900
icttattcgg	caacattgaa	tgacaaagca	attgtagaag	taccagaatc	taatgatgta	960
icattttaact	atggtaataa	tccagatcac	gggaataactc	caaagccgaa	taagccaaat	1020
raaaacggcg	atttgacatt	gaccaagaca	tgggttgatg	ctacaggtgc	accaattccg	1080
ictggagctg	aagcaacggt	cgatttggtt	aatgctcaga	ctggtaaagt	tgtacaaact	1140

gtaactttga	caacagacaa	aaatacagtt	actgttaacg	gattggataa	aaatacagaa	1200
tataaattcg	ttgaacgtag	tataaaaagg	tattcagcag	attatcaaga	aactactaca	1260
gctggagaaa	ttgctgtcaa	gaactggaaa	gacgaaaatc	caaaaccact	tgatccaaca	1320
gagccaaaag	ttgttacata	tggtaaaaag	tttgtcaaaag	ttaatgataa	agataaatcgt	1380
ttagctgggg	cagaatttgt	aattgcaaat	gctgataatg	ctgggtcaata	tttagcacgt	1440
aaagcagata	aagtgtgtca	agaagagaag	cagttgggtg	ttacaacaaa	ggatgcttta	1500
gatagagcag	ttgctgtcta	taacgctctt	actgcacaac	aacaaaactca	gcaagaaaaa	1560
gagaaagtgt	acaaagctca	agctgcttat	aatgctgtctg	tgattgtctgc	caacaatgca	1620
tttgaatggg	tggcagataa	ggacaatgaa	aatgttgtga	aattagtcttc	tgatgcacaa	1680
ggtcgctttg	aaattacagg	ccttcttgca	ggtacatatt	acttagaaga	aacaaaacag	1740
cctgctgggt	atgcattact	aactagccgt	cagaaatttg	aagtcactgc	aacttcttat	1800
tcagcgactg	gacaaggcat	tgagtatact	gctgggttcag	gtaaagatga	cgctacaaaa	1860
gtagtcaaca	aaaaaatcac	tatcccacaa	acgggtggta	ttggtacaat	tatctttgct	1920
gtagcggggg	ctgcgattat	gggtattgca	gtgtacgcat	atgttaaaaa	caacaaagat	1980
gaggatcaac	ttgct					1995

SeqID 24

atggcggtta	tgccgtatcc	gctgggtgtct	cgcttgtatt	atcgagtggg	atcaaatcaa	60
caaatgtgctg	actttgataa	ggaaaaagca	acgttggatg	aggctgacat	tgatgaacga	120
atgaaattgg	cacaagcctt	caatgactct	ttgaataatg	tagtgagtgg	cgatccttgg	180
tcggaagaaa	tgaagaaaaa	agggcgagca	gagtatgcac	gtatgttaga	aatccatgag	240
cggatggggc	atgtggaaat	ccccgttatt	gacgtggatt	tgccggttta	tgctgggtact	300
gctgaagagg	tattgcagca	aggggctggg	catctagagg	gaacttctct	gccgatcgga	360
ggcaattcga	cccatgcggt	gattacggca	catacagggt	tgccaacagc	taagatgttt	420
acggatttga	ccaaacttaa	agttggggat	aagttttatg	tgcaacaat	caagggaagt	480
atggcctatc	aagtggatca	agtaaagggtg	attgagccga	cgaactttga	tgattttattg	540
attgtaccag	gtcatgatta	tgtgaccttg	ctgacttgta	cgccatacat	gatcaatacc	600
catcgtctat	tggttcgggg	gcacccggata	ccgtacgtag	cagagggtga	ggaagaattt	660
attgcagcaa	acaaactcag	tcactcttat	cgctacctgt	tttatgtggc	agttgggttg	720
attgtgattc	ttttatggat	tattcgacgc	ttgcgcaaga	agaaaaaaca	accggaaaag	780
gctttgaagg	cgctgaaagc	agcaagggaag	gaagtgaagg	tggaaggatg	acaacag	837

SeqID 25

atgtcaagga	ctaaactacg	agccttattg	ggatacttgt	tgatgttggt	agcctgtttg	60
attcctattt	attgttttgg	acagatgggtg	ttgcagctct	ttggacaggt	gaaaggtcat	120
gctacatttg	tgaaatccat	gacaactgaa	atgtaccaag	aacaacagaa	ccattctctc	180
gcctacaatc	aacgcttggc	ttcgcaaaat	cgcatgttag	atcctttttt	ggcggaggga	240
tatgaggtca	attaccaagt	gtctgacgac	cctgatgcag	tctatggtta	cttgtctatt	300
ccaagtgttg	aaatcatgga	gccggtttat	ttgggagcag	attatcatca	tttagggatg	360
ggcttggtct	atgtggatgg	tacaccgctg	cctctggatg	gtacagggat	tcgctcagtg	420
attgctgggc	accgtgcaga	gccaaagccat	gtctttttcc	gccatttgga	tcagctaaaa	480
gttgagagtg	ctctttatta	tgataatggc	caggaaattg	tagaatatca	gatgatggac	540
acagagatta	ttttaccgtc	ggaatgggaa	aaattagaat	cggttagctc	taaaaaatc	600
atgaccttga	taacctgcga	tccgattcct	acotttaata	aacgcttatt	agtgaatttt	660
gaacgagtcg	ctgtttatca	aaaatcagat	ccacaaacag	ctgcagttgc	gagggttgct	720
tttacgaaag	aaggacaatc	tgtatcgctg	gttgcaacct	ctcaatgggt	gtaccgtggg	780
ctagtggtag	tggcatttct	gggaatcctg	tttgttttgt	ggaagctagc	acgtttacta	840
cgaggga						849

SeqID 26

atgaagaatc	cattttttga	aagacgttgt	cgttacagta	ttcgttaagtt	atcagtagga	60
gcctgtctcg	tgatgattgg	tgctgtttta	tttgtgtgtc	cagccttggc	tgaagaaact	120
gcagttcctg	aaaatagcgg	agctaataca	gagcttgttt	caggagagag	tgagcattcg	180
accaatgaag	ctgataagca	gaatgaaggg	gaacatgcta	gagaaaacaa	gctagaaaag	240
gcagaaggag	tagcgatagc	atctgaaact	gcttcgccag	caagcaatga	agctgcaact	300
actgaaactg	cagaagcagc	tagcgagctg	aaaccagagg	aaaaagcaag	tgagggtggt	360
gcagaaacac	catctgcaga	agcaaaacct	aagtctgaca	aggaaacaga	agcaaaagccc	420
gaagcaacta	accaagggga	tgagtctaaa	ccagcagcag	aagctaataa	gactgaaaaa	480
gaagtccagc	cagatgtccc	taaaaaatca	gaaaaaacat	taaaaccaaa	ggaaatcaaa	540
tttaattctt	gggaagaatt	gttaaaatgg	gaaccaggtg	ctcgtgaaga	tgatgctatt	600
aaccgcggat	ctgttgtcct	cgcttcacgt	cggacaggtc	atttagtcaa	tgaaaaagct	660
agcaagggaag	caaaagttca	agccttatca	aacaccaatt	ctaaagcaaa	agaccatgct	720
tctgttggtg	gagaagagtt	caaggcctat	gcttttgact	attggcaata	tctagattca	780
atggctctct	gggaaggtct	cgtaccaact	cctgacgtta	ttgatgcagg	tcaccgtaac	840
ggggttcctg	tatacgttac	actcttcttc	aactgggtcta	atagtattgc	agatcaagaa	900
agatttgctg	aagctttgaa	gcaagacgca	gatggtagct	tcccaattgc	ccgtaaattg	960
gtagacatgg	ccaagtatta	tggtctatgat	ggctattttca	tcaaccaaga	aacaactgga	1020
gatttggtta	aacctcttgg	agaaaagatg	cgccagttta	tgctctatag	caaggaatat	1080

gctgctaagg	taaaccatcc	aatcaagtat	tcttggtacg	atgccatgac	ctataactat	1140
ggacgttatc	atcaagatgg	tttgggagaa	tacaactacc	aattcatgca	accagaagga	1200
gataaggttc	cggcagataa	cttcttttgct	aactttaact	gggataaggc	taaaaatgat	1260
tacactattg	caactgccaa	ctggattggg	cgtaatcctt	atgatgtatt	tgcaggtttg	1320
gaattgcaac	aggggtggtc	ctacaagaca	aagggttaagt	ggaatgacat	tttagacgaa	1380
aatgggaaat	tgcgcttttc	tcttggttta	tttgcccag	ataccattac	aagttttaga	1440
aaaactggtg	aagattatca	taaaaaatgaa	gatattctct	ttacagggtta	tcaaggagac	1500
cctactggcc	aaaaaccagg	tgacaaagat	tggtatggta	ttgctaacct	agttgaggac	1560
cgtacgccag	cggtaggtta	tacttttact	acttctttta	atacagggtca	tggtaaaaaa	1620
tggttcgtag	atggtaagggt	ttctaaggat	tctgagtggg	attatcggtc	agtatcagggt	1680
gttcttccaa	catggcgctg	gtggcagact	tcaacagggg	aaaaacttcg	tgcagaatat	1740
gattttacag	atgcctataa	tgccgggaaat	tcccttaaat	tctctggtga	tgtagccgggt	1800
aagacagatc	aggatgtgag	actttattct	actaagttag	aagtaactga	gaagaccaa	1860
cttcgtgttg	cccacaaggg	aggaaaaggt	tctaaagttt	atatggcatt	ctctacaact	1920
ccagactaca	aattcgatga	tgcagatgca	tggaaaagagc	taaccctttc	tgacaactgg	1980
acaaatgaag	aatttgatct	tagctcacta	gcggttaaaa	ccatctatgc	agtcaacta	2040
tttttcgagc	atgaagggtc	tgtaaaagat	tatcagttta	acctaggaga	attaactatc	2100
tgggacaatc	accaagagcc	acaatcgccg	acaagctttt	ctgtagtga	acaatctctt	2160
aaaaatgcc	agaagcgga	agcagttgtg	caatttaaag	gcaacaagga	tgcagatttc	2220
tatgaagttt	atgaaaaaga	tggagacagc	tggaaattac	taactggctc	atcttctaca	2280
actatttatc	taccaaaggt	tagccgctca	gcaagtgtct	agggtacaac	tcaagaactg	2340
aagggtgtag	cagtcggtaa	aaatggaggt	cggtcagaag	ctgcaaccac	aacctttgat	2400
tggggtatga	ctgtaaaaga	taccagccta	ccaaaaccac	tagctgaaaa	tatcggtcca	2460
ggtgcaacag	ttattgatag	tactttccct	aagactgaag	gtggagaagg	tattgaagggt	2520
atgttgaaag	gtaccattac	tagcttgtca	gataaatggt	cttcagctca	gttgagtgggt	2580
agtgtggata	ttcgtttgac	caagccacgt	accgttgtta	gatgggtcat	ggatcatgca	2640
ggagctgggtg	gtgagtctgt	taacgatggc	ttgatgaaca	ctaaagacct	tgacctttat	2700
tataaagatg	cagatgggtga	gtggaagcta	gctaaggagg	tccgtggtaa	caaagcacac	2760
gtgacagata	tcactcttga	taaaccaatc	actgctcaag	actggcgctt	gaatgttgtc	2820
acttctgaca	atggaactcc	atggaaggct	attcgtatct	ataactggaa	aatgtatgaa	2880
aagcttgata	ctgagaggtg	caatattccg	atggccaagg	ctgcagcccg	ttctctagge	2940
aataacaagg	tacaagttgg	ctttgcagat	gtaccggctg	gagcaactat	taccgtttat	3000
gataatccaa	attctcaaac	tccgctcgca	accttgaaga	gcgaagttgg	aggagacctt	3060
gcaagtgcac	atcttgattt	gacaaatcaa	tctggtcttc	tttattatcg	taccagtttg	3120
ccaggcaagg	aaattagtaa	tgtcctagca	gtttccgttc	caaaagatga	cagaagaatc	3180
aagtcagtea	gcctagaaac	aggacctaa	aaaacaagct	acgccgaagg	ggaggatttg	3240
gaccttagag	gtggtgttct	tgcagttcag	tatgaaggag	gaactgagga	cgaactcatt	3300
cgcttaactc	acgcaggtgt	atcagtatca	ggttttgata	cgcacataaa	gggagaacag	3360
aatcttactc	tcgaatattt	gggacaaccg	gtaaatgcta	atttgtcagt	gactgtcact	3420
ggccaagaag	aagcaagtcc	gaaaactatt	ttgggaattg	aagtaagtca	ggaaccgaaa	3480
aaagattacc	tagttgggtga	tagcttagac	ttgtctgaag	gacgctttgc	agtggcttat	3540
agcaatgaca	ccatggaaga	acattccttt	actgatgagg	gagttgaaat	ttctggttac	3600
gatgctcaaa	agactggctg	tcaaaccctg	acgcttcatt	accaaggcca	tgaagttagc	3660
tttgatgttt	tggtatctcc	aaaagcagca	ttgaacgatg	agtacctcaa	acaaaaatta	3720
gcagaagttg	aagctgctaa	gaacaagggtg	gtctataact	ttgcttcac	agaagtaaaa	3780
gaagccttct	tgaagcaat	tgaagcgcc	gaacaaggtg	tgaagacca	tgaaactagc	3840
acccaagatc	aagtcaatga	ccgacttaac	aaattgacag	aagctcataa	agctctgaat	3900
ggtcaagaga	aatttacgga	agaaaagaca	gagcttgatc	gcttaacagg	tgaggttcaa	3960
gaactcttgg	ctgccaacc	aaaccatcct	tcaggttctg	ccctagctcc	gcttcttgag	4020
aaaaacaagg	ccttggttga	aaaagtagat	ttgagtcag	aagagcttac	aacagcgaaa	4080
cagagtctaa	aagatctgggt	tgctttattg	aaagaagaca	agccagcagt	ctttctgat	4140
agtaaaacag	gtgttgaagt	acacttctca	aataaagaga	agactgtcat	caagggtttg	4200
aaagtagagc	gtgttcaagc	aagtgtgaa	gagaagaaat	actttgctgg	agaagatgct	4260
catgtctttg	aaatagaagg	tttggatgaa	aaagggtcaag	atgttgatct	ctcttatgct	4320
tctattgtga	aaatcccaat	tgaaaaagat	aagaaagtta	agaaagtatt	tttcttacct	4380
gaaggcaaa	aggcagtaga	attggctttt	gaacaaacgg	atagtcatgt	tatctttaca	4440
gcacctcact	ttactcatta	tgcttttgggt	tatgaatctg	ctgaaaaacc	acaacctgct	4500
aaaccagcac	cacaaaacac	agtccttcca	aaacctactt	atcaaccgac	ttctgatcaa	4560
caaaaggctc	ctaaattgga	agttcaagag	gaaaagggtg	cctttcatcg	tcaagagcat	4620
gaaaatactg	agatgctagt	tggggaacaa	cgagtcatca	tacagggacg	agatggactg	4680
ttaagacatg	tctttgaagt	tgatgaaac	ggtcagcgtc	gtcttcgttc	aacagaagtc	4740
atccaagaag	cgattccaga	aattgttgaa	attggaacaa	aagtaaaaac	agtaccagca	4800
gtagtagcta	cacaggaaaa	accagctcaa	aatacagcag	ttaaatcaga	agaagcaagc	4860
aaacaattgc	caaatacagg	aacagctgat	gctaataag	ccctaatagc	aggcttagcc	4920
agccttggtc	ttgctagttt	agccttgacc	ttgagacgga	aaagagaaga	taaagat	4977

SeqID 27

atgtcaatta	catcatttgg	aaaaagaatt	caagatatca	ctcgaaacga	tgctgggtgtt	60
------------	------------	------------	------------	------------	-------------	----

aatggtgatg	ctcaacgtat	tgagcaaatg	tcttggttat	tattcttaaa	aatttatgat	120
agccgtgaaa	tggtttggga	attagaagaa	gacgagtatg	agtcaattat	cccagaggaa	180
ttaaaaatggc	gaaattgggc	tcatgctcaa	aatggggaac	gggtattgac	aggcgatgaa	240
ttacttgatt	ttgtcaataa	caagttatct	aaagagttag	aagagcttga	aataacttca	300
aatatgccta	ttcgaaaaac	gattgttaaa	tcagcttttg	aagatgcgaa	caactatatg	360
aaaaatggcg	tcttggttacg	ccaagtcatc	aatgttattg	atgaagttga	tttcaatagc	420
cctgaagatc	gtcattcggt	taatgatatt	tacgaaaaaa	ttcttaaaaga	tattcaaaat	480
gctgggaact	caggagaatt	ttatacgcca	cgtgcagcga	ctgattttat	tgccgaagtt	540
cttgacccaa	aacttggaga	atcaatggca	gaccttgctt	gcggaacagg	aggcttcttg	600
acttcgactc	tgaaccggtt	aagtagtcaa	cgtaaaaacta	gtgaagatac	caaaaaatat	660
aatacagctg	tttttgggtat	tgaaaagaaa	gcatttcttc	atctttttagc	agttacaaat	720
ctgtttcttc	acgaaattga	tgaccctaaa	attgttcatg	gaaatacttt	ggagaaaaat	780
gttcgtgaat	atcaggatga	tgaaaaattt	gacattatta	tgatgaatcc	accttttgga	840
gggtcagaat	tagaacaat	aaaaaataac	tttcagcag	aattacggag	ttctgaaaca	900
gctgatttat	ttatggctgt	cattatgtat	cgtttgaaag	aaaatggctg	tggtggagtt	960
attttacctg	atggttttct	atttgggtgaa	gggtgtaaaaa	ctcgcttgaa	acaaaaactg	1020
gtagatgagt	tcaacttgca	tacgattatt	aggttgcttc	atagtgtctt	tgaccgctat	1080
acaggaatcc	atcgaacat	tcttttcttt	gataaaaaca	agaaaacaga	agaaacttgg	1140
ttttatcggt	tagatatgcc	agatgggtat	aaaaatttct	cgaaaactaa	gccgatgaag	1200
tcagaacact	tcaatcctgt	tcgtgactgg	tgggaaaaatc	gtgaagagat	tctggaaggt	1260
aagttctaca	aatctaaatc	atttacacct	agtgaattgg	ctgagttgaa	ttataattta	1320
gaccagtgtg	actttccaaa	agaggaagag	gaaatcttaa	atccctttga	gttgattcag	1380
aattatcaag	cggaaagagc	aactttaaat	cataagattg	ataatgtatt	agctgatatt	1440
ttgcagttgt	tgagggacaa	a				1461

SeqID 28

atgaacaata	ctgaatttta	tgatcgtctg	ggggatatcca	aaaacgcttc	ggcagacgaa	60
atcaaaaagg	cttatcgtaa	gctttccaaa	aaatatcacc	cagatatcaa	caaggagcct	120
ggtgctgagg	acaagtacaa	ggaagtcaa	gaagcctatg	agactttgag	tgacgaccaa	180
aaacgtgctg	cctatgacca	gtatgggtct	gcaggcgcca	atggtgggtt	tggtggagct	240
gggtgggttcg	gcggtttcaa	tggggcaggt	ggcttcggtg	gttttgagga	tattttctca	300
agtttctctg	gcggaggcgg	ttcttcgcgc	aatccaaaacg	ctcctcgcca	aggagatgat	360
ctccagtatc	gtgtcaattt	gacctttgaa	gaagctatct	tcggaactga	gaagggaagt	420
aagtatcatc	gtgaagctgg	ctgtcgtaca	tgtaatggat	ctggtgctaa	gccagggaca	480
agtcacgtca	cttgtggacg	ctgtcatggc	gctgggtgtca	ttaacgtcga	tacgcagact	540
cctcttggtg	tgatgcgtcg	ccaagtaacc	tgtgatgtct	gtcacggctg	aggaaaagaa	600
atcaaatatc	catgtacaac	ctgtcatgga	acaggtcatg	agaaaacaagc	tcatagcgta	660
catgtgaaaa	tccttgcgtg	tgtggaaaca	ggtcaacaaa	ttcgccctgc	tggtcaaggt	720
gaagcaggct	ttaacgggtg	accttatggg	gactttgatg	tagtagtttc	tgtggaagct	780
agcgacaagt	ttgaacgtga	aggaacgact	atcttctaca	atctcaacct	caactttgtc	840
caagcggctc	ttggtgatac	agtagatatt	ccaactgttc	acggtgatgt	tgaattgggt	900
attccagagg	gaactcagac	tggtaaagaag	ttccgcctac	gtagtgaagg	ggcaccgagc	960
cttcgtggcg	gtgcagttgg	tgaccaatac	gttactgtta	atgtcgtaac	accgacaggc	1020
ttgaacgacc	gccaaaaagt	agccttgaaa	gaattcgcgg	ctgctgggtg	cttgaaagta	1080
aatccaaaga	aaaaaggtct	ctttgaccat	attaaagatg	cctttgatgg	agaa	1134

SeqID 29

atgaatccta	atcttttttag	aagcgtcgag	ttttatcaga	gacgttacca	taactatgcg	60
acagtgttaa	ttatacctct	ttcattacta	tttactttca	tcttgatttt	ctcccttggt	120
gccacaaaag	aaattactgt	tacttcccaa	ggagaaatcg	cccctacaag	tgtcattgcc	180
tccattcagt	caaccagtga	taatcctatc	ctagctaata	atttagtggc	aaatcaagta	240
gttgaaaaag	gggacttact	catcaaatac	tctgaaacaa	tggaagaaag	tcagaaaact	300
gccttagcaa	ctcaattaca	aagacttgag	aagcaaaaag	aaggacttgg	aattttgaaa	360
caaagcttag	aaaaagcgac	tgatcttttt	tctggcgagg	atgaattttg	ctaccataat	420
accttttatga	attttactaa	acaatcccat	gatattgaac	tggttatcac	aaagactaac	480
accgaagtgt	caaatacagc	taactctttc	aatagcagtt	catcagctat	tgaacaagaa	540
attacaaaag	ttcaacaaca	aattggagaa	tatcaagagt	tgagagatgc	tatcataaat	600
aacagagcac	gcttaccaac	tggcaatccg	caccagtcaa	ttttgaatcg	ttatcttgta	660
gcctcacaag	gacaaacaca	aggaactgca	gaggagccat	ttttatctca	aattaatcaa	720
agtattgcag	gtcttgatc	atctatcgca	agcctcaaaa	ttcagcaagc	tggtatcgga	780
agtgtagcaa	cttatgataa	cagtttagca	accaaaattg	aagtactccg	cactcagttt	840
ttacagacag	cctcacagca	acaactaact	gtggagaatc	aattaacaga	attaaaagta	900
caactagatc	aagccacaca	gcgtttggaa	aacaatacct	taacctcccc	aagtaaagggt	960
atcgttcatc	tgaacagcga	atttgaaggt	aaaaatagaa	ttccaactgg	tacagaaatt	1020
gctcaaatat	tcctgtcat	cacagataca	agagaagtac	taatcactta	ctacgtatct	1080
tctgactatc	tacctctact	agataaagga	caaactgtaa	gattaaaact	ggagaagatt	1140
ggaaatcacg	gcaccacat	catcgcccaa	cttcagacaa	ttgatcaaac	tcctaccaga	1200
acagagcaag	gaaatctctt	taaaattaacc	gctcttgcaa	aactatctaa	cgaggatagt	1260

aaactcatcc	aatatggctt	acaaggctgc	gtcactagtg	taactacaaa	gaaaacatat	1320
tttgattatt	tcaaagataa	aattttaaca	cattctgat			1359

SeqID 30

atgtcaaaga	aactcaatcg	taaaaaacaa	ttacgaaatg	gcctccgtcg	cgcagggtgcc	60
ttttcaagta	cgggtgactaa	ggtttagat	gagacaaaa	aagtcgtgaa	gcgtgcagaa	120
cagtcagcaa	gcgcagctgg	taaggctgtt	tctaaaaaag	ttgaacaagc	agtagaagct	180
accaaagagc	aagctcaaaa	agtagcta	tctgtagaag	atgttcgagc	aaatttggtt	240
ggacttccac	ttgatcgtgc	caagactttc	tatgatgaag	gaatcaagtc	tgttcagat	300
ttcaaaaact	ggactgaaaa	agaactcctt	gccttgaaag	gaatcggccc	agctaccatc	360
aagaaattga	aagaaaatgg	catcaagttc	aag			393

SeqID 31

ttgattagcc	ttttcggcct	tgtctgtgcc	aaaccagtcc	aggctgatac	aagtatcgca	60
gacattcaaa	aaagaggcga	actggttgtc	ggtgtcaaac	aagacgttcc	caattttggt	120
tacaaagatc	ccaagaccgg	tacttattct	ggtatcgaaa	cgcacttggc	caagatggta	180
gctgatgaac	tcaagggtcaa	gattcgtat	gtgccggtta	cagcacaac	ccgcggcccc	240
cttctagaca	atgaacaggt	cgatatggat	atcgcgacct	ttaccatcac	ggacgaacgc	300
aaaaaactct	acaactttac	cagtcacctac	tacacagacg	cttctggatt	tttggtcaat	360
aaatctgcc	aaatcaaaaa	gattgaggac	ctaaacggca	aaaccatcgg	agtcgcccc	420
ggttctatca	cccaacgcct	gattactgaa	ctgggtaaaa	agaaaggtct	gaagtttaa	480
ttcgtcgaa	ttggttccta	cccagaattg	attacttccc	tgacagctca	tcgtatcgat	540
accttttccg	ttgaccgctc	tattctatct	ggctacacta	gtaaacggac	agcactacta	600
gatgatagtt	tcaagccatc	tgactacggt	attgttacca	agaaatcaaa	tacagagctc	660
aacgactatc	ttgataaact	ggttactaaa	tggagcaagg	atggtagttt	gcagaaaactt	720
tatgaccgtt	acaagctcaa	accatctagc	catactgcag	at		762

SeqID 32

atgagtaata	tcagtttaac	aacacttggt	ggtgtgcgtg	agaatggaaa	aaatatgtac	60
attgctgaaa	ttggagagtc	cattttttgt	ttgaatgtag	ggttaaaata	tcctgaaaat	120
gaacaattag	gggtcgatgt	ggtgattcca	aacatggatt	acctttttga	aaatagcgac	180
cgtattgctg	gggttttctt	gacctacggg	catgcggatg	ccattggtgc	tctaccgtat	240
ctcttggcag	aggctaaagt	tctgtattt	gggtctgagt	tgaccattga	gttggcaag	300
ctctttgtca	aaggaaatga	tgccgttaag	aaatttaatg	atttccatgt	cattgatgag	360
aatacggaga	ttgatttttg	tgggacagtg	gtttccttct	tccctacgac	ttactccgtt	420
ccagagagtc	tgggaattgt	cttgaagaca	tcggaaggaa	gcacgtttta	tacaggtgac	480
ttcaaatgtg	accaaacggc	tagtgaatct	tatgcaactg	attttgctcg	tttggcagag	540
attggtcgtg	acggcgtcct	ggctctcctc	agtgattcgg	ccaatgcaga	cagcaatatt	600
cagggtggcta	gtgaaagtga	agttagggtg	gaaattaccc	aaactattgc	tgactgggaa	660
ggctcgtatca	tcgttcgagc	tgtttccagt	aatctttctc	gtattcagca	gatttttgac	720
gctgcggata	aaacagggtcg	acgtatcgtc	ttgacaggat	ttgatattga	aaatatcgtc	780
cgcacagcga	ttcgtcttaa	gaagttgtct	ttagccaacg	aaattctttt	gattaagcct	840
aaagatatgt	ctcgtcttga	agaccatgag	ttgattatct	ttgagacagg	tcgtatgggt	900
gagcctatca	atggacttcg	taagatgtcg	attggtcgcc	atcgttatgt	agaaatcaag	960
gatggggacc	tagtctatat	tgtacggct	ccgtctattg	ctaaagaagc	ctttgttgcg	1020
cgtgtggaaa	atagtattta	tcaggcaggt	gggttgttca	aattgattac	ccaaagttaa	1080
catgtatcag	ggcacggaaa	tgtgctgtat	ttgcagctga	tgatcaatct	tttgcaacct	1140
aagtacctct	tcctgttcca	aggggagtat	cgtgagttgg	atgctcacgc	taaggctgcc	1200
atggcagttg	ggatgttgc	agaacgcac	ttcattccta	aaaaggggac	gaccatggct	1260
tacgagaatg	gagactttgt	tccagctgga	tcggtttcag	caggagatat	cttgattgat	1320
gggaatgcc	ttggtgatgt	tggaaatgtt	gttcttcgtg	accgtaaggt	cttgtcagag	1380
gatggaattt	tcacgtgtgc	tattacagtc	aaccgtcgtg	agaagaaaat	tgtggctagg	1440
gctcgtgttc	acacgcgtgg	atgtgtttat	ctcaagaaga	gtcgcgatat	tctccgtgaa	1500
agttcagaat	tgattaacca	aacggtagaa	gagtatcttc	aaggagatga	ctttgactgg	1560
gcagatctca	aaggttaagg	tcgtgacaat	ctgaccaagt	acctcttga	tcaaaaccaag	1620
cgtcgccag	ccattttacc	agtagtcatg	gaagcaaaa			1659

SeqID 33

atgaaaaaaa	gtacagtatt	gtcattaacc	acagctgcag	ttatttttagc	agcctatgcc	60
cctaagtagg	tagtcttagc	agacacatct	agctctgaag	atgctttaaa	catctctgat	120
aaagaaaaag	tagcagaaaa	taaagagaaa	catgaaaata	tccatagtgc	tatggaaact	180
tcacaggatt	ttaaagagaa	gaaaacagca	gtcattaagg	aaaaagaagt	tgtagtaaaa	240
aatcctgtga	tagacaataa	cactagcaat	gaagaagcaa	aatcaaaaga	agaaaattcc	300
aataaatccc	aaggagatta	tacggactca	tttgtgaata	aaaacacaga	aatcccaaa	360
aaagaagata	aagttgtcta	tattgtgtaa	tttaagata	aagaatctgg	agaaaaagca	420
atcaaggaac	tatccagtct	taagaataca	aaagttttat	atacttatga	tagaattttt	480
aacggtagtg	ccatagaaac	aactccagat	aacttggaca	aaattaaaca	aatagaaggt	540
atttcatcgg	ttgaaagggc	acaaaaagtc	caacccatga	tgaatcatgc	cagaaaggaa	600

attggaggttg	aggaagctat	tgattaccta	aagtctatca	atgctccgtt	tgggaaaaat	660
ttt gatggta	gaggatggt	catttcaaat	atcgatactg	gaacagatta	tagacataag	720
gctatgagaa	tcgatgatga	tgccaaagcc	tcaatgagat	ttaaaaaaga	agacttaaaa	780
ggcactgata	aaaattatgt	gttgagtgt	aaaatccctc	atgctgtcaa	ttattataat	840
ggtggcaaaa	tcactgtaga	aaaatatgat	gatggaaggg	attattttga	cccacatggg	900
atgcataattg	cagggtattct	tgctggaaat	gatactgaac	aagacatcaa	aaactttaac	960
ggcatagatg	gaattgcacc	taatgcacaa	attttctctt	acaaaatgta	ttctgacgca	1020
ggatctgggt	ttgctgggtga	tgaacaatg	tttcatgcta	ttgaagattc	tatcaaacac	1080
aacgttgatg	ttgtttcggg	atcatctggg	tttacaggaa	caggctctgt	aggtgagaaa	1140
tattggcaag	ctattcgggc	attaagaaaa	gcaggcattc	caatggttgt	cgctacgggt	1200
aactatgcga	cttctgcttc	aagttcttca	tgggatttag	tagcaaataa	tcctctgaaa	1260
atgaccgaca	cttggaaatgt	aacacgaact	gcagcacatg	aagatgcgat	agcggctcgt	1320
tctgctaaaa	atcaaacagt	tgagtttgat	aaagttaaca	taggtggaga	aagttttaa	1380
tacagaaata	taggggcctt	tttgcataag	agtaaaatca	caacaaatga	agatggaaca	1440
aaagctccta	gtaaattaaa	atttgtatat	ataggcaagg	ggcaagacca	agatttgata	1500
ggtttggatc	ttaggggcaa	aattgcagta	atggatagaa	tttatacaaa	ggattttaa	1560
aatgctttta	aaaaagctat	ggataagggt	gcacgcgcca	ttatggttgt	aaatactgta	1620
aattactaca	atagagataa	ttggacagag	cttccagcta	tgggatatga	agcggatgaa	1680
ggtactaaaa	gtcaagtgtt	ttcaatttca	ggagatgatg	gtgtaaagct	atggaacatg	1740
attaatcctg	ataaaaaaac	tgaagtcaaa	agaaataata	aagaagattt	taaagataaa	1800
ttggagcaat	actatccaat	tgatatggaa	agttttaatt	ccaacaaacc	gaatgtaggt	1860
gacgaaaaag	agattgactt	taagtttgca	cctgacacag	acaaagaact	ctataaagaa	1920
gatcatcatcg	ttccagcagg	atctacatct	tgggggccaa	gaatagattt	actttttaa	1980
cccgatgttt	cagcacctgg	taaaaatatt	aatccacgc	ttaatgttat	taatggcaaa	2040
tcaacttatg	gctatatgtc	aggaactagt	atggcgactc	caatcgtggc	agcttctact	2100
gttttgatta	gaccgaaatt	aaaggaaatg	cttgaaagac	ctgtattgaa	aaatcttaag	2160
ggagatgaca	aaatagatct	tacaagtctt	acaaaaattg	ccctacaaaa	tactgcgcga	2220
cctatgatgg	atgcaacttc	ttggaagaa	aaaagtcaat	actttgcctc	acctagacaa	2280
cagggagcag	gcctaattaa	tgtggccaat	cttttgagaa	atgaagttgt	agcaactttc	2340
aaaaaactg	attctaaagg	tttggttaac	tcatatgggt	ccatttctct	taaagaaata	2400
aaaggtgata	aaaaatactt	tacaatcaag	cttcacaata	catcaaacag	acctttgact	2460
tttaaaagttt	cagcatcagc	gataactaca	gattctctaa	ctgacagatt	aaaacttgat	2520
gaaacatata	aagatgaaaa	atctccagat	ggtaagcaaa	ttgttccaga	aattcaccca	2580
gaaaaagtca	aaggagcaaa	tatcacattt	gagcatgata	ctttcactat	aggcgcaaat	2640
tctagctttg	atttgaatgc	ggttataaat	gttgagagg	ccaaaaacaa	aaataaattt	2700
gtagaatcat	ttattcattt	tgagtcagt	gaagaaatgg	aagctctaaa	ctccaacggg	2760
aagaaaataa	acttccaacc	ttctttgtcg	atgcctctaa	tgggatttgc	tgggaattgg	2820
aaccacgaac	caatccttga	taaatgggct	tgggaagaag	ggtcaagatc	aaaaaactg	2880
ggaggttatg	atgatgatgg	taaaccgaaa	cttcaggaa	ccttaataaa	gggaattggg	2940
ggaggaacatg	gtatagataa	atttaatcca	atcaggagtt	tacaaaatag	aaaagataaa	3000
aatacaacat	ccctggatca	aaatccagaa	ttatttgctt	tcaataacga	agggatcaac	3060
gctccatcat	caagtgggtc	taagattgct	aacatttatc	ctttagattc	aaatggaaat	3120
cctcaagatg	ctcaacttga	aagaggatta	acaccttctc	cacttgattt	aagaagtgc	3180
gaagaaggat	tgatttcaat	agtaaataca	aataaaggag	gagaaaatca	aagagactta	3240
aaagtcatctt	cgagagaaca	ctttattaga	ggaattttta	attctaaaag	caatgatgca	3300
aagggaatca	aatcatctaa	actaaaagt	tggggtgact	tgaagtggga	tggactcatc	3360
tataatccta	gaggtagaga	agaaaatgca	ccagaaagta	aggataatca	agatcctgct	3420
actaagataa	gaggtcaatt	tgaaccgatt	gcggaagggtc	aatattttcta	taaattttaa	3480
tatagattaa	ctaaagatta	cccatggcag	gtttcctata	ttcctgtaaa	aattgataac	3540
accgccccta	agattgtttc	ggttgatttt	tcaaatcctg	aaaaaattaa	gttgattaca	3600
aaggataactt	atcataaggt	aaaagatcag	tataagaatg	aaacgctatt	tgcgagagat	3660
caaaaagaac	atcctgaaaa	atttgacgag	attgcgaacg	aagtttggt	tgctggcgcc	3720
gctcttggtta	atgaagatgg	agaggttgaa	aaaaatcttg	aagtaactta	cgcaggtgag	3780
ggtcaaggaa	gaaatagaaa	acttgataaa	gacggaaata	ccatttatga	aattaaaggt	3840
gcgggagatt	taaggggaaa	aatcattgaa	gtcattgcat	tagatgggtc	tagcaatttc	3900
acaaagattc	atagaattaa	atttgctaatt	caggctgatg	aaaaggggat	gatttcttat	3960
tatctagtag	atcctgatca	agattcatct	aaatatcaaa	agcttggcga	gattgcagaa	4020
tctaaattta	aaaatttagg	aaatggaaaa	gagggtagtc	taaaaaaaga	tacaactggg	4080
gtagaacatc	atcatcaaga	aatgaagag	tctattaaag	aaaaatctag	ttttactatt	4140
gatagaaata	tttcaacaat	tagagacttt	gaaaaataag	acttaagaa	actcattaaa	4200
agaaatttta	gagaagttga	tgattttaca	agtgaactg	gtaagagaat	ggaggaatac	4260
gattataaat	acgatgataa	aggaaatata	atagcctacg	atgatgggac	tgatctgaa	4320
tatgaaactg	agaaacttga	cgaaatcaaa	tcaaaaattt	atggtgttct	aagtccgtct	4380
aaagatggac	actttgaaat	tcttggaag	ataagtaatg	tttctaaaaa	tgccaaggta	4440
tattatggga	ataactataa	atctatagaa	atcaaagcga	ccaagtatga	tttccactca	4500
aaaacgatga	catttgatct	atagcctaatt	attaatgata	ttgtggatgg	attagctttt	4560
gcaggagata	tgagattatt	tgttaaagat	aatgatcaga	aaaaagctga	aattaaaatt	4620
agaatgcctg	aaaaaattaa	ggaaactaaa	tcagaatatc	cctatgtatc	aagttatggg	4680

aatgtcatag	aattagggga	aggagatctt	tcaaaaaaca	aaccagacaa	tttaactaaa	4740
atggaatctg	gtaaaatcta	ttctgattca	gaaaaacaac	aatatctgtt	aaaggataat	4800
atcattctaa	gaaaaggcta	tgcactaaaa	gtgactacct	ataatcctgg	aaaaacggat	4860
atggttagaag	gaaatggagt	ctatagcaag	gaagatatag	caaaaatata	aaaggccaat	4920
cctaactctaa	gagccctttc	agaaacaaca	atttatgctg	atagtagaaa	tggtgaagat	4980
ggaagaagta	cccaatctgt	attaatgtcg	gctttggacg	gctttaacat	tataaggtat	5040
caagtgttta	catttaaaat	gaacgataaa	ggggaagcta	tcgataaaga	cggaatctt	5100
gtgacagatt	cttctaaact	tgtattattt	ggtaaggatg	ataaagaata	cactggagag	5160
gataagttca	atgtagaagc	tataaaagaa	gatggctcca	tggtatttat	tgataccaaa	5220
ccagttaaacc	tttcaatgga	taagaactac	tttaatccat	ctaaatctaa	taaaatttat	5280
gtacgaaatc	cagaatttta	tttaagaggt	aagatttctg	ataagggtgg	ttttaactgg	5340
gaattgagag	ttaatgaatc	ggttgtagat	aattatttaa	tctacggaga	tttacacatt	5400
gataacacta	gagattttta	tattaagctg	aatgttaaag	acggtgacat	catggactgg	5460
ggaatgaaag	actataaagc	aaacggattt	ccagataaag	taacagatat	ggatggaaat	5520
gtttatcttc	aaactggcta	tagcgatttg	aatgctaaag	cagttggagt	ccactatcag	5580
tttttatatg	ataatgttaa	accggaagta	aacattgcat	ctaagggaaa	tactagtatc	5640
gaatatgctg	atggaaaatc	tgtagtcttt	aacatcaatg	ataaaagaaa	taatggattc	5700
gatggtgaga	ttcaagaaca	acatatttat	ataaatggaa	agaatatac	atcatttaat	5760
gatatttaaac	aaataataga	caagacacta	aacattaaga	ttggtgtaaa	agattttgca	5820
agaaatacaa	ccgtaaaaga	attcatttta	aataaagata	cgggagaggt	aagtgaatta	5880
aaacctcata	gggtaactgt	gaccattcaa	aatggaaaag	aatgagttc	aacgatagtg	5940
tcggaagaag	atttttattt	acctgtttat	aaggggtgaat	tagaaaaagg	ataccaattt	6000
gatggttggg	aaattttctg	tttcgaaggt	aaaaaagacg	ctggctatgt	tattaatcta	6060
tcaaagata	cctttataaa	acctgtattc	aagaaaatag	aggagaaaaa	ggaggaagaa	6120
aataaaccta	cttttgatgt	atcgaaaaag	aaagataacc	cacaagtaaa	ccatagtcaa	6180
ttaaatagaaa	gtcacagaaa	agaggattta	caaagagaag	agcattcaca	aaaaatctgat	6240
tcaactaagg	atgttacagc	tacagttctt	gataaaaaaca	atatcagtag	taaatcaact	6300
actaacaatc	ctaataagtt	gccaaaaact	ggaacagcaa	gcggagccca	gacactatta	6360
gctgccggaa	taatgtttat	agtaggaatt	tttcttggat	tgaagaaaaa	aatcaagat	6420

SeqID 34

atggggaaaag	gccattggaa	tcggaaaaga	gtttatagca	ttcgtaagtt	tgctgtggga	60
gcttgctcag	taatgattgg	gacttgtgca	gttttattag	gaggaaatat	agctggagaa	120
tctgtagttt	atgctggatga	aacacttatt	actcatactg	ctgagaaacc	taaaaggagaa	180
aaaatgatag	tagaagaaaa	ggctgataaa	gctttggaaa	ctaaaaatat	agttgaaagg	240
acagaacaaa	gtgaacctag	ttcaactgag	gctattgcat	ctgagaagaa	agaagatgaa	300
gccgtaactc	caaaagagga	aaaagtgtct	gctaaaccgg	aagaaaaagc	tccaaggata	360
gaatcacaaag	cttcaaatca	agaaaaaccg	ctcaaggaaag	atgctaaagc	tgtaacaaat	420
gaagaagtga	atcaaatgat	tgaagacagg	aaagtggatt	ttaatcaaaa	ttggtacttt	480
aaactcaatg	caaattctaa	ggaagccatt	aaacctgatg	cagacgtatc	tacgtggaaa	540
aaattagatt	taccgtatga	ctggagtatc	tttaacgatt	tcgatcatga	atctcctgca	600
caaaatgaag	gtggacagct	caacggtggg	gaagcttggt	atcgcaagac	tttcaaacta	660
gatgaaaaaag	acctcaagaa	aatgttcgc	cttacttttg	atggcgtcta	catggattct	720
caagtttatg	tcaatggtca	gttagtgggg	cattatccaa	atggttataa	ccagtctcca	780
tatgatataca	ccaaatacct	tcaaaaagat	ggtcgtgaga	atgtgattgc	tgtccatgca	840
gtcaacaaac	agccaagttag	ccgttggtat	tcaggaagtg	gtatctatcg	tgatgtgact	900
ttacaagtga	cagataaggt	gcatgttgag	aaaaatggga	caactatttt	aacacccaaa	960
cttgaagaac	aacaacatgg	caaggttgaa	actcatgtga	ccagcaaaaat	cgtcaataacg	1020
gacgacaaag	accatgaact	tgtagccgaa	tatcaaatcg	ttgaacgagg	tggtcatgct	1080
gtaacaggct	tagttcgtac	agcagtcgt	accttaaaag	cacatgaatc	aacaagccta	1140
gatgcgattt	tagaagttga	aagaccaaaa	ctctggactg	ttttaaatga	caaacctgcc	1200
ttgtacgaat	tgattacgcg	tgtttaccgt	gacggtcaat	tggttgatgc	taagaaggat	1260
ttgtttggtt	accgttacta	tcactggact	ccaaatgaag	gtttctcttt	gaatggtgaa	1320
cgtattaaat	tccatggagt	atccttgcac	cacgacctatg	gggcgcttgg	agcagaagaa	1380
aactataaag	cagaatatcg	ccgtctcaaa	caaatgaagg	agatgggagt	taactccatc	1440
cgtacaaccc	acaaccctgc	tagtgagcaa	accttgcaaa	tcgcagcaga	actaggttta	1500
ctcgttcagg	aagaggcctt	tgatacgtgg	tatggtggca	agaaacctta	tgactatgga	1560
cgtttctttg	aaaaagatgc	cactcaccca	gaagctcgaa	aaggtgaaaa	atggtctgat	1620
tttgacctac	gtaccatggt	cgaaaagaggc	aaaaacaacc	ctgctatctt	catgtggtca	1680
attggtaatg	aaataggtga	agctaatggt	gatgccact	ctttagcaac	tgtaaactgt	1740
ttggttaagg	ttatcaagga	tggtgataag	actcgctatg	ttaccatggg	agcagataaa	1800
ttccggttctg	gtaatggtag	cggagggcat	gagaaaattg	ctgatgaact	cgatgctgtt	1860
ggatttaact	attctgaaga	taattacaaa	gcccttagag	ctaagcatcc	aaaatggttg	1920
atttatggat	cagaaacatc	ttcagctacc	cgtacacgtg	gaagttacta	tcgccttgaa	1980
cgtgaattga	aacatagcaa	tggaactgag	cgtaattatg	aacagtcaga	ttatggaat	2040
gatcgtgtgg	gttgggggaa	aacagcaacc	gcttcattgga	cttttgaccg	tgacaacgct	2100
ggctatgctg	gacagtttat	ctggacaggt	acggactata	ttggtgaacc	tacaccatgg	2160
cacaaccaa	atcaaacctc	tgtaagagc	tcttactttg	gtatcgtaga	tacagccggc	2220

attccaaaac	atgacttcta	tctctaccaa	agccaatggg	tttctgttaa	gaagaaaccg	2280
atggtagacc	ttcttcctca	ctggaactgg	gaaaacaaag	aattagcatc	caaagtagct	2340
gactcagaag	gtaagattcc	agttcgtgct	tattcgaatg	cttctagtgt	agaattgttc	2400
ttgaatggaa	aatctcttgg	tcttaagact	ttcaataaaaa	aacaaaccag	cgatggggcg	2460
acttaccaag	aaggtgcaaa	tgctaataaa	ctttatcttg	aatggaaaag	tgctatcaaa	2520
ccaggtacct	tggaaagcaat	tgctcgtgat	gaatctggca	aggaaaattgc	tcgagataag	2580
attacgactg	ctggtaagcc	agcggcagtt	cgtcttatta	aggaagacca	tcgatttgca	2640
gcagatggaa	aagacttgac	ttacatctac	tatgaaattg	ttgacagcca	ggggaatgtg	2700
gttccaactg	ctaataatct	ggttcgtctc	caattgcatg	gccaaaggtc	actggctcgg	2760
gtagataacg	gagaacaagc	cagccgtgaa	cgtataaagg	cgcaagcaga	tggttcttgg	2820
attcgtaag	catttaattg	taaaggtgtt	gccattgtca	aatcaactga	acaagcaggg	2880
aaattcaccc	tgactgccc	ctctgatctc	ttgaaatcga	accaagtcac	tgtctttact	2940
ggtaagaaag	aaggacaaga	gaagactgtt	ttggggacag	aagtgccaaa	agtacagacc	3000
attattggag	aggcacctga	aatgcctacc	actgttcctg	ttgtatacag	tgatggtagc	3060
cgtgcagaac	gtcctgtaac	ctggtcttca	gtagatgtga	gcaagcctgg	tattgtaacg	3120
tgaaaaggtg	tggctgacgg	acgagaagta	gaagctcgtg	tagaagtgat	tgctcttaaa	3180
tcagagctac	cagttgtgaa	acgtattgct	ccaaatactg	acttgaattc	tgtagacaaa	3240
tctgtttcct	atgttttgat	tgatggaagt	gttgaagagt	atgaagtggg	caagtgggag	3300
attgccgaag	aagataaagc	taagttagca	attccaggtt	ctcgtattca	agcgaccggg	3360
tatttagaag	gtcaaccaat	tcattgcaacc	cttgtggtag	aagaaggcaa	tcctgcggca	3420
cctgcagtac	caactgtaac	ggttgggtgg	gaggcagtaa	caggtcttac	tagtcaaaaa	3480
ccaatgcaat	accgcactct	tgcttatgga	gctaagttgc	cagaagtcac	agcaagtgcg	3540
aaaaatgcag	ctgttacagt	tcttcaagca	agcgacgcaa	acggcatgcg	tgcgagcatc	3600
tttattcagc	ctaaagatgg	tggccctctt	caaacctatg	caattcaatt	ccttgaagaa	3660
gcgccaaaaa	ttgctcactt	gagcttgcaa	gtggaaaaag	ctgacagtct	caaagaagac	3720
caaactgtca	aatgtgtcgg	tcgagctcac	tatcaagatg	gaacgcaagc	tgtattacca	3780
cctgataaag	taaccttctc	tacaagtggg	gaaggggag	tcgcaattcg	taaaggaatg	3840
gttaggttgc	ataagccagg	agcagtcact	ctgaacgctg	aatatgaggg	agctaagagc	3900
caagttgaac	tcactatcca	agccaatact	gagaagaaga	ttgcgcaatc	catccgtcct	3960
gtaaatgtag	tgacagattt	gcattcaggaa	ccaagtcttc	cagcaacagt	aacagttgag	4020
tatgacaaa	gtttccctaa	aactcataaa	gtcacttggc	aagctattcc	gaaagaaaaa	4080
ctagactcct	atcaaacatt	tgaagtacta	ggtaaagttg	aagggaattga	ccttgaagcg	4140
cgtgcaaaa	tctctgtaga	aggtatcgtt	tcagttgaag	aagtcagtgt	gacaactcca	4200
atcgacaga	caccacaatt	accagaaaag	gttcggacat	atgattcaaa	tggtcacggt	4260
tcattcagta	aggttgcatt	ggatgcgatt	cgtccagagc	aatacgcata	ggaagggtgc	4320
tttacagtta	atggtcgtct	agaaggtacg	caattaacaa	ctaaacttca	tggtcgcgta	4380
tctgtctaaa	ctgagcaagg	tgcaaacatt	tctgaccaat	ggaccgggtc	agaattgcc	4440
cttgcccttg	cttcagactc	aaatccaagc	gaccagttt	caaagtgtta	tgacaagctc	4500
atttctctaca	ataaccaacc	agccaatcgt	tggaacaaact	ggaatcgtac	taattccgaa	4560
gcttcagtcg	gtgttctgtt	tggaattcca	ggatatctga	gcaaacgctc	cgttgataat	4620
ctaagtgtcg	gattccatga	agaccatgga	gttggtgtac	cgaagtctta	tggtgattgag	4680
tattatgttg	gtaagactgt	cccaacagct	cctaaaaacc	ctagttttgt	tggtaatgag	4740
gaccatgtct	ttaatgattc	tgccaactgg	aaaccagtta	ctaattctaaa	agcccctgct	4800
caactcaagg	ctggagaaat	gaaccacttt	agctttgata	aagttgaaac	ctatgctgtt	4860
cgtattcgca	tggttaaaagc	agataacaag	cgtggaaacgt	ctatcacaga	ggtacaaaac	4920
tttgcgaaac	aagttgcggc	agccaagcaa	ggacaacaaa	gaatccaagt	tgacggcaaa	4980
gacttagcaa	acttcaaccc	tgatttgaca	gactactacc	ttgagttctg	agatggaaaa	5040
gttccggcag	tcacagcaag	tgtagcaaac	aatggtctcg	ctaccgctcg	tccaagcggt	5100
cgtgaaggtg	agccagttcg	tgctatcgcg	aaagctgaaa	atggcgacat	cttaggagaa	5160
tcctgctcgc	acttcactaa	ggataagagc	ttactttctc	ataaaccagt	tgctgcgggt	5220
aaacaagctc	gcttgctaca	agtaggtcaa	gcacttgaat	tgccgactaa	ggttccaggt	5280
tacttcacag	gtaaaagcgg	ctacgaacaa	aaagacctga	cagttgaatg	ggaagaagtt	5340
ccagcggaaa	atctgacaaa	agcaggtcaa	tttactgttc	gaggccgtgt	ccttggtagt	5400
aaccttggtg	ctgagatcac	tgtacgagtg	acagacaaac	ttggtgagac	tctttcagat	5460
aaccttaact	atgatgaaa	cagtaaccag	gcctttgctt	cagcaaccaa	tgatattgac	5520
aaaaactctc	atgaccgctg	tgactatctc	aatgacggag	atcattcaga	aaatcgctcg	5580
tggaacaaact	ggtcaccaac	accatcttct	aatccagaag	tatcagcggg	tggtgattttc	5640
cgtgaaaatg	gtaagattgt	agaacggact	gttacacaag	gaaaagttca	gttctttgca	5700
gatagtggta	cggatgcacc	atctaaactc	gttttagaac	gctatgtcgg	tccagagttt	5760
gaagtgccaa	cctactattc	aaactaccaa	gcctacgacg	cagaccatcc	attcaacaat	5820
ccagaaaaat	gggaagctgt	tccttatcgt	cgggataaag	acattgcagc	tggtgatgaa	5880
atcaacgtaa	catttaaaagc	tatcaaaagc	aaagctatga	gatggcgtat	ggagcgtaaa	5940
gcagataaga	gcggtgttgc	gatgattgag	atgaccttcc	ttgcaccaag	tgaattgcct	6000
caagaaagca	ctcaatcaaa	gattcttgta	gatggaaaag	aacttgctga	tttcgctgaa	6060
aatcgtcaag	actatcaaat	tacctataaa	ggtcaacggc	caaaagcttc	agttgaagaa	6120
aacaatcaag	tagcttcaac	tgtggtagat	agtggaagag	atagctttcc	agtaacttgt	6180
gcctcgtttt	cagaaaagtg	aaaacaagtc	aagggaatacc	gtatccactt	gactaaggaa	6240
aaaccagttt	ctgagaagac	agttgctgct	gtacaagaag	atcttccaaa	aatcgaattt	6300

gttgaaaaag	atttggcata	caagacagtt	gagaaaaaag	attcaacact	gtatctaggt	6360
gaaactcgtg	tagaacaaga	aggaaaagtt	ggaaaagaac	gtatctttac	agcgattaat	6420
cctgatggaa	gtaagggaaga	aaaactccgt	gaagtggtag	aagttccgac	agaccgcatc	6480
gtcttggttg	gaaccaaac	agtagctcaa	gaagctaaaa	aaccacaagt	gtcagaaaaa	6540
gcagatacaa	aaccaattga	ttcaagtga	gctagctaaa	ctaataaagc	ccagttacca	6600
agtacaggta	gtgcggcaag	ccaagcagca	gtagcagcag	gtttaactct	tctagggttg	6660
agtgacggat	tagtagttac	taaaaggtaaa	aaagaagac			6699

SeqID 35

atggctcctt	ctgtagtggg	cgcagccacc	tatcactatg	taaataaaga	gattattttca	60
caagaagcta	aagatttaata	tcagacagga	aagcctgaca	ggaatgaagt	tgtatatggt	120
ttggtgtatc	aaaaagatca	gttgcctcaa	acagggacag	aagcatctgt	tttgacagct	180
tttggtttgc	tgactgttgg	gagcttgctt	ttaatctaca	agagaaagaa	aattgctagc	240
gtctttctag	ttggagctat	gggattggta	gttcttccta	gtgcaggggc	tgtagacca	300
gttgcgaccc	tagcgtctggc	tagtcgagag	ggtgttgttg	aaatggaggg	ctatcgctat	360
gttggttattc	tatcaggtga	catcctcaaa	acgcttggtc	tggacactgt	tttagaagaa	420
acctcagcaa	aacctggaga	ggtgactgtg	gtcgaagtgt	agactcctca	atcaataaca	480
aatcaggagc	aagctaggac	agaaaaccaa	gtagtagaga	cagaggaagc	tccaaaagaa	540
gaagcaccta	aaacagaaga	aagtccaaag	gaagaaccaa	aatcggaggt	aaaacctact	600
gacgacaccc	ttcctaaagt	agaagagggg	aaagaagatt	cagcagaacc	agctccagtt	660
gaagaagtag	gtggagaagt	tgagtcaaaa	ccagaggaaa	aagtagcagt	taagccagaa	720
agtcaacct	cagacaaccc	agctgaggaa	tcaaaagtgt	aacaagcagg	tgaaccagtc	780
gcgcgaagag	aagacgaaaa	ggcaccagtc	gagccagaaa	agcaaccaga	agctcctgaa	840
gaagagaagg	ctgtagagga	aacaccgaaa	caagaagagt	caactccaga	taccaaggct	900
gaagaaactg	tagaaccaaa	agaggagact	gttaatcaat	ctattgaaca	accaaaggtt	960
gaaacgcctg	ctgtagaaaa	acaaacagaa	ccaacagagg	aaccaaaagt	tgaacaagca	1020
ggtgaaccag	tcgcgccaag	agaagacgaa	caggcaccaa	cggcaccagt	tgagccagaa	1080
aagcaaccag	aagttcctga	agaagagaag	gctgtagagg	aaacaccgaa	accagaagat	1140
aaaataaagg	gtattggtac	taaaagaacca	gttgataaaa	gtgagttaaa	taatcaaat	1200
gataaagcta	gttcagtttc	tcctactgat	tattctacag	caagttacaa	tgctcttgga	1260
cctgttttag	aaactgcaaa	aggtgtctat	gcttcagagc	ctgtaaaaca	gcctgaggtg	1320
aatagcgaga	caataaaact	taaaacggct	attgacgctc	taaaacgttg	taaaactgaa	1380
taaaacaata	cgattgcaga	tgcaaaaaca	aaggtaaaaa	aacattacag	tgatagaagt	1440
tggaacaaac	tccaaactga	agttacaaag	gctgaaaaag	ttgcagctaa	tacagatgct	1500
aaacaaagtg	aagttaacga	agctgttgaa	aaattaactg	caactattga	aaaattggtt	1560
gaattatctg	aaaagccaat	attaacattg	actagtaccg	ataagaaaat	attggaacgt	1620
gaagctgttg	ctaagtatac	tctagaaaat	caaaacaaaa	caaaaatcaa	atcaatcaca	1680
gctgaattga	aaaaaggaga	agaagttatt	aatactgtag	tccttacaga	tgacaaggta	1740
acaacagaaa	ctataagcgc	tgcatttaag	aacctagagt	actacaaaga	atacacccta	1800
tctacaacta	tgatttacga	cagaggtaac	ggtgaagaaa	ctgaaactct	agaaaatcaa	1860
aatattcaat	tagatcttaa	aaaagttgag	cttaaaaata	ttaaacgtac	agatttaatc	1920
aaatacgaaa	atggaaaaga	aactaatgaa	tcactgataa	caactattcc	tgatgataag	1980
agcaattatt	atttaaaaaat	aacttcaaat	aatcagaaaa	ctacattact	agctgttaaa	2040
aatatagaag	aaactacggg	taacggaaca	cctgtatata	aagttacagc	aatcgcagac	2100
aatttagtct	ctagaactgc	tgataataaa	tttgaagaag	aatacgttca	ctatattgaa	2160
aaacctaag	tccacgaaga	taatgtatat	tataatttca	aagaattagt	ggaagctatt	2220
caaaacgatac	cttcaaaaga	atatcgtctg	ggacaatcaa	tgagcgctag	aaatgttgtt	2280
cctaattggaa	aatcatatat	cactaaagaa	ttcacaggaa	aacttttaag	ttctgaagga	2340
aaacaatttg	ctattactga	attggaacat	ccattattta	atgtgataac	aaacgcaacg	2400
ataaataatg	tgaattttga	aaatgtagag	atagaacgtt	ctggtcaaga	taatattgca	2460
tcattagcca	atactatgaa	aggttcttca	gttattacaa	atgtcaaaat	tacaggcaca	2520
ctttcaggtc	gtaataatgt	tgctggattt	gtaataataa	tgaatgatgg	aactcgtatt	2580
gaaaatggtg	ctttcttttg	caaactacac	tctacaagtg	gaaatggctc	tcatacaggg	2640
ggaattgcag	gtacaaacta	tagaggaatt	gttagaaaag	catatgttga	tgctactatt	2700
acaggaaaaca	aaacacgcgc	cagcttggtt	gttcctaaag	tagattatgg	attaactcta	2760
gaccatctta	ttggtacaaa	agctctccta	actgagtcgg	ttgtaaaagg	taaaatagat	2820
gtttcaaatc	cagtagaagt	tgaggaataa	gcaagtaaga	cttggcctgt	aggtacggta	2880
agtaattctg	tcagctatgc	taagattatc	cgtggagagg	agttattcgg	ctctaacgac	2940
gttgatgatt	ctgattatgc	tagtgctcat	ataaaaagatt	tatatgcggt	agagggatat	3000
tcgtcaggta	atagatcatt	taggaaatct	aaaacattta	ctaaattaac	taaagaacaa	3060
gctgatgcta	aagttactac	tttcaatatt	actgctgata	aattagaag	tgatctatct	3120
cctcttgcaa	aacttaatga	agaaaaagcc	tattctagta	ttcaagatta	taacgctgaa	3180
tataaccaag	cctataaaaa	tcttgaaaaa	ttaataccat	tctacaataa	agattatatt	3240
gtatatcaag	gtaataaatt	aaataaagaa	caccatctaa	atactaaaga	agttctttct	3300
gttaccgoga	tgaacaacaa	tgagtttatc	acaaacctag	atgaagctaa	taaaattatt	3360
gttcaactatg	cggacggtac	aaaagattac	tttaacttgt	cttctagcag	tgaaggttta	3420
agtaatgtaa	aagaatatac	tataactgac	tttaggaatta	aataataacc	taatctggtt	3480
caaaaagata	acactactct	tgttaatgat	ataaaatcta	ttttagaatc	agtagagctt	3540

cagtctcaaa	cgatgtatca	gcattctaaat	cgattaggtg	actatagagt	taatgcaatc	3600
aaagattttat	atttagaaga	aagcttcaca	gatgttaaag	aaaacttaac	aaacctaatac	3660
acaaaattag	ttcaaaacga	agaacatcaa	ctaaatgatt	ctccagctgc	tcgtcaaatg	3720
attcgtgata	aagtcgagaa	aaacaaagca	gctttattac	taggtttaac	ttacctaaat	3780
cgttactatg	gagttaaatt	tggtgatggt	aattttaaaag	aattaatgct	attcaaacca	3840
gatttctatg	gtgaaaaagt	tagcgtatta	gacagattaa	ttgaaatcgg	ttctaaagag	3900
aacaacatta	aagggttcacg	tacattcgac	gcattcgggtc	aagtattggc	taaataatact	3960
aaatcaggta	atttagatgc	atTTTTaaat	tataatagac	aattgttcac	aaatatagac	4020
aatatgaacg	attgggtttat	tgatgctaca	gaagaccatg	tctacatcgc	agaacgcgct	4080
tctgaggtcg	aagaaattaa	aaattctaaa	catcgtgcat	tcgataattt	aaaacgaagt	4140
caccttagaa	atactatact	ccactactg	aatttgata	aagcacatct	ttatttaatt	4200
tcaaatata	atgcaattgc	ctttggtagt	gcagagcgat	taggtaaaaa	atcattagaa	4260
gatattaaag	atategttaa	caaagctgca	gatgggtata	gaaactatta	tgatttctgg	4320
tatcgtctag	cgtctgataa	cgtaaaca	cgactactaa	gagatgctgt	tattcctatt	4380
tgggaagggt	ataacgctcc	tggtggatgg	gttgaaaaat	atggccgcta	taataccgac	4440
aaagtatata	ctcctcttag	agaattcttt	ggctctatgg	ataagtatta	taattataat	4500
ggaacaggag	cttatgctgc	tatatatcct	aactctgatg	atattagaac	tgatgtaaaa	4560
tatgttcatt	tagaaatggg	tggtgaatac	gggtatttcag	tttacacaca	tgaacaaca	4620
cacgtcaacg	accgtgcat	ttacttaggt	ggctttggac	accgtgaagg	tactgatgct	4680
gaagcatatg	ctcagggtat	gctacaaact	cctgttactg	gtagtggatt	tgatgagttt	4740
gggtctcttag	gtattaatat	gggtatttaa	cgcaaaaatg	atgggaatca	gtggtatatt	4800
acagatccaa	aaactctaaa	aacacgagaa	gatatttaata	gatataatga	gggttataat	4860
gacactttaa	ctcttcttga	tgaatttgag	gctgaatctg	tgatttctca	acaaaaataa	4920
gatttaaata	gtgcatgggt	caaaaaata	gatagagaat	accgtgataa	caataaatta	4980
aatcaatggg	ataaaattcg	aaatctaagt	caagaagaga	aaaatgaatt	aaatattcaa	5040
tctgttaatg	atttagttga	tcaacaatta	atgactaatc	gcaatccagg	taatggatatc	5100
tataaacccg	aagcaattag	ctataacgat	caatcacctt	atgtaggtgt	tagaatgatg	5160
accggtatct	acggaggtaa	tactagttaa	gggtctcctg	gagctgtttc	attcaaacat	5220
aatgctttta	gattatgggg	ttactacgga	tacgaaaatg	gggtcttagg	ttatgcttca	5280
aataaatata	aacaacaatc	taaaacagat	gggtgagtctg	ttctaagtga	tgaatatatt	5340
atcaagaaaa	tatctaacaa	tacatttaat	actattgaag	aatttaaaaa	agcttacttc	5400
aaagaagtta	aagataaagc	aacgaaagga	ttaacaacat	tcgaagtaaa	tggttcttcc	5460
gtttcatcat	acgatgattt	actgacattg	tttaaagaag	ctgttaaaaa	agatgccgaa	5520
actcttaaac	aagaagcaaa	cggtataata	acagtatcta	tgaataatac	agttaaatta	5580
aaagaagctg	tttataagaa	acttcttcaa	caaacaaata	gctttaaaaa	ttcaatcttt	5640
aaa						5643

SeqID 36

atgaataaac	gtctattttc	aaaaatgagt	ctgggtgacgt	tgccaatttt	agccttggtt	60
tcacaatcag	ttttggcgga	agaaaacatc	catttttcga	gctgtaagga	agcttgggcg	120
aatggctatt	cggatattca	cgaggagaa	cctgggtatt	ctgccaagtt	agaccgtgat	180
catgatgggt	tggcttgcca	attgaaaaat	gctcctaagg	gtgcttttaa	agcaaacag	240
tcaacggcta	ttcaaatcaa	cacaagtcca	gcaacaacaa	gtgggtgggt	taagcaggac	300
ggcgcttggt	actactttga	tggaaatgga	aactagtga	aaaatgcatg	gcagggaagc	360
tattacctga	aagctgatgg	taaaatggca	cagagtgaat	ggatttatga	ctcttcttat	420
caagcttggt	attatttgaa	atcagatggt	tcttatgcaa	aaaatgcatg	gcaaggagct	480
tattacctta	aatcaaacgg	taaaatggca	caaggtgagt	gggtttatga	ttcttcttac	540
caagcatggt	attacttgaa	atcagatggt	tcatatgctc	gcaatgcatg	gcaaggaaac	600
tactatttga	aatcagatgg	taaaatggct	aaaggtgaat	gggtttatga	tgccacctat	660
aaagcttggt	attatttgac	atcagatggt	tcttatgctt	acagtacatg	gcaaggaaat	720
tactatctaa	aatcggatgg	taaaatggct	gtcaatgaat	gggttgatgg	tggaaggtat	780
atgttgggcg	ctgacggagt	ttggaaggaa	gttcaagcaa	gtacagcttc	ttctagtaat	840
atagcaata	gtgaatattc	tgctgcttta	ggaaggcaa	aaagttataa	ttcgttatctc	900
acatgtcaa	aaaaacgtat	gtatagacaa	ttaactctg	attttgataa	attttcaaat	960
atgcagctc	aatatgccat	tgatcattta	gatgat			996

SeqID 37

atgaagtaa	tagatcaatt	taaaaataag	aaagtccttg	ttttaggttt	ggccaagtct	60
atgtaatctg	cagctcggtt	gttggaacag	ctaggtgcca	ttgtgacagt	aaatgatggg	120
aaacctttcg	aggacaatcc	agctgcccaa	agtttgctgg	agaagggat	caaggtcatt	180
acaggtggcc	atcctttgga	actcttggt	gaagagtttg	cccttatggg	gaaaaatcca	240
atgacccct	acaacaatcc	catgattgaa	aaggctttgg	ccaagggaat	tccagtcttg	300
ctgaggtgg	aattggctta	tttgatttca	gaagcaccga	ttattgggtat	cacaggatcg	360
acggtaaga	caaccacaac	gactatgatt	ggggaagttt	tgactgctgc	tgccaacat	420
gtcttttat	caggaatat	cggtatcca	gctagtacgg	ttgctcaaat	agcatcagat	480
aggacacgc	ctgttatgga	actttcttct	ttccaactca	tggtgttca	agaattccat	540
cagagattg	cggttattac	caacctcatg	ccaactcata	tcgactacca	tggttcattt	600
cggaaatag	tagcagccaa	gtggaatata	cagaacaaga	tgacagcagc	tgatttctct	660

gtcttgaact	ttaatcaaga	cttggcaaaa	gacttgactt	ccaagacaga	agccactgtt	720
gtaccatttt	caacacttga	aaaggttgat	ggagcttata	tggagatgg	tcaactctac	780
ttccgtggtg	aagtagtcat	ggcagcgaat	gaaatcgggtg	ttccaggtag	ccacaatgtg	840
gaaaatgccc	ttgcgactat	tgctgtagcc	aagcttcgtg	atgtggacaa	tcaaaccatc	900
aaggaaactc	tttcagcett	cggtgggtgc	aaacaccgtc	tccagtttgt	ggatgacatc	960
aagggtgtta	aattctataa	cgacagtaaa	tcaactaata	tcttggctac	tcaaaaagcc	1020
ttgtcaggat	ttgacaacag	caaggtcgtc	ttgattgcag	gtggtttggg	ccgtggcaat	1080
gagtttgacg	aattgggtgcc	agacattact	ggactcaaga	agatgggtcat	cctgggtcaa	1140
tctgcagaac	gtgtcaaacg	ggcagcagac	aaggctgggtg	tcgcttatgt	ggagggcaga	1200
gatattgcag	atgcgacccg	caaggcctat	gagcttgcca	ctcaaggaga	tgtggttctt	1260
cttagtcctg	ccaatgctag	ctgggatatg	tatgctaact	ttgaagtacg	tggcgacctc	1320
tttatcgaca	cagtagcgga	gttaaaaaga				1350

SeqID 38

atgaagaaaa	aatttgcctt	atcgtttgtg	gcgcttgcaa	gtgtagcact	tcttgcagcc	60
tgtggagaag	tgaagtctgg	agcagtcac	actgctggta	actcagtaga	ggaaaagaca	120
attaaaatcg	ggtttaactt	tgaagaatca	ggttcttttag	ctgcatacgg	aacagctgaa	180
caaaaagggtg	cccaattggc	tgttgatgaa	atcaatgccg	caggtgggtat	cgatggaaaa	240
caaatcgaag	tagtcgataa	agataataag	tctgaaacag	ctgaggctgc	ttcagttaca	300
actaaccttg	taaccaatc	taaagtatca	gcagtcgtag	gacctgcgac	atctggtgcg	360
actgcagctg	cggtagcgaa	cgctacaaaa	gcaggtgttc	cattgatctc	accaagtgcg	420
actcaagatg	gattgactaa	aggtcaagat	tacctcttta	ttggaacttt	ccaagatagc	480
ttccaaggaa	aaattatctc	aaactatggt	tctgaaaaat	taaatgctaa	gaaagtgtgt	540
ctttacactg	acaatgccag	tgactatgct	aaagggattg	caaatcttt	ccgcgagtca	600
tacaaggggtg	aatcgttgc	agatgaaact	ttcgtagcag	gtgacacaga	cttccaagca	660
gcctttacaa	aatgaaaagg	gaaagacttt	gatgctatcg	ttgttcctgg	ttactataat	720
gaggctggta	aaattgtaaa	ccaagcgcgt	ggcatgggaa	ttgacaaacc	aatcgttgggt	780
ggtgatggat	tcaacgggtg	ggagtgttga	caacaagcaa	ctgctgaaaa	agcatcaaac	840
atctacttta	tctcaggctt	ctcaactact	gtagaagttt	cagctaaagc	taaagccttc	900
cttgacgctt	accgtgctaa	gtacaatgaa	gagccttcaa	catttgcagc	cttggcttat	960
gattcagttc	accttgtagc	aaacgcagca	aaaggtgcta	aaaattcagg	tgaatcaag	1020
aataaaccttg	ctaaaacaaa	agattttgaa	ggtgtaactg	gtcaaaacag	cttcgatgca	1080
gaccacaaca	cagtcaaaac	tgcttacatg	atgaccatga	acaatggtaa	agttgaagca	1140
gcagaagttg	taaaacca					1158

SeqID 39

atgagttatt	tagaagttaa	aaatctgagt	cacggttttg	gtgaccgtgc	aatttttgaa	60
gatgtgtcct	tccgtctcct	caaggagaaa	catatcgcc	tggctgggtgc	caatgggtgaa	120
ggaaaatcaa	cctttatgag	tatcgtgact	ggtaaaaatgc	tgccagatga	aggaaaaggt	180
gagtggtcca	aatatgtgac	ggctgggttac	ttggatcagc	actctgtcct	tgctgaaaga	240
cagtcgggtgc	gtgatgttct	ccgtacggct	tttgatgagc	ttttcaaagc	tgaagctcgt	300
atcaatgacc	tctatatgaa	aatggctgaa	gacggcgcgg	atgttgatgc	tctcatggaa	360
gaagtaggag	aacttcaaga	cgtctggag	agtcgtgatt	tctatacctt	ggatgctaag	420
attgacgaag	tagcgcgtgc	tcttgggtgt	atggactttg	gcatggatac	ggatgtaact	480
tctttgtcag	gtgggcaaa	aaccaagggtg	cttttggcaa	aacttctcct	tgaaaagcct	540
gatattctgc	tggtggacga	gccgaccaac	tacttggatg	ctgagcatat	tgattggctc	600
aagcgctatc	tccaaaacta	tgagaatgcc	tttgttctca	tttcgcacga	tattccattc	660
ctcaatgacg	ttattaatat	tgtctatcat	gtggaaaaatc	aacagctgac	gcgttactct	720
ggtgactact	accagttcca	agaagtttat	gctatgaaga	aatctcagct	agaggcagcc	780
tacgaacgcc	agcagaaaga	gattgcagac	ctcaaggact	ttgtggctcg	taataaagcc	840
cgtgttgcaa	ctcgtaatat	ggctatgtct	cgtcaaaaga	aattggataa	gatggatatt	900
atcgaactcc	aaagtggaga	accaaaccac	tcctttgatt	tcaaaccagc	tcgtacacca	960
gggcgcttta	tcttccaagc	caagaacttg	caaattgggt	acgaccgtcc	tcttactaag	1020
cctttaaatc	ttaccttcga	acgcaatcaa	aaggttgoga	ttattgggtgc	taatgggtatt	1080
ggaaaaacaa	ctctcttgaa	gagtctcttg	ggcattatct	cgccaatcgc	tgggggaagtg	1140
jagcgtggag	attattttaga	acttgggttat	tttgagcagg	aagtagaagg	cggtaatcgc	1200
aaactcctc	ttgaagctgt	ctgggaatgcc	tttctgccc	ttaatcaagc	agaagtccgt	1260
jagcccttg	cccggttggtg	tttgacaacc	aaacatattg	aaagccagat	tcaagtatta	1320
acagggggag	agcaagccaa	ggttcgtttc	tgtctcttga	tgaatcgtga	aaacaacggt	1380
ctagtgtcgg	acgagccgac	caaccatttg	gatgtggatg	caaaggatga	gctcaaacgc	1440
jctctcaag	aatatagggg	atctatcctt	atggtctgcc	acgagccaga	cttttatgaa	1500
jgctggatag	accaaatatg	ggattttta	aattttaact			1539

SeqID 40

itgaagaaaa	agaatggtaa	agctaaaaag	tggcaactgt	atgcagcaat	cggtgctgcg	60
igtgtagttg	tattgggtgc	tggggggatt	ttactcttta	gacaaccttc	tcagactgct	120
taaaagatg	agcctactca	tcttgttggt	gccaaggaag	gaagcgtggc	ctcctctggt	180
tattgtcag	ggacagtaac	agcaaaaaat	gaacaatatg	tttattttga	tgctagtaag	240

ggtgatttag	atgaaatcct	tgtttctgtg	ggcgataagg	tcagcgaagg	gcaggcctta	300
gtcaagtaca	gtagttcaga	agcgcaggcg	gcctatgatt	cagctagtcg	agcagtagct	360
agggcagatc	gtcatatcaa	tgaactcaat	caagcacgaa	atgaagccgc	ttcagctccg	420
gctccacagt	taccagcgcc	agtaggagga	gaagatgcaa	cgggtgcaaag	cccaactcca	480
gtggctggaa	attctgttgc	ttctattgac	gctcaattgg	gtgatgcccg	tgatgcgcgt	540
gcagatgctg	cggcgcaatt	aagcaaggct	caaagtcaat	tggaatgcaac	aactgttctc	600
agtaccctag	agggcaactgt	ggtcgaagtc	aatagcaatg	tttctaaatc	tccaacaggg	660
gcgagtcaag	ttatggttca	tattgtcagc	aatgaaaatt	tacaagtcaa	gggagaattg	720
tctgagtaca	atctagccaa	cctttctgta	ggtcaagaag	taagctttac	ttctaaagtg	780
tatcctgata	aaaaatggac	tgggaaatta	agctatat	ctgactatcc	taaaaacaat	840
ggtgaagcag	ctagtccagc	agccgggaat	aatacaggtt	ctaaataccc	ttatactatt	900
gatgtgacag	gcgaggttgg	tgatttgaaa	caagggtttt	ctgtcaacat	tgaggttaaa	960
agcaaaacta	aggctattct	tgttcctgtt	agcagtctag	taatggatga	tagtaaaaaat	1020
tatgtctgga	ttgtggatga	acaacaaaag	gctaaaaaag	ttgaggtttc	attgggaaat	1080
gctgacgcag	aaaatcaaga	aatcacttct	ggtttaacga	acggtgctaa	ggtcatcagt	1140
aatccaacat	cttccttgga	agaaggaaaa	gaggtgaagg	ctgatgaagc	aactaat	1197

SeqID 41

tcagaaacaa	atcacgaaat	tgattcaaat	tttgcaggtc	gtttaaatat	cctgcgtgcg	60
ggtgttcttg	atgctaacga	tgaattatt	tcattgctg	gtgtggttat	cggagttgcc	120
agtgccacga	ccaatatctg	gattatcttt	ttatcaggtt	ttacggctat	cttagctggt	180
gccttttcaa	tggtgtgtgg	agaatatgta	tccgtttcaa	ctccaaaaga	taccgaggaa	240
gctgccgttt	gcgagaaaaa	actcttgcta	gaccaagata	gggaactagc	caaaaaatcc	300
ctctatgctg	cttatatcca	aaatggagaa	ttcaaaaactt	ctgcccact	cttgaccaat	360
aagatctttc	ttaaaaatcc	actcaaggct	ctggtagagg	aaaaatatgg	gattgagtat	420
gaagaattta	ccaatccttg	gcacgctgcc	atttctagct	tcgttgccctt	tttctctaga	480
agtttgcttc	caatgctgtc	agtgaccatt	tttccaagtg	attaccgcat	ccctgctacc	540
gtccttattg	tcggtgtggc	ccttcttctc	actggttaca	caagtgttag	acttggaata	600
gccccaacca	aaacagctat	gattcggaac	cttgctattg	gtctcttgac	catgggagtt	660
accttctctg	tcggacaact	tttcagcatt				690

SeqID 42

atgaaaaaga	aattaactag	tttagcactt	gtaggcgctt	ttttaggttt	gtcatgggat	60
gggaatgttc	aggctcaaga	aagttcagga	aataaaatcc	actttatcaa	tgttcaagaa	120
ggtggcagtg	atgcgattat	tcttgaaagc	aatggacatt	ttgccatggt	ggatacagga	180
gaagattatg	atttcccaga	tggaaagtga	tctcgctatc	catggagaga	aggaattgaa	240
acgtcttata	agcatgttct	aacagaccgt	gtctttcgtc	gtttgaagga	attgggtgtc	300
caaaaacttg	attttatttt	ggtgacccat	accacacagt	atcatattgg	aaatggtgat	360
gaattactgt	ctacctatcc	agttgaccga	gtctatctta	agaaatatag	tgatagtcgt	420
attactaatt	ctgacgtctc	attgggataat	ctgtatggct	atgataaggt	tttacagact	480
gctgcagaaa	aaggtgtttc	agttattcaa	aatatcacac	aaggggatgc	tcatttttcag	540
tttggggaca	tggatattca	gctctataat	tatgaaaatg	aaactgattc	atcgggtgaa	600
ttaaagaaaa	tttgggatga	caattccaat	tccttgatta	gcgtggtgaa	agtcaatggc	660
aagaaaattt	accttggggg	cgatttagat	aatgttcatg	gagcagaaga	caagtatggt	720
cctctcattg	gaaaagttag	ttgatgaag	tttaatcatc	accatgatac	caacaaatca	780
aataccaagg	atttcattaa	aaatttgagt	ccgagtttga	ttgttcaaac	ttcggatagt	840
ctaccttgga	aaaatggtgt	tgatagttag	tatgttaatt	ggctcaaaga	acgaggaatt	900
gagagaatca	acgcagccag	caaagactat	gatgcaacag	tttttgatat	tcgaaaagac	960
ggttttgtca	atatttcaac	atcctacaag	ccgattccaa	gttttcaagc	tggttggcat	1020
aagagtgcac	atgggaactg	tggttatcaa	gcgcctgatt	ctacaggaga	gtatgctgtc	1080
ggttggaatg	aaatcgaagg	tgaatggtat	tactttaacc	aaacgggtat	cttggttacag	1140
aatcaatgga	aaaaatggaa	caatcattgg	ttctatttga	cagactctgg	tgcttctgct	1200
aaaaattgga	agaaaatcgc	tggaaatctg	tattatttta	acaaaagaaa	ccagatggaa	1260
attgggttga	ttcaagataa	agagcagtg	tattatttgg	atgttgatgg	ttctatgaag	1320
acaggatggc	ttcaatatat	ggggcaatgg	tattactttg	ctccatcagg	ggaaatgaaa	1380
atgggctggg	taaaagataa	agaaacctgg	tactatatgg	attctactgg	tgatcatgaag	1440
acaggtgaga	tagaagttgc	tgggtcaacat	tattatctgg	aagattcagg	agctatgaag	1500
caaggctggc	ataaaaaggc	aaatgattgg	tatttctaca	agacagacgg	ttcacgagct	1560
gtgggttggg	tcaagacaaa	ggataaatgg	tacttcttga	aagaaaatgg	tcaattactt	1620
gtgaacggta	agacaccaga	aggttatact	gtggattcaa	gtggtgcctg	gttagtggat	1680
gtttcgatcg	agaaatctgc	tacaattaaa	actacaagtc	attcagaaat	aaaagaatcc	1740
aaagaagtag	tgaaaaagga	tcttgaaaat	aaagaaacga	gtcaacatga	aagtgttaca	1800
aatttttcaa	ctagtcaaga	tttgacatcc	tcaacttcac	aaagctctga	aacgagtgtg	1860
aacaaatcgg	aatcagaaca	g				1881

SeqID 43

atggacttag	gtcccaccca	aagaggtatt	agtgtcgtgt	ctcaatctta	tatcaatggt	60
atcgggtgctg	gtttggcagg	ttctgaagca	gcttaccaaa	tcgcagagcg	tggtattcca	120

gttaaaactat	atgaaatgcg	tgggtgtcaag	tctacacccc	agcataaaaac	agacaattttt	180
gctgagttgg	tttgttccaa	ttcttttgcgt	ggggatgctt	tgacaaatgc	agttggtcctt	240
ctcaagggaag	aaatgcgctcg	cttgggttct	ggttatcttgg	aatctgctga	ggctacacgt	300
gttcctgcag	gtggtgccct	tgcagtggac	cgtgatggtt	tctctcaaat	ggtgaccgaa	360
aaagtgtcca	accacccctt	gattgaagtg	gttcgtgatg	aaattacaga	attgcccaga	420
gatgcttatta	cggttatcgc	tactggtcct	ttgacaagtg	atgccttggc	tgaaaagatt	480
catgctctta	atgacggtgc	tggtttttat	ttctacgatg	cggcagcgcc	tattatcgat	540
gtcaacacta	tcgatatgag	caaggtctac	ctcaaatcac	gttatgataa	gggagaagcg	600
gcctacctca	atgcccctat	gaccaagcaa	gaatttatgg	atttccatga	agctttggtc	660
aatgcagaag	aagcaccgct	tagttctttt	gaaaaagaaa	agtactttga	aggatgtatg	720
cctatcgaag	tcatggccaa	acgtggcatt	aaaactatgc	tttatggccc	tatgaagcca	780
gtcggctctg	agtaccocaga	cgactataca	ggacctcgtg	atggagaatt	taaaacacct	840
tatgcggttg	tgcaacttcg	tcaggataat	gcagctggta	gcctctacaa	tattgttggg	900
ttccagaccc	acctcaaatg	gggagaacaa	aagcgtgtct	tccaaatgat	tccgggtcctt	960
gaaaatgctg	agtttgtccg	ttatgggtgtg	atgcatcgca	attcttacat	ggattcacca	1020
aatcttcttg	agcagactta	ccgttcttaag	aaacaaccaa	atctcttctt	tgctggtcaa	1080
atgacgggtg	tggaaaggcta	tgttgagtgc	gcggcttcag	gcttagttgc	gggaattaac	1140
gcagctcgtc	tcttcaagga	agaaagcgag	gctattttcc	cggagacgac	agcgattgga	1200
agcttagctc	attacattac	ccatgccgac	agcaaacatt	tccaaccaat	gaatgtcaat	1260
tttgggatca	tcaaggagtt	ggaaggcgag	cgtatccgtg	ataagaaggc	tcgttatgaa	1320
aaaattgcag	agcgtgccct	tgcgcactta	gaggaaat	tgactgtc		1368

SeqID 44

atgttaatcg	gaatcccaaa	agaaattaaa	aataacgaaa	accgtgtcgc	cctcacacct	60
gcaggtgttc	atagcttagt	tagtcgtggt	catcgtgtcc	ttatcgaaac	aaatgctggt	120
ctcggttctg	gctttactga	tgctgactat	caaaagcaag	gagctgagat	tgctcgctact	180
gctgggtgaag	cttgggcagc	agagttggtt	gtgaaagtaa	aagaatcttt	aagttctgaa	240
tacgggttact	tgcgcgacga	tcttcttctc	ttcacctact	tgacatggc	cgtgctcca	300
gaattagcag	atgctatggt	aacagcaaaa	acaactgaaa	ctgttcgtga	caatcaagga	360
caactaccgc	tcctcgttcc	tatgagttag	gttgacggc	gtatggctgt	tcaaatcgga	420
gctcacttcc	ttactaagca	agctgggtgg	tctggtgttc	tacttgggtg	tgtaccaggt	480
gttccaaaag	gaaaagtaac	tatcatcggt	gggtggtgtc	tcggtagaca	tgctgcccg	540
atcgcccttg	gtcttgggtg	tcaagttagt	atcttagata	ttagttccaa	gcgtctctca	600
gttctagaag	aagtccttgg	aagtcaaat	caaactctta	tgtctaattc	attcaacatt	660
gaagcaagtg	tgagagatgc	tgatgtggtg	attggagcca	ttctcatccc	tggtgcaaaa	720
gcaccggaat	tggtgacaga	tgagatggtc	aaacaaatgc	gtccaggctc	tgtatcgttg	780
acgttgctgt	tgaccaaggt	ggcggttatc	aaacagctga	ccgtgtgaca	acgcacgatg	840
aaccggtcta	tgaaaaacac	ggtgttctcc	actatgccgt	tgccaatc	cctggtgctg	900
ttgctcgac	ttcaaccatc	gccctaacca	atgtcactct	tccttatata	gaagctttgg	960
ctggcaagg	attcgcacaa	gcaatctctg	aagatgaagg	cttgctgcaa	ggtgtgacta	1020
cttatcaagg	ttacttgact	aacctaccag	ttgctcaagg	acttaatcgt	gactacactg	1080
atatcaatga	tttagta					1097

SeqID 45

atgaaaatta	ataaaaaata	tctagcaggt	tcagtgccag	tccttgccct	aagtgtttgt	60
tcctatgaac	ttggtcgtca	ccaagctggt	cagggttaaga	aagagtctaa	tcgagtttct	120
tatatagatg	gtgatcaggc	tggtcaaaaag	gcagaaaact	tgacaccaga	tgaagtcagt	180
aagaggagg	ggatcaacgc	cgaacaaatc	gtcatcaaga	ttacggatca	aggttatgtg	240
acctctcatg	gagaccatta	tcattactat	aatggcaagg	tccttatga	tgccatcatc	300
agtgaagagc	tcctcatgaa	agatccgaat	tatcagttga	aggattcaga	cattgtcaat	360
gaaatcaagg	gtggttatgt	tatcaaggta	gatggaaaat	actatgttta	octtaaggat	420
gcagctcatg	cggataatat	tcggacaaaa	gaagagatta	aacgtcagaa	gcaggaaacac	480
agtcataatc	acgggggtgg	ttctaaccgat	caagcagtag	ttgcagccag	agcccaagga	540
cgctatacaa	cggatgatgg	ttatatcttc	aatgcatctg	atatcattga	ggacacgggt	600
gatgcttata	tcgttctctca	cggcgacctat	taccattaca	ttcctaagaa	tgagttatca	660
gctagcgagt	tagctgctgc	agaagcctat	tggaaaggga	agcagggatc	tcgtccttct	720
tcaagttcta	gttataatgc	aaatccagct	caaccaagat	tgtagagaa	ccacaatctg	780
actgtcactc	caacttatca	tcaaaatcaa	ggggaaaaca	tttcaagcct	tttacgtgaa	840
ttgtatgcta	aacccttatc	agaacgccat	gtggaatctg	atggccttat	tttcgaccca	900
gcgcaaatca	caagtcaaac	cgcagaggtg	gtagctgtcc	ctcatggtaa	ccattaccac	960
tttatccctt	atgaacaaat	gtctgaattg	tcaaaacgaa	ttgctcgat	tattccctt	1020
cgttatcggt	caaaccattg	ggtaccagat	gaagaccag	aacaaccaag	tccacaatcg	1080
actccggaac	ctagtccaag	tccgcaacct	gcaccaaatc	ctcaaccagc	tccaagcaat	1140
ccaattgatg	agaaattggt	caaagaagct	gttcgaaaag	taggcgatgg	ttatgtcttt	1200
gaggagaatg	gagtttctcg	ttatatccca	gccaaaggatc	tttcagcaga	aacagcagca	1260
ggcattgata	gcaaaactggc	caagcaggaa	agtttatctc	ataagctagg	agctaagaaa	1320
actgacctcc	catctagtga	tcaataaagg	cttatgactt	actagcaaga		1380
attcaccaag	atttacttga	taataaagg	cgacaagttg	atcttgaggc	tttgataaac	1440

ctgttggaac	gactcaagga	tgtcccaagt	gataaagtca	agttagtggg	tgatattctt	1500
gccttcttag	ctccgattcg	tcattccagaa	cgttttaggaa	aaccaaatgc	gcaaattacc	1560
tacactgatg	atgagattca	agtagccaag	ttggcaggca	agtacacaac	agaagacggt	1620
tatatctttg	atcctcgtga	tataaccagt	gatgaggggg	atgcctatgt	aactccacat	1680
atgacccata	gccactggat	taaaaaagat	agtttgtctg	aagctgagag	agcggcagcc	1740
caggcttatg	ctaaagagaa	aggtttgacc	cctccttcga	cagaccatca	ggattcagga	1800
aatactgagg	caaaaggagc	agaagctatc	tacaaccgcg	tgaaagcagc	taagaagggtg	1860
ccacttgatc	gtatgcctta	caatcttcaa	tatactgtag	aagtcaaaaa	cggtagttta	1920
atcatacctc	attatgacca	ttaccataac	atcaaatctg	agtgggttga	cgaaggcctt	1980
tatgaggcac	ctaaggggta	tactcttgag	gatcttttgg	cgactgtcaa	gtactatgtc	2040
gaacatccaa	acgaacgtcc	gcattcagat	aatgggtttg	gtaacgctag	cgaccatggt	2100
cgtaaaaaata	aggtagacca	agacagtaaa	cctgatgaag	ataaggaaca	tgatgaagta	2160
agtgaagcaa	ctcaccctga	atctgatgaa	aaagagaatc	acgctgggtt	aaatccttca	2220
gcagataatc	tttataaacc	aagcactgat	acggaagaga	cagaggaaga	agctgaagat	2280
accacagatg	aggctgaaat	tcctcaagta	gagaattctg	ttattaacgc	taagatagca	2340
gatgcggagg	ccttgctaga	aaaagtaaca	gacccctagta	ttagacaaaa	tgctatggag	2400
acattgactg	gtctaaaaag	tagtcttctt	ctcggaaacga	aagataataa	cactatttca	2460
gcagaagtag	atagtctctt	ggctttgtta	aaagaaagtc	aaccggctcc	tatacag	2517

SeqID 46

atgaaattta	gtaaaaaata	tatagcagct	ggatcagctg	ttatcgtatc	cttgagtcta	60
tgtgcctatg	cactaaacca	gcacgttcg	caggaaaata	aggacaataa	tcgtgtctct	120
tatgtggatg	gcagccagtc	aagtcagaaa	agtgaaaact	tgacaccaga	ccagggttagc	180
cagaaagaag	gaattcaggc	tgagcaaatt	gtaatcaaaa	ttacagatca	gggctatgta	240
acgtcacacg	gtgaccacta	tcattactat	aatgggaaag	ttccttatga	tgccctcttt	300
agtgaagaac	tcttgatgaa	ggatccaaac	tatcaactta	aagacgctga	tattgtcaat	360
gaagtcraag	gtggttatat	catcaaggtc	gatggaaaat	attatgtcta	cctgaaagat	420
gcagctcatg	tcagtaaatgt	tcgaactaaa	gatgaaatca	atcgtcaaaa	acaagaacat	480
gtcaaagata	atgagaaggt	taactctaata	gttgctgtag	caaggctctca	gggacgatat	540
acgacaaatg	atggttatgt	ctttaatcca	gctgatatta	tcgaagatac	gggtaatgct	600
tatatcgctc	ctcatggagg	tcactatcac	tacattccca	aaagcgattt	atctgctagt	660
gaattagcag	cagctaaagc	acatctggct	ggaaaaaata	tgcaaccgag	tcagttaagc	720
tattcttcaa	cagctagtga	caataacacg	caatctgtag	caaaaggatc	aactagcaag	780
ccagcaataa	aatctgaaaa	tctccagagt	cttttgaagg	aactctatga	ttcacctagc	840
gcccaacggt	acagtgaatc	agatggcctg	gtccttgacc	ctgctaagat	tatcagtcgt	900
acaccaaatg	gagtgcgat	tcgcgatggc	gaccattacc	actttattcc	ttacagcaag	960
ctttctgcct	tagaagaaaa	gattgccaga	atggtgccta	tcagtggaac	tggttctaca	1020
gtttctacaa	atgcaaaacc	taatgaagta	gtgtctagtc	taggcagctc	ttcaagcaat	1080
cttctcttct	taacgacaag	taaggagctc	tcttcagcat	ctgatgggtta	tatttttaat	1140
ccaaaagata	tcggtgaaga	aacggctaca	gcttatattg	taagacatgg	tgatcatttc	1200
cattacattc	caaaatcaaa	tcaaattggg	caaccgactc	ttccaaacaa	tagtctagca	1260
acaccttctc	catctcttcc	aatcaatcca	ggaacttcac	atgagaaaca	tgaagaagat	1320
ggatacggat	ttgatgctaa	tcgtattatc	gctgaagatg	aatcagggtt	tgatcatgag	1380
cacggagacc	acaactatta	tttcttcaag	aggacttga	cagaagagca	aattaaggct	1440
gcgcaaaaac	atttagagga	agttaaaact	agtcataatg	gattagattc	tttgtcatct	1500
catgaacagg	attatccaag	taatgccaaa	gaaatgaaag	atttagataa	aaaaatcgaa	1560
gaaaaaattg	ctggcattat	gaaacaatat	ggtgtcaaac	gtgaaagtat	tgctgtgaat	1620
aaagaaaaaa	atgcgattat	ttatccgcat	ggagatcacc	atcatgcaga	tcggattgat	1680
gaacataaac	cggttggaat	tggtcattct	cacagtaact	atgaactgtt	taaacccgaa	1740
gaaggagttg	ctaaaaaaga	agggaaataa	gtttatactg	gagaagaatt	aacgaatggt	1800
gttaatttgt	taaaaaatag	tacggttaat	aatcaaaaact	ttactctagc	caatgggtcaa	1860
aaacgcggtt	cttttaggtt	tcgcgctgaa	ttggagaaaa	aattaggtat	caatatgcta	1920
gtaaaattaa	taacaccaga	tggaaaagta	ttggagaaag	tatctggtaa	agtattttgga	1980
gaaggagtag	ggaatattgc	aaactttgaa	ttagatcaac	cttatttacc	aggacaaaca	2040
tttaagtata	ctatcgcttc	aaaagattat	ccagaagtaa	gttatgatgg	tacattttaca	2100
gttccaacct	ctttagctta	caaaatggcc	agtcacaaacga	ttttctatcc	tttccatgca	2160
ggggatactt	atttaagagt	gaaccctcaa	tttgacgtgc	ctaaaggaac	tgatgcttta	2220
gtcagagtgt	ttgatgaatt	tcatggaaat	gcttatattg	aaaataacta	taaagttgggt	2280
gaaatcaaat	taccgattcc	gaaattaaac	caagggaacaa	ccagaacggc	cggaaataaa	2340
attcctgtaa	ccttcatggc	aaatgcttat	ttggacaatc	aatcgactta	tattgtggaa	2400
gtacctatct	tggaaaaaga	aaatcaaaact	gataaaccac	gtattctacc	acaattttaaa	2460
aggaataaag	cacaagaaaa	ctttaaactt	gatgaaaagg	tagaagaacc	aaagactagt	2520
gagaaggtag	aaaaagaaaa	actttctgaa	actgggaata	gtactagtaa	ttcaacgtta	2580
gaagaagttc	ctacagtggg	tcctgtacaa	gaaaaagtag	caaaatttgc	tgaaagttat	2640
gggatgaagc	tagaaaaatgt	cttggttaat	atggacggaa	caattgaatt	atattttacca	2700
tcgggagaag	ctattaaaaa	gaatatggca	gatttttacag	gagaagcacc	tcaaggaaat	2760
ggtgaaaaata	aaccatctga	aaatggaaaa	gtactactctg	gaacagttga	gaaccaacca	2820
acagaaaaata	aaccagcaga	ttctttacca	gaggcaccac	acgaaaaacc	tgtaaaacca	2880

gaaaactcaa	cggataatgg	aatgttgaat	ccagaagggg	atgtggggag	tgaccctatg	2940
ttagatccag	cattagagga	agctccagca	gtagatcctg	tacaagaaaa	attagaaaaa	3000
tttacagcta	gttacggatt	aggcttagat	agtgttatat	tcaatatgga	tggaacgatt	3060
gaattaagat	tgccaagtgg	agaagtgata	aaaaagaatt	tatctgatct	catagcg	3117

SeqID 47

atgaaaattt	tattttgtagc	agcagagggg	gcaccctttt	caaaaacagg	tggtttggga	60
gacgtcattg	gcgctcttcc	aaaatcactg	gtaaaagctg	ggcacgaagt	tgcaagtatt	120
ttacctact	atgatattgg	agaggctaaa	tttggaatc	agattgaaga	tggtctcat	180
tttgaggtga	gcgttggttg	gcgagacag	tattgtggaa	ttaagaaaac	agtattaaat	240
gggtgaacct	tctactttat	tgacaatcaa	tattatttct	tccgtgggtca	tggttacggg	300
gattttgtag	acggagaacg	ctttgccttt	ttccaactgg	ctgccattga	ggctatggaa	360
aggattgact	ttattcctga	tcttctccat	gttcctgact	accatacagc	tatgattcct	420
ttcttgttga	aggaaaaata	ccgttggatt	caagcctatg	aggacattga	aacagtttta	480
accattcata	atttagaatt	ccaaggacaa	ttttcagaag	gaatgttggg	tgattttgtt	540
ggagttggct	ttgaacgtta	cgctgatggc	acccttcgat	ggaacaactg	tctgaactgg	600
atgaaggcag	gtattctcta	tgcaaacctg	gtttcaaccg	ttcacctag	ctatgctcat	660
gaaattatga	ctagtcatgt	tggaatgaat	ttggatcaga	ttcttaaaat	ggagctcggg	720
aaagtatctg	gtatcgtgaa	tggttgattg	gctgatcttt	ataatcctca	gacggatgct	780
cttttagact	atcatttcaa	tcaggaagat	ttgtctggga	aagccaaaaa	taaggcaaaa	840
ttgcaagaaa	gagttggctt	gcctgttaga	gcagacgttc	cactgggtggg	aattgtttct	900
cgtttgacac	gtcaaaaagg	ttttgatgtg	gtggctcgaa	gtcttcacca	tatcttgcaa	960
gaagatgttc	agattgttct	tttgggaact	ggcgaatccag	cctttgaagg	agctttctca	1020
tggtttgctc	agatttacct	agacaagcta	tcacaaata	tcacttttga	tgtaaaactt	1080
gctcaggaaa	tctacgctgc	ttgtgacctc	ttcctcatgc	caagtctgtt	tgaaacctgt	1140
ggcttgcctc	aaatgatggc	tatgcgttat	ggaaccttgc	cattgggtcca	tgaaagtggg	1200
ggcttgcgag	atacagttcg	cgctttcaat	ccaatcgaag	gaagcggtag	tggttttagc	1260
tttgacaatc	tatctcctta	ttggttaaat	tggactttcc	aaacagcatt	ggacttgtat	1320
agaaaccatc	cagacatttg	gagaaacctc	caaaaacaag	ctatggagag	tgacttctca	1380
tggtatagag	cctgcaagtc	ataccttgac	ttgtaccata	gtttagttaa	t	1431

SeqID 48

atggaaaaag	attttgggtga	aaaacaagag	cgtttttcat	ttagaaaatt	atcagtagga	60
cttgtatctg	caacgatttc	aagtttattt	tttatgtctg	tattagctag	ttcatctgtg	120
gatgctcaag	aaactgcggg	agttcactat	aaatatgtgg	cagattcaga	gctatcatca	180
gaagaaaaag	agcagcttgt	ctatgatatt	ccgacatacg	tgagaaatga	tgatgaaact	240
tattatcttg	tttataagtt	aaattctcaa	aatcaactgg	cggaaattggc	aaatactgga	300
agcaagaatg	agaggcaagc	cctagttgct	ggtgctagct	tagctgctat	gggaatttta	360
attttggctg	tttccaagaa	aaagggttaag	aataaaacgg	tattacattt	agtattgggt	420
gcagggtatg	gaaatgggtg	cttagtttca	ttccatgctt	tagaaaatca	tcttttgcta	480
aattacaata	cggactatga	attgacctct	ggagaaaaat	tacctcttcc	taaagagatt	540
tcagggttaca	cttatattgg	atatatcaaa	gagggaaaaa	cgacttctga	gtctgaagta	600
agtaatcaaa	agagttcagt	tgccactcct	acaaaacaac	aaaagggtgga	ttataatggt	660
acaccgaatt	ttgtagacca	tccatcaaca	gtcaagcta	ttcaggaaca	aacacctgtt	720
tcttcaacta	agccgacaga	agttcaagta	gttgaaaaac	ctttctctac	tgaattaatc	780
aatccaagaa	aagaagagaa	acaatcttca	gattctcaag	aacaattagc	cgaacataag	840
aatctagaaa	cgaagaaaga	ggagaagatt	tctccaaaag	aaaagactgg	ggtaaatata	900
ttaaatccac	aggatgaagt	tttatcaggt	caattgaaca	aacctgaact	cttatatcgt	960
gaggaaacta	tgagagacaa	aatagatttt	caagaagaaa	ttcaagaaaa	tcttgattta	1020
gctgaaggaa	ctgtaaagag	aaaacaagaa	ggttaaatag	gtaagaaagt	tgaaactcgt	1080
agaatattct	ctgtaaacaa	ggaagaagtt	tcgcgagaaa	ttgtttcaac	ttcaacgact	1140
gcgcctagtc	caagaatagt	cgaaaaaggt	actaaaaaaa	ctcaagttat	aaaggaaaca	1200
cctgagactg	gtgtagaaca	taaggacgta	cagtctggag	ctattgttga	accgcgaatt	1260
cagcttgagt	tgcccgaagc	tgtagtaagt	gacaaaggcg	aaccagaagt	tcaacctaca	1320
ttacctgaag	cagttgtgac	cgacaaaggt	gagactgagg	ttcaaccaga	gtcgccagat	1380
actgtggtaa	gtgataaagg	tgaaaccagag	caggtagcac	cgcttccaga	atataagggt	1440
aatattgagc	aagtaaaacc	tgaaactccg	gttgagaaga	ccaaagaaca	aggtccagaa	1500
aaaactgaag	aagttccagt	aaaaccaaca	gaagaaacac	cagtaaatcc	aaatgaaggt	1560
actacagaag	gaacctcaat	tcaagaagca	gaaaatccag	ttcaacctgc	agaagaatca	1620
acaacgaatt	cagagaaggt	atcaccagat	acatctagca	aaaatactgg	ggaagtgtcc	1680
agtaatccta	gtgattcgac	aacctcagtt	ggagaatcaa	ataaaaccaga	acataatgac	1740
tctaaaaatg	aaaattcaga	aaaaactgta	gaagaagttc	cagtaaatcc	aaatgaaggc	1800
acagtagaag	gtacctcaaa	tcaagaaaca	gaaaaaccag	ttcaacctgc	agaagaaaca	1860
caaacaaact	ctgggaaaat	agctaacgaa	aatactggag	aagtatccaa	taaacctagt	1920
gattcaaaac	caccagttga	agaatcaaat	caaccagaaa	aaaacggaac	tgcaacaaaa	1980
ccagaaaaat	caggtaatat	aacatcagag	aatggacaaa	cagaaccaga	accatcaaaa	2040
ggaaattcaa	ctgaggtatg	ttcaaccgaa	tcaaacacat	ccaattcaaa	tggaaccgaa	2100
gaaattaaac	aagaaaatga	actagaccct	gataaaaagg	tagaagaacc	agagaaaaca	2160

cttgaattaa	gaaatgtttc	cgacctagag	ttatacagtt	tgtcaaattg	tacttataaa	2220
caacacattt	cgtagagca	agttccaagc	aatccaaata	gctactttgt	taaagtgaag	2280
tcttcttcat	tcaaagatgt	atacctacca	gtagcatcaa	tatcagagga	aagaaaaaat	2340
gataaaatcc	tttataaaat	cacagcaaaa	gtagagaagc	ttcagcagga	gatagaaagc	2400
agatataaag	ataattttac	cttctatcta	gctaagaagg	gaacagaaga	aacaacaaac	2460
ttactcttct	ttagtaaatct	ggtcaaagct	ataaaccaaa	atocctctgg	aacctatcat	2520
tttagcgcca	gcttgaatgc	taacgaagtg	gagcttggtc	ctgatgaaag	atcctatatc	2580
aaggacacct	ttactggctg	tttaatcggg	gaaaaagatg	gcaagaatta	tgctatctat	2640
aatttgaaaa	aacctctgtt	tgaaaacttg	agtgggtgcta	cagtagaaaa	actgagtcta	2700
aaaaatggtg	ctatttcagg	gaaagatgat	atcggttcac	tggaatga	agctcagaat	2760
aacacaaaaa	ttaagcaagt	tcacgtcgat	ggtgtcttgg	ctggtgaacg	tggtatcggt	2820
ggtttgctgg	ctaaggctga	gcaatcaagc	atcacagaga	gcagtttcaa	gggaagaatt	2880
atcaacactt	atgaaacgac	tgctgcctac	aatatcggtg	gtatggctcg	tcatttgaca	2940
gggtgacaagg	ctttacttac	taagtcaaaa	gcgacagtag	ccatttcatc	taacacaaat	3000
acttcagatc	agactgtggg	tggaacttgc	ggcctagtag	accgagatgc	acagatccaa	3060
gatagctatg	ctgaagggtga	tatcaacaat	gtcaagcact	ttggtagagt	cgctggagtg	3120
gcaggcaatt	tggtggatcg	aacttctggt	gatgttaggc	atgctggaag	tttgaccaat	3180
gttctcagcg	atgttaatgt	aaccaacgga	aatgccatca	ctgggtacca	ctataacgaa	3240
atgaaggtaa	aggacacatt	cagcagcaag	gccaacagag	tctacaatgt	caccttggtc	3300
aaggatgagg	tcgtcagcaa	ggaatccttt	gaagaaagag	gaacaatgct	agatgcttct	3360
caaattgcaa	gcaaaaaagc	agaaatcaat	cctctcattt	taccaacagt	ggagccactt	3420
tcaacaagtg	gcaaaaaaga	cagtgttttt	tctaagggtg	cctattatca	agctaagcgc	3480
aaacttgactt	ataaaaaacat	tgaaaaattg	ctacctttct	acaacaaggc	aacctctgtc	3540
aaatacggaa	accctgggtcaa	tgagaacagt	cttttatatc	aaaaagaact	cttgtcagca	3600
gtcatgatga	aggacaacca	agtcattaca	gacattgttt	ctaacaacaa	gactgcaaac	3660
aaactcttgc	ttcactacaa	ggatgattta	tctgagaagc	tggtatctca	ataccagaat	3720
gatttcgcca	aattagcaga	atatagtctg	ggcaatactg	gacttctcta	tacgccaaac	3780
caattctctgt	atgaccaaac	ctctatcatc	aagcaagtct	tacctgactt	acaaaagggt	3840
gactatcatt	cagaagccat	cagaaagacg	ctgggtattt	ctccaaacgt	caagcaaac	3900
gagctctatc	tagaagacca	gttcgccaaa	acaaaacaac	aactggaaga	cagtttgaaa	3960
aaactcttgt	cagcggatgc	tggaactggc	agtgttaacc	ccgtcactga	aggttatctt	4020
gtagataaaa	tcaaacgcaa	caaggaagcc	ttgtactttg	gcttgacctg	tctggaacgg	4080
tggtataaact	ttagctatgg	tcaggtgaat	gtcaaagacc	tagttctgta	ccatttggac	4140
ttctttggta	aggggaatgc	ttcaccatta	gatactctga	ttgagttggg	taaatctggc	4200
tttaacaatc	ttctagctaa	gaataatgtc	gatacttatg	gtatcagctc	tgccagtcac	4260
catggaacga	cagatttgtt	tagcacgctg	gaacattacc	gaaaagtctt	tttaccacaa	4320
acaagcaata	atgactgggt	taaatcagag	actaaggctt	acattgtcga	agaaaaatcc	4380
actatcgag	aggtgaaaa	gaagcaaggg	ttagctggca	ccaagtattc	tatcggtggt	4440
tatgatcgta	tcacgagtg	cacatggaaa	taccgcaata	tggtcttgcc	tctctgacc	4500
ttgccagaga	tgatcggtat	tgctatctcg	accatgtcta	gtctaggatt	tggaagcttat	4560
gatcgctacc	gcagtagtga	ccataaagcg	ggcaaggctc	tcaatgattt	tggtgaagaa	4620
aatgcgcgtg	aaacagccaa	acgtcagcga	gatcactacg	attattggta	tcgtattttt	4680
gacgacaatg	cacgtgaaaa	actttataga	aatattttgc	tttacgatgc	ttataaaatt	4740
ggcgatgata	ataccgtagg	gaaagctaca	gaagtggcag	attttgataa	tccaaactct	4800
gcaatgcaac	atctcttggg	acctgttgga	aataaagttg	ggcataatca	acacggtgct	4860
tatgctacag	gtgatgcagt	ttatttatatg	ggttatcgaa	tggttgataa	ggatggagct	4920
attacttata	cgcatgagat	gacacatgac	tcagatcagg	acatttatct	tggaagatat	4980
ggctgaagaa	gtggcttggg	accagagttc	tttgctaaag	gattattaca	agcaccagac	5040
catccagatg	atgcgaccat	taccatcaac	tccatcttga	aacattcaaa	atctgatagt	5100
acagaaagtc	gacgattaca	agtacttgat	ccaactacaa	gatttaataa	tcgagatgat	5160
ttgaagcaat	atgtccacaa	catgtttgac	gttggtttata	tggttgaata	tctcgaagga	5220
aattcaattc	ttaaattgga	tacgaatcaa	aaacaacaac	ttcttagaaa	agttacaaat	5280
gagtaccatc	ctgatcctga	tggaataaag	gtctatgcaa	caaatgttgt	cagaaatcta	5340
acagtagaag	aagttgaaag	actacgttca	ttcaatgatt	tgattgataa	taatatctct	5400
tcgtctaggg	aatatgcctc	aggtaaatac	gaaagaaatg	gctacttcac	tattaagtta	5460
tttgaccaga	tttatgctgc	attaagtaat	gatataggaa	caccaggtga	cctgatggga	5520
cgctgatatg	ccatgaact	actagctgct	aaaggcttta	aagatgggat	ggtagcatat	5580
atctcaaacc	aatacgaaga	agaagccaaa	caaaagggca	agacaatcaa	tctctacggg	5640
aaaacaagag	gtttggttac	agatgacttg	gttttggaag	aggtatttaa	taaccaatat	5700
catacttgga	gtgagtttaa	gaaagctatg	tatcaagaac	gacaagatca	gtttgataga	5760
ttgaacaaag	ttacttttaa	tgatacaaca	cagccttggc	aaacatttgc	caagaaaact	5820
acaagcagtg	tagatgaatt	acagaaatta	atggacgttg	ctgttcgtaa	ggatgcagaa	5880
cacaattact	accattggaa	taactacaat	ccagacatag	atagtgaagt	ccacaagctc	5940
aagagagcaa	tctttaaagc	ctatcttgac	caaacaaatg	attttagaag	ttcaattttt	6000
gagaataaaa	aa					6012

SeqID 49

atgaaaatta ataaaaata tctagcaggt tcagtggcag tccttgccct aagtgtttgt

60

tcctatgagc	ttggacgtta	ccaagctggt	caggataaga	aagagtctaa	tcgagttgct	120
tatatagatg	gtgatcaggc	tggtaaaaag	gcagaaaact	tgacaccaga	tgaagtcagt	180
aagagggagg	ggatcaacgc	cgaacaaatt	gttatcaaga	ttacggatca	aggttatgtg	240
acctctcatg	gagaccatta	tcattactat	aatggcaagg	ttccttatga	tgccatcatc	300
agtgaagagc	tcctcatgaa	agatccgaat	tatcagttga	aggattcaga	cattgtcaat	360
gaaatcaagg	gtggttatgt	cattaaggtg	aacggtaaat	actatgttta	ccttaaggat	420
gcagctcatg	cggataatat	tcggacaaaa	gaagagatta	aacgtcagaa	gcaggaaacgc	480
agtcataatc	ataactcaag	agcagataat	gctgttgctg	cagccagagc	ccaaggacgt	540
tatacaacgg	atgatgggta	tatcttcaat	gcactctgata	tcattgagga	cacgggtgat	600
gcttatatcg	ttcctcacgg	cgaccattac	cattacattc	ctaagaatga	gttatcagct	660
agcgagttag	ctgctgcaga	agcctattgg	aatgggaagc	agggatctcg	tccttcttca	720
agttctagtt	ataatgcaa	tccagctcaa	cgaagattgt	cagagaacca	caatctgact	780
gtcactccaa	cttatcatca	aaatcaaggg	gaaaacattt	caagcctttt	acgtgaattg	840
tatgctaaac	ccttatcaga	acgccatgtg	gaatctgatg	gccttatttt	cgaccacgag	900
caaatacaca	gtcgaaccgc	cagaggtgta	gctgtccctc	atggtaacca	ttaccacttt	960
atcccttatg	aacaaatgtc	tgaattggaa	aaacgaattg	ctcgtattat	tcccttcgt	1020
tatcgttcaa	accattgggt	accagattca	agaccagaag	aaccaagtcc	acaaccgact	1080
ccagaacctg	gtccaagtcc	gcaaccagct	caagcaatc	caattgatga	gaaattgggtc	1140
aaagaagctg	ttcgaaaagt	agggcatggt	tatgtctttg	aggagaatgg	agtttctcgt	1200
tatatccag	ccaaggatct	ttcagcagaa	acagcagcag	gcattgatag	caaactggcc	1260
aagcaggaaa	gtttatctca	taagctagga	actaagaaaa	ctgacctccc	atctagtgat	1320
cgagaatttt	acaataaggc	ttatgactta	ctagcaagaa	ttcaccaaga	tttacttgat	1380
aataaagggtc	gacaagttga	ttttgaggct	ttggataacc	tgttggaacg	actcaaggat	1440
gtctcaagtg	ataaagtcaa	gttagtgtaa	gataattcttg	ccttcttagc	tccgattcgt	1500
catccagaac	gttttaggaa	accaaagcgc	caaattacct	acactgatga	tgagattcaa	1560
gtagccaagt	tggcaggcaa	gtacacaaca	gaagacgggt	atatctttga	tcctcgtgat	1620
ataaccagtg	atgaggggga	tgccatgta	actccacata	tgacctatag	ccactggatt	1680
aaaaaagata	gtttgtctga	agctgagaga	gcggcagccc	aggcttatgc	taaagagaaa	1740
ggtttgaccc	ctccttcgac	agaccatcag	gattcaggaa	atactgaggc	aaaaggagca	1800
gaagctatct	acaaccgcgt	gaaagcagct	aagaagggtc	cacttgatcg	tatgccttac	1860
aatcttcaat	atactgtaga	agtcaaaaac	ggtagtttaa	tcatacctca	ttatgacctat	1920
taccataaca	tcaaatgtga	gtggtttgac	gaaggccttt	atgaggcacc	taaggggtat	1980
actcttgagg	atcttttggc	gactgtcaag	tactatgtcg	aacatccaaa	cgaacgtccg	2040
cattcagata	atgggttttg	taacgttagc	gaccatgttc	aaagaaacaa	aaatgggtcaa	2100
gctgatacca	atcaaacgga	aaaaccgaag	gcaggagaaac	ctcagacaga	aaaacctgag	2160
gaagaaaccc	ctcgagaaga	gaaaccgcaa	agcgagaaac	cagagtctcc	aaaaccaaca	2220
gaggaaccag	aagaatcacc	agaggaatca	gaagaacctc	aggctcgagac	tgaagaggtt	2280
gaagaaaaac	tgagagaggc	tgaagattta	cttggaaaaa	tccaggatcc	aattatcaag	2340
tccaatgcc	aagagactct	cacaggatta	aaaaataatt	tactatttgg	caccagagac	2400
aacaatacta	ttatggcaga	agctgaaaaa	ctattggctt	tattaaagga	gagtaag	2457

SeqID 50

ttgattttaa	gtgtttgttc	ttacgagttg	ggactgtatc	aagctagaac	ggttaaggaa	60
aataatcgtg	tttcctatat	agatggaaaa	caagcgacgc	aaaaaacgga	gaatttgact	120
cctgatgagg	ttagcaagcg	tgaaggaaac	aatgctgagc	aaatcgtcat	caagataaca	180
gaccaaggtc	atgtcacttc	acatggcgac	cactatcatt	attacaatgg	taaggttcct	240
tatgacgcta	tcacagtgta	agaattactc	atgaaagatc	caaaactata	gctaaaagat	300
gaggatattg	ttaatgaggt	caaggggtgga	tatgttatca	aggtagatgg	aaaatactat	360
gtttacetta	aggatgctgc	ccacgcggat	aacgtccgta	caaaagagga	aatcaatcga	420
caaaaacaag	agcatagtca	acatcgtgaa	ggtggaactc	caagaaacga	tgggtgctgt	480
gccttggcac	gttcgcaagg	acgtatatac	acagatgatg	gttatatctt	taatgcttct	540
gatatacatg	aggatactgg	tgtatgcttat	atcgttcttc	atggagatca	ttaccattac	600
attcctaaga	atgagttatc	agctagecag	ttggctgctg	cagaagcctt	cctatctggt	660
cgaggaaatc	tgtcaaattc	aagaacctat	cgccgacaaa	atagcgataa	cacttcaaga	720
acaaactggg	taccttctgt	aagcaatcca	ggaactacaa	atactaacac	aagcaacaac	780
agcaacacta	acagtcaagc	aagtcaaagt	aatgacattg	atagtctctt	gaaacagctc	840
tacaaactgc	ctttgagtca	acgacatgta	gaactctgat	gccttgtctt	tgatccagca	900
caaatacaca	gtcgaacagc	tagaggtgtt	gcagtgccac	acggagatca	ttaccacttc	960
atcccttact	ctcaaagtgc	tgaattggaa	gaacgaatcg	ctcgtattat	tcccttcgt	1020
tatcgttcaa	accattgggt	accagattca	aggccagaac	aaccaagtcc	acaaccgact	1080
ccggaacctc	gtccaggccc	gcaacctgca	ccaaactctta	aaatagactc	aaattcttct	1140
ttggttagtc	agctggtagc	aaaagttggg	gaaggatagc	tattcgaaga	aaaggccatc	1200
tctcgttatg	tctttgcgaa	agattttacca	tctgaaactg	ttaaaaatct	tgaagcaag	1260
ttatcaaaac	aagagagtg	ttcacacact	ttactgctta	aaaaagaaaa	tgttgctcct	1320
cgtgaccaag	aattttatga	taaagcatat	aatctgttaa	ctgaggctca	taaagccttg	1380
tttgaaaata	agggtcgtaa	ttctgatttc	caagccttag	acaaattatt	agaacgcttg	1440
aatgatgaat	cgactaataa	agaaaaattg	gtagatgatt	tattggcatt	cctagcacca	1500
attaccatc	cagagcgact	tggcaaacca	aattctcaaa	ttgagtatac	tgaagacgaa	1560

gttcgtattg	ctcaattagc	tgataagtat	acaacgtcag	atgggtacat	ttttgatgaa	1620
catgatataa	tcagtgatga	aggagatgca	tatgtaacgc	ctcatatggg	ccatagtcac	1680
tggattggaa	aagatagcct	ttctgataag	gaaaaagttg	cagctcaagc	ctatactaaa	1740
gaaaaaggta	tcctacctcc	atctccagac	gcagatgtta	aagcaaatcc	aactggagat	1800
agtgcagcag	ctatttacaa	tcgtgtgaaa	ggggaaaaac	gaattccact	cgttcgactt	1860
ccatatatgg	ttgagcatat	agttgaggtt	aaaaacggta	atttgattat	tcctcataag	1920
gatcattacc	ataatattaa	atctgcttgg	tttgatgata	acacatacaa	agctccaaat	1980
ggctatacct	tggagatttt	gtttgcgacg	attaagtact	acgtagaaca	ccctgacgaa	2040
cgtccacatt	ctaattgatg	atggggcaat	gccagtgagc	atgtgttagg	caagaaagac	2100
cacagtgaag	atccaaataa	gaacttcaaa	gcgatgaag	agccagttag	ggaaacacct	2160
gctgagccag	aagtcctcca	agtagagact	gaaaaagtag	aagcccaact	caaagaagca	2220
gaagttttgc	ttgcgaaagt	aacggattct	agctgaaag	ccaatgcaac	agaaactcta	2280
gctggtttac	gaaataattt	gactcttcaa	attatggata	acaatagtat	catggcgaaa	2340
gcagaaaaat	tacttgcggt	gttaaaagga	agtaatcctt	catctgtaag	taaggaaaaa	2400
ataaac						2406

SeqID 51

atgccagtag	aaattaaaac	cactaaaagaa	atctcatccta	aaatctatgc	ctacaccaca	60
ccgacagtaa	ccagtaataa	aggctggatt	aagattgggt	atacagaacg	tgatgtcaca	120
caacgtatca	aggagcaaac	gcatacagct	catatagcta	cagatgtctt	atggactggg	180
gatgcagctt	atcacagaaga	gcctgataag	gggaaaactt	tcaaggacca	tgatttccac	240
catttccttt	ctttccatga	tgtagaacgt	cgtcccaaga	cggaatgggt	ctattttaat	300
ggaactcctg	aaaaatcaaa	aaatcttttt	gataagtttg	ttcagcatga	tttgcctggg	360
tatcagcctg	gaaaaggaca	ggactatact	ctgcgacaag	agcaagaaga	agcagttgct	420
aagacattag	cttattttcca	agaacatgct	ggaggcaagt	ttctctggaa	tgccaagcca	480
cgctttggta	aaaccttgct	tacctatgac	ctagctcgac	ggatggaagc	tgtcaatgtc	540
ctaattgtaa	caaaccgccc	tgccattgct	aactcatggg	atgatgattt	tgaacatttc	600
atagcaggtc	aaacgactta	caagtttggg	tctgaatcag	atagccttaa	gagtcgtcca	660
atcttgtcac	gacaagaatt	tcttgggtatt	ttagctgacg	atgtaagaca	acttgccttt	720
atcagctccc	aagacttgaa	aggatctggt	tatttaggtg	gagagcacga	taaactcaaa	780
tgggttaactg	atctgcattg	ggacttgggt	gttattgacg	aggtcatga	aggagttgat	840
accttcaaga	ctgaccaagc	ctttaataag	attcgacgaa	atcttactct	gcatttgtca	900
ggtacatcat	ttaaagcatt	ggctaaagga	gattttacag	aggaacaaat	ctacaactgg	960
tcttatgctg	atgagcaggg	tgctaagtat	tcgtgggtct	ttgagcaaga	agaggaaaat	1020
ccttatgaaa	gcttgcctca	gttgaatctc	tttaccctatc	aaatgtctca	gatgatggc	1080
gaaaagttag	aaaaaggcgc	tcagatcgat	gggtgaaaata	ttgactatgt	ttttgactta	1140
agtgaatttt	tcgctacaga	tgataaaggg	aaatttattc	atgagcatga	tgtcagaaat	1200
tgggttagata	ctctatcaag	caatgaaaaa	tatccatttt	caaccaaaga	actccgtaat	1260
gaactcaagc	atactttttg	gcttttagaa	cgtgtcgctg	cggccaaagc	attaaaagcc	1320
ctactagaag	aacaccaaat	ctatgaaaac	tatgagatcg	ttctagctgc	tggtgacgga	1380
cgtatgtccg	aagaagacga	taaagtcaaa	ctcaaactct	tggacttggg	tagaaaagcg	1440
atagcagaga	atgacaaaac	cattacccta	tcggttgggc	agctgacgac	agggtgctact	1500
atccctgaat	ggacagggtg	attgatgtta	tcaaatttga	aatcaccagc	tcttttatatg	1560
caggccgcct	tccgtgtctc	aaatccttac	tcatggagcg	ataacaaagg	aatcactttt	1620
cgcaaagaaa	gagcctatgt	atcttgacttt	gcgcgggaaa	gaaccttgat	tctctttgat	1680
gagtttgcca	acaacttatt	gcttgtaact	gcagctggta	gaggaaactc	agctacacgc	1740
gaagaaaata	ttagagaatt	attaaacttc	tttccaatta	ttgccgaaga	ccgtgtctgg	1800
aagatgggtg	aaattgatgc	aaaggcagtt	ctaaccactc	ctcgccagat	aaaagctaga	1860
gaagttctta	aacgaggttt	tatgtccaat	ctcttatttg	ataatattag	tggatttttc	1920
caagcaagtc	aaacagtttt	agatatttta	aatgagctgc	cagttgaaaa	ggaagggaag	1980
gtacaagata	gttctgattt	attagatttt	tcagatgtta	cagtcgatga	tgagggaagt	2040
gcagtagtag	accatgaaat	tgtagttaat	cagcaaatgc	gacttttttg	tgaaaaagtt	2100
tatggacttg	gtgaatctgt	tgctgagtta	gtcacaaaag	atgaggaacg	aactcaaaaa	2160
cagctgggtca	atgacttgag	taagaccgtt	tcttcagtga	ttgtagagga	attgaaagca	2220
gattattctc	taaaaacaag	ggaaactgag	caaattaaga	aacaaattac	agcaacactt	2280
gagaattgaa	ttcgaaaaaa	tgatatcgaa	agaaaaattt	ctgaagctca	tatcaagcaa	2340
gagttgcaac	agcagctcaa	agaaagcaat	gataaagcgc	aaaaagataa	gattcaagaa	2400
gatttggaag	aacgttttaga	agaaaataaa	ctcattcata	aagaaaaact	agaacaaaca	2460
ctcaaaaaag	aagtggaaaa	aatgcctgag	aaatttatcg	aacaggttga	gataaaacgt	2520
gtggaacagt	tgaacaatc	agctcaagat	gaaattcgtg	accattttacg	aggggtttgca	2580
agaacaattc	caagttttat	tatggcttac	ggtgatcaaa	ctctaacact	tgataatttt	2640
gatgcctttg	ttcctgaaca	tgttttttat	gaagtaacag	ggattacgat	tgatcatttt	2700
agatatttgc	ggagtggtgg	gcaggatttt	gcagggcatc	tctttgataa	agcaacattt	2760
gacgaagcta	ttcaagaatt	tcttcgcaag	aaaaaggagt	tggcggatta	ttttaaagat	2820
caaaaagaag	acatttttga	ctatattcca	ccgcagaaga	ccaaccaaact	tttctactct	2880
aaacgagtg	tgaagaggt	ggtagatgat	ttggaaaaag	aaaatccagg	gattttttgat	2940
gatccatcta	agacttttat	tgattttatat	atgaagtcag	gcctctatat	tgcagaactt	3000
gtgaagcggg	tatataatag	caatggcttg	aaagaggcct	ttccaaatcc	tgaagaacgc	3060

ttaaaaacata	ttttggaaaa	gcaagtttat	ggatttgcct	cgtctgagat	tatctataac	3120
atctccacta	atcttatatt	tggcaatctt	tctaaagata	tcagtaggaa	gaattttgtt	3180
ttagcagata	ccattccagc	ggctaagaa	gggagcattc	aaaagttggt	tgatttcctat	3240
tttgaaaata	at					3252

SeqID 52

atgaaaaaaa	tactaattgt	agatgatgag	aaaccaatct	cggatattat	caagtttaaat	60
atgaccaagg	aaggttacga	agttgttaact	gcttttaatg	gtcgtgaagc	gctagagcaa	120
tttgaagcag	agcaaccaga	tattattatt	ctggatttga	tgcttccaga	aattgatggg	180
ttagaagttg	ctaagaccat	tcgtaagaca	agcagtgtgc	ccattcttat	gctttcagcc	240
aaagatagtg	aatttgataa	ggttatcggg	ttggaacttg	gggcagatga	ctatgtaaca	300
aaaccttctt	ccaatcgtga	gttgccagcg	cgtgttaaag	ctcttctgcg	tcgttctcaa	360
cctatgccag	tagatgggtc	ggaagcagat	agtaaacctc	aacctatcca	aattggggat	420
ttagaaattg	ttccagacgc	ctacgtggct	aaaaaatatg	gcgaagaact	agacttaacc	480
catcgtgaat	ttagctttt	gtatcattta	gcctgcata	caggtcaagt	catcacgcgc	540
gaacacttgc	ttgagactgt	ctgggggttat	gactattttg	gtgatgtccg	tacagtgtgat	600
gtgactgtac	gacgtctgcg	tgagaagatt	gaagatacgc	ccagccgacc	agagtatatc	660
ttgacgcgcc	gtggtgtagg	gtattacatg	agaaataatg	ct		702

SeqID 53

atgaagaaaa	aatttctagc	atcttttcta	atctttattcc	caattttctc	attaggtatt	60
gccaaagcag	aaacgattaa	gattgtttct	gataccgctt	atgcaccttt	tgagtttaaa	120
gattcagatc	aaacttataa	aggaattgat	gttgacatta	ttacaaaagt	cgctgagatt	180
aaaggctgga	acattcagat	gtcctatcct	ggatttgacg	cagcagtcac	tgccggtcaa	240
gctgggcaag	ccgacgctat	catggcaggg	atgacaaaga	ctaaagaacg	tgaaaaagtc	300
ttcaccatgt	ctgatactta	ctatgatata	aaagtgtgca	ttgctactac	aaagtccac	360
aaaattagca	agtagaccca	attaactggc	aaaacggttg	gtgttaaaaa	cgggaactgcc	420
gctcaacgtt	tccttgaaac	aatcaaagat	aaatacggct	ttactattaa	aacatttgac	480
actggtgatt	taataaaca	cagcttgagt	gctggtgcca	tcgatgccat	gatggatgac	540
aaacctgtta	tcgaatatgc	cattaaccaa	ggtcaagacc	tccatattga	aatggatggt	600
gaagctgtag	gaagtgttgc	tttcgggtgtg	aaaaaaggaa	gtaaatatga	gcacctggtt	660
actgaattta	accaagcctt	gtctgaaatg	aaaaaagatg	gtagtcttga	taaaattatc	720
aagaaatgga	ctgcttcac	atcttcagca	gtgccaacta	caactactct	cgcaggatta	780
aaagctattc	ctgttaaggc	taaatatatc	attgccagcg	attcttcttt	tgcccccttt	840
gttttccaaa	attcaagcaa	ccaatacaact	ggtattgata	tggaattgat	taaggcaatc	900
gctaaagacc	aaggttttga	aattgaaatc	accaaccctg	gttttgatgc	tgctatcagt	960
gctgtccaag	ctggtcaagc	cgatggtatc	atcgctggtg	tgctgtcac	agatgctcgt	1020
aaggcaactt	ttgacttctc	agaatcatac	tacactgcta	ataccattct	tggtgtcaaa	1080
gaatcaagca	atattgcttc	ttatgaagat	ctaaaaggaa	agacagtcgg	tggttaaaac	1140
ggaactgctt	ctcaaacctt	cctaacagaa	aatcaagcaa	aatacggcta	caaaatcaaa	1200
acctttgctg	atggttcttc	aatgtatgac	agtttaaaac	ctggtgcca	tgatgccggt	1260
atggtatgat	aacctgttct	caaatattct	atcagccaag	gtcaaaaatt	gaaaactcca	1320
atctctggaa	ctccaatcgg	tgaaacagcc	tttgccgtta	aaaaaggagc	aaatccagaa	1380
ctgattgaaa	tggtcaacaa	cggacttgca	aaccttaaa	caaacgggtga	attccaaaag	1440
attcttgaca	aatacctagc	tagcgaatct	tcaactgctt	caacaagtac	tggtgacgaa	1500
acaacgctct	ggggcttgct	tcaaaacaac	tacaaacaac	tccttagcgg	tccttggtatc	1560
actcttgctc	tagctcttat	ctcatttgct	atcgccattg	tcacgggaat	tatcttcggt	1620
atgtttagcg	ttagccata	caaatctctt	cgcgtcatct	ctgagatttt	cgttgacggt	1680
attcgtggta	ttccattgat	gattcttgca	gccttcatct	tctggggaat	tccaaacttc	1740
atcgagtcta	tcacaggcca	acaaagccca	attaacgact	ttgtagctgg	aaccattgcc	1800
ctctcactca	atgcggctgc	ttatatcgct	gaaatcgctc	gtggtgggtat	tcaggccggt	1860
ccagttggcc	aaatggaagc	cagccgaagc	ttgggtatct	cttatggaaa	aaccatgcgt	1920
aagattatct	tgccacaagc	aactaaattg	atgttgccaa	actttgtcaa	ccaattcgtt	1980
atcgctctta	aagatacaac	tatcgtatct	gctatcggtt	tggttgaaat	cttccaaact	2040
ggtaagatta	tcattgctcg	taactaccaa	agtttcaaga	tgtatgcaat	ccttgctatc	2100
ttctatcttg	taattatcac	acttttgact	agactagcga	aacgcttaga	aaagaggatt	2160
cgt						2163

SeqID 54

atggcatttg	aaagttaaac	agaacgtttg	cagaacgtct	ttaaaaatct	acgtaaaaaa	60
ggaaaaatct	ctgaatctga	tgccaagag	gcaaccaag	aaattcgctt	ggccttgctc	120
gaggccgacg	ttgcttgcc	tggtgtaaag	gactttatca	agaaagttcg	tgagcgtgca	180
gtcgggcatg	aggtcattga	tacacttaat	cctgcgcaac	agattattaa	aatcgttgat	240
gaggaattga	cagcgtttt	aggttctgat	acggcagaaa	ttatcaagtc	acctaagatt	300
ccaaccatca	tcagtgatgt	tggtttacaa	ggggctggta	aaacaacctt	tgctggtaaa	360
ttggccaaca	aactcaagaa	agaagaaaat	gctcgtcctt	tgatgattgc	ggcggatatt	420
tatcgtccag	ctgccattga	ccagcttaag	accttgggac	aacagattga	tgtgcctgtc	480
tttgcaactg	gaacagaagt	accagctgtt	gagattgtac	gtcaagggtt	ggagcaagcc	540

caaactaatc	ataacgacta	tgtcttgatt	gatactgcgg	gtcgtttgca	gattgatgag	600
ctcctcatga	atgagcttcg	tgatgtgaaa	gcattggctc	aaccaaatga	aatcttgctt	660
gtcgttgatg	ctatgattgg	tcaggaagca	gccaatgttg	cgcgtgagtt	taatgctcag	720
ttggaagtga	ctggggcat	ccttaccaag	attgatggcg	atactcgtgg	tggtgctgct	780
ctgtctgttc	gtcacattac	tggaaaacca	atcaagttca	ctggtacagg	tgaagaagatt	840
acggacattg	aaaccttcca	cccagaccgc	atgtctagcc	gtatccttgg	tatgggggat	900
atgctcactt	tgattgagaa	agcttctcag	gaatacgtatg	aacaaaaagc	ccttgaaatg	960
gctgagaaga	tgcgcgaaaa	cacctttgat	tttaattgatt	tcacgtatca	attagatcag	1020
gtgcaaaata	tggggccgat	ggaagacttg	ctcaagatga	ttccagggtat	ggccaacaat	1080
ccagcccttc	aaaacatgaa	gggtgatgaa	cgccagattg	ctcgtaaaacg	tgccattgtg	1140
tcttcgatga	cacctgaaga	gcgtgaaaac	ccagatttgt	taaatccaag	ccgtcgcctg	1200
cgtattgtcg	ctgggtctgg	aaatacattc	gtcgaagtca	ataaattcat	caaggacttt	1260
aaccaggcta	aacagctcat	gcagggtgtt	atgtctgggg	atatgaataa	aatgatgaag	1320
caaattgggga	ttaatccaaa	taaccttcct	aaaaatatgc	caaatatggg	aggaatggat	1380
atgtctgccc	ttgaagggaat	gatgggacaa	ggcgggtatgc	ctgacttatc	agctctcgga	1440
ggagcaggaa	tgccagatat	gagccagatg	tttggtggcg	gtttgaaagg	taaaattggt	1500
gaatttgcca	tgaaacagtc	catgaaacgt	atggctaaca	aaatgaagaa	agcgaagaag	1560
aaacgcaag						1569

SeqID 55

atgagccaaa	tttggactaa	agaaaaat	ataagccaag	ttcaagggtg	agtcattggt	60
tcttgtcaag	ctttacctgg	tgaagccctt	tataatgaag	aatttagctt	gatgcctttt	120
atgggtaaa	cagctttaga	ggcaggagca	gtgggcattc	gcgcaaatc	tgtgcgtgat	180
attaaagcaa	ttcagaaagt	agtagattta	ccaataattg	gaattatcaa	aagggattat	240
ccacctcaag	aacctatata	tactgctacg	atgaagaag	tagatgaact	tgtagaatgc	300
ggaacaacag	tcattgcatt	tgatgcaact	ttaagaccaa	gatatgatgg	cttagttgtc	360
agtgaattta	tcaaaaaaat	aaaagaaaa	tatccgaatc	aattgctgat	ggcggatgta	420
agtaatttag	atgaaggtct	ctatgcattt	aatcaggcg	ttgattttgt	tggtacaaca	480
ttatcagggt	acacaagtac	aagtgtacaa	tcagatgagc	ctgattttga	actaatgaaa	540
aaattggctg	attttaatat	tccggttaatt	gccgaaggaa	aaattcatta	tccagaacaa	600
ttaaaaaag	cttatagttt	aggtgttacc	agtgtagtca	ttggtggagc	gattacacgt	660
ccaaaagaaa	ttgctcagcg	atttattaat	gtcatcaaa			699

SeqID 56

atgagatatt	taactgcagg	agaatcacac	ggcccccgtc	taacagctat	tattgagggg	60
attccagctg	gacttccatt	gacagctgag	gatatcaatg	aggaccttag	acgccgtcag	120
ggtggctacg	gtcgtgggtg	tcgtatgaag	attgagaatg	accagggttg	ctttacttcg	180
ggcgttcgcc	acgggaagac	gacaggggcg	cctattacta	tggatgtcat	caataaggac	240
caccagaaat	ggctggacat	catgtctgcg	gaggacattg	aagaccgcct	taaaagcaag	300
cggaaaatta	ctcatcctcg	cccaggctcat	gcgatttg	ttggggggat	taagtaccgt	360
tttgatgatt	tgcgaaattc	tttgaggcgt	tcatcagctc	gtgaaaccac	catgcgggtg	420
gcagttggtg	cagtagccaa	acgcctcttg	gctgagctgg	atatggagat	tgccaaccat	480
gtcgtggtct	ttggtggcaa	ggaatcgcgt	gttcctgaaa	atctgacagt	cgctgaaatt	540
aagcaaaag	ctgcccgatc	tgaagtttct	attgtcaacc	aagaacgaga	acaggaaatc	600
aaggactata	ttgaccaaat	caaacgtgat	ggtgatacca	tcggtggggg	tgtggagaca	660
gtcgtcggag	gcgttcaggt	tgttcttggt	tccatgtcc	aatgggtag	aaaattggat	720
gcaagattgg	ctcaagctgt	tgtctctatc	aatgccttta	aaggggtgga	atttggctct	780
ggctttgagg	ctggttatcg	taaaggcagc	caagttatgg	atgaaattct	ctggtctaaa	840
gaagacggtt	atactcgcgg	taccaataat	ctaggtggtt	ttgaaggtgg	tatgactaat	900
gggcaaccca	tcgttgttcg	tgggtgcag	aaaccattc	ctactcttta	taaacctctt	960
atgagtgtgg	atatcgaaac	ccacgaacct	tacaaggcaa	ccgtggagag	aagtgatccg	1020
actgctcttc	cagctgcagg	aatggtcatg	gaagcagttg	tagcaacggg	tctggcgcaa	1080
gaaatcctcg	aaaaattctc	atcagataat	cttgagggaac	taaaagaagc	ggtagccaaa	1140
caccgagact	atacaagaa	ctat				1164

SeqID 57

atggtagtta	tgaatagaat	aagagtcagc	aaaagggttg	aaaagaagct	tgctaagggg	60
ctagttttac	tagaagccag	tgatcttgag	aatgtcaatc	tttaaggatca	ggaagtagag	120
gtgcagggtc	aggaaggaaa	ctttcttggtg	actgcctacc	tttctcagca	aaacaagggc	180
ttgggctggt	ttatcagcaa	agacaagggtg	gccttcaatc	aagctttctt	tgaacggttg	240
tttagaaaa	ccaaagaaaa	gagaaacgcc	tactatcaag	atgatttgac	aactgccttt	300
cgtctcttta	atcaagagg	agatggcctt	tggggtctga	cagtggacct	ttatggcgac	360
tacgccgtct	tttcttggtg	taactcttat	gtttatcaga	ttcgtcagac	tatatcagaa	420
gccttttagac	aggttttccc	tgaggtttta	ggagcttatg	agaaaaatccg	ctttaagggt	480
ttggactatg	aatctgcccc	tgtttatggt	caagaagcac	ctgacttttt	caatgtttta	540
gaaaatggtg	tcctgtatca	agtctttatg	aatgatggct	tgatgacagg	aattttctca	600
gaccagcatg	aggttcgcgg	tagtttagtt	gacggcttgg	ctatgggtta	atccttactc	660
aatatgtttt	cctacacagc	ggctttttca	gtagctgcgg	ccatgggagg	agctagccat	720

acaacttctg	ttgatctagc	caaacgttca	cgagaattgt	ctcaagcgca	ttttcaggca	780
aatgggctca	gcacagacga	gcatcgtttt	atagtcattg	atgtctttga	gtatttcaaa	840
tatgccaaac	gcaaagactt	gacctacgat	gtgattgtcc	tagatccgcc	tagctttgct	900
cggataaaaa	aacaaacttt	ctctgtgccc	aaggattatc	acaagttgat	ttcccagagt	960
cttgagattt	taaatccggg	agggattatc	attgccagta	ccaatgctgc	caatgtttcc	1020
cgtcagaagt	ttacagaaca	aattgataaa	ggttttgcag	gaagaagtta	ccagatttta	1080
aacaaatatg	gtcttccagc	agattttgcc	tataataaaa	aagatgaaag	tagtaattac	1140
ctcaaggtga	ttagtatgaa	ggttagtaaa				1170

SeqID 58

atgacaaaa	cattaaaaacg	tcctgaggtt	ttatcacctg	cagggacttt	agagaagcta	60
aaggtagctg	ttcagtatgg	agcagatgct	gtctttatcg	gtggtcaggc	ctatggtctt	120
cgtagccgtg	cgggaaactt	tactttcgaa	cagatggaag	aaggcgtgca	gtttgcggcc	180
aagtatgggtg	ccaaggtcta	tgtagcggct	aatatgggtta	tgcacgaagg	aaatgaagct	240
gggtgctgggtg	agtgggttccg	taaactgcgt	gatatcggtg	ttgcagcagt	tatcgtatct	300
gacccagcct	tgattatgat	tgcagtgaat	gaagcaccag	gccttgaaat	ccacctttct	360
acccaagcca	gtgccactaa	ctatgaaacc	cttgagttct	ggaaagagct	aggcttgact	420
cgtgtcgttt	tagcgcgtga	ggttttcaatg	gaagaattag	ctgagatccg	caaacgtaca	480
gatgttgaaa	ttgaagcctt	tgtccatgga	gctatgtgta	tttcatactc	tggacgttgt	540
actctttcaa	accacatgag	tatgcgtgat	gccaaccgtg	gtggatgttc	tcagtcattgc	600
cgttggaagt	acgaccttta	cgatatgcca	tttgggaaag	aacgtaagag	tttgcagggt	660
gagattccag	aagaattttc	aatgtcagcc	gttgacatgt	ctatgattga	ccacattcca	720
gatgatggtg	aaaatgggtg	ggacagtcct	aaaatcgaag	gacgtatgaa	gtctattcac	780
tacgtatcaa	cagtaaccac	ctgctacaag	gctgctgtgg	atgcctatct	tgaagtcctt	840
gaaaagtttg	aagctatcaa	acaagacttg	gtggacgaga	tgtggaaggt	tgcccaacgt	900
gaactggcta	caggattttta	ctatggtaca	ccatctgaaa	atgagcagtt	gtttggtgct	960
cgccgtaaaa	ttcctgagta	caagtttgct	gctgaagtgg	tttcttatga	tgatgcggca	1020
caaacagcaa	caattcgtca	acgaaatgtc	attaacgaag	gggaccaagt	tgaattttat	1080
ggtccagggt	tccgtcattt	tgaaacctat	attgaagatt	tgcatgatgc	caaaggcaat	1140
aaaatcgacc	gcgctccaaa	tccaatggaa	ctattgacta	ttaaggtgcc	tcaaccggtt	1200
caatcaggag	atatgggttcg	tgcattaaaa	gaaggactca	tcaatcttta	taaggaagat	1260
ggaaccagcg	tcacagttcg	agct				1284

SeqID 59

atgaatacct	atcaattaaa	taatggagta	gaaattccag	tattgggatt	tggaaactttt	60
aaggctaagg	atggagaaga	agcctatcgt	gcagtgtag	aagccttgaa	ggctgggtat	120
cgtcatattg	atagggcgcc	gattttatcag	aatgaagaaa	gtgttggtca	agcaatcaaa	180
gatagcggag	ttccacgtga	agaaatgttc	gtaactacca	agctttggaa	tagtcagcaa	240
acctatgagc	aaactcgtca	agctttggaa	aaatctatag	aaaaactggg	cttggattat	300
ttggatttgt	atttgattca	ttggccgaac	ccaaaaccgc	tcagagaaaa	tgcgcagtag	360
aaaactcgca	atgcggaagt	ttggagagcg	atggaagacc	tctatcaaga	agggaaaatc	420
cgtgctatcg	gcgttagcaa	tttcttccc	catcatttgg	atgccttgct	tgaactgca	480
actatcgctc	ctgcggtcaa	tcaagttcgc	ttggcgccag	gtgtgtatca	agatcaagtc	540
gtagcttact	gtcgtgaaaa	gggaatttta	ttggaagctt	gggggccttt	tggacaagga	600
gaactgtttg	atagcaagca	agtccaagaa	atagcagcaa	atcacggaaa	atcggttgc	660
cagatagcct	tggcctggag	cttggcagaa	ggatttttac	cacttccaaa	atctgtcaca	720
acctctcgta	ttcaagctaa	tcttgattgc	tttggaaattg	aactgagtc	tgaggagaga	780
gaaaccttaa	aaacgattgc	tgttcaatcg	ggtgctccac	gagttgatga	tgtggatttc	840

SeqID 60

ttgagtgaag	agtcaagaga	agaagagaaa	ttaagcttta	aagagcagat	tctgagagat	60
ttagaaaaag	taaaaggcta	tgatgaagtt	ctgaaagaag	atgaggcagt	agttcgcact	120
cctgcaaatg	aaccttcaac	tgaagaactc	atggctgatt	ccttgctaac	ggttagaggag	180
attatgagaa	aagctcctac	cgtgcctact	cacccaagtc	aaggtgtacc	agcttctcca	240
gcagatgaga	ttcaaaagaga	aactcctggt	gttccaagtc	atccaagtc	agatgtacct	300
tcttctccag	cggaaagaaag	tggatcaaga	ccagggtccag	gtcctgttag	acctaaagaaa	360
cttgaaagag	aatacaatga	aaccccaaca	agggtagctg	tttctatatac	gacggcagag	420
aaaaaagcag	aacaagcagg	tccagaaaca	cctacgcctg	ctacagaaac	agtggatatac	480
atcagagata	catcacgtcg	tagccgtaga	gaaggagcaa	aaccggttaa	gcctaagaaa	540
gagaagaagt	cacatgtgaa	agcttttgtg	atttcattcc	ttgtattcct	tgccttgctc	600
tcagcaggtg	gttacttttg	ttaccagtac	ctgctagatt	ccttattacc	tatcgatgct	660
aatttctaaga	aatatgtgac	ggttggaaat	ccagaagggt	caaacgttca	agaaatcggg	720
acgacgcttg	aaaaagctgg	tttggttaaag	catggctctga	tttttagttt	ttatgccaaag	780
tataaaaaatt	ataccgactt	gaaagcagggt	tactacaatt	tgcataagag	tatgagtaca	840
gaagacttac	tcaaaagagt	gcaaaaaggt	ggaacagatg	aaccgcaaga	acctgtactt	900
gcgactttga	caattccaga	aggttatacc	ttggatcaga	ttgctcaagc	tgtgggtcaa	960
ttgcaagggtg	acttcaaaaga	gtcttttgaca	gcggaggctt	tcttggctaa	agttccaagat	1020
gagacgttta	tcagtcaagc	agtagcgaaa	tatcctactt	tactggaaaag	tttgctctga	1080

aaagacagcg	gtgcgcgtta	tcgtttggaa	ggataccttt	tcccagctac	atactctatc	1140
aaggaaagca	caactattga	gagcttgatt	gatgagatgt	tagctgctat	ggataagaac	1200
ctatctcctt	actatagtac	tatcaaactc	aaaaacttga	ctgtcaatga	gttggtgacc	1260
attgcttcct	tggctgaaaa	agaagggtgcc	aagacagaag	atcgtaagct	cattgcaggt	1320
gtattctaca	atcgtttgaa	tcgtgatatg	ccacttcaaa	gtaatatgtc	aatcttgtat	1380
gccaagggaa	aactggggca	aaatatcagt	ctagctgagg	atgttgcgat	tgataccaac	1440
attgattcac	cttataatgt	ttataaaaat	gtagggtctca	tgcttggtcc	agtcgatagt	1500
ccaagtctgg	atgcgattga	gtcaagcatt	aatcaaaacta	agagcgataa	cctctacttt	1560
gtagcagatg	tcacagaagg	caagggtctac	tatgctaaca	atcaagaaga	ccacgaccgc	1620
aatgtcgctg	aacatgtcaa	cagcaaatta	aac			1653

SeqID 61

atgaaacaag	aacgatttcc	attggtgtca	gatgacgagg	tcatgttgac	tgaaatgccca	60
gtcatgaatc	tctatgatga	gtctgatctg	atcagtaata	tcaaggggtga	gtatcgagat	120
aaaaattatt	tagaatgggc	tcctattgct	gaagaaaaac	cagtaaaacc	gattgaaaag	180
caagtcgaaa	aacctaaaaa	ggctccttta	gggggttaaaa	aagaaggaaa	gagctatgcg	240
gaggtggcgc	gtgaagaagc	gcgtgcggac	ttgaaaaaga	aacgctctgc	taactacca	300
actcaggatt	tcagccttgc	gagacgtcat	tctcagccca	gtctagttag	acaggggcaat	360
caaccgacag	ctcctttcca	aaaggaaaat	cctgggtgaat	ttgtcaaata	tagccaaaaa	420
ttgacccagt	ctcattatat	cttggcggaa	gaagttcatt	ctatccctac	caagaatgaa	480
gaagtgtcag	cacctgctcc	aaagaaaaac	aattatgatt	ttctaagaa	gagccaaatc	540
tacaataaaa	aaagtaaaaca	aacagaacaa	gaacgtcggg	ttgcccaaga	gttgaatctg	600
accagaatga	cagaa					615

SeqID 62

atgaaaaagt	ctaagagcaa	atatctaacc	ttggcagggtc	ttgtcctggg	tacaggaggtt	60
ttattgagcg	cgtgtggaaa	ttctagcacg	gcgtcaaaaa	cctacaacta	tgtttattca	120
agtgtatccat	ctagcttgaa	ctatctagca	gaaaaccgcg	cagcaacatc	cgatattggt	180
gcaaattttg	tagacgggtt	attagaaaat	gaccaatatg	ggaatattat	tccatcatta	240
gcagaggatt	ggactgtttc	tcaggacgggt	ttgacctata	cctacaaact	tcgttaaggat	300
gccaagtgggt	ttactttctga	gggagaagaa	tatgcgcctg	taactgcccc	ggattttgtg	360
acagggtttgc	aatatgcagc	tgataaaaaa	tcagaagcct	tgtatctagt	gcaggactct	420
gttgctgggtt	tggatgacta	tatcactgggt	aaaacaagcg	acttttcaac	tgtcgggtgtc	480
aaggcacttg	atgaccaaac	gggttcaatat	actttgggtta	aaccagaact	ttactggaat	540
tcaaaaaacac	ttgcaacgat	actttttcct	gttaatgcag	atttccctgaa	atcaaaagggt	600
gatgattttg	ggaaggcgga	tccatctagt	attttgtaca	atggaccttt	cttgatgaaa	660
gcacttgtct	caaaatctgc	tattgaaat	aagaaaaacc	ctaattactg	ggatgctaag	720
aatgtccttg	tagacgatgt	gaaattgacc	tactatgatg	gtagegacca	agaatcactg	780
gaacgtaatt	ttacagctgg	tgcttatact	acggctcgct	tttttcttaa	cagctccagc	840
tatgaaggga	ttaaagaaaa	atacaaaaac	aatatcatct	atagtatgca	aaattcaact	900
tcattatttct	ttaattttta	cctagatagg	aagtcttaca	attatacttc	taaaaacaagt	960
gacattgaaa	agaaatcgac	tcaggaagca	gttctcaata	aaaacttccg	tcaggctatc	1020
aattttgctt	ttgacagaa	atcctatggg	gctcagctctg	aagggaagaa	aggtgcaaca	1080
aagattttgc	gtaacctagt	ggttcctcca	aactttgtca	gtatcaagggt	aaaagacttt	1140
gggtgaagtg	tagcctctaa	gatggtaaac	tatggtaagg	aatggcaagg	tatcaacttt	1200
gcggatgggtc	aagaccctta	ctacaatcct	gagaaagcca	aggctaagtt	tgcggaagct	1260
aagaaagaac	tcgaagcaaa	gggtgttcaa	ttcccaatcc	acttgataa	gactgtggaa	1320
gtaacagata	aagtaggcat	acaaggagtt	agttctatca	aacaatcaat	tgaatctggt	1380
ttagggtctg	ataatgtagt	gattgacatt	cagcaattaa	catcagatga	gtttgacagt	1440
tcaggctact	ttgctcaaac	agctgctcag	aaagattatg	atttatatca	tgccgggttg	1500
ggacctgatt	atcaagacc	gtcaacctat	ctcgatatatt	ttaataactaa	tagtggagga	1560
tttctgcaaa	atcttggtg	agagcctgggt	gaggccaatg	acaaggctaa	ggcagttgga	1620
ctggatgtct	atactcaaat	gttggaagaa	gctaataaag	agcaagatcc	ggccaaacgt	1680
tatgagaaat	atgctgatat	tcaagcttgg	ttgattgata	gttctttagt	tcttccaagt	1740
gtttcgcgtg	ggggaacacc	atcattgaga	agaaccgtac	catttgctgc	tgccatgggt	1800
ttaaccggta	caaaaggggt	tgaatcatat	aaatacctca	aagtacaaga	taagattgtc	1860
acaaacagacg	aatatgcaaa	agccagagaa	aatgggttga	aagaaaaaga	agaatccaat	1920
aaaaaagccc	aagaagaatt	ggcaaaacat	gtcaaa			1956

SeqID 63

gtggaacagc	attcagatgt	ctgtttacatt	ttttatagga	gagaaagatt	gaaaaacaaa	60
attggattag	caagtatctg	tttactaggc	ttggcaacta	gtcatgtcgc	tgcaaatgaa	120
actgaagtag	caaaaacttc	gcaggataga	acgacagctt	caagtagttc	agagcaaaat	180
cagtcctcta	ataaaacgca	aacgagcgca	gaagtacaga	ctaattgctgc	tgcccactgg	240
gatggggatt	attatgtaaa	ggatgatgggt	tctaagctc	aaagtgaatg	gatttttgac	300
aactactata	aggtttggtt	ttatattaat	tcagatgggtc	gttactcgca	gaatgaatgg	360
actggaaatt	actacctgaa	atcaggtgga	tatatggccc	aaaacgagtg	gatctatgac	420
agtaattaca	agagttgggt	ttatctcaag	tcagatgggg	cttatgctca	tcaagaatgg	480

caattgattg	gaaataagtg	gtactacttc	aagaagtggg	gttacatggc	taaaagccaa	540
tggcaaggaa	gttattttct	gaatggctca	ggagctatga	tgcaaaatga	atggctctat	600
gatccagcct	attctgctta	tttttatcta	aaatccgatg	gaacttatgc	taaccaagag	660
tggcaaaaag	tgggaggcaa	atgggtactat	ttcaagaagt	ggggctatat	ggctcggaat	720
gagtggaag	gcaactacta	tttgactgga	agtggtgcca	tggcgactga	cgaagtgatt	780
atggatggta	ctcgctatat	ctttgcggcc	tctggtgagc	tcaaaagaaa	aaaagatttg	840
aatgtcggct	gggttcacag	agatggtaag	cgctatttct	ttaataatag	agaagaacaa	900
gtgggaaccg	aacatgctaa	gaaagtcatt	gatatttagt	agcacaatgg	tcgtatcaat	960
gattggaaaa	aggttattga	tgagaacgaa	gtggatgggt	tcattgttcg	tctaggttat	1020
agcggtaaa	aagacaagga	attggcgcat	aacattaagg	agttaaaccg	tctgggaatt	1080
ccttatgggt	tctatctcta	tacctatgct	gaaaaatgaga	ccgatgctga	gagtgacgct	1140
aaacagacca	ttgaacttat	aaagaaatc	aatatgaacc	tgtcttacc	tatctattat	1200
gatgttgaga	attgggaata	tgtaaataag	agcaagagag	ctccaagtga	tacaggcact	1260
tgggttaaaa	tcatacaaaa	gtacatggac	acgatgaagc	aggcggtta	tcaaaatgtg	1320
tatgtctata	gctatcgtag	tttattacag	acggttttaa	aacacccaga	tattttaaaa	1380
catgtaaa	ggtagcggc	ctatacgaat	gctttagaat	gggaaaacc	tcattattca	1440
ggaaaaaag	gtggcaata	tacctctct	gaatacatga	aaggaatcca	agggcgcgta	1500
gatgtcagcg	tttgggtat					1518

SeqID 64

atggcaaaag	aaccgtggca	agaagatatc	tatgatcaag	aagaatcaag	agcagagcgt	60
cggcatcgaa	accacggagg	ggctgatagg	atggctaatc	gtattttgac	gacccatgct	120
agtattttct	ttgtaattgt	gggtggtagt	gtcatcgctc	tcactctatc	atcatcgggg	180
gggagtaatc	gcacagcagc	cttaaaaagg	tttcatgatt	ctgatgccag	tgtagtacaa	240
atctcatctt	caagtagttc	tcagcctgag	cagagttcag	agccagaatc	tacttctagt	300
agttcagaag	aagctgctaa	tctgaagga	acgattaaag	ttctcgagg	agaaggggaa	360
gcagctattg	ccgctcgtgc	aggaatctcc	attgctcagt	tagaggcctt	gaatcctggg	420
cacatggcta	caggatcttg	gtttgcta	ccaggtgatg	ttataaaaa	aaaa	474

SeqID 65

atgccaat	catcattaga	aataaaggac	aagacttttg	gaactcgatt	cagaggtttt	60
gatccagaag	aagtcgatga	attttttagat	attgtgggtc	gtgattacga	agatcttgtg	120
cgtgcgaatc	atgataaaaa	tttgcgtatt	aagagtttag	aagagcggtt	gtcttacttt	180
gatgaaataa	aagattcatt	gagccagtct	gtatttgattg	ctcaggatag	agctgagaga	240
gtgaaacagg	cggcgcatga	acgttcaaac	aatatcattc	atcaagcaga	gcaagatgag	300
caacgcttgt	tggagaagac	taaatataag	gcaaacgaga	ttcttcgtca	agcaactgat	360
aatgctaaga	aagtcgctgt	tgaacagaaa	gaattgaaga	acaagagccg	tgtcttccac	420
caacgtctca	aatctacaat	tgagagtcag	ttggctattg	ttgaatcttc	agattgggaa	480
gatattctcc	tccaacagc	tacttatctt	caaacagtg	atgaagcctt	taaagaagt	540
gttagcgaag	tacttgagga	accgattcca	gctccaattg	aagaagaacc	aattgatatg	600
acacgtcagt	tctctcaagc	agaaatggca	gaattacaag	ctcgtattga	ggtagccgat	660
aaagaattgt	ctgaatttga	agctcagatt	aaacaggaag	tgggaagctc	aactcctgta	720
gtgagtcctc	aagttgaaga	agagcctctg	ctcatccagt	tggcccaatg	tatgaagaac	780
cagaag						786

SeqID 66

atgtctttaa	aagatagatt	cgatagattt	atagattatt	ttacggagga	tgaggattca	60
agtctccctt	atgaaaaaag	agatgagcct	gtgtttactt	cagtaaatc	ttcacaggaa	120
ccggtctctc	caatgaatca	accttcacag	tcggctggca	caaaagagaa	caatatcacc	180
agacttcatg	caagacaaca	ggaattggca	aatcagagtc	agcgtgcaac	ggataaggct	240
attatagatg	ttcgttatcc	tagaaaatat	gaggatgcaa	cagaaattgt	tgattttattg	300
gcaggaaaacg	aaagtatctt	gattgatttt	cagtatatga	cagaggtgca	ggctcgtcgt	360
tgtttggact	atttggatgg	agcttgtcat	gttttagctg	gaaatttgaa	aaaggtagct	420
tctaccatgt	atttgttgac	accagtgaac	gttattgtaa	atgttgaaga	tatccgttta	480
ccagatgaag	atcaacaggg	tgagttcggg	tttgatatga	agcgaataag	agtacga	537

SeqID 67

atgtcagatt	tgaaaaaata	cgaaggtgtc	attccagcct	tctacgcag	ttatgatgat	60
caaggagaag	taagcccaga	acgtacgcgt	gccttggttc	aatacttcat	tgataaagg	120
gttcaaggct	tttatgtcaa	tggttcttct	ggtgaatgta	tctaccaaa	cgttgaagat	180
cgcaagttga	ttttggaaga	agtcagggcg	tgagccaaa	gtaaattgac	cattattgct	240
catgttgctt	gcaataatac	taaagatagt	atggaacttg	ctcgccatgc	tgaaagcttg	300
ggagtagatg	ctattgcaac	gattccacca	atttatttcc	gcttgccaga	atactcagtt	360
gcaaaatact	ggaacgat	cagttctgca	gctccaaaca	cagactacgt	gatttacaac	420
attcctcaat	tggcaggggt	tgctttgact	ccaagccttt	acacagaaat	gttgaaaaat	480
cctcgtgtta	tgggtgtgaa	gaactcttct	atgccagttc	aagatatcca	aacctttgtc	540
agccttggtg	gagaagacca	tatcgtcttt	aatggctcctg	atgagcagtt	cctaggagga	600
cgctcatg	gggctagggc	tggtatcggg	ggtacttatg	gtgctatgcc	agaactcttc	660

ttgaaactca	atcagttgat	tgcggataag	gacctagaaa	cagcgcgtga	attgcagtat	720
gctatcaacg	caatcattgg	taaactcact	tctgctcatg	gaaatatgta	cggtgtcatc	780
aaagaagtct	tgaaaatcaa	tgaaggcttg	aatattggat	ctgttcgttc	accattgaca	840
ccagtgactg	aagaagatcg	tccagttgta	gaagcggctg	ctgccttgat	tcgtgaaacc	900
aaggagcgct	tcctc					915

SeqID 68

atgaataaaa	gagggtcttta	ttcaaaaacta	ggaatttccg	ttgtaggcat	tagtctttta	60
atgggagtc	ccactttgat	tcctgcgaat	gaattaaact	atgggtcaact	gtccatatct	120
cctatttttc	aaggaggttc	atatcaactg	aacaataaga	gtatagatat	cagctctttg	180
ttattagata	aattgtctgg	agagagtcag	acagtagtaa	tgaaatttaa	agcagataaa	240
ccaaactctc	ttcaagcttt	gtttggccta	tctaatagta	aagcaggctt	taaaaataat	300
tacttttcaa	ttttcatgag	agattctggg	gagataggty	tagaaataag	agacgcccaa	360
aagggaataa	attattttatt	ttccagacca	gcttcattat	ggggaaaaca	taaaggacag	420
gcagttgaaa	atacactagt	atttgtatct	gattctaaag	ataaaacata	cacaatgtat	480
gttaatggaa	tagaagtgtt	ctctgaaaca	gttgatacat	ttttgccaat	ttcaaatata	540
aatggtatag	ataaggcaac	actaggagct	gttaatcgtg	aaggtaagga	acattacctc	600
gcaaaaggaa	gtattgatga	aatcagtccta	tttaacaaag	caattagtga	tcagggaagt	660
tcaactattc	ccttgtcaaa	tccatttcag	tttaattttcc	aatcaggaga	ttctactcaa	720
gctaactatt	ttagaatacc	gacactatat	acattaagta	gtggaagagt	tctatcaagt	780
attgatgcac	gttatggtgg	gactcatgat	tctaaaagta	agattaatat	tgccacttct	840
tatagtgatg	ataatgggaa	aacgtggagt	gagccaattt	ttgctatgaa	gtttaatgac	900
tatgaggagc	agttagttaa	ctggccacga	gataataaat	taaaagaatag	tcaaattagt	960
ggaagtgcct	cattcataga	ttcatccatt	gttgaagata	aaaaatctgg	gaaaacgata	1020
ttactagctg	atgttatgcc	tgcgggtatt	ggaaataata	atgcaaataa	agccgactca	1080
ggttttaaa	aaataaatgg	tcattattat	ttaaaactaa	agaagaatgg	agataacgat	1140
ttccggtata	cagttagaga	aaatgggtgc	gtttataatg	aaacaactaa	taaacctaca	1200
aattatacta	taaatgataa	gtatgaagtt	ttggaggagg	gaaagtcttt	aacagtcgaa	1260
caatatctcg	ttgattttga	tagtggctct	ttaagagaaa	ggcataatgg	aaaacagggt	1320
cctatgaatg	ttttctacaa	agattcgtta	tttaaagtga	ctcctactaa	ttatatagca	1380
atgacaacta	gtcagaatag	aggagagagt	tggaacaat	ttaagtgtt	gcctccgttc	1440
ttaggagaaa	aacataatgg	aacttactta	tgtcccgac	aaggttttag	attaaaatca	1500
agtaacagat	tgatttttgc	aacatatact	agtggagaa	taacctatct	cattttctgat	1560
gatagtggtc	aaacatggaa	gaaatcctca	gcttcaattc	cgtttaaaaa	tgcaacagca	1620
gaagcacaaa	tgggtgaact	gagagatggg	gtgattagaa	cattcttttag	aacctacaca	1680
ggtaagatag	cttatatgac	tagtagagat	tctggagaaa	catggtcgaa	agtttcgtat	1740
attgatggaa	tccaacaaac	ttcatatggc	acacaagtat	ctgcaattaa	atactctcaa	1800
ttaattgatg	gaaaagaagc	agtcattttg	agtacaccaa	attctagaag	tgcccgcaag	1860
ggaggccaat	tagttgtcgg	tttagtcaat	aaagaagatg	atagtattga	ttggaaatac	1920
cactatgata	ttgatttgcc	tctgtatggg	tatgcctatt	ctgcgattac	agaattggca	1980
aatcatcaca	taggtgtact	gtttgaaaaa	tatgattcgt	ggtcgagaaa	tgaattgcat	2040
ttaagcaatg	tagttcagta	tatagatttg	gaaattaatg	atttaacaaa	a	2091

SeqID 69

atgaatcggg	gtgttcaaga	acgtaagtgt	cgttatagca	ttaggaaact	atcggtagga	60
gcggtttcta	tgattgtagg	agcagtggta	tttggaacgt	ctcctgtttt	agctcaagaa	120
ggggcaagtg	agcaacctct	ggcaaatgaa	actcaacttt	cgggggagag	ctcaacccta	180
actgatacag	aaaagagcca	gccttcttca	gagactgaac	tttctggcaa	taagcaagaa	240
caagaaagga	aagataagca	agaagaaaaa	attccaagag	attactatgc	acgagatttg	300
gaaaatgtcg	aaacagtgat	agaaaaagaa	gatgttgaaa	ccaatgcttc	aaatgggtcag	360
agagttgatt	tatcaagtga	actagataaa	ctaaagaaac	ttgaaaacgc	aacagttcac	420
atggagttaa	agccagatgc	caaggcccca	gcattctata	atctcttttc	tgtgtcaagt	480
gctactaaaa	aagatgagta	cttcaactatg	gcagtttaca	ataatactgc	tactctagag	540
gggctgtggt	cggatgggaa	acagttttac	aataattaca	acgatgcacc	cttaaaagtt	600
aaaccagggtc	agtggaattc	tgtgactttc	acagttgaaa	aaccgacagc	agaactacct	660
aaaggccgag	tgcgcctcta	cgtaaacggg	gtattatctc	gaacaagtct	gagatctggc	720
aatttcatata	aagatatgcc	agattgaacg	catgtgcaaa	tcggagcaac	caagcgtgcc	780
aacaatacgg	tttgggggtc	aaatctacag	attcggaatc	tcactgtgta	taactcgtgct	840
ttaacaccag	aagaggtaca	aaaacgtagt	caacttttta	aacgctcaga	tttagaaaaa	900
aaactacctg	aaggagcggc	tttaacagag	aaaacggaca	tattcgaaag	cgggcgtaac	960
ggttaacccaa	ataaagatgg	aatcaagagt	tatcgtattc	cagcacttct	caagacagat	1020
aaaggcaactt	tgatcgaggg	tgcagatgaa	cgcgctctcc	attcgagtga	ctggggtgat	1080
atcggtatgg	tcacagacag	tagtgaagat	aatggtaaaa	cttgggggtga	ccgagtaacc	1140
attaccaact	tacgtgacaa	tccaaaagct	tctgacccat	cgatcggttc	accagtgaat	1200
atcgatatgg	tggtggttca	agatcctgaa	accaaacgaa	tcttttctat	ctatgacatg	1260
ttcccagaag	ggaagggaa	ctttggaatg	tcttcacaaa	aagaagaagc	ctacaaaaaa	1320
atcgatggaa	aaacctatca	aatcctctac	cgtgaaggag	aaaaggagc	ttataccatt	1380
cgagaaaatg	gtactgtcta	tacaccagat	ggtaaggcga	cagactatcg	cgttgttgta	1440

gacccgtgta	aaccagccta	tagcgacaag	ggtgatctat	acaaggggtga	ccaattacta	1500
ggaaatatct	acttcacaac	aaacaaaact	tctccattta	gaattgccaa	ggatagctat	1560
ctatggatgt	cctacagtga	tgacgacggg	aagacatggt	cagctcctca	agatattact	1620
ccgatgggtca	aagccgattg	gatgaaattc	ttgggtgtag	gtcctggaac	aggaattgta	1680
cttcgggaatg	ggcctcaca	gggacggatt	ttgataccgg	tttatacgac	taataatgta	1740
tctcacttag	atggctcgca	atcttctcgt	gtcatctatt	cagatgatca	tggaaaaact	1800
tggcatgctg	gagaagcggg	caacgataac	cgtcaggtag	acgggtcaaaa	gatccactct	1860
tctacgatga	acaatagacg	tgcgcaaaat	acagaatcaa	cgggtggtaca	actaaacaat	1920
ggagatgtta	aactctttat	gcgtgggttg	actggagatc	ttcaggttgc	tacaagtaaa	1980
gacggaggag	tgacttgggg	gaaggatata	aaacggttat	cacaggttaa	agatgtctat	2040
gttcaaatgt	ctgctatcca	tacgatgcac	gaaggaaaag	aatacatcat	cctcagtaat	2100
gcagggtggac	cgaaacgtga	aaatgggatg	gtccacttgg	cacgtgtcga	agaaaatggg	2160
gagttgactt	ggctcaaaca	caatccaatt	caaaaaggag	agtttgccta	taattcgctc	2220
caagaattag	gaaatgggga	gtatggcatc	ttgtatgaac	atactgaaaa	aggacaaaat	2280
gcctataccc	tatcatttag	aaaatttaat	tgggaatttt	tgagcaaaaa	tctgatttct	2340
cctaccgaag	cgaactagag	agatgggcaa	aggagagatg	ggcaaaggag	ttattggctt	2400
ggagttcgag	tcagaagtat	tggtaacaa	ggctccaacc	cttcaattgg	caaatggtaa	2460
aacagcgact	ttcctaacc	agtatgatag	caagaccttg	ttgtttgcag	tagataagga	2520
agatatcgga	caggaaatta	ttggtatagc	taaaggaagc	atcgaaagta	tgcataatct	2580
tctctgtaaat	ctagcaggtg	ccagagttcc	tggcggagta	aatggtagca	aagcagcggg	2640
gcataaggtt	ccagaattta	cagggggagt	taatggtaca	gagccagctg	ttcatgaaat	2700
cgcagagtat	aagggatctg	attcgcttgt	aactcttact	acaaaaaaag	attatactta	2760
caaaagctcct	cttgcctcag	aggcacttcc	tgaacacagga	aacaaggaga	gtgacctcct	2820
agcttcacta	ggactaacag	ctttcttcc	tggctctgtt	acgctagggg	aaaagagaga	2880
acaa						2884

SeqID 70

atgatccaaa	tcggcaagat	ttttgccgga	cgctatcgga	ttgtcaaaca	gattggctga	60
ggagggtatg	cggatgtcta	cctagccaaa	gacttaatct	tagatgggga	agaagtggca	120
gtgaagggtc	tgaggaccaa	ctaccagacg	gaccgatag	ctgtagctcg	ttttcagcgt	180
gaagcgagag	ctatggcaga	tctagaccat	cctcatatcg	ttcggataac	agatattggc	240
gaggaagacg	gtcaacagta	cctagctatg	gagtatgtgg	ctggactgga	cctcaaacgc	300
tatatcaagg	aacattatcc	tctttcta	gaagaagcag	tccgtatcat	gggacaaatt	360
ctcttgagta	tgcgcttgcc	ccatactcga	ggaattgttc	acagggactt	gaaacctcaa	420
aatatcctct	tgacaccaga	tgggactgcc	aaggtcacag	actttgggat	tgctgtagcc	480
tttgacagaga	caagtctgac	ccagactaac	tcgatgttgg	gctcagttca	ttacttgtca	540
ccagagcagg	cgcgtgggtc	gaaggcgact	gtgcagagtg	atatctatgc	catggggatt	600
attttctatg	agatgctgac	aggccatata	ccttatgacg	gggatagcgc	ggtgaccatt	660
gccctccagc	atttccagaa	acccctgccg	tccgttattg	cagaaaaatc	atctgtacct	720
caggctttag	aaaatgttat	tatcaaggca	actgctaaaa	agttgaccaa	tcgctaccgc	780
tcgggtttcag	agatgtatgt	ggacttgtct	agtagcttgt	cctacaatcg	tagaaatgaa	840
agtaagttaa	tctttgatga	aacgagcaag	gcagatacca	agaccttgcc	gaaggtttct	900
cagagtacct	tgacatctat	tctaagggtt	caagcgcaaa	cagaacacaa	atcaatcaaa	960
aaccacaagcc	aggctgtgac	agaggaaaact	taccaaccac	aagcaccgaa	aaaacataga	1020
tttaagatgc	gttacctgat	tttgttggcc	agccttgtat	tgggtggcagc	ttctcttatt	1080
tggatactat	ccagaactcc	tgcaccatt	gccattccag	atgtggcagg	tcagacagtt	1140
gcagaggcca	aggcaacgct	caaaaaagcc	aattttgaga	ttggtgagga	gaagacagag	1200
gctagtga	agggtgaaga	agggcggatt	atccgtacag	atcctggcgc	tggaaactggt	1260
cgaagaaga	gaacgaaaat	caattttggt	gtctcatcag	gcaagcaatc	tttccaaatt	1320
agtaattatg	tcggtcggaa	atcctctgat	gtcattgcgg	aattaaaaga	gaaaaaagtt	1380
ccagataatt	tgattaaaat	tgaggaagaa	gagtcgaatg	agagtgaggc	tggaaacggtc	1440
ctgaagcaaa	gtctaccaga	aggtacgacc	tatgacttga	gcaaggcaac	tcaaatgtgt	1500
ttgacagtag	ctaaaaaagc	tacgacgatt	caattaggga	actatattgg	acggaactct	1560
acagaagtaa	tctcagaact	caagcagaag	aaggttcctg	agaatttgat	taagatagag	1620
gaagaagagt	ccagcgaaa	cgaaccagga	acgattatga	aacaaagtcc	aggtgcccga	1680
acgacttatg	atgtgagtaa	acctactcaa	attgtcttga	cagtagctaa	aaaagtata	1740
agtgttgcca	tgccgagtta	catttggttct	agcttggagt	ttactaagaa	caatttgatt	1800
caaattgttg	ggattaagga	agctaataata	gaagttgtag	aagtgacgac	agcgcctgca	1860
ggtagtgcag	aaggcatggg	tgttgaacaa	agtcctagag	caggtgaaaa	ggtagacctc	1920
aataagacta	gagtcaagat	ttcaatctac	aaacctaaaa	caacttcagc	tactcct	1977

SeqID 71

atgacaaaac	taatctttat	ggggaccccc	gacttttcag	caacagtctt	aaaaggactt	60
ttgacagatg	accggttacga	aattcttagcc	gttgtgaccc	agccagaccg	tgctgttggg	120
cgtaaaaaac	ttatccaaga	aaccccagtc	aagcaggctg	ccaaggaagc	aggactatct	180
atctaccaac	ctgaaaaatt	atctggaagt	ccagagatgg	aagatcttat	gaagctagga	240
gcagatggaa	ttgtgactgc	tgcttttggg	cagtttctcc	caagcaaaact	ccttgatagc	300
atggactttg	ctgtcaacgt	tcattgcctcc	ctccttcccta	gacaccgtgg	tgggtgcgcct	360

atccattatg	ccttgattca	aggggatgag	gaagctgggt	tgaccatcat	ggaaatgggt	420
aaggaaatgg	atgcaggaga	tatgatttct	cgtcgcagca	ttccgatcac	agatgaggac	480
aatgttggca	ccttgtttga	aaaattggcg	ctagttggtc	gtgatttgct	tttggacact	540
ctgcctgcct	atattgctgg	tgatatcaaa	cctgaaccgc	aggatacgag	tcaggttacc	600
ttctctccaa	atataaagcc	agaggaagaa	aaactggact	ggaacaaaac	caatcgtcaa	660
ctctttaacc	aaattcgtgg	aatgaacccc	tgccctgttg	ccataacttt	ccttaagggc	720
gaccgcttta	agatttatga	agccctacca	gtgaaggtc	agggaaatcc	aggtgagatt	780
ctctctatcg	gcaagaaaga	attgattgtc	gcaacggctg	aaggggctct	atccctcaaa	840
caagtgcagc	cagctggtaa	gcctaagatg	gacattgctt	ccttcctcaa	cggagtggga	900
cgtacattga	ctgtaggaga	acgatttggt	gac			933

SeqID 72

gtgttttagac	gtttaggtea	agattttccag	cttaggaaag	tgaaaaagat	tttaaagcag	60
attaatgccc	tgaaaggcaa	gatgtcctct	ctttcggatc	aagaattagt	agctaaaaca	120
gtagagtttc	gtcagcgtct	ttccgaggga	gaaagtctag	acgatatttt	ggttgaagct	180
tttgctgtgg	tgctgaagc	agataagcgg	atlttaggga	tgtttcctta	tgatgttcaa	240
gtcatgggag	ctattgtcat	gcactatgga	aatgttgctg	agatgaatac	gggggaaggt	300
aagaccttta	cagctaccat	gcctgtctat	ttgaacgctt	tttcaggaga	aggagtgtg	360
gttggtgactc	ctaagttagta	tttatcaaa	cgtgatgccg	aggaaatggg	tcaagtttat	420
cgttttctag	gattgaccat	tggtgtacca	tttacggaag	atccaaagaa	ggagatgaaa	480
gctgaagaaa	agaagcttat	ctatgcttcg	gatatcatct	acacaaccaa	tagtaattta	540
ggttttgatt	atctaataatga	taacctagcc	tcgaatgaag	aaggtaagtt	tttacgaccg	600
tttaactatg	tgattattga	tgaaattgat	gatattcttg	tgatagtg	acaaactcct	660
ctgattattg	cgggttctcc	tcgtgttcag	tctaattact	atgcgatcat	tgatacactt	720
gtaacaacct	tggtcgaagg	agaggattat	atctttaaag	aggagaaaga	ggaggtttgg	780
ctcactacta	agggggccaa	gtctgctgag	aatttcctag	ggattgataa	tttatacaag	840
gaagagcatg	cgtcttttgc	tcgtcatttg	gtttatgcga	ttcgagctca	taagctcttt	900
actaaagata	aggactatat	cattcgtgga	aatgagatgg	tactggttga	taagggaaca	960
gggctgtctaa	tggaatgac	taaacctcaa	ggaggtctcc	atcaggctat	tgaagccaag	1020
gaacatgtca	aattatctcc	tgagacgcgg	gctatggcct	cgatcaccta	tcagagtctt	1080
tttaagatgt	ttaataagat	atctggtatg	acagggacag	gtaaggctcg	ggaaaaagag	1140
tttattgaaa	cttacaatat	gtctgtagta	cgcatctcaa	ccaatcgtcc	gagacaacgg	1200
attgactatc	cagataatct	atatatcact	ttacctgaaa	aagtgtatgc	atccttggag	1260
tacatcaagc	aataccatgc	taagggaat	cctttactcg	ttttttagg	ctcagttgaa	1320
atgtctcaac	tctattcgtc	tctcttgttt	cgtgaaggga	ttgccataaa	tgctcctaat	1380
gctaataatg	cggcgctgga	ggctcagatt	atctccgagt	caggtcagat	gggggctgtg	1440
acagtggcta	cctctatggc	aggacgtggt	acggatatca	agcttggtaa	aggagtcgca	1500
gagcttgggg	gcttgattgt	tattgggact	gagcggatgg	aaagtcagcg	gatcgaccta	1560
caaattcgtg	gccgttctgg	tcgtcaggga	gatcctggta	tgagtaaaat	ttttgtatcc	1620
ttagaggatg	atgttatcaa	gaaatttggt	ccatcttggg	tgcatataaa	gtacaaagac	1680
tatcaggttc	aagatatgac	tcaaccggaa	gtattgaaag	gtcgtaaata	ccggaaacta	1740
gtcgaanaag	ctcagcatgc	cagtgatagt	gctggacgtt	cagcacgtcg	tcagactctg	1800
gagtatgctg	aaagtatgaa	tatacaacgg	gatatagtct	ataaagagag	aaatcgtcta	1860
atagatgggt	ctcgtgactt	agaggatggt	gttggtggata	tcattgagag	atatacagaa	1920
gaggtagcgg	ctgatcacta	tgctagtctg	gaattattgt	ttcactttat	tgtgaccaat	1980
attagttttc	atgttaaaaga	ggttccagat	tatatagatg	taactgacaa	aactgcagtt	2040
cgtagcttta	tgaagcaggt	gattgataaa	gaactttctg	aaaagaaaga	attacttaat	2100
caacatgact	tatatgaaca	gtttttacga	ctttcactgc	ttaaagccat	tgatgacaac	2160
tgggtagagc	aggttagacta	tctacaacag	ctatccatgg	ctatcggtgg	tcaatctgct	2220
agtcagaaaa	atccaatcgt	agagtactat	caagaagcct	acgcgggctt	tgaagctatg	2280
aaagaacaga	ttcatgcgga	tatggtgcgt	aatctcctga	tggggctggt	tgagggtcact	2340
ccaaaagggtg	aaatcgtgac	tcattttcca				2370

SeqID 73

atgaccgaaa	cggtagaaga	taaagtaagt	cattcaatta	ctgggcttga	tatcctcaag	60
gggtagtttg	ctgcgggagc	tgctataagt	ggaaccgttg	caactcaaac	gaaggatatt	120
acaaatgagt	cagcagtact	tgaaaaaact	gtagagaaaa	cggtatgctt	ggcaacaaat	180
gatacagtag	ttctaggtac	gatatctaca	agtaattcag	cgagttcaac	tagtttgtca	240
gcttcagagt	cggcaagtac	atctgcactc	gagtcagcct	caaccagcgc	ttcgacctca	300
gcaagtacaa	gtgcatcaga	atcagcaagt	acatcggctt	cgacaagtat	ttctgcatca	360
tctactgtgg	taggttcaca	aacagctgcc	gctacagaag	caactgctaa	gaaggctgaa	420
gaagatcgta	agaaaccagc	tagtgattat	gtagcatcag	ttacaaatgt	caatctccaa	480
tcttatgcta	agcgcagcaa	gcgttcagtg	gattccatcg	agcaattgct	ggcttctata	540
aaaaatgctg	ctgttttttc	tggcaatacg	attgtaaaatg	gcgcccctgc	aattaatgca	600
agtctaaaca	ttgctaaaag	tgagacaaaa	gtttatacag	gtgaagggtg	agattcggtta	660
tatcgtgttc	caatttacta	taaattgaaa	gtgacaaatg	atgggttcaaa	attgcacttt	720
acctatacgg	ttacgtatgt	gaatctctaaa	acaaatgatc	ttggtaatat	atcaagtatg	780
cgtcctggat	attctatcta	taattcaggt	acttcaacac	aaacaatgtt	aaccttggc	840

agtgatcttg	gtaaacccttc	aggtgtaaag	aactacatta	ctgacaaaaa	tggtagacag	900
gttctatcct	ataatacatc	tacaatgacg	acgcagggtg	gtgggtatac	ttggggaaat	960
ggtgccccaa	tgaatggttt	ctttgctaag	aaaggatatg	gattaacatc	atcttggact	1020
gtaccaatta	ctggaacgga	tacatccctt	acatttacc	cttacgctgc	tagaacagat	1080
agaattggaa	ttaactactt	caatgggtga	ggaagggtag	ttgaatctag	cacgaccagt	1140
cagtcacttt	cacagtctaa	gtcactctca	gtaagtgcga	gtcaaaagcgc	ctcagcttca	1200
gcatacaaaa	gtgcgtcggc	ttcagcatca	accagtgcct	cggcttcagc	gtcaaccagt	1260
gcgtcagctt	cagcaagtac	cagtgcctca	gtctcagcat	caacaagtgc	ttcagcctca	1320
gcatacgaaa	gtgcctcggc	ttcagcaagc	acatcagcat	ctgaatcagc	gtcaaccagt	1380
gcttcggcct	cagcaagtac	cagtgcctca	gcttcagcat	caaccagcgc	ctcggcctca	1440
gcaagcacct	cagcttctga	atcggcctca	accagcgcct	cggcctcagc	aagcactca	1500
gcttctgaat	cggcctcaac	cagcgcctca	gcctcagcat	caacgagtgc	ttcggcctca	1560
gcaagcacaa	gcgcctcggg	ttcagcatca	acgagtacgt	cagcttcagc	gtcaaccagt	1620
gcttcagcct	cagcatcaac	aagtgcgtca	gcctcagcaa	gtatctcagc	gtctgaatcg	1680
gcatacaacga	gtgcgtctga	gtcagcatca	acgagtacgt	cagcctcagc	aagcactca	1740
gcttctgaat	cggcctcaac	cagtgcgtca	gcctcagcat	cgacaagcgc	ctcagcttca	1800
gcaagtacaa	gtgcctcagc	ctcagcgtcg	acaagtgcgt	cggcctcaac	cagtgcactct	1860
gaatcggcat	caaccagtgc	gtcagcctca	gcaagtacta	gtgcctcggc	ttcagcatca	1920
accagtgcct	cggcctcagc	gtcaaccagt	gcgtcagctt	cagcaagtac	cagtgcctca	1980
gtctcagcat	caacaagtgc	ttcagcctca	gcatacgaaa	gtgcctcggc	ttcagcaagc	2040
acatcagcat	ctgaatcagc	gtcgacaagc	gcctcagctt	cagcaagtac	cagtgcgtca	2100
gcctcagcgt	cgacaagtgc	gtcagcctca	gcaagtacta	gtgcctcagc	ttcagcatca	2160
acgagtgcgt	cggcctcggc	gtcaaccagt	gcatacaggt	cagcaagtac	cagtgcgtca	2220
gcttcggcat	caacaagtgc	ctcggcctca	gcaagcacca	gtgcgtcggc	ttcagcaagt	2280
actagcgcct	cagcctcagc	ctcaaccagt	gcgtcagcct	cagcaagtac	ctcagcgtct	2340
gaatcggcat	caacgagtgc	gtcgccttca	gcaagtacta	gcgcctcagc	ctcagcgtca	2400
acaagtgcgt	cggcctcagc	gtcaaccagt	gcgtctgaat	cggcatcaac	gagtgcgtcc	2460
gcttcagcaa	gtactagcgc	ctcagcctca	gcgtcaacaa	gtgcctcggc	ttcagcatca	2520
acgagtgcgt	ccgcttcagc	aagtactagc	gcctcagcct	cagcgtcaac	aagtgcctcg	2580
gcttcagcgt	caacgagtgc	gtctgagtca	gcatacaacga	gtgcgtcagc	ctcagcaagc	2640
acatcagcct	ctgaatctgc	atcaaccagt	gcgtcagcct	cagcatcgac	aagcgcctca	2700
gcttcagcaa	gtaccagtgc	gtcagcctca	gcgtcgacaa	gtgcgtcggc	ttcagcaagt	2760
accagtgcgt	cagcctcagc	aagtaccagt	gcgtcagcct	cagcgtcgac	aagtgcgtcg	2820
gcctcaacca	gtgcctcaga	atcggcatca	accagtgcgt	cagcctcagc	aagtactagt	2880
gcatacagctt	cagcatcaac	gagtgcctcg	gcttcagcat	caaccagtgc	atcagagtca	2940
gcaagtacaa	gtgcgtcagc	ttcgcgtca	acaagtgcct	cggcctcagc	aagtactagc	3000
gcctcagcct	cagcgtcaac	aagtgcctca	gcttcggcgt	caaccagcgc	ctcggcctca	3060
gcaagtatct	cagcgtctga	atcggcatca	acaagtgcct	cggcctcagc	atcaaccagt	3120
gcatacagctt	cagcaagcac	cagtgcgtcg	gcctcagcaa	gcaccagcgc	gtctgaatcc	3180
gcatacaacca	gtgcctcagc	ttcagcaagt	acctcagcat	ctgaatcagc	atcaacaagt	3240
gcctcggcct	cagcaagcac	aagtgcctca	gcctcagcaa	gtatctcagc	gtctgaatcg	3300
gcatacaacga	gtgcgtcggc	ttcagcaagt	actagcgcct	cagcatcagc	gtcaacaagt	3360
gcttcggcct	cagcgtcaac	gagtgcgtct	gagtgcagcat	caacgagtac	gtcagcctca	3420
gcaagcacat	cagcttctga	atcgcctca	accagtgcgt	cagcctcagc	atcgacaagc	3480
gcctcagcct	cagcaagtac	cagtgcgtca	gcctcagcaa	gtaccagtgc	ttcagcctca	3540
gcgtcgacaa	gtgcgtcggc	ctcaaccagt	gcatactgaat	cggcatcaac	cagtgcgtca	3600
gcctcagcaa	gtactagcgc	ctcagcctca	gcatacaacga	gtgcgtcggc	ttcagcaagt	3660
actagtgcgt	cagcctcagc	aagtactagc	gcctcagcct	cagcgtcgac	aagcgcctca	3720
gcttcagcaa	gtaccagtgc	gtcagcctca	gcgtcgacaa	gtgcgtcggc	ttcagcaagt	3780
acctcagcgt	ctgaatcagc	atcaacaagt	gcgtcggcct	cagcatcaac	gagtgcctca	3840
gcttcagcat	caacaagtgc	ttcagcctca	gcaagtacaa	gtgcgtcggc	ttcagcatca	3900
acgagtgcct	cagtctcagc	gtcaaccagt	gcctctgaat	ccgcctcaac	aagtgcctcg	3960
gcttcagcaa	gcaccagtgc	ttcggcctca	gcgtcaacga	gtgcgtctga	gtcagcatca	4020
acgagtgcgt	cagcctcagc	aagcacatca	gcttctgaat	ctgcctcaac	cagtgcgtca	4080
gcttcggcat	caacaagcgc	ctcggcctca	gcaagtacaa	gtgcctcagc	ctcagcatca	4140
accagtgcgt	cagcctcagc	ctcaacaagt	gcttcagcct	cagcgtcaac	cagtgcctcg	4200
gcttcagcaa	gtaccagtgc	gtcagcctca	gcaagcacaa	gtgcgtcagc	ttcagcatca	4260
accagtgcct	cggcctcggc	atcaacaagt	gcctcagcat	cagcatcaac	gagtgcgtca	4320
gcctcagcaa	gtactagtgc	atcagcatca	gcatacaacca	gtgcctcagc	ctcagcaagt	4380
atctcagcgt	ctgaatcggc	atcaacgagt	gcatacagcat	cagcatcaac	gagtgcctcg	4440
gcttcagcgt	caaccagtgc	atcagctca	gcaagcacca	gtgcgtcggc	ttcagcatca	4500
acgagtgcct	cagcctcagc	aagtatctca	gcgtctgaat	cggcatcaac	gagtgcgtca	4560
gcctcagcaa	gtactagtgc	atcggcctca	gcaagcacca	gtgcgtcggc	ttcagcatca	4620
accagtgcct	cagcctcagc	aagtatctca	gcgtctgaat	cggcatcaac	gagtgcgtca	4680
gcctcagcaa	gtactagtgc	atcagcatca	gcatacaacga	gtgcctcggc	ttcagcaagt	4740
accagcgcct	cagcctcagc	aagcacatca	gcgtcagcct	cagcaagtac	cagcgcctca	4800
gcctcagcaa	gcaccagtgc	ctcagcctca	gcaagtacaa	gtgcgtcagc	ctcagcgtcg	4860
acaagtgcgt	cggcctcagc	aagtacctca	gcgtctgaat	cagcatcaac	gagtgcctca	4920

gcttcagcat	caacaagtgc	ttcagcttca	gcaagtacca	gtgcgtcggc	ttcagcatca	4980
acgagtgcct	cagtctcagc	gtcaaccagt	gcctctgaat	cagcatcaac	aagtgcctcg	5040
gcttcagcaa	gcaccagtgc	gtcggcttca	gcaagtacta	gtgcatcggc	ttcagcatcg	5100
acaagtgcgt	ctgaatcggc	atcaacagag	gcttcggctt	cagcatcaac	gagtgcgtca	5160
gcctcagcaa	gcacatcagc	ttctgaatct	gcatcaacca	gtgcgtccgc	ttcagcgtca	5220
accagtgcgt	cggcttcagc	gtcgacaagt	gcttcggctt	cagcatcaac	gagtgcgtcg	5280
gcctcagcaa	gcgcaagtac	ctcagcgtca	gcttcggcct	caaccagtgc	gtcggcttca	5340
gcaagcacia	gtgcgtcagc	ctcagcaagt	atctcagcgt	ctgaatcggc	atcaacgagt	5400
gcgtctgagt	cagcatcaac	gagtacgtca	gcctcagcaa	gcacatcagc	ttctgaatct	5460
gcatcaacca	gtgcgtcagc	ctcagcatcg	acaagcgctt	cagcttcagc	aagtaccagt	5520
gcttcagcct	cagcgtcgac	aagtgcgtcg	gcctcaacca	gtgcatctga	atcggcatca	5580
accagtgcgt	cagcctcagc	aagtactagt	gcatcagctt	cagcatcaac	gagtgcctcg	5640
gcttcagcat	caaccagtgc	ctcggcttca	gcgtcaacca	gtgcgtcagc	ttcagcaagt	5700
accagtgcct	cagtctcagc	atcaacaagt	gcttcagcct	cagcatcgac	aagtgcctcg	5760
gcttcagcaa	gcacatcagc	atctgaatca	gcgtcgacaa	gcgcctcagc	ttcagcaagt	5820
accagtgcgt	cagcctcagc	gtcgacaagt	gcgtcagcct	cagcaagtac	tagtgcatca	5880
gcttcagcat	caacgagtgc	atcggcttcg	gcgtcaacca	gtgcatcaga	gtcagcaagt	5940
accagtgcgt	cagcttcggc	atcaacaagt	gcctcggctt	cagcaagcac	cagtgcgtcg	6000
gcttcagcaa	gtactagcgc	ctcagcctca	gcctcaacca	gtgcgtcagc	ctcagcaagt	6060
atctcagcgt	ctgaatcggc	atcaacgagt	gcgtccgctt	cagcaagtac	tagcgcctca	6120
gcctcagcgt	caacaagtgc	atcggcttca	gcgtcaacga	gtgcgtctga	atcggcatca	6180
acgagtgcgt	ccgcttcagc	aagtactagc	gcctcagcct	cagcgtcaac	aagtgcctcg	6240
gcttcagcat	caacgagtgc	gtcggcttca	gcaagtacta	gcgcctcagc	ctcagcgtca	6300
acaagtgcgt	cggcttcagc	gtcaacgagt	gcgtctgagt	cagcatcaac	gagtgcgtca	6360
gcctcagcaa	gcacatcagc	ttctgaatct	gcatcaacca	gtgcgtcagc	ctcagcatcg	6420
acaagcgctt	cagcttcagc	aagtaccagt	gcgtcagcct	cagcgtcgac	aagtgcgtcg	6480
gcttcagcaa	gtaccagtgc	gtcagcctca	gcaagtacca	gtgcgtcagc	ctcagcgtcg	6540
acaagtgcgt	cggcctcaac	cagtgcctct	gaatcggcat	caaccagtgc	gtcagcctca	6600
gcaagtacta	gtgcatcagc	ttcagcatca	acgagtgcgt	cggcttcagc	atcaaccagt	6660
gcacatcagc	cagcaagtac	cagtgcgtca	gtctccgcat	caacaagtgc	ctcggcttca	6720
gcaagtacta	gcgcctcagc	ctcagcgtca	acaagtgcct	cagcttcggc	gtcaaccagc	6780
gcctcggcct	cagcaagtac	ctcagcgtct	gaatcggcat	caacaagtgc	ctcggcttca	6840
gcatcaacga	gtgcatcagc	ctcagcaagc	accagtgcgt	cggcctcagc	aagcaccagc	6900
gcgtctgaat	ccgcatcaac	cagtgcctca	gcttcagcaa	gtacctcagc	atctgaatca	6960
gcatcaacaa	gtgcatcggc	ttcagcaagc	acaagtgcct	cagcctcagc	aagtatctca	7020
gcgtctgaat	cggcatcaac	gagtgcgtcc	gcttcagcaa	gtactagcgc	ctcagcatca	7080
gcgtcaacaa	gtgcttcggc	ttcagcgtca	acgagtgcgt	ctgagtgcgc	atcaacgagt	7140
acgtcagcct	cagcaagcac	atcagcttct	gaatctgcat	caaccagtgc	gtcagcctca	7200
gcatcgacaa	gcgcctcagc	ttcagcaagt	accagtgcgt	cagcctcagc	aagtaccagt	7260
gcttcagcct	cagcgtcgac	aagtgcgtcg	gcctcaacca	gtgcatctga	atcggcatca	7320
accagtgcgt	cagcctcagc	aagtactagc	gcctcagcct	cagcatcaac	gagtgcgtcc	7380
gcttcagcaa	gtactagtgc	atcagcatca	gcatcaacga	gtgcatcggc	ttcagcaagt	7440
accagcgcct	cagcttcagc	aagcaccagt	gcgtcagcct	cagcaagtac	cagcgcctca	7500
gcctcagcaa	gcaccagtgc	ctcagcttca	gcaagtacca	gtgcgtcagc	ctcagcgtcg	7560
acaagtgcgt	cggcttcagc	aagtacctca	gcgtctgaat	cagcatcaac	gagtgcctca	7620
gcttcagcat	caacaagtgc	ttcagcttca	gcaagtacca	gtgcgtcggc	ttcagcatca	7680
acgagtgcct	cagtctcagc	gtcaaccagt	gcctctgaat	cagcatcaac	aagtgcctcg	7740
gcttcagcaa	gcaccagtgc	gtcggcttca	gcaagtacta	gtgcatcggc	ttcagcatcg	7800
acaagtgcgt	ctgaatcggc	atcaacgagt	gcttcggctt	cagcatcaac	gagtgcgtca	7860
gcctcagcaa	gcacatcagc	ttctgaatct	gcatcaacca	gtgcgtccgc	ttcagcgtca	7920
accagtgcgt	cggcttcagc	gtcgacaagt	gcttcggctt	cagcatcaac	gagtgcgtcg	7980
gcctcagcaa	gcgcaagtac	ctcagcgtca	gcttcggcct	caaccagtgc	gtcggcttca	8040
gcaagcacia	gtgcgtcagc	ctcagcaagt	atctcagcgt	ctgaatcggc	atcaacgagt	8100
gcgtcggcct	cagcaagcgc	aagtacctca	gcgtcagctt	ccgcctcaac	cagtgcgtcg	8160
gcttcagcaa	gcacaagtgc	gtcagcctca	gcaagtatct	cagcgtctga	atcggcatca	8220
acgagtgcgt	ctgagtgcgc	atcaacgagt	acgtcagcct	cagcaagcac	atcagcttct	8280
gaatcggcat	caaccagtgc	gtcagcctca	gcatcgacaa	gcgcctcagc	ttcagcaagt	8340
accagtgcct	cagcctcagc	gtcgacaagt	gcgtcggcct	caaccagtgc	atctgaatcg	8400
gcatcaacca	gtgcgtcagc	ctcagcaagt	actagtgcgt	cagcttcagc	atcaacgagt	8460
gcatcggcct	cagcatcaac	cagtgcctcg	gcttcagcgt	caaccagtgc	gtcagcttca	8520
gcaagtacca	gtgcttcagt	ctcagcatca	acaagtgcct	cagcctcagc	atcgacaagt	8580
gcctcggcct	cagcaagcac	atcagcatct	gaatcagcgt	cgacaagtgc	gtcggcctca	8640
accagtgcct	ctgaatcggc	atcaaccagt	gcgtcagcct	cagcaagtac	tagtgcatca	8700
gcttcagcat	caacgagtgc	atcggcttcg	gcgtcaacca	gtgcatcaga	gtcagcaagt	8760
accagtgcgt	cagcttcggc	atcaacaagt	gcctcggcct	cagcaagcac	atcagcatct	8820
gaatcagcgt	caaccagtgc	ttcggcttca	gcaagtacca	gtgcttcagc	ttcagcatca	8880
accagcgcct	cggcctcagc	aagcacctca	gcttctgaat	cggcctcaac	cagcgcctcg	8940
gcctcagcaa	gcacctcagc	ttctgaatcg	gcctcaacca	gcgcctcagc	ctcagcatca	9000

acgagtgctt	cggtttcagc	aagcacaagc	gcctcggggt	cagcatcaac	gagtacgtca	9060
gcttcagcgt	caaccagtgc	ttcagcctca	gcatcaacaa	gtgcgtcagc	ctcagcaagt	9120
atctcagcgt	ctgaatcggc	atcaacagag	gcgtctgagt	cagcatcaac	gagtacgtca	9180
gcctcagcaa	gcacctcagc	ttctgaatcg	gcctcaacca	gtgcgtcagc	ctcagcatcg	9240
acaagcgctt	cagcttcagc	aagtaccagt	gcttcagcct	cagcgtcgac	aagtgcgtcg	9300
gcctcaacca	gtgcatctga	atcggcatca	accagtgcgt	cagcctcagc	aagtactagt	9360
gcatcggctt	cagcatcaac	cagtgcctcg	gcttcagcgt	caaccagtgc	gtcagcttca	9420
gcaagtacca	gtgcttcagt	ctcagcatca	acaagtgcct	cagcctcagc	atcgacaagt	9480
gcctcggctt	cagcaagcac	atcagcatct	gaatcagcgt	cgacaagcgc	ctcagcttca	9540
gcaagtacca	gtgcgtcagc	ctcagcgtcg	acaagtgcgt	cagcctcagc	aagtactagt	9600
gcatcagctt	cagcatcaac	gagtgcctcg	gcttcggcgt	caaccagtgc	atcagagtca	9660
gcaagtacca	gtgcgtcagc	ttccgcatca	acaagtgcct	cggtttcagc	aagcaccagt	9720
gcgtcggctt	cagcaagtac	tagcgcctca	gcctcagcct	caaccagtgc	gtcagcctca	9780
gcaagtacct	cagcgtctga	atcggcatca	acgagtgcgt	ccgtttcagc	aagtactagc	9840
gcctcagcct	cagcgtcaac	aagtgcctcg	gcttcagcgt	caacgagtgc	gtctgaatcg	9900
gcatcaacga	gtgcgtccgc	ttcagcaagt	actagcgcct	cagcctcagc	gtcaacaagt	9960
gcatcggctt	cagcatcaac	gagtgcgtcc	gcttcagcaa	gtactagcgc	ctcagcctca	10020
gcgtcaacaa	gtgcatcggc	ttcagcgtca	acgagtgcgt	ctgagtcagc	atcaacgagt	10080
gcgtcagcct	cagcaagcac	atcagcttct	gaatctgcat	caaccagtgc	gtcagcctca	10140
gcatcgacaa	gcgcctcagc	ttcagcaagt	accagtgcgt	cagcctcagc	gtcgacaagt	10200
gcgtcggctt	cagcaagtac	cagtgcgtca	gcctcagcaa	gtaccagtgc	gtcagcctca	10260
gcgtcgacaa	gtgcgtcggc	ctcaaccagt	gcatctgaat	cgcatcaac	cagtgcgtca	10320
gcctcagcaa	gtactagtgc	atcagcttca	gcatcaacga	gtgcatcggc	ttcagcatca	10380
accagtgcct	cagagtcagc	aagtaccagt	gcgtcagctt	ccgcatcaac	aagtgcctcg	10440
gcttcagcaa	gtactagcgc	ctcagcctca	gcgtcaacaa	gtgcttcagc	ttccgcgtca	10500
accagcgcct	cggcctcagc	aagtatctca	gcgtctgaat	cgcatcaac	aagtgcctcg	10560
gcttcagcat	caacgagtgc	atcagcttca	gcaagcacca	gtgcgtcggc	ctcagcaagc	10620
accagcgcgt	ctgaatccgc	atcaaccagt	gcctcagctt	cagcaagtac	ctcagcatct	10680
gaatcagcat	caacaagtgc	ctcggcttca	gcaagcacaa	gtgcttcagc	ctcagcaagt	10740
atctcagcgt	ctgaatcggc	atcaacgagt	gcgtccgctt	cagcaagtac	tagcgcctca	10800
gcatcagcgt	caacaagtgc	ttcggcttca	gcgtcaacga	gtgcgtctga	gtcagcatca	10860
acgagtacgt	cagcctcagc	aagcacatca	gcttctgaat	ctgcatcaac	cagtgcgtca	10920
gcctcagcat	cgacaagcgc	ctcagcttca	gcaagtacca	gtgcgtcagc	ctcagcaagt	10980
accagtgcct	cagcctcagc	gtcgacaagt	gcgtcggcct	caaccagtgc	atctgaatcg	11040
gcatcaacca	gtgcgtcagc	ctcagcaagt	actagcgcct	cagcctcagc	atcaacgagt	11100
gcgtccgctt	cagcaagtac	tagtgcctca	gcttcagcaa	gtactagcgc	ctcagcctca	11160
gcgtcgacaa	gcgcctcagc	ttcagcaagt	accagtgcgt	cagcctcagc	gtcgacaagt	11220
gcgtcggctt	cagcaagtac	ctcagcgtct	gaatcagcat	caacaagtgc	gtcggcttca	11280
gcatcaacga	gtgcatcagc	ttcagcatca	acaagtgcct	cagcttcagc	aagtaccagt	11340
gcgtcggctt	cagcatcaac	gagtgcctca	gcttcagcgt	caaccagtgc	ctctgaatcc	11400
gcatcaacaa	gtgcctcggc	ttcagcaagc	accagtgcct	cggtttcagc	gtcaacgagt	11460
gcgtctgagt	cagcatcaac	gagtgcgtca	gcctcagcaa	gcacatcagc	ttctgaatct	11520
gcatcaacca	gtgcgtcagc	ttccgcatca	acaagcgcct	cggcctcagc	aagtacaagt	11580
gcttcagcct	cagcatcaac	cagtgcctca	gcttcagcct	caacaagtgc	ttcagcctca	11640
gcgtcaacca	gtgcctcggc	ttcagcaagt	accagtgcgt	cagcttcagc	aagcaccaagt	11700
gcgtcagctt	cagcatcaac	cagtgcctcg	gcttcggcct	caacaagtgc	ctcagcatca	11760
gcatcaacga	gtgcgtcagc	ctcagcaagt	actagtgcct	cagcatcagc	atcaaccagt	11820
gcatcagcct	cagcaagtac	ctcagcgtct	gaatcggcat	caacgagtgc	atcagcatca	11880
gcatcaacga	gtgcatcggc	ttcagcgtca	accagtgcct	cagtctcagc	aagcaccagt	11940
gcgtcggctt	cagcatcaac	gagtgcctca	gcctcagcaa	gtatctcagc	gtctgaatcg	12000
gcatcaacga	gtgcgtcagc	ctcagcaagt	actagtgcct	cggtttcagc	aagcaccagt	12060
gcgtcggctt	cagcatcaac	cagtgcctca	gcctcagcaa	gtatctcagc	gtctgaatcg	12120
gcatcaacga	gtgcgtcagc	ctcagcaagt	actagtgcct	cagcatcagc	atcaacgagt	12180
gcatcggctt	cagcaagtac	cagcgcctca	gcttcagcaa	gcaccagtgc	gtcagcctca	12240
gcaagtacca	gcgcctcagc	ctcagcaagc	accagtgcct	cagcttcagc	aagtaccagt	12300
gcgtcagcct	cagcgtcgac	aagtgcgtcg	gcttcagcaa	gtacctcagc	gtctgaatca	12360
gcatcaacga	gtgcatcagc	ttcagcatca	acaagtgcct	cagcttcagc	aagtatctca	12420
gcgtctgaat	cgcatcaac	gagtgcgtcc	gcttcagcaa	gtactagcgc	ctcagcatca	12480
gcgtcaacaa	gtgcttcggc	ttcagcgtca	acgagtgcgt	ctgagtcagc	atcaacgagt	12540
acgtcagcct	cagcaagcac	atcagcttct	gaatctgcat	caaccagtgc	gtcagcctca	12600
gcatcgacaa	gcgcctcagc	ttcagcaagt	accagtgcgt	cagcctcagc	aagtaccagt	12660
gcttcagcct	cagcgtcgac	aagtgcgtcg	gcctcaacca	gtgcatctga	atcggcatca	12720
accagtgcgt	cagcctcagc	aagtactagc	gcctcagcct	cagcatcaac	gagtgcgtcc	12780
gcttcagcaa	gtactagtgc	atcagcttca	gcaagtacta	gcgcctcagc	ctcagcgtcg	12840
acaagcgcct	cagcttcagc	aagtaccagt	gcgtcagcct	cagcgtcgac	aagtgcgtcg	12900
gcttcagcaa	gtacctcagc	gtctgaatca	gcatcaacaa	gtgcgtcggc	ttcagcatca	12960
acgagtgcct	cagcttcagc	atcaacaagt	gcttcagctt	cagcaagtac	cagtgcgtcg	13020
gcttcagcat	caacgagtgc	ttcagcttca	gcgtcaacca	gtgcctctga	atccgcatca	13080

acaagtgcct	cggttcagc	aagcaccagt	gcttcggctt	cagcgtcaac	gagtgcgtct	13140
gagtcagcat	caacgagtgc	gtcagcctca	gcaagcacat	cagcttctga	atctgcatca	13200
accagtgcgt	cagcttccgc	atcaacaagc	gcctcggcct	cagcaagtac	aagtgcctca	13260
gcctcagcat	caaccagtgc	atcagcttca	gcctcaacaa	gtgcttcagc	ctcagcgtca	13320
accagtgcct	cggttcagc	aagtaccagt	gcgtcagctt	cagcaagcac	aagtgcgtca	13380
gcttcagcat	caaccagtgc	ttcggcttcg	gcatcaacaa	gtgcctcagc	atcagcatca	13440
acgagtgcgt	cagcctcagc	aagtactagt	gcatcagcat	cagcatcaac	cagtgcacat	13500
gcctcagcaa	gtatctcagc	gtctgaatcg	gcatcaacga	gtgcatcagc	atcagcatca	13560
acgagtgcgt	cggttcagc	gtcaaccagt	gcatcagctt	cagcaagcac	cagtgcgtcg	13620
gcttcagcat	caacgagtgc	ctcagcctca	gcaagtatct	cagcgtctga	atcggcatca	13680
acgagtgcgt	cagcctcagc	aagtactagt	gcatcggctt	cagcaagcac	cagtgcgtcg	13740
gcttcagcat	caaccagtgc	ctcagcctca	gcaagtatct	cagcgtctga	atcggcatca	13800
acgagtgcgt	cagcctcagc	aagtactagt	gcatcagcct	cagcatcaac	gagtgcacat	13860
gcttcagcaa	gtaccagcgc	ctcagcttca	gcaagcacca	gtgcgtcagc	ctcagcaagt	13920
accagcgcct	cagcctcagc	aagcaccagt	gcctcagctt	cagcaagtac	cagtgcgtca	13980
gcctcagcat	caacaagtgc	ttcagcttcg	gcctcaacaa	gtgcgtcagc	ttcagcatca	14040
acgagtgcgt	cggttcagc	aagcaccagt	gcctcggcct	cagcaagcac	cagtgcctca	14100
gcttcagcat	caacaagtgc	gtcagcttca	gcaagtacat	cagtttcaaa	ttcagcaaac	14160
cattcgaaact	cacaagtggg	aaatacttct	ggatcgacag	gtaaatccca	aaaagaattg	14220
cctaatacag	gtactgagtc	gtcaattgga	tctgtgttac	ttggagtctt	agcagctggt	14280
acaggtattg	gattgggttcg	gaaacgccgt	aaacgtgatg	aagaagag		14328

SeqID 74

atgtcaaacg	aaaaaacac	aaacactaac	gtagaaaaga	aagatgctac	tgttgtagct	60
cacgaaatca	aaggggaact	tacttacgaa	gataaagtta	tccaaaaaat	cattggctct	120
tcactagaaa	acgtttcagg	tcttttgga	atcgatggtg	gtttcttctc	aaatcttaaa	180
gaaaaaatcg	ttaacagcga	tgacgtaaca	agtgggtgta	acgtagaagt	tggtaaaaca	240
caagttgcag	ttgacttaaa	cgttattggt	gagtaccaa	aaaatgttcc	agctttatat	300
tcagaaatca	gagaaatcgt	atcttcagaa	gttgctaaaa	tgactgactt	ggaaattggt	360
gaaatcaacg	taaacgttgt	cgacatcaaa	actaaagaac	agcatgaagc	agactcagta	420
agccttcaag	atcgcgtatc	tgacgttgct	gaatcaacag	gagaattcac	ttcagaacaa	480
ttcgaaaaag	ctaaatctgg	tcttggatct	ggtttctcaa	ctgttcaaga	aaaagtttag	540
gaaggtgtag	aagctgttaa	aggtgcagca	aatgggtgtg	tatctcacga	aaacactcgt	600
gtaaac						606

SeqID 75

atgacaaaaag	aaaaaatgt	aattttgact	gctcgcgata	ttgtcgtgga	atgttgacgtt	60
cgtgacaaaag	tattgacagc	cattcgcggc	gtttcccttg	aactagtcca	aggagaagta	120
ttagccttg	taggtgagtc	aggatcaggt	aaatctgttt	tgacaaagac	cttcacaggt	180
atgctcgaag	aaaatggtcg	tattgcccaa	ggtgatttgg	actaccgtgg	tcaggacttg	240
acagctttat	cttctcacia	ggattgggaa	caaattcgtg	gtgctaagat	tgcgactatc	300
ttccaggacc	caatgactag	tttggacccc	attaaaacaa	ttggtagtca	gattacagaa	360
gttattgttaa	aacaccaagg	aaaaacagct	aaagaagcga	aagaattggc	cattgactac	420
atgaataagg	ttggcattcc	agacgcagat	agacgtttta	atgaataccc	attccaatat	480
tctggaggaa	tgcgtcaacg	tatcgttatt	gctattgccc	ttgcctgccc	acctgatgct	540
ttgatctgtg	atgagccaac	aactgccttg	gatgttaacta	ttcaagctca	gattattgat	600
ttgctaaaaat	ctttacaaaa	cgagtatcat	ttcacaacaa	tctttattac	ccacgacctt	660
ggtgtggtgg	caagtattgc	ggataaggta	gcggttatgt	atgcaggaga	aatcggttag	720
tatggaacgg	ttgaggaagt	cttctatgac	cctcgcctac	catatacatg	gagtctcttg	780
tctagcttgc	ctcagcttgc	tgatgataaa	ggggatcttt	actcaatccc	aggaaacact	840
cogtcacttt	atactgacct	gaaaagggat	gcttttgcc	tgcttctga	ctacgcaatg	900
cagattgact	tcgaacaaaa	agctcctcaa	ttctcagtat	cagagacaca	ttgggctaaa	960
acttggcttc	ttcatgagga	tgctccgaaa	gtagaaaaac	cagctgtgat	tgcaaatctc	1020
catgataaga	tccgtgaaaa	aatgggattt	gcccatctgg	ctgac		1065

SeqID 76

atgaaaaaaa	atcgtgtatt	tgctacagca	ggtcttgttt	tattagcagc	aggtgtactt	60
gcagcatgca	gttcttcaaa	atcatctgat	tcatcagccc	ctaaagctta	tggctatggt	120
tatacagcag	accagaaaac	cttggactac	ctgatttcaa	gtaaaaatag	tacaacagta	180
gtgacttcaa	atgggattga	tggtttatct	actaacgata	attacggtaa	tcttgcctct	240
gcagttgcag	aggattggga	agtctctaag	gatgggttga	cctacactta	taagattcgt	300
aaaggggtta	aatgggttac	ctctgatgga	gaagaatatg	cagaggtgac	ggctaaagat	360
ttcgtgacg	gtttaaaaac	cgcagcagat	aaaaaatcag	aagctatgta	tttagctgaa	420
aattcgggtta	aaggcttggc	agattatcta	tcaggaaactt	caacagattt	ttcaacagtt	480
ggtgtcaagg	cggttgatga	ttatacgtta	caatacactt	tgaaccagcc	tgaaccgttc	540
tggaaactcta	agttgacctt	ttctatcttc	tggcctctga	atgaagaatt	cgaacatca	600
aaaggaagcg	atcttgcata	accaacagat	cgcacatcct	tgctttataa	tggtccattc	660
ttgttgaaag	ggttgactgc	aaaatcttct	gtagagtttg	taaaaaatga	gcaatatggg	720

gataaagaaa	atgtccacct	agatactatc	aatctagctt	actatgatgg	atcagatcag	780
gagtcgctag	agcgtaactt	cactagtggg	gcttatagtt	atgcccgctc	ttaccctacc	840
agctccaact	attctaaggt	tgcagaagaa	tacaaggaca	atatctatta	cacacaatca	900
ggctctggga	ttgctgggtc	gggtgtgaat	attgatcgcc	aaagttacaa	ctatacttct	960
aaaactacag	attcagagaa	agtagctact	aagaaggcat	tgcttaacaa	agatttccgt	1020
caagccttga	atcttgcctc	tgatcgctca	gcttactcag	ctcaaatcaa	tggtaaagat	1080
ggagcagctt	tagcagttcg	taatttattt	gtaaaaccag	actttgtttc	agctggtgag	1140
aagacctttg	gtgatttagt	cgctgctcaa	cttctgctt	atgggtgatga	gtggaaagggt	1200
gtgaatttag	ctgatgggca	ggatggttta	ttcaatgctg	acaaggccaa	ggcagagttt	1260
gcgaaagcta	agaaagcttt	agaagcagac	ggcggttcagt	ttcctattca	tctggacgtt	1320
ccagtagacc	aagcatcaaa	aaactacata	tctcgatttc	agtcctttaa	acaatctgta	1380
gaaacagttc	ttggtgttga	aaatgtcgtt	gttgatattc	aacaaatgac	aagtgatgaa	1440
ttccttaata	ttacttacta	tgctgccaat	gcttcatctg	aggattggga	tgtatcagga	1500
ggagtttcat	gggggcccaga	ctatcaagac	ccatctactt	acctggatat	tttaaaaaaca	1560
actagcagtg	aaactacaaa	aacatattta	ggatttgata	atccaaatag	cccttcagta	1620
gttcaagttg	gtttgaaaga	atacgataaa	ttagttgatg	aagctgccag	agagacaagc	1680
gacttgatga	tccgttatga	aaaatgatga	gcggctcaag	catgggtgac	agatagttca	1740
ctctttattc	ctgctatggc	ttcttctggt	gcagcaccag	tgctttcacg	aattgttcca	1800
tttactggag	cttctgcgca	aacaggctct	aaggggtcag	atgtttactt	caaataatttg	1860
aatcaccaag	ataaagtggt	gactaaggaa	gagtatgaaa	aagctcgtga	aaaatggttg	1920
aaagaaaaag	ctgaatcaaa	tgagaaagct	caaaaagaat	tggaagtc	tgtgaag	1977

SeqID 77

atggaaatta	atgtgagtaa	attaagaaca	gatttgcctc	aagtcggcgt	gcaaccatat	60
aggcaagtac	acgcacactc	aactgggaat	ccgcattcaa	ccgtacagaa	tgaagcggat	120
tatcactggc	ggaaagaccc	agaattaggt	tttttctcgc	acattgttgg	gaacggttgc	180
atcatgcagg	taggacctgt	tgataatggt	gcctgggacg	ttgggggcgg	ttggaatgct	240
gagacctatg	cagcggttga	actgattgaa	agccattcaa	ccaaagaaga	gttcatgacg	300
gactaccgcc	tttatatcga	actcttacgc	aatctagcag	atgaagcagg	tttgccgaaa	360
acgcttgata	cagggagttt	agctggaatt	aaaacgcacg	agtattgcac	gaataaccaa	420
ccaaacaacc	actcagacca	cgttgaccct	tatccatata	ttgctaaatg	gggcatttagc	480
cgtgagcagt	ttaagcatga	tattgagaac	ggcttgacga	ttgaaacagg	ctggcagaag	540
aatgacactg	gctactggta	cgtacattca	gacggctctt	atccaaaaga	caagtttgag	600
aaaatcaatg	gcacttggta	ctactttgac	agttcaggct	atatgcttgc	agaccgctgg	660
aggaagcaca	cagacggcaa	ctgggtactgg	ttcgacaact	caggcgaaat	ggctacaggc	720
tggaagaaaa	tgcgtgataa	gtggtactat	ttcaacgaag	aaggtgccat	gaagacaggc	780
tgggtcaagt	acaaggacac	ttgggtactac	ttagacgcta	aagaaggcgc	catggtatca	840
aatgccttta	tccagtcagc	ggacggaaca	ggctgggtact	acctcaaacc	agacggaaca	900
ctggcagaca	agccagaatt	cacagtagag	ccagatggct	tgattacagt	aaaa	954

SeqID 78

atgaaaaaaa	aatattggac	tttagcgata	ttattctttt	gtttgttcaa	taattctgtt	60
actgctcaag	aaatacctaa	aaatcttgat	ggcaatataa	ctcacactca	gactagcgaa	120
agtttttctg	aatctgatga	aaaacagggt	gactattcta	ataaaaaatca	agaagaagta	180
gaccaaataa	aatttcgtat	tcaaatcgat	aagacagaat	tattttgtaac	aacagataaa	240
catttagaaa	aaaactgttg	ttaattggaa	cttgaaccac	aaataaataa	cgatattgtt	300
aactctgaaa	gtaataattt	actaggcgaa	gataatttag	ataataaaat	taaggaaaat	360
gtttctcatc	tagataatag	aggaggaaat	atagagcatg	acaaagataa	cttagaatcg	420
tcgattgtaa	gaaaaatga	atgggatata	gataaagtta	ctggtggagg	cgaaagttaa	480
aaattatatt	ctaaaagtaa	ttctaaagtt	tcaattgcta	ttttagattc	aggagtcgat	540
ttacaaaata	ctggattact	gaaaaatctt	tcaaatcact	caaaaaacta	tgtccccaat	600
aaaggatatt	taggaaaaga	ggaggggagag	gaagggaata	tatcagatat	tcaagataga	660
ttaggtcatg	gtacggctgt	tgtagctcaa	attgtagggg	atgacaaat	taatggagta	720
aatcctcacg	ttaatatata	cgtctataga	atatttggta	agtcgtcagc	tagtccagat	780
tggattgtaa	aagcaatttt	tgatgctgta	gatgatggca	atgatattat	caatcttagt	840
actggacaat	atttaattgat	tgatggagaa	tatgaggacg	gaacaaatga	ttttgaaaca	900
tttttgaaat	ataaaaaggc	tattgattac	gcgaatcaaa	aaggagtaat	tatagtagct	960
gcattagggg	atgactccct	aaatgtatca	aatcagtcag	atttattgaa	acttattagt	1020
tcacgcaaaa	aagtaagaaa	accaggatta	gtagttgatg	ttccaagtta	tttctcatct	1080
acaatttcgg	tccggggcat	agatcgctta	ggtaatttat	cagatttttag	caataaaggg	1140
gattctgatg	caatatatgc	gcctgcaggc	tcaacattat	ctctttcaga	attaggactt	1200
aataacttta	ttaatgcaga	aaaatataaa	gaagatttga	ttttttcggc	aacactagga	1260
ggatatacgt	atctttatgg	aaactcattt	gctgctccta	aagtttctgg	tgcgatttga	1320
atgattattg	ataaatacaa	attaaaagat	cagccctata	attatatgtt	tgtaaaaaaa	1380
ttctggaaga	aacattacca	g				1401

SeqID 79

atgaaaaaag	atgagttatt	tgaaggcttt	tacctaataca	aatcagctga	cctgaggcaa	60
------------	------------	------------	-------------	------------	------------	----

actcgagctg	ggaaaaacta	cctagccttt	accttccaag	atgatagtgg	cgagattgat	120
gggaagctct	gggatgcccc	acctcataac	attgaggcct	ttaccgcagg	taaggttgct	180
cacatgaaag	gacgccgaga	agttttataac	aatccccctc	aagtcacatca	aattactctc	240
cgcctgcctc	aagctgggtga	acccaatgac	ccagctgatt	tcaaggtcaa	gtcaccagtt	300
gatgtcaagg	aaattcgtga	ctacatgtcg	caaatgattt	tcaaaattga	aaatcctgtc	360
tggcaacgga	ttgtccgaaa	tctctacacc	aagtatgata	aggaattcta	ctcctatcca	420
gctgccaaaga	ccaaccacca	tgcccttgaa	acgggcttgg	cctatcatac	ggcgaccatg	480
gtgcgtttgg	cagacgctat	tagcgaagtt	tatcctcagc	tcaataagag	cctgctctat	540
gcgggggatta	tggtgcatga	cttagctaag	gtcatcgagt	tgacggggcc	agaccagaca	600
gagtacacag	tgcgaggtaa	tcttcttgga	catatcgctc	tcattgatag	cgaaattacc	660
aagacagtta	tggaaactcg	catcgatgat	accaaggaag	aagtcgtttt	gcttcgtcat	720
gtcatcctca	gtcaccacgg	cttgcttgag	tatggaagcc	cagtcgctcc	acgcattatg	780
gaagcagaga	ttatccatat	gattgacaat	ctggatgcaa	gcagatgat	gatgtcaaca	840
gctcttgctt	tggtggataa	aggagagatg	accaataaaa	tcttcgctat	ggataatcgt	900
tccttctata	aaccagattt	agat				924

SeqID 80

gtgacgattc	taggaaaaga	tacagttcaa	caatctgcga	aaggtgaatc	tgtaaactcaa	60
gaagctacac	cagagtataa	gctagaaaat	acaccaggtg	gagataaggg	aggcaataact	120
ggaagctcag	atgctaatagc	gaatgaaggc	ggtggtagcc	aggcgggtgg	atcagctcac	180
acagggttcac	aaaactcagc	tcaatcacaa	gcttctaagc	aattagctac	tgaaaaagaa	240
tcagctaaaa	atgccattga	aaaagcagcc	aaggacaagc	aggatgaaat	caaaggcgca	300
ccgctttctg	ataaaagaaa	agcagaactt	ttagcaagag	tggaaagcaga	aaaacaagca	360
gctctcaaaag	agattgaaaa	tgcgaaaact	atggaagatg	tgaaggaagc	agaaacgatt	420
ggagtgcgaag	ccattgccat	ggttacagtt	cctaagagac	cagtggctcc	taatgctgct	480
cctaagacaa	caagtgcacc	gcaagcaact	gcaggaacaa	tgcaagatgt	tacctaccag	540
tcacctgctg	gcaaacaatt	acctaacaca	ggttcagcat	caagtgcagc	acttgctagt	600
cttgggtctag	tggtggcaac	aagtggtttt	gctttgctag	gaagaaagac	tagacgtaga	660
aaa						663

SeqID 81

atgaatgcag	atgatacagt	aaccatttat	gatgtcgctc	gtgaagcagg	tgtttccatg	60
gcgacgggtca	gccgtgtggt	caatggcaat	aaaaatgtaa	aagagaatac	ccgtaaaaaa	120
gtgctagagg	taattgatcg	tttgatttat	cgtccaaatg	cagttgcgcg	tggtccttgc	180
agtaaaaaaga	caaccactgt	cgggtgcgtg	attccaaata	ttaccaatgg	ttatttttcg	240
agtttggtcta	aggggattga	tgatattgca	gaaatgtaca	agtacaatat	tgtcctagct	300
aatagcgatg	aagataacga	gaaagaagtt	tctgttgtca	ataccctctt	ttcaaagcag	360
gtagatggca	ttatctatat	ggggtatcac	ttgacagata	aaattcgctc	agaatttttcg	420
cgttcacgta	ctccgattgt	tctcgcagga	actgtcgatg	ttgagcacca	gttgccaagt	480
gtcaatatattg	actataagca	agcaacaatt	gatgcagtga	gttaccttgc	taaaagaaat	540
gagcgtattg	ctttcgtttag	cgggtccgcta	gtggatgaca	tcaatggtaa	ggttcgttta	600
gttggctaca	aggaaacctt	gaaaaaagca	ggaatcactt	atagtgaggg	tttgggtattt	660
gaatctaaat	atagctatga	tgatggttac	gccttagcag	agcgtttgat	ttcatcaaat	720
gcaactgcag	cagttgtgac	agggtgatgag	ttggcagcag	gagtcctgaa	cggtttggtc	780
gataaagggtg	tttctgtgcc	agaagatttt	gaaattatta	ctagtgatga	ttcacaaatc	840
tcacgcttta	cccgccaaa	cttgacaacg	attgcccaac	ctctttatga	ccttggtgcc	900
attagtatgc	gtatgttgac	caagattatg	cataaggaag	agttggaaga	acgtgaagtt	960
ctcttacctc	atggtttgac	agaacgtagc	tcaacacgaa	aacgtaaa		1008

SeqID 82

atgaaaaaaa	agttagtatt	tcctaactctg	ttttggtggg	gagctgcttc	tagcggacct	60
cagacagaag	gtcaatatgg	aaaagtacat	gaaaaatgta	tggactactg	gttcaaaacg	120
catccagaag	attttttcga	taatgtcggg	cctctttag	ccagtaactt	ttttcatact	180
tacaccgaag	atttccactt	gatgaaggaa	attggagtta	attcctttccg	cacttccatc	240
caatggagtc	gactcatcaa	gaatttagag	acaggtgagc	ctgatccaaa	aggatttgct	300
ttctacaattg	ccatcattga	agaagctaaa	aagaaccaga	tggatcttgt	gatgaattta	360
catcattttg	atttaccagt	ggaacttctt	caaaaatacg	gtggttgagg	aagcaaacat	420
gtagtggagt	tattcgtgaa	gtttgccaag	actgctttca	catgctttgg	agataagggt	480
cattactgga	caactttcaa	tgagccaatg	gtcattccag	aagcaggata	cttatatgct	540
ttccattatc	caaatctaaa	aggaaaggga	aaagaggccg	tacaagtcac	ctataatcta	600
aaccttgcta	gtgcaaaagt	gattcaacta	tatcgctcat	tagaacttga	tggaaagatt	660
gggattattt	taaaacttgac	acctgcttat	ccaagaaagta	attctccaga	agacttagaa	720
gcaagtcgat	ttacagatga	cttctttaac	aaagtcttct	tgaatccagc	tggttaaagga	780
actttcccag	aaagattggt	aaaacagcta	gagagagatg	gcgtgttatg	gagtcatacc	840
gaaaaagagc	ttcaactgat	gaaatcaaat	acggttgatt	ttcttgaggt	aaactactac	900
catccaaaac	gtgttcaagc	acaagcaaat	cctgaggaat	atcagacgcc	ctggatgcca	960
gaccaatact	tcaaagagta	tgaatggctg	gagcgtcgca	tgaatccata	tcgtggttgg	1020
gaaatttttc	cgaaagccat	ttatgatatt	gctatgattg	tgaaggaaga	atatggtaat	1080

atcccatggt	ttatcagtga	aaacggaatg	gggtgtgaaa	acgaagcacg	gtttatcgat	1140
gaaaaatggag	ttatcgatga	cgtgtatcgt	attgaatttt	atgaagaaca	tttaagatgg	1200
ctacataaag	ccattgaaga	gggaagtcaac	tgttttgat	accacgcttg	gaccgcattt	1260
gattgctggt	cttggaataa	tgcataataag	aatcgtttacg	gatttatctc	cggtgattta	1320
gaaacgcaaa	agagaacccat	caagagctca	ggaagatggg	atcgcaaatg	aagtgacaat	1380
aacgggtttg	aagtagaaat	tgaggag				1407

SeqID 83

gtggaaaatc	ttacgaattt	ttacgaaaag	tatcgtgtct	atctgactcg	tccacgttta	60
gagcttttgg	cagtagttac	cattgttttc	tgtgtgttac	tcgtcttttt	tctaaatatt	120
ccaggaaaag	gtgtcttaaa	actcgataat	ggaacgattg	tttatgatgg	cagtcttgct	180
cgcggtaaaa	tgaatggcca	aggtaccatt	accttccaaa	atggagacca	atatacaggt	240
ggcttcaaca	atggagcctt	caacggaaaa	ggtacctttc	aatctaaaga	aggetggacc	300
tacgaagggtg	attttgtaaa	tggtcaggct	gaaggaaaag	ggaaactaac	aacagaacaa	360
gaagtcggtt	atgaaggaac	ttttaaacaa	ggcgtttttc	aacaaaaa		408

SeqID 84

atgttgaata	agataagaga	ctatttagac	tttgcgtggt	tgcagtaccg	taatcctgat	60
aaagcgggag	cagagcgaga	gaagatgctg	gcattccgcc	acaaaggaca	agaggcccgga	120
aaggttttta	cagaactggc	caaagccttt	caagcaagcc	atccagaatg	gcaactccaa	180
cagactagcc	agtggatgaa	tcaggcccag	cgtttgagac	cacatttttg	ggtttatcta	240
cagagagacg	gacaagtga	agaacctatg	atggccttac	gtttgtatgg	gacatctact	300
gacttttgaa	ttcttttgga	agtcagtttc	atcgaaacgta	agaaggatga	gcaaactctg	360
ggcaagcagg	ccaaagtttt	agacattcca	accgttaaag	ggatttatta	tctaacttac	420
tctaattggtc	aaagtcaacg	gtgggaggcg	aatgaagaaa	agcgtcgtac	tttacgcgag	480
aaggtgagaa	gtcaagaagt	tcgaaaagtt	ttagtgaagg	tagatgttcc	tatgacagaa	540
aattcgtctg	aagaagaaat	cgtagaaggc	ttattgaagt	cttattctaa	aattcttccc	600
tattatctag	ctacgagaaa	a				621

SeqID 85

atggttcaga	acagttgttg	gcaatcaaag	agccataagg	tcaaggcttt	taccttggtta	60
gaatccctgc	ttgccctcat	tgtcatcagt	gggggattac	tcctttttca	agctatgagt	120
cagctcctca	tttcagaagt	tcgtaccag	caacaaagcg	agcaaaaagg	gtggctcttg	180
tttgtggacc	aacttgaggt	agaattagac	cgttcgcagt	tcgaaaaagt	agaaggcaat	240
cgctataaca	tgaagcaaga	tggcaaggac	atcgccatcg	gtaagtcaaa	gtcagatgat	300
ttccgtaaaa	cgaatgctcg	tggtcgaggt	tatcagccta	tggtttatgg	actcaaatct	360
gtacggatta	cagaggacaa	tcaactgggt	cgctttcatt	tcagattcca	aaaaggctta	420
gaaagggagt	tcattctatcg	tgtggaaaaa	gaaaaaagt			459

SeqID 86

atgaaaaaaa	tgatgacatt	cttgaaaaaa	gctaagggtta	aagctttttac	attggtggag	60
atgttggttg	tcttgctgat	tatcagcgtg	cttttcttgc	tctttgtacc	taatctgacc	120
aagcaaaaag	aagcagtcaa	tgacaaagga	aaagcagctg	ttgttaagggt	ggtggaaagc	180
caggcagaac	tttatagctt	agaaaaaat	gaagatgcta	gcctaagaaa	gttacaagca	240
gatggacgca	tcacgggaaga	acaggctaaa	gcttataaag	aatacaatga	taaaaatgga	300
ggagcaaatc	gtaagtcaa	tgat				324

SeqID 87

atgacatcaa	aagttagaaa	ggcagtcac	cctgctgctg	gactaggaac	tcgattttta	60
ccagcaacca	aggecccttg	caaagaaatg	ttgccaatcg	tagacaaacc	aactatccag	120
tttatcgtgg	aagaagctct	caaatcaggt	attgaagata	ttctagttgt	cactggtaaa	180
tcaaaacgtt	ctattgagga	ccactttgat	tcaaacttcg	aattggaata	taacctcaaa	240
gaaaaaggga	aaacagatct	tttgaagcta	gttgataaaa	caactgacat	gcgtctgcat	300
tttatccgcc	aaactcatcc	acgcggtctc	ggagatgctg	ttttgcaagc	caaggctttc	360
gtcggaaatg	aaccttttgt	cgttatgctt	ggtgatgact	tgatggatat	cacagacgaa	420
aaggctgttc	cacttaccaa	acaactcatg	gatgactacg	agcgtaccca	cgcgtctact	480
atcgctgtca	tgccagtccc	tcagacgaa	gtatctgctt	acggggttat	tgctccgcaa	540
ggcgaaggaa	aagatggtct	ttacagtgtt	gaaacctttg	ttgaaaaacc	agctccagag	600
gacgctccta	gcgaccttgc	tattatcgga	cgctacctcc	tcacgcctga	aatttttgag	660
attctcga	agcaagctcc	aggtgcagga	aatgaaattc	agctgacaga	tgcaatcgac	720
acctcaata	aaacacaacg	tgtatttgct	cgtgagttca	aaggggctcg	ttacgatgtc	780
ggagacaagt	ttggcttcat	gaaaacatcc	atcgactacg	ccctcaaaaca	cccacaagtc	840
aaagatgatt	tgaagaatta	cctcatccaa	cttggaagaa	aattgactga	gaaggaa	897

SeqID 88

atgcaaaaatc	aattaaatga	attaaaacga	aaaatgctgg	aattttttcca	gcaaaaacaa	60
aaaaataaaa	aatcagctag	acctggcaag	aaaggttcaa	gtaccaaaaa	atctaaaacc	120
ttagataagt	cagtcatttt	cccagctatt	ttactgagta	taaaagcctt	atttaactta	180

ctctttgtac	tcggttttct	aggaggaatg	ttgggagctg	ggattgcttt	gggatacggg	240
gtggccttat	ttgacaaggt	tcgggtgcct	cagacagaag	aattgggtgaa	tcagggtcaag	300
gacatctctt	ctatttcaga	gattacctat	tcggacggga	cggtagattgc	ttccatagag	360
agtgatttgt	tcgcgacttc	tatctcatct	gagcaaat	cggaaaatct	gaagaaggct	420
atcattgcga	cagaagatga	acactttaaa	gaacataagg	gtgtagtacc	caaggcgggtg	480
attcgtgcga	ccttggggaa	attttaggt	ttgggttcct	ctagtggggg	ttcaaccttg	540
accagcaac	taattaaaca	gcagggtggt	ggggatgcgc	cgaccttggc	tcgtaaggcg	600
gcagagattg	tggatgctct	tccttggaa	cgcgccatga	ataaagatga	gattttaacg	660
acctatctca	atgtggctcc	ctttggccga	aataataagg	gacagaatat	tcaggggct	720
cggcaagcag	ctgagggaat	tttcgggtga	gatgccagtc	agttgactgt	tcctcaagca	780
gcatttttag	caggacttcc	acagagtccc	attacttact	ctccttatga	aaatactggg	840
gagttgaaga	gtgatgaaga	cctagaat	ggcttaagac	gggctaaggc	agttctttac	900
agtatgtatc	gtacagggtc	attaagcaaa	gacgagtatt	ctcagtacaa	ggattatgac	960
cttaaacagg	actttttacc	atcgggcacg	gttacaggaa	tttcacgaga	ctattttatac	1020
tttacaactt	tggcagaagc	tcaagaacgt	atgtatgact	atctagctca	gagagacaat	1080
gtctccgcta	aggagttgaa	aaatgaggca	actcagaagt	tttatcgaga	tttggcagcc	1140
aaggaaattg	aaaatgggtg	ttataagatt	actactacca	tagatcagaa	aattcattct	1200
gccatgc aaa	gtcgggttgc	tgattatggc	tatcttttag	acgatgggaa	aggtcgtgta	1260
gaagtaggga	atgtcttgat	ggataaccaa	acagggtgcta	ttctaggcct	tgtagggtgt	1320
cgtaattatc	aagaaaatca	aaataatcat	gcctttgata	ccaaacgttc	gccagcttct	1380
actaccaagc	ccttgctggc	ctacgggtatt	gctattgacc	agggcttgat	gggaagtga	1440
acgattctat	ctaactatcc	aacaaacttt	gctaattggca	atccgattat	gtatgcta	1500
agcaaggga	caggaatgat	gaccttggga	gacagctctga	actattcatg	gaatatccct	1560
gcttactgga	cctatcgat	gctccgtgaa	aagggtgttg	atgtcaaggg	ttatatggaa	1620
aagatgggtt	acgagattcc	tgagtacggt	attgagagct	tgccaatggg	tgggtgtatt	1680
gaagtcacag	ttgccagca	taccaatggc	tatcagacct	tagctaataa	tggagtttat	1740
catcagaagc	atgtgatttc	aaagattgaa	gcagcagatg	gtagagtgg	gtatgagtat	1800
caggataaac	cggttcaagt	ctattcaaaa	gctactgcga	cgattatgca	gggattgcta	1860
cgagaagtct	tatctctctg	tgtgacaaca	accttcaagt	ctaacctgac	ttctttaaat	1920
cctactctgg	ctaattgcaga	ttggattggg	aagactggta	caaccaacca	agacgaaaat	1980
atgtggctca	tgctttcgac	acctagatta	acctagggtg	gctggattgg	gcatgatgat	2040
aatcattcat	tgtcacgtag	agcagggttat	tctaataact	ctaattacat	ggctcatctg	2100
gtaaatgcga	ttcagcaagc	ttccccaaagc	atttggggga	acgagcgctt	tgctttagat	2160
cctagtgtag	tgaatcgga	agtcttgaaa	tcaacaggtc	aaaaaccaga	gaagggttct	2220
gttgaaggaa	aagaagtaga	ggtcacaggt	tcgactgtta	ccagctattg	ggctaataag	2280
tcaggagcgc	cagcgacaag	ttatcgcttt	gctattggcg	gaagtgatgc	ggattatcag	2340
aatgcttgg	ctagtattgt	ggggagtccta	ccaactccat	ccagctccag	cagttcaagt	2400
agtagttcta	gcgatagcag	taactcaagt	actacacgac	cttcttcttc	aaggggcgaga	2460
cga						2463

SeqID 89

atgtcatcta	aatttatgaa	gagcgctgcg	gtgcttggaa	ctgctacact	tgctagcttg	60
cttttggtag	cttgcggaag	caaaactgct	gataagcctg	ctgattctgg	ttcatctgaa	120
gtcaaagaac	tcactgtata	tgtagacgag	ggatataaga	gctatattga	agagggttgc	180
aaagcttatg	aaaaagaagc	tggagtaaaa	gtcactctta	aaactggtga	tgctctagga	240
ggctcttgata	aactttctct	tgacaaccaa	tctggtaatg	tccttgatgt	tatgatggct	300
ccatacgacc	gtgtaggtag	ccttgggtct	gacggacaac	tttcagaagt	gaaattgagc	360
gatgggtgcta	aaacagacga	cacaactaaa	tctcttgtaa	cagctgctaa	tggtaaagt	420
tacgggtgctc	ctgccgttat	cgagtcactt	gttatgtact	acaacaaaga	cttgggtgaaa	480
gatgctccaa	aaacatttgc	tgacttggaa	aaccttgcta	aagatagcaa	atacgcattc	540
gctgggtgaag	atggtaaaaac	tactgccttc	ctagctgact	ggacaaactt	ctactataca	600
tatggacttc	ttgccggtaa	cgggtgcttac	gtctttggcc	aaaacggtaa	agacgctaaa	660
gacatcggtc	ttgcaaacga	cgggttctatc	gtaggatca	actacgctaa	atcttggtag	720
gaaaaatggc	ctaaagggtat	gcaagataca	gaagggtctg	gaaactta	ccaaactcaa	780
ttccaagaag	gtaaaacagc	tgctatcatc	gacggacctt	ggaaagctca	agcctttaaa	840
gatgctaaag	taaaactacgg	agttgcaact	atcccaactc	ttccaaatgg	aaaagaatat	900
gctgcattcg	gtgggtggtaa	agcttgggtc	attcctcaag	cggtaagaa	ccttgaagct	960
tctcaaaaat	ttgtagactt	ccttgttgca	actgaacaac	aaaaagtatt	atatgataag	1020
actaacgaaa	tcccagctaa	tactgaggct	cggttcatacg	ctgaaggtaa	aaacgatgag	1080
ttgacaacag	ctgttatcaa	acagttcaag	aacactcaac	cactgccaaa	catctctcaa	1140
atgtctgcag	tttgggatcc	agcgaaaaat	atgctctttg	atgctgtaag	tgggtcaaaaa	1200
gatgctaaaa	cagctgctaa	cgatgctgta	acattgatca	aagaacaat	caaacaaaaa	1260
tttgggtgaa						1269

SeqID 90

atgatagata	aagtggtcag	gaacctactc	ctgacctttt	tcttttgcaa	aatgacaaaa	60
atcataattt	ttttgacaac	tatacttgct	aaaaagaaaa	agatatgtta	caatgaattc	120
aagttaagaa	ataggaagca	gaaaggagtt	ataatgtggg	tactaggatt	tatactattt	180

atgattttct	tttattctaa	taattctaaa	aaaatcaaga	aactagagaa	taaaatcaaa	240
agacttgagc	gaaaagagaa	aggaaacgca	gaaatgtcga	gattattaca	agaaatgatt	300
ggaaaggaac	caattataac	gggagtgtat	attgggccag	ataactggga	agttgtggat	360
gttgatgagg	aatgggtaaa	gctacgacgt	gtagataata	cgggaaaaga	aaaattcaag	420
ttgcaacgta	ttgaggatat	ccaaaccgtt	gaatttgacg	gagag		465

SeqID 91

atgattttta	gtaaaaatag	agaagatggg	ttaagaaaat	ttgcgactaa	catccgatta	60
aatactctta	gaacattgaa	tcatcttgga	ttcggacatt	acggaggaag	tctgtctatc	120
gtagaagttt	tagcgggtgct	ttatgggtgaa	ataatgccaa	tgactccaga	aatatttgca	180
gcacgagata	gagattattt	catattatca	aaaggtcacg	gaggaccagc	tctatacagt	240
acactctatt	tgaatggttt	ctttgacaaa	gaattcttat	attcttttaa	tacaaatgga	300
accaaattac	cgtctcatcc	tgatagaaat	ctaacgccag	gcatagatat	gacaacgggc	360
tcttttaggac	aaggaattag	tgttgcaact	ggacttgcac	atggctcagag	aataagaaag	420
agtccctttt	atacttacgc	tattgttgga	gatgggtgag	taaatgaggg	acaatgttgg	480
gaggctatac	agtttgcttc	tcatcaacag	ttatccaact	taattgtatt	tggtgatgat	540
aacaaaaaac	aatttagatg	ttttacaaag	gatatttgta	atccagggtga	tttcgtagaa	600
aaattttcag	catttggatt	tgaatccatt	agggtcaagg	gttcagatat	tagagaaatt	660
tatgaaggga	ttgtccaatt	aaaacagtca	aataattcat	cacctaagtg	cattgtatta	720
gaactactta	aagggtcaagg	ggttcaagag	ctggaagaaa	tgaaatccaa	tcatcatctt	780
cgcctactg	tagaggagaa	acaaatgtta	acttcagttg	tagaaagatt	aagtcaggaa	840
ttggaggaaa	cagaa					855

SeqID 92

atgaaaaaaa	ctacaatatt	atcattaact	acagctgcgg	ttatttttagc	agcatatgtc	60
cctaataaac	caatcctagc	agatactcct	agttcgggaag	taatcaaaga	gactaaagtt	120
ggaagtatta	ttcaacaaaa	taatatacaa	tataagggtc	taactgtaga	aggtaacata	180
ggaactgttc	aagtgggtaa	tggagtact	cctgtagagt	ttgaagctgg	tcaagatgga	240
aaaccattca	cgtatctac	aaaaatcaca	gtagggtgata	aagtatttac	cgttactgaa	300
gtagctagtc	aagcttttag	ttattatcca	gatgaaacag	gtagaattgt	ctactatcct	360
agctctatta	ctatcccac	aagcataaaa	aaaatacaaa	aaaaaggctt	ccatggaagt	420
aaagctaaaa	ctattatttt	tgacaaaggc	agtcagctgg	agaaaattga	agatagagct	480
tttgattttt	ctgaattaga	agagattgaa	ttgcctgcat	ctctagaata	tattggaaca	540
agtgcatttt	cttttagtca	aaaattgaaa	aagctaacct	tttctcaag	ttcaaaatta	600
gaattaatat	cacatgaggc	ttttgcta	ttatcaaat	tagagaaact	aacattacca	660
aatcggtta	aaacattagg	aagtaatcta	tttagactca	ctactagctt	aaaacatggt	720
gatgttgaag	aaggaaatga	atcgtttgc	tcagttgatg	gtgttttgtt	ttcaaaagat	780
aaaacccaat	taattttatta	tccaagtcaa	aaaaatgacg	aaagttataa	aacgcctaag	840
gagacaaaag	aacttgcac	atattcgttt	aataaaaatt	cttacttgaa	aaaactcgaa	900
ttgaatgaag	gtttagaaaa	aatcggtact	tttgcatttg	cagatgcgat	taaacttgaa	960
gaaattagct	taccaaatag	tttagaaact	attgaacgtt	tagcctttta	cggtaattta	1020
gaattaaaag	aacttatatt	accagataat	gttaaaaatt	ttggtaaca	cgttatgaac	1080
ggtttaccaa	aattaaaaag	tttaacaatt	ggtaataata	tcaactcatt	gccgtccttc	1140
ttcctaagtg	gcgtcttaga	ttcattaaag	gaaattcata	ttaagaataa	aagtacagag	1200
ttttctgtga	aaaaagatac	atttgaatt	cctgaaactg	ttagttcta	tgtaacatca	1260
gaacatataa	aagatgttct	taaatcaaat	ttatctacta	gtaatgatat	cattgttgaa	1320
aaagtagata	atataaaaca	agaaactgat	gtagctaaac	ctaaaaagaa	ttctaactcag	1380
ggagttagtg	gttgggttaa	agacaaaggt	ttatggtatt	acttaaacga	atcaggttca	1440
atggctactg	gttgggttaa	agacaaaggt	ttatggtatt	acttaaacga	atcaggttca	1500
atggctactg	gttgggttaa	agacaaaggt	ttatggtatt	acttaaacga	atcaggttca	1560
atggctactg	gttgggttaa	agacaaaggt	ttatggtatt	acttaaacga	atcaggttca	1620
atggctactg	gttgggttaa	agacaaaggt	ttatggtatt	acttaaacga	atcaggttca	1680
atggctactg	gttgggttaa	agacaaaggt	ttatggtatt	acttaaacga	atcaggttca	1740
atggctactg	gttgggttaa	agacaaaggt	ttatggtatt	acttaaacga	atcaggttca	1800
ttattagtaa	acacgactac	acccgatggc	tatcgagtca	atgctaacgg	tgagtgggta	1860
gga						1863

SeqID 93

atggtaagat	ttacaggact	tagtctcaaa	caaacgcaag	ctattgaggt	tttaaaaggt	60
cacatttctc	taccagatgt	ggaagtggct	gtcactcagt	ctgaccaagc	atctatctct	120
atcgagggtg	aggaaggtca	ctatcaattg	acctaccgca	aacctcacca	actttatcgt	180
gccttctcct	tggttgtaac	agttctagca	gaagctgata	aagtagagat	tgaggaaaca	240
gcagcttacg	aagatttggc	ttacatgggt	gactgttctc	gaaatgcggg	gctgaatgtg	300
gcttctgcca	agcagatgat	tgagatatgt	gctctcatgg	gctactcaac	ctttgagctt	360
tacattggaag	acacttacca	gattgaaggg	cagccttact	ttggctattt	ccgtggagct	420
tattcagcag	aggagtgtga	ggaaatcgaa	gcctatgcc	aacagtttga	cgtgaccttt	480
gtaccatgca	tccagacctt	ggccacttg	tcggcctttg	tcaaatgggg	tgtcaaggaa	540
gtgcaggagc	tccgtgatgt	agaggacatt	cttctcattg	gcgaagaaaa	ggtttatgac	600

ttgattgatg	gcatgtttgc	cacgttgtct	aaactgaaga	ctcgcaaggt	caatatcggg	660
atggacgaag	cccacttggg	tggtttggga	cgctacctga	ttctgaacgg	tgttgtggat	720
cgtagtctcc	tcatgtgcca	acacttggag	cgctgtctgg	atattgctga	caaatatggg	780
ttccactgcc	agatgtggag	tgatatgttc	ttcaaactca	tgtcagcgga	tggccagtac	840
gaccgtgatg	tggaaattcc	agaggaaact	cgtgtctacc	tagaccgtct	caaagaccgt	900
gtgactctgg	tttactggga	ttattatcag	gatagcgagg	aaaaatacaa	cgtaatttc	960
cgcaatcatc	acaagattag	ccatgacctt	gcatttgcag	ggggagcttg	gaagtggatt	1020
ggctttacac	ctcacaacca	ttttagccgt	ctagtggcta	tcgaggctaa	taaagcctgc	1080
cgtgccaatc	agattaaaga	agtcctcgta	acgggttggg	gagacaatgg	tgggtgaaact	1140
gccagttctt	ctatcctacc	aagcttgcaa	atctgggcag	aactcagcta	tcgcaatgac	1200
ctagatgggt	tgtctgcgca	cttcaagacc	aatactgggt	taacgggttg	ggattttatg	1260
cagattgacc	ttgccaacct	cttaccagac	ctaccaggca	atctcagcgg	tatcaatccc	1320
aaccgctatg	ttttttatca	ggatatctct	tgtccgattc	ttgatcaaca	catgacacct	1380
gaacaggaca	aaccgcactt	cgctcaggct	gctgagacgc	ttgctaacat	taaagaaaaa	1440
gctggaaact	atgcctatct	ctttgaaact	caggcccagt	tgaatgctat	tttaagtagc	1500
aaagtagatg	tgggacgacg	cattcgtcag	gcctaccaag	cggtatgata	agaaagttta	1560
caacaaatcg	ccagacaaga	attaccagaa	cttagaagcc	aaattgaaga	cttccatgcc	1620
ctcttttagc	accaatggct	gaaagaaaac	aaggtctttg	gtttggatag	agttgacatc	1680
cgtatgggcg	gactcttgca	acgcatacaa	cgagcagaaa	gccgtatcga	ggtttatctg	1740
gctggtcagc	ttgaccgcac	cgacgagctg	gaagtggaaa	tcctaccatt	tactgacttc	1800
tacgcagaca	aggatttcgc	agcaactaca	gcccaaccagt	ggcataccat	tgcgacagcg	1860
tcgacgattt	atacgact					1878

SeqID 94

atgtctaat	catttgtcaa	gttgttagtc	tctcaattat	ttgcaaattt	agcagatatt	60
ttcttttagag	taacaatcat	tgctaacata	tacattat	caaaatcagt	aattgccaca	120
tcactagtct	ctatcttaat	aggaatatcc	tcttttggg	cgagtctttt	agttccgttg	180
gttactaaaa	ggtttagcgt	aaataggggt	ttatctttat	ctcaatttgg	aaagactata	240
ttattggcga	tactggtagg	aatgtttacc	gtaatgcaat	ccgtagcgcc	tttgggtgac	300
tatctatttg	ttgttgcaat	ttccatacta	gatgggtttg	cagcaaccgt	ttcctatgct	360
attgtgccac	gctatgcgac	cgatttgggt	aaggctaatt	cagccttctc	aatgactggg	420
gaagctgttc	aattgatagg	ttggggatta	ggtggactct	tgtttgcaac	aattgggtctg	480
ttacctacca	cgtgtatcaa	tttagtcttg	tatatcattt	ctagctttct	gatgttattt	540
cttcttaacg	ctgaagtggg	ggtgttagag	tcagaaacta	atcttgaat	tttgtctcaa	600
ggttggaagt	tagttgctag	aaatcctaga	ttaagacttt	ttgtatcagc	aaatttattg	660
gaaatttttt	caaatacgat	ttgggtttct	tccattatac	ttgtttttgt	aacggagtta	720
ttaaataaaa	cggaaagtta	ctggggatat	tctaatacag	catactctat	tgggtattata	780
attagtggct	taattgcttt	taggctatct	gaaaagtctc	ttgtctgctaa	a	831

SeqID 95

atgtttgcat	caaaaagcga	aagaaaagta	cattattcaa	ttcgtaaatt	tagtggttga	60
gtagctagt	tagttgttgc	cagtcttgtt	atgggaagt	tggttcatgc	gacagagaac	120
gagggagcta	cccaagtacc	cacttcttct	aatagggcaa	atgaaagtca	ggcagaacaa	180
ggagaacaac	ctaaaaaact	cgattcagaa	cgagataagg	caaggaaaga	ggtcgaggaa	240
tatgtaaaaa	aaatagtggg	tgagagctat	gcaaaatcaa	ctaaaaagcg	acatacaatt	300
actgttagct	tagttaacga	gttgaacaa	ataagaacg	agtatttgaa	taaaattagt	360
gaatcaacct	cagaaaagcca	actacagata	ctgatgatgg	agagtcgata	aaaagtagat	420
gaagctgtgt	ctaagtttga	aaaggactca	tcttcttctg	caagttcaga	ctcttccact	480
aaaccggaag	cttcagatac	agcgaagcca	aacaagccga	cagaaccagg	agaaaaggta	540
gcagaagcta	agaagaaggt	tgaagaagct	gagaaaaaag	ccaaggatca	aaaagaagaa	600
gatcgtcgta	actaccaac	cattacttac	aaaacgcttg	aacttgaaat	tgtgtagctc	660
gatgtggaag	ttaaaaaagc	ggagcttgaa	ctagtataag	tgaaagctaa	cgaacctcga	720
gacgagcaaa	aaattaagca	agcagaagcg	gaagttgaga	gtaaacagc	tgaggctaca	780
aggttaaaaa	aatcaagac	agatcgtgaa	gaagcagaag	aagaagctaa	acgaagagca	840
gatgctaag	agcaaggtaa	accaaagggg	cgggcaaaac	gaggagtctc	tggagagcta	900
gcaacacctg	ataaaaaaga	aaatgatcgc	aagtcctcag	attctagcgt	aggtgaagaa	960
actcttccaa	gcccatccct	gaaaccagaa	aaaaaggtag	cagaagctga	gaagaaggtt	1020
gaagaagcta	agaaaaaagc	cgaggatcaa	aaagaagaag	atcgccgtaa	ctaccaacc	1080
aatacttaca	aaacgcttga	acttgaaatt	gctgagtcgg	atgtggaagt	taaaaaagcg	1140
gagcttgaac	tagtaaaaaga	ggaagctaag	gaacctcgaa	acgaggaaaa	agtttaagcaa	1200
gcaaaagcgg	aagttgagag	taaaaaagct	gaggctacaa	ggttagaaaa	aatcaagaca	1260
gctgtaaaaa	aagcagaaga	agaagctaaa	cgaaaagcag	cagaagaaga	taaagttaaa	1320
gaaaaaccag	ctgaacaacc	acaaccagcg	ccggctccaa	aagcagaaaa	accagctcca	1380
gctccaaaac	cagagaatcc	agctgaacaa	ccaaaagcag	aaaaaccagc	tgatcaacaa	1440
gctgaagaag	actatgctcg	tagatcagaa	gaagaatata	atcgcttgac	tcaacagcaa	1500
ccgccaaaaa	ctgaaaaaac	agcacaacca	tctactccaa	aaacaggctg	gaaacaagaa	1560
aacggtatgt	ggtacttcta	caatactgat	ggttcaatgg	cgacaggatg	gctccaaaac	1620
aatggctcat	ggtactacct	caacagcaat	ggcgctatgg	cgacaggatg	gctccaaaac	1680

aatggttcat	ggtactatct	aaacgcta	aat	ggttcaatgg	caacaggatg	gctccaaaac	1740
aatggttcat	ggtactacct	aaacgcta	aat	ggttcaatgg	cgacaggatg	gctccaatac	1800
aatggctcat	ggtactacct	aaacgcta	aat	ggttcaatgg	cgacaggatg	gctccaatac	1860
aatggctcat	ggtactacct	aaacgcta	aat	ggtgatatgg	cgacagggtt	ggtgaaagat	1920
ggagatacct	ggtactatct	tgaagcatca		ggtgctatga	aagcaagcca	atggttcaaa	1980
gtatcagata	aatgggtacta	tgtcaatggc		tcagggtgcc	ttgcagtcaa	cacaactgta	2040
gatggctatg	gagtcfaatgc	caatgggtgaa		tgggtaaac			2079

SeqID 96

atgaactatt	caaaagcatt	gaatgaatgt	atcgaaagt	cctacatggt	tgctggacat	60
tttggagctc	gttatctaga	gtcgtggcac	ttgttgattg	ccatgtctaa	tcacagttat	120
agtgtagcag	gggcaacttt	aaatgattat	ccgtatgaga	tggaccgttt	agaagaggtg	180
gcttttgaa	tgactgaaac	ggactatagc	caggatgaaa	cctttacgga	attgccgttc	240
tcccgtcgtt	tgacagttct	ttttgatgaa	gcagagtatg	tagcgtcagt	ggtccatgct	300
aagggtactag	ggacagagca	cgtcctctat	gcgattttgc	atgatagcaa	tgcttggcg	360
actcgtatct	tggaagggc	tggtttttct	tatgaagaca	agaaagatca	ggtcaagatt	420
gctgctcttc	gtcgaaat	agaagaacgg	gcaggctgga	ctcgtgaaga	tctcaaggct	480
ttacgccaac	gccatcgtac	agtagctgac	aagcaaaatt	ctatggccaa	tatgatgggc	540
atgccgcaga	ctcctagtgg	tggtctcgag	gattatacgc	atgatttgac	agagcaagcg	600
cgttctggca	agttagaacc	agtcacgtgg	cgggacaagg	aaatctcacg	tatgattcaa	660
atccttgagcc	ggaagactaa	gaacaaccct	gtccttgggtg	gggatgctgg	tgctgggaaa	720
acagctctgg	cgcttgggtc	tgcccagcgt	attgctagt	gtgacgtgcc	tgccggaatg	780
gctaagatgc	gcgtgttaga	acttgatttg	atgaatgtcg	ttgcaggagc	acgcttccgt	840
ggtgactttg	aagaacgcac	gaataaatatc	atcaaggata	ttgaagaaga	tgcccaagtc	900
atcctcttta	tcgatgaact	ccacaccatc	atgggttctg	gtagcgggat	tgattcgact	960
ctggatgcgg	ccaatatctt	gaaaccagcc	ttggcgcgtg	gaactttgag	aacggttggt	1020
gccactactc	aggaagaata	tcaaaaacat	atcgaaaaag	atgcggcact	ttctcgtcgt	1080
ttcgctaaag	tgacgattga	agaaccaagt	gtggcagata	gtatgactat	tttacaagg	1140
ttgaaggcga	cttatgagaa	acatcacctg	gtacaaatca	cagatgaagc	ggttgaaaca	1200
gcggttaaga	tggtctcatg	ttatttaacc	agtcgtcact	tgccagactc	tgctatcgat	1260
ctcttggatg	aggcggcagc	aacagtgcac	aataaggcaa	agcatgtaaa	agcagacgat	1320
tcagatttga	gtccagctga	caaggccctg	atggatggca	agtggaaaca	ggcagcccag	1380
ctaactcgca	agaagagga	agtacctgtc	tacaaagact	tggtgacaga	gtctgatatt	1440
ttgaccacct	tgagtcgctt	gtcaggaatc	ccagttcaaa	aactgactca	aacggatgct	1500
aagaagtatt	taaatcttga	agcagaactc	cataaacggg	ttatcgggtc	agatcaagct	1560
gtttcaagca	ttagccgtgc	cattcgccgc	aaccagtcag	ggattcgcag	tcataagcgt	1620
ccgattgggt	cctttatgtt	cctagggcct	acaggtgtcg	ggaaaactga	attagccaag	1680
gctctggcag	aagttctttt	tgacgacgaa	tcagccctta	tccgctttga	tatgagttag	1740
tatatggaga	aatttgcagc	tagtcgtctc	aacggagctc	ctccaggcta	tgtaggatat	1800
gaagaagggtg	gggagttgac	agagaagggt	cgcaataaac	cctattccgt	tctcctcttt	1860
gatgaggttag	agaaggccca	cccagatatac	tttaattgtt	tcttgcaggt	tctggatgac	1920
ggtgtcttga	cagatagcaa	gggacgcaag	gtcgattttt	caaataccat	tatcattatg	1980
acatcgaaatc	taggtgcgac	tgcccttctg	gatgataaga	ctgttgggtt	tggggctaag	2040
gatattcgtt	ttgaccagga	aaatatggaa	aaacgcacgt	ttgaagaact	gaaaaaagct	2100
tatagaccgg	aattcatcaa	ccgtattgat	gagaagggtg	tcttccatag	cctatctagt	2160
gatcatatgc	aggaagtgg	gaagattatg	gtcaagcctt	tagtggaag	tttgactgaa	2220
aaaggcattg	acttgaaatt	acaagcttca	gctctgaaat	tgtagcaaaa	tcaaggatat	2280
gaccagaga	tgaggagctg	cccacttcgc	agaacccctg	aaacagaagt	ggaggacaag	2340
ttggcagaa	ttcttctcaa	gggagattta	gtggcaggca	gcacacttaa	gattgggtgc	2400
aaagcaggcc	agttaaaatt	tgatattgca				2430

SeqID 97

atgaaaaatt	taccgtttat	agcaagagga	acaagttatt	acttgaagat	gtcagttaaa	60
aagcttgttc	cttttttagt	agtaggattg	atgctagcag	ctggatgatg	tgctatgccc	120
tattccagag	gaaatggatc	gattgcgcgt	ggggatgatt	atcctgctta	ttataaaaat	180
gggagccagg	agattgatca	gtggcgcag	tattctcgtc	agtgtacttc	ttttgtagcc	240
tttcgtttga	gtaatgtcaa	tggttttgaa	attccggcag	cttatggaaa	tgccgaatgaa	300
tggggacatc	gtgctcgtcg	ggaagggtat	cgtgtagata	atacaccgac	gattgggtcc	360
attacttgg	acttcgagg	aacttatggt	catgttgcc	gggtgtcaaa	tgtaatggga	420
gatcagattg	agattgagga	atataactat	ggttatacag	aatcctataa	taaacgagtt	480
ataaaagcaa	acacgatgac	aggatttatt	catttttaag	atttggatgg	tgccagtggt	540
gggaatagtc	aatcctcaac	ttcaacaggc	ggaactcatt	attttaagac	caagtctgct	600
attaaaactg	aacctctagc	tagcgggaact	gtgattgatt	actattatcc	tggggagaa	660
gttcattatg	atcagatact	tgaaaaagac	ggctataagt	ggttgagtta	tactgcctat	720
aatggaaagct	atcgttatgt	tcaattggag	gtctgaata	aaaatcctct	aggtaattct	780
gttctttctt	caacaggtgg	aactcattat	tttaagacca	agtctgctat	caaaactgaa	840
cccctagtta	gtgcaactgt	gattgattac	tattatcctg	gagagaaggt	tcattatgat	900
caaattctcg	aaaaagacgg	ctacaagtg	ttgagttata	cggcttataa	cggagagtcgt	960

cgctatatac	agctagaggg	agtgacttct	tcacaaaatt	atcagaatca	atcaggaaac	1020
atctctagct	atggatccca	tagtagttca	actgtcgggt	ggaagaaaat	aatggtagt	1080
tggtatcatt	tcaaatcaaa	tggttctaaa	tcaacaggat	ggctgaaaga	cggttctagc	1140
tggtattatt	tgaattatc	tggtgaaatg	cagacaggat	ggttaaagga	aatggtttg	1200
tggtattatc	tggttagttc	aggggcaatg	aaaacaggct	ggtaccaggt	ctctggtaag	1260
tggtattatt	cttactcttc	agggcgctta	gctgttaata	cgacggtgga	tggtacaga	1320
gtaaacagtg	atggagaacg	agta				1344

SeqID 98

atgaaagtaa	tcttttttagc	agatgttaaa	ggaaaaggta	aaaaaggcga	aattaaggaa	60
gtaccaacag	ggtatgcgca	aaactttctt	atcaaaaaga	atctagccaa	agaagcgact	120
gctcaagctg	taggtgaact	tcgtggtaaa	caaaaatcgg	aagaaaaagc	tcacgctgag	180
atgattgcag	aaggaaaagc	aattaaagca	caacttgaag	cagaagaaac	tgttgtagaa	240
tttgttgaaa	aagttgggtcc	agatggctgt	acctttgggt	ctattacca	taagaagatt	300
gcagaagaat	tgcaaaagca	atgttggaatt	aagattgata	aacgtcatat	tcaagtacaa	360
gctccgattc	gagcgggttg	tttgattgat	gtgccagtga	aatctatca	agatatcaca	420
agtgtaatca	atcttcgtgt	gaaagaaggga				450

SeqID 99

atgaagaaaa	aaatcttagc	gtcactttta	ttaagtacag	taatggtttc	tcaagtagct	60
gttttaacaa	ctgcgcagtc	agaaacgact	gatgacaaaa	ttgctgctca	agataataaa	120
attagtaact	taacagcaca	acaacaagaa	gcccataaac	aagttgacca	aattcaggag	180
caagtatcag	ctattcaagc	tgagcagctc	aacttgcaag	ctgaaaatga	tagattacaa	240
gcagaatcta	agaaactcga	gggtgagatt	acagaacttt	ctaaaaacat	tgtttctcgt	300
aaccaatcgt	tggaaaaaca	agctcgtagt	gctcaaacaa	atggagccgt	aactagctat	360
atcaataacca	ttgtaaactc	aaaatcaatt	acagaagcta	tttcacgtgt	tgctgcaatg	420
agtgaatcgt	tatctgcaaa	caacaaaatg	ttagaacaac	aaaaggcaga	taaaaagct	480
atctctgaaa	aacaagtagc	aaataatgat	gctatcaata	ctgtaattgc	taatacaaca	540
aaattggctg	atgatgctca	agcattgact	acgaacacag	cagaactaaa	agctgctgaa	600
ttaagtcttg	ctgctgagaa	agcgacagct	gaaggggaaa	aagcaagtct	attagagcaa	660
aaagcagcag	ctgaggcaga	ggctcgtgca	gctgcggtag	cagaagcagc	ttataaagaa	720
aaacgagcta	gccacaacaa	atcagtactt	gcttcagcaa	acactaactt	aacagctcaa	780
gtgcaagcag	tatctgaatc	tgacgacgca	cctgtccgtg	caaaagtctg	tccaacatac	840
agtacaaacg	cttcaagtta	tccaattgga	gaatgtacat	ggggagttaa	aacattggca	900
ccttgggctg	gagactactg	gggtaatgga	gcacagtggg	ctacaagtgc	agcagcagca	960
ggtttccgta	caggttcaac	acctcaagtt	ggagcaattg	catgttgga	tgatggtgga	1020
tatggtcacg	tagcggttgt	tacagctgtt	gaatcaacaa	cacgtatcca	agtatcagaa	1080
tcaaattatg	caggtaatcg	tacaattgga	aatcaccggt	gatggttcaa	tccaacaaca	1140
acttctgaag	gttttgttac	atatatttat	gcagat			1176

SeqID 100

atggtaaaaa	gacgtataag	gagagggacg	agagaacctg	aaaaagttgt	tgttcctgag	60
caatcatcta	ttccttcgta	tcctgtatct	gttacatcta	accaaggaa	agatgtagca	120
gtagaaccag	ctaaagcagt	tgctccaaca	acagactgga	aacaagaaaa	tggtatgtgg	180
tatttttata	atactgatgg	ttccatggca	acaggttggg	tacaagttaa	tagttcatgg	240
tactacctca	acagcaacgg	ttctatgaaa	gtcaatcaat	ggttccaagt	tggtggtaaa	300
tggtattatg	taaatacatc	gggtgagtta	gcggtcaata	caagtataga	tggtatata	360
gtcaatgata	atgggtgaatg	ggtgcgt				387

SeqID 101

gagttgcgac	ggctatcaag	gttgggtggac	caggagctct	atgttggtatg	tggtatggcg	60
ctttcttttg	aatggctacc	aagtatgcgg	aaggactctt	ggccatcaaa	taccgcacca	120
aggacgacca	tggtgcag					138

SeqID 102

gactgtatca	ggaacaaccc	gttcacacgc	gatgaaccaa	acaaaacgtg	ccgtaaaacc	60
aaaccttcaa	aaagttactg	ttcttatcga	tggt			93

SeqID 103

ggacaaagaa	accctcgaag	aattgaaaga	gttatcagaa	tggtcagaac	gaaaccaaga	60
atatctaaaa	aagaaggc					78

SeqID 104

cagaggaagc	tggtcaaaat	cttccacctc	ttccagaaga	aaagtgggtg	gaaccagaaa	60
tcattcctgcc	tcaagctgaa	cttaaatcc	ctgaacagga	agatgactca	gatgacgaag	120
atgttcagggt	cgatttttca	gccaaagaag	cccttgaata	caaaactcca	agcttacaac	180
tctttgcacc	agataaacca	aaagatcagt	ctaaagagaa	gaaaattgtc	agagaaaata	240
tcaaaatct						249

SeqID 105

ttggtgatta	tagttttgaa	aatccagtcc	aaatcggaga	cagactttat	tttcaagaca	60
tggccattta	ttcttttgtc	aaaaataata	cctttaatgg	tattggattg	ccaagtctct	120
atctcatgga	cgaacagga	gactgtagct	tactcaaagc	ttttggctat	caagacttta	180
aaggagatt	atcatgatgg	acagtccaaa	aaaattaggg	tatcacatgc	cagcagagta	240
cgaaccccat	catggtaccc	tcatgatatg	gccgactcga	ccaggatcat	ggccttttca	300
aggaaaggct	gc					312

SeqID 106

gagagactac	cagcttttcc	tagaagtctt	tcaggaggga	agttggacca	aggcggaacc	60
aaagaaaaag	gctcggatgg	aagaagtcct				90

SeqID 107

agaaattgcc	tctctacttg	gaaaagctcc	tcaaactatc	acactgaaat	caagcgtggg	60
acagtccgac	aatgtcttgg	aaaagggcgc	ttcaaagagg	tttattctgc	cgactacgct	120
caacagtctt	atgaaaacaa	tcgcaagcgc	tcggtaaga	aatcaagctt	gaccaaggaa	180
ctaaaggaaa	agattctcca	ctatcataac	caaaaatttt	cgctgaaat	gatggttatg	240
gctaaagggg	ttaacgtggg	aatttcaacc	atttactatt	ggattcatca	tggaaaattg	300
gggttaagca	agcaggattt	gctttaccct	agaaaaggaa	aagcgcttaa	gaaacaggct	360
agcaccaact	ttaaacctgc	tggtcaatcc	atcgaacagc	ggcctgaagc	tatcaatctt	420
cgcttgagga	atgggcacta	tgagattgat	acggttctac	ttacgagatc	gaaaaactac	480
tgcttgattg	tcttgacgga	tcgaaagagt	agacatcaga	tcattccgatt	gattccaaat	540
aaaagtgtctg	aggtgggtcaa	tcaggctcta	aaactcatct	taaaacaaca	caagattctt	600
tccatcacgg	cagataatgg	aacggaattc	aatcgcttgt	ttgatataat	ttctgaggag	660
cacatctatt	atgcgcaccc	ctatgcctct	tgggaaaggg	gaactaatga	gaatcacaac	720
aggctcatte	gtagatagtt	acctaaggga	accaagaaaa	tgactcccaa	agaagtcgca	780
ttcatcgaaa	agtggattaa	caactatcct	aaaaaatgct	tggactacaa	gtcaccacga	840
gaagacttct	ggatgggttaa	cttgaacttg	aaatttagca	aatggaaat	aattttttatt	900
aaacgcttcc	aa					912

SeqID 108

cctgtcatga	ctatctcatc	gcctactatg	aaaaacatgg	atttgtcaac	gaaggccagt	60
cccagtcaac	ctttgcaggg	gaaacatggg	atgatatggg	ctgggaaa		108

SeqID 109

acatcatcaa	taaggataca	cacaaggaaa	tcatcgccaa	actggactac	gacgccccat	60
cttgccctga	gtgcggaaac	caat				84

SeqID 110

tacttccttc	cacacaagta	tgccagagaa	agcttatcgc	taccctctac	caacaaaata	60
ttacacagaa	aacaaggttc	g				81

SeqID 111

gcagccttca	aaaaagatca	aattaatgag	cggtgcgaga	aattaggtaa	gttaaaacct	60
attacaataa	attacaacgg	aaaatcagaa	gtaattgata	gtaaagaaaa	attacaagag	120
cttatgaata	aagccgttaa	agacgaagtg	gctcaataa			159

SeqID 112

gcttatgcgc	attctaaaag	aagcgtgga	agtggcaggg	caggaggcag	acaatgtctt	60
tgccaatgtc	aaaataaatg	taggagagat	tttaagtat			99

SeqID 113

cacggccgac	cttatcataa	gcctcaccaa	ccgcatcatc	acgggtttcc	ccaacaatct	60
tataatctcc	tgctccgaa	acataaacca	actctgtgtg	tccgccgc		108

SeqID 114

aaaggaaaaa	tctctctgct	accaaggcta	accactcaaa	gatggcaag	aaaaatccgc	60
cctgactcac	gtaagtcagc	aaataataaa	gcaaaccttg	acttccataa	tagtgcgtgt	120
aaatcttccc	tgtctgatga	agcgcccaac	ctgcataaaa	atcctgcact	tcttggtcac	180
tcattaagtc	gagtaatagc	ggtactccta	gagttatccc	cgttacaagc	gtactccata	240
gtaaaatttt	caccaaagga	agacgacttg	attcacgatg	atgcgattct	tgttcgattt	300
ggtattctag	aggttcacga	ttctccttat	gaacttcttc	tactctacca	tacacactca	360
tatcgtttct	cctgttcaat	ttatctgtct				390

SeqID 115

tttacggtaa	gccatgtatt	cctcctttat	ttatctttta	atccaagacc	caaatacatg	60
agtttgagtt	tcacttcttc	caaaactctg	cgtccaagat	ttcgtacttt	catcatctct	120

gcttcagatt	tttctgtcaa	atcatgcaca	gtattgatac	cggcacgttt	taaacagttg	180
tatgaacgca	cagacaagtc	cagttcctca	atcgtacgat	ctaaaatacg	gtcgtcagat	240
tcagtatcag	cttcttttcat	cacttcagtt	gacttagcaa	tctcagtaag	atttgtaaac	300
aaatcaagat	gttctgtcaa	aatacgtgct	gaaagcccta	aagcatcttc	tggaataatt	360
gttccatttg	tcaagatttc	aagggttaat	ttgtcgaaac	catcattgct	acctacacga	420
gcaggttcca	ct					432

SeqID 116						
cttgtctgca	tgaagaataa	gggctgctac	aaggaaagaa	acaactgctg	ccac	54

SeqID 117						
ttccattatt	tgtaaaata	cttttttagtt	tcagcaataa	cgactggcga	caagaccaag	60
agggcaatca	agtttggcag	agccatcaag	gcgttaacga	tatctgcgat	aatccagacc	120
atatccaact	cgataaatcc	tcctaacaag	accatgagca	caaaaaccac	acgg	174

SeqID 118						
ggaaaagaagg	tattcataaa	ataccctcta	tcaagagtct	cctcaaaaac	aggaccgatg	60
attacaggca	ggacaaaaga	taagatagtc	gataaaaagg	ttgggtgtcc	atttgaaaaa	120
agcacggtaa	aatactcatc	a				141

SeqID 119						
tcttcaccag	tttttcttaa	acttgtaatg	gtatctgggg	caaataaacc	aagagaaagg	60
cgcaatttcc	cattttctgc	taaaatgtca	ttccacttaa	cctttgtctt	g	111

SeqID 120						
tacttaactt	ccttctcagt	tccgaagata	gcttcttcaa	aggtcaaatt	gacacgatac	60
tgagatcat	ctccttggcg	aggagcggtt	ggattgcgcg	aagaaccgcc	tccgccgaag	120
aaacttgaga	aaatatcctc	aaaaccaccg	aagccacctg	ccccattgaa	accgccgaaa	180
ccaccagctc	caccaaaaacc	accattggcg	cctgcagcac	catactggtc	a	231

SeqID 121						
cagtcatggc	gtcctatttc	agattcaaaa	tgctatacac	aagaaaaact	cactatcccc	60
attaaaagaa	gaaaagacat	caaggacttc	taccacaatt	ccatccaaag	acacaaaaac	120
agccataaga	gtcacctcct	tgattcctat	aggctgatta	taacaagact	ggctgaaatt	180
gtacatgaaa	ataaaatcct	aatagtactc	attttgtatg	tgactaatat	tccgtctcgc	240
tccagaagggt	acgaagtaaa	tagagtt				267

SeqID 122						
ctgtttcgtt	tttatcgtgt	aattgttctt	tatcgagggt	ggcatattta	tcttttaatt	60
cttgtgaatt	tgcatgacgt	tcaaaacgtt	ttccgaaagg	atcgattcct	tgttcgcgga	120
gcgagccat	tttttcacgg	cgaacgatct	gctggtcatt	tagttcttcc	atatgttctg	180

SeqID 123						
ataactcacc	ctccactaaa	ccctgagcat	tttgtttcaa	gagtcttttc	atctcttggt	60
ttgaagtctt	atcagccaaa	agatgataga	tttctgagaa	agccttcaga	tagtaggcat	120
cctgaatcag	gtaatagcgg	aaaatggcag	gttctaaatt	cccctcttgt	aattgtaaaa	180

SeqID 124						
acattggcta	aagcagtcgg	tttgatgtat	tctccaccaa	ttccaccaa	accattctta	60
ggccgaataa	cgacagattc	gtcttctata				90

SeqID 125						
cctggttctc	cattttcaga	gatttccgggt	gcaggatttt	ttgggtgctc	gaaacgaata	60
tttccacgtc	caccacgacc	accgtgggca	acgataaatt	cttgcccatg	ttcaatcaaa	120
tctgttaaaa	ccttgccagt	ctccgcatca	cgaacagtcg	taccttgggg	tactcgaaact	180
ctaaggctct	cagcaccacg	accatgcac	cctttgggtca	tccctttttc	accagaatca	240
gccttgaaa						249

SeqID 126						
ataaattcct	tgaccttggc	cacatcctta	tccaaaagaa	gggcaccaag	aaaggcttca	60
aaggcatcac	caagaatggg	gtcacgattg	cgaccacctg	atttttcttc	ccctttaccc	120
aacttgataa	actggtcaaa	ctggcaatca	cgcgcaaaac	cagctaaact	ctcctcacgg	180
acaatcatag	cacggagttt	tgataggtca	ccttcaggct	ttttaggata	ttttttatat	240
agatattctg	aaatcaataa	ctgtagaaca	gcgtctccta	aaaattccaa	gcgttcattg	300
tgtgaaattt	ttaagaggcg	gtgctcattg	gca			333

SeqID 127						
ccaataggaa	aaaggaattg	taaagctgaa	tgccaatccc	accacctgct	tgaaaagcag	60

aagaccttcc	agtcaagaaa	gaccaagaga	tatggggcaa	gccccgaacc	aagatataga	120
gaatcaagga	agccaagatt	gtcacaa				147
SeqID 128						
cagccattgg	gacactcgaa	agccgaagaa	catgagacta	tctgttcgca	taccttcgat	60
aaccatacga	ccgaaaccat	accaaataca	gtaaaaggcc	gtgatatgac	ctcgtctgag	120
actcttccat	ttcgtctaa	aatcagaat	caaggcaaaag	ccaagcagat	tcca	174
SeqID 129						
ccttgcctct	tacctgatta	tgggctggtt	ggttctggct	atcattcctg	ccattatcag	60
tcaaacgaca	cccgttttct	ggagtctcat	ggtaactggc	ggactctgtt	atacagttgg	120
agctggattt	tatgccaaga	aaaaacctta	ttccacatg	atttggcatc	tctttatcct	180
agctgcgtcc	gcacttcaat	acatcgctat	tgtttattac	atgtaaaaaa	gttgagaaat	240
tcaatctcaa	cttttttctt	tacacatatt	gataaagtac	tggtgcaagc	gcacatcatc	300
agtcaattct	ggatgaaaag	aacttaccaa	catatttttt	tcttgggctg	caacaatttg	360
attgttcaat	gttgc					375
SeqID 130						
cgagtaaaag	ataatcatct	ggataagctt	gtgaaagctc	ttctaaaaag	gcgttcatcc	60
actcagtatt	acatccacca	gctattaaga	aaaatgattc	gcctgtatgg	gcatcaacag	120
ctccataaca	atagcgaaat	tctcgtatat	agtgactatg	gacatgtgga	cctactecta	180
ttggagacca	acaagatccc	agtttac				207
SeqID 131						
caagtcacat	aaatagacat	agcaactaca	aataaaacgg	aatctgtaaa	gagccaaagt	60
gagagagaaa	agaaaagatt	gacaagcagt	aataactata	aggttagagg	gcgaccgata	120
SeqID 132						
gcctttaaga	gttccaaggt	cccatcactt	gatccatcat	cgacaaagac	atactcgatt	60
tctgtttcca	aatctggaag	taaagcttcc	agagcc			96
SeqID 133						
gataaaaactg	acccactggc	taggaaactt	cctgacaaaa	gtaagccgtc	aacttccttt	60
tgcaccaaat	cactttctcc	cgtaaacatg	gcttcattga	cttcgcgcaa	gccttccaaa	120
accaaggcat	cactaggaat	ctgctctcct	gcagacaaac	gaatgacatc	tcctagcact	180
aattcttcag	gattaagagc	aacttcc				207
SeqID 134						
ttatgccgat	tacaaacaca	agcaaggcca	cgagggtctg	tgaccaatct	aacgaagcaa	60
aataaggtat	atagatacct	aaattatctc	cgccagacgc	aattgtcagc	aatg	114
SeqID 135						
tgcatcctaaa	gcattggcaa	tgagggacag	tgcaaaggca	atagttgtta	cgtaggcaag	60
gagattcatc	ttgcccccat	atccgatata	gttggtcaca	aaggcaaaaga	ggaaggcgat	120
gatggaaatg	atgatggccg	ccaattttac	ctgttttttg	ctcatttggt	tgggtctgcc	180
ttcttgcgaa	gcttcccact	tctttatagc	aaagggtataa	atgaggaagg	tgacgggata	240
ggtaaatgatg	gcgccttat	ttccaaggat	ataatcaata	gcaccggaca	aaatggtatt	300
aacaatacca	aagtaatttc	cccatttget				330
SeqID 136						
acgtccacga	agctgggtat	cgatacgacg	actttcatga	cgttctgtac	caataacaca	60
aagtcctcca	agttcacgaa	caccttcacc	aagcttgatg	tgggtaccac	gaccggccat	120
gttgggtgcy	atggtaacgg	caccacgttg	accagcattc	atgatgattt	gggcttctct	180
atagtgggtt	ttggcattca	agacttcgtg	aggaacacca	gctgcaacca	atttcttaga	240
aatgtagtca	ctagtctcaa	ccgctactgt	accaaccaag	acagggtgac	ccttttggtg	300
acgagcctta	acgtcttcga	caaccgcttt	aaacttagat	tcgatacttg	cataaagaag	360
gtc						363
SeqID 137						
atctctactg	gtgtaccgac	ctgttcgatg	tatccattgt	taaagactgc	aattctatca	60
gataaagtca	aggcttcctc	t				81
SeqID 138						
taaagtacca	tgtccagcat	aaagtcaatc	ttgtgctctt	taccgacaca	caccattttc	60
tcaaaatcag	ccatatacacc	aaaaagagga	tccactgcca	ta		102
SeqID 139						
agctgctcat	actcatctac	caactccaag	gcatgctcaa	tcgctcggtt	atcaaaacca	60

acaatattca	tctgtgtcac	acccatctca	gcagccaagg	caattttcttc	tgccctcacga	120
cctgcaaatt	cttctacatt	caagtgtgta	tgtgtatcaa	aatcatcttc	ttctaaccctc	180
gttttctatc	ttctattata	ccaaaaaaga	ggagggggcac	ctaatttttc	ggtttcccct	240
cctctcttca	atagagagct	attctgctat	cttttctatc	cgatattgcc	catctcctat	300
tccacagtta	gagacagaag	agattggcta	cat			333

SeqID 140

gtaacatctt	gcattgttcc	tgcaattgct	tgcggtgcac	ttgttgtctt	aggagcagca	60
ttaggagcca	ctggtctctt	aggaactgta	accatggcaa	tggtctgcac	tccaatcgtt	120
tctgttctct	tcacatcttc	catagttttc	gcattttcaa	tctctttgag	agctgcttgt	180
ttttctgctt	ccactcttgc	taaaagttct	gctttttctt	tatcagaaag	cggtgcgcct	240
ttgatttcat	cctgcttgc	cctggctgct	ttttcaatgg	catttttagc	tgattctttt	300
tcagtagcta	attgcttaga	agcttgtgat				330

SeqID 141

tattctcctt	tcaaccactc	cattctcata	aggaaaacga	cgaaaatcat	aaatccaaac	60
cccaaagcac	cacgaatgaa	ttggcggaagc	aaggtttggt	caaaccaacc	tgtaaacatt	120
tccactaacc	ataccaagag	tgacaggccg	ataaagaaa			159

SeqID 142

gattatttca	agtttcgaac	aacttttaca	agattttcta	cagtaaagcc	atattctgcc	60
aatacttttg	gtgctggggc	agaggctccg	aaggtatcaa	tacctagaac	ggcaccatcg	120
agaccaacat	attgttacca	gttt				144

SeqID 143

agaggcagac	gtggattatg	cgttgcacga	atcaaggctc	ctagactagt	cattaaacct	60
aagagaacaa	tcgatccgcg	taccaaagat	agatacagtc	caccactctc	agctacatcc	120
ctctccgtcc	ccaaaagtc	tatcatctct	ttcccagcga	agatggacaa	aaatcctaaa	180
aggaaactta	atagtaagg	aatcttcaac	gcctcagtc	ca		222

SeqID 144

actcctccat	ataccaaaat	tcctgccaaa	acagctataa	taccatttat	ttcagctcaa	60
gatttcaacc	aagcccaacg	gctctctgga				90

SeqID 145

MSKNIVQLNNSFIQNEYQRRRYLMKERQKRNRFMGGVLILIMLLFILPTFNLAQSYQQLLQRRQQLADLQTQYQTLSDKDKKE
TAFATKLKDEYAAKYTRAKYYSKSREKVYTIPTDLLQR

SeqID 146

MDKKLLLLIDGSSVAFRAFFALYQQLDRFKNVAGLHTNAIYGFQMLSHLLERVEPSHILVAFDAGKTTFRTEMYADYKGGRA
KTPDEFREQFPFIRELLDHMGIRHYDLAQYEADDIIGTLDKLAEQDGFDTITVSGDKDLIQLTDEHTVVEISKKGVAEFEAFT
PDYLMEEMLTTPAQFIDLKALMGDKSDNIPGVTKVGEKTGIKLLLEHGSLEGIYENIDGMKTSKMKENLINDKEQAFLSKTLA
TIDTKAPIAIGLEDLVYSGPDVENLGKFYDEMFGFKQLKQALNVSSADVSESLDFTIVDQISQDMLSEESIHFHFLFGENYHTT
NLVGVFWSCGDKLYATDKLELLQDPIFKDFLEKTSRVDYDFKKVKVLLQRFQVLDLQAPAFDIRLAKYLLSTVEDNEIATIASI
YGQTYLVDDDETfYFGKGVKKAIPEREKFLHLACKLAVLVETEPILLEKLSENGQLELLYDMEQPLAFVLAKMEIAGIMVKKEI
LLEMQAENELVIEKLTQEIYELAGEEFNVNSPKQLGVLLFEKLGPLEYTKKTKTGYSTAVDVLERLAPIIVKKILDYRQI
AKIQSTYVIGLQDWILADGKIHTRYVQDLTQTGRLLSSVDNPNLQNI PARLEQGRLLIRKAFVPEWEDSVLLSSDYSQIELRVLAH
ISKDEHLIKAFQEGADIHTSTAMRVFGIERPDDVTANDRRNAKAVNFGVVYGISDFGLSNNLGISRKEAKAYIDTYFERPPGI
KNYMEVVRREARDKGYVETLFRRRRELDPINSRNFNIRGFAERTAINSPIQGSAADILKIAMIQLDKALVAGGYQTKMLLQVH
DEIVLEVPKSELVEMKKLVKQTMEEAIQLSVPLIADENEGATWYEA

SeqID 147

MGMAAFKPNPNQYKAITIAQTLGDDASSEELAGRYGSAVQCTEVTASNLSVTKTKATVVEKPLKDFRSTSDQSGWVESNGKW
YFYESGDVKTGWKTDGKWWYLLNDLGVMQTGFVKFSGSWYLLSNSGAMFTGWTGDSRWFFYFDGSGAMKTGWYKENGTYWYLD
EAGIMKTGWFKVGPWHYYAYGSGALAVSTTTPDGYRVNGNGEWN

SeqID 148

MSRKSIGEKHSFMRKLSVGLVSVTVSSFFLMSQGIQSVSADNMESPIHYKYMTEGKLTDDEKSLLVEALPQLAEESDDTTY
LVYRSQQFLPNTGFNPTVGTFLLTAGLSLLVLLVSKRENGKKRLVHFLLLTSMGVQLLPASAFGLTSQILSAYNSQLSIGVGE
HLPEPLKIEGYQYIGYIKTKKQDNTELSTVDGKYSAQRDSQPNSTKTSDDVHSADLEWNQGGKVSLOGEASGDDGLSEKSS
IAADNLSSNDSFASQVEQNPDHKGESVVRPTVPEQGNPVSATTVQSAEEVLATNDRPEYKLPLETGKTQEPGHEGEAAVRE
DLPVYTKPLETKGTQGPGEHEGEAAVREEEPAYTEPLATKGTQEPGHEGKATVREETLEYTEPVATKGTQEPGEHEGEAAVEEL
PALEVITRNRTIENIPYTTEEIQDPTLLKNRRIERQAGTRTIQYEDYIVNGNVVETKEVSRTEVAPVNEVVKVGLTVKV
KPTVEITNLTKVENKKSITVSYNLIDTTSAYVSAKTQVFHGDKLVEVDIENPAKEQVISGLDYTPYTVKTHLTYNLGENNE
ENTETSTQDFQLEYKKIEIKDIDSVELYKENDRYRRYLSLSEAPTDYAKYFVKVKSDFKEMYLVPVKSITENTDGTYKVTVA
VDQLVEEGTDGYKDDYTFYVAKSKAEQPGVYTSFKQLVTAMQSNLGVYTLASDMTAEVSLGDKQTSYLTGAFTGSLIGSDG
TKSYAIYDLKKPLFDTLNGATVRDLDIKTVSADSKENVAALAKAANSANINNVAVEGKISGAKSVAGLVAATNTVIENSFT

GKLIANHQDSNKNNDTGGIVGNITGNSRVNKRVDALISTNARNNNQTAGGIVGRLENGALISNSVATGEIRNGQGYSRVGGI
VGSTWQNGRVNNVVSNDVGDGYVITGDQYAAADVKNASTSVDNRKADRFAKLKSKDQIDAKVADYGITVTLDDTGQDLKRNL
REVDYTRLNKAERKVAYSNIEKLMPPFNKDLVVHYGNKVATTDKLYTTELLDVVPMKDEVVTDINNKKNSINKVMLHFKD
NTVEYLDVTFKFNINSQVIEYNVTGKEYIFTPEAFVSDYTAITNNVLSDLQNVTLNSEATKKVLGAANDAALDNLVLDROFE
EVKANIAEHLRKVLAMDKSINTTGDGVVEYVSEKIKNNKEAFMLGLTYMNRWYDINYGKMNKDLSTYKFDNNGNETSTLDT
IVALGNSGLDNLASNTVGLYANKLASVKGEDSVDFVEAYRKLFLPNKTNNEWFKENTKAYIVEMKSDIAEVREKQESPTAD
RKYSLGVDYDRISAPSWGHSMLPLLTLPESVYISSNMSTLAFGSYERYRDSVDGVILSGDALRTYVRNRVDIAAKRHRDHY
DIWYNLLDSASKEKLFERSVIYDGFNVKDETGRTYWARLTDKNIGSIKEFFGPGVKWYFYNSSAGAYANGSLTHFVLDRLDLD
YGTSVYTHEMVHNSDSAIYFEGNGRREGLAGAELYALGLLQSVDSVNSHILALNTLYKAEKDDLNRHLTYNPFVERFDSDEALQS
YMHGSYDVMTLDAMEAKAILAQNNMDVKKWFRKIENYVVRDTRHNKDTAGNKRVRPLTDEEVANLTSLSNLIIDNDIINRRSY
DDSREYKRNYYTISMFSPVYAALSNSKGAPGDIIMFRKIAYELLAEGYHKGFLPYVSNQYGABAFASGSKTFSSWHGRDVAL
VTDDLVFKKVFNGEYSSWADFFKAMFKQRIDKQDNLPITIQYELGNPNSTKEVTITTAQMQLLINEAAKIDITNIDRATSH
TPASWVHLLKQKIYNAYLRITDDFRNSIYK

SeqID 149

MKFNPNQRYTRWSIRRLSVGVASVVVASGFFVLVGQPSVRADGLNPTPGQVLPBETSGETKEDLSEKPGDVTLTQAKPEGVT
GNTNSLPTPTERTTEVSEETSPSSLDTLFEKDEEAQKNPELTDVLKETVDTADVDGTQASPAETTPEQVKGGVKENTKDSIDVP
AAYLEKAEKGPPFTAGVNVQIPIYELFAGDGMLTRLLLKASDNAPWSDNGTAKNPALPPLEGLTKGKYFYEVLDNGNTVGKQGG
ALIDQLRANGTQTYKATVKVGNKDGKADLTNLVATKNVDININGLVAKETVQKAVADNVKDSIDVPAAYLEKAKGEGPFTAG
VNHVPIYELFAGDGMLTRLLLKASDKAPWSDNGDAKNPALSPLGENVKTGQYFYQVALDGNVAGKEKQALIDQFRANGTQTY
SATVNVYGNKDGKPDLDNIVATKKVTININGLISKETVQKAVADNVKDSIDVPAAYLEKAKGEGPFTAGVNVHPIYELFAGDGM
LTRLLLKASDKAPWSDNGDAKNPALSPLGENVKTGQYFYQVALDGNVAGKEKQALIDQFRANGTQTYSATVNVYGNKDGKPDLDNIVATKKVTIK
WSDNGDAKNPALSPLGENVKTGQYFYQVALDGNVAGKEKQALIDQFRANGTQTYSATVNVYGNKDGKPDLDNIVATKKVTIK
INVKETSDTANGSLSPSNSGSGVTMPMHNHATGTTDSMPADTMTSSTNTMAGENMAASANKMSDMMSEDKAMLPTGETQTS
MASIGFLGLALAGLLGGLGLKNKKEEN

SeqID 150

MKSITKKIKATLAGVAALFAVFAPSFVSAQESSSTYTVKEGDTLSEIAETHNTTVEKLAENNHIDNIHLIYVDQELVIDGPVAP
VATPAPATYAAAPAAQDETVSAPVAETPVVSETTVVSTVSGSEAEAKEWIAQKESGGSYTATNGRYIGRYQLTDSYLNNGDYSAEN
QERVADAYVAGRYGSWTAAKNFWLNGWY

SeqID 151

MNKKKMILTSLASVAILGAGFVTSQPTFVRAEESPOVVEKSSLEKKYEEAKAKADTAKKDYETAKKKAEDAQKKYEDDQKRTE
EKARKEAEASQKLNDAVAVQNAVKEYREVQNRQSKYKSDAEYQKKLTEVDSKIEKARKEQQDLQNKFNVRVAVVPEPNALA
ETKKKAEEAKAEKVAKRKYDYATLKVALLAKKEVEAKELEIEKLQYEISTLEQEVATAQHQVDNLKLLAGADPDGTEVIEA
KLKKGAEALNAKQAEAKKQTELEKLLDSLDPEGKTQDELDKEAEAEALDKADELQNKVADLEKEISNLEILLGGADPEDDT
AALQNKLAAKKAELAKKQTELEKLLDSLDPEGKTQDELDKEAEAEALDKADELQNKVADLEKEISNLEILLGGADSEDDTAA
LQNKLATKKAELEKTQKELDAALNELGPDGDEEETPAPAPQEQPAPAPKPEQAPAPAPKPEQAPAPAPKPEQAPAP
APKPEQAPKPEKPAEPTQPEKPATPKTGWKQENGWYFYNTDGSMAIGWLQNGSWYYLNANGAMATGWVKDGTWYYLEAS
GAMKASQWFKVSDKWYYVNSNGAMATGWLQYNGSWYYLNANGDMATGWLQYNGSWYYLNANGDMATGWAKVNGSWYYLNANGA
MATGWAKVNGSWYYLNANGSMATGWVKDGTWYYLEASGAMKASQWFKVSDKWYYVNGLGALAVNTTVDGYKVNANGEW

SeqID 152

MKKIVLVSLAFLFVLVCGGQKKETGPATKTEKDTLOSALPVIENAEKNTVVTKTLVLPKSDDGSSQQTQITTYKDTFLSLAIQ
QKRPVSDDELKTYIDQHGVEETQKALLEAEKDKSIIIBARKLAGFKLETLLSATELQTTTSFDFQVLDVKKASQLEHLKNIGL
ENLLKNEPSKYISDRLANGATEQ

SeqID 153

MFEVEEWLHRSRIGLNFRLGRLMGMQAVDILLGNPEQSYPPIHVTGTNGKGSTIAFMRELFMGHGKKVATFTSPHIVSINDRICI
NGQPIADADFIRLTDQVKEMEKTLTQTPAQLSFFELLTLVAFLYFREQEVLDVLEVGIGGLLDTNNVTGEFAVITSIGLDH
QETLGDLSLEAIAEQKAGIFKAGKKAIVIAKLPPPEARLACQKKAESLAVNLYQAGQDFLMLNGDFSSLLNLSQLNIGLEGVYQQ
ENAAALALQTFLLFMRERKEAVDEQAVRKALEQTHWAGRLERIRPQIYLDGAHNLPALTRLAEFIKEKEQEGYRPQILFGSLKR
KDYQGMGLGYLTEKLPQVELKVTGFDYQGALDERDVTGYDIVSSYREFISDFEERADAQDLLFVTGSLYFISEVRGYLLDREQI
N

SeqID 154

VGIRVYKPTTNGRRNMTSLDFAEITTSPEKSLVALKSKAGRNNNGRITVRHQGGGHRFYRLVDFKRKNKNVEAVVKTIEY
DPNRSANIALVHYTDGVKAYIIAPKGLEVGQRIVSGPEADIKVGNALPLANIPVGTLIHNIELKPGRGGELVRAAGASAQVLG
SEGKYVLVRLQSGEVRMILGTCRATVGVVGNQHGVLVNLGKAGRSRWKIRPTVRGSMVNPNDHPHGGGEGKAPVGRKAPSTP
WGPALGLKTRNKKAKSDKLIVRRRNEK

SeqID 155

MAKKSMAVAREAKRQKIVDRYAEKRAALKAAGDYEGLSKLPNASPTRLHNRCRVTRGRPHSVYRKFGLSRIAIFRELAHKGQIPG
VTKASW

SeqID 156

MDIRQVTTETIAMIEEQNFDIRTITMGISLLDCIDPDINRAAEKIYQKITTKAANLVAVGDEIAAELGPIVKNKRVSVTPISLI
GAATDATDYVVLAKALDKAAKEIGVDFIGGFSALVQKGYQKGBEILINSIPRALAETDKVCSSVNIIGSTKSGINMTAVADMGR
IIKETANLSDMGVAKLVVFANAVEDNPFMAGAFHGVGEADVINVGVSGPGVVKRALEKVRGQSFVVAETVKKTAFAKITRIG
QLVQGMASERLGVFEFVIDLSLAPTAVGDSVARVLEEMGLETVGTHGTTAALALLNDQVKKGGVMACNQVGGLSGAFIPVSE
DEGMIAAVQNGSSLNLEKLEAMTAICSVGLDMIAIPEDTPAETIAAMIADAAIGVINMKTAVRIIPKGKEGDMIEFEGGLLGT
APVMKVNAGASSVDFISRGQIPAPIHSFKN

SeqID 157

MVNTFVARTTIKTEYFGSLTERMNKYREDVLNKKPYIDAERAVLATRAYERYKEQPNVLKRAYMLKEILENMTIYIEEESMIA
GNQASSNKDAPIFPEYTLFVLNEDLFEKRDGDVFIYIETETKEQLRSIAPFWEMNNLRARAGALLPEEVSVMETGFFGMEG
KMNSGDAHLAVNYQKLLQFGLRGFEERARKAKVALDLTDPASIDKYHFYDSIFIVIDAIKVYAKRFVALAKSLAENANPKRKK
ELLEIADICSRVPYEPATTFAEAIQSVWFIQCILQIESNGHSLSYGRFDQYMPYMKADLESGETEDSIVERLTNLWIKTTIT
INKVRSQSHTFSSAGSPYQNVITIGGQTRDKKDAVNPLSYLVLSVAQTHLPQPNLTVRYHAGLDARFMNECEIVMKLGFGMP
AFNNDIEIIPSPFIAGVLEDDAYDYSAGCVETAVPGKWGYRGTGMSYMNFPKVLITMNDGIDPASGKRFAFSPGRFKDMKN
FSELENAWDKTLRYLTRMSVIVENSIDLSLREVPDILCSALTDDCIGRGKHLKEGGAVDYDISGLQVGIANLSDSLAAIKKL
VFEEERISPSQLWHALETDYAGEEGKVIQEMLIHDAPKYGNDDYADKLVTAAVDIYVDEIAKYPNTRYGRGPIGGIRYSGTS
SISANVGGQGRGTLATPDGRNAGTPLAEGCSPSHNMDOHGPTSVLKS SVKLPDTEIVGGVLLNQKVNQPTLAKBEDKLLKLIALL
RTFFNRLHGYHIQYNNVVSRETLIDAQKHPEKHRDLIVRVAGYSAFFNVLSKATQDDIIGRTEHTL

SeqID 158

MSQAQYAGTGRKNAVARVRLVPGTGKITVNKKDVEEYIPHADLRLVINQPFVAVTSTVGSYDVFNVIGGGYAGQSGAIRHGI
ARALLQVDPDFRDSLKRAGLLTRDSRKVERKKPGLKKARKASQFSKR

SeqID 159

LEKKLTIKDIAEMAQTSKTTVSFYLNKGYEKMSQETREKIEKVIHETNYKPSIVARSLSNKRKTLIGVLIGDITNSFSNQIVK
GIEDIASQNGYQVMIGNSNYSQSEEDRYIESMLLLGVDFIIQPTSNFRKYSRIIDEKKKKMVFFDSQLYEHRTSWVKTNNDY
AVYDMTQSCIEKGYEHFLITADTSRLSTRIERASGFVDALTDANMRHASLTIEDKHTNLEQIKEFLQKEIDPDEKTLVFIPN
CWALPLVFTVIKELNYNLPQVGLIGFDNTEWTCFSSPSVSTLVQPSFEEGQQATKILIDQIEGRNQEERQOVLDCSVNWKEST
F

SeqID 160

MNKGLEFEKRCYKSIKFKSLGVASVMIGAAFFGTSPVLADSVQSGSTANLPADLATALATAKENDGRDPEAPKVGEDQGSPEVT
DGPKEEELLALKEKEKPAEEKPKEDKPAAPKPKTPTPEWQTVANKEQQGTVTIREKGVRYNQLSSSTAQNNDNAGKPALE
KKGLTVDANGNATVDLTFFKDDSEKGSRFQVFLKFKDTKNNVFGYDKDGFWEYKSPPTSTWYRGSRAVAPETGSTNRLSIT
LKSDGQLNASNNDVNLFDVTPLPAAVNDHLKNEKKILLKAGSYDDERTVVSVKTDNQEGVKTEDTPAEKETGPEVDDSKVTYD
TIQSKVLKAVIDQAFPRVKEYSLNGHTLPGQVQVQFNQVFINNHRITPEVTYKKINETTAEYLMKLRDDAHLINAEMTVRLQVV
DNQLHFDVTKI VMHNQVTPGQKIDDESILLSSISFLGNALVSVSSNQTAGKFDGATMSNTHVSGDDHIDVTNPMKDLAKGYM
YGFVSTDKLAAGVWSNSQNSYGGGSNDWTRLTAYKETVGNANYVGIHSSSEWQWEKAYKGI VFPPEYTKELPSAKVVITEDANAD
KNVDWQDGALEYRSIMNNPQGWEEKVKDITAYRIAMNFGSQAQNFVGLMTLDGIKKINLHTDGLGQGVLLKGYGSEGHDSGHLNY
ADIGKRIGGVEDFKTLIEKAKKYGAHLGIHVNASETYPESKYFNEKILRNKPDGSYSYGNWLDQGINIDAAYDLAHLRLARW
EDLKKKLGDLDFIYVDVWNGQSGDNGAWATHVLAKINKQGRFAIEWGHGGEYDSTFHHWAADLTGGYTNKGINSAITR
FIRNHQKDAWVGDRSYGGAANYPLLGGYSMKDFEGWQGRSDYNGYVTNLFAHDVMTKYFQHFTVSKWENGTPVTMTDNGSTY
KWTPEMRVELVDADNNKVVTRKSNVDNSPQYRERTVTNLNGRV IQDGSAYLTPWNWDANGKKLSTDEKEMMYFNTQAGATTWT
LPSPWAKSKVYMLKLTQDKTEEQELTVKDGKITLDDLANQPYVLYRSKQTNPEMSWSEGMHIYDQGFNSGTLKHWITISGDAS
KAETVKSQGANLMLRIQGNKEKVS LTQKLTGLKPNTKYAVYVGVNDNRNSNAKASITVNTGEKEVTTYTNKSLALNYVKAYAHNT
RRDNATVDDTSYFQNMAYFFTADVSNVTLTSLREAGDQATYFDEIRTFENSSMYGDKHDTGKGTFFKQDFENVAQGIFFPV
VGGVEGVEDNRTLSEKHNPYTQRGWNGKKVDDVIEGNWSLKTNGLVSRRLVYQTI PQNFRFEAGKTYRVTFEYAGSDNTY
AFVVGKGEFGQSGRRGTQASNLEMHEL PNTWTD SKKAKATFLVTGAETGDTWVGIYSTGNASNTRGDSGGNANFRGYNDFMMD
NLQIEBITLTGKMLTENALKNYLPTVAMTNYTKESMDALKEAVFNLSQADDISVEEARAEIAKIEALKNALVQKKTALVADD
FASLTAPAQAQEGLANAFDGNVSSLWHTSWNGGDVGKPATMVLKEPTEITGLRYVPRGSGSGNGLRDVCLVVTDESGKHTFT
ATDWPNNKPKDIDFGKTIKAKKIVLTGKTYGDGDKYQSAABELIFTRPQVAETPLDLSGYEALVKAQKLTDKDNQEEVAS
VQASMKYATDNHLLTERMVEYFADYLNQLKDSATKPDAPTVEKPEFKLRLASEQKTPDYKQEIARPETPEQILPATGESQS
DTALILASVSLALSALFVVKTKD

SeqID 161

MNKPTILRLIKYLSISFLSLVIAAIVLGGGVFFYYVSKAPSLSESKLVATTSSKIYDNKNQLIADLGSERRVNAQANDIPTDL
VKAIVSIEDHRFFDHRGIDTIRILGAFLRLNQSNSLQGGSTLTQQLIKLTYFSTSTSDQTI SRKAQEAWLAIQLEQKATKQEI
LTYINKVYMSNGNYGMQTAAQNYGKDLNNLSLPQLALLAGMPQAPNQYDPYSHPEAAQDRRLVLSEMKNQGYISAEQYK
AVNTPITDGLQSLKSASNYPAYMDNYLKEVINQVEEFTGYNLLTGMVDVYTNVDQEAQKHLWDIYNTDEYVAYPDELQVAST
IVDVSNGKVIAQLGARHQSSNVSGINQAVETNRDWGSTMKPI TDYAPALEYGVYDSTATIVHDEPNYPGTNTFPVYNWDRGY
FGNITLQYALQQSRNVPAVETLNKVGLENRAKTFNLGLGIDYPSIHSNAISSNTTESDKKYGASSEKMAAAYAFANGGTYYK
PMYIHKVVFSDGSEKEFSNVGTRAMKETAYMMTDMKTVLTYGTGRNAYLAWLPQAGKTGTSNYTDEEIHKTSSQFVAPD
ELFAGYTRKYSMAVWTGYSNRLTPLVGNLTVAKVYRSMMTYLSSEGSNPEDWNIPEGLYRNGEFVFKNGARSTWNSPAPQQP
PSTESSSSSSSSTSQSSSTTPSTNNSTTNPNNNNTQQSNTTTPDQONQNPQAPQ

SeqID 162

MSKKRRNRHKKEQEPQDFDEAKELTVGQAIRKNEEVESGVLPEDSILDKYVKQHRDEIEADKFATRQYKKEEFVETQSLDD
LIQEMREAVEKSEASSEVPSSSEDILLPLPLDDEEQGLDPLLLDDENPTMTEEEVEEQNLSRLDQEDSEKKSKRGFILTILA

MKNPFFERRCRYSIKRLSVGACSLMIGAVLFGAPALAEETAVPENSANTELVSGESEHSTNEADKQNEGEHARENKLEKABG
VALIASETASPASNEAATTETAEAAASAKPEEKASEVVAETPSAEAKPKSDKETEAKPEATNQGDSEKPAAEANKTEKEVQPDV
PKNTEKTLKPKEIKFNSWHEELKWEPEGAREDDAINRGSVVLASRRRTGHLVNEKASKEAKVQALSNTNSKAKDHASVGGEEFKA
YAFDYWQYLDMSMVFEGLVPTPDVIDAGHRNGVPVYGTLFNFWSNSIADQERFAEALKQDADGSFPIARKLVDMAKYGYDGY
FINQETTGDGLVKPLGEGKMRQFMLYSKEYAAKVNHPIKYSWYDAMTYNYGRYHQDGLGEYNYQFMQPEGDKVPADNFFANFNWD
KAKNYTTIATANWIGNRPYDVFAGLELQGGGSYTKVKVNDILDENGKRLSLGLFAPDITISLGKTGEDYHKNEIDFFTGQY
GDPTGQKPGDKDWYGIANLVADRTPAVNGTFTTSFNTGHGKKVFDGKVKSDSEWNYRSVSGVLPTWRWWQTSSTGEKLRAEYD
FTDAYNGGNSLKFSGDVAGKTDQVRLYSTKLEVTETKRLVAHKGKGSKVMAFSTTPDYKFDVDDAKWELTLDSDNWNEE
FDLSSLAGKTIYAVKLFFEHEGAVKDYQFNLGQLTISDNHQEPQSPTSFSVVKQSLKNAQAEAEAVQFKGNKADFYEVYEKD
GDSWKLLTGSSTTIYLPKVSRSASAQGTTOELKVAVGKNGVRSEAAATTTFDWGMTVKDTSLPKPLAENIVPGATVIDSTFP

KTEGEGEGIEGMLNGTITSLSDKWSSAQLSGSVDIRLTKPRTVVRVWMDHAGAGGESVNDGLMNTKDFDLYYKDADGEWKLAK
VRGNKAHVTDITLDKPITAQDWRNLNVVTSNDNGTPWKAIRIYNWKMYPEKLDTESVNI PMAKAAARS LGNNKVQVGFADVPAGAT
ITVYDNPNSQTPLATLTKSEVGGDLASAPLDLTNQSGLLYYRTQLPGKEISNVLA VSVPKDDRRIKSVSLETGPKKTSYAEGED
LDLRGGVLRVQYEGGTDELIRLTHAGVSVSGFDTHHKGEQNLTLQYLQGPVNANLSVTVTGQDEASPKTILGIEVSQEPKKD
YLVGDSLDSLSEGRFAVAYSNDTMEHSFTDEGVEISGYDAQTKGRQTLTLHYQGHEVSVFDVLVSPKAAALNDEYKQKLAEVEA
AKNKKVYNFASSEVKEAFLKAEAAEQVLKDHTSTQDQVNDRLNKLTEAHKALNGQEKFTTEKTELDRLTGFEVQELLAAKPN
HPSGSALAPLLEKNKALVEKVDLSPEELTTAKQSLKDLVALLKEDKPAVFSDSKTGVEVHFSNKEKTVIKGLKVERVOASAE
KKYFAGEDAHVFEIEGLDEKGQDVLDSYASIVKIPKEDKKVKKVFFLPEGKEAVELAFEQTD SHVIFTAPHFTHYAFVYESA
EKPQPAKPAQNTVLPKPTYQPTSDQQKAPKLEVEQEEKVAFHRQEHENTEMLVGEQRVIIQGRDGLLRHVFEVDENGQRRLRS
TEVIQEAIP EIVEIGTKVKTVPVAVATQEKPAQNTAVKSEASKQLPNTGTADANEAL IAGLASLGLASLALTLRRKREDKD

SeqID 171

MSITSFVKRIQDITRNDAGVNGDAQRIEQMSWLLFLKIYDSREMVELEDEYESI IPEELKWRNWAHAQNGERVL TGDELLD
FVNNKLFKELKELEITSNMPKIRKTI VKS FADANNYMKNGVLLRQVINVIDEVD FNSPEDRHSFNDIYEKILKDIQNAGNSGE
FYTPRAATDFIAEVLDPKLGESMADLACGTGGFLTSTLNRLLSSQRKTS EDTKKYNTAVFGIEKKAFFPHLLAVTNLFLHEIDDP
KIVHGNTLEKNVREYTDDEKFDIIMNPPFGGSELETIKNNFPAELRSSETADLFMAVIMYRLKENGVRGVILPDGFLFGEGV
KTRLKQKLVD EFNLHTIIRLPHSVFAPYTG IHTNLFFDKTKTEETWFYRLDMPDGYKNFSKTKPMKSEHFNVRDWWENRE
EILEGKFYKSKSFTPS ELAELNYNLDQCDPKEEEEILNPFELIQNYQAERATLNHKIDNVLADILQLLEDK

SeqID 172

MNNTFEYDRLGVSKNASADEIKKAYRKL SKKYHPDINKEPGAEDKYKEVQEA YETLSDDQKRAAYDQYGAAGANGGFGGAGGF
GGFNGAGGFGGFEDIFSSFFGGGSSRNPNAPRQGGDLQYRVNLT FEEAIFGTEKEVKYHREAGCRT CNGSGAKPGTSPVTCG
RCHGAGVINVD TQTPLGMMRRQVTCDVCHGRGKEIKYPC TCHGTGHEKQAHSVHVKIPAGVETGQQIRLAGQGEAGFNGGFPY
GDLYVVVSVEASDKFEREGTTIFYNLNLNFVQAALGDTVDIPTVHGDVELVIPEGTQTGKKFRLRSKGAPSLRGGAVGDQYVT
VNVVPTPTGLNDRQKVALKEFAAAGDLKVNPKKKGFFDHIDAFDGE

SeqID 173

MNPNLFRSVEFYQRRYHNYATVLIIPLSLLFTFILIFSLVATKEITVTSQGEIAPTSVIA SIQSTSDNPILANHLVANQVVEK
GDLLIKYSETMEESQKTALATQLQRLEKQKEGLGILKQSLEKATDLFSGEDEFYHNTFMNFTKQSHDIELGITKTNTVEVSNQ
ANLSNSSSSAIEQEITKVOQQIGEYQELRDAIINNRRARLPTGNPHQSILNRYLVASQGGTQGTAEFPFLSQINQSIAGLESSI
ASLKIQQAGIGSVATYDNSLATKIEVLRTQFLQTASQQQLTVENQLTELKVQLDQATQRL ENNTLTSPSKGIVHLNSEFEGKN
RIPTGTETIAQIFPVITDTREVLITYYVSSDYLPLLDKGQTVRLKLEKIGNHGT TIIGQLQTIDQTPTRTEQGNLFKLTALAKL
SNEDSKLIQYGLQGRVTSVTTKKTFFDYFKDKILTHSD

SeqID 174

MSKKNLNRKQLRNLRRAGAFSSVTVKVDETCKVVKRAEQSASAAKAVSKKVEQAVEATKEQAQKVANSVEDFAANLGGLP
LDRAKTFYDEGIKSASDFKNWTEKELLALKGIGPATIKKLKENGIKFK

SeqID 175

LISLFLGAAAKPVQADTSIADIQKRGELVVGKQDVPNFGYKDPKGTGYSIETDLAKMVADELKVKIRYVPVTAQTRGPLLD
NEQVMDIATFTTITDERKKLYNFTSPYYTDASGFLVNKSAKIKKIEDLNGKTIGVAQGSITQRLITELGKKKGLKFKFVELGS
YPELITSLHAHRIDTFSVDRSILSGYTSKRTALLDDSFKPSDYGIVTKKSNTLNDYLDNLVTKWSKDGSLQKLYDRYKLPKS
SHTAD

SeqID 176

MSNISLTTLGGVRENGKNMYIAEIGESIFVLNVGLKYPENEQLGVDVVI PNMDYLFENS DRIAGVFLTHGHADAIGALPYLLA
EAKVPVFGSELTIELAKLFVKGNDAVKKFNDFHVIDENTEIDFGGTVVSFFPTTYSVPESLGIVLKTSEGSIVYTGDFKFDQT
ASESYATDFARLAEIGRDGVLALLSDSANADSNIQVASESEVRDETQTOTIADWEGRII VAAVSSNLSRIQQIFDAADKTGRRI
VLTGFDIENIVRTAIRLKLKSLANEILLIKPKDMSRFEDHELIILETGRMGEPINGLRKMSIGRHYRYVEIKDGDVLVIATAPS
IAKEAFVARVENMIYQAGGVVKLITQSLHVS GHGNVRDLQMLINLLQPKYLPVQGEYRELD AHAAMA VGMPLPERIFIPKK
GTTMAYENGDFVPAGSVSAGDILIDGNAIGDVGNVLRDLRQKVLSEDGIFIVAITVNRREKKI VARARVHTRGFVYLKSRDIL
RESSELINQTV EYELQGD DFDWADLKGKVRDNLTKYLFQDQTKRRPAILPVVMEAK

SeqID 177

MKKSTVLSLTAAVILAAYAPNEVV LADTSSSEDALNISDKEKVAENKEKHENIHSAMETSQDFKEKKTAVIKEKEVVSKNPV
IDNNTSNEEAKIKEENS NKSQGDYTD SFVNKNTENPKKEDKVVIYAEFKDKESGEKA I KESSLKNTKVLYTYDRI FNGSAIE
TTPDNLDKIKQIEGISSVERAQKVQPMNHARKEIGVEEAIDYLSINAPFGKNFDGRGMVISNIDTGTDRHKAMRIDDDAK
ASMRFKKEDLKGTDKNYWLSDKIPHAFNYNGGKITVEKYDDGRDYDFPHGMH IAGILAGNDTEQDIKNFNGIDGIAPNAQIF
SYKMYSDAGSGFAGDETMFHAIEDSIKHNVVSVSSGFTGTGLVGEKYWQAIRALRKAGIPMVVATGN YATSASSSSWDLVA
NNHLKMTDTGNVTRTA AHEDAIAVASAKNTVEFDKVNIGGESFKYRNIGAFFDKSKITTNEDGTKAPSKLKFVYIGKGQDQD
LIGLDLRGKIAVMDRIYTKDLKNAFKKAMDKGARAIMVNTVNYNRDNWTELPAMGYEAD EGTQSQVFSISGDDGVKLWNMI
NPDKKTEVKKRNKEDFKDKLEQYYPIDMESFNSNKPVNDEKEIDFKFAPDPTDKELYKEDIIVPAGTSWGPRI DILLKLPDVS
APGKNIKSTLNVINGKSTYGYMSGTSMATPIVAASTVLIRPKLEMLERPVLKNLKGDDKIDLTSLTKIALQNTAREPMDATS
WKEKSQYFASPRQQAGLINVANALRNEVVATFKNTDSKGLVNSYGSISLKEIKGDKKYFTIKLHNTSNRPLTFKVSASAITT
DSLTDRLKLD ETKDEKSPDGKQIVPEIHPEKVKGANITFEHDTFTIGANSSFDLNAVINVGEAKNKNKFVESFHFESVEEM
BALNSNGKKINFQPSLSMLMGFAGNWNHEPILDKWAWEEGSRSKTLGGYDDDGKPKIPGTLNKGIGGEHGIDKFPNAGVIQ
RKDKNTTSLDQNP ELFAFNNEGINAPSSSGSKIANIYPLDSNGNPQDAQLERGLTPSPVLVRS AEEGLISIVNTNKEGENQD
LKVISREHFIRGILNSKSNDAKGIKSSKLKVWGD LKWDGLIYNPRGREENAPESKDNQDPATKIRGQFEPIAEGQYFYKFKYR

LTKDYPWQVSYIPVKIDNTAPKIVSVDFSNPEKIKLITKDTYHKVKDQYKNETLFARDQKEHPEKFDEIANEVWYAGAALVNE
DGEVEKNLEVTYAGEGQGRNRKLDKDGNTIYEIKGAGDLRGKIIIEVIALDGSSNFTKIHRIKFANQADEKGMISYLLVDPDQD
SSKYQLGEIAESKPKNLGNGKEGSLKDDTTGVEHHHQENEESEIKESSFTIDRNISTIRDFENKDLKKLIKFKFREVDFTS
ETGKRMEEYDYKYDDKGNIIAYDDGTDLEYETEKLDEIKSKIYGVLSPSKDGHFELGKISNVSKNAKVYVGNKYSEIKAT
KYDFHSKTMTFDLYANINDIVIDGLAFAGDMRLFVKDNDQKAEIKIRMEPEKIKETKSEYPYVSSYGNVIELGEGDLKKNKPDN
LTKMESGKIYSDSEKQQLLDKNIILRKGYALKVTTYNPCKTMDLENGVYSKEDIKIQKANPNLRALSETTIYADSRNVED
GRSTQSVLMSALDGFNIIRYQVFTFKMNDKGEAIDKDGNLVTDSSKLVLFKGDDKEYTGEDKFNVEAIKEDGSMFLDITKPVN
LSMDKNYFNPSKSNKIYVRNPEFYLRGKISDKGGFNWELRVNESVVDNYLIYGDLDHIDNTRDFNKLNVKGDIMDWGMKDYK
ANGFPDKVTMDGNVYLQGTGYSDLNAKAVGVHYQFLYDNUKPEVNIDPKGNTSIEYADGKSVVFNINDKRNNGFDGEIQEHI
YINGKEYTSFNDIKQIDKTLNLIKIVVKDFARNTTVKEFILNKDTGEVSELKPHRVTVTIQNGKEMSSTIVSEEDFILPVYKG
ELEKGYQFDGWEISGFEGKKGADAGVYNLSKDTFIKPVFKIEEKEEENKPTFDVSKKKNPNQVNHSQLNESHKEDLQREEH
SQKSDSTKDVTTATVLDKNNISSKSTNNPNKLPKTGTASGAQTLAAGIMFIVGIFLGLKKKNQD

SeqID 178

MGKGHWNRKRVYSIRKFAVGACSVMIGTCAVLLGGNIAGESVYVYADETLITHTAEPKPEEKMIVEEKADKALETKNIVERTEC
SEPSSTEAIASEKKEDEAVTPKEEKVSAPKEEKAPRIESQASNQEKPLKEDAKAVTNEEVNQMIEDRKVDNFQNWYFKLNANS
KBAIKPDADVSTWKKLDLPYDWSIFNDFDHESPAQNEGGQLNGGEAWYRKTFKLDEKDLKKNVRLTFDGVYMDSQVYVNGQLV
GHYPNGYNQFSYDITKYLQKDGRENVIHAVHNKQSSRWYSGSGIYRDVTLQVTDKVHVEKNGTTILTPKLEEQQHGKVEVE
VTSKIVNTDDKDELVAEYQIVERGGHAVTGLVRTASRTLKAHESTSLDAILEVERPKLWTVLNDKPALEYELTRVYRDGQLV
DAKKDLFGYRYHHWTNNEGFLNGERIKFHGVSLLHHDHGALGABENYKAEYRRLKQMKEMGVNSIRTTNHPASEQTLQIAAEI
GLLVQEEAFDTWYGGKPYDYGRFFEKDATHEARKGEKWSDFDLRTMVERGKNNPAIFMWSIGNEIGEANGDAHSLATVKRI
VKVIKDVMTKTRYVTMGADKFRFGNGSGGHEKIADELDAWGFNYSEDNYKALRAKHPKWLIIYGETSSATRTGSSYRPERELR
HSNGPERNYEQSDYGNDRVWGKGTATASWTFDRDNAGYAGQFIWGTGTYIGEPTPHNQNQTPVKSSYFGIVDTAGIPKHDFY
LYQSQWVSVKKKPMVHLLPHWNWENKELASKVADSEGKIPVRAYSNASSVELFLNGKSLGLKTFNKKQTSRGTYQEGANANE
LYLEWKVAYQPGTLEAIARDESKEIARDKITTAGKPAAVRLIKEDHAIADGKDLTYIYVEIVDSQGNVPTANNLVRFLQLE
GQGQLVGVNDGEQASREYKAQADGWSIRKAFNGKGVAIVKSTEQAGKFTLTAHSDLLKSNQVTVFTGKKEGQEKTVLGTVEI
KVQTIIGEAEMPTTVFVYSDGSRAERPVTWSSVDVSKPGIIVTVKGMADGREVEARVEVIALKSELPPVKRIAPNTDLNSVI
KSVSYVLIDGSVEEYEDVKWEIAEEDKAKLAIPGSRIQATGYLEGQPIHATLVVEEGNPAAPAVPTVTVGGEAFTGLTSQKPM
QYRTLAYGAKLPEVTASAKNAAVTVLQASAANGMRASIFIQPKDGGPLQTYAIIQFLEEAPKIAHLSLQVEKADSLKEDQTVKI
SVRAHYQDGTQAVLPADKVTFTSTSGEVEAIRKGMLELHKPGAVTLNAYEGAKDQVELTIQANTEKKIAQSIRPVNVVTDLF
QEPSPATVTVYDYKGFPKTKHVTWQAIPEKCLDSYQTFEVLGKVEGIDLEAKVSVVEGIVSVVEVSVTTPIAEAPQLPESV
RTYDSNGHVSSAKVANDAIRPEQYAKEGVFTVNGRLEGTQLTKLHVRSVAQTEQGANSIQWTGSELPLAFASDSNPSDPVE
NVNDKLISYNNQANRWNTNWRNTPNASVGVLFQDGSILSKRSVDNLSVGFHEDHGVGVKPSYVIEYVVGKTVTAPKNPSF
GNEDHVFNDSANWKPVTNLKAPAKQKAGEMNHFSFDKVTYAVRIRMVKADNKRGTSTIEVQIFAKQVAAKQQTTRIQVDFG
DLANFNPDLDYYLESDGKVPVATASVSNNGLATVVPVSVREGEPPVRVIAKAENGDIIGEYRLHFTKDKSLLSHKPVAAVKQ
RLQVGOALELPTKVPVYFTGKDGVEYTKDLTVEWEEVPAENLTAKAGQTVRGRVLGSLNVAEITVRVTDKLGFTLSDNPNYDI
NSNQAFASATNDIDKNSHDRVYLDNDGHSNRRWTNWSPTSSNPEVSAGVIFRENGKIVERTVQGVQFPADSGTDAPS
LVLERVYVGEFVPTYSYQAYDADHPFNPNENWEAVPYRADKIDAGDEINVTFKAIKAKAMRWRMERKADKSGVAMIEW
FLAPSELQBSTQSKILVDGKELADFAENRQDYQITTKGQRPKVSVEENNQVASTVVDSEDSFPVLVRLVSESGKQVEYKRI
HLTKEKPVSEKTVAAVQEDLPKIEFVEKDLAYKTVEKKDSTLYLGETRVEQEGKVGKERIFTAINPDGSKEEKLREVVEVPTI
RIVLVGTPKPAQEAQKPVSEKADTKPIDSSASQTNKAQLPSTGSAASQAQVAAAGLTLGLSAGLVVTKGKKED

SeqID 179

MAPSVVDAATYHYVNKEIISQEAQDLIQTKGKPDRENVVYGLVYQKQDLPQTGTASVLTAFGLLTGVSLLLLIYKRKKIASVFI
VGAMGLVVLPSAGAVDPVATLALASREGVMEGYRYVGYLSDGILKTLGLDVTLEETSAKPGEVTVVEVETPQSITNQEQAI
TENQVVEETERAPKEEAPKTEESPKKEPKSEVKPTDDTLPKVEEGKEDSAEPAPVEEVGGEVESKPEEKVAVKPSQPSDKPAI
ESKVEQAGEVPAPREDEKAPVEPEKQPEAPEEKEAVEETPKQESTPDTKAETVEPKEETVNQSIQPKVETPAVEKQTEP
EEPKEVQAGEVPAPREDEQAPTAPVEPEKQPEVPEEKEAVEETPKPEDKIKGIGTKEPVDKSELNNQIDKASSVSPTDYSTA
YNALGPVLETAAGVYASEPVKQPEVNSETNKLKTAIDALNVKTELNNIADAKTKVKEHYSDRSQNLQTEVTKAEKVAAN
DAKQSEVNEAVEKLTATIEKLVELSEKPIILTLSTDKKILEREAVAKYTLENQNKTKIKSITAELEKKEEVINTVVLTDKVT
TETISAAFNLEYKEYTLSTTMIYDRNGEETETLENQNIQLDLKKVELKNIKRTDLIKYENGKETNESLITTIPTDKSNY
LKITSNNQKTTLAVKNIEETTNGTFVYKVTAIADNLVSRADNKFEEYVHYIEKPKVHEDNVYVNFELVEAIQNDPSKI
YRLQGSMSARNVVPNGKSYITKEFTGKLLSSEKQFAITELEHPLFNVITNATINNVPENVEIERSGQDNIASLANTMKGS
VITNVKITGTLSSGRNNVAGFVNMNDGTRIENVAFFGKLHSTSGNGSHTGGIAGTNYRGIVRKAYVDAITGNKTRASLLVPI
VDYGLTLDLHLIGTKALLTESVVKGIDVSNPVEVGAIAASKTWPVGTVSNVSVYAKIIRGEELFGSNDVDSYASAHIKDLV
VEGYSSGNRSFRKSKTFTKLTKEQADAKVTTFNITADKLESLSPLAKLNEEKAYSSIQDYNAEYNQAYKNLEKLIIPFYND
IVYQGNKLNKEHHLNTEKVLSTAMNNNEFITNLDEANKIIVHYADGTDYFNLSSSSEGLSNVKEYTITDLGIKYTPNIVQ
DNTTLVNDIKSILESVELQSQTMYQHLNRLGDYRVNAIKDLVLEESFTDVKENLTLTKLVQNEEHQLNDSAPARQMIKDK
EKNAALLGLTYLNRYYGVKFGDVNIKELMLFKPDFYGEKVSVDRLIEIGSKENNIKGSRTFADFQVLAKYTKSGNLDAL
LNNRQLFTNIDNMDFIDATEDHVYIAERASEVEEIKNSKHRAFDNLKRSHLNTLLPLNIDKAHLYLISYNAIAFGS
ERLGKKSLEDIKDIVNKADGVRNYDFWYRLASDNVQRLLRDAVPIWEGYNAPGGWVEKYGRYNTDKVYTPLEFFFGPM
KYNNYNGTGAYAAIYPSDDIRTDVKYVHLEMVGEYGISVYTHETHVNDRAIYLGFGHREGTDAAEYAAQGMQTPVTGSGI
DEFGSLGINNVFKRNDGNQWYITDPKTLKTREDINRYMKGYNDTLTLLEIEAESVISQONKDLNSAWFKKIDREYRDNNKI
NQWDKIRNLSQEEKNELNIQSVDNLVDQQLMTNRNPNNGIYKPEAISYNDQSPYGVVRMTGIYGGNTSKGAPGAVSFKHNAI
RLWGYGYENGFLGYASNKYKQSKTDGESVLSDEYIIKKISNNTFNTIEEFKKAYFKEVKDKATKGLTTFEVNGSSVSSYDI
LLTLFKEAVKKAETLQKANGNKTVSMNNTVKLKEAVYKLLQQTNSFKTSIFK

SeqID 180

MNKRFLSKMSLVTLPLILALFSQSVLAEENIHFSSCKEAWANGYSIDIHEGEPGYSAKLDRDHDGVACELKNAPKGAFKAKQSTA
IQINTSSATTSGWVKQDGAWYFFDGNLNVKNAWQGSYYLKADGKMAQSEWIYDSSYQAWYYLKS DGSYAKNAWQGA YYLKS
GKMAQGEWVYDSSYQAWYYLKS DGSYARNWQGNYYLKS DGSYAKNAWQGA YYLKS DGSYAYSTWQGNYYLKS DGSY
AVNEWVDGGRYVVGADGVWKEVQASTASSSNSNSSEYSAALGKAKSYNSL FHMSSKKRMYRQLTSD FDKFSNDAAQYAI DHDLD

SeqID 181

MKVIDQFKNKKVLVLGLAKSGESAARLLDKLGAIVTVNDGKPPEDNPAAQSLLEEGIKVITGGHPLELLDEEFALMVKNPGIF
YNNPMIEKALAKGIPVLTEVELAYLISEAPIIGITGSNGKTTTTT MIGEVLTAAGQHGLLSGNIGYPASQVAQIASDKDTLV
ELSSFQLMGVQEFHPEIAVITNLMPHIDYHGSFSEYVAAKWNIQNKMTAADFLVLNFNQDLAKDLT SKTEATVVPFSTLEKV
DGAYLEDGQLYFRGEVVMANIEIGVPGSHNVENALATIAVAKLRDNDQTIKETLSAFGGVKHRLQFVDDIKGVKFYNDKST
NILATQKALSGFDNSKVVLIAGGLDRGNEFDELVPDITGLKKMVLGQSAERVKRAADKAGVAYVEATDIADATRKAYELATC
GDVVLSPANASWDMYANFEVRGDLFIDTVAELEKE

SeqID 182

MKKKFALSFVALASVALLAACGEVKSAGVNTAGNSVEEKTIKIGFNFEESSGLAAYGTAEQKGAQLAVDEINAAGGIDGKQIE
VVDKDNKSETAEASVTNLVTQSKVS AVVGPATSGATAA VANATKAGVPLISPSATQDGLTKGQDYLFITGTFQDSFQGKII
SNYVSEKLNAAKVVLYTDNASDYAKGIKSFRESYKGEIVADETFVAGD TDFQAALTKMKGKDFDAIVVPGYYNEAGKIVNQA
RGMGIDKPIVGGDGFNGEEFVQQAATAEKASNIYFISGFS TTVEVS AKAKAFLDAYRAKYNEEPSTFAALAYDSVHLVANA AK
AKNSGEIKNNLAKTKDFEGVTGQTSFDADHNTVKTAYMMTMNNGKVEAAEVVKP

SeqID 183

MSILEVKNLSHGFGDRAIFEDVSFRLLKGEHIGLVGANGEGKSTFMSIVTGKMLPDEGKVEWSKYVTAGYLDQHSVLAERQSV
RDVLR TAFDEL FKAEBARINDLYMKMAEDGADVDALMEHVGEQDRLES RDTLD AKIDEVARALGVMDFGMDT DVTSLSGGC
RTKVL LAKL LLEKPDILLDEPTNYLDAEHIDWLKRYLQNYENAFVLISHDIPFLNDVINIVYHVENQQLTRYSGDY YQFQEV
YAMKKSQLEAAYERQKEIADLKDFVARNKARVATRN MAMSRQKKLDKMDIIELOSEKPKPSFDFKPARTPGRFIFQAKNLQI
GYDRPLTKPLNLTFFERNQKVAII GANGIGKTTLLKSLGII SPIAGEVERGDYLELGYFEQVEGNGRQTPLEAVWNAFPALN
QAEVRAALARCGLTTKHIESQIQVLSSGGEQAKVRFCLLMNRNNVVLVLEPTNHLDVDADKDELKRALKEYRGSILMVCHEPDI
YEGWIDQIWDFFNNLT

SeqID 184

MKKKNGKAKKWQLYAAIGAASVVVLGAGGILLFRQPSQTALKDEPHTLVVAKESVASSVLLSGTVTAKNEQYVYFDASKGDI
DEILVSVGDKVSEGGALVKYSSSEAQAAYDSASRAVARADRHINELNQARNEAASAPAPQLPAPVGGEDATVQSPTPVAGNSV
ASIDAQLGDARDARADAAAQLSKAQSQLDATTVLSTLEGTVEVNSNVSKSPTGASQVMVHIVSNENLQVKGELSEYNLANLE
VGQEVSTSKVYPDKKWTGKLSYISDYPKNNGEAASPAAGNNTGSKYPYTTIDVTGEVGD LKQGFVSNIEVKS KTKAILVPVSE
LVMDDSKNYVWIVDEQQA KAKKVEVSLGNADAENQETSGLTNGARVISNPTSSLEEGKEVKADEATN

SeqID 185

SETNHEIDS NFAGRLN ILRAGVLDANDGII SIAGVVIGVASATTNIWII FLSGFTAILAGAFSMAGGEYVS VSTPKDTEEA
SREKLLLDQDRELAKKSLYAAIYQNGEFKTS AQLLTN KIFLKNPLKALVERKYGIEYEFTNPWHAAISSFVAFFLRSLP
SVTIFPSDYRIPATVLI VGVALLLTGYTSARLGKAPKTAMIRNLAIGLLTMGVTFLLGQLFSI

SeqID 186

MKKKLTSLALVGAFGLSWYGNVQAQESSGNKIHFINVQEGGSDAIILESNGHFAMVDTGEDYDFPDGSDSRYPWREGIETS
KHLVLTDRVFRRLKELGVQKLD FVLVTHTHSDHIGNVDELLSTYPVDRVYLKKSYSRITNSERLWDNLGYDKVLQTAEEKG
SVIQNTIQGDAHFQFGMDIQLYNYENETDSSGELKKIWDNDSNLSISVVKVNGKKIYLGDDLNVHGAEDKYGLPIGKVDL
KFNHHHTNKSNTKDFIKNLSPSLIVQTSDSL PWKNGVDSEYVNW LKERGIERINAASKDYDATVFDIRKDG FVNISTSYKP
PSFQAGWHKSAYGNWWYQAPDSTGEYAVGWNEIEGEWYFFNQTGILLQNWKKWNNHWFYLTDSGASAKNWKKIAGI WYFFN
ENQMEIGWIQDKEQWYYLDVDGSMKTGWLQYMGQWYFAPSGEMKMGWVKDKETWY YMDSTGVMTGTEIEVAGQHYYLED SGF
MKQGW HKKANDWYFYKT DGSRAVGWIKDKDKWYFLKENGQLLVNGKTPEGYTV DSSGAWLVDSIEKSATIKTTS HSEIKES
EVVKDLENKETSQHESVTNFSTSQDLTSSTSQSSETSVNKSESEQ

SeqID 187

MDLGPTQRGISVVSQS YINVIAGLAGSEAA YQIAERGIPVKLYEMRGVKSTPQHKT DNFAELVCSNSLRGDAL TNAVGLLKE
EMRRLGSVILESAEATRV PAGGALAVDRDGF SQMVTEK VANHPLIEVVRDEITELPTDVTIATGPLTSDALAEKIHALNDG
AGFYFYDAAAPIIDVNTIDMSKVYLKSRDYKGEAA YLNAPMTKQEFMD FHEALVNAEEAPLS SFEKEKYFEGCMP IEVMAKRC
IKTMLYGPMKPVGLEYPDDYTGPRDGEFKTPYAVVQLRDNAAAGSLYNIVGFQTHLKWGEQKRVFQMI PGLENAEFVRGVMF
RNSYMDSPNLL EQTYRSKKQPNLFFAGQMTGVEGVVESAASGLVAGINARLFKEESEAI FPETTAIGSLAHYTHADSKHFC
PMNVNFIIKELEGERIRD KARYEKIAERALADLEEF LTV

SeqID 188

MLIGIPKEIKNNENRVALTPAGVHSLVSRGHRVLIETNAGLGS GF TADYQKQGA EIVATAGEAWAAELVVKVKESLSSEYGY
LRDDLLLF TYLHMAA APELADAMLTAKTTETVRDNQQLPLLVPMSEVAGRMVQIGAHFLTQAGGSGVLLGGVPGVPKGK
TIIGGGVVGTHAARIALGLGAQVTTILDISSKRLSVLEEVFGS QIQTLMSNSFNIEASVRDADVVIGAILIPGAKAPELVTTDEN
VKQMRPGSVSLTLLLT KVALSKQLTVQRTMNPMSMKNVTVFSTMPLEISLVRLLALQSPSPMSLFLISKWLAKDSHKQSLKMKF
CVKVL LKIVTLTYQLLKD LITVTTLSMT

SeqID 189

MKINKKYLKAGSVAVLALSVCSEYELGRHQAGQVKKESNRVSYIDGQAGQKAENLTPDEVSKREGINAEQIVIKITDQGYVTSH
GDHYHYNGKVPYDAIISEELLMKDPNYQLKDSIDVNEIKGGYVIVKVDGKYVYVLKDAAHADNIRTKEEIKRQKQEHSHNHGG
GSNDQAVVAARAQGRYTTDDGYIFNASDIIEDTGDAYIVPHGDHYHYIPKNELASASELAAAEAYWNGKQGSRPSSSSSYNANP
AQPRLESENHNLTVPTTYHQNGENISSLLRELYAKPLSERHVESDGLIFDPAQITSRTARGVAVPHGNHYHFIPYEQMSELEK
RIARIIPLRYSNNHWVPDSRPEQSPQSTPEPSPSPQAPNPQPAPSNPIDKLVKEAVRKVGDDGYVFEENGVSRYIPAKDLS
AETAAGIDSKLAKQESLSHLKCAKKTDLPSDREFYNKAYDLLARIHQDLDLNDKGRQVDFEALDNLLERLKDVPSDKVKLVDD
ILAFAPIRHPERLGKPNQAITTYTDDIEIQVAKLAGKYTTEDGYIFDPRDITSDEGDAYVTPHMTSHHWIKKDSLSEAERAAAC
AYAKEKGLTPPSTDHQDSGNTAEKGAEEIYNRVKAAKVPDLRMPYNLQYTFEVKNGSLIIPHYDHYHNIKFEWFDEGLYEAP
KGYTTLEDLLATVKYVVEHPNERPHSDNGFGNASDHVRKNKVDQDSKPEDKEHDEVSEPTHPESDEKENHAGLNPSADNLYKF
STDTEETEEEAEDTTDEAEIPQVENSVINAKIADAEALLEKVTDPISIRQNAMETLTGLKSSILLGTDMNTISAEVDSLALLI
KESQPAPIQ

SeqID 190

MKFSKKYIAAGSAVIVLSLCAVALNQHRSQENKDNRRVSYVDGSSQSSQKSENLTDPQVSQKEGIAEQIVIKITDQGYVTSH
GDHYHYNGKVPYDALFSEELLMKDPNYQLKDADIVNEVKGYYIIVKVDGKYVYVLKDAAHADNVRTKDEINRQKQEHVKDNEK
VNSNVAVARSQGRYTTNDGYVFNPAIDIEDTGNAYIVPHGGHYHYIPKSDLSASELAAAKAHLAGKNMQPSQLSYSSSTASDNN
TQSVAKGSTSKPANKSENLOQLLKELYDPSAQRYSESGLVDFDPAKIIISRTPNGVAIPHGDHYHFIPYSKLSALEEKIARMV
PISGTGSTVSTNAKPNVSVSLGSLSSNPSSLTTSKELSSASDGYIFNPKDIVEETATAYIVRHGDHGFHYIPKSNQIQOPTLF
NNSLATPSPSLPINFPGTSHEKHEEDGYGFANRIIAEDESGFVMSHGDHNYHFFKKDLTEEQIKAAQKHLBEVKTSNGLDSI
SSHEQDYPNAKEMKDLDDKKIEEKIAGIMKQYGVKRESIVVNKEKNAIIPHGDHHDADPIDEHKKVPGIGHSHSNYELFKPEE
GVAKKEGNKVYTGELTNVNNLLKNSTFNNQNFLLANGQKRVSFSPPELEKKLGINMLVKLITPDGKVLKGVSGKVFGEVGC
NIANFELDQPYLPQDFTKKTITASKDYPEVSYDGTFTVPTSLAYKMASQCTIFYPFHAGDTYLRVNPQFAVPKGTDALVRVDFEF
HGNAYLENNYKVGEEKLPIPKLNQGTTRTAGNKIPVTFMANAYLDNQSTYIIVEVPILEKENQTDKPSILPQFKRKAQENLKI
DEKVEEPTKSEKVEKEKLSGTNSTSNSTLEEVPTVDPVQEKVAKFAESYGMKLENVLFNMDGTIELYLPSEGEVICKNMADFTI
GEAPQNGENKPSSENGKVSTGTVENQPTENKPADSLPEAPNEKPKVPENSTDNMGLNPEGNVGSDFPMLDPALEEAPAVDPVQE
KLEKFTASYGLGLDSVIFNMDGTIELRLPSGEVICKNLSDLIA

SeqID 191

MKILFVAAGAPFSKTTGGLGDVIGALPKSLVKAGHEVAVILPYDMVEAKFGNQIEDVLHFEVSVGWRQYCGIKKTVLNGVI
FYFIDNQYFFFRGHVYGDFFDGERFAFFQLAAIEAMERIDFIPDLLHVHDYHTAMIPFLLKEKYRWIQAYEDIETVLTIHNL
FQGGQFSEGMLGDLFGVGFERIADGTLRWNNCLNWMKAGILYANRVSTVSPSYAHEIMTSQFGCNLDQILKMESGKVGSGIVNGI
DADLYNPQTDALLDYHFNQEDLSGKAKNKAQLQERVGLPVRADVPLVIGIVSRLTROKGFVVDVESLHHILOQEDVQIVLLGTGI
PAFEGAFSWFAQYIPDKLSTNTITFDVLAQEIYAACDLFLMPSRFEPCGLSQMMAMRYGTLPLVHEVGGRLDTRAFNPPIEGE
GTGFSFDNLSPYWLNTFTQALDLYRNHPDIWRNLQKQAMESDFSWDTACKSYLDLYHSLVN

SeqID 192

MEKYFGEKQERFSFRKLSVGLVSATISSLFFMSVLASSSVDAQETAGVHYKYVADSELSSEEKKQLVYDIPTYVENDDETYI
VYKLSNQQLAELPNTGSKNERQALVAGASLAAMGILIFAVSKKKVKNKTVLHLVLVAGIGNVGLVSVALENHLLNNTDY
ELTSGEKLPLPKIEISGYTYIGYIEGKTTSESEVSNQKSSVATPTTKQKVDYVNTPNFVDHPSTVQAIQEQTVPVSTKPTVEVC
VVEKPPSTELINPRKEEKQSSDSQEQLAHEKNLETKEBEKISPEKKTGVNTLNPQDEVLSGQLNKPELLYREETMETKIDFQE
EIQENPDLAEGTVRVKQEGKLGKKEIIVRIFSVNKEEVSREIVSTSTTAPSPRIVEKGTQVKEQPETGVEHKDVQSGAI
VEPAIQPELPEAVVSDKGEPEVQPTLPEAVVTDKGETEVQPESPDTPVSDKGEPEQVAPLPEYKGNIEQVKPETPVEKTKEQC
PEKTEEVVPVKTEETPVNPNEGTTEGTSIQEAENPVQPAEESTTSEKVSPTSSKNTGEVSSNPNSDSTTSVGESNKPENHNS
KNENSEKTVEEVVPVNPNEGTVEGTSNQETEKPVQPAEETQTNNGKIANENTGEVSNKPSDKPPVEESNQPEKNGTATKPENE
GNTTSENGQTEPEPSNGNSTEDVSTESNTSNNGNEEIKQENELDPDKKVEEPEKTELRNVSDLELYSLNNGTYKQHISLEC
VPSNPNSYFVKVKSSEFKDVLVVASISEERKNDKILYKITAKEKLOQEBESRYKDNFTFYLAKEGTEETTNTFSFNLVKA
INQNPSTGYHLAASLNANEVELGPDESYIKDTFTGRLIGEKDGNAYIYNLKKPLFENLSGATVEKLSLKNVAISGKDDIGS
LANEAQNNTKIKQVHVDGVLAGEGIGGLLAKAEQSSITESSEFKGRIINTYETTAAYNIGGMVGHLTGDKALLTKSKATVAIS
SNTNTSDQTVGLGLAGLDVDRDAQIQDSYAEQDINNKHGFRVAGVAGNLWDRTSGDVRHAGSLTNVLSVNVNTNGNAITGYHYH
EMKVKDTFSSKANRVYNVTLVKDEVVSKESEFERGTMLDASQIASKKAEINPLILPTVEPLSTSGKKDSDFSKVAYYQAKRNI
TYKNIKELLFPYKATIVKYGNLVNENSLLYQKELLSAVMMKDNQVITDIVSNKQATANKLLLHYKDDLSEKLDLYQNDFAKI
AEYSLGNTGLLYTPNQFLYDQTSIIKQVLPDLQKVDYHSEAIRKTLGISPNVKQTELYLEDQFAKTKQLEDKLLKLLSADAG
LASANPVTGELYVDKIKRNEKALLGLTYLERWYNFSYQGVNVKDLVLYHLDFFGKGNASPLDTLIELGKSGFNLLAKNNVI
TYGISLASQHGTTDLFSTLEHYRKVFLPNTSNNDWFKSETKAYIVEEKSTIEEVKTKQGLAGTKYSIGVYDRITSATWKYRN
VLPLLTLPERSVFVISTMSSLGFGAYDRYSSDHKAGKALNDFVEENARETAKRQORDHYDYWYRILDDNAREKLYRNILLYDA
YKFGDDNTVGKATEVADFNDPNPAMQHFFGPGVGNKVGHNGHAYATGDVAYYMGYRMLDKDGAITYTHEMTHSDQDIYLG
GRRSGLGPEFFAKGLLQAPDHPDDATITINSILKHSKSDSTESRRLQVLDPTTRFNNADDLKQYVHNMFDVVMYLEYEGNSI
LKLDTNQKQQLLRKVTNEYHPDPDGNKVYATNVVRNLTVEEVERLRSFNDLIDNNILSSREYASGKYERNGYFTIKLFAPITYA
ALSNDIGTPGDLMGRRRIAYELLAAGKFKDGMVPIYSNQYEEAAKQKGTINLYGKTRGLVTDLDLVLEKVFNNQYHTWSEFKKA
MYQERQDQFDRLNKVTFTNDTTPQWQTFAKKTTSSVDELQKLMVAVRKDAEHNYHWNYPNDIDSEVHKLKRAIFKAYLDQI
NDFRSSIFENKK

SeqID 193

MKINKKYLKAGSVAVLALSVCSEYELGRYQAGQDKKESNRVAYIDGQAGQKAENLTPDEVSKREGINAEQIVIKITDQGYVTSH
GDHYHYNGKVPYDAIISEELLMKDPNYQLKDSIDVNEIKGGYVIVKVDGKYVYVLKDAAHADNIRTKEEIKRQKQERSHNNHS
RADNAVAARAQGRYTTDDGYIFNASDIIEDTGDAYIVPHGDHYHYIPKNELASASELAAAEAYWNGKQGSRPSSSSSYNANP
QPRLESENHNLTVPTTYHQNGENISSLLRELYAKPLSERHVESDGLIFDPAQITSRTARGVAVPHGNHYHFIPYEQMSELEK
IARIIPLRYSNNHWVPDSRPEEPSPQSTPEPSPSPQAPSNPIDKLVKEAVRKVGDDGYVFEENGVSRYIPAKDLSAETAAGI

DSKLAKQBSLSHKLGTKKTDLPSDDREFYNKAYDLLARIHQDLDLNDKGRQVDFEALDNLRLERLKDVSDDKVKLVEDILAFILAF
IRHPERLGKPNQAITYTDEDEIQVAKLAGKYTTEDGYIFDPRDITSDEGDAYVTPHMTSHWIKKDSLSEAERAAQAYAKEKG
LTPPSTDHQDSGNTAEKGAEIYNRVKAACKVPLDRMPYNLYQYTVVEVKNGLIIPHYDHYHNIKFEWFDEGLYEAPKGYTLET
LLATVKYVVEHPNERPHSDNGFGNASDHVQRNKGQADTNQTEKPSSEKPKTEKPEETPREKPKSEKPSKPTTEPEESE
BESEEPQVETEKVEEKLREAEDLLGKIQDPPIKSNAKETLTGLKNNLLFGTQDNNTIMAEAEKLLALLKESK

SeqID 194

LILSVCSYELGLYQARTVKENNRVSYIDGKQATQKTENLTPDEVSKREGINAEQIVIKITDQGYVTSBGDHYHYNGKVPYDA
IISEELMKDPNYKLDKEDIVNEVKGYYVIVKVDGKYVYVLDAAHADNVRTKEEINRQKQEHSHQREGGTFRNDGAVALLARSQ
GRYTTDDGYIFNASDIIEDTGDAYIVPHGDHYHYIPKNELASASELAAAEAFLSGRGNLSNSRTYRRQNSDNTSRTNWVPSVSN
PGTTNTNTSNNSNTNSQASQSNIDSLKQLYKPLSQRHVESDGLVDFPAQITSRTARGVAVPHGDHYHFIYPSQMSLEER
IARIIPLYRSNHNWVPSRPEQPSPOPTPEPSPGPQAPNLKIDSNSSLVSQLVRKVGEGYVFEKGISRYVFAKDLPSSETVK
NLESKLSKQESVSHLTAKKENVAPRDQEFYDKAYNLLTEAHKALFENKGRNSDFQALDKLLERLNDESTNKEKLVDDLLAFL
APITHPERLGKPNQIETYTEDEVRIAQLADKYTTSDGYIFDEHDIISDEGDAYVTPHMGHSHWIGKDSLSDKEKVAAQAYTKE
KGILPPSPDADVKANPTGDSAAAIYNRVKGKRIPLVRLPYMVEHTVEVKNGLIIPKHQHYHNIKFAWFDDHTYKAPNGYTL
EDLFATIKYVVEHPDERPHSNDGWNASEHVLGKDHSEDPNKNFKADEEPVEETPAEPEVPQVETEKVEAQLKEAEVLLAKV
TDSSLKANATETLAGLRNNLTLQIMDNNSIMAEAEKLLALLKGSNPSSVSKEKIN

SeqID 195

MPVEIKTKKEIHPKIYAYTTPVTSTNEGWIKIGYTERDVTQRIKEQTHAHATDVLWTGDAAYTEEPDKGKTFKDHFHFL
SFHDVERRPKTEWFYFNGTPEKSNLFDKQVQHDLSGYQPGKGQDYTLRQEQEEAVAKTLAYFQEHAGGKFLWNAPRFGKTL
STYDLARRMEAVNVLIIVTNPAIANASWYDDFETFIAGQTYKFVSESDLSKSRPILSRQEFGLILADDVRQLAFISLQDLKGS
VYLGEHDKLKWVTDLHWDLLVIDEAHEGVDTPKTDQAFNKIRRNFTLHLSGTSFKALAKGDFTEEQIYNWSYAEQAAYSW
SLEQEEENPYESLPQLNLFTYQMSQMIKEKLEKGAQIDGENIDYVFDLSEFFATDDKGKFIHEHVRNWLDTLSSNEKYPFST
KELRNELKHTFWLLERVASAKALKALLEHPIYENYEIVLAAGDGRMSEDDKVKLKSLLVRKAIENDKTITLSVGQLTTG
VTIPEWTGVLMLSNLKS PALYMQAAFRAQNPYSWSDNKGHNFRKERAYVDFAPERTLILFDEFANNNLLVTAAGRGT SATRE
ENIRELLNFFPIIAEDRAGKMVEIDAKAVLTTPROIKAREVLKRGFMSNLLFDNISGIFQASQTVLDILNELPVEKEGKVQDS
SDLLDFSDVTVDDENAVVDHEIVVNQMRFLGKGVYGLGESVAELVTKDEERTQKQLVNDLSKTVSSVIVEELKADYSKTR
ETEQIKQKITATLENEIRKNDIERKISEAHIKQELQOQLKEANDKAQDKIQEDLEKRLEENKLIHKEKLEQTLKKEVEKMP
KFIEQVEIKRVEQLKQSAQDEIRDHLRGFARTIPSFIMAYGDQTLTLDNFDAFVPEHVFEVETGITIDQFRYLRDGGQDFAGH
LFDKATFDEAIQEFRLRKKKELADYFKDQKEDIFYIIPQKTNQIFTPKRVVVKRMVDDLEKENPGIFDDPSKTFIDLYMKSGLY
IAELVKRLYNSNGLKEAFPNPPEERLKHILEKQVYGFAPSEIYINISTNFI FGNLSKDISRKNFVLADTTPAAKEGSIQKLVD
SFENN

SeqID 196

MKKILIVDDEKPISDIIFKNMTKEGYEVVTA FNGREALEQFEAEQPDIIILDMLPEIDGLEVAKTIRKTSVPIMLLSAKDS
EFDKVIQLELGADDYVTKPFSNRELQARVKALLRRSQPMFVDGQGEADSKPQPIQIGDLEIVPDAYVAKKYGEELDLTHREFEL
LYHLASHTGQVITREHLLLETVWGYDYFGDVRTVDVTVRRLREKIEDTPSRPEYILTRRGVGYMRNNA

SeqID 197

MKKKFLAFLLLILFPIFISLGIKAETIKIVSDTAYAPFEFKDSQTYKGIDVDIINKVAEIKGWNQMSYPGFDAAVNAVQAGQ
ADAIMAGMTKTKEREKVFTMSDTYYDTKVVIATTKSHKISKYDQLTGKTVGVKNGTAAQRFLKETIKDKYGFITIKTFTDGLMN
NSLSAGAIIDAMMDKPVIEYAINQGGDLHIEMDGEAVGSFAFGVKKGSKYEHVTEFNFQALSEMCKDGSLLDKI IKKWTA SSS
AVPTTTTLAGLKAIPVKAKEYIASDSSFPAPFVQNSSNQYTGIDMELIKALAKDQGFIEITNPGFDAAISAVQAGQADGIIA
GMSVTDARKATFDFSESYYTANTILGVKESNIA SYEDLKGKTVGVKNGTASQTFLTENQSKYGYKIKTFADGSSMYDSLNTG
AIDAVMDDEFVLKYSISQGGQLKTPISGTPIGETAFVKKGANPELIEMFNGLANL KANGFQKILDKYLA SSESSTASTV
DETTLWGLLQNNYKQLLSGLGTLALALISFAIAIVIGIIFGMFSVSPYKSLRVISEIFVDVIRGIPLMILAAFIWGPINFI
ESITGQQSPINDFVAGTIALSLNAAAYIAEIVRGGIQA VVGQMEASRSLGISYGMTMRKIILPQATKMLLPNFVNQFVIALK
DTTIVSAIGLVELFQGTGKII IARNYQSFMYAILAIFYLVIITTLTRLAKRLEKRIR

SeqID 198

MAFESLTERLQNVFKNLRKKKISESDVQEATKEIRLALLLEADVALPVVKDFIKKVRERAVGHEVIDTLNPAQQI IKIVDEEL
TAVLGSDTA EI IKS PKIPTIIMMVGLQGAGKTTFAGKLANKLKEENARPLMIAADIYRPA AIDQLKTLGQQIDVPV FALGTE
VPAVEIVRQGLEQAQTNHNDYVLIDTAGRLQIDELLMNELRDVKALAQPNELLLVVDAMIGQEAANVAREFNAQLEVTGVILT
KIDGDRGGAALSVRHITGKPIKFTGTGEKITDIETFHPDRMSSRLGMGDMTLIEKASQEYDEQKALEMAEKMENTFDN
DFIDQLDQVQNMGP MEDLLKMPGMANNPALQNMKVDERQIARKRAIVSSMTPEERENPDLLNPSRRRRRIAAGSGNTFVEVKN
FIKDFNQAKQLMQGVMSGDMNMMKQMGINPNLKNMPPNMGMDMSALEGMMGQGGMPDLSALGGAGMPDMSQMFGGGLKKG
IGEFAMKQSMKRMANKMKKAKKRRK

SeqID 199

MSQIWTKEKFISQVQGGVIVSCQALPGEALYNEEFSLMPFMAKAALEAGAVGIRANSVRDIKAIQKVVDLPIIGI IKRDYPPQ
EPYITATMKEVDELVECGTTVIAFDATLRPRYDGLVSEFIKKIKEKYPNQLLMADVSNLDEGLYAFKSGVDVFGTTL SGYTS
TSVQSDPEPDFELMKKLADFNIPVIAEGKIHYPEQLKKA YSLGVTSSVIGGATRPKEIAQRFINVIK

SeqID 200

MRYLTAGESHGPRLTAIEGIPAGLPLTAEDINEDLRRRQGGYGRGGRMKIENDQVFTSGVRHGKTTGAPITMDVINKDHQK
WLDIMS AEDIEDRLKSKRKITHPRPGHADLVGGIKYRFDDLRNLSLERSSARETTMRVAVGAVAKRLLAELDMEIANHV VVFGG
KEIDV PENLTVAEIKQRAAQSEVSIVNQEREQEIKDYIDQIKRDGTIGGVVETVVGVPVGLGSYVQWDRKLDARLAQAVVS

INAFKGVFGLGFAGYRKGSQVMDEILWSKEDGYTRRTNNLGGFEGGMTNGQPIVVRGVMKPIPTLYKPLMSVDIETHEPYK
ATVERSDPTALPAAGMVMEAVVATVLAQEILEKFSSDNLEELKEAVAKHRDYTKNY

SeqID 201

MVVMNRIRVSKRVEKKLAKGLVLEASDLENVNLKDQEEVEVQGOEGNFLTAYLSQQNKGLGWFISKDKVAFNQAFFETLFRK
AKEKRNAYYQDDLTAFRLFNQEGDGFGLTVDLYGDYAVFSWYNSYVYQIRQTISEAFRQVFPEVLGAYEKIRFKGLDYESA
HVVYQGEAPDFNFVLENGVLYQVFMNDGLMTGIFLDQHEVRGSLVDGLAMGKSLNMFSTYTAAPSVAAMGGASHTTSVDLAKR
SRELSQAHFQANGLSTDEHRFVMDVFFYFKYAKRKDLTYDVIIVLPPSFARNKKQTFSSVAKDYHKLISQSLEILNPGGIITA
STNAANVSRQKFTEQIDKGFAGRSYQILNKYGLPADFAYNKKDESSNYLKVISMKVSK

SeqID 202

MTKTLKRPEVLSPAGTLEKLKVAVQYGADEVFIGGQAYGLRSRAGNFTFEQMEEGVQFAAKYGAKVYVAANMVMHEGNEAGAG
EWFRLKRDIGIAAVIVSDPALIMIAVTEAPGLEIHLSTQASATNYETLEFWKELGLTRVVLAREVSMEEAEIRKRTDVEIEA
FVHGAMCISYSGRCTLSNHMSMRDANRGCSQSCRWKYDLYDMPFGKERKSLQGEIPEEFSMSAVDMSMIDHIPDMIENGVD
LKIEGRMKSIIHYVSTVTNICYKAAVDAYLESPEKFEAIKQDLVDEMVKVAQRELATGFYGTPTSENEQLFGARRKIPEYKFVAE
VVSYYDAAQTATIRQRNVINEGDQVEFYGPGFRHFETYIEDLHDAKGNKIDRAPNFMELLTIKVPQPVQSGDMVRALKEGLIN
LYKEDGTSVTVRA

SeqID 203

MNTYQLNNGVEIPVLGFGTFKAKDGEEAYRAVLEALKAGYRHIDTAAYQNEESVQQAIDSGVPREEMFVTTKLWNSQQTYE
QTRQALEKSIIEKGLDYLIDLYLHWPNNPKPLRENDWKTNAEVRWRAMEDLYQEGKIRAIQVSNFLPHHLDALLETATIVPAV
NQVRLAPGVYQDQVVAYCREKGILLEAWGPFPGQEGELFDSKQVQEIQAANHGKSAQIALAWSLAEGFLPLPKSVTTSRIQANLD
CFGIELSHEERETLKTIAVQSGAPRVDDVDF

SeqID 204

LSEKSRREEKLSFKEQILRDLEKVKGYDEVLKEDEAVVRTPANEPSTEELMADSLSTVEEIMRKAPTVPTHPSQGVSPASPADE
IQRETGVPVSHPSQDVPSSPAEESGSRPGPGPVRPKKLEREYNETPTRVAVSYTTAEKKAQAGPETPTPATETVDIIRDTSR
RSRREGAKPVKPKKEKKSHVKAFFVISFLVFLALLSAGGYFGYQVYVLDLSLLPIDANSKKYVTGIVEGSNVQEIQTTEKAGLV
KHGLIFSFYAKYKNYTDLKAGYYNLQKSMSTEDLLKELQKGGTDEPQEPVLATLTIPGYTLDQIAQAVGQLQGDFFKESLTAE
AFLAKVQDETFFISQAVAKYPTLLESPLVKDVGARYRLEGYLFPATYSIKESTTIESLIDEMLAAMDKNLSPYYSTIKSKNLTV
NELLTIASLVEKEGAKTEDRKLIAGVFYNNRLNRDMPLOSNIAILYAQGKLGQNI SLAEDVAIDTNIDSPYNNVKNVGLMPGPV
DSPSLDAIESSINQTKSDNLYFVADVTEGKVVYANNQEDHNRNVAEHVNSKLN

SeqID 205

MKQERFPLVSDDEVMLTEMPVMNLYDESDLISNIKGEYRDKNYLEWAPIAEKPKVPIEKQVEKPKKAPLGVKKEGKSYAEVA
REEARADLKKKRSANYLTQDFSLARRHSQPSLVRQGNQPTAPFQKENPGEFVKYSQKLTQSHYILAEVHSIPTKNEEVSAPA
PKKNYDFLKKSQIYNKSKSQTEQERRVAQELNLTTRMTE

SeqID 206

MKKSKSKYLTLAGLVLTGVLSSACGNSSTASKTYNYVYSSDPSSSLNYLAENRAATSDIVANLVDGLENQYGNIIIPSLAED
WTVSQDGLTYTYKLRKDAKWFPTSEGEFYAPVTAQDFVTGLQYAADKKSEALYLVDQSVAGLDDYITGKTSDFFSTVGKALDDQ
TVQYTLVKPELYWNSKTLATILFFVNADFLKSKGDDFGKADPSSILYNGPFLMKALVSKSAIEYKKNPNYWDKNNVVDVVKL
TYDQSDQESLERNFTAGAYTTARLFNSSSYEGIKEKYKNNIYSMNSTSYFFNFNLDKRSYNYTSKTSIDIEKKSTQEA
NKNFRQAINFAFDRTSYGAQSEGEKATKILRNLVPPNFVSIKGDFFGEVASKMVNNGKEWQGINFADGQDPYNNPEKAKA
KFAEAKKELEAGVQFPPIHLDKTVEVTDKVGIIQGVSSIKQSIESVLGSDNVVIDIQQLTSDFFDSSGYFAQTAQKDYDLYHG
GWGPDYQDPSTYLDIFNTNSGGFLQNLGLEPGEANDKAKAVGLDVYTMLEEANKQDPAKRYEKYADIQAWLIDSSLVLPV
SRGTPSLRRTVPFAAAYGLTGTGKGVESYKYLKVQDKIVTTDEYAKAREKWLKEEESNKKAEELAKHVK

SeqID 207

VEQHSVDVCYIFYRRERLKTIGLASICLLGLATSHVAANETEVAKTSQDTTASSSSEQNQSSNKTQTSAEVQTNAAHWDGD
YYVKDDGSKAQSEWIFDNYKAWFYINSRGYSQNEWHGNYLLKSGGYMAQNEWIYDSNYKSWFYLSKGAYAHQEWQLIGNK
WYFYFKWGYMAKSQWQGSYFLNGQGAMMONEWLYDPAYSAYFYLSKSDGTANQEWQKVGKWKWYFYFKWGYMARNEWQGNYYLT
GSGAMATDEVIMDGTRYIFAASGELKEKKDLNVGWVHRDGRKYFFNNREEQVGTTEHAKKVIDISEHNGRINDWKKVIDENEVD
GVIVRLGYSGKEDKELAHNIKELNRLGIPYGVLYTYAENETDAESDAKQTIELIKKYNMNLSPYPIYDVENWEYVNNKSKRAP
SDTGTWVKIINKYMDTMKQAGYQNVYVYSYRSLQLTRLKHPDILKHVNVVAAAYTNALWENPHYSKKGWQYTSSEYMKGIQ
RVDVSVWY

SeqID 208

MAKEPWQEDIYQEESSRAERRHRNHGGADRMANRILITILASIFFVIVVMVIVLIYLLSSGGSNRTAALKGFHDSASVQISS
SSSSQPEQSSEPESTSSSSSEEAANPEGTIKVLAGEGEAAIAARAGISIAQLEALNPGHMATGSWFANPGDVIIK

SeqID 209

MPITSLEIKDKTFGRFRGFDPEEVDEFDLDIVVRDYEDLVRANHDKNLRIKSLEERLSYFDEIKDLSQSQSVLIAQDTAERVQ
AAHERSNNIIHQAEQDAQRILLEAKYKANEILRQATDNAKKAVAVETEELKNKSRVHFQRLKSTIESQLAIVESSDWEDILRPT
ATYLTQSDAEAFKEVSEVLGEPIPAPIEBEPIDMTRQFSQAEMAELQARIEVADKELSEFEAQIKQVEAPTVPVSPQVEBEP
LLIQLAQCMKNQK

SeqID 210

MSLKDRFDRFIDYFTEDEDSSLPYEKRDEPVFTSVNSSQEPALPMNQPSQSAGTKENNITRLHARQQELANQSRATDKVIID
VRYPRKYEDATEIVDLLAGNESILIDFQYMTVEVQARRCLDYLDGACHVLAGNLKKVASTMYLLTPVNVIVNVEDIRLPDEDQQ
GEFGFDMKRNVR

SeqID 211

MSDLKKYEGVIPAIFYACYDDQGEVSPERTRALVQYFIDKGVQGLYVNGSSGECIYQSVEDRKLILEEVMMAVAKGKLTIIAHVA
CNNTKDSMELARHAESLGVDIAIATIPPIYFRLPEYSVAKYWNDISSAAPNTDYVIYNIQOLAGVALTPSLYTEMLKNPRVIGV
KNSSMPVQDIQTFVSLGGEDHIVFNGPDEQFLGGRLMGARAGIGGTYGAMPFLFLKLNQLIADKDLETARELQYAINAIGKL
TSAHGNMYGVIKEVLKINEGLNIGSVRSPLTPVTEEDRPVVEAAAALIRETKERFL

SeqID 212

MNKRGLYSKLGISVVGISLLMGVPTLIHANELNYGQLSISPIFQGGSYQLNKSIDISSLLLDKLSGESQTVVMKFKADKPN
LQALFGLSNSKAGFKNNYFSIFMRDSGEIGVEIRDAQKGINYLFSRPASLWGKHKGQAVENTLVFVSDSKDITYMYVNGIEV
FSETVDTFLPISNINGIDKATLGAVNREGKEHYLAKGSIDEISLFNKAIHQEVSTIPLSNPFQILFQSGDSTQANYFRIPTL
YTLSSGRVLSSIDARYGGTHDSKSKINIATSYDDNGKTWSEPIFAMKFNDYEEQLVYWPDRNKLKNSQISGSASFIDSSIVE
DKKSGKTIILLADVMPAGIGNNNANKADSGFKEINGHYLKLKNGDNDFRYTVRENGVVYNETTNKPTNYTINDKYEVLEGGK
SLTVEQYSVDFDSGSLRERHNGKQVPMNVFYKDSLFFKVTPTNYIAMTTSQNRGESWEQFKLLPPFLGKHNGLTYLCPGQGLAL
KSSNRLIFATYTSGLTYLISDDSGQWKKSSASIPFKNATAEAQMVELRDGVIRTFRTTTGKIAYMTSRDSETWSKVSYI
DGIQQTSTYGTQVSAIKYSQIDGKEAVILSTPNSRSRKGQGLVVLVKNKEDDSIDWKYHYDIDLPSYGYAYSATITELPNHHI
GVLFKEYDSWSRNLHLNBNVQYIDLEINDLTK

SeqID 213

MNRSVQERKCRYRIRKLSVGAVMIVGAVVFGTSPVLAQEGASEQPLANETQLSGESSTLTDTEKSQPSSETELSGNKQEQER
KDKQEEKIPRDYIARDLENVETVIEKEDVETNASNGQVRDLSSSELDKLLKENATVHMEFKPDAKAPAFYNLFSVSSATKKDE
YFTMAVYNNATLEGRGSDGKQFYNNYNDAPLKVPGQWNSVTFTVEKPTAELPKGRVRLYVNGVLSRTSLRSGNFIDKMPDV
THVQIGATKRANNTVWGSNLQIRNLTVYNRALTPEEVQKRSQFLFKRSLEKKLPEGAALTEKTDIFESGRNGNPNKDGKISYR
IPALLKTDKGTIAGADERRLHSSDWGDIGMVIIRSEDNGKTWGDRTITNLNRNPKASDPSIGSPVNIDMLVQDPETKRIF
SIYDMFPEGKGFISMSQKEEAYKKIDGKTYQILYREGEKGAYTIRENGTVYTPDGKATDYRVVDPVKPAYSDKGDLYKGDQ
LLGNIYFTTNKTSPPFRIAKDSYLWMSYSDDDGKTWSAPQDITPMVKADWMKFLGVGPGTGIVLNRNGPHKGRILIPVYTTNNVS
HLDGSQSSRVLYSDDHGKTWHAGEAVNDNRQVDGQKIHSSTMNRRQAQNTSTVQLNNGDVLFMRGLTGDLQVATSKDGGV
TWEKDIKRYPVQKDVYVQMSAIHTMEHKEYIILSNAGGPKRENGMVHLARVEENGELTWLKHNPQKGEFAYNSLQELNGE
YGILYEHETEKGQONAYTSLFRKFNWEFLSKNLISPTANRDQRRDQORSYWLGVRLRSIGQQGSNPSIGKWSNDFPNPQDLV
VCSRGYRTGNYWYSRKHRYASSCKSSRCQSSWRSKWQSSGASSRIYRGSWYRASCNRRVGFACNSYKKRLYLQSSSSCS
AGTSNRKQGEPPSFTRTNSFLPWSVYAREKERT

SeqID 214

MIQIGKIFAGRYRIVKQIGRGGMADVYLAKDLILDGEEVAVKVLRTNYQTDPIAVARFQREARAMADLDHPIVRITDIGEED
GOQYLAMEYVAGLDLKRYIKEHYPLSNEEAVRIMGQILLAMRLAHTRGIVHRDLKPQNILTPDGTAKVTFDGIIVAFATSL
TQTNMGLGSVHYLSPEQARGSKATVQSDIYAMGIIIFYEMLTGHIPIYDGSADVIALQHFKPLPSVIAENPSVPQALENVIIK
ATAKLTNRYSRVSSEMYVDLSSSLSYNRRNESKLIFDETSTKADTKTLPKVSQSTLTSIPKVQAQTEHKSINKNSQAVTEETQ
PQAPKXHRFKMRYLILLASLVLVAASLIWILSRTPATIAIPDVAGQTVAAKATLKKANFETGEEKTEASEKVEEGRIIRTDP
GAGTGRKEGKTINLVVSSGKQSFQISNYVGRSSDVIAELKEKKVPDNLIKIEEESNESEAGTVLQSLPEGTTYDLSKATQ
IVLTVAKKATTIQLGNYIGRNSTEVISELKQKKVPENLIKIEEESSESEPGTIMGQSPGAGTTYDVSKPTQIVLTVAKKVTS
VAMPSYIGSSLEFTKNLIQIVGIKEANIEVEVTTAPAGSAEGMVVEQSPRAGEKVDLNKTRVKISYKPKTTSATP

SeqID 215

MTKLIFMGTPDFSATVLKGLLTDDRYEILAVVTQPDRAVGRKKVQIETPVKQAAKEAGLSIYQPEKLSGSPEMEDLMKLADG
IVTAAFGQFLPSKLLDSMDFAVNVHASLLPRHRGGAPIHYALIQQDEEAGVTIMEMVKEMDAGDMISRRSIPITDEDNVGTLF
EKLALVGRDLLDLTPAYLAGDIKPEPQDTSQVTFSPNIKPEEEKLDWNKTNRQLFNQIRGMNPWPVAHTFLKGRDFKIYEAL
PVEGQGNPGEILSIGKKELIVATAEGALSLKQVQPAKPKMDIASFLNGVGRTLTVGERFGD

SeqID 216

VFRRLGQDFQLRKVKILKQINALKGKMSSLSQDELVAKTVEFRQLRSEGESLDDILVEAFVVRREADKRILGMFPYDVQVMG
AIVMHYGNVAEMNTGEGKTLTATMPVYLNAPSGEGVMVVTPNYLSKRDAEEMGQVYRFLGTIGVPFTEDPKKEMKAEKKL
IYASDIYTTNSNLGFDYLDNDLASNEEGKFLRPFNYVIDEIDILLDSAQTPLIAGSPRVQSNYYAIIDTLVTTLVEGED
YIFKEKEEVWLTTKGAKSAENFLGIDNLYKEEHASFAHLLVYAIRAHKLFKDKDYIIRGNEMVLVDKGTGRLEMMENTKLQGG
LHQATEAKEHVKLSPETRAMASTYQSLFKMFNKISGMTGTGKVAEKEFIETYNMSVVRIPTNRPRQRIDYPDNLYITLPEKV
YASLEYIKQYHAKGNPLLVFVGSVEMSQLYSSLLFREGIAHNVLNANNAAREAQIISSESGQMGAVTVATSMAGRGTDITKLKGG
VAELGGLIVIGTERMESQRIDLQIRGRSGRQGDPGMSKFFVSLLEDDVIKKFGPSWVHKYKDYQVQDMQPEVLKGRKRYKLV
EKAQHASDSAGRSARRQTLEYAESMNIQRDIYKERNRLIDGSRDLEDVVVDIIERYTEEVAADHYASRELLFHFIVTNISFH
VKEVPDYIDVTDKTAVRSFMKQVIDKELSEKKELLNOHDLYEQFLRLSLLKAIDDNWVEQVDYLQQLSMAIGGQSASQKNPIV
EYYQEAYAGFEAMEQIHADMVNRNLLMGLVEVTPKGEIVTHFP

SeqID 217

MTETVEDKVSHTITGLDILKGIYAAGAVISGTVATQTKVFTNESAVLEKTVEKTDALATNDTVVLGTISTSNSASSTLSASE
SASTSASEASTSASTSASTSASEASTSASTSASTSASTSASTSASTSVVGSQTAAATEATAKKVEEDRKKPASDYVASVTNVNLQSYAKRR
KRSVDSIEQLLASIKNAAVFSGNTIVNGAPAINASLNAKSETKVYTGEVDSVYRVPIYYKLKVTNDGSKLTFTYTVTVYNP
KTNDLGNISSMRPGYSIYNSGTSTQTMLTGSDLGKPSGVKNYITDKNGRQVLSYNTSTMTTQSGSYTWNGAQMNFGFAKKG

SeqID 220

MKKNRVFATAGLVLLAAGVLAACSSSSKSSDSSAPKAYGYVYTADPETLDYLISKNSTTVVTSNGIDGLFTNDNYGNLAPAVA
EDWEVSKDGLTYYTKIRKGVKWFSTSDGEYAEVTAQDFVNGLKHAADKSEAMYLENSVKGLADYLSGTSTDFSTVGKAVD
DYTLQYTLNQBPFWNSKLTYSIFWPLNEEFETSKGSDFAKPTDPTSLLYNGPFLLKGLTAKSSVEFVKNEQYWDKENVHLD
INLAYYDGSQDSESLERNFTSGAYSARLYPTSSSNYSKVAEEYKDNIIYTTQSGSGIAGLGVNIDRQSYNYTSKTTDSEKVATK
ALLNKDFRQALNFALDRSAYSQAINGKDGAAALAVRNLFVKPDPVSAGEKTFGDLVAAQLPAYGDEWKGVNLADGQDGLFNADK
AKAEFAKAKKALEADGVQFPIHLDVFPVQASKNYISRIQSFKQSVETVLGVENVVVDIQMTSDEFLNITYYAANASSEDWDV
SGGVSWGPDYQDPSTYLDILKTTSSSETTKTYLGFDPNPNPSVQVGLKEYDKLVDEAARETSDLNVRYEKYAAAQAWLTDSSL
FIPAMASSGAAPVLSRIVPFTGASAQTGSKGSDVYFKYLSQDKVVTKEEYKAREKWLKEKAESNEKAQKELASHVK

SeqID 221

MEINVSKLRTDLPQVGVQPYRQVHAHSTGNPHSTVQNEADYHWRKDPGLGFFSHIVGNGCIMQVGPVDNGAWDVGGGWNAAEY
AAVELIESHSTKEEFMTDYRLYIELLRNLADEAGLPKTLDTGSLAGIKTHEYCTNNQPNHSDHVDPPYLAKWGISREQFKH
DIENGLTIETGWQKNDTGYYVHSDGSYPKDKFEKINGTWYYFDSSGYMLADRWRKHTDGNWYWFNDSGEMATGWKKLADKWY
YFNEEGAMKTGWVKYKDTWYYLDAKEGAMVSNAFIQSADGTGWYYLKPDTLADKPEFTVEPDGLITVK

SeqID 222

MKKKYWTLAILFFCLFNNSVTAQEIPKNLDGNITHTQTSESFSSEDEKQVDYSNKNQEEVDQNKFRIQIDKTELFVTTDKHLE
KNCKLELEPQINNDIVNSESNNLLGEDNLDNKIKENVSHLDNRGGNIEHDKDNLESSIVRKYEWIDKVTGGGESYKLYSKS
NSKVSIAILDGVDLQNTGLLKNLSNHSKNYVVPNGYLGKEEGEIIISDIQDRLGHGTAVVAQIVGDDNNGVNPVHNINVY
RIFGKSSASPDWIVKAIFDAVDDGNDIINLSTGQYLMIDGEYEDGTNDFETFLKYKKAIDYANQKGVIIAALGNDSLNVSQ
SDLLKLISRRKKVRKPGLVVDVPSYFSSITSVGGIDRLGNLSDFSNKGDSDAIYAPAGSTLSLSLGLNNFINAEKYKEDWIF
SATLGGYTYLYGNSFAAPKVSAGAIAMIIDKYKLDQPYNYMFVKKFWKKHYQ

SeqID 223

MKKDELFEFGFYLIKSADLRQTRAGKNYLAFTFQDDSGEIDGKLWDAQPHNIEAFTAGKVHMKGRREVYNNTPQVNQITLRLP
QAGEPNDPADFKVKSFPVDVKEIRDYMSQMFKFIENPVWQRIVRNLYTKYKFEFYSYPAKTNHHAFFETGLAYHTATMVRLADA
ISEVYPQLNKSLLYAGIMLHDLAKVIELTGPDQTEYTVRGNLLGHIALIDSEITKTVMELGIDDTKEEVVLLRHVILSHHGLL
EYGSFVRPRIMEAEIIHMDNLDASMMMSTALALVDKGEMTNKIFAMDNRSFYKPDLD

SeqID 224

VTILGKDTVQSSAKGESVTQEATPEYKLENTPGDGKGGNTGSSDANANEGGGSQAGGSAHTGSQNSAQSQASKQLATEKESAK
NAIEKAAKDKQDEIKGAPLSDKEKAELLARVEAEKQAALKEIENAKTMEDVKEAETIGVQALAMVTVPKRPVAPNAAPKTTSA
PQATAGTMQDVTYQSPAGKQLPNTGSASSAALASLGLVVATSGFALLGRKTRRRK

SeqID 225

MNADDVTIYDVAREAGVSMATVSRVNGNKNVKNENTRKKVLEVIDRLDYRPNVARGLASKKTTTVGVVPIPNTNGYFSSLA
KGIDDAEMYKYNIVLANSDEDENEKEFVSVVNTLFSKQVDGIIYMGYHLTDKIRSEFSRSRTPIVLAGTVDVEHQLPSVNIDYK
QATIDAVSYLAKENERIAFVSGPLVDDINGKVRVLGVYKETLKKAGITYSEGLVFESKYSYDDGYALAERLISSNATAAVVTGD
ELAGVNLGLADKGVSVPEDEFEITSDDSQISRFTRNLTIAQPLYDLGAISMRMLTKIMHKELEEREVLLPHGLTERSS
RKRK

SeqID 226

MKKKLVPNLFWWGAASSGPQTEGQYGVHENVMYWFKTHPEDFDNGVPLVASNFFHTYTEDFHLMEIGVNSFRTSIQWS
RLIKNLETGEPPDKGIAFYNAIEEAKNQMDLVMNLHHFDLPVELLQKYGGWESKHVVELFVKFAKTAFTCFGDKVHYWTTF
NEPMVPEAGYLYAFHYPNLKGKGKEAVQVIYNLNLASAKVIQLYRSLELDGKIGIILNLTTPAYPRSNSPEDLEASRFTDDFF
NKVFLNPAVKGTFFPERLVKQLERDGLWSHTEKELQLMKSNTVDLGVNYHPRVQAQANPEEYQTPWMPDQYFKEYEWLER
RMNPPYRGWEIFPKAIYDIAMIVKEEYGNIPWFISENGMGVNEARFIDENGVIDDVYRIEFYEEHLRWLHKAIEEGSHCFGYH
AWTAFDCWSWNNAYKNRYGFIISVDLETQKRTIKSSGRWYRKVSDNNGFEVEIEE

SeqID 227

VENLTNIFYEKYRVYLTRPRLLELLAVVTIVFCAVLVFFLNI PGKGVKLKLDNGTIVYDGS�VRGKMNGQGTITFQNGDQYTGGFN
NGAFNGKGTFSKSGEWTYEGDFVNGQABEGKGLTTEQEUVVYEGTFFKQGVFQK

SeqID 228

MLNKIRDYLDFAQLQYRNPDKAGAEREKMLAFRHKGQEARVFTTELAKAFQASHPEWQLQOTSQWMNQARLRPHFWVYLQRD
GQVTEPMALRLYGTSTDFGISLEVSFIERKKDEQTLGKQAKVLDIPTVKGIYYLTYSNGQSQRWEANEKRRRLTREKVRSQE
VRKVLVKVDVPMTESSSEEEIVEGLLSYSKILPYLATRK

SeqID 229

MVQNSCWQSKSHKVKAFITLLESLLALIVISGGLLLFQAMSQLLISEVRYQQQSEQKEWLLFVDQLEVELDRSQFEKVEGNRLY
MKQDGKDIAIGKSKSDDFRKTNARGRGYQPMVYGLKSVRITEDNQLVRFHFQFQKGLEREFIYRVEKEKS

SeqID 230

MKKMNTFLKAKVKAFITLVEMLVLLIISVLFLFVFNLTQKEAVNDKGAADVVKVVESQAELYSLEKNEDASLRKLQADGR
ITEBQAKAYKEYNDKNGGANRKNVD

SeqID 231

MTSKVRKAVIPAAGLGRFLPATKALAKEMPLIVDKPTIQFIVEEALKSGIEDILVVTGKSKRSIEDHFDNSNFELEYNLKEKG
 KTDLLKLVDKTTDMRLHFIRQTHPRGLGDAVLQAKAFVGNPEFVVMGLGDDMDITDEKAVPLTKQLMDDYERTHASTIAVMPV
 PHDEVSAVGVIAPQGEKGDGLYSVETFEKPAPEADAPSDLAIGRYLLTPEIFEILEKQAPGAGNEIQLTDAIDTLNKTQRFV
 AREFKGARYDVGDKFGFMKTSIDYALKHPQVKDDLKNYLIQLGKELTEKE

SeqID 232

MQNQLNELKRMLEFFQKQKNKSARPGKKSSTKSKTLDKSVIFPAILLSIKALFNLLFVLGFLGGMGLGAGIALGYGVAI
 FDKVRVPQTEELVNQVKDISSISEITYSDGTVIASIESDLLRTSISSEQISENLKKAIIATEDEHFKEHKGVPKAVIRATLC
 KRVGLGSSSGGSLTLQQLIKQVVGDAPTLARKAAEIVDALALERAMNKDEILTTYLNVAFPGRNNKGQNIAGARQAEGIFC
 VDASQLTVPQAAFLAGLPQSPITYSPYENTGELKSDLEDLEIGLRRKAVLYSMYRTGALS KDEYSQYKDYLKQDFLPSGTVT
 GISRDYLYFTTLAEAQERMYDYLAQRDNVSAKELKNEATQKFYRDAAKEIENGKYKITTTIDQKIHSAMQSAVADYGYLLDI
 GTGRVEVGNVLMNDQTGAILGFVGGGRNYQENQNNHAFDTRKSPASTTKPELLAYGIAIDQGLMGSETILSNYPTNFANGNPIMY
 ANSKGTGMNTLGEALNYSWNI PAYWYRMLREKGV DVKGMEKMGYELPEYGIESLPMGGGIEVTVAQHTNGYQTLANNGVYH
 QKHVISKIEAADGRVVYEQDKPVQVYSKATATIMQGLLEVLSSRVTTTFKSNLTSNLPTLANADWIGKTGTNTQDENMWLM
 LSTPRLTLGGWIGHDDNHSLSRRAGYSNNSNYMAHLVNAIQASPSIWGNERFALDPSVVKSEVLKSTGQKPEKVSVEGKEVE
 VTGSTVTSYWANKSGAPATSYRFAIGGSDADYQNAWSSIVGSLPTPSSSSSSSSSSSSSDSSNSSTTRPSSSRARR

SeqID 233

MSSKFMKSAAVLGTATLASLLLVACGSKTADKPADSGSSEVKELTVYVDEGYKSYIEEVAKAYEKEAGVKVTLTKTGDALGGLI
 KLSLDNQSGNVDPVMMAPYDRVGLSGSDGQLSEVKLSDGAKTDDTTKSLVTAANGKVYGAPAVIESLVMYKNLVDKAPKTI
 ADLENLAKDSKYAFAGEDGKTAFADLWNTFYTYTGLLAGNGAYVFGQNGKDAKDIGLANDGSIVGINYAKSWYEWKPMQI
 TEGAGNLIQTFQEGKTAIIDGPWKAQAFKDAKVNYGVATIPTLNPKGEYAAFGGKAWVIPAQAVKNLEASQKFVDFLVATIE
 QQKVLVDKTNELIPANTEARSYABGKNDELTTAVIKQFKNTQPLPNISQMSAVWDPAKNMLFDAVSGQKDAKTAANDAVTLIKI
 TIKQKFGI

SeqID 234

MIDKVVRLNLLTFFFCMTKIIIFLTTLVKKKKICYNEFKLRNRKQKGVIMWVLGFILFMIFFYSNNSKKIKKLENKIKRLI
 RKEKGNAMSRLLQEMIGKEPIITGVYIGPDNWEVVDVDEEWVKLRVDNTGKEKEFKLQRIEDIQTVEFDGE

SeqID 235

MILSKNREDGLRKFATNIRLNTLRLTNHLGFGHYGSSLSIVEVLAVLYGEIMPMTPEIFAARDRDYFILSKGHGGPALYSTLJ
 LNGFFDKFELYSLNTNGTKLPSHPDRNLTPGIDMTTGSGLQGQISVATGLAYGQIRKSPFYTYAIVGDGELNEGQCWEAIQF
 SHQQLSNLIVFVDDNKKQLDGFTKDICNPGDFVEKFSAFGESIRVKGSDIREIYEGIVQLKQSNNSSPKICVLDTIKQGQV
 ELEEMKSNHHLRPTVEEKQMLTSVVERLSQELEETE

SeqID 236

MKKTILSLTTAAVILAAYVPNEPILADTPSSEVIKETKVGSIQNNIKYKVLTVEGNIGTVQVGNVTPVEFEAGQDGKPI
 TIPTKITVGDVFTVTEVASQAFSYPDETGRIVYYPSSITIPSSIKKIQKGFHGSKAKTIIFDKGSQLEKIEDRAFDFSEI
 EEIELPASLEYIGTSAFSFSQKLKLTFSSSSKLELISHEAFANLSNLEKLTLPKSVKTLGSLNLFRLTTSKHXVDVEEGNESI
 ASVDGVLFSKDKTQLIYPSQKNDESYPKETKELASYSFNKNSYLKLELNEGLEKIGTFADADAIKLEISLPSNLETI
 RLAFYGNLELKEILIPDNVKNFGKHVMNGLPKLKSITIGNNINSLPSFSLSGVLDLSKEIHIKNKSTEFVSKDTFAIPETVI
 FYVTSEHIKVDLKSNSLTSNDIIEKVDNIKQETDVAKPKNSNQGVGVWVKDKGLWYLLNESGSMATGWVKDKGLWYLLNES
 GSMATGWVKDKGLWYLLNESGSMATGWVKDKGLWYLLNESGSMATGWVKDKGLWYLLNESGSMATGWVKDKGLWYLLNESGS
 ATGWVTVSGKWYTYNSGDLVNTTTPDGYRVNANGEWV

SeqID 237

MVRFTGLSLKQTAIEVLKGHISLPDVEAVTQSDQASISIEGEEGHYQLTYRKPQLYRALSLLVTVLAEADKVEIEEQAAJ
 EDLAYMDCSRNAVNLNVAQMIELALMGYSTFELYMEDTYQIEGQPYFGYFRGAYSAAELQEIAYAAQDFVTFVPCIQJ
 LAHLSAFVWGVKEVQELRDVEDILLIGEEKVYDLIDGMFATLSKLKTRKVNIGMDEAHLVGLGRYLILNGVDRSLLMCQHI
 ERVLDIADKYGFHCQMWSDMFFKLMSADGQYDRDVEIPEETRVYLDRLKDRVTLYWDYYQDSEKYNRNFRNHKKISHDLAI
 AGGAWKWIGFTPHNHSRLVAIEANKACRANQIKEVITVGWGDNGGETAQFSILPSLQIWAELSYRNDLGLSAHFKTNTGLI
 VEDFMQIDLANLLPDLPGNLSGINPNRYVYQDILCPILDQHMTPEQDKPHFAQAAETLANIKEKAGNYAYLFETQAQLNAII
 SSKVDVGRRIQAYQADDKESLQIARQELPELRSQIEDFHAFSHQWLKENKVFGLDVTDIRMGGLLQRIKRAESRIEVLJ
 GQLDRIDELEVEILPFTDFYADKDFATTANQWHTIATASTIYTT

SeqID 238

MSNSFVKLLVSOLFANLADIFFRVTIIANIYIISKSVIATSLVPILIGISSFVASLLVPLVTKRLALNRVLSLSQFGKTILLJ
 ILVGMFTVMQSVAPLVTYLFVVAISILDGFAAPVSYAIVPRYATDLGKANSALSMTEAVQLIGWGLGGLLPATIGLLPTTCJ
 NLVLYIISFSLFLPNAEVEVLESETNLEILLKGWKLVARNRLRFLVANSALLEIFSNTIIVSSIIILVFTELLNKTESYWC
 YSNTAYSIGIIISGLIAFRLSEKFLAAKWEPLFTPNLKTIONPNTSLDLPGWFLSPNGCFLLDKKEFPLYGISVEKNTKRKI
 THMNSLPNHHFQNSFYQLSFDGGHLTQYGGLIFFQELFSQKLKERISKYLVNTDQRRYCRYSDSDILVQFLFQLLTGYGTI
 YACKELSADAYFPKLEGGQLASQPTLSRFLSRTDEETVHSLRCLNLELVEFFLQFHQLNQLIVDIDSTHTTYGKQEGVAYT
 AHYRAHGYPHYAFEGKTGYCFNAQLRPGNRYCSEADSFITPVLERFNQLLFMDSGFATPKLYDLIEKTYQYYLIKLLKNJ
 VLSRLGDLSLPCQDEDLTILPHSAYSETLYQAGSWSHKRRVCQFSEKEGNLFYDVISLVTNMTSGTSQDQFQLYRGRGQAI
 NFIKEMKEGFFGDKTDSSTLIKNEVRMMMSCIAYNLYFLFKHLAGGDFQTLTIKFRHFLHVVGKCVRTGRKQLLKLSSLYZ
 YSELSFALYSRIRKVNLLNLPVPEPPRRKASLMMH

SeqID 239

MFASKSERKVHYSIRKFSVGVASVVVASLVMGSVVHATENEGATQVPTSSNRANESQAEQGEQPKKLDSEKDKARKEVEEYVK
KIVGESYAKSTKKRHTITVALVNELNNIKNEYLNKIVESTSESQILMMESRSKVDEAVSKFEKDSSTSSSTKPEASD
TAKPNKPTPEGBKVAEAKKVEAEKKAQDQKEEDRRNYPTITYKTLELEIAESDVEVKAELELVKVKANEPDEQKIKQAE
AEVESKQAEATRLKKIKTDREEAEAEKRRADAKEQKPKGRAKRGVPGELATPDKKENDAKSSDSSVGEETLPSPSLKPEKK
VAEAEKKVEAEKKAEDQKEEDRRNYPTNTYKTLELEIAESDVEVKAELELVKEEAKPRNEEKVKQAKAEVESKKAETRI
EKIKTDKKAEEERAKRKAEEEDKVKEKPAEQQPAPAPAKAEKPAAPKPKPENPAEQPKAEKPADQQAEDYARRSEEEYNRLTQ
QQPKTEKPAQSPSTPKTGWKQENGWYFYNTDGSMTGWLQNGNSWYYLNSNGAMATGWLQNGSWYYLNGSMATGWLQNN
GSWYYLNGSMATGWLQYNGSWYYLNGSMATGWLQYNGSWYYLNGDMATGWVKDGTWYYLEASGAMKASQWPKVSDK
WYYVNGSGALAVNTTVDGYGVNANGEWVN

SeqID 240

MNYSKALNECIESAYMVAGHFGARYLESWHLLIAMSNHYSVAGATLNDYPYEMDRLEEVALELTETDYSQDETFTTELPSRF
LQVLFDAAEYVASVVHAKVLGTEHVLYAILHDSNALATRILERAGFSYEDKKDQVKIAALRRNLEERAGWTREDLKALRQRHF
TVADKQNSMANMMGMPQTPSGGLEDYTHDLTEQARSGLKEPVGIRDKBISRMQILSRKTKNNPVLVGDAVGKTALALGLAÇ
RIASGDVPAEMAKMRVLELDLMNVVAGTRFRGDFEERMNNI IKDIEEDGQVILFIDELHTIMGSGSGIDSTLDAANILKPALA
RGTLRTVGATTQEEYQKHIEKDAALSRRFAKVITIEEPSVADSMTILQGLKATYKHHRVQITDEAVETAVMMAHRYLTSRHLI
DSAILDLDEAAATVQNKAKHVKADDSDLSPADKALMDGKWKQAQQLIAKEEEVPVKDLVTESDILTTLRLSGIPVQKLTQI
DAKKYLNLEAEHLKRVIGQDQAVSSISRIRRNQSGIRSHKRPISFMFLGPTGVGKTELAKALAEVLFDDDESALIRFDMSEY
MEKFAASRLNGAPPGYVGYEEGGELTEKVRNKPYSVLLFDEVEKAHPDIFNVLLQVLDDGVLTDSKGRKVDFSNTIIIMTSNI
GATALRDDKTGVFGAKDIRFDQENMEKRMFEELKKAYRPEFINRIDEKVVFHSLSSDHMQEVVKIMVKPLVASLTEKGIDLKI
QASALKLLANQGYDPEMGARPLRRTLQTEVEDKLAELLLKGDVLVAGSTLKIGVKAGQLKFDIA

SeqID 241

MKILPFIARGTSYLYKMSVKKLVFVLVGLMLAAGDSVYAYSRGNGSIARGDDYPAYYKNGSQEIDQWRMYSRQCTSFVAFRI
SNVNGFEIPAAYGNANEGHRARREGYRVDNPTTIGSITWSTAGTYGHVAVWSNMVMDQIEIEEYNYGYTESYNKRVIKANT
TGFIFKDLDDGSGVNSQSSTSTGGTHYFKTKSAIKTEPLASGTVIDYYPGEKVHYDQILEKDGKWLSTAYNGSYRYVQI
EAVNKNPLGNSVLSSTGGTHYFKTKSAIKTEPLVSATVIDYYPGEKVHYDQILEKDGKWLSTAYNGSRRYIQLEGVTSSÇ
NYQNQSGNISSYSHSSSTVGWKKINGSWYHFKSNGSKSTGWLKDGSSWYYLKLSGEMQTGWLKENGWYLLGSSGAMKTGW
QVSGKWYYSYSSGALAVNTTVDGYRVNSDGERV

SeqID 242

MKVIPLADVKGKKGKEIKEVPTGYAQNFLIKKNLAKEATAQAVGELRGKQKSEKKAHAEMIAEGKAIIKAQLEAEETVVEFVI
KVGPDGRFTGSITNKKIAEELQKQFGIKIDKRHIQVQAPIRAVGLIDVPVKIYQDITSVINLRVKEG

SeqID 243

MKKKILASLLLSTVMVSQVAVLTTAHAETDDKIAAQDNKISNLTAQQQEAQKQVDQIQEQVSAIQAEQSNLQAENDRLQAEÇ
KKLEGEITELSKNIVSRNQSLKQARSQATNGAVTSYINTIVNSKSI TEAISRVAAAMSEIVSANNKMLEQQKADKKAISEKQ
ANNDIAINTVIANQQKLADDAQALTTKQAEKAAELSLAAEKATAEGEKASLLEQKAAAEAEARAAVAEAAAYKEKRASQQQS
LASANTNLTAQVQAVSESAAAPVRAKVRPTYSTNASSYPIGECTWGVKTLAPWAGDYWGNGAQWATSAAAAGFRTGSTPQVG
IACWNDGGYGHVAVVTAVESTTRIQVSESNYAGNRTIGNHRGFNPTTSEGFTVYIYAD

SeqID 244

MVKRRIRRGTRPEKVVVPEQSSIPSYPVSVTSNQGTDVAVEPAKAVAPTDDWKQENGWYFYNTDGSMTGWVQVNSSWYYI
NSNGSMKVNQWFQVGKWWYVNTSGELAVNTSIDGYRVNDNGEWR

SeqID 245

ELRRLSRLVDQELYFGCGWRLSLEWLPSMRKDSWPSNTAPRTTMVQ

SeqID 246

DCIRKQPFTRDEPNKTCRKTGPSKSYCSYRW

SeqID 247

GQRNPRRIERVIRMAETKPRISKKEG

SeqID 248

QRKLFKIFHLFQKSGWNQKSSCLKLNLSLNRKMTQMTKMFRSIFQPKKPLNTNFQAYNSLHQINQKISLKRRLSEKISKÇ

SeqID 249

LVIIVLKIQSKSETDFIFKTWPFFILLSKIIPLMVLDCCQVSISWTNRETVAYSKLLAIKTLKGDYHDGQSKKIRLSHASRVRTI
SWYPHDMADSTRIMAFSRKGC

SeqID 250

ERLPAPFRSLSGRKLDOGGTKEKSGDGRSP

SeqID 251

RNCLSTWKKSSSNYHTEIKRGTVRQCLGKGRFKEVYSADYAQQSYENNKRKRSVKKSSLTKELKEKILHYHNQKFSPEMMVMAKÇ
VNVGISTIIYWIHGGKLGSLKQDILLYPRKGKALKKQASTNFKPAGQSIEQRPEAINLRLENGHYEIDTVLLTRSKNYCLIVLÇ
DRKSRHQIIRLIPNKSAEVVNQALKLILKQHKILSITADNGTEFNRLFDIFSEEHIIYAHYPYASWERGNTENHNRLIRR

SeqID 252

PVMTISSTPMKNMDLSTKASPSQPLQKGHMIWSGK

SeqID 253

TSSIRIHTRKSSPNWTTTTPHLALSAETN

SeqID 254

YFLPHKYARESLSLPSTNKLHRKQGS

SeqID 255

AAFKKDQINERVEKLGKLPITINYNGKSEVIDSKEKLQELMNKAVKDEVAQI

SeqID 256

AYAHSKRSAGSGRAGGRQCLCQCQNKCRDFFKY

SeqID 257

HGRPYHKPHQPHHHGFPQQSYNLLPPKHKPTLCVRR

SeqID 258

KGKILLPLRLTTQRWQRKIRPDSRKSANNKANLDFHNSRCKSSLSDEAPNLHKNPALLVHSLSRVIAVLLELSPLQAYSIVKI
SPKEDDLIHDDAILVRFGILEVHDSPEYELLLLYHTHSYRFSCSIYLS

SeqID 259

FTVSHVFLLYLSFNPRPKSMSLSFTSSKLLRPRFRFTFIISASDFSVKSCTVLIPARFKQLYERTDKSSSSIVRSKIRSSDSV
ASFITSDVLAISVRFVNKSRCSVKIRAESPASSGIIIVPFVKISRVNLSKPSLLPTRAGST

SeqID 260

LVCMKNGKCYKERNNCCH

SeqID 261

FHYLSKYFLVSAITTDGDKTKRAIKFGRAIKALTISAIQTISNSINPPNKTMTSTKTTR

SeqID 262

GKKVFIKYPLSRVSSKTGPMITGRTKDKIVDKKVGCPFEKSTVKYSS

SeqID 263

SSPVFPKLVMSGANKPRERRNFFSSKMSFHLTFVL

SeqID 264

YLTFSVPKIASSEKVLTRYWRSSPWGAFGLREEPPPPKLEKISSKPPKPPAPLKPPKPPAPPKPPPLAPAPYWS

SeqID 265

QSWRPDPDSKCYTQEKLTIPKRRKDIDFYHNSIQRHKNSHKSHLLDSYRLIITRLAEIVHENKILIVLILYVTNIPSRRI
YEVNRV

SeqID 266

LFRFYRVIVLYRGWHIYLLILVNLQYVQNVFRKDRFLVRGAQPFPHGERSAGHLVLPYVL

SeqID 267

ITHPPLNPEHFVSRVFSSSLGLKSYQPKDDRFLRKPSDSRHPESGNSGKWQVLNSPLVIVK

SeqID 268

TLAKAVGLMYSPPIPPKPFLGRITTDSSSI

SeqID 269

PGSPFSEISGAGFFGVAKRIFPRPPRPWATINSCPCSIKSVKTLPVASARTVPCGTRTLRSSAPRPCIPLVIFSPESAL

SeqID 270

INSLTLATSLSKRRAPRKASKASPRMVSRLRPPDFSSPLPNLINWSNWQSRAPAKLSSRTIARSFDRSPSGFLGYFLYRY
EINNCRITASPKNSKRSLSCEIFKRRCSLA

SeqID 271

PIGKRNCBAEQSHHLEKQKTFQSRKTKRYGASPEPRYRESRKPRLSQ

SeqID 272

QPLGHSKAEHEHTICSHTFDNHTTETIPNQVKGRDMTSSETLPFPSKNQNGKAKQIP

SeqID 273

PCSLPDYGLVSGYHSCHYQSNDRFLSHGNWRTLLYSWSWILCQEKTLFPHDLASLYPSCVRTSIHRYCLLVHKLRNSIS
TFFFTHTIDKVLVQAHIIISQFWMKRTYQHIFFLGCNNLIVHCC

SeqID 274

RVKDNHLDKLVKALLKRRSSTQYYIHQLLRKMIRLYGHQQLHNNSEILVYSDYGHVDLLLLLETNKIPVY

SeqID 275

QVIKIDIATTNKTESVKSQSEREKKRLTSSNILKVRGRPI

SeqID 276

AFKSSKVPSLDPSSTKTYISVSKSGSKASRA

SeqID 277

DKTDPLARKLPDKSKPSTSFCTKSLSPVNMASLTSAPKPSKTKASLGICSPADKRMTSPSTNSSGLRATS

SeqID 278

LCRLQTQARPRGSVTNLTKQNKVYRYLNYLRQTQLSAM

SeqID 279

CIQSIGNEGQCKGNSCYVGKEIHLAPISDIVGHKKEEGDDGNDGRQFYLFHLVGSFAFLRSFPLLYSKGINEEGDGIGND
GRLISKDIINSTGQNGINNTKVISPFA

SeqID 280

TSTKLVIDTTTFMTFCTNNTKSSKFTNTFTKLDVGTTRHVGCDCGNGTTLSIHDDLGFSSIVVFGIQDFVRNTSCNQFLRNVV
TSFNRYCTNQDRLTLLVTSLVNFVFNRFKLRFDTCIKKV

SeqID 281

ISTGVPTCSMYPLLKTAILSDKVKASS

SeqID 282

LSTMSSIKSILCSLPHTHTIFSKSAISPKRGSTAI

SeqID 283

SCSYSSTNSKACISIVGLSKPTIFICVTPISAAKAISSASRPANSSTFKCVSVSKIISNLVIFYLLLYQKRGAPNFSVSPPLF
NRELFICYLFYPILPISYSTVRDRRDWLH

SeqID 284

VTSCIVPAVACGALVVLGAALGATGLLGTVTMMACTPIVSASFSTSSIVFAFSISLRAACFSASTLAKSSAFSLSESGAPLIS
SCLSLAAFSMAFLADSFSVANCLEACD

SeqID 285

YSPFNHSILIRKTKKIINPNPKAPRMNWRSKVWSNQPVNISTNHTKSDRPIKK

SeqID 286

DYFKERTTTFTRFSTVKPYSANTFGAGAEAPKVSIPRTAPSRPTYLYQF

SeqID 287

RGRRLGLCVARIKAPRLVIKPKRTIDPPTKDRYSPPLSATSLVVPKSPIISFPKMDKNPKRKLNSKVIFNASVT

SeqID 288

TPPYTKIPAKTAIIPFISAQDFNQQRLSG

SeqID 289

ATGAAGAAAAAATCTTAGCGTCACTTTTATTAAAGTACAGTAATGGTTTCTCAAGTAGCTGTTTAACTGCGCATGCAGA
AACGACTGATGACAAAATTGCTGCTCAAGATAATAAAATTAGTAACTTAACAGCACACAACAAGAAGCCCAAAAACAAGTTG
ACCAAATTCAGGAGCAAGTATCAGCTATTCAAGCTGAGCAGTCTAACTTGCAAGCTGAAAATGATAGATTACAAGCAGAATCT
AAGAACTCGAGGGTGAGATTACAGAACTTTCTAAAAACATTGTTTCTCGTAACCAATCGTTGGAAAAACAAGCTCGTAGTGC
TCAACAAATGGAGCCGTAAGTATATCAATACCATTGTAAGTCAAAATCAATTACAGAAGCTATTTACAGTGTGCTG
CAATGAGTGAAATCGTATCTGCAACAAACAAAATGTTAGAACAAACAAAGGCAGATAAAAAGCTATTTCTGAAAAACAAGTA
GCAAAATATGATGCTATCAATACTGTAATTGCTAATCAACAAAAATGGCTGATGATGCTCAAGCATTGACTACGAAACAGGC
AGAACTAAAGCTGCTGAATTAAGTCTTGCTGCTGAGAAAGCGACAGCTGAAGGGGAAAAAGCAAGTCTATTAGAGCAAAAAG
CAGCAGCTGAGGCAGAGGCTCGTGACAGCTGCGGTAGCAGAAGCAGCTTATAAAGAAAAACGAGCTAGCCAACAACAATCAGTA
CTTGCTTCAGCAACACTAACTTAACAGCTCAAGTGCAAGCAGTATCTGAATCTGCAGCAGCACCTGTCCGTGCAAAAAGTTCG
TCCAACATACAGTACAAACGCTTCAAGTTATCCAATTGGAGAATGTACATGGGGAGTAAAAACATTGGCACCTTGGGCTGGAG
ACTACTGGGGTAATGGAGCACAGTGGGCTACAAGTGACAGCAGCAGCAGGTTTCCGTACAGGTTCAACACCTCAAGTTGGAGCA
ATTGCATGTTGGAATGATGGTGGATATGGTCACGTAGCGTTGTTACAGCTGTTGAATCAACAACACGTATCCAAGTATCAGA

ATCAAATTATGCAGGTAATCGTACAATTGGAAATCACCGTGGATGGTTCAATCCAACAACAACCTCTGAAGGTTTTGTTACAT
ATATTTATGCAGAT

SeqID 290

ATGAAGAAAAAATCTTAGCGTCACTTTTATTAAGTACAGTAATGGTTTCTCAAGTAGCTGTTTTAACTGCGCATGCAGA
AACGACTGATGACAAAATTGCTGCTCAAGATAATAAAATTAGTAACCTTAACAGCACAAACAAGAAGCCCAAAAACAAGTTG
ACCAAATTCAGGAGCAAGTATCAGCTATTCAAGCTGAGCAGTCTAAGCTGCAAGCTGAAAATGATAGATTACAAGCAGAATCT
AAGAACTCGAGGGTGAGATTACAGAACCTTTCTAAAAACATTGTTTCTCGTAACCAATCGTTGGAAAAACAAGCTCGTAGTGC
TCAACAAAATGGAGCCGTAAGTATATCAATACCATTGTAACTCAAAATCAATTACAGAAGCTATTTACAGTGTGCTG
CAATGAGTGAAATCGTATCTGCAAAACAACAAATGTTAGAACACAAAAGCCAGATAAAAAAGCTATTTCTGAAAAACAAGTA
GCAAAATGATGCTATCAATACTGTAATTGCTAATCAACAAAAATTGGCTGATGATGCTCAAGCATTGACTACGAAACAGGC
AGAAGTAAAGCTGCTGAATTAAGTCTTGCTGCTGAGAAAGCGACAGCTGAAGGGGAAAAAGCAAGTCTATTAGAGCAAAAAC
CAGCAGCTGAGGCAGAGGCTCGTGACGCTCGGTAGCAGAAGCAGCTTATAAGAAAAACGAGCTGGCCAACAACATCAGTA
CTTGCTTCAGCAACACTAAGTAAACAGCTCAAGTGCAAGCAGTATCTGAATCTGCAGCAGCACCTGTCCGTGCAAAAGTTCC
TCCAACATACAGTACAAACGCTTCAAGTTATCCAATTGGAGAATGTACATGGGGAGTAAAAACATTGGCACCTTGGGCTGGAC
ACTACTGGGGTAATGGAGCAGTGGGCTACAAGTGCCAGCAGCAGGCTTCCGTACAGGTTCAACACCTCAAGTTGGAGCA
ATTGCTGTTTGGAAATGATGGTGGATATGGTCAGTACGCGTTGTTACAGCTGTTGAATCAACACACGTAATCCAAGTATCAG
ATCAAATTATGCAGGTAATCGTACAATTGGAAATCACCGTGGATGGTTCAATCCAACAACAACCTCTGAAGGTTTTGTTACAT
ATATTTATGCAGAT

SeqID 291

ATGATCCAAATCGGCAAGATTTTTGCGGACGCTATCGGATTGTCAAACAGATTGGTTCGAGGAGGTATGGCGGATGTCTACCT
AGCCAAAGACTTAATCTTAGATGGGGAAGAAGTGGCAGTGAAGGTTCTGAGGACCAACTACCAGACGACCCGATAGCTGTAG
CTCGTTTTCAGCGTGAAGCGAGAGCTATGGCAGATCTAGACCATCCTCATATCGTTCCGATAACAGATATTGGCGAGGAAGAC
GGTCAACAGTACCTAGCTATGGAGTATGTGGCTGGACTGGACCTCAAACGCTATATCAAGGAACATTATCCTCTTTCTAATGA
AGAAGCAGCCCGTATCATGGGACAAATTTCTTGGCTATGCGCTTGGCCCATACTCGAGGAATTGTTACAGGGACTTGAAAC
CTCAAAATATCCTCTTGACACCAGATGGGACTGCCAAGTCAAGACTTTGGGATTGCTGTAGCCTTTGCAGAGACAAGTCTG
ACCCAGACTAACTCGATGTTGGGCTCAGTTCACTTGTGTCACCAGAGCAGGCGGGTGGTTTCAAGGCGACTGTGCAAGTGA
TATCTATGCCATGGGGATTATTTTCTATGAGATGCTGACAGGCCATATCCCTTATGACGGGGATAGCGCGGTGACCATTGCC
TCCAGCATTTCCAGAAACCCCTGCCGTCCGTTATTGACAGAAATCCATCTGTACCTCAGGCTTTAGAAAATGTTATTATCAAG
GCAACTGCTAAAAAGTTGACCAATCGCTACCGCTCGGTTTCAGAGATGTATGTGGACTTGTCTAGTAGCTTGTCTTCAATCG
TAGAAATGAAAGTAAGTTAATCTTTGATGAAACGAGCAAGGCAGATACCAAGACCTTGCCGAAGGTTTCTCAGAGTACCTTGA
CATCTATTCTTAAGGTTCAAGCGCAAAACAGAACACAAATCAATCAAAAACCCAAGCCAGGCTGTGACAGAGGAACTTACCA
CCACAAGCACCGAAAAACATAGATTTAAGATGCGTTACCTGATTTTTGTTGGCCAGCCTTGTATTGGTGGCAGCTTCTCTTA
TTGGATACTATCCAGAACTCCTGCAACCATTTGCCATTCCAGATGTGGCAGGTGACAGAGTTGCAGAGGCCAAGGCAACGCTC
AAAAAGCCAAATTTTGAGATTGGTGAAGAGAGACAGAGGCTAGTGAAAGGTTGGAAGAAGGGCGGATTATCCGTACAGATCCT
GGCGCTGGAACTGGTTCGAAAAGAGGAACGAAAATCAATTTGGTTGTCTCATCAGGCAAGCAATCTTTCAAATTAGTAATTT
TGTCGGTCGGAAATCCTCTGATGTCATTGCGGAATTAAGAGAAAAAGTTCCAGATAATTTGATTAAAAATTGAGGAAGAAC
AGTCGAATGAGAGTGAGGCTGGAAACGGTCTGAAGCAAAGTCTACCAGAAGGTACGACCTATGACTTGAGCAAGGCAACTCA
ATTGTCTTGACAGTAGCTAAAAAGTTACAAGTGTGCGCATGCGAGTTACATTGGTTCTAGCTTGGAGTTTACTAAGAACAF
TTTGATTCAAATTTGGGATTAAAGGAAGCTAATATAGAAAGTTGTAGAAAGTGACGACAGCGCCTGCAGGTAGTGCAGAAGGC
TGGTTGTTGAAACAAAGTCTTAGAGCAGGTGAAAAGGTAGACCTCAATAAGACTAGAGTCAAGATTTCAATCTACAAACCTAA
ACAACCTCAGCTACTCCT

SeqID 292

ATGATCCAAATCGGCAAGATTTTTGCGGACGCTATCGGATTGTCAAACAGATTGGTTCGAGGAGGCATGGCGGATGTCTACCT
AGCCAAAGACTTAATCTTAGATGGGGAAGAAGTGGCAGTGAAGGTTCTGAGGACCAACTACCAGACGACCCGATAGCTGTAG
CTCGTTTTCAGCGTGAAGCGAGAGCTATGGCAGATCTAGACCATCCTCATATCGTTCCGATAACAGATATTGGTGAGGAAGAC
GGTCAACAGTATCTTCAATGGAGTATGTTGCTGGACTAGACCTCAAACGCTATATCAAGGAACATTATCCTCTTTCTAATGA
AGAAGCAGTCCGTATCATGGGACAAATTTCTTGGCTATGCGCTTGGCCCATACTCGAGGAATTGTTACAGGGACTTGAAAC
CTCAAAATATCCTTTTGACACCAGATGGGACGCGCAAGGTCAAGACTTTGGGATTGCTGTAGCCTTTGCAGAGACAAGTCTG
ACCCAGACTAACTCGATGTTGGGCTCAGTTCACTTGTGTCACCAGAGCAGGCGGTGGTTTCAAGGCGACTGTGACAGAGTGA
TATCTATGCCATGGGGATTATTTTCTATGAGATGTTGACAGGCCATATCCCTTATGACGGGGATAGCGCGGTGACCATTGCC
TCCAGCATTTCCAGAAACCCCTGCCGTCCGTTATTGACAGAAATCCATCTGTACCTCAGGCTTTAGAAAATGTTATTATCAAG
GCAACTGCTAAAAAGTTGACCAATCGCTACCGCTCGGTTTCAGAGATGTATGTGACTTGTCTAGTAGCTTGTCTTCAATCG
TAGAAATGAAAGTAAGTTAATCTTTGATGAAACGAGCAAGGCAGATACCAAGACCTTGCCGAAGGTTTCTCAGAGTACCTTGA
CATCTATTCTTAAGGTTCAAGCGCAGACAGAACACAAATCAATCAAAAACCCAAGCCAGGCTGTGACAGAGGAACTTACCA
CCACAAGCACCGAAAAACATAGATTTAAGATGCGTTACCTGATTTTTGTTGGCCAGCCTTGTATTGGTGGCAGCTTCTCTTA
TTGGATACTATCCAGAACTCCTGCAACCATTTGCCATTCCAGATGTGGCAGGTGACAGAGTTGCAGAGGCCAAGGCAACGCTC
AAAAAGCCAAATTTTGAGATTGGTGAAGAGAGACAGAGGCTAGTGAAAGGTTGGAAGAAGGGCGGATTATCCGTACAGATCCT
GGCGCTGGAACTGGTTCGAAAAGAGGAACGAAAATCAATTTGGTTGTCTCATCAGGCAAAACAATCCTTCCAAATTAGTAATTT
TGTCGGCCGGAATCTTCTGATGTTATCGCGGAATTAAGAGAAAAAGTTCCAGATAATTTGATTAAAAATTGAGGAAGAAC
AGTCGAATGAGAGTGAGGCTGGAAACGGTCTGAAGCAAAGTCTACCAGAAGGTACGACCTATGACTTGAGCAAGGCAACTCA
ATTGTTTTGACAGTAGCTAAAAAGCTACGACGATTCAATTAGGGAACCTATATTGGACGGAACCTCTACAGAGTAATCTCAG
ACTCAAGCAGAAGAAGGTTCTTGAGAAATTTGATTAAAGTAGAGGAAGAAGAGTCCAGCGAAAGCGAACCGGAACGATTATGA
AACAAAGTCAGGTCGCGGAACGACTTATGATGTGAGTAAACCTACTCAAATTTGTTGACAGTAGCTAAAAAGTTACAAGT
GTTGCCATGCCAGTTACATTGGTTCCAGCTTGAGTTTACTAAGAACAAATTTGATTCAAATTTGTTGGGATTAAAGGAAGCTAA

TATAGAAGTTGTAGAAGTGACGACAGCGCCTGCAGGTAGTGTAGAAGGCATGGTTGTTGAACAAAGTCCTAGAGCAGGTGAAA
AGGTAGACCTAAATAAGACTAGAGTCAAGATTTCAATCTACAAACCTAAAACAACTTCAGCTACTCCT

SeqID 293

ATGATCCAAATCGGCAAGATTTTTGCCGGACGCTATCGGATTGTCAAACAGATTGGTCGAGGAGGTATGGCGGATGTCTACCT
AGCCAAAGACTTAATCTTAGATGGGGAAGAAGTGGCAGTGAAGGTTCTGAGGACCAACTACCAGACGGACCCGATAGCTGTAG
CTCGTTTTTCAGCGTGAAGCGAGAGCTATGGCAGATCTAGACCATCCTCATATCGTTCCGATAACAGATATTGGTGAGGAAGAC
GGTCAACAGTATCTTGCAATGGAGTATGTTGCTGGACTAGACCTCAAACGCTATATCAAGGAACATTATCCTCTTTCTAATGA
AGAAGCAGTCCGTATCATGGGACAAATCCTCCTAGCCATGCGTTTGGCCCATACCAGAGGAATTGTTCAAGGGACTTGAAAC
CTCAAAATATCCTTTTGACACCAGATGGGACTGCCAAGGTCAAGACTTTGGGATTGCTGTAGCCTTTGCAGAGACAAGTCTG
ACCCAGACTAACTCGATGTTGGGCTCAGTTTATTCTTGTCTCCCGAGAGCAGGCGCGTGGTTTGAAGGCGACTGTGCAGAGTGA
TATCTATGCTATGGGGATTATTTTCTATGAGATGTTGACAGGCCATATCCTTATGACGGGGATAGCGCGGTGACCATTGGCC
TCCAGCATTTCCAGAAACCCCTGCCGTCCGTTATTGCAGAAAATCCATCTGTACCTCAGGCTTTAGAAAATGTTATTATCAAG
GCAACTGCTAAAAAGTTGACCAATCGCTACCGCTCGGTTTTCAGAGATGTATGTGGACTTGTCTAGTAGCTTGTCTTACAATCG
TAGAAATGAAAGTAAGTTAATCTTTGATGAAACAGGACAGGACAGATACCAAGACCTTGCCGAAGGTTTCTCAGAGTACCTTG
CATCTATTCTAAGGTTCAAGCGCAGACAGAACACCAATCAATCAAAAACCCAAGCCGGGCTGTGACAGAGGAACTTACCA
CCACAAGCACCGAAAAACATAGATTTAAGATGCGTTACCTGATTGTTGGCCAGCCTTGTAATTGGTGGCAGCTTCTCTTA
TTGGATACTATCCAGAACTCCTGCAACCATTTGCCATTCCAGATGTGGCAGGTGACAGAGTTGACAGGGCCAGGCAACGCTCF
AAAAAGCCAATTTTGAGATTGGTGAGGAGAAGACAGAGGCTAGTGAAGAGGTGAAGAAGGGCGGATTATCCGTACAGATCC
GGCGCTGGAACCTGGTCGAAAAGAAGGAACGAAAATCAATCTGGTTGTCTCATCAGGCAACCAATCCTTCCAAATTAGTAATT
TGTCGCGCCGGAATCTTCTGATGTTATCGCGGAATTAAGAGAGAAAAAGTTCCAGATAATTTGATTAAAAATTGAGGAAGAAC
AGTCGAATGAGAGTGAGGCTGGAACGGTCTGAAGCAAAGTCTACCAGAAGGTACGACCTATGACTTGAGCAAGGCAACTCA
ATTGTTTGGACAGTAGCTAATAAGCTACGACGATTAATTAAGGAACTATATTGGACGGAACCTACAGAAAGTAACTCTCAG
ACTCAAGCAGAGAAGGTTCTTGAGAAATTTGATTAAAGATAGAGGAAGAAGAGTCCAGCGAAAGCGAACCCAGGAACGATTATG
AACAAAGTCCAGGTGCCGGAACGACTTATGATGTGAGTAAACCTACTCAAATTTGTTGACAGTAGCTAAAAAGTTTACAAG
GTTGCCATGCCGAGTTACATTGGTTCCAGCTTGGAGTTTACTAAGAACAAATTTGATTCAAATTTGTTGGGATTAAAGGAAGCTA
TATAGAAGTTGTAGAAGTGACGACAGCGCCTGCAGGTAGTGACAGAGGCATGGTTGTTGAACAAAGTCCTAGAGCAGGTGAA
AGGTAGACCTCAATAAGACTAGAGTCAAGACTTCAATCTACAAACCTAAAACAACTTCAGCTACTCCT

SeqID 294

ATGATCCAAATCGGCAAGATTTTTGCCGGACGCTATCGGATTGTCAAACAGATTGGTCGAGGAGGCATGGCGGATGTCTACCT
AGCCAAAGACTTAATCTTAGATGGGGAAGAAGTGGCAGTGAAGGTTCTGAGGACCAACTACCAGACGGACCCGATAGCTGTAC
CTCGTTTTTCAGCGTGAAGCGAGAGCTATGGCAGATCTAGACCATCCTCATATCGTTCCGATAACAGATATTGGTGAGGAAGA
GGTCAACAGTATCTTGCAATGGAGTATGTTGCTGGACTAGACCTCAAACGCTATATCAAGGAACATTATCCTCTTTCTAATG
AGAAGCAGTCCGTATCATGGGACAAATCTCTTGGCTATGCGCTTGGCCCATACTCGAGGAATTGTTCAAGGGACTTGAAA
CTCAAAATATCCTTTTGACACCAGATGGGACGGCCAAGGTCAAGACTTTGGGATTGCTGTAGCCTTTGCAGAGACAAGTCT
ACCCAGACTAACTCGATGTTGGGCTCAGTTTATTCTTGTCAACAGAGCAGGCGCGTGGTTTGAAGGCGACTGTGCAGAGTG
TATCTATGCCATGGGGATTATTTCTATGAGATGTTGACAGGCCATATCCTTATGACGGGGATAGCGCGGTGACCATTGGC
TCCAGCATTTCCAGAAACCCCTGCCGTCCGTTATTGCAGAAAATCCATCTGTACCTCAGGCTTTAGAAAATGTTATTATCAG
GCAACTGCTAAAAAGTTTGACCAATCGCTATCGCTCGGTTTCAGAGATGTATGTAGACTTGTCTAGTAGCTTGTCTTACAATC
TAGAAATGAAAGTAAGTTAATCTTTGATGAAACGAGCAAGGCAGATACCAAGACCTTGCCGAAGGTTTCTCAGAGTACCTTG
CATCTATTCTAAGGTTCAAGCGCAGACAGGACACAAATCAATCAAAAACCCAAGCCAGGCTGTGACAGAGGAACTTACCA
CCACAAGCACCGAAAAACATAGATTTAAGATGCGTTACCTGATTGTTGTTGGCCAGCCTTGTAATTGGTGGCAGCTTCTCTTA
TTGGATACTATCCGAACCTCTGCAACCATTTGCCATTCCAGATGTGGCAGGTGACAGAGTTGACAGAGGCCAAGGCAACGCTC
AAAAAGCCAATTTTGAGATTGGTGAGGAGAAGACAGACTGAGTGAAGAAGGTGAAGAAGGGCGGATTATCCTGTTACAGATCC
GGCGCTGGAACCTGGTCGAAAAGAAGGAACGAAAATTAATCTGGTTGTCTCATCAGGCAACCAATCCTTCCAAATTAGTAATT
TGTCGCGCCGGAATCTTCTGATGTTATCGCGGAATTAAGAGAGAAAAAGTTCCAGATAATTTGATTAAAAATTGAGGAAGAA
AGTCGAATGAGAGTGAGGCTGGAACGGTCTGAAGCAAAGTCTACCAGAAGGTACGACCTATGACTTGAGCAAGGCAACTCA
ATTATTTTGACAGTAGCTAAAAAGCTACGACGATTAATTAAGGAACTATATTGGACGGAACCTCTACAGAAGTAACTCTCAG
ACTCAAGCAGAGAAGGTTCTTGAGAAATTTGATTAAAGATAGAGGAAGAAGAGTCCAGCGAAAGCGAACCCAGGAACGATTATG
AACAAAGTCCAGGTGCCGGAACGACTTATGATGTGAGTAAACCTACTCAAATTTGTCTTGACAGTAGCTAAAAAGTTTACAAG
GTTGCCATGCCGAGTTACATTGGTTCCAGCTTGGAGTTTACTAAGAACAAATTTGATTCAAATTTGTTGGGATTAAAGGAAGCTA
TATAGAAGTTGTAGAAGTGACGACAGCGCCTGCAGGTAGTGACAGAGGCATGGTTGTTGAACAAAGTCCTAGAGCAGGTGAA
AGGTAGACCTAAATAAGACTAGAGTCAAGATTTCAATCTACAAACCTAAAACAACTTCAGCTACTCCT

SeqID 295

ATGATCCAAATCGGCAAGATTTTTGCCGGACGCTATCGGATTGTCAAACAGATTGGTCGAGGAGGCATGGCGGATGTCTACCT
AGCCAAAGACTTAATCTTAGATGGGGAAGAAGTGGCAGTGAAGGTTCTGAGGACCAACTACCAGACGGACCCGATAGCTGTAC
CTCGTTTTTCAGCGTGAAGCGAGAGCTATGGCAGATCTAGACCATCCTCATATCGTTCCGATAACAGATATTGGTGAGGAAGA
GGTCAACAGTATCTTGCAATGGAGTATGTTGCTGGACTAGACCTCAAACGCTATATCAAGGAACATTATCCTCTTTCTAATG
AGAAGCAGTCCGTATCATGGGACAAATCTCTTGGCTATGCGCTTGGCCCATACTCGAGGAATTGTTCAAGGGACTTGAAA
CTCAAAATATCCTTTTGACACCAGATGGGACTGCCAAGGTCAAGACTTTGGGATTGCTGTAGCCTTTGCAGAGACAAGTCT
ACCCAGACTAACTCGATGTTGGGCTCAGTTTATTCTTGTCAACAGAGCAGGCGCGTGGTTTGAAGGCGACTGTGCAGAGTG
TATCTATGCCATGGGGATTATTTCTATGAGATGTTGACAGGCCATATCCTTATGACGGGGATAGCGCGGTGACCATTGGC
TCCAGCATTTCCAGAAACCCCTGCCGTCCGTTATTGCAGAAAATTCATCTGTACCTCAGGCTTTAGAAAATGTTATTATCAA
GCAACTGCTAAAAAGTTGACCAATCGCTATCGCTCGGTTTTCAGAGATGTATGTAGACTTGTCTAGTAGCTTGTCTTACAATC
TAGAAATGAAAGTAAGTTAATCTTTGATGAAACGAGCAAGGCAGATACCAAGACCTTGCCGAAGGTTTCTCAGAGTACCTTG
CATCTATTCTAAGGTTCAAGCGCAGACAGAACACCAATCAATCAAAAACCCAAGCCAGGCTGTGACAGAGGAACTTACCA

CCACAAGCACCGAAAAACATAGATTTAAGATGCGTTACCTGATTTTGTGGCCAGCCTTGTATTGGTGGCAGCTTCTCTTAT
TTGGATACTATCCAGAACTCCTGCAACCATTTGCCATTCCAGATGTGGCAGGTGAGACAGTTGACAGAGGCCAAGGCAACGCTCA
AAAAAGCCAATTTTGGAGATTGGTGAGGAGAAGACAGAGGCTAGTGAAAAGGTGGAAGAAGGGCGGATTATCCGTACAGATCCT
GGCGCTGGAACCTGGTCGAAAAGAAGGAACGAAAATTAATCTGGTTGTCTCATCAGGCAACAATCCTTCCAAATTAGTAATTA
TGTCGGCCGGAAATCTTCTGATGTTATCGCGGAATTAAGAAGAAAAAGTTCCAGATAATTTGATTAAAAATTGAGGAAGAAG
AGTCGAATGAAAGTGAGGCTGGAACCGTCTGAAGCAAAAGTCTACCAGAAGGTACGACCTATGACTTGAGCAAGGCAACTCAA
ATTGTTTTGACAGTAGCTAAAAAGCTACGACGATTCAATTAGGGAACCTATATTGGACGGAACCTACAGAAGTAATCTCAGA
ACTCAAGCAGAAGAAGGTTCTGAGAAATTGATTAAAGTAGAGGAAGAAGATCCAGCGAAAGCGAACCCAGGAACGATTATGA
AACAAAGTCCAGGTGCCGGAACGACTTATGATGTGAGTAAACCTACTCAAATTGTCTTGACAGTAGCTAAAAAGTTACAAGT
GTTGCCATGCCGAGTTACATTGGTTCCAGCTTGGAGTTTACTAAGAACAAATTGATTCAAATTGTTGGGATTAAGGAAGCTAA
TATAGAAGTTGTAGAAGTGACGACAGCGCTGACGTTAGTGTAGAAGGCATGGTTGTTGAACAAAGTCTAGAGCAGGTGAAA
AGGTAGACCTAAATAAGACTAGAGTCAAGATTTCAATCTACAAACCTAAACCAACTTCAGCTACTCCTTAA

SeqID 296

ATGTTTGCATCAAAAAGCGAAAGAAAAGTACATTATTCAATTCGTAAATTTAGTATTGGAGTAGCTAGTGTAGCTGTGTCAC
TCTTGTATTGGGAAGTGTGGTTTCATGCGACAGAGAACGAGGGAAGTACCCAGCAGCCACTTCTTCTAATATGGCAAGACAG
AACATAGGAAAGCTGCTAAACCAAGTCGTGATGAATATATAGAAAAAATGTTGAGGGAGATTCAACTAGATAGAAGAAAAA
ACCCAAAATGTGCGCTTAAACATAAAGTTGAGCGCAATTAACCGAAGTATTGCGTGAATTAATGTTTGAAGAGAAGTC
GAAAGATGAGTTGCCGTGAGAAATAAAGCAAAGTTAGACGCAGCTTTTGAAGAGTTTAAAAAGATACATTGAAACCCAGGAG
AAAAGGTAGCAGAAGCTAAGAGAAGGTTGAAGAAGCTAAGAAAAAGCCGAGGATCAAAAAGAAGAAGATCGTCGTAACCTAC
CCAACCAATACCTTACAAAACGCTTGAACCTGAAATTTGCTGAGTTGATGTGAAAGTTAAAGAAGCGGAGCTTGAACCTAGTAA
AGAGGAAGCTAAAGAAATCTCGAAACGAGGGCACAATTAAGCAAGCAAAAGAGAAAGTTGAGAGTAAAAAGCTGAGGCTACA
GGTTAGAAAACATCAAGACAGATCGTAAAAAAGCAGAAGAAGTCTAAACGAAAAGCAGATGCTAAGTTGAAGGAAGCTAA
GTAGCGACTTCAGATCAAGGTAAACCAAAGGGGCGGGCAAAACGAGGAGTTCTTGAGAGCTAGCAACACCTGATAAAAAAG
AAATGATGCGAAGTCTTCAGATTCTAGCGTAGGTGAAGAACTCTTCCAAGCTCATCCCTGAAATCAGGAAAAAGGTAGCAG
AAGCTGAGAAGAAGGTTGAAGAAGCTGAGAAAAAGCCAGGATCAAAAAGAAGAAGATCGCCGTAACTACCCAACCAATAC
TACAAAACGCTTGACCTTGAATTTGCTGAGTCCGATGTGAAAGTTAAAGAAGCGGAGCTTGAACCTAGTAAAAAGGAGCTA
GGAACCTCGAGACGAGGAAAAAATTAAGCAAGCAAAAGCGAAAGTTGAGAGTAAAAAGCTGAGGCTACAGGTTGAGTAAAC
TCAAGACAGATCGTAAAAAAGCAGAAGAAGTCTAAACGAAAAGCAGCAGAGAAGATAAAGTTAAAGAAAAACCGCTGA
CAACCACAACCGCGCCGCTACTCAACCAGAAAAACCGCTCCAAAACCGAGAGAAGCCAGCTGAACAACCAAAAGCAGAAA
AACAGATGATCAACAAGCTGAAGAAGACTATGCTCGTAGATCAGAAGAAGAAATAATCGCTTGACTCAACAGCAACCGCCA
AACTGAAAAACCGACACAACCATCTACTCCAAAACAGGCTGGAACAAGAAAAACGGTATGTGGTACTTCTACAATACTGA
GGTTCAATGGCAACAGGATGGCTCCAAAACACGGTTTCATGGTACTATCTAAACGCTAATGGTGTCTATGGCGACAGGATGGCT
CCAAAACAAATGGTTTCATGGTACTATCTAAACGCTAATGGTTCAATGGCAACAGGATGGCTCCAAAACAAATGGTTTCATGGTACT
ACCTAAACGCTAATGGTGTCTATGGCGACAGGATGGCTCCAATACAATGGTTTCATGGTACTACCTAAACAGCAATGGCGCTAT
GCGACAGGATGGCTCCAATACAATGGCTCATGGTACTACCTCAACGCTAATGGTGTATATGGCGACAGGATGGCTCCAAAAC
CGGTTTCATGGTACTACCTCAACGCTAATGGTGTATATGGCGACAGGATGGCTCCAATACAACGGTTTCATGGTATTACCTCAAC
CTAATGGTGTATATGGCGACAGGTTGGGTGAAAGATGGAGATACCTGGTACTATCTTGAAGCATCAGGTGCTATGAAAGCAAG
CAATGGTTCAAGGTATCATGATAAATGGTACTATGCTCAATGGCTCAGGTGCCCTTGACAGTCAACACAACCTGTAGATGGCTATG
AGTCAATGCCAATGGTGAATGGGTAAACTAA

SeqID 297

ATGTTTGCATCAAAAAGCGAAAGAAAAGTACATTATTCAATTCGTAAATTTAGTATTGGAGTAGCTAGTGTAGTTGTTGCCA
TCTTGTATTGGGAAGTGTGGTTTCATGCGACAGAGAACGAGGGAGTACCCAGTACCCACTTCTTCTAATAGGGCAATGAA
GTCAGGTAGAACAAAGGAGAACAACTTAAAAAACCTCGATTTCAGAACGAGATAAGGCAAGGAAAGAGGTCGAGGAATATGTAA
AAAATAGTGGGTGAGAGCTATGCAAAATCAACTAAAAAGCGACATACAATTAAGTGTAGCTCTAGTTAACGAGTTGAACAACA
TAAGAACGAGTATTTGAATAAATAGTTGAATCAACCTCAGAAAGCCAACTACAGATACTGATGATGGAGAGTCGATCAAAA
TAGATGAAGCTGTGCTAAGTTTGAAGGAGTCACTTCTTCTGTCAGTTTCAGACTCTTCCACTAAACCGGAAGXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXXXXTGTGAGTCCGATGTGGAAGTTAAAAAGCGGAGCTTGAACCTAGTAAAA
AGGAAGCTAAGGAACCTCGAAACGAGGAAAAAGTTAAGCAAGCAAAAGCGGAAGTTGAGAGTAAAAAAGCTGAGGCTACAAG
TTAGAAAAATCAAGACAGATCGTAAAAAAGCAGAAGAAGCTTAAACGAAAAGCAGCAGAAGAAGATAAAGTTAAAGAAA
ACCAGCTGAACAACCAACAGCGCCGGCTCCAAAAGCAGAAAAACCGCTCCAGCTCCAAAACCGAGAAATCCAGCTGAA
AACCAAAAGCAGAAAAACCGCTGATCAACAAGCTGAAGAAGACTATGCTCGTAGATCAGAAGAAGAAATAATCGCTTGAC
CAACAGCAACCGCCAAAACTGAAAAACCGACACAACCATCTACTCCAAAACAGGCTGGAACAAGAAAAACGGTATGTGGT
CTTCTACAATAGTGTGTTCAATGGCGACAGGATGGCTCCAAAACAAATGGCTCATGGTACTACCTCAACAGCAATGGCGCT
TGGCGACAGGATGGCTCCAAAACAAATGGTTTCATGGTACTATCTAAACGCTAATGGTTCAATGGCAACAGGATGGCTCCAAA
AATGGTTTCATGGTACTACCTAAACGCTAATGGTTCAATGGCGACAGGATGGCTCCAATACAATGGCTCATGGTACTACCTAA
CGCTAATGGTTCAATGGCGACAGGATGGCTCCAATACAATGGCTCATGGTACTACCTAAACGCTAATGGTGTATATGGCGACA
GTTGGGTGAAAGATGGAGATACCTGGTACTATCTTGAAGCATCAGGTGCTATGAAAGCAAGCCAATGGTTCAAGTATCAGA
AAATGGTACTATGCTCAATGGCTCAGGTGCCCTTGACAGTCAACACAACCTGTAGATGGCTATGGAGTCAATGCCAATGGTGAAT
GGTAAAC

SeqID 298

XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXCTTGAATTTGCTGAGTCCGATGTGGAAGTTAAAAAGCGGAG
TTGACTAGTAAAGAGGAAGCTAAGAAGCCTTTAAACGAGGGCACAATTAGGCAAGCAAAAGCGGAAGTTGAGAGTAAAAAG
TGAGGCTACAAGGTTAGAAAAAATCAAGACAGATCGTAAAAAAGCAGAAGAAGCTAAACGAAGAGCAGCAGAAGAAGAT
AAGTTAAAGAAAAACCGCTGAACAACCAACAGCGCCCGCCCTCAACCGAAGAAACCACTGAAGAGCCTGAAGATCC
GTTCCAGCTCCAAAACCGAGAGAAGCCAGCTGAACAACCAAAACCGAGAGAAGCCAGCTGAACAACCAAAACCGAGAGAAGCCAG

TGAACAACCAAAAGCAGAAAAACAGATGATCAACAAGCTGAAGAAGACTATGCTCGTAGATCAGAAGAAGATATAATCGCT
TGACTCAACAGCAACCGCAAAACAGAGCAACAGCTCCTGCACCAAAATAGGCTGGAAACAAGAAAAAGGATGTGGTAC
TTCTACAATACTGATGGTTCAATGGCGACAGGATGGCTCCAATACAATGGCTCATGGTATTACCTAAACGCTAACGGTTCAAT
GGCAACAGGTTGGGTGAAAGATGGAGATACCTGGTACTATCTTGAAGCATCAGGTGCTATGAAAGCAAGCCAATGGTTCAAAG
TATCAGATAAATGGTACTATGTCAATGGCTCAGGTGCCCTTGCAGTCAACACAACCTGTAGATGGCTATGGAGTCAATGCCAAT
GGTGAATGGGTAAAC

SeqID 299

ATGTTTGCATCAAAAAGCGAAAGAAAAGTACATTATTCAATTTCGTAAATTTAGTGTGGAGTAGCTAGTGTAGCTGTTGCCAG
TCTTGTATTAGGGAAGTGTGGTTTCATGCGACAGAGAACGAGAGAACTACCCAAAGTACCCACTTCTTCTAATAGGGGAAAGCCAG
AACGTAGGAAAGCTGCTGAACAATTTCGATGAATATATAAAACAAATGATCCAATTAGATAAAAGAAAAACATACCCAAATTTA
GCCTTCAACATACAGTTGAGCAGAAATTAACCGAGTATTTGAATGGATTAAAGAGAAAGTTCGGAAGCTGAGTTGCCGTCAA
AATAAAGCAGAGTTAGACGCAGCTTTTAAGCAGTTTAAAAAGATACATTACCAACAGAACAGAAAAAAGTAGCAGAAG
CTGAGAAGAAGGTTGAAGAAGCTGAGAAGAAGTAGCAGAAGCTAAGAAAAAGCCAGGCTCAAAAAGAAGAGATCACCGT
AACTACCCAACCATTTACTTACAAAACGCTTGACCTTGAATTTGCTGAGTTTCGATGTGAAAGTTAAAGAAGCGGAGCTTGAAC
AGTAAAAAAGGAAGCTGACGAATCTCGAAACGAGGGCACAATTAACCAAGCAAAAGCGAAAGTTGAGAGTGAAGAGCTGAGG
CTACAAGGTTAAAAAAATCAAGACAGATCGTGAAAAAGCAGAAGAAGAGCTAAACGAAGAGCAGATGCTTAAAGAGCA
GATGAATCAXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXATTGCTGAGTCCGATGTGAAAGTTAAAGAAGCGG
AGCTTGAAGTGTAAAGAGGAAGCTAAGGAATCTCGAAACGAGGAAAAATTAAGCAAGCAAAAGCGAAAGTTGAGAGTAA
AAAGCTGAGGCTACAAGTTAGAAAAATCAAGACAGATCGTAAAAAGCAGAAGAAGAGCTAAACGAAGAGCAGCAGAAG
AGATAAAGTTAAAGAAAAACAGCTGAACAACCAACAGCGCGCGCTCCAAAACAGAGAATCCAGCTGAAGAGCCTGAG
ATCCAGTTCCAGCTCCAAAACAGAGAATCCAGCTGAACAACCAAAAGCAGAAAAACAGCTGATCAACAAGCTGAAGAAG
TATGCTCGTAGATCAGAAGAAGATATAATCGCTTGACTCAACAGCAACCGCCAAAACAGAGCAACAGCTCCTGCACCA
AATAGGCTGGAAAACAGAAAAACGGTATGTGGTACTTCTACAATACTGATGGTTCAATGGCGACCGGATGGCTCCAAA
CAATGCTCATGGTACTACCTCAACAGCAATGGCGCTATGGCGACAGGATGGCTCCAAAACATGGTTTATGGTACTATCTAAACGCT
AATGGTTCAATGGCAACAGGATGGCTCCAAAACATGGTTTATGGTACTACCTCAACGCTAATGGTGATATGGCGACAGGAT
GCTCCAATACAATGGCTCATGGTACTACCTCAACGCTAATGGTGATATGGCGACAGGATGGCTCCAATACAATGGCTCATGG
ACTACCTAAACGCTAATGGTGATATGGCGACAGGATGGCTCCAATACAATGGCTCATGGTACTATCTAAACGCTAATGGTG
ATGGCGACAGGTTGGGTGAAAGATGGAGATACCTGGTACTATCTTGAAGCATCAGGTGCTATGAAAGCAAGCCAATGGTTCA
AGTATCAGATAAATGGTACTATGTCAATGGCTCAGGTGCCCTTGCAGTCAACACAACCTGTAGACGGCTATGGAGTCAATGCC
ATGGTGAATGGGTAAAC

SeqID 300

ATGTTTGCATCAAAAAGCGAAAGAAAAGTACATTATTCAATTTCGTAAATTTAGTATTGGAGTAGCTAGTGTAGCTGTTGCTAC
CTTGTTCCTTAGGAGGAGTAGTCCATGCGAGAGGGTTAGAAGTGAGAATACCCCAAGGTTACATCTAGTGGGGATGAAGTC
ATGAATATATAAAAAAATGTTGAGTGAGATCCAATTAGATAAAAGAAAACATACCCACAATTTGCGCTTAAACCTAAAGTT
AGCAGAATTAACCGAGTATTTGTATAAATTAAGTTAATGTTTGAAGAAGAAAGTCAAAAGCTGAGTTGACCTCAAAAAC
AAAAAAGAGGTAGACGCAGCTTTTGAGAAGTTTAAAAAGATACATTGAAACTAGGAGAAAAGGTAGCAGAAGCAGAGA
AGGTTGAAGAAGCTAAGAAAAAGCCAAGGATCAAAAAGAGAAGATCACCGTAACTACCCAAACCAATCTTACAAAGACGCT
GAACTTGAAATTTGCTGAGTCCGATGTGAAAGTTAAAGAGCGGAGCTTGAACCTATTGAAAGAGGAAGCTAAACCTCGAAACG
GGACACAATTAACCAAGCAAAAGCGAAAGTTAAGAGTGAACAAGCTGAGGCTACAAGGTTAAAAAAATCAAGACAGATCGT
AACAGCTGAGGCTACAXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXATTGCTGAGTCCGATGTGAAAGTTA
AGAAGCGGAGCTTGAACTAGTAAAGAGGAAGCTAAGGAACCTCGAGACGAGGAAAAATTAAGCAAGCAAAAGCGGAAGTT
AGAGTAAACAGCTGAGGCTACAAGGTTAGAAAAATCAAGACAGATCGTAAAAAGCAGAAGAAGCTAAACGAAGAAAGC
GCAGAAGAAGATAAGTTTAAAGAAAAACAGCTGAACAACCAACAGCGCGCGCTCCTCAACAGAAAAACCAACTCCA
ACCAGAAAAACAGCTCCAGCTCCAAAACAGAGAATCCAGCTGAACAACCAAAAGCAGAAAAACAGCTGATCAACAAGCT
AAGAAGACTATGCTCGTAGATCAGAAGAAGATATAATCGCTTGACTCAACAGCAACCGCCAAAACCTGAAAAACAGCA
CCATCTACTCCAAAACAGGCTGGAAAAAGAAAAACGGTATGTGGTACTTCTACAATACTGATGGTTCAATGGCGACAGGAT
GCTCCAATACAATGGCTCATGGTACTACCTAAACGCTAATGGTGATATGGCGACAGGATGGCTCCAAAACATGGTTTATGG
ACTACCTAAACGCTAATGGTGATATGGCGACAGGATGGCTCCAAAACATGGCTCATGGTACTACCTAAACGCTAATGGTGA
ATGGCGACAGGATGGCTCCAAAACATGGCTCATGGTACTACCTAAACGCTAATGGTGATATGGCGACAGGTTGGGTGAAAG
TGGAGATACCTGGTACTATCTTGAAGCATCAGGTGCTATGAAAGCAAGCCAATGGTTCAAAGCATCAGATAAATGGTACTAT
TCAATGGCTCAGGTGCCCTTGCAGTCAACACAACCTGTAGATGGCTATGGAGTCAATGCCAATGGTGAATGGGTAAAC

SeqID 301

ATGTTTGCATCAAAAAGCGAAAGAAAAGTACATTATTCAATTTCGTAAATTTAGTATTGGAGTAGCTAGTGTAGCTGTTGCCA
TCTTGTATTAGGGAAGTGTGGTTTCATGCGACAGAGAGGAGGTAACCTACCCAAAGTACCCACTTATTCTAATATGGCAAGACA
AACATAGGAAAGCTGCTAAACAAGTCGTCGATGAATATATAGAAAAATGTTGAGGGAGATTCAATTAGATAGAAGAAAAA
ACCCAAAATTTGCGCTTCAACATGAAGTTGAGCGCAATTAACCGAGTATTTGTATGGATTAAAGAGAAAGTTCGGAAGCTG
GTTGCCGTATCGGAAGCTGAGTTGCCGTGAGAAGTAAAGCAAAGTTAGACGCAGCTTTTGAAGCAGTTTAAAAAGATACA
TGAACCTAGGAGAAAAGTAGCAGAAGCTGAGAAGAAGGTTGAGAAGCTGAGAAAAAGCCAGGCTCAAAAAGAGAAGA
CGCCGTAACCTACCCAAACCATTACTTACAAAACGCTTGACCTTGAATTTGCTGAGTCCGATGTGGAAGTTAAAAAGCGGAGC
TGAACCTATTGAAGAGGAAGCTAAACCTCGAAACAAGGACACAATTAAGCAAGCAAAAGCGAAAGTTGAGAGTAAAAAGCT
AGGCTACAAAGTTAGAAGAAATCAAGACAGATCGTAAAAAGCAGAAGAAGCTAXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXATTGCTGAGTCCGATGTGAAAGTTAAAGAAGCGGAGCTTGAACCTAGTAAAGAGGAAGCTAAGGAATC
CGAAACGAGGAAAAAGTTAAGCAAGCAAAAGCGAAAGTTGAGAGTAAAAAGCTGAGGCTACAAGGTTAGAAAAATCAAGA
AGATCGTAAAAAAGCAGAAGAAGCTAAACGAAGAGCAGCAGAAGAAGATAAAGTTAAAGAAAAACAGCTGAACAACCAACA
CAGCGCGGCTCCTCAACAGAAAAACCACTGAAGAGCCTGAGAATCCAGCTCCAGCTCCAAAACCTGAGAAACCACTGA

CAACCAAAAGCAGAAAAACCAGCTGATCAACAAGCTGAAGAAGACTATGCTCGTAGATCAGAAGAAGAATATAATCGCTTGAC
TCAACAGCAACCGCCAAAAAAGCTGAAAAACCAGCACAACCATCTACTCCAAAAACAGGCTGGAAAAAAGAAACGGTATGTTGGT
ACTTCTACAATACTGATGGTTCAATGGCGACAGGATGGCTCCAAAAACAATGGCTCATGGTACTACCTCAACAGCAATGGCGCT
ATGGCGACAGGATGGCTCCAATACAATGGTTTATGGTACTACCTCAACGCTAATGGTGATATGGCGACAGGATGGCTCCAAAA
CAATGGTTTATGGTACTACCTCAACGCTAATGGTGATATGGCGACAGGATGGCTCCAATACAATGGTTTATGGTACTACCTCA
ACGCTAATGGTGATATGGCGACAGGATGGCTCCAAAAACAATGGCTCATGGTACTACCTAAACGCTAATGGTGATATGGCGACA
GGTTGGGTGAAAGATGGAGATACCTGGTACTATCTTGAAGCATCAGGTGCTATGAAAGCAAGCCAATGGTTCAAAGTATCAGA
TAAATGGTACTATGTCAATGGCTCAGGTGCCCTTGCACTCAACACAACCTGTAGATGGCTATGGAGTCAATGCCAATGGTGAAT
GGGTAAAC

SeqID 302

ATGTTTGCATCAAAAAGCGAAAGAAAAGTACATTATTCAATTTCGTAAATTTAGTATTGGAGTAGCTAGTGTAGCTGTTGCTAG
CTTGTCTTAGGAGGAGTAGTCCATGCGAGAAGGGGTTAGAAGTGAGAATACCCCAAGGTTACATCTAGTGGGGATGAAGTCG
ATGAATATATAAAAAAATGTTGAGTGAGATCCAATTAGATAAAAGAAAACATACCCACAATTTGCGCTTAAACCTAAAGTTG
AGCAGAAATTAACCGGAGTATTTGTATAAATTAAGTTAATGTTTGAAGAAAAGTCAAAAGCTGAGTTGACGCTCAAAAAAC
AAAAAAGAGGTAGACGCGAGCTTTTGAAGGTTTAAAAAGATACATTGAACTAGGAGAAAAGGTAGCAGAAGCTCAGAAGA
AGTTTGAAGGCTAAGAAAAAAGCCCAAGGATCAAAAAGAAAGAGATCACCGTAACCTACCAACCAATCTTCAAAAAACGCTT
GAACCTGAAATTGCTGAGTCCGATGTGAAAGTTAAAGAAGCGGAGCTTGAACCTATTGAAAGAGGAAAGCTAAAACTCGAAACGA
GGACACAATTAACCAAGCAAAAGCGAAAGTTAAGAGTGAAACAAGCTGAGGCTACAAGGTTAAAAAATCAAGACAGATCGTG
AACAGCTGAGGCTACAAGGTTAGAAAAACATCAAGACAGATCGTGAAAAAGCAGAAGAAGCTAAACGAAAAGCAGAAAXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXCTTGAATTTGCTGAGTCCGATGTGAAAGTTAAAGAAGCGGAGCTTGAAC
TAGTAAAGAGGAAGCTAAGGAATCTCGAAACGAGGAAAAAGTTAAGCAAGCAAAAGCGAAAGTTGAGAGTAAACAAGCTGAC
GCTACAAGGTTAGAAAAAATCAAGACAGATCGTAAAAAGCAGAAGAAGCTAAACGAAAAGCAGCAGAAGAAGATAAAGT
TAAAGAAAAACAGCTGAACAACCAACAACAGCGCGCGCTCTCAACCAGAAAAACAGCTCCAGCTCCAAAAACAGAGAATC
CAGCTGAACAACCAAAAGCAGAAAAACAGCTGATCAACAAGCTGAAGAAGACTATGCTCGTAGATCAGAAGAAGAATATAA
CGCTTGACTCAACAGCAACCGCCAAAAAAGTAAAAACAGCACAACCATCTACTCCAAAAACAGGCTGGAAACAGAAAAACG
TATGTGGTACTTCTACAATACTGATGGTTCAATGGCGACAGGATGGCTCCAATACAATGGCTCATGGTACTACCTAAACGCT
ATGGTGATATGGCGACAGGATGGCTCCAAAAACAATGGTTTATGGTACTACCTAAACGCTAATGGTGATATGGCGACAGGAT
CTCCAAAAACAATGGCTCATGGTACTACCTAAACGCTAATGGTGATATGGCGACAGGATGGCTCCAAAAACAATGGCTCATGGT
CTACCTAAACGCTAATGGTGATATGGCGACAGGTTGGGTGAAAGATGGAGATACCTGGTACTATCTTGAAGCATCAGGTGCT
TGAAAGCAAGCCAATGGTTCAAAGCATCAGATAAATGGTACTATGTCAATGGCTCAGGTGCCCTTGCACTCAACACAACGT
GATGGCTATGGAGTCAATGCCAATGGTGAATGGGTAAAC

SeqID 303

ATGTTTGCATCAAAAAGCGAAAGAAAAGTACATTATTCAATTTCGTAAATTTAGTATTGGAGTAGCTAGTGTAGCTGTTGCCA
TCTTTTTATGGGAAGTGTGGTTTATGCGACAGAGAAGGAGGTAACCTACCAAGTAGCCACTTCTTCTAATAAGGCAAATAAA
GTCAGACAGAACATATGAAAGCTGCTAAACAAGTGCATGAATATATAAAAAAAGCTCCAATTAGATAGAGAAAAACATAC
CAAAATGTCCGCTTACTCAAAAGTTGGGCGTAATTAACCGGAGTATTTGCATGGATTAAGTGTTCAAAAAAGAAAGTCGG
AGCTGAGTTGCGCTGAGGATAAAGCAAGTTAGACGCAAGCTTTTGAAGCAGTTTAAAAAAGATACATTACCAACAGAACCA
GAAAAAAGGTAGCAGAAGCTGAGAAGAAGGTTGAAGAAGCTAAGAAAAAAGCCGAGGATCAAAAAGAAAAAGATCTCCGTAA
TACCAACCAATACTTACAAAACGCTTGAACCTTGACATTTGCTGAGTCCGATGTGGAAGTTAAAAAAGCGGAGCTTGAAC
AAAAGGAGCTACAGGAATCTCGAGACGAGAAAAAATTAATCAAGCAAGCGAAAGTTGAGAATAAAAAAGCTGATGCTA
AAGGXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXGTCCAAAACGGTATGTGGTACTTCTACAATACTGATGG
TCAATGGCAACAGGCTGGCTCCAAAACAATGGCTCATGGTACTACCTCAACAGCAATGGCGCTATGGCGACAGGATGGCTCC
AAACAATGGCTCATGGTACTACCTCAACAGCAATGGCGCTATGGCGACAGGATGGCTCCAATACAATGGTTTATGGTACTAC
TCAACGCTAATGGTGATATGGCGACAGGATGGTTCCAATACAATGGTTTATGGTACTACCTCAACGCTAATGGTGATATGGC
ACAGGATGGTTCCAATACAATGGTTTATGGTACTACCTCAACGCTAATGGTGATATGGCGACAGGATGGTTCCAATACAATG
TTTATGGTACTACCTCAACGCTAATGGTGATATGGCGACAGGATGGCTCCAATACAATGGTTTATGGTACTACCTCAACAGC
ATGGTGCTATGGTAACAGGATGGCTCCAAAACAATGGCTCATGGTACTACCTAAACGCTAACGGTTCAATGGCAACAGATTG
GTGAAAGATGGAGATACCTGGTACTATCTTGAAGCATCAGGTGCTATGAAAGCAAGCCAATGGTTCAAAGTATCAGATAAAT
GTACTATGTCAATGGCTCAGGTGCCCTTGCACTCAACACAACCTGTAGATAGCTATAGAGTCAATGCCAATGGTGAATGGGTAA
AC

SeqID 304

MKKKILASLLSTVMVSQVAVLTTHAETDDDKIAAQDNKISNLTAQQQEAQKQVDQIQEQVSAIQAEQSNLQAENDRLQAE
KKLEGEITELSKNIVSRNQSLKQARSQAQTNGAVTSYINTIVNSKSITEAISRVAAAMSEIVSANNKMLEQQKADKKAISEKQ
ANNDAINTVIANQQKLADDAQALTTKQAEKAAELSLAEKATAEGEKASLLEQKAAAEAEARAAVAEAAAYKEKRASQQQS
LASANTNLTAQVQAVSESAAAPVRAKVRPTYSTNASSYPIGECTGWVKTLAPWAGDYWGNGAQWATSAAAAGFRTGSTPQVG
IACWNDDGGYGHVAVVTAVESTTRIQQVSESNYAGNRTIGNHRGWFPNTTPEGFVITYAD

SeqID 305

MKKKILASLLSTVMVSQVAVLTTHAETDDDKIAAQDNKISNLTAQQQEAQKQVDQIQEQVSAIQAEQSNLQAENDRLQAE
KKLEGEITELSKNIVSRNQSLKQARSQAQTNGAVTSYINTIVNSKSITEAISRVAAAMSEIVSANNKMLEQQKADKKAISEKQ
ANNDAINTVIANQQKLADDAQALTTKQAEKAAELSLAEKATAEGEKASLLEQKAAAEAEARAAVAEAAAYKEKRAGQQQS
LASANTNLTAQVQAVSESAAAPVRAKVRPTYSTNASSYPIGECTGWVKTLAPWAGDYWGNGAQWATSAAAAGFRTGSTPQVG
IACWNDDGGYGHVAVVTAVESTTRIQQVSESNYAGNRTIGNHRGWFPNTTSEGFVITYAD

SeqID 306

SeqID 307

SeqID 308

SeqID 309

SeqID 310

SeqID 311

SeqID 312

```
seqid 312
MFASKSERKSTHVSIRKFSVGVASVVVASLVMSGVVHATENEGATQVPTSSNRANESQAEQGEQPKKLLDSERDKARKEVEEYV.
KIVGESYAKSTKKRHTTTVALVNELNNIKNEYLNKIVESTSESQQLIIMMESRSKVDEAVSKFEKDSPSSSSSDSSTKPEXX
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXAESDVEVKAELELVKEEAKPRNEEKVKQAKAEV.
SKKAAATRLPEKIKTDRKKAEEERAKRAAEEDVKKEKPAEQPPAPAPKAEKPAPAPKPNPAEQPKAEKPADQQAEEYARR.
EEEYNRLTQQQPPKTEKPAQPSTPKTGWKQENGMMWYFYNTDGSMTAGWLQNNGSWYYLNSNGAMATGWLQNNGSWYYLNG.
MATGWLQNNGSWYYLNGSAMATGWLQYNGSWYYLNGSAMATGWLQYNGSWYYLNGAMDTGWVKDGDWTWYYLEASGAMK.
SOWFKVDKSWYYVNGSGALAVNTTVDGYGVNANGEVN
```

XXXKLKLLSPMWKCLKRSLTSKEEAKPLNEGTRQ
AKAEVESKKAEATRLEKIKTDRKKAEEEAARRAAEDKVKEKPAEQPPAPAPQPEKPTEEPENPVPAPKPEKPAEQPKPEKP
AEQPKPEKPAEQPKAEKTDQQAEDYARRSEEEYNRLTQQQPQKPEQPAPAPKIGWKQENGWIFYNTDGSMTAGWLQYNGS
WYYLNANGSMATGWVKDGDWTWYYLEASGAMKASQWFKVSDKWYYVNGSGALAVNTTVDGYGVNANGEWVN

MFASKSERKVHYSIRKFSVGVASVAVASLVMGSVVHATENERTTQVPTSSNRGKPERRKAAEQFDEYINKMIQLDKRKHTQNL
AFNIQLSRIKTEYLNGLKEKSEALPSKIAELDAAFKQFKKDTLPTEPEKKVAAEAKKVEEAKKVAEAKKKAKAQKEEDHR
NYPTITYKTLDEIAEFDVKVKEAELELVKKEADESRNEGTINQAKAKVSEKAEATRLKIKTDREKAEERAAKRRADAEQ
DESXXXIAESDVKVKEAELELVKKEAKESRNEEKIK
QAKAKVESKKAETRLKIKTDREKAEERAAKRAAEEDKVKEKPAEQPPAPAPKPNPAEENPVAPKPNPAEQPKAEK
PADQQAEDYARRSEEEYNRLTQQQPPKPEQPAPAPKIGWKQNGMWWFYNTDGSMTATGWLQNNGSWYYLNSNGAMATGWLQN
NGSWYYLNGAMDMATGWLQYNGSWYYLNGAMDMATGWLQYNGSWYYLNGAMDMATGWLQYNGSWYYLNGAMDMATGWLQYNGSWYYLNGAMD
WYYLEASGAMKASOWFKVSDKWYYVNGSGALAVNTTVDQYGVNANGEWVN

MFASKSERKVHYSIRKFSIGVASVASLFLGGVVHAEGBVRSENTPKVTSSGDEVDEYIKKMLSEIQLDKRKHTNHFALNLKI
SRIKTEYLYKLKLVNVLEEKSKAELTSKTKKEVDAAFEKFKKDTLKLGEKVAAEQKKVEEAKKAKDQKEEDHRNYPNTYTKTI
ELEIAESDVKVKEAELELLKEEAKTRNEDTINQAKAVKSEQEAEATRLKKIKTDRQEAETXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXIAESDVKVKEAELELVKEEAKPRDEEIKIQAQAEVSKQAEATRLKIKTDRK
AEEEEAKRKAEEEDKVKEKPAEQPPAPAPQPEKPTPKPEKPAPAPKPNPAEQPKAEKPADQQAEEYARRSEEEYNRLTOQC
PKTEKPAQPSTPKTGWKQENGMMWYFYNTDGSMTGWLQYNGSWYLLNANGDMATGWLQNGSWYLLNANGDMATGWLQNGS
WYLLNANGDMATGWLQNGSWYLLNANGDMATGWVKDGTWYLLASGAMKASQWFKASDKWYVYNGSGALAVNTTVDGYGVN
ANGWVN

MFASKSERKVHYSIRKFSIGVASVAVASLVMSGSVVHATEKEVTTQVPTYNSMAKTEHRKAAQVVDEYIEKMLREIQDRRK:
TQNFAPNMKLSAIKTEYLYGLKEKSEAEPLSSEAEPLSEVKAKLDAAFEQFKKDTLKLGEKVAAEAKKVAEAEKKAKAQKEE:
RRNYPTITYKTLDLLEIAESDVEVKKAELELLKEEAKTRNKDTIKQAKAKVESKKAEEATKLEIKTRDKKAEAEAXXXXXXXXX:
XX:
IAESDVVKVEAELELVKEEAKESRNEEKVKQAKAKVESKKA:
ATRLEKIKTRDKKAEAEAKRRAAEEDKVKEKPAEQPQAPAPQPEKPTEEPENPAPAPKPEKPAEQPKAEKPADQQAEDYARF:
SEEEYNRLTQQQPPKTEKPAQPSTPKTGWKQENGMMWYFYNTDGSMTAGWLQNNGSWYYLNSNGAMATGWLQYNGSWYYLNGAN:
DMATGWLQNNGSWYYLNGANDMATGWLQYNGSWYYLNGANDMATGWLQNNGSWYYLNGANDMATGWLKDGDTWYYLEASGAMF:
ASOWFKVSDKYYWYNGSGALAVNTTVDGYGVNANGEWVN

MFASKSERKVHYSIRKFSIGVASVAVASLFLGGVVHAEGRSENTPKVTSSGDEVDEYIKKMLSEIQLDKRKHTNHFALNLKI
SRIKTEYLYKLKVNVLEEKSKAELTSKTKKEVDAAEFEKFKDITLKLGEKVAAEQKKVEEAKKAKDQKEEDHRNYPTNTYKTI
ELEIAESDVVKKEAELELELLKEEAKTRNEDTINQAKAKVKSEQAEATRLKKIKTDREQAEATRLENIKTDREKAAEEAKRAEX
XXXLEIAESDVVKKEAELELVKEEAKESRNEEKVKQAI
AKVESKQAEATRLKIKTDRKKAEEEEAKRKAAEEDKVKEKPAEQPQPAPAPQPEKPAPAPKPENPAEQPKAEKPADQQAED
ARRSEEEYNRLTQQPPKTEKPAQPSTPKTGWKQENGMMWYFYNTDGSMTAGWLQYNGSWYYLNGDMDATGWLQNNGSWYYL
ANGMDATGWLQYNGSWYYLNGDMDATGWLQNNGSWYYLNGDMDATGWLQNNGSWYYLNGDMDATGWLQNNGSWYYLNGDMDATGWLQNNGSWYYL
GALAVNTTVDQYGVNANGENVN

MFASKSERKVHYSIRKFSIGVASVAVASLFMGSVVHATEKEVTTQVATSSNKANKSQTEHMKAAKQVDEYIKKKQLDRRKH
QNVGILLTKLGVITKEYLHGLSVSKKSEAEPLSEIKAKLDAAFEQFKDITLPTPEGKKVAEAEKKVEEAKKKAEDQKEKDLR
YPTNTYKTLBLELDAESDVEVKKAELELVKGSYRNLETRKKLIKQSEKLRIKKMLNGAXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXQVNGMWYFYNTDGSMTATGWLQNGSWYYLNSNGAMATGWLQNNGSWYYLNSNGAMATGWI
QYNGSWYYLNSNGDMATGWFQYNGSWYYLNSNGDMATGWFQYNGSWYYLNSNGDMATGWFQYNGSWYYLNSNGDMATGWLQYI
GSWYYLNSNGAMVMTGWLQNNGSWYYLNSNGSMATDVKDGDTVYLYLEASGAMKASQWFKVSDKWYYVNGSGALAVNTTVDSYI
VNANGEWVN

Note: "X" represents undefined/missing nucleotides or amino acids due to unavailable sequencing information.

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
28 October 2004 (28.10.2004)

PCT

(10) International Publication Number
WO 2004/092209 A3

(51) International Patent Classification⁷: **C07K 14/315**,
16/12, 19/00, 16/46, C12N 5/12, 15/02, A61K 39/09,
C12Q 1/68, G01N 33/569, A61P 31/04

(21) International Application Number:
PCT/EP2004/003984

(22) International Filing Date: 15 April 2004 (15.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
03450087.6 15 April 2003 (15.04.2003) EP

(71) Applicant (*for all designated States except US*): INTER-
CELL AG [AT/AT]; Campus Vienna Biocenter 6, A-1030
Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): MEINKE, Andreas
[DE/AT]; Piettegassee 26/1, A-3013 Pressbaum (AT).
NAGY, Eszter [HU/AT]; Taborstrasse 9, A-1020 Vienna
(AT). HANNER, Markus [AT/AT]; Jacquingasse 5/6,
A-1030 Vienna (AT). DEWASTHALY, Shailesh [IN/AT];
Anschützgassee 23/10, A-1150 Vienna (AT). STIER-
SCHNEIDER, Ulrike [AT/AT]; Kaiserstrasse 66/2/14,
A-1070 Vienna (AT).

(74) Agent: SONN & PARTNER; Riemergasse 14, A-1010
Vienna (AT).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,

AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Euro-
pean (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,
GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for all designations*
- *of inventorship (Rule 4.17(iv)) for US only*

Published:

- *with international search report*
- *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments*

(88) Date of publication of the international search report:
9 December 2004

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: S. PNEUMONIAE ANTIGENS

(57) Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from *S. pneumoniae*, methods for isolating such antigens and specific uses thereof.



WO 2004/092209 A3

INTERNATIONAL SEARCH REPORT

Inter al Application No
PCT/EP2004/003984

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K14/315 C07K16/12 C07K19/00 C07K16/46 C12N5/12
C12N15/02 A61K39/09 C12Q1/68 G01N33/569 A61P31/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, EMBL, EMBASE, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 02/083855 A (CHAKRAVARTI DEB NARAYAN ; RUSSELL DAVID PARRISH (US); WOOTERS JOSEPH L) 24 October 2002 (2002-10-24) page 85, line 15 - page 108, line 4 claims 1-11,25-28,59-71,96,105 see in particular SEQ ID Nos. 209 and 424.	1,2, 5-11, 14-37
X	WO 02/077021 A (CHIRON SPA ; MASIGNANI VEGA (IT); FRASER CLAIRE (US); TETTELIN HERVE () 3 October 2002 (2002-10-03) page 8, line 30 - page 34, line 40 see in particular SEQ ID Nos. 4715 and 4716. claims 1-16	1,2, 5-11, 14-37
	----- -/-- -----	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
 "E" earlier document but published on or after the international filing date
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 "O" document referring to an oral disclosure, use, exhibition or other means
 "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
 "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
 "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
 "&" document member of the same patent family

Date of the actual completion of the international search

25 August 2004

Date of mailing of the international search report

25. 10. 2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Ulbrecht, M

INTERNATIONAL SEARCH REPORT

Inte.....al Application No

PCT/EP2004/003984

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HOSKINS J ET AL: "Genome of the Bacterium Streptococcus pneumoniae Strain R6" JOURNAL OF BACTERIOLOGY, WASHINGTON, DC, US, vol. 183, no. 19, October 2001 (2001-10), pages 5709-5717, XP002231307 ISSN: 0021-9193 cited in the application the whole document	1,2, 5-11, 14-37
X	-& DATABASE EMBL EBI; 7 September 2001 (2001-09-07), HOSKINS ET AL.: "Streptococcus pneumoniae R6 section 1" XP002293255 retrieved from HTTP://WWW.EBI.AC.UK Database accession no. AE008385 cited in the application the whole document	1,2, 5-11, 14-37
X	TETTELIN H ET AL: "Complete genome sequence of a virulent isolate of Streptococcus pneumoniae" SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 293, no. 5529, 2001, pages 498-506, XP002218261 ISSN: 0036-8075 cited in the application the whole document	1,2, 5-11, 14-37
X	-& DATABASE EMBL EBI; 31 July 2001 (2001-07-31), TETTELIN ET AL.: "Streptococcus pneumoniae TIGR4 section 1" XP002293256 retrieved from HTTP://WWW.EBI.AC.UK Database accession no. AE007318 cited in the application the whole document	1,2, 5-11, 14-37
A	NABORS G S ET AL: "Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules" VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 18, no. 17, March 2000 (2000-03), pages 1743-1754, XP004190054 ISSN: 0264-410X the whole document	1,2, 5-11, 14-37

-/-

INTERNATIONAL SEARCH REPORT

Intern

al Application No

PCT/EP2004/003984

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	BETHE GESINA ET AL: "The cell wall-associated serine protease PrtA: A highly conserved virulence factor of Streptococcus pneumoniae" FEMS MICROBIOLOGY LETTERS, vol. 205, no. 1, 27 November 2001 (2001-11-27), pages 99-104, XP002293235 ISSN: 0378-1097 the whole document	1,2, 5-11, 14-37
A	WIZEMANN T M ET AL: "Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection" INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, US, vol. 69, no. 3, March 2001 (2001-03), pages 1593-1598, XP002263818 ISSN: 0019-9567 the whole document	1,2, 5-11, 14-37
A	OVERWEG K ET AL: "The putative proteinase maturation protein A of Streptococcus pneumoniae is a conserved surface protein with potential to elicit protective immune responses" INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, US, vol. 68, no. 7, July 2000 (2000-07), pages 4180-4188, XP002158137 ISSN: 0019-9567 the whole document	1,2, 5-11, 14-37
A	WO 02/059148 A (CISTEM BIOTECHNOLOGIES GMBH ; AHSEN UWE (AT); ETZ HILDEGARD (AT); HAFN) 1 August 2002 (2002-08-01) the whole document	1,2, 5-11, 14-37

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2004/003984

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

see annex

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

Invention 1: claims 1,2,5-11,14-37 (all partially)

An isolated nucleic acid molecule encoding a hyperimmune serum-reactive antigen or fragment thereof as defined in claim 1, but referring only to SEQ ID No. 1; a vector comprising said nucleic acid molecule; a host cell comprising said vector; a hyperimmune serum-reactive antigen comprising the amino acid sequence of SEQ ID No. 145; a fragment of the said hyperimmune serum-reactive antigen as defined in claim 14; a method of producing the said *S. pneumoniae* hyperimmune serum-reactive antigen or fragment thereof; a process for producing a cell which expresses the said *S. pneumoniae* hyperimmune serum-reactive antigen or fragment thereof; the use of the said nucleic acid molecule or the said hyperimmune serum-reactive antigen or fragment thereof for the manufacture of a pharmaceutical preparation; an antibody, or at least an effective part thereof which binds at least to a selective part of the said hyperimmune serum-reactive antigen or fragment thereof; a hybridoma cell line which produces the said antibody; a method of producing the said antibody; the use of said antibody for the preparation of a medicament for treating or preventing *S. pneumoniae* infections; an antagonist which binds to the said hyperimmune serum-reactive antigen or fragment thereof; a method of identifying an antagonist capable of binding to the said hyperimmune serum-reactive antigen or of reducing or inhibiting the interaction activity of the said hyperimmune serum-reactive antigen or fragment thereof; the use of the said hyperimmune serum-reactive antigen or fragment thereof for the isolation and/or purification and/or identification of an interaction partner; a process for in vitro diagnosing a disease or a bacterial infection based on determining the presence of the said nucleic acid sequence or the presence of the said hyperimmune serum-reactive antigen or fragment thereof; the use of said hyperimmune serum-reactive antigen or fragment thereof for the generation of a peptide binding thereto i.e. an anticaline, for the manufacture of a functional nucleic acid i.e. an aptamer or a spiegelmer, or of a functional ribonucleic acid i.e. a ribozyme, an antisense nucleic acid or a siRNA.

Inventions 2-45: claims 1,2,5-11,14-37 (all partially)

Idem as invention 1, but each of the inventions 2-45 referring to one of the further SEQ ID Nos. mentioned in claim 1 together with its respective corresponding SEQ ID No. according to claim 11.

Inventions 46-121: claims 3-10,12,14-37 (all partially)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Idem as invention 1, but each of the inventions 46-121 referring to one of the SEQ ID Nos. mentioned in claim 3 together with its respective corresponding SEQ ID No. according to claim 12.

Inventions 122-133: claims 4-10,13-37 (all partially)

Idem as invention 1, but each of the inventions 122-133 referring to one of the SEQ ID Nos. mentioned in claim 4 together with its respective corresponding SEQ ID No. according to claim 13.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inter.

Int. Application No

PCT/EP2004/003984

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 02083855	A	24-10-2002	CA	2444133 A1	24-10-2002
			WO	02083855 A2	24-10-2002
WO 02077021	A	03-10-2002	CA	2439431 A1	03-10-2002
			EP	1373513 A2	02-01-2004
			WO	02077021 A2	03-10-2002
WO 02059148	A	01-08-2002	AT	410798 B	25-07-2003
			AT	1302001 A	15-12-2002
			BR	0207067 A	15-06-2004
			CA	2436057 A1	01-08-2002
			CZ	20032201 A3	17-03-2004
			WO	02059148 A2	01-08-2002
			EP	1355930 A2	29-10-2003
			NO	20033364 A	24-09-2003

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☒ **FADED TEXT OR DRAWING**

☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)